PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	KRISHNA, TSR; KONG, XP; GARY, S; BURGERS, PM; KURIYAN, J				KRISHNA, TSR; KONG, XP; GARY, S; BURGERS, PM; KURIYAN, J			CRYSTAL-STRUCTURE OF THE EUKARYOTIC DNA-POLYMERASE PROCESSIVITY FACTOR PCNA	CELL			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION FACTOR-C; SACCHAROMYCES-CEREVISIAE; ACCESSORY PROTEINS; AUXILIARY PROTEIN; ESCHERICHIA-COLI; III HOLOENZYME; DELTA; BACTERIOPHAGE-T4; REFINEMENT	The crystal structure of the processivity factor required by eukaryotic DNA polymerase delta, proliferating cell nuclear antigen (PCNA) from S. cerevisiae, has been determined at 2.3 Angstrom resolution. Three PCNA molecules, each containing two topologically identical domains, are tightly associated to form a closed ring. The dimensions and electrostatic properties of the ring suggest that PCNA encircles duplex DNA, providing a DNA-bound platform for the attachment of the polymerase. The trimeric PCNA ring is strikingly similar to the dimeric ring formed by the beta subunit (processivity factor) of E. coli DNA polymerase III holoenzyme, with which it shares no significant sequence identity. This structural correspondence further substantiates the mechanistic connection between eukaryotic and prokaryotic DNA replication that has been suggested on biochemical grounds.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Rockefeller University; Washington University (WUSTL)	KRISHNA, TSR (corresponding author), ROCKEFELLER UNIV, MOLEC BIOPHYS LABS, NEW YORK, NY 10021 USA.		Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45547, R01 GM032431, GM32431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAND SR, 1994, J IMMUNOL, V152, P4120; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CHA TA, 1988, EUKARYOTIC DNA REPLI, P1; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1991, DNA REPLICATION; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, J MOL BIOL, V241, P265, DOI 10.1006/jmbi.1994.1495; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; MIYACHI K, 1978, J IMMUNOL, V121, P2228; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MULLER F, 1994, J BIOL CHEM, V269, P17086; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOSSAL NG, 1984, BACTERIOPHAGE T4, P71; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PODUST VN, 1993, J BIOL CHEM, V25, P841; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROOS G, 1993, LAB INVEST, V68, P204; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TAN CK, 1986, J BIOL CHEM, V261, P2310; TINKER RL, 1994, IN PRESS EMBO J; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wells A.F., 1984, STRUCTURAL INORGANIC; WOLD MS, 1988, CANCER CELL, V6, P133; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YODER BL, 1991, J BIOL CHEM, V266, P22689; ZENG XR, 1994, J BIOL CHEM, V269, P13748; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	56	766	785	27	183	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1233	1243		10.1016/0092-8674(94)90014-0	http://dx.doi.org/10.1016/0092-8674(94)90014-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001157				2022-12-28	WOS:A1994PZ86000014
J	WILSON, KP; BLACK, JAF; THOMSON, JA; KIM, EE; GRIFFITH, JP; NAVIA, MA; MURCKO, MA; CHAMBERS, SP; ALDAPE, RA; RAYBUCK, SA; LIVINGSTON, DJ				WILSON, KP; BLACK, JAF; THOMSON, JA; KIM, EE; GRIFFITH, JP; NAVIA, MA; MURCKO, MA; CHAMBERS, SP; ALDAPE, RA; RAYBUCK, SA; LIVINGSTON, DJ			STRUCTURE AND MECHANISM OF INTERLEUKIN-1-BETA CONVERTING-ENZYME	NATURE			English	Article							RECEPTOR ANTAGONIST PROTEIN; COLLAGEN-INDUCED ARTHRITIS; DEATH GENE CED-3; CELL-DEATH; 3-DIMENSIONAL STRUCTURE; MOLECULAR-CLONING; SIDE-CHAIN; PAPAIN; RESOLUTION; IL-1-BETA	Interleukin-1 beta converting enzyme (ICE) processes an inactive precursor to the proinflammatory cytokine, Interleukln-1 beta, and may regulate programmed cell death in neuronal cells. The high-resolution structure of human ICE In complex with an inhibitor has been determined by X-ray diffraction. The structure confirms the relationship between human ICE and cell-death proteins in other organisms. The active site spans both the 10 and 20K subunits, which associate to form a tetramer, suggesting a mechanism for ICE autoactivation.			WILSON, KP (corresponding author), VERTEX PHARMACEUT INC,40 ALLSTON ST,CAMBRIDGE,MA 02139, USA.							BENDER PE, 1989, A REP MED CHEM, V25, P185; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHAPMAN KT, 1992, BIOORG MED CHEM LETT, V2, P613, DOI 10.1016/S0960-894X(01)81209-9; DINARELLO CA, 1992, IMMUNOL REV, V127, P119, DOI 10.1111/j.1600-065X.1992.tb01411.x; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; Drenth J., 1987, BIOL MACROMOL, V3, P312; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GEIGER T, 1993, CLIN EXP RHEUMATOL, V11, P515; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAMMERBERG C, 1992, J CLIN INVEST, V90, P571, DOI 10.1172/JCI115896; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; MANDRUPPOULSEN T, 1993, CYTOKINE, V5, P185, DOI 10.1016/1043-4666(93)90003-N; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; MENARD R, 1991, BIOCHEMISTRY-US, V30, P8924, DOI 10.1021/bi00101a002; MENARD R, 1991, BIOCHEMISTRY-US, V30, P5531, DOI 10.1021/bi00236a028; MILLER DK, 1993, ANN NY ACAD SCI, V696, P133; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NETT MA, 1992, J IMMUNOL, V149, P3254; NETTGIORDALISI MA, 1993, J CELL BIOCH B, V17, P117; NORONHA IL, 1993, KIDNEY INT, V43, P682, DOI 10.1038/ki.1993.98; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; POLGAR L, 1973, EUR J BIOCHEM, V33, P104, DOI 10.1111/j.1432-1033.1973.tb02660.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SANDBERG JO, 1993, DIABETES, V42, P1845, DOI 10.2337/diabetes.42.12.1845; SHIVERS BD, 1993, J CELL BIOCH B, V17, P119; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WOOLEY PH, 1993, ARTHRITIS RHEUM, V36, P1305, DOI 10.1002/art.1780360915; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; 1979, SUITE PROGRAMS PROTE; 1992, QUANTA VERSION 4 0B	45	734	779	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					270	275		10.1038/370270a0	http://dx.doi.org/10.1038/370270a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035875				2022-12-28	WOS:A1994NZ22900055
J	WILLIAMS, C				WILLIAMS, C			ABC OF SPORTS MEDICINE - ASSESSMENT OF PHYSICAL PERFORMANCE	BRITISH MEDICAL JOURNAL			English	Article											WILLIAMS, C (corresponding author), UNIV LOUGHBOROUGH,LOUGHBOROUGH,ENGLAND.								0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					180	184		10.1136/bmj.309.6948.180	http://dx.doi.org/10.1136/bmj.309.6948.180			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044099	Green Published			2022-12-28	WOS:A1994NY22900027
J	STEIN, DS; GRAHAM, NMH; PARK, LP; HOOVER, DR; PHAIR, JP; DETELS, R; HO, M; SAAH, AJ				STEIN, DS; GRAHAM, NMH; PARK, LP; HOOVER, DR; PHAIR, JP; DETELS, R; HO, M; SAAH, AJ			THE EFFECT OF THE INTERACTION OF ACYCLOVIR WITH ZIDOVUDINE ON PROGRESSION TO AIDS AND SURVIVAL - ANALYSIS OF DATA IN THE MULTICENTER AIDS COHORT STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; DOSE ZIDOVUDINE; CLINICAL COURSE; HOMOSEXUAL MEN; INFECTION; COMPLEX; HIV-1; PREVALENCE; EFFICACY	Objective: To examine the effect of acyclovir use on disease progression and survival in human immunodeficiency virus (HIV)-seropositive persons treated with zidovudine. Setting: Four university-based or -affiliated clinics. Design: Prospective cohort study of homosexual and bisexual men with semi-annual follow-up. Intent-to-treat Cox models were fit to determine the relation between the use of acyclovir (modeled as a time-dependent covariate) and disease progression, controlling for baseline and time-dependent clinical and laboratory prognostic variables. The acquired immunodeficiency syndrome (AIDS)-free duration and survival time were calculated from the first use of zidovudine. Analysis included study visits 7 to 17 (from 1987 to 1992). Patients: 786 HIV-seropositive participants in the Multicenter AIDS Cohort Study who began zidovudine therapy before a clinical diagnosis of AIDS; of these, 515 subsequently received acyclovir. Participants were asked at each visit whether they had ''used any medication for health reasons not related to AIDS or if they had taken any medication to help fight AIDS or the HIV virus''; 488 patients indicated acyclovir use under either or both questions, and 242 patients indicated only the latter use. Results: The use of acyclovir for any indication was not associated with an effect on progression to AIDS but was associated with a 26% decrease in the risk for death (relative hazard, 0.74; P = 0.07). The use of acyclovir for HIV infection was also not associated with an effect on progression to AIDS but was associated with a 36% decrease in the risk for death (relative hazard, 0.64; P = 0.01). To further investigate these findings, we examined dose, constancy, and timing of acyclovir use. The median daily dose of acyclovir used for HIV infection was between 600 and 800 mg. No apparent dose effect on survival was found. Longer uninterrupted use of acyclovir for any indication was associated with an 18% decrease in the risk for death for three or more consecutive visits (relative hazard, 0.82; P = 0.23), a 28% decrease for four or more consecutive visits (relative hazard, 0.72; P = 0.09), and a 7% decrease per visit based on the cumulative number of visits while the patient received acyclovir (relative hazard, 0.93 per visit increase; P = 0.03). Use of acyclovir for any indication and use of acyclovir for HIV infection were each associated with a 44% decreased probability of death if the drug was used after AIDS developed (P = 0.007 and P = 0.005, respectively) but not before. To further investigate the prolongation of survival, two landmark analyses were done. The first analysis began at a landmark of 1 year after initiation of zidovudine therapy and compared three groups of patients: those who used acyclovir at or before this landmark, those who had never started acyclovir or started the drug after the landmark, and those who had never used acyclovir. The 90% survival times were 1325, 1059, and 982 days, respectively. The second analysis began at a landmark of developing either a CD4 count less than 50 cells/mu L or clinical AIDS. The 90% survival times for the three groups were 398, 261,and 176 days, respectively.	NIAID, BETHESDA, MD USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; NORTHWESTERN UNIV, CHICAGO, IL USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA USA; UNIV PITTSBURGH, PITTSBURGH, PA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins University; Northwestern University; University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NIAID NIH HHS [UO1-AI-35040, UO1-AI-35039, UO1-AI-35041] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035041, U01AI035040, U01AI035039] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS D, 1993, AIDS HIV TREATMENT D, P5; ALDHOUS P, 1992, NATURE, V355, P102; BONETTI A, 1989, ANN INTERN MED, V111, P293, DOI 10.7326/0003-4819-111-4-293; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; COOPER DA, 1993, AIDS, V7, P197, DOI 10.1097/00002030-199302000-00007; COOPER DA, 1991, AIDS, V5, P933, DOI 10.1097/00002030-199108000-00003; DORSKY DI, 1987, ANN INTERN MED, V107, P859, DOI 10.7326/0003-4819-107-6-859; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; FIDDIAN AP, 1989, J INFECTION, V18, P79, DOI 10.1016/S0163-4453(89)80084-2; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; GOLDEN MP, 1992, J INFECT DIS, V166, P494, DOI 10.1093/infdis/166.3.494; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; HENG MCY, 1994, LANCET, V343, P255, DOI 10.1016/S0140-6736(94)91110-X; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; LAURENCE J, 1990, J INFECT DIS, V162, P338, DOI 10.1093/infdis/162.2.338; LAVELLE J, 1992, 8 INT C AIDS AMST; LONGINI IM, 1993, AM J EPIDEMIOL, V137, P1229, DOI 10.1093/oxfordjournals.aje.a116625; MANN SL, 1984, J INFECT DIS, V149, P1026, DOI 10.1093/infdis/149.6.1026; MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487; MITSUYA H, 1987, NATURE, V325, P773, DOI 10.1038/325773a0; MUNOZ A, 1993, AM J EPIDEMIOL, V137, P423, DOI 10.1093/oxfordjournals.aje.a116691; PEDERSEN C, 1992, AIDS, V6, P821, DOI 10.1097/00002030-199208000-00009; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; ROGERS MF, 1983, ANN INTERN MED, V99, P151, DOI 10.7326/0003-4819-99-2-151; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V268, P1702, DOI 10.1001/jama.268.13.1702; SMITH M S, 1991, Antiviral Chemistry and Chemotherapy, V2, P29; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; TARTAGLIONE TA, 1991, ANTIMICROB AGENTS CH, V35, P2225, DOI 10.1128/AAC.35.11.2225; WHITLEY RJ, 1992, NEW ENGL J MED, V327, P782; YOULE M, 1992, 8 INT C AIDS AMST; ZUCCONI SL, 1994, J ACQ IMMUN DEF SYND, V7, P607; 1987, MMWR MORBMORTAL S15, V36, pS3; 1991, SAS SOFTWARE VERSION; [No title captured]	37	77	77	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					100	108		10.7326/0003-4819-121-2-199407150-00004	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017721				2022-12-28	WOS:A1994NW18600004
J	TOYOSHIMA, H; HUNTER, T				TOYOSHIMA, H; HUNTER, T			P27, A NOVEL INHIBITOR OF G1 CYCLIN-CDK PROTEIN-KINASE ACTIVITY, IS RELATED TO P21	CELL			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; TGF-BETA; DEPENDENT KINASES; G(1); PHASE; PHOSPHORYLATION; PROLIFERATION; SUPPRESSION; FIBROBLASTS	Using a yeast interaction screen to search for proteins that interact with cyclin D1-Cdk4, we identified a 27 kDa mouse protein related to the p21 cyclin-Cdk inhibitor. p27 interacts strongly with D-type cyclins and Cdk4 in vitro and more weakly with cyclin E and Cdk2. In mouse fibroblasts, p27 is associated predominantly with cyclin D1-Cdk4. Recombinant p27 is a potent inhibitor of cyclin D1-Cdk4 and cyclin A-Cdk2 protein kinase activity and a weaker inhibitor of cyclin B1-Cdc2. Overexpression of p27 in Saos-2 cells causes G1 arrest. p27 protein levels do not change as serum-stimulated quiescent mouse fibroblasts progress through the cell cycle. p27 is identical to p27(Kip1), a cyclin-Cdk inhibitor present in TGF beta-treated cells. p27 has the hallmarks of a negative regulator of G1 progression and may mediate TGF beta-induced G1 arrest.			TOYOSHIMA, H (corresponding author), SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA39780, CA14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	1959	2042	0	61	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					67	74		10.1016/0092-8674(94)90573-8	http://dx.doi.org/10.1016/0092-8674(94)90573-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033213				2022-12-28	WOS:A1994NX32800009
J	COTE, J; QUINN, J; WORKMAN, JL; PETERSON, CL				COTE, J; QUINN, J; WORKMAN, JL; PETERSON, CL			STIMULATION OF GAL4 DERIVATIVE BINDING TO NUCLEOSOMAL DNA BY THE YEAST SWI/SNF COMPLEX	SCIENCE			English	Article							TRANSCRIPTION FACTOR ACCESS; XENOPUS-LAEVIS OOCYTES; TUMOR VIRUS PROMOTER; SACCHAROMYCES-CEREVISIAE; ASSEMBLY INVITRO; GLUCOCORTICOID RECEPTOR; HISTONE COMPLEXES; GENES; PROTEINS; ACTIVATORS	The SWI/SNF protein complex is required for the enhancement of transcription by many transcriptional activators in yeast. Here it is shown that the purified SWI/SNF complex is composed of 10 subunits and includes the SWI1, SW12/SNF2, SWI3, SNF5, and SNF6 gene products. The complex exhibited DNA-stimulated adenosine triphosphatase (ATPase) activity, but lacked helicase activity. The SWI/SNF complex caused a 10- to 30-fold stimulation in the binding of GAL4 derivatives to nucleosomal DNA in a reaction that required adenosine triphosphate (ATP) hydrolysis but was activation domain-independent. Stimulation of GAL4 binding by the complex was abolished by a mutant SWI2 subunit, and was increased by the presence of a histone-binding protein, nucleoplasmin. A direct ATP-dependent interaction between the SWI/SNF complex and nucleosomal DNA was detected. These observations suggest that a primary role of the SWI/SNF complex is to promote activator binding to nucleosomal DNA.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA; PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, University Pk, PA 16802 USA; PENN STATE UNIV, CTR GENE REGULAT, University Pk, PA 16802 USA; UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Massachusetts System; University of Massachusetts Worcester			Cote, Jacques/I-8901-2014; Quinn, Janet/AAR-9957-2021	Cote, Jacques/0000-0001-6751-555X; 	NIGMS NIH HHS [R37 GM049650, GM49650-01, R01 GM049650, GM47867-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049650, R37GM047867, R01GM047867, R37GM049650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; COTE J, 1991, MOL CELL BIOL, V11, P655; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; FINLEY RL, 1990, MOL CELL BIOL, V10, P5663, DOI 10.1128/MCB.10.11.5663; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; JUAN LJ, IN PRESS COLD SPRING; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KLADDE MP, 1994, P NATL ACAD SCI USA, V91, P1361, DOI 10.1073/pnas.91.4.1361; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KRUGER W, UNPUB; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LI BY, 1994, J BIOL CHEM, V269, P7756; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; Maxam A M, 1980, Methods Enzymol, V65, P499; MCMURRAY CT, 1986, P NATL ACAD SCI USA, V83, P8472, DOI 10.1073/pnas.83.22.8472; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PETERSON C, UNPUB; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RANDAZZO FM, 1994, DEV BIOL, V161, P229, DOI 10.1006/dbio.1994.1023; RHODES D, 1989, METHOD ENZYMOL, V170, P575; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SEALY L, 1989, METHOD ENZYMOL, V170, P612; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	57	728	740	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	1994	265	5168					53	60		10.1126/science.8016655	http://dx.doi.org/10.1126/science.8016655			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016655				2022-12-28	WOS:A1994NV30100024
J	GONCZY, P; THOMAS, BJ; DINARDO, S				GONCZY, P; THOMAS, BJ; DINARDO, S			ROUGHEX IS A DOSE-DEPENDENT REGULATOR OF THE 2ND MEIOTIC DIVISION DURING DROSOPHILA SPERMATOGENESIS	CELL			English	Article							MATURATION-PROMOTING FACTOR; CDC2 PROTEIN-KINASE; CELL-CYCLE; M-PHASE; FISSION YEAST; TYROSINE PHOSPHORYLATION; ACTIVATES P34CDC2; STERILE MUTATIONS; GENETIC-ANALYSIS; MITOTIC CONTROL	During spermatogenesis, germ cells execute two meiotic divisions, then withdraw from the cell cycle and initiate postmeiotic differentiation. We show that the gene roughex (rux) is a dose-dependent regulator of meiosis II during Drosophila spermatogenesis. rux mutant germ cells execute the two meiotic divisions, but then undergo an additional M phase resembling an extra meiosis II. Conversely, germ cells with excess rux function fail to undergo meiosis II. rux does not appear to act directly at meiosis II. Rather, rux appears to act through cyclin A during premeiotic G2 to regulate meiosis II. We propose that cyclin A-cdc2 kinase at the G2 to M transition of meiosis I activates a target necessary for meiosis II, thereby coupling the two meiotic divisions.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	GONCZY, P (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.			Gonczy, Pierre/0000-0002-6305-6883; DiNardo, Stephen/0000-0003-4131-5511				ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BONACCORSI S, 1988, GENETICS, V120, P1015; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CASTRILLON DH, 1993, GENETICS, V135, P489; Cooper KW, 1950, BIOL DROSOPHILA, P1; COURTOT C, 1992, DEVELOPMENT, V116, P405; DOREE M, 1983, DEV BIOL, V99, P489, DOI 10.1016/0012-1606(83)90298-1; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FERELL JE, 1991, MOL CELL BIOL, V11, P1965; FRITZNIGGLI H, 1972, CYTOBIOLOGIE, V5, P12; FULLER MT, 1993, DEV DROSOPHILA MELAN, V1, P71; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; GONCZY P, 1992, DEVELOPMENT, V114, P89; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HACKSTEIN JHP, 1991, EUR J CELL BIOL, V56, P151; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HUNT T, 1993, CELL CYCLE, P167; KEMPHUES KJ, 1982, CELL, V31, P655, DOI 10.1016/0092-8674(82)90321-X; Kimble J, 1988, NEMATODE CAENORHABDI, P191; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LIFSCHYTZ E, 1977, DEV BIOL, V58, P276, DOI 10.1016/0012-1606(77)90092-6; LIFSCHYTZ E, 1977, CHROMOSOMA, V64, P371, DOI 10.1007/BF00294944; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RONCHI E, 1993, CELL, V74, P347, DOI 10.1016/0092-8674(93)90425-P; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHUPBACH T, 1991, GENETICS, V129, P1119; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STERN B, 1993, DEVELOPMENT, V117, P219; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Tates AD, 1971, THESIS RIJKSUNIVERSI; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; WHITECOOPER H, 1993, J CELL SCI, V106, P1035; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	75	49	50	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1015	1025		10.1016/0092-8674(94)90441-3	http://dx.doi.org/10.1016/0092-8674(94)90441-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020092				2022-12-28	WOS:A1994NV42500010
J	HO, MF; CHELLY, J; CARTER, N; DANEK, A; CROCKER, P; MONACO, AP				HO, MF; CHELLY, J; CARTER, N; DANEK, A; CROCKER, P; MONACO, AP			ISOLATION OF THE GENE FOR MCLEOD SYNDROME THAT ENCODES A NOVEL MEMBRANE-TRANSPORT PROTEIN	CELL			English	Article							BLOOD-GROUP SYSTEM; AMINO-ACID TRANSPORTER; X-LINKED MYOPATHY; GLUTAMATE TRANSPORTER; MUSCULAR-DYSTROPHY; RAT-BRAIN; EXPRESSION; CLONING; DNA; PHENOTYPE	Mcleod syndrome is an X-linked multisystem disorder characterized by abnormalities in the neuromuscular and hematopoietic systems. We have assembled a cosmid contig of 360 kb that encompasses the McLeod gene locus. A 50 kb deletion was detected by screening DNA from patients with radiolabeled whole cosmids, and two transcription units were identified within this deletion. The mRNA expression pattern of one of them, designated as XK, correlates closely to the McLeod phenotype. XK encodes a novel protein with structural characteristics of prokaryotic and eukaryotic membrane transport proteins. Nucleotide sequence analysis of XK from two unrelated McLeod patients has identified point mutations at conserved splice donor and acceptor sites. These findings provide direct evidence that XK is responsible for McLeod syndrome.	UNIV LONDON ST GEORGES HOSP, SCH MED, MED GENET UNIT, LONDON SW17 0RE, ENGLAND; UNIV MUNICH, NEUROL KLIN, D-81366 MUNICH 70, GERMANY	St Georges University London; University of Munich	HO, MF (corresponding author), JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND, OXFORD OX3 9DU, ENGLAND.		Monaco, Anthony P/A-4495-2010; Chelly, Jamel/J-7528-2015; Danek, Adrian/G-7339-2011	Monaco, Anthony P/0000-0001-7480-3197; Chelly, Jamel/0000-0002-0939-8719; Danek, Adrian/0000-0001-8857-5383; Crocker, Paul/0000-0001-6230-0293				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; BERTELSON CJ, 1986, AM J HUM GENET, V423, P703; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BRADLEY WG, 1978, NEUROLOGY, V28, P670, DOI 10.1212/WNL.28.7.670; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CALLENDER R, 1977, ANNU REV BIOPHYS BIO, V6, P33, DOI 10.1146/annurev.bb.06.060177.000341; CARPENTER S, 1979, BRAIN, V102, P147, DOI 10.1093/brain/102.1.147; CARTER ND, 1990, J MED GENET, V27, P345, DOI 10.1136/jmg.27.6.345; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE WG, 1990, J BIOL CHEM, V265, P17070; COULSON AFW, 1987, COMPUT J, V30, P420, DOI 10.1093/comjnl/30.5.420; DANEK A, 1994, NEUROLOGY, V44, P117, DOI 10.1212/WNL.44.1.117; DANEK A, 1990, ANN NEUROL, V28, P720, DOI 10.1002/ana.410280521; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GALEY WR, 1978, VOX SANG, V34, P152, DOI 10.1111/j.1423-0410.1978.tb02458.x; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HARDIE RJ, 1989, Q J MED, V71, P291; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HATA A, 1988, J BIOCHEM-TOKYO, V103, P302, DOI 10.1093/oxfordjournals.jbchem.a122265; HO MF, 1991, J HUM GENET, V50, P317; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KABACK HR, 1987, BIOCHEMISTRY-US, V26, P2071, DOI 10.1021/bi00382a001; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIRK K, 1994, J BIOL CHEM, V269, P3339; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUYPERS FA, 1985, FEBS LETT, V184, P20, DOI 10.1016/0014-5793(85)80644-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LEE S, 1993, BLOOD, V81, P2804; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; LEMOINE C, 1990, P NATL ACAD SCI USA, V87, P230, DOI 10.1073/pnas.87.1.230; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Marsh W L, 1987, Transfus Med Rev, V1, P4; MARSH WL, 1981, VOX SANG, V40, P403, DOI 10.1111/j.1423-0410.1981.tb00728.x; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; ORKIN SH, 1984, ANNU REV GENET, V18, P131; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIINES G, 1992, NATURE, V360, P464; REDMAN CM, 1986, J BIOL CHEM, V261, P9521; REDMAN CM, 1988, BRIT J HAEMATOL, V68, P131, DOI 10.1111/j.1365-2141.1988.tb04191.x; REDMAN CM, 1993, SEMIN HEMATOL, V30, P209; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STECK TL, 1989, CELL SHAPE DETERMINA; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; SWASH M, 1983, BRAIN, V106, P717, DOI 10.1093/brain/106.3.717; SYMMANS WA, 1979, BRIT J HAEMATOL, V42, P575, DOI 10.1111/j.1365-2141.1979.tb01170.x; TREISMAN R, 1982, CELL, V29, P90; UHL GR, 1992, TRENDS PHARMACOL SCI, V13, P421, DOI 10.1016/0165-6147(92)90133-Q; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; VANHEIJNE G, 1986, EMBO J, V6, P3021; WEIL D, 1988, J BIOL CHEM, V263, P8561; WEXLER NS, 1991, ANNU REV NEUROSCI, V14, P503, DOI 10.1146/annurev.neuro.14.1.503; WIMER BM, 1977, BRIT J HAEMATOL, V36, P219, DOI 10.1111/j.1365-2141.1977.tb00642.x; WITT TN, 1992, J NEUROL, V239, P302, DOI 10.1007/BF00867584; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	76	197	208	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					869	880		10.1016/0092-8674(94)90136-8	http://dx.doi.org/10.1016/0092-8674(94)90136-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004674				2022-12-28	WOS:A1994NT33100012
J	COHEN, TJ; GOLDNER, BG; MACCARO, PC; ARDITO, AP; TRAZZERA, S; COHEN, MB; DIBS, SR				COHEN, TJ; GOLDNER, BG; MACCARO, PC; ARDITO, AP; TRAZZERA, S; COHEN, MB; DIBS, SR			A COMPARISON OF ACTIVE COMPRESSION-DECOMPRESSION CARDIOPULMONARY-RESUSCITATION WITH STANDARD CARDIOPULMONARY-RESUSCITATION FOR CARDIAC ARRESTS OCCURRING IN THE HOSPITAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURVIVAL; CHEST; DOGS; COMA; VEST; CPR	Background. Recent studies have demonstrated improved cardiopulmonary circulation during cardiac arrest with the use of a hand-held suction device (Ambu CardioPump) to perform active compression-decompression cardiopulmonary resuscitation (CPR). The purpose of this study was to compare active compression-decompression with standard CPR during cardiac arrests in hospitalized patients. Methods. All patients over the age of 18 years who had a witnessed cardiac arrest while hospitalized at our center were enrolled in this trial; they were randomly assigned according to their medical-record numbers to receive either active compression-decompression or standard CPR. The study end points were the rates of initial resuscitation, survival at 24 hours, hospital discharge, and neurologic outcome. Compressions were performed according to the recommendations of the American Heart Association (80 to 100 compressions per minute; depth of compression, 3.8 to 5.1 cm [1.5 to 2 in.]; and 50 percent of the cycle spent in compression). Results. Sixty-two patients (45 men and 17 women) with a mean age (+/-SE) of 68+/-2 years were entered into the trial. Sixty-two percent of the patients who underwent active compression-decompression were initially resuscitated, as compared with 30 percent of the patients who received standard CPR (P<0.03); 45 percent of the patients who underwent active compression-decompression survived for at least 24 hours, as compared with 9 percent of patients who underwent standard CPR (P<0.004). Two of the 62 study patients survived to hospital discharge; both were randomly assigned to receive active compression-decompression. Neurologic outcome, as measured by the Glasgow coma score, was better with active compression-decompression (8.0+/-1.3) than with standard CPR (3.5+/-0.3; P<0.02). Conclusions. In this preliminary study, we found that, as compared with standard CPR, active compression-decompression CPR improved the rate of initial resuscitation, survival at 24 hours, and neurologic outcome after in-hospital cardiac arrest. Larger trials will be required to assess the potential benefit in terms of long-term survival.			COHEN, TJ (corresponding author), N SHORE UNIV HOSP, CORNELL UNIV MED COLL, DEPT MED, ELECTROPHYSIOL SECT, MANHASSET, NY 11030 USA.							BIRCHER N, 1980, CRIT CARE MED, V8, P147, DOI 10.1097/00003246-198003000-00012; COHEN TJ, 1992, JAMA-J AM MED ASSOC, V267, P2916, DOI 10.1001/jama.267.21.2916; COHEN TJ, 1992, AM HEART J, V124, P1145, DOI 10.1016/0002-8703(92)90393-A; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; FEINSTEIN AR, 1977, CLIN BIOSTATISTICS; FENELEY MP, 1988, CIRCULATION, V77, P240, DOI 10.1161/01.CIR.77.1.240; HALPERIN HR, 1993, NEW ENGL J MED, V329, P762, DOI 10.1056/NEJM199309093291104; HALPERIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2940, DOI 10.1001/jama.267.21.2940; HALPERIN HR, 1986, CIRCULATION, V74, P1407, DOI 10.1161/01.CIR.74.6.1407; KERN KB, 1985, CRIT CARE MED, V13, P899, DOI 10.1097/00003246-198511000-00009; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; LINDNER KH, 1993, CIRCULATION, V88, P1254, DOI 10.1161/01.CIR.88.3.1254; MAIER GW, 1986, CIRCULATION, V74, P51; MULLIE A, 1988, LANCET, V1, P137; RUBEN H, 1966, ACTA ANAESTH SCAND, V10, P31, DOI 10.1111/j.1399-6576.1966.tb00329.x; SACK J B, 1992, Journal of the American Medical Association, V267, P379, DOI 10.1001/jama.267.3.379; SACK JB, 1992, CIRCULATION, V86, P1692, DOI 10.1161/01.CIR.86.6.1692; SHULTZ JJ, 1992, CIRCULATION, V86, P234; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TEASDALE G, 1974, LANCET, V2, P81; TORTOLANI AJ, 1990, RESUSCITATION, V20, P115, DOI 10.1016/0300-9572(90)90047-I; TSITLIK JE, 1983, CRIT CARE MED, V11, P685, DOI 10.1097/00003246-198309000-00003; TUCKER KJ, 1993, J AM COLL CARDIOL, V22, P1485, DOI 10.1016/0735-1097(93)90561-E; URBERG M, 1987, J FAM PRACTICE, V25, P41	24	111	111	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1918	1921		10.1056/NEJM199312233292603	http://dx.doi.org/10.1056/NEJM199312233292603			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM885	8018138				2022-12-28	WOS:A1993MM88500003
J	HOSODA, K; HAMMER, RE; RICHARDSON, JA; BAYNASH, AG; CHEUNG, JC; GIAID, A; YANAGISAWA, M				HOSODA, K; HAMMER, RE; RICHARDSON, JA; BAYNASH, AG; CHEUNG, JC; GIAID, A; YANAGISAWA, M			TARGETED AND NATURAL (PIEBALD-LETHAL) MUTATIONS OF ENDOTHELIN-B RECEPTOR GENE PRODUCE MEGACOLON ASSOCIATED WITH SPOTTED COAT COLOR IN MICE	CELL			English	Article							HIRSCHSPRUNGS-DISEASE; AGANGLIONIC MEGACOLON; NERVOUS-SYSTEM; BINDING-SITES; NEURAL CREST; DELETION; CLONING; PROTEIN; LIGAND; IRIDES	Endothelins act on two subtypes of G protein-coupled receptors, termed endothelin-A and endothelin-B receptors. We report a targeted disruption of the mouse endothelin-B receptor (EDNRB) gene that results in aganglionic megacolon associated with coat color spotting, resembling a hereditary syndrome of mice, humans, and other mammalian species. Piebald-lethal (s') mice exhibit a recessive phenotype identical to that of the EDNRB knockout mice. In crossbreeding studies, the two mutations show no complementation. Southern blotting revealed a deletion encompassing the entire EDNRB gene in the s(1) chromosome. A milder allele, piebald (s), which produces coat color spotting only, expresses low levels of structurally intact EDNRB mRNA and protein. These findings indicate an essential role for EDNRB in the development of two neural crest-derived cell lineages, myenteric ganglion neurons and epidermal melanocytes. We postulate that defects in the human EDNRB gene cause a hereditary form of Hirschsprung's disease that has recently been mapped to human chromosome 13, in which EDNRB is located.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235; MONTREAL GEN HOSP,DEPT PATHOL,MONTREAL,PQ H3G 1A4,CANADA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; McGill University	HOSODA, K (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.			Hammer, Robert E./0000-0001-5487-7551				ANDERSON DJ, 1994, FASEB J, V8, P707, DOI 10.1096/fasebj.8.10.8050669; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAI H, 1993, J BIOL CHEM, V268, P3463; BAYNASH AG, 1994, CELL, V79; BOLGER GT, 1990, J CARDIOVASC PHARM, V16, P367, DOI 10.1097/00005344-199009000-00004; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; DEOL MS, 1967, J EMBRYOL EXP MORPH, V17, P535; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; IKADAI H, 1979, Congenital Anomalies, V19, P31; INAGAKI H, 1991, GASTROENTEROLOGY, V101, P47, DOI 10.1016/0016-5085(91)90458-W; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JACKSON IJ, 1991, BIOESSAYS, V13, P439, DOI 10.1002/bies.950130903; KAPUR RP, 1992, DEVELOPMENT, V116, P167; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LAMONT MA, 1989, J MED GENET, V26, P100, DOI 10.1136/jmg.26.2.100; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; LIANG JC, 1983, ARCH OPHTHALMOL-CHIC, V101, P69, DOI 10.1001/archopht.1983.01040010071011; LYON MF, 1988, GENETIC VARIANTS STR; MAYER TC, 1977, DEV BIOL, V56, P255, DOI 10.1016/0012-1606(77)90268-8; MCCABE L, 1990, AM J MED GENET, V36, P336, DOI 10.1002/ajmg.1320360319; METALLINOS DL, 1994, GENETICS, V136, P217; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; PUFFENBERGER EG, 1994, CELL, V79; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHAH KN, 1981, J PEDIATR-US, V99, P432, DOI 10.1016/S0022-3476(81)80339-3; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; STEEL KP, 1992, DEVELOPMENT, V115, P1111; WEBSTER W, 1973, J EMBRYOL EXP MORPH, V30, P573; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YADA Y, 1991, J BIOL CHEM, V266, P18352; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320; YOHN JJ, 1994, BIOCHEM BIOPH RES CO, V201, P449, DOI 10.1006/bbrc.1994.1722; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	48	805	836	0	27	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1267	1276		10.1016/0092-8674(94)90017-5	http://dx.doi.org/10.1016/0092-8674(94)90017-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001159				2022-12-28	WOS:A1994PZ86000017
J	BASOGLU, M; PAKER, M; OZMEN, E; TASDEMIR, O; SAHIN, D				BASOGLU, M; PAKER, M; OZMEN, E; TASDEMIR, O; SAHIN, D			FACTORS RELATED TO LONG-TERM TRAUMATIC STRESS RESPONSES IN SURVIVORS OF TORTURE IN TURKEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORLD-WAR-II; VIETNAM VETERANS; COMBAT VETERANS; FOLLOW-UP; DISORDER; PRISONERS; PSYCHOPATHOLOGY; EXPERIENCE; DIAGNOSES; SAMPLE	Objective.-To examine factors related to long-term psychological functioning in political ex-prisoners who had been subjected to systematic torture. Design.-The psychological status of 55 tortured political activists, 55 nontortured political activists, and 55 subjects with no history of torture or political activism was assessed using Structured Clinical Interview for DSM-III for psychiatric assessment, Semi-structured Interview for Survivors of Torture, and other self-rated and assessor-rated measures of anxiety, depression, and posttraumatic stress disorder (PTSD). Correlational and multiple regression analyses were used to assess the independent effects of precaptivity, captivity, and postcaptivity variables as predictors of long-term psychological status among the torture survivors. Setting.-Istanbul, Turkey. Main Outcome Measures.-Number of lifetime and current PTSD symptoms, and scores on the Beck Depression Inventory, Hamilton Depression Rating, Hamilton Anxiety Scale, and State-Trait Anxiety Inventory. Results.-Effect of captivity experience on various life areas leg, family and social, economic, and employment status) and other postcaptivity psychosocial stressors were associated with PTSD symptoms, anxiety, and depression. Perceived severity of torture was related to PTSD symptoms but not to anxiety or depression. Lack of social support predicted anxiety and depression but not PTSD. Family history of psychiatric illness correlated with higher scores on most measures. Impact of captivity experience on family was the strongest predictor of PTSD symptoms. Conclusions.-These findings point to three types of stressors related to different aspects of psychopathology in survivors of torture: perceived severity of torture, secondary effects of captivity experience on various life areas, and general psychosocial stressors following captivity. Different interventions may be needed for three components of survivors' traumatic experience: cognitive and behavioral strategies for treatment of PTSD symptoms, marital or family strategies for minimizing the impact of the trauma on the family, and strategies for enhancing social support to minimize postcaptivity depression and anxiety.	NEW SCH SOCIAL RES,NEW YORK,NY; BAKIRKOY PSYCHIAT HOSP,ISTANBUL,TURKEY; UNIV ISTANBUL,DEPT PSYCHIAT,ISTANBUL,TURKEY	The New School; Istanbul Bakirkoy Mental Health & Neurology Training & Research Hospital; Istanbul University	BASOGLU, M (corresponding author), UNIV LONDON,INST PSYCHIAT,99 DENMARK HILL,LONDON SE5 8AF,ENGLAND.		Basoglu, Metin/A-1394-2008	Paker, Salih Murat/0000-0001-9203-7609				BASOGLU M, 1993, JAMA-J AM MED ASSOC, V270, P606, DOI 10.1001/jama.270.5.606; BASOGLU M, 1994, AM J PSYCHIAT, V151, P76; Basoglu M., 1992, TORTURE ITS CONSEQUE, P182; Basoglu M., 1992, TORTURE ITS CONSEQUE, P402; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BEEBE GW, 1975, AM J EPIDEMIOL, V101, P400, DOI 10.1093/oxfordjournals.aje.a112108; BRESLAU N, 1987, AM J PSYCHIAT, V144, P578; ENGDAHL BE, 1991, J NERV MENT DIS, V179, P181, DOI 10.1097/00005053-199104000-00001; FOA EB, 1989, BEHAV THER, V20, P155, DOI 10.1016/S0005-7894(89)80067-X; FOY DW, 1987, J CLIN PSYCHOL, V43, P28, DOI 10.1002/1097-4679(198701)43:1<28::AID-JCLP2270430105>3.0.CO;2-J; FOY DW, 1984, J CONSULT CLIN PSYCH, V52, P70; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; GREEN BL, 1990, AM J PSYCHIAT, V147, P729; HAMILTON M, 1969, PSYCHIAT NEUROL NEUR, V72, P201; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Hisli, 1998, TURKISH J PSYCHOL, V6, P118; HYER L, 1988, PSYCHOL REP, V63, P271, DOI 10.2466/pr0.1988.63.1.271; Keane T. M., 1992, TORTURE ITS CONSEQUE, P363; KEANE TM, 1985, J CONSULT CLIN PSYCH, V53, P95, DOI 10.1037/0022-006X.53.1.95; KLONOFF H, 1976, J NERV MENT DIS, V163, P246, DOI 10.1097/00005053-197610000-00003; KLUZNIK JC, 1986, AM J PSYCHIAT, V143, P1443; KRAL VA, 1967, CAN PSYCHIAT ASSOC J, V12, P175, DOI 10.1177/070674376701200210; LAUFER RS, 1984, J HEALTH SOC BEHAV, V25, P65, DOI 10.2307/2136705; MILLER TW, 1989, COMPR PSYCHIAT, V30, P139, DOI 10.1016/0010-440X(89)90066-7; Mineka S, 1989, STRESS PERSONAL CONT; MOLLICA RF, 1992, TORTURE ITS CONSEQUE, P253; ONER N, 1982, STATE TRAIT ANXIETY; ROBERT JA, 1985, J PERS ASSESS, V49, P226, DOI 10.1207/s15327752jpa4903_1; Saporta Jose A., 1992, TORTURE ITS CONSEQUE, P151; SHERWOOD RJ, 1990, PSYCHOL REP, V66, P623, DOI 10.2466/PR0.66.2.623-631; SOLOMON Z, 1988, J ABNORM PSYCHOL, V97, P302, DOI 10.1037/0021-843X.97.3.302; SOMNIER FE, 1986, BRIT J PSYCHIAT, V149, P323, DOI 10.1192/bjp.149.3.323; SOUTHWICK SM, 1993, AM J PSYCHIAT, V150, P1020; SPEED N, 1989, J NERV MENT DIS, V177, P147, DOI 10.1097/00005053-198903000-00004; SPIELBERGER CD, 1970, MANUAL STAI; SPITZER RL, 1983, STRUCTURED CLIN INTE; SUTKER PB, 1993, AM J PSYCHIAT, V150, P240; 1987, DIAGNOSTIC STATISTIC	38	83	84	1	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					357	363		10.1001/jama.272.5.357	http://dx.doi.org/10.1001/jama.272.5.357			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NY903	8028166				2022-12-28	WOS:A1994NY90300027
J	NELLEN, D; AFFOLTER, M; BASLER, K				NELLEN, D; AFFOLTER, M; BASLER, K			RECEPTOR SERINE/THREONINE KINASES IMPLICATED IN THE CONTROL OF DROSOPHILA BODY PATTERN BY DECAPENTAPLEGIC	CELL			English	Article							TGF-BETA FAMILY; POSTERIOR COMPARTMENT BOUNDARY; DORSAL-VENTRAL PATTERN; POLARITY GENE HEDGEHOG; 2ND CHROMOSOME; GERM LAYERS; II RECEPTOR; CYTOGENETIC ANALYSIS; SPATIAL EXPRESSION; BICOID PROTEIN	Members of the TGF beta superfamily of secreted signaling molecules regulate growth and cellular patterning during development and interact with specific type I and type II membrane receptors possessing a cytoplasmic serine/threonine kinase domain. We describe two members of the type I receptor family in Drosophila and demonstrate that they are encoded by the genes saxophone (sax) and thick veins (tkv). Further, we show that mutations that abolish sex or tkv activity cause phenotypes similar to partial or complete loss of activity, respectively, of the TGF beta homolog decapentaplegic (dpp). We propose that specification of distinct cell fates in response to different concentrations of dpp may be achieved combinatorially by the sax and tkv receptors.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel				Basler, Konrad/0000-0003-3534-1529; Affolter, Markus/0000-0002-5171-0016				AFFOLTER M, 1993, DEVELOPMENT, V117, P1199; ARORA K, 1992, DEVELOPMENT, V114, P1003; ASHBURNER M, 1989, DROSOPHILA LABORATOR; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; CHASAN R, 1993, DEV DROSOPHILA MELAN, V1, P387; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DEFRUTOS R, 1990, METHODS MOL CELL BIO, V2, P32; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEITZLER P, 1993, GENETICS, V135, P105; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JURGENS G, 1986, ROUX ARCH DEV BIOL, V195, P359, DOI 10.1007/BF00402870; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAWRENCE PA, 1972, DEV SYSTEMS INSECTS, V2, P157; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; RAY RP, 1991, DEVELOPMENT, V113, P35; Rushlow C, 1990, Adv Genet, V27, P277; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUPBACH T, 1989, GENETICS, V121, P101; SEGAL D, 1985, GENETICS, V109, P119; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SZIDONYA J, 1988, GENET RES, V51, P197, DOI 10.1017/S0016672300024290; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TOROK T, 1993, GENETICS, V135, P71; WHARTON KA, 1993, DEVELOPMENT, V117, P807; Wieschaus E., 1986, P199; WINICK J, 1993, DEVELOPMENT, V119, P1055; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; XU T, 1993, DEVELOPMENT, V117, P1223	69	249	253	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					225	237		10.1016/0092-8674(94)90293-3	http://dx.doi.org/10.1016/0092-8674(94)90293-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044837	Green Accepted			2022-12-28	WOS:A1994NZ24200007
J	BODEN, G; MURER, E; MOZZOLI, M				BODEN, G; MURER, E; MOZZOLI, M			GLUCOSE-TRANSPORTER PROTEINS IN HUMAN INSULINOMA	ANNALS OF INTERNAL MEDICINE			English	Article							BETA-CELL LINE; GENE-EXPRESSION; MESSENGER-RNA; RAT; SEQUENCE; LIVER	Objective: To determine the reason patients with insulinoma are unable to cease insulin secretion during hypoglycemia. Patients: Five patients with insulinoma. Design: All patients fasted for up to 25 hours, during which blood was obtained serially for determination of glucose and insulin concentrations. Insulinomas were surgically removed from all patients and Glut 1 and Glut 2 transporter proteins were measured in solubilized tumor membranes by immune blotting. Results: in all patients, serum insulin concentrations failed to decrease to less than 30.0 pmol/L (<5.0 mu U/mL) and C-peptide concentrations to less than 0.08 nmol/L during hypoglycemia (glucose concentration, <2.2 mmol/L) that was induced by fasting. The islet cell tumors from all five patients contained Glut 1, a low-K-m glucose transporter protein, which is not normally present in beta-cells. Glut 2, a high-K-m glucose transporter protein, which is normally prevalent in beta-cells, was undetectable in one patient and was present in what appeared to be low concentrations in the remaining four patients. Conclusions: Our data are compatible with the concept that continued glucose transport, mediated by the low-K-m Glut 1 glucose transporter, was responsible for continued insulin release during hypoglycemia in these patients.			BODEN, G (corresponding author), TEMPLE UNIV HOSP & MED SCH, 3401 N BROAD ST, PHILADELPHIA, PA 19140 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007988] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00349] Funding Source: Medline; NIA NIH HHS [R01 AG-07988] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BODEN G, 1989, GASTROENTEROL CLIN N, V18, P831; CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; GERSGIBU, 1990, METHOD BIOCHEM ANAL, V33, P1; GORUS FK, 1984, J BIOL CHEM, V259, P1196; HARRIS V, 1979, METHOD HORM RADIOIMM, P643; INAGAKI N, 1992, DIABETES, V41, P592, DOI 10.2337/diabetes.41.5.592; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; ORCI L, 1989, SCIENCE, V245, P295, DOI 10.1126/science.2665080; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RASTOGI GK, 1970, DIABETOLOGIA, V6, P445, DOI 10.1007/BF01212080; SALTIS J, 1991, J BIOL CHEM, V266, P261; SEINO Y, 1993, J CLIN ENDOCR METAB, V76, P75, DOI 10.1210/jc.76.1.75; SOELDNER JS, 1965, DIABETES, V14, P771, DOI 10.2337/diab.14.12.771; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; YASUNAMI Y, 1987, J CLIN ENDOCR METAB, V65, P110, DOI 10.1210/jcem-65-1-110	24	31	34	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					109	112		10.7326/0003-4819-121-2-199407150-00005	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017722				2022-12-28	WOS:A1994NW18600005
J	ONEILL, EM; REBAY, I; TJIAN, R; RUBIN, GM				ONEILL, EM; REBAY, I; TJIAN, R; RUBIN, GM			THE ACTIVITIES OF 2 ETS-RELATED TRANSCRIPTION FACTORS REQUIRED FOR DROSOPHILA EYE DEVELOPMENT ARE MODULATED BY THE RAS/MAPK PATHWAY	CELL			English	Article							ACTIVATED PROTEIN-KINASE; SUBSTRATE RECOGNITION; TYROSINE KINASE; DOMAIN PROTEIN; GENE; PHOSPHORYLATION; RAS1; IDENTIFICATION; PHOTORECEPTOR; EXPRESSION	We show that the activities of two Ets-related transcription factors required for normal eye development in Drosophila, pointed and yan, are regulated by the Ras1/MAPK pathway. The pointed gene codes for two related proteins, and we show that one form is a constitutive activator of transcription, while the activity of the other form is stimulated by the Ras1/MAPK pathway. Mutation of the single consensus MARK phosphorylation site in the second form abrogates this responsiveness. yan is a negative regulator of photoreceptor determination, and genetic data suggest that it acts as an antagonist of Ras1. We demonstrate that yan can repress transcription and that this repression activity is negatively regulated by the Ras1/MAPK signal, most likely through direct phosphorylation of yan by MAPK.			ONEILL, EM (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033135, R37GM033135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KARPEN GH, 1992, GENETICS, V132, P737; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELNICK MB, 1993, DEVELOPMENT, V118, P127; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ONEILL EM, 1994, THESIS U CALIFORNIA; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHOLZ H, 1993, GENETICS, V135, P455; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; XU T, 1993, DEVELOPMENT, V117, P1223; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	39	584	590	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					137	147		10.1016/0092-8674(94)90580-0	http://dx.doi.org/10.1016/0092-8674(94)90580-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033205				2022-12-28	WOS:A1994NX32800016
J	JUSTICE, AC; BERLIN, JA; FLETCHER, SW; FLETCHER, RH; GOODMAN, SN				JUSTICE, AC; BERLIN, JA; FLETCHER, SW; FLETCHER, RH; GOODMAN, SN			DO READERS AND PEER REVIEWERS AGREE ON MANUSCRIPT QUALITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC			Objective.-To study readers' judgments of manuscript quality and the degree to which readers agreed with peer reviewers. Design.-Cross-sectional study. Setting.-Annals of Internal Medicine. Subjects.-One hundred thirteen consecutive manuscripts reporting original research and selected for publication. Each of two manuscript versions (one before and one after revision) was judged by two readers, randomly sampled from those who said (based on the title) that they would read the article; one peer reviewer (peer), chosen in the usual way for Annals; and one expert in clinical research methods (expert). Each judge completed an instrument that included a 10-point subjective summary grade of manuscript quality. Main Outcome Measures.-Agreement on the 10-point summary grade of manuscript quality between reader-expert, reader-peer, and reader-reader. Results.-Readers and peers gave high grades (77% and 73% gave a grade of 5 or better, respectively), while experts were more critical (52% gave a grade of 5 or better; P<.0001). Agreement was relatively high among judge groups (in all cases, >69%) but agreement beyond chance was poor (kappa<0.04). One third of readers (33%) thought that the manuscript had little relevance to their work. Conclusion.-Readers, like most peer reviewers, are generally satisfied with the quality of manuscripts but would like research articles to be more relevant to their clinical practice.	UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; ANNALS INTERNAL MED,EDITORIAL OFF,PHILADELPHIA,PA; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	University of Pennsylvania; Johns Hopkins University	JUSTICE, AC (corresponding author), UNIV PENN,MED CTR,CTR CLIN EPIDEMIOL & BIOSTAT,420 SERV DR,FLOOR 2L,NURSING EDUC BLDG,PHILADELPHIA,PA 19104, USA.			Goodman, Steven/0000-0002-3872-5723				GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18	2	40	41	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					117	119		10.1001/jama.272.2.117	http://dx.doi.org/10.1001/jama.272.2.117			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015119				2022-12-28	WOS:A1994NV42400009
J	KASSIRER, JP; CAMPION, EW				KASSIRER, JP; CAMPION, EW			PEER-REVIEW - CRUDE AND UNDERSTUDIED, BUT INDISPENSABLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		UNCERTAINTY; DECISIONS				KASSIRER, JP (corresponding author), NEW ENGLAND JOURNAL MED,10 SHATTUCK ST,BOSTON,MA 02115, USA.							ALTMAN LK, 1990, ETHICS POLICY SCI PU; BAILAR JC, 1985, NEW ENGL J MED, V312, P654, DOI 10.1056/NEJM198503073121023; Elstein AS, 1978, MED PROBLEM SOLVING; INGELFINGER FJ, 1974, AM J MED, V56, P686, DOI 10.1016/0002-9343(74)90635-4; KASSIRER JP, 1978, ANN INTERN MED, V89, P245, DOI 10.7326/0003-4819-89-2-245; KUIPERS B, 1988, COGNITIVE SCI, V12, P177, DOI 10.1207/s15516709cog1202_2; KUIPERS B, 1984, COGNITIVE SCI, V8, P363; MOSKOWITZ AJ, 1988, ANN INTERN MED, V108, P435, DOI 10.7326/0003-4819-108-3-435; Newell A., 1972, HUMAN PROBLEM SOLVIN; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P91, DOI 10.1016/0895-4356(91)90205-N; RELMAN AS, 1990, WESTERN J MED, V153, P520; RELMAN AS, 1989, NEW ENGL J MED, V321, P827, DOI 10.1056/NEJM198909213211211; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; 1990, JAMA-J AM MED ASSOC, V263, P1317	14	168	174	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					96	97		10.1001/jama.272.2.96	http://dx.doi.org/10.1001/jama.272.2.96			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015140				2022-12-28	WOS:A1994NV42400003
J	RICHARDS, T; SMITH, R; COLLINS, K; HUNTER, W; CECI, A; STEIN, H; BAERT, A; HAYES, A				RICHARDS, T; SMITH, R; COLLINS, K; HUNTER, W; CECI, A; STEIN, H; BAERT, A; HAYES, A			HOW SHOULD EUROPEAN HEALTH-POLICY DEVELOP - A DISCUSSION	BRITISH MEDICAL JOURNAL			English	Discussion													Ceci, Adriana/D-1328-2014						0	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					116	121		10.1136/bmj.309.6947.116	http://dx.doi.org/10.1136/bmj.309.6947.116			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038646	Green Published			2022-12-28	WOS:A1994NW71600032
J	STOLTZFUS, A; SPENCER, DF; ZUKER, M; LOGSDON, JM; DOOLITTLE, WF				STOLTZFUS, A; SPENCER, DF; ZUKER, M; LOGSDON, JM; DOOLITTLE, WF			TESTING THE EXON THEORY OF GENES - THE EVIDENCE FROM PROTEIN-STRUCTURE	SCIENCE			English	Article							TRIOSEPHOSPHATE ISOMERASE GENE; MULTIPLE SEQUENCE ALIGNMENT; INTRON-DEPENDENT EVOLUTION; ALCOHOL-DEHYDROGENASE GENE; PYRUVATE-KINASE GENE; ASPERGILLUS-NIDULANS; MOLECULAR ANALYSIS; SPLICE SITES; IN-PIECES; CHICKEN	A tendency for exons to correspond to discrete units of protein structure in protein-coding genes of ancient origin would provide clear evidence in favor of the exon theory of genes, which proposes that split genes arose not by insertion of introns into unsplit genes, but from combinations of primordial mini-genes (exons) separated by spacers (introns). Although putative examples of such correspondence have strongly influenced previous debate on the origin of introns, a general correspondence has not been rigorously proved. Objective methods for detecting correspondences were developed and applied to four examples that have been cited previously as evidence of the exon theory of genes. No significant correspondence between exons and units of protein structure was detected, suggesting that the putative correspondence does not exist and that the exon theory of genes is untenable.	WASHINGTON UNIV,CANADIAN INST ADV RES,INST BIOMED COMP,PROGRAM EVOLUT BIOL,ST LOUIS,MO 63110; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Washington University (WUSTL); Indiana University System; Indiana University Bloomington	STOLTZFUS, A (corresponding author), DALHOUSIE UNIV,CANADIAN INST ADV RES,DEPT BIOCHEM,PROGRAM EVOLUT BIOL,HALIFAX B3H 4H7,NS,CANADA.		Logsdon, John M/B-7812-2009; Stoltzfus, Arlin/D-8551-2011	Stoltzfus, Arlin/0000-0002-0963-1357; Doolittle, W. Ford/0000-0002-4675-8832	NIGMS NIH HHS [GM-35087] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035087] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLAKE C, 1983, NATURE, V306, P535, DOI 10.1038/306535a0; BLAKE CCF, 1978, NATURE, V273, P267, DOI 10.1038/273267a0; BOLTON W, 1970, NATURE, V228, P551, DOI 10.1038/228551a0; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P142; BURKE J, 1987, PROTEINS, V2, P177, DOI 10.1002/prot.340020303; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; COLE KP, 1992, GENE, V122, P255, DOI 10.1016/0378-1119(92)90213-9; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; COUTURE M, 1994, MOL GEN GENET, V243, P185, DOI 10.1007/BF00280316; CRABB DW, 1989, GENOMICS, V5, P906, DOI 10.1016/0888-7543(89)90133-X; CRAIK CS, 1983, SCIENCE, V220, P1125, DOI 10.1126/science.6344214; DARNELL JE, 1978, SCIENCE, V202, P1257, DOI 10.1126/science.364651; DEGRAAFF L, 1988, CURR GENET, V14, P553, DOI 10.1007/BF00434080; DENNIS ES, 1984, NUCLEIC ACIDS RES, V12, P3983, DOI 10.1093/nar/12.9.3983; DIBB NJ, 1989, EMBO J, V8, P2015, DOI 10.1002/j.1460-2075.1989.tb03609.x; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DOOLITTLE RF, 1991, SCIENCE, V253, P677, DOI 10.1126/science.1871603; DOOLITTLE WF, 1993, NATURE, V361, P403, DOI 10.1038/361403a0; DOOLITTLE WF, 1987, AM NAT, V130, P915, DOI 10.1086/284755; DOOLITTLE WF, 1978, NATURE, V272, P581, DOI 10.1038/272581a0; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; DUESTER G, 1986, NUCLEIC ACIDS RES, V14, P1931, DOI 10.1093/nar/14.5.1931; DUESTER G, 1986, J BIOL CHEM, V261, P2027; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GILBERT W, 1994, GENE, V135, P137; GO M, 1987, COLD SPRING HARB SYM, V52, P915, DOI 10.1101/SQB.1987.052.01.100; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GWYNNE DI, 1987, GENE, V51, P205, DOI 10.1016/0378-1119(87)90309-X; HICKEY DA, 1989, J THEOR BIOL, V137, P41, DOI 10.1016/S0022-5193(89)80148-1; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KERSANACH R, 1994, NATURE, V367, P387, DOI 10.1038/367387a0; LONBERG N, 1985, CELL, V40, P81, DOI 10.1016/0092-8674(85)90311-3; MICHELSON AM, 1985, P NATL ACAD SCI USA, V82, P6965, DOI 10.1073/pnas.82.20.6965; MOENS L, 1993, FEBS LETT, V320, P284, DOI 10.1016/0014-5793(93)80604-S; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; NAKANO T, 1991, BIOCHIM BIOPHYS ACTA, V1090, P273, DOI 10.1016/0167-4781(91)90118-6; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; PATTHY L, 1991, BIOESSAYS, V13, P187, DOI 10.1002/bies.950130408; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; POHAJDAK B, 1993, FEBS LETT, V320, P281, DOI 10.1016/0014-5793(93)80603-R; PRESS WH, 1992, NUMERICAL RECIPES C, P282; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; STOLTZFUS A, 1993, CURR BIOL, V3, P215, DOI 10.1016/0960-9822(93)90336-M; STONE EM, 1985, NATURE, V313, P498, DOI 10.1038/313498a0; STRAUS D, 1985, MOL CELL BIOL, V5, P3497, DOI 10.1128/MCB.5.12.3497; TITTIGER C, 1993, NATURE, V361, P470, DOI 10.1038/361470a0; WATSON JD, 1987, MOL BIOL GENE, P1145; ZUKER M, UNPUB; [No title captured]	56	194	198	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					202	207		10.1126/science.8023140	http://dx.doi.org/10.1126/science.8023140			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023140				2022-12-28	WOS:A1994NV95700027
J	KINDIG, DA; LIBBY, D				KINDIG, DA; LIBBY, D			HOW WILL GRADUATE MEDICAL-EDUCATION REFORM AFFECT SPECIALTIES AND GEOGRAPHIC AREAS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To project specialty and geographic impacts of workforce reform proposals on the practice output of graduate medical education (GME). Design.-A demographic life-table model to predict GME output was developed using 1987 cohort data from the Association of American Medical Colleges Annual GME Census. The 1992 GME cohort was used as a baseline to compare the simulated impact of alternate specialty and regional policies. Setting.-Allopathic and osteopathic GME programs in the United States. Main Outcome Measure.-Projected number of physicians (MDs and DOs) entering nine categories of practice specialty at the conclusion of GME. Results.-lf GME input is reduced to 110% of US medical graduates with 55% entering practice as generalists (including obstetrics and gynecology), then the total number of first-year positions will decline from 24 433 to 18 783, and the total number of residents in GME would decline from 103 858 to 80 699 at equilibrium. Even with a 110% restriction on GME input, the overall physician-to-population ratio will continue to grow, albeit at a much slower rate. The number of generalists leaving GME annually would increase by 742 (9%) and the number of specialists would decline by 6517 (44%). At the regional level, allocating GME positions by prorating to the current distribution results in less change than would prorating positions to regional populations. Conclusion.-Achieving national goals of reduced aggregate physician production, reduced specialist supply, and generalist increases will require significant alterations in the GME pool. Adequate time and funding for resident substitution will be required for hospitals to develop alternate models of providing service to allow national workforce goals to be met.	UNIV WISCONSIN,SCH MED,DEPT PREVENT MED,HLTH POLICY PROGRAM,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison								CHIANG CL, 1984, LIFE TABLE ITS APPLI; CLAWSON DK, 1993, ROLES PHYSICIAN ASSI; COHEN J, 1993, NEW ENGL J MED, V328, P1810; DORNER FH, 1991, ACAD MED, V66, P540, DOI 10.1097/00001888-199109000-00011; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; KNICKMAN JR, 1992, ACAD MED, V67, P429, DOI 10.1097/00001888-199207000-00003; LUKE R, 1993, AM J MED, V95, pR1; ROEHRIG C, 1988, SPECIALTY DISTRIBUTI, P2; STODDARD JJ, 1994, JAMA-J AM MED ASSOC, V272, P53, DOI 10.1001/jama.272.1.53; TODD JS, 1992, JAMA-J AM MED ASSOC, V268, P1133, DOI 10.1001/jama.268.9.1133; WEINER J, 1993, ASSESSING IMPACT MAN; WHITCOMB M, 1993, ANAL METHODOLOGIES A; 1994, ANAL ADM HLTH PROPOS; 1993, PRESIDENTS HLTH SECU; 1992, IMPROVING ACCESS HLT; 1994, 4TH C REC IMPR ACC H; 1981, MODELING RES DATA TE, P2; 1994, WORKSHOP GME DATA CO; 1993, ACAD MED, V68, P1	19	30	31	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					37	42		10.1001/jama.272.1.37	http://dx.doi.org/10.1001/jama.272.1.37			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU485	8007077				2022-12-28	WOS:A1994NU48500027
J	BLAND, JM; ALTMAN, DG				BLAND, JM; ALTMAN, DG			STATISTICS NOTES .2. REGRESSION TOWARDS THE MEAN	BRITISH MEDICAL JOURNAL			English	Note									IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	BLAND, JM (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							Galton F., 1886, J ANTHR I, V15, P246, DOI 10.2307%2F2841583	1	386	392	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1499	1499		10.1136/bmj.308.6942.1499	http://dx.doi.org/10.1136/bmj.308.6942.1499			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019287	Green Published, Bronze			2022-12-28	WOS:A1994NQ22900026
J	FLEETWOOD, J; UNGER, SS				FLEETWOOD, J; UNGER, SS			INSTITUTIONAL ETHICS COMMITTEES AND THE SHIELD OF IMMUNITY	ANNALS OF INTERNAL MEDICINE			English	Article							CONSULTATIONS	Institutional ethics committees have been hailed as a good resource for physicians confronting complex ethical issues in patient care. Physicians may seek ethics committee consultations to receive impartial assistance in decision making, to resolve conflicts, and to avoid cumbersome court procedures and unwieldy litigation. The endorsement of ethics committees by the President's Commission, the American Hospital Association, the American Medical Association, and the Department of Health and Human Services, along with recent state legislation governing committees in Maryland, New Jersey, and Hawaii, raises questions about the proper scope and authority of ethics committees. We examined the accountability of institutional ethics committees and argue against immunity-conferring statutes that shield physicians who follow a committee's advice from civil and criminal liability.			FLEETWOOD, J (corresponding author), MED COLL PENN, DEPT COMMUNITY & PREVENT MED, 3300 HENRY AVE, PHILADELPHIA, PA 19129 USA.							[Anonymous], 1985, JAMA-J AM MED ASSOC, V253, P2698; BLADES CE, 1989, BIOLAW, V2, P317; CAPRON AM, 1985, J COLLEGE U LAW, V11, P66; Cohen M, 1992, Camb Q Healthc Ethics, V1, P33; Cranford R E, 1985, Law Med Health Care, V13, P52; CRANFORD RE, 1984, I ETHICS COMMITTEES, P6; Fletcher J C, 1992, QRB Qual Rev Bull, V18, P12; FLETCHER JC, 1991, MARYLAND LAW REV, V50, P860; FOST N, 1985, JAMA-J AM MED ASSOC, V253, P2687, DOI 10.1001/jama.253.18.2687; FRYREVERE S, 1992, ACCOUNTABILITY BIOET, V83, P93; FURROW BR, 1988, NOTRE DAME J LAW ETH, V317, P187; GIBSON JM, 1986, HASTINGS CENT REP, V16, P9, DOI 10.2307/3563266; GOLDMAN J, 1982, JAMA-J AM MED ASSOC, V248, P197, DOI 10.1001/jama.248.2.197; HARDING T, 1989, J MED ETHICS, V15, P191, DOI 10.1136/jme.15.4.191; Hoffman Diane, 1991, MD Law Rev, V50, P746; Hoffmann D E, 1991, Law Med Health Care, V19, P105; LAPUMA J, 1989, ARCH INTERN MED, V149, P1109, DOI 10.1001/archinte.149.5.1109; LO B, 1987, NEW ENGL J MED, V317, P46, DOI 10.1056/NEJM198707023170110; Loewy E H, 1990, HEC Forum, V2, P351, DOI 10.1007/BF00113950; MACKLIN R, 1984, I ETHICS COMMITTEES, P157; MERRITT AL, 1987, SOUTHERN CALIF LAW R, V60, P1239; MORENO JD, 1991, MARYLAND LAW REV, V50, P595; PERKINS HS, 1988, AM J MED, V85, P761; ROBERTSON JA, 1991, ISSUES LAW MED, V7, P83; Ross J W, 1990, HEC Forum, V2, P289, DOI 10.1007/BF00057828; ROSS JW, 1986, HDB HOSPITAL ETHICS, V10, P57; SIEGLER M, 1988, AM J MED, V85, P759; Staubach S M, 1989, HEC Forum, V1, P209, DOI 10.1007/BF00122365; SWENSON MD, 1992, ARCH INTERN MED, V152, P694, DOI 10.1001/archinte.152.4.694; THOMASMA DC, 1991, THEOR MED, V12, P129, DOI 10.1007/BF00489793; WOLF SM, 1986, HASTINGS CENT REP, V16, P12, DOI 10.2307/3563267; Wolf Susan M, 1991, MD Law Rev, V50, P798; Youngner S J, 1984, Law Med Health Care, V12, P21; 1986, HDB HOSPITAL ETHICS, V57, P110; 1992, ACCREDITATION MANUAL, P106; 1984, FED REG         0112, V49, P1622; 1992, NEW YORK STATE TASK, V13, P266; 1983, DECIDING FOREGO LIFE, P155	38	23	23	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					320	325		10.7326/0003-4819-120-4-199402150-00010	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8024652				2022-12-28	WOS:A1994MW10300010
J	REISMAN, RE				REISMAN, RE			INSECT STINGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							STOPPING VENOM IMMUNOTHERAPY; DIAGNOSTIC METHODS; NATURAL-HISTORY; YELLOW JACKET; ALLERGY; BEE; HYPERSENSITIVITY; ALLERGENICITY; ANTIGENICITY; ANAPHYLAXIS		SUNY BUFFALO,SCH MED,BUFFALO,NY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BROWN H, 1970, ARCH INTERN MED, V125, P665, DOI 10.1001/archinte.125.4.665; BRUMMERKORVENKONTIO H, 1994, J ALLERGY CLIN IMMUN, V93, P551, DOI 10.1016/S0091-6749(94)70066-4; CHAFEE FH, 1970, ACTA ALLERGOL, V25, P292, DOI 10.1111/j.1398-9995.1970.tb01265.x; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; FRAZIER CLAUDE A., 1964, SOUTHERN MED J, V57, P1028, DOI 10.1097/00007611-196409000-00006; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GOLDBERG A, 1988, ANN ALLERGY, V61, P177; GOLDEN D B K, 1991, Journal of Allergy and Clinical Immunology, V87, P237, DOI 10.1016/0091-6749(91)91675-J; GOLDEN DBK, 1989, ALLERGY PROC, V10, P103, DOI 10.2500/108854189778960964; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V83, P273; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P482, DOI 10.1016/0091-6749(81)90102-0; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; KOCHUYT AM, 1994, CLIN EXP ALLERGY, V24, P35, DOI 10.1111/j.1365-2222.1994.tb00914.x; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P391, DOI 10.1016/0091-6749(77)90024-0; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; MCKENNA WR, 1992, PEDIATR ASTHMA ALLER, V4, P275; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V67, P290, DOI 10.1016/0091-6749(81)90024-5; MUELLERHL, 1959, NEW ENGL J MED, V161, P374; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1984, J ALLERGY CLIN IMMUN, V73, P246, DOI 10.1016/S0091-6749(84)80015-9; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V84, P331, DOI 10.1016/0091-6749(89)90417-X; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V83, P1049, DOI 10.1016/0091-6749(89)90446-6; SCHUBERTH KC, 1988, J ALLERGY CLIN IMMUN, V81, P200, DOI 10.1016/0091-6749(88)90364-8; SCHWARTZ HJ, 1990, J ALLERGY CLIN IMMUN, V85, P709, DOI 10.1016/0091-6749(90)90188-A; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X	39	91	95	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					523	527		10.1056/NEJM199408253310808	http://dx.doi.org/10.1056/NEJM199408253310808			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD072	8041420				2022-12-28	WOS:A1994PD07200008
J	GOODMAN, SN; BERLIN, JA				GOODMAN, SN; BERLIN, JA			THE USE OF PREDICTED CONFIDENCE-INTERVALS WHEN PLANNING EXPERIMENTS AND THE MISUSE OF POWER WHEN INTERPRETING RESULTS	ANNALS OF INTERNAL MEDICINE			English	Article							SAMPLE-SIZE DETERMINATION; RANDOMIZED CONTROL TRIAL; CLINICAL-TRIALS; II ERROR; P-VALUES; STATISTICAL SIGNIFICANCE; TESTS; BETA; GUIDELINES; ENOUGH	Although there is a growing understanding of the importance of statistical power considerations when designing studies and of the value of confidence intervals when interpreting data, confusion exists about the reverse arrangement: the role of confidence intervals in study design and of power in interpretation. Confidence intervals should play an important role when setting sample size, and power should play no role once the data have been collected, but exactly the opposite procedure is widely practiced. In this commentary, we present the reasons why the calculation of power after a study is over is inappropriate and how confidence intervals can be used during both study design and study interpretation.	UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	GOODMAN, SN (corresponding author), JOHNS HOPKINS UNIV, SCH MED,CTR ONCOL,DIV BIOSTAT,550 N BROADWAY, SUITE 1103, BALTIMORE, MD 21205 USA.			Goodman, Steven/0000-0002-3872-5723				BAILAR JC, 1988, ANN INTERN MED, V108, P266, DOI 10.7326/0003-4819-108-2-266; BARNETT V, 1982, COMP STATISTICAL INF; BEAL SL, 1989, BIOMETRICS, V45, P969, DOI 10.2307/2531696; BERGER J, 1988, IMS SERIES, V6; BERGER JO, 1988, AM SCI, V76, P159; BERRY G, 1986, MED J AUSTRALIA, V144, P618, DOI 10.5694/j.1326-5377.1986.tb112339.x; BICKEL P, 1977, MATH STATISTICS, P171; Box G.E., 2011, BAYESIAN INFERENCE S, V40; BRAITMAN LE, 1988, ANN INTERN MED, V108, P296, DOI 10.7326/0003-4819-108-2-296; BRAITMAN LE, 1991, ANN INTERN MED, V114, P515, DOI 10.7326/0003-4819-114-6-515; BRISTOL DR, 1989, STAT MED, V8, P803, DOI 10.1002/sim.4780080705; BROWN CG, 1987, ANN EMERG MED, V16, P183, DOI 10.1016/S0196-0644(87)80013-6; CASELLA G, 1987, J AM STAT ASSOC, V82, P106, DOI 10.2307/2289130; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; DALY LE, 1991, BRIT MED J, V302, P333, DOI 10.1136/bmj.302.6772.333; DETSKY AS, 1985, ARCH INTERN MED, V145, P709, DOI 10.1001/archinte.145.4.709; DIAMOND GA, 1983, ANN INTERN MED, V98, P385, DOI 10.7326/0003-4819-98-3-385; DYKEN ML, 1983, STROKE, V14, P2, DOI 10.1161/01.STR.14.1.2; EDLUND MJ, 1985, J PSYCHIAT RES, V19, P563, DOI 10.1016/0022-3956(85)90074-3; EDWARDS AWF, 1972, LIKELIHOOD; EDWARDS W, 1963, PSYCHOL REV, V70, P193, DOI 10.1037/h0044139; EVANS M, 1985, BRIT J SURG, V72, P256, DOI 10.1002/bjs.1800720403; FLETCHER RH, CLIN EPIDEMIOLOGY ES, P1; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; Good I J, 1950, PROBABILITY WEIGHING; GOODMAN SN, 1992, STAT MED, V11, P875, DOI 10.1002/sim.4780110705; GOODMAN SN, 1988, AM J PUBLIC HEALTH, V78, P1568, DOI 10.2105/AJPH.78.12.1568; GOODMAN SN, 1993, AM J EPIDEMIOL, V137, P485, DOI 10.1093/oxfordjournals.aje.a116700; GORDON I, 1987, AM J EPIDEMIOL, V125, P158, DOI 10.1093/oxfordjournals.aje.a114499; GREENLAND S, 1988, AM J EPIDEMIOL, V128, P231, DOI 10.1093/oxfordjournals.aje.a114945; INGELFINGER JA, 1987, BIOSTATISTICS CLIN M; JOHNSTONE DJ, 1986, STATISTICIAN, V35, P491, DOI 10.2307/2987965; MCHUGH RB, 1984, CONTROL CLIN TRIALS, V5, P157, DOI 10.1016/0197-2456(84)90121-1; MOSKOWITZ G, 1983, ALCOHOL CLIN EXP RES, V7, P42, DOI 10.1111/j.1530-0277.1983.tb05409.x; Oakes M., 1986, STAT INFERENCE COMME; OTTENBACHER KJ, 1990, AM J PHYS MED REHAB, V69, P102, DOI 10.1097/00002060-199004000-00011; POOLE C, 1987, AM J PUBLIC HEALTH, V77, P195, DOI 10.2105/AJPH.77.2.195; PRATT JW, 1965, J ROY STAT SOC B, V27, P169; RAJU TNK, 1992, AM J DIS CHILD, V146, P407, DOI 10.1001/archpedi.1992.02160160027007; ROTHMAN KJ, 1978, NEW ENGL J MED, V299, P1362; ROYALL RM, 1986, AM STAT, V40, P313, DOI 10.2307/2684616; SATTEN GA, 1990, AM J EPIDEMIOL, V131, P177, DOI 10.1093/oxfordjournals.aje.a115472; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; SIMON R, 1985, CANCER TREAT REP, V69, P1; SMITH AH, 1992, EPIDEMIOLOGY, V3, P449, DOI 10.1097/00001648-199209000-00011; SPIEGELHALTER DJ, 1986, STAT MED, V5, P1, DOI 10.1002/sim.4780050103; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; [No title captured]	49	467	471	0	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					200	206		10.7326/0003-4819-121-3-199408010-00008	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017747				2022-12-28	WOS:A1994NY33800008
J	JAMES, AF; XIE, LH; FUJITANI, Y; HAYASHI, S; HORIE, M				JAMES, AF; XIE, LH; FUJITANI, Y; HAYASHI, S; HORIE, M			INHIBITION OF THE CARDIAC PROTEIN-KINASE A-DEPENDENT CHLORIDE CONDUCTANCE BY ENDOTHELIN-1	NATURE			English	Article							GUINEA-PIG ATRIA; AUTONOMIC REGULATION; MYOCYTES; CELLS; CONTRACTION; ACTIVATION; MECHANISM; RECEPTOR; SUBUNITS; ISOZYME	ENDOTHELIN-1 is a peptide hormone constitutively secreted by vascular and endocardial endothelial cells(1-3). Secretion of endothelin-1 is increased under certain pathophysiological conditions, including coronary vasospasm, cardiac ischaemia and myocardial infarction. We have examined the effect of endothelin-1 on the protein kinase A (PKA)-dependent chloride current in voltage-clamped guinea pig ventricular myocytes. This conductance, induced by catecholamines through beta-adrenergic receptors, counteracts the simultaneously increased L-type calcium current by shortening the action potential duration(4-6). We report here that endothelin-1, acting through ET(A) (endothelin-1-selective) receptors, inhibited the current through a pertussis toxin-sensitive mechanism, analogous to muscarinic receptors, by reducing the intracellular cyclic AMP concentration. This effect of endothelin-1 should help protect the ventricle against potentially arrhythmogenic shortening of the action potential during ischaemia when the circulating levels of catecholamines are increased.	KYOTO UNIV,FAC MED,DEPT INTERNAL MED 3,KYOTO 606,JAPAN; CIBA GEIGY JAPAN LTD,INT RES LABS,TAKARAZUKA,HYOGO 665,JAPAN; NATL INST PHYSIOL SCI,DEPT CELLULAR & MOLEC PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			Horie, Minoru/ABG-7128-2020					BAHINSKI A, 1989, NATURE, V340, P718, DOI 10.1038/340718a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; HARVEY R D, 1990, Journal of Cardiovascular Electrophysiology, V1, P309, DOI 10.1111/j.1540-8167.1990.tb01072.x; HARVEY RD, 1990, J GEN PHYSIOL, V95, P1077, DOI 10.1085/jgp.95.6.1077; HARVEY RD, 1989, SCIENCE, V244, P983, DOI 10.1126/science.2543073; HAYNES WG, 1993, CLIN SCI, V84, P485, DOI 10.1042/cs0840485; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HORIE M, 1992, J PHYSIOL-LONDON, V455, P235, DOI 10.1113/jphysiol.1992.sp019299; HWANG TC, 1992, J GEN PHYSIOL, V99, P465, DOI 10.1085/jgp.99.4.465; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; JAMES AF, 1993, CARDIOVASC DRUG REV, V11, P253, DOI 10.1111/j.1527-3466.1993.tb00190.x; JONES LG, 1992, AM J PHYSIOL, V263, pH1447, DOI 10.1152/ajpheart.1992.263.5.H1447; KIM D, 1991, CIRC RES, V69, P250, DOI 10.1161/01.RES.69.1.250; KOHMOTO O, 1993, AM J PHYSIOL, V265, pH793, DOI 10.1152/ajpheart.1993.265.3.H793; LAUER MR, 1992, J PHYSIOL-LONDON, V448, P729, DOI 10.1113/jphysiol.1992.sp019067; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; MEBAZAA A, 1993, AM J PHYSIOL, V265, pH1841, DOI 10.1152/ajpheart.1993.265.5.H1841; ONO K, 1994, NATURE, V370, P301, DOI 10.1038/370301a0; REID JJ, 1989, EUR J PHARMACOL, V168, P93, DOI 10.1016/0014-2999(89)90637-7; SOKOLOVSKY M, 1992, NEUROCHEMISTRY, V59, P809; TAKAI M, 1992, BIOCHEM BIOPH RES CO, V184, P953, DOI 10.1016/0006-291X(92)90683-C; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOHSE N, 1990, BRIT J PHARMACOL, V99, P437, DOI 10.1111/j.1476-5381.1990.tb12944.x; VOGELSANG M, 1994, J CARDIOVASC PHARM, V23, P344, DOI 10.1097/00005344-199402000-00025; WANG JX, 1993, AM J PHYSIOL, V265, pH2168, DOI 10.1152/ajpheart.1993.265.6.H2168	26	83	84	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					297	300		10.1038/370297a0	http://dx.doi.org/10.1038/370297a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035878				2022-12-28	WOS:A1994NZ22900065
J	FITZGERALD, FT				FITZGERALD, FT			THE TYRANNY OF HEALTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											FITZGERALD, FT (corresponding author), UNIV CALIF DAVIS,MED CTR,SACRAMENTO,CA 95817, USA.							BEAUCHAMP TL, 1979, PRINCIPLES BIOMEDICA, P284; ILLICH I, 1974, LANCET, V1, P918	2	83	83	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					196	198		10.1056/NEJM199407213310312	http://dx.doi.org/10.1056/NEJM199407213310312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008035				2022-12-28	WOS:A1994NW79700012
J	HORN, DL; HEWLETT, D; HAAS, WH; BUTLER, WR; ALFALLA, C; TAN, E; LEVINE, A; NAYAK, A; OPAL, SM				HORN, DL; HEWLETT, D; HAAS, WH; BUTLER, WR; ALFALLA, C; TAN, E; LEVINE, A; NAYAK, A; OPAL, SM			SUPERINFECTION WITH RIFAMPIN-ISONIAZID-STREPTOMYCIN-ETHAMBUTOL (RISE)-RESISTANT TUBERCULOSIS IN 3 PATIENTS WITH AIDS - CONFIRMATION BY POLYMERASE CHAIN-REACTION FINGERPRINTING	ANNALS OF INTERNAL MEDICINE			English	Note							MYCOBACTERIUM-TUBERCULOSIS; EXOGENOUS REINFECTION; COMPLEX		LINCOLN MED & MENTAL HLTH CTR, DEPT MED, BRONX, NY 10451 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA; MEM HOSP RHODE ISL, PROVIDENCE, RI USA	Centers for Disease Control & Prevention - USA								BATES JH, 1976, AM REV RESPIR DIS, V114, P353; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; HAAS WH, 1993, J CLIN MICROBIOL, V31, P1293, DOI 10.1128/JCM.31.5.1293-1298.1993; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; RALEIGH JW, 1973, AM REV RESPIR DIS, V108, P639; RALEIGH JW, 1975, AM REV RESPIR DIS, V112, P497; ROMEYN JA, 1970, AM REV RESPIR DIS, V101, P923; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1992, 1992 WORLD C TUB BET; 1993, MMWR-MORBID MORTAL W, V42, P427	10	39	41	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					115	116		10.7326/0003-4819-121-2-199407150-00007	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017724				2022-12-28	WOS:A1994NW18600007
J	JUDSON, HF				JUDSON, HF			STRUCTURAL TRANSFORMATIONS OF THE SCIENCES AND THE END OF PEER-REVIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		PUBLICATION; PHYSICS; MAIL				JUDSON, HF (corresponding author), STANFORD UNIV,PROGRAM HIST & PHILOSOPHY SCI,BLDG 370,ROOM 111,STANFORD,CA 94305, USA.							[Anonymous], 1991, BIOTECHNOLOGY GLOBAL; BROOKS H, 1990, RES SYSTEM TRANSITIO, P163; BURNHAM JC, 1990, JAMA-J AM MED ASSOC, V263, P1323, DOI 10.1001/jama.263.10.1323; Chubin DE, 1990, PEERLESS SCI PEER RE, P83; Cozzens Susan E., 1990, RES SYSTEM TRANSITIO, P345; de Price D. J. S., 1963, LITTLE SCI BIG SCI, P10; EVANS AT, 1993, 2ND INT C PEER REV B, P11; GARFUNKEL JM, 1990, JAMA-J AM MED ASSOC, V263, P1369, DOI 10.1001/jama.263.10.1369; Hartman A., 1992, SOCIOMEDIA MULTIMEDI, P175; Judson Horace Freeland, 1992, CODE CODES SCI SOCIA, P37; KRIGE J, 1990, RES SYSTEM TRANSITIO, P179; Krimsky S., 1991, BIOTECHNICS SOC RISE; KRONICK DA, 1990, JAMA-J AM MED ASSOC, V263, P1321, DOI 10.1001/jama.263.10.1321; KRUMENAKER L, 1993, SCIENCE, V260, P1066, DOI 10.1126/science.8493543; LEDERBERG J, 1993, SCIENTIST, V7, P10; LEDERBERG J, 1993, SCIENTIST, V7, P14; MARSHALL E, 1993, SCIENCE, V262, P1364; MCCUTCHEN CW, 1991, TECH REV         OCT, P28; MCCUTCHEN CW, 1991, TECHNOL REV      OCT, P40; Nelson L L., 1991, BUSINESS BIOTECHNOLO, P39; RELMAN AS, 1984, NEW ENGL J MED, V311, P405; RENNIE D, 1991, JAMA-J AM MED ASSOC, V266, P266, DOI 10.1001/jama.266.2.266; RIP A, 1990, RES SYSTEM TRANSITIO, P887; STIX G, 1994, SCI AM, V270, P110, DOI 10.1038/scientificamerican0294-110; SWAZEY JP, 1993, AM SCI, V81, P542; TAUBES G, 1993, SCIENCE, V259, P1246, DOI 10.1126/science.259.5099.1246; TAUBES G, 1993, SCIENCE, V262, P173, DOI 10.1126/science.262.5131.173-a; WULF WA, 1993, SCIENCE, V261, P854, DOI 10.1126/science.8346438; WULF WA, 1989, UNPUB NATIONAL COLLO; ZUCKERMAN H, 1971, MINERVA, V9, P66, DOI 10.1007/BF01553188; 1993, NATIONAL COLLABORATO	31	44	45	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					92	94		10.1001/jama.272.2.92	http://dx.doi.org/10.1001/jama.272.2.92			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015139				2022-12-28	WOS:A1994NV42400002
J	JOHNSON, R				JOHNSON, R			WHERE HAVE ALL THE PENNIES GONE - THE WORK OF MANCHESTER MEDICAL AUDIT ADVISORY GROUP	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE	Medical audit has its critics, who point to the large sums of MIS cash that seem to be disappearing down a medical plughole. These criticisms are recognised by medical audit advisory groups but there are many reasons why the work of these groups has not yet resulted in many publications in journals or bumped up health indicators. After discussing the criticism this article describes the work of the medical audit advisory group in Manchester. Real changes in cooperative working with general practice teams and between practices are taking place, and improved relationships between general practice and the hospitals are being helped by joint audit work. The Manchester group is also working to help in setting standards and to cooperate with purchasing. The work of the group is changing as it develops.			JOHNSON, R (corresponding author), POSTGRAD HLTH SCI CTR,MANCHESTER M13 9BZ,LANCS,ENGLAND.							BAKER R, 1991, BRIT MED J, V303, P32, DOI 10.1136/bmj.303.6793.32; Baker R, 1993, MEASUREMENT PATIENTS; BENETT IJ, IN PRESS DIABETIC ME; DERRY J, 1991, BRIT MED J, V303, P1247, DOI 10.1136/bmj.303.6812.1247; DRUMMOND MF, 1980, PRINCIPLES EC APPRAI, P116; FOXALL M, 1993, AUDIT TRENDS, V1, P99; GROL R, 1988, J ROY COLL GEN PRACT, V38, P10; HUGHES J, 1990, MED AUDIT GENERAL PR; Humphrey C, 1993, Qual Health Care, V2, P232, DOI 10.1136/qshc.2.4.232; JOHNSON R, 1993, AUDIT TRENDS, V1, P756; MAYNARD A, 1993, HLTH SERVICE J, V103, P21; 1993, CHANGING CHILDBIRTH; 1985, WHAT SORT DOCTOR; 1990, HLTH SERVICE DEV WOR; 1992, 2ND HOUS COMM HLTH C; 1991, WORKING MAAG	16	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					98	102		10.1136/bmj.309.6947.98	http://dx.doi.org/10.1136/bmj.309.6947.98			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038680	Green Published			2022-12-28	WOS:A1994NW71600024
J	DJERASSI, C; LEIBO, SP				DJERASSI, C; LEIBO, SP			A NEW LOOK AT MALE CONTRACEPTION	NATURE			English	Editorial Material							UNITED-STATES MEN; PROSTATE-CANCER; VASECTOMY; SPERM; CRYOPRESERVATION; OLIGOSPERMIA; COHORT		UNIV GUELPH, ONTARIO VET COLL, GUELPH N1G 2W1, ON, CANADA	University of Guelph	DJERASSI, C (corresponding author), STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA.							ANDERSON NG, COMMUNICATION; ANDERSON NG, Patent No. 5092466; ASHWOODSMITH MJ, 1977, CIBA F S, V52, P251; BARWIN BN, 1986, ANDROLOGY MALE FERTI, P461; BELKER AM, 1987, UROL CLIN N AM, V14, P597; DJERASSI C, 1981, POLITICS CONTRACEPTI, pCH5; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P873, DOI 10.1001/jama.269.7.873; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P878, DOI 10.1001/jama.269.7.878; GLENISTER PH, 1990, GENET RES, V56, P253, DOI 10.1017/S0016672300035357; HEALY B, 1993, JAMA-J AM MED ASSOC, V269, P2620, DOI 10.1001/jama.269.20.2620; IRITANI A, 1980, 9TH INT C AN REPR AI, V1, P115; IRVINE DS, 1986, HUM REPROD, V1, P539, DOI 10.1093/oxfordjournals.humrep.a136470; LEIBO SP, UNPUB; LELANNOU D, 1989, HUM REPROD, V4, P757; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; LIU DY, 1992, FERTIL STERIL, V58, P465; MARTIN RH, 1991, MOL REPROD DEV, V30, P159, DOI 10.1002/mrd.1080300213; MUMFORD SD, 1977, VASECTOMY COUNSELING; Ross John A., 1993, FAMILY PLANNING POPU; SALAMON S, 1974, J REPROD FERTIL, V37, P433, DOI 10.1530/jrf.0.0370433; SHERMAN JK, 1977, TECHNIQUES HUMAN AND, P399; Short R.V., 1985, P24; SHULMAN S, 1986, ANDROLOGY MALE FERTI, P399; SILBER SJ, 1989, HUM REPROD, V4, P318, DOI 10.1093/oxfordjournals.humrep.a136896; SOKOL RZ, 1987, FERTIL STERIL, V47, P356; Triazolam's status in European Community, 1991, LANCET, V338, P1586; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; 1988, ARTIFICIAL INSEMINAT	28	8	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 7	1994	370	6484					11	12		10.1038/370011a0	http://dx.doi.org/10.1038/370011a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015592				2022-12-28	WOS:A1994NV71100024
J	KING, JB				KING, JB			ABC OF SPORTS MEDICINE - MANAGEMENT OF THE ACUTELY INJURED JOINT	BRITISH MEDICAL JOURNAL			English	Article									ROYAL LONDON HOSP,LONDON E1 1BB,ENGLAND	Barts Health NHS Trust; Royal London Hospital	KING, JB (corresponding author), LONDON HOSP,COLL MED,ACAD DEPT SPORTS MED,LONDON E1 1BB,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					46	49		10.1136/bmj.309.6946.46	http://dx.doi.org/10.1136/bmj.309.6946.46			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044071	Green Published			2022-12-28	WOS:A1994NV89100030
J	LEWIS, PA; DUNN, RB; VETTER, NJ				LEWIS, PA; DUNN, RB; VETTER, NJ			NHS AND COMMUNITY-CARE-ACT-1990 AND DISCHARGES FROM HOSPITAL TO PRIVATE RESIDENTIAL AND NURSING-HOMES	BRITISH MEDICAL JOURNAL			English	Article									ST MARTINS HOSP,BATH BA2 5RP,AVON,ENGLAND		LEWIS, PA (corresponding author), UNIV WALES COLL MED,CARDIFF CF4 4XN,S GLAM,WALES.							CHALLIS D, 1991, AGE AGEING, V20, P236, DOI 10.1093/ageing/20.4.236; 1992, 4TH WELSH AFF COMM R; 1993, NO TIME LOSE	3	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					28	29		10.1136/bmj.309.6946.28	http://dx.doi.org/10.1136/bmj.309.6946.28			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044064	Green Published			2022-12-28	WOS:A1994NV89100021
J	STEIMLE, V; SIEGRIST, CA; MOTTET, A; LISOWSKAGROSPIERRE, B; MACH, B				STEIMLE, V; SIEGRIST, CA; MOTTET, A; LISOWSKAGROSPIERRE, B; MACH, B			REGULATION OF MHC CLASS-II EXPRESSION BY INTERFERON-GAMMA MEDIATED BY THE TRANSACTIVATOR GENE CIITA	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; GUANYLATE-BINDING-PROTEIN; TRANS-ACTING PROTEIN; TYROSINE PHOSPHORYLATION; IFN-GAMMA; TRANSCRIPTION; INDUCTION; CELLS; ALPHA; ACTIVATION	Major histocompatibility complex (MHC) class II genes are expressed constitutively in only a few cell types, but they can be induced in the majority of them, in particular by interferon-gamma (IFN-gamma). The MHC class II transactivator gene CIITA is defective in a form of primary MHC class II deficiency. Here it is shown that CIITA expression is controlled and induced by IFN-gamma. A functional CI ITA gene is necessary for class II induction, and transfection of CIITA is sufficient to activate expression of MHC class II genes in class II-negative cells in the absence of IFN-gamma. CIITA is therefore a general regulator of both inducible and constitutive MHC class II expression.	UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,MOLEC GENET LAB,CH-1211 GENEVA 4,SWITZERLAND; HOP NECKER ENFANTS MALAD,INSERM,U132,F-15015 PARIS,FRANCE	University of Geneva; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Mühlethaler-Mottet, Annick/H-2848-2019	Mühlethaler-Mottet, Annick/0000-0001-8274-0907				ALLEN JM, 1988, NUCLEIC ACIDS RES, V16, P11824, DOI 10.1093/nar/16.24.11824; AMALDI I, 1989, J IMMUNOL, V142, P999; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BLANAR MA, 1988, P NATL ACAD SCI USA, V85, P4672, DOI 10.1073/pnas.85.13.4672; BONO MR, 1991, P NATL ACAD SCI USA, V88, P6077, DOI 10.1073/pnas.88.14.6077; CELADA A, 1989, EUR J IMMUNOL, V19, P1103, DOI 10.1002/eji.1830190621; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; CHENG YSE, 1986, J INTERFERON RES, V6, P417, DOI 10.1089/jir.1986.6.417; COGSWELL JP, 1991, CRIT REV IMMUNOL, V11, P87; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LISOWSKAGROSPIE.B, IN PRESS HUM MOL GEN; MAFFEI A, 1987, J IMMUNOL, V139, P942; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, UNPUB; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0; ZIEGLER A, 1986, IMMUNOBIOLOGY, V171, P77, DOI 10.1016/S0171-2985(86)80019-5	30	685	704	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					106	109		10.1126/science.8016643	http://dx.doi.org/10.1126/science.8016643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016643				2022-12-28	WOS:A1994NV30100037
J	VANDENBROUCKE, JP				VANDENBROUCKE, JP			SHOULD YOU EAT MEAT, OR ARE YOU CONFOUNDED BY METHODOLOGICAL DEBATE	BRITISH MEDICAL JOURNAL			English	Article											VANDENBROUCKE, JP (corresponding author), LEIDEN UNIV HOSP,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BRESLOW NE, 1987, STATISTICAL METHODS, V2, P151; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P136; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P92; DOLL R, 1956, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5001.1071; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; MONSON RR, 1990, OCCUPATIONAL EPIDEMI, P53; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P45; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; THOROGOOD M, 1994, BRIT MED J, V308, P1665	9	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1671	1671						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025459				2022-12-28	WOS:A1994NU48300018
J	CLELAND, WW; KREEVOY, MM				CLELAND, WW; KREEVOY, MM			LOW-BARRIER HYDROGEN-BONDS AND ENZYMATIC CATALYSIS	SCIENCE			English	Article							TRANSITION-STATE ANALOGS; DELTA-5-3-KETOSTEROID ISOMERASE; TRIOSEPHOSPHATE ISOMERASE; OROTIDYLATE DECARBOXYLASE; CARBOXYPEPTIDASE-A; INHIBITOR-BINDING; CRYSTAL-STRUCTURE; ACTIVE-SITE; MECHANISM; DEHYDROGENASE	Formation of a short (less than 2.5 angstroms), very strong, low-barrier hydrogen bond in the transition state, or in an enzyme-intermediate complex, can be an important contribution to enzymic catalysis. Formation of such a bond can supply 10 to 20 kilocalories per mole and thus facilitate difficult reactions such as enolization of carboxylate groups. Because low-barrier hydrogen bonds form only when the pK(a)'s (negative logarithm of the acid constant) of the oxygens or nitrogens sharing the hydrogen are similar, a weak hydrogen bond in the enzyme-substrate complex in which the pK(a)'s do not match can become a strong, low-barrier one if the pK(a)'s become matched in the transition state or enzyme-intermediate complex. Several examples of enzymatic reactions that appear to use this principle are presented.	UNIV MINNESOTA,DEPT CHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	CLELAND, WW (corresponding author), UNIV WISCONSIN,INST ENZYME RES,MADISON,WI 53705, USA.				NIGMS NIH HHS [GM 18938] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018938, R01GM018938] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUDARI K, 1979, J AM CHEM SOC, V101, P3688, DOI 10.1021/ja00507a059; ADAMS MJ, 1973, P NATL ACAD SCI USA, V70, P1968, DOI 10.1073/pnas.70.7.1968; ALBRECHT G, 1984, Z NATURFORSCH A, V39, P986; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; BLANCHARD JS, 1980, BIOCHEMISTRY-US, V19, P4506, DOI 10.1021/bi00560a019; BRANT DA, 1963, J AM CHEM SOC, V85, P2204, DOI 10.1021/ja00898a003; BUEHNER M, 1974, J MOL BIOL, V90, P25, DOI 10.1016/0022-2836(74)90254-X; CLELAND WW, 1992, BIOCHEMISTRY-US, V31, P317, DOI 10.1021/bi00117a001; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GERIT JA, 1993, BIOCHEMISTRY-US, V32, P11943; GERIT JA, 1993, J AM CHEM SOC, V115, P11552; GILLI P, 1994, J AM CHEM SOC, V116, P909, DOI 10.1021/ja00082a011; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008; KAPLAN AP, 1991, BIOCHEMISTRY-US, V30, P8165, DOI 10.1021/bi00247a011; KARPUSAS M, 1990, BIOCHEMISTRY-US, V29, P2213, DOI 10.1021/bi00461a002; KIM H, 1990, BIOCHEMISTRY-US, V29, P5546, DOI 10.1021/bi00475a019; KIM HD, 1991, BIOCHEMISTRY-US, V30, P8171, DOI 10.1021/bi00247a012; KINTANAR A, 1991, J BIOL CHEM, V266, P17222; KREEVOY MM, 1980, J AM CHEM SOC, V102, P3315, DOI 10.1021/ja00530a002; KULIOPULOS A, 1991, BIOCHEMISTRY-US, V30, P3169, DOI 10.1021/bi00227a003; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LI YK, 1993, BIOCHEMISTRY-US, V32, P1816, DOI 10.1021/bi00058a016; LODI PJ, 1991, BIOCHEMISTRY-US, V30, P6948, DOI 10.1021/bi00242a020; NEIDHART DJ, 1991, BIOCHEMISTRY-US, V30, P9264, DOI 10.1021/bi00102a019; NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5948, DOI 10.1021/bi00416a019; PORTER DJT, 1980, J BIOL CHEM, V255, P4772; REMINGTON J, 1992, CURR OPIN STRUCT BIO, V2, P730; SCHLOSS JV, 1980, BIOCHEMISTRY-US, V19, P2358, DOI 10.1021/bi00552a012; SHOSTAK K, 1992, BIOCHEMISTRY-US, V31, P12155, DOI 10.1021/bi00163a026; SMILEY JA, 1992, BIOCHEMISTRY-US, V31, P12162, DOI 10.1021/bi00163a027; TRONRUD DE, 1986, EUR J BIOCHEM, V157, P261, DOI 10.1111/j.1432-1033.1986.tb09664.x; USHER KC, IN PRESS BIOCHEMISTR; VIOLA RE, 1984, ARCH BIOCHEM BIOPHYS, V228, P415, DOI 10.1016/0003-9861(84)90005-5; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10526, DOI 10.1021/bi00498a015; ZENG BF, 1991, J AM CHEM SOC, V113, P3838, DOI 10.1021/ja00010a028	36	1028	1037	3	150	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1887	1890		10.1126/science.8009219	http://dx.doi.org/10.1126/science.8009219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009219				2022-12-28	WOS:A1994NT84700034
J	WOLIN, SL				WOLIN, SL			FROM THE ELEPHANT TO ESCHERICHIA-COLI - SRP-DEPENDENT PROTEIN TARGETING	CELL			English	Review							SIGNAL-RECOGNITION PARTICLE; ESCHERICHIA-COLI RIBONUCLEOPROTEIN; ENDOPLASMIC-RETICULUM MEMBRANE; 4.5S RNA; SACCHAROMYCES-CEREVISIAE; SEQUENCE RECOGNITION; TRANSLOCATION; EXPORT; SUBUNIT; GENE		YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University	WOLIN, SL (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510, USA.		Wolin, Sandra/H-2333-2016	Wolin, Sandra/0000-0001-6730-0399				BERMAN AI, 1993, EMBO J, V12, P879; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BROWN S, 1991, NEW BIOL, V3, P430; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; Judson HF., 1979, 8 DAY CREATION; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LARSEN N, 1993, NUCLEIC ACIDS RES, V21, P3019, DOI 10.1093/nar/21.13.3019; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	28	61	63	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					787	790		10.1016/0092-8674(94)90124-4	http://dx.doi.org/10.1016/0092-8674(94)90124-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004667				2022-12-28	WOS:A1994NT33100002
J	VANCE, ML				VANCE, ML			MEDICAL PROGRESS - HYPOPITUITARISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GROWTH-HORMONE TREATMENT; NONFUNCTIONING PITUITARY-ADENOMAS; TRANS-SPHENOIDAL SURGERY; DEFICIENT ADULTS; ENDOCRINE FUNCTION; RADIATION-THERAPY; SHEEHANS SYNDROME; TUMORS; WOMEN; APOPLEXY				VANCE, ML (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, BOX 511, CHARLOTTESVILLE, VA 22908 USA.							ANNEGERS JF, 1978, MAYO CLIN PROC, V53, P641; ARAFAH BM, 1990, J CLIN ENDOCR METAB, V71, P323, DOI 10.1210/jcem-71-2-323; ARAFAH PM, 1986, J CLIN ENDOCR METAB, V62, P1173, DOI 10.1210/jcem-62-6-1173; ASA SL, 1981, ANN INTERN MED, V95, P166, DOI 10.7326/0003-4819-95-2-166; BARKAN AL, 1989, AM J MED SCI, V298, P38, DOI 10.1097/00000441-198907000-00007; BLACKETT PR, 1982, METABOLISM, V31, P117, DOI 10.1016/0026-0495(82)90121-4; CARDOSO ER, 1984, NEUROSURGERY, V14, P363, DOI 10.1227/00006123-198403000-00021; CAREY PO, 1988, J UROLOGY, V140, P76, DOI 10.1016/S0022-5347(17)41491-1; CONSTINE LS, 1993, NEW ENGL J MED, V328, P1208; CONSTINE LS, 1993, NEW ENGL J MED, V328, P87, DOI 10.1056/NEJM199301143280203; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; CUNEO RC, 1991, J APPL PHYSIOL, V70, P688, DOI 10.1152/jappl.1991.70.2.688; EBERSOLD MJ, 1986, J NEUROSURG, V64, P713, DOI 10.3171/jns.1986.64.5.0713; EDWARDS OM, 1986, MEDICINE, V65, P281; EIHOLZER U, 1986, EUR J PEDIATR, V145, P128, DOI 10.1007/BF00441873; FINDLAY JC, 1987, J CLIN ENDOCR METAB, V64, P266, DOI 10.1210/jcem-64-2-266; GOLD EB, 1981, EPIDEMIOL REV, V3, P163, DOI 10.1093/oxfordjournals.epirev.a036232; GREENSPAN SL, 1989, ANN INTERN MED, V110, P526, DOI 10.7326/0003-4819-110-7-526; HARRIS PE, 1989, Q J MED, V71, P417; ISHIKAWA SE, 1988, ENDOCRINOL JAPON, V35, P665; JADRESIC A, 1987, ACTA ENDOCRINOL-COP, V115, P301, DOI 10.1530/acta.0.1150301; JORGENSEN JOL, 1991, ACTA ENDOCRINOL-COP, V125, P449; JORGENSEN JOL, 1989, LANCET, V1, P1221; KELLY TM, 1984, ANN INTERN MED, V101, P629, DOI 10.7326/0003-4819-101-5-629; KLEINBERG DL, 1983, NEW ENGL J MED, V309, P704, DOI 10.1056/NEJM198309223091205; KLIBANSKI A, 1980, NEW ENGL J MED, V303, P1511, DOI 10.1056/NEJM198012253032605; KLIMAN B, 1984, SECRETORY TUMORS PIT, P191; KURLAND LT, 1958, J NEUROSURG, V15, P627, DOI 10.3171/jns.1958.15.6.0627; LAM KSL, 1987, J CLIN ENDOCR METAB, V64, P418, DOI 10.1210/jcem-64-3-418; LAWS ER, 1987, ENDOCRIN METAB CLIN, V16, P647, DOI 10.1016/S0889-8529(18)30467-5; LINFOOT JA, 1980, P SERONO S, V29, P515; LITTLEY MD, 1989, Q J MED, V70, P145; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MAY ME, 1985, AM J MED, V79, P679, DOI 10.1016/0002-9343(85)90517-0; MCGAULEY GA, 1989, ACTA PAEDIATR SCAND, P70; MERIMEE TJ, 1972, METABOLISM, V21, P1053, DOI 10.1016/0026-0495(72)90036-4; MIURA M, 1989, SURG NEUROL, V32, P463, DOI 10.1016/0090-3019(89)90013-X; MOLITCH ME, 1985, J CLIN ENDOCR METAB, V60, P698, DOI 10.1210/jcem-60-4-698; NAKAGAWA Y, 1984, NEURORADIOLOGY, V26, P473, DOI 10.1007/BF00342684; NELSON PB, 1989, NEUROSURGERY, V24, P398, DOI 10.1227/00006123-198903000-00015; OOI TC, 1986, CAN J NEUROL SCI, V13, P70, DOI 10.1017/S0317167100035836; PERCY AK, 1972, NEUROLOGY, V22, P40, DOI 10.1212/WNL.22.1.40; POCECCO M, 1988, HELV PAEDIATR ACTA, V42, P289; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; SAMAAN NA, 1982, INT J RADIAT ONCOL, V8, P1857, DOI 10.1016/0360-3016(82)90442-4; SANDLER LM, 1987, J CLIN ENDOCR METAB, V65, P441, DOI 10.1210/jcem-65-3-441; SAUDER SE, 1984, J CLIN ENDOCR METAB, V59, P941, DOI 10.1210/jcem-59-5-941; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; SHERIF IH, 1989, CLIN ENDOCRINOL, V30, P613, DOI 10.1111/j.1365-2265.1989.tb00265.x; SHONE GR, 1991, J ROY SOC MED, V84, P140, DOI 10.1177/014107689108400308; SNYDER PJ, 1986, AM J MED, V81, P457, DOI 10.1016/0002-9343(86)90299-8; STALLA GK, 1988, HORM RES, V29, P191, DOI 10.1159/000181001; STEVENAERT A, 1986, J CLIN ENDOCR METAB, V62, P1044, DOI 10.1210/jcem-62-5-1044; van Lindert E J, 1991, Br J Neurosurg, V5, P129, DOI 10.3109/02688699108998458; VANCE ML, 1990, ANN INTERN MED, V112, P668, DOI 10.7326/0003-4819-112-9-668; VANCE ML, 1989, J CLIN ENDOCR METAB, V68, P336, DOI 10.1210/jcem-68-2-336; VANCE ML, 1991, 73RD ANN M WASH, P249; Veldhuis J D, 1980, Endocr Rev, V1, P100; WAKAI S, 1981, J NEUROSURG, V55, P187, DOI 10.3171/jns.1981.55.2.0187	60	167	170	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	1994	330	23					1651	1662		10.1056/NEJM199406093302306	http://dx.doi.org/10.1056/NEJM199406093302306			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP220	8043090				2022-12-28	WOS:A1994NP22000006
J	MARTEAU, T				MARTEAU, T			ACTIVE CASCADE SCREENING FOR CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Note											MARTEAU, T (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,PSYCHOL & GENET RES GRP,GROUND FLOOR,LONDON SE1 9RT,ENGLAND.			Marteau, Theresa/0000-0003-3025-1129				1993, GENETIC SCREENING ET; 1993, SICKLE CELL THALASSA; 1989, PRENATAL DIAGNOSIS G	3	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1468	1468		10.1136/bmj.308.6942.1468	http://dx.doi.org/10.1136/bmj.308.6942.1468			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019279	Green Published			2022-12-28	WOS:A1994NQ22900014
J	BENNETT, DH; TAMBEUR, LJMT; CAMPBELL, WB				BENNETT, DH; TAMBEUR, LJMT; CAMPBELL, WB			USE OF COUGHING TEST TO DIAGNOSE PERITONITIS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL DEVON & EXETER HOSP,DEPT SURG,EXETER EX2 5DW,DEVON,ENGLAND	University of Exeter								DIXON JM, 1991, BRIT MED J, V302, P386, DOI 10.1136/bmj.302.6773.386; LIDDINGTON MI, 1991, BRIT J SURG, V78, P795, DOI 10.1002/bjs.1800780710; MOORE SW, 1958, SURG CLIN N AM, V38, P371; PROUT WG, 1970, BRIT J SURG, V57, P508, DOI 10.1002/bjs.1800570706	4	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1336	1336						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019222				2022-12-28	WOS:A1994NM98900023
J	KATZ, AM				KATZ, AM			THE CARDIOMYOPATHY OF OVERLOAD - AN UNNATURAL GROWTH-RESPONSE IN THE HYPERTROPHIED HEART	ANNALS OF INTERNAL MEDICINE			English	Review							CONVERTING ENZYME-INHIBITORS; MYOCARDIAL INFARCT SIZE; CARDIAC-FAILURE; C-MYC; VASODILATOR THERAPY; MITOCHONDRIAL-DNA; ANGIOTENSIN-II; PROTOONCOGENE EXPRESSION; RETINOBLASTOMA PROTEIN; ISOSORBIDE DINITRATE	Heart failure is a progressive condition with a Ei-year survival of less than 50%. This poor prognosis, which can be reproduced by overloading the hearts of experimental animals, may reflect molecular abnormalities caused when overload stimulates adult cardiac myocytes to undergo hypertrophy. Because these terminally differentiated cells have little or no capacity to divide, hypertrophy represents an unnatural growth response; however, the mechanism by which overload shortens survival remains speculative. Modification of this unnatural growth response by converting enzyme inhibitors and nitrates, which have growth inhibitory as well as vasodilator effects, may contribute to the ability of these drugs to improve prognosis in patients with heart failure.			KATZ, AM (corresponding author), UNIV CONNECTICUT, CTR HLTH, SCH MED, DIV CARDIOL, FARMINGTON, CT 06030 USA.				NHLBI NIH HHS [HL-33026] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033026] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANVERSA P, 1990, CIRC RES, V67, P871, DOI 10.1161/01.RES.67.4.871; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BARJON JN, 1987, J AM COLL CARDIOL, V9, P622, DOI 10.1016/S0735-1097(87)80057-8; BATHON JM, 1991, ANNU REV PHARMACOL, V31, P129; BRISTOW MR, 1994, CIRCULATION, V89, P1632, DOI 10.1161/01.CIR.89.4.1632; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; COHENJJ, 1993, IMMUNOL TODAY, V14, P126; Cohn J. N., 1993, CIRCULATION S, V87, pVI; COHN JN, 1989, NEW ENGL J MED, V320, P729, DOI 10.1056/NEJM198903163201109; COHN JN, 1977, NEW ENGL J MED, V297, P27; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1977, NEW ENGL J MED, V297, P254; COLLINS MKL, 1993, TRENDS BIOCHEM SCI, V18, P307, DOI 10.1016/0968-0004(93)90042-L; CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812; CURFMAN GD, 1991, NEW ENGL J MED, V325, P1509, DOI 10.1056/NEJM199111213252111; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; DIES F, 1986, CIRCULATION, V74, P38; DZAU VJ, 1994, CIRCULATION, V89, P493, DOI 10.1161/01.CIR.89.1.493; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EICHHORN EJ, 1992, AM J MED, V92, P527, DOI 10.1016/0002-9343(92)90750-6; ELKAYAM U, 1990, CIRCULATION, V82, P1954, DOI 10.1161/01.CIR.82.6.1954; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARHY RD, 1992, BIOCHEM BIOPH RES CO, V182, P283, DOI 10.1016/S0006-291X(05)80142-1; FARHY RD, 1993, CIRC RES, V72, P1202, DOI 10.1161/01.RES.72.6.1202; FELDMAN AM, 1993, NEW ENGL J MED, V329, P149, DOI 10.1056/NEJM199307153290301; FERGUSON DW, 1989, CIRCULATION, V80, P65, DOI 10.1161/01.CIR.80.1.65; FISHER ML, 1994, J AM COLL CARDIOL, V23, P943, DOI 10.1016/0735-1097(94)90641-6; FLINT A, 1870, PRACTICAL TREATISE D, P33; FRODSHAM G, 1992, EUR J PHARMACOL, V211, P383, DOI 10.1016/0014-2999(92)90396-L; FURBERG CD, 1988, AM J CARDIOL, V62, pA41, DOI 10.1016/S0002-9149(88)80084-5; GARR MD, 1992, CLIN RES, V40, pA702; GARRISON JC, 1990, PHARMACOL BASIS THER, P749; GOLDSTEIN RE, 1991, CIRCULATION, V83, P52, DOI 10.1161/01.CIR.83.1.52; GREENBERG S, 1990, J CARDIOVASC PHARM, V15, P900, DOI 10.1097/00005344-199006000-00007; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; HARRIS P, 1983, CARDIOVASC RES, V17, P437, DOI 10.1093/cvr/17.8.437; HARRIS P, 1983, CARDIOVASC RES, V17, P313, DOI 10.1093/cvr/17.6.313; HARRIS P, 1983, CARDIOVASC RES, V17, P373, DOI 10.1093/cvr/17.7.373; HARTMAN JC, 1993, J CARDIOVASC PHARM, V21, P996, DOI 10.1097/00005344-199306000-00022; HARTMAN JC, 1993, EUR J PHARMACOL, V234, P229; HIRSCH AT, 1992, CIRCULATION, V86, P1566, DOI 10.1161/01.CIR.86.5.1566; HJALMARSON A, 1991, EUR HEART J, V12, P63, DOI 10.1093/eurheartj/12.suppl_F.63; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; INGWALL JS, 1993, CIRCULATION, V87, P58; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; KAJSTURA J, 1994, CIRC RES, V74, P383, DOI 10.1161/01.RES.74.3.383; Katz A. M., 1992, PHYSL HEART; KATZ AM, 1990, CARDIOLOGY, V77, P346, DOI 10.1159/000174624; KATZ AM, 1986, CIRCULATION, V73, P184; KATZ AM, 1990, J MOL CELL CARDIOL, V22, P739, DOI 10.1016/0022-2828(90)90086-H; KATZ AM, 1988, J MOL CELL CARDIOL, V20, P355, DOI 10.1016/S0022-2828(88)80069-5; KATZ AM, 1975, NEW ENGL J MED, V293, P1184, DOI 10.1056/NEJM197512042932309; KATZ AM, 1990, NEW ENGL J MED, V322, P100; KATZ AM, 1973, CIRCULATION, V47, P1076, DOI 10.1161/01.CIR.47.5.1076; KOMURO I, 1988, CIRC RES, V62, P1075, DOI 10.1161/01.RES.62.6.1075; KOMURO I, 1990, J BIOL CHEM, V265, P3595; LANG D, 1992, EUR J PHARM-MOLEC PH, V226, P259, DOI 10.1016/0922-4106(92)90070-C; Lauder Brunton T, 1867, LANCET, V90, P97, DOI DOI 10.1016/S0140-6736(02)51392-1; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; LINZ W, 1992, J CARDIOVASC PHARM, V20, pS83, DOI 10.1097/00005344-199200209-00015; LINZ W, 1989, CLIN EXP HYPERTENS A, V11, P1325, DOI 10.3109/10641968909038172; MACLELLAN WR, 1993, CIRC RES, V73, P783, DOI 10.1161/01.RES.73.5.783; MASON DT, 1964, J CLIN INVEST, V43, P532, DOI 10.1172/JCI104939; MEERSON F Z, 1961, Cor Vasa, V3, P161; MOMBOULI JV, 1992, J CARDIOVASC PHARM, V20, pS74, DOI 10.1097/00005344-199200209-00014; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; MULVAGH SL, 1987, BIOCHEM BIOPH RES CO, V147, P627, DOI 10.1016/0006-291X(87)90977-6; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; Newman T J, 1988, Am J Med, V84, P140, DOI 10.1016/0002-9343(88)90221-5; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; OBAYASHI T, 1992, AM HEART J, V124, P1263, DOI 10.1016/0002-8703(92)90410-W; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OSLER W, 1892, PRINCIPLES PRACTICE, P634; PACKER M, 1993, NEW ENGL J MED, V329, P201, DOI 10.1056/NEJM199307153290310; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PACKER M, 1990, CIRCULATION, V82, P2254, DOI 10.1161/01.CIR.82.6.2254; PACKER M, 1992, J AM COLL CARDIOL, V20, P248, DOI 10.1016/0735-1097(92)90167-L; PACKER M, 1980, CIRCULATION S, V6, P59; PFEFFER JM, 1985, CIRC RES, V57, P84, DOI 10.1161/01.RES.57.1.84; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1985, CIRCULATION, V72, P406, DOI 10.1161/01.CIR.72.2.406; REMES AM, 1994, J AM COLL CARDIOL, V23, P935, DOI 10.1016/0735-1097(94)90640-8; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SARNOFF SJ, 1952, CIRCULATION, V6, P63, DOI 10.1161/01.CIR.6.1.63; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SCHROR K, 1992, J CARDIOVASC PHARM, V20, pS68, DOI 10.1097/00005344-199200209-00013; SCHWARTZ K, 1993, J AM COLL CARDIOL, V22, pA30, DOI 10.1016/0735-1097(93)90459-E; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STARKSEN NF, 1986, P NATL ACAD SCI USA, V83, P8348, DOI 10.1073/pnas.83.21.8348; SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TAM SKC, 1993, CIRCULATION, V88, P240; URETSKY BF, 1990, CIRCULATION, V82, P774, DOI 10.1161/01.CIR.82.3.774; URETSKY BF, 1993, J AM COLL CARDIOL, V22, P955, DOI 10.1016/0735-1097(93)90403-N; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N; YUSUF S, 1990, CIRCULATION, V82, P673; 1991, LANCET, V337, P885	112	175	177	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					363	371		10.7326/0003-4819-121-5-199409010-00009	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042826				2022-12-28	WOS:A1994PD70100009
J	WIESEN, AR; HOSPENTHAL, DR; BYRD, JC; GLASS, KL; HOWARD, RS; DIEHL, LF				WIESEN, AR; HOSPENTHAL, DR; BYRD, JC; GLASS, KL; HOWARD, RS; DIEHL, LF			EQUILIBRATION OF HEMOGLOBIN CONCENTRATION AFTER TRANSFUSION IN MEDICAL INPATIENTS NOT ACTIVELY BLEEDING	ANNALS OF INTERNAL MEDICINE			English	Note							UNITED-STATES; BLOOD; COLLECTION		WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center								Barnes A, 1993, HEMATOLOGY CLIN LAB, P1653; GROVERASMUSSEN M, 1961, NEW ENGL J MED, V264, P1034, DOI 10.1056/NEJM196105182642006; HUBER H, 1964, BRIT J HAEMATOL, V10, P567, DOI 10.1111/j.1365-2141.1964.tb00733.x; Johnston M, 1985, TRANSFUSION THERAPY, P35; Jones J, 1993, BLOOD TRANSFUSION CL, P423; KEELING RP, 1987, FUNDAMENTALS CLIN HE, P932; MCCULLOUGH J, 1993, JAMA-J AM MED ASSOC, V269, P2239, DOI 10.1001/jama.269.17.2239; MOLLISON PL, 1947, CLIN SCI, V6, P137; NADLER SB, 1962, SURGERY, V51, P224; OCONNELL B, 1988, TRANSFUSION, V28, P66, DOI 10.1046/j.1537-2995.1988.28188127957.x; Rovin BH., 1989, MANUAL MED THERAPEUT, P221; Sekhsaria S, 1991, J Perinatol, V11, P161; Simon TL, 1991, PRINCIPLES TRANSFUSI, P97; SIMPSON MB, 1984, LABORATORY HEMATOLOG, P1149; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WIDMANN FK, 1985, TECHNICAL MANUAL AM, P7; WINTROBE MM, 1981, CLIN HEMATOLOGY, P8	19	64	69	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					278	280		10.7326/0003-4819-121-4-199408150-00009	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037410	Green Submitted			2022-12-28	WOS:A1994PB10200009
J	BURKE, JF; PIRSCH, JD; RAMOS, EL; SALOMON, DR; STABLEIN, DM; VANBUREN, DH; WEST, JC				BURKE, JF; PIRSCH, JD; RAMOS, EL; SALOMON, DR; STABLEIN, DM; VANBUREN, DH; WEST, JC			LONG-TERM EFFICACY AND SAFETY OF CYCLOSPORINE IN RENAL-TRANSPLANT RECIPIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALLOGRAFT RECIPIENTS; FOLLOW-UP; RANDOMIZED TRIAL; AUTOIMMUNE-DISEASES; REJECTION EPISODES; DRUG THERAPY; RISK-FACTORS; TRIPLE-DRUG; NEPHROTOXICITY; IMMUNOSUPPRESSION	Background and Methods. The safety of long-term immunosuppression with cyclosporine in renal-transplant recipients is not well understood. This drug may cause a progressive toxic nephropathy, but it also preserves renal function because it prevents rejection. To determine the effect of cyclosporine on renal function and graft rejection, we conducted a retrospective analysis of data on 1663 renal-transplant recipients at six centers. Results. The rate of graft survival was 78 percent (median follow-up, 36 months). Grafts were lost in 279 patients (17 percent), mostly because of acute rejection (68 patients) or chronic graft dysfunction that was unresponsive to a reduction in the dose of cyclosporine (125 patients); 92 patients died with functioning grafts. The median change in the serum creatinine concentration in all patients after transplantation was less than 0.001 mg per deciliter per month (<0.09 mu mol per liter per month). Patients who had episodes of rejection had decreased rates of long-term graft function and survival. Eight percent of patients with functioning grafts at one year had first episodes of rejection more than one year after transplantation. These late first rejections were associated with noncompliance with therapy (in 34 percent), blood cyclosporine concentrations that were marginally lower than those of patients who had no episodes of rejection, and a low rate of successful reversal of rejection (77 percent, vs. 97 percent in patients with rejection during the first year; P<0.001). Conclusions. The majority of renal-transplant patients tolerate long-term cyclosporine therapy without evidence of progressive toxic nephropathy. Graft failure is most often due to rejection.	THOMAS JEFFERSON UNIV HOSP, TRANSPLANT PROGRAM, PHILADELPHIA, PA USA; UNIV WISCONSIN, TRANSPLANT PROGRAM, MADISON, WI USA; BRIGHAM & WOMENS HOSP, RENAL TRANSPLANT PROGRAM, BOSTON, MA 02115 USA; UNIV FLORIDA, KIDNEY TRANSPLANT PROGRAM, GAINESVILLE, FL USA; EMMES CORP, POTOMAC, MD USA; VANDERBILT UNIV, CTR TRANSPLANT, NASHVILLE, TN USA; GEISINGER MED CTR, DEPT SURG, TRANSPLANT SECT, DANVILLE, PA 17822 USA	Jefferson University; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Brigham & Women's Hospital; State University System of Florida; University of Florida; Emmes Corporation; Vanderbilt University; Geisinger Medical Center			Salomon, Daniel/E-9380-2012					ALMOND PS, 1992, TRANSPLANTATION, V53, P316, DOI 10.1097/00007890-199202010-00012; ALMOND PS, 1993, TRANSPLANTATION, V55, P752, DOI 10.1097/00007890-199304000-00013; AMEND W, 1990, CLIN TRANSPLANT, V4, P341; BASADONNA GP, 1993, TRANSPLANTATION, V55, P993, DOI 10.1097/00007890-199305000-00007; BENMAIMON CS, 1991, TRANSPL P, V23, P1260; BRINKER KR, 1990, TRANSPLANTATION, V50, P43, DOI 10.1097/00007890-199007000-00009; CALNE RY, 1987, LANCET, V2, P506; CANAFAX DM, 1988, CLIN TRANSPLANT, V3, P110; Cecka J M, 1989, Clin Transpl, P425; CECKA JM, 1992, TRANSPLANTATION, V53, P59, DOI 10.1097/00007890-199201000-00011; DELMONICO FL, 1990, TRANSPLANTATION, V49, P899, DOI 10.1097/00007890-199005000-00013; DIETERLE A, 1990, TRANSPLANTATION, V49, P1093, DOI 10.1097/00007890-199006000-00013; FEUTREN G, 1992, NEW ENGL J MED, V326, P1654, DOI 10.1056/NEJM199206183262502; GREENBERG A, 1990, TRANSPLANTATION, V50, P589, DOI 10.1097/00007890-199010000-00012; GULANIKAR AC, 1992, TRANSPLANTATION, V53, P323, DOI 10.1097/00007890-199202010-00013; HARDER F, 1983, Lancet, V2, P986; KUPIN WL, 1987, TRANSPLANTATION, V43, P214, DOI 10.1097/00007890-198702000-00010; LEWIS RM, 1989, TRANSPLANTATION, V47, P266, DOI 10.1097/00007890-198902000-00014; LEWIS RM, 1989, TRANSPLANTATION, V48, P177; LORBER MI, 1987, AM J KIDNEY DIS, V9, P476, DOI 10.1016/S0272-6386(87)80074-4; MERION RM, 1984, NEW ENGL J MED, V310, P148, DOI 10.1056/NEJM198401193100303; MIHATSCH MJ, 1988, TRANSPLANT P, V20, P759; MIHATSCH MJ, 1988, KLIN WOCHENSCHR, V66, P43, DOI 10.1007/BF01713009; MYERS BD, 1988, KIDNEY INT, V33, P590, DOI 10.1038/ki.1988.38; PONTICELLI C, 1988, TRANSPLANTATION, V45, P913, DOI 10.1097/00007890-198805000-00014; PONTICELLI C, 1988, TRANSPLANTATION, V45, P908, DOI 10.1097/00007890-198805000-00013; ROCHER LL, 1984, TRANSPLANTATION, V38, P669, DOI 10.1097/00007890-198412000-00024; ROTH D, 1991, Journal of the American Society of Nephrology, V2, P815; SALOMON D, 1991, TRANSPLANT P, V23, P1018; SALOMON DR, 1991, TRANSPLANT P, V23, P2115; SINCLAIR NR, 1986, NEW ENGL J MED, V314, P1219; VERSLUIS DJ, 1987, TRANSPLANTATION, V44, P387, DOI 10.1097/00007890-198709000-00012; WRENSHALL LE, 1990, TRANSPLANTATION, V50, P233, DOI 10.1097/00007890-199008000-00012	33	244	247	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					358	363		10.1056/NEJM199408113310604	http://dx.doi.org/10.1056/NEJM199408113310604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA374	8028616				2022-12-28	WOS:A1994PA37400004
J	WANG, YH; AMIRHAERI, S; KANG, S; WELLS, RD; GRIFFITH, JD				WANG, YH; AMIRHAERI, S; KANG, S; WELLS, RD; GRIFFITH, JD			PREFERENTIAL NUCLEOSOME ASSEMBLY AT DNA TRIPLET REPEATS FROM THE MYOTONIC-DYSTROPHY GENE	SCIENCE			English	Article							FRAGILE-X; MUTATIONS; SEQUENCE; INSTABILITY; EXPANSION; DISEASE	The expansion of CTG repeats in DNA occurs in or near genes involved in several human diseases, including myotonic dystrophy and Huntington's disease. Nucleosomes, the basic structural element of chromosomes, consist of 146 base pairs of DNA coiled about an octamer of histone proteins and mediate general transcriptional repression. Electron microscopy was used to examine in vitro the nucleosome assembly of DNA containing repeating CTG triplets. The efficiency of nucleosome formation increased with expanded triplet blocks, suggesting that such blocks may repress transcription through the creation of stable nucleosomes.	UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; TEXAS A&M UNIV,INST BIOSCI & TECHNOL,HOUSTON,TX 77030	University of North Carolina; University of North Carolina Chapel Hill; Texas A&M University System					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030822, R01GM031819] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30822, GM31819, GM42342] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIRHAERI S, UNPUB; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; Kang S.-G., UNPUB; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MUZARD G, 1990, EMBO J, V9, P1289, DOI 10.1002/j.1460-2075.1990.tb08238.x; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; RICHARDS RI, 1992, NAT GENET, V1, P7, DOI 10.1038/ng0492-7; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; STELLWAGEN NC, 1983, BIOCHEMISTRY-US, V22, P6186, DOI 10.1021/bi00295a023; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WANG Y, UNPUB; 1993, CELL, V72, P971	25	203	208	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					669	671		10.1126/science.8036515	http://dx.doi.org/10.1126/science.8036515			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036515				2022-12-28	WOS:A1994NZ53800035
J	LIAO, H; LI, G; YEN, TJ				LIAO, H; LI, G; YEN, TJ			MITOTIC REGULATION OF MICROTUBULE CROSS-LINKING ACTIVITY OF CENP-E KINETOCHORE PROTEIN	SCIENCE			English	Article							TAU-PROTEIN; MAP2; SEQUENCE; MITOSIS; TUBULIN; CELLS; DNA	CENP-E is a kinesin-like protein that is transiently bound to kinetochores during early mitosis, becomes redistributed to the spindle midzone at anaphase, and is degraded after cytokinesis. At anaphase, CENP-E may cross-link the interdigitating microtubules in the spindle midzone through a motor-like binding site at the amino terminus and a 99-amino acid carboxyl-terminal domain that bound microtubules in a distinct manner. Phosphorylation of the carboxyl terminus by the mitotic kinase maturation promoting factor (MPF) inhibited microtubule-binding activity before anaphase. Thus, MPF suppresses the microtubule cross-linking activity of CENP-E until anaphase, when its activity is lost.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center				JOHNSON, HEATHER/0000-0001-7468-0705; Yen, Tim/0000-0003-2159-0997	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044762] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [GM-44762-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; MCINTOSH JR, 1989, SCIENCE, V246, P622; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Sawin K E, 1991, Trends Cell Biol, V1, P122, DOI 10.1016/0962-8924(91)90117-R; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	15	117	120	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					394	398		10.1126/science.8023161	http://dx.doi.org/10.1126/science.8023161			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023161				2022-12-28	WOS:A1994NW81600040
J	SCHECTER, AD; CHESEBRO, JH; FUSTER, V				SCHECTER, AD; CHESEBRO, JH; FUSTER, V			REFRACTORY PRINZMETAL ANGINA TREATED WITH CYPROHEPTADINE	ANNALS OF INTERNAL MEDICINE			English	Note							SEROTONIN; ENDOTHELIUM; PIGS		MASSACHUSETTS GEN HOSP, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986				DECATERINA R, 1984, CIRCULATION, V69, P889, DOI 10.1161/01.CIR.69.5.889; DROUET L, 1990, J CARDIOVASC PHARM, V16, pS49, DOI 10.1097/00005344-199000163-00012; LERMAN A, 1993, CIRCULATION, V88, P2923, DOI 10.1161/01.CIR.88.6.2923; MCFADDEN EP, 1991, NEW ENGL J MED, V324, P648, DOI 10.1056/NEJM199103073241002; NAGASAWA K, 1989, CIRC RES, V65, P272, DOI 10.1161/01.RES.65.2.272; PEROUTKA SJ, 1990, J CARDIOVASC PHARM, V16, pS8, DOI 10.1097/00005344-199000163-00003; SHIMOKAWA H, 1991, J AM COLL CARDIOL, V17, P1197, DOI 10.1016/0735-1097(91)90854-3; VANHOUTTE PM, 1991, J CARDIOVASC PHARM, V17, pS6; WILLERSON JT, 1991, J CARDIOVASC PHARM, V17, pS13; YAMAMOTO Y, 1987, CIRC RES, V61, P772, DOI 10.1161/01.RES.61.6.772	10	9	9	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					113	114		10.7326/0003-4819-121-2-199407150-00006	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017723				2022-12-28	WOS:A1994NW18600006
J	BERO, LA; GLANTZ, SA; RENNIE, D				BERO, LA; GLANTZ, SA; RENNIE, D			PUBLICATION BIAS AND PUBLIC-HEALTH POLICY ON ENVIRONMENTAL TOBACCO-SMOKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine the tobacco industry's claim that publication bias against negative studies invalidates the risk assessment of environmental tobacco smoke (ETS) conducted by the US Environmental Protection Agency and other reviews of the health effects of ETS. Design.-Determination of the number of published original research articles that tested the hypothesis that ETS exposure is associated with adverse health effects and that reported statistically significant (''positive'') or nonsignificant (''negative'') results; the number of articles that concluded that ETS is a health risk; and unpublished studies on the effects of ETS on health. Participants.-Articles identified by a computerized search of the medical literature supplemented with material obtained from the tobacco industry and hand searching. Articles were classified as peer-reviewed journal articles or articles from sponsored symposia. Main Outcome Measure.-The statistical significance of results reported in the article and whether or not the article concluded that ETS exposure is a health risk. Results.-More symposium articles than journal articles were reviews (46% vs 6%; P=.0001). More original journal articles than original symposium articles reported the use of statistical tests (96% vs 54%; P=.0001). Of articles with statistical analyses, similar proportions of journal articles and symposium articles reported statistically significant results (57% vs 47%; P=.329). The conclusions of 80% of the original journal articles were positive, compared with 51% of the original symposium articles (P=.006). Conclusions.-There is no publication bias against statistically nonsignificant results on ETS in the peer-reviewed literature. The high proportion of articles in symposia that reach the conclusion that ETS is not harmful primarily results from the inclusion of review articles.	UNIV CALIF SAN FRANCISCO, SCH MED, DIV CARDIOL, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, SCH PHARM, DIV CLIN PHARM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BERO, LA (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, INST HLTH POLICY STUDIES, 1388 SUTTER ST, 11TH FLOOR, SAN FRANCISCO, CA 94109 USA.							[Anonymous], 1986, ENV TOBACCO SMOKE ME; ARMITAGE AK, 1993, J SMOKING RELATED DI, V4, P27; BERO LA, 1994, JAMA-J AM MED ASSOC, V271, P612, DOI 10.1001/jama.271.8.612; BERO LA, 1993, TOB CONTROL, V2, P103; BROWNSON RC, 1987, AM J EPIDEMIOL, V125, P25, DOI 10.1093/oxfordjournals.aje.a114509; BUTLER TL, 1988, THESIS U CALIFORNIA; CALDWELL ADS, 1992, J SMOKING REL DISORD, V4, P1; CATANOSO J, 1992, NEWS REC        0926, pA1; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; CHALMERS TC, 1982, T AM CLIN CLIMAT ASS, V8, P388; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; FEUER G, UNPUB ASSESSMENT HLT; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HUBER GL, 1991, CONSUMERS RES    JUL, P10; HUMBLE CG, 1987, AM J PUBLIC HEALTH, V77, P598, DOI 10.2105/AJPH.77.5.598; KILPATRICK SJ, 1992, INT SURG, V77, P131; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; Lam W. K., 1985, THESIS U HONG KONG; LEE PN, 1992, ENV TOBACCO SMOKE MO; MANTEL N, 1989, INT CONGR SER, V860, P155; MCNAMEE R, 1989, BRIT J IND MED, V46, P143; OLDAKER GB, 1989, J NATL CANCER I, V81, P1424, DOI 10.1093/jnci/81.18.1424; OLDAKER GB, UNPUB ETS PASSENGER; POCOCK SJ, 1990, STAT MED, V9, P657, DOI 10.1002/sim.4780090612; RENNIE D, 1992, JAMA-J AM MED ASSOC, V267, P411, DOI 10.1001/jama.267.3.411; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; STERLING T, UNPUB COMP RISK CHRO; STERLING TD, 1959, J AM STAT ASSOC, V54, P30, DOI 10.2307/2282137; STERLING TD, 1992, EPIDEMIOLOGY, V3, P11, DOI 10.1097/00001648-199201000-00004; STERLING TD, UNPUB BIAS DIAGNOSIS; SUGITA M, 1992, JPN J CLIN ONCOL, V22, P354; SVENSSON C, 1988, SMOKING PASSIVE SMOK; SZKLO M, 1991, J CLIN EPIDEMIOL, V44, pS109; VANDENBROUCKE JP, 1988, BRIT MED J, V296, P391, DOI 10.1136/bmj.296.6619.391; VARELA LR, 1987, THESIS YALE U; WEETMAN DF, 1992, INDOOR ENVIRON, V1, P197; WELLS AJ, 1988, BRIT MED J, V296, P1128, DOI 10.1136/bmj.296.6629.1128-a; WOODWARD A, 1991, EUR J CANCER, V27, P1472, DOI 10.1016/0277-5379(91)90034-B; WU AHT, 1988, CASE CONTROL STUDY L; 1990, MAILING TOBACCO ACTI; 1984, CIGARETTE SMOKE NONS; SMOKING RESTRICTIONS; 1986, DHHS CDC878398 US DE, P332; 1990, HLTH EFFECTS PASSIVE; 1990, SCI DOES NOT SUPPORT; ENV TOBACCO SMOKE HL; SMOKERS RIGHTS WORKP; SMOKING WORKPLACE SO; 1992, RESPIRATORY HLTH EFF; 1986, TOBACCO SMOKE NONSMO	55	45	46	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					133	136		10.1001/jama.272.2.133	http://dx.doi.org/10.1001/jama.272.2.133			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015124				2022-12-28	WOS:A1994NV42400014
J	GARFUNKEL, JM; ULSHEN, MH; HAMRICK, HJ; LAWSON, EE				GARFUNKEL, JM; ULSHEN, MH; HAMRICK, HJ; LAWSON, EE			EFFECT OF INSTITUTIONAL PRESTIGE ON REVIEWERS RECOMMENDATIONS AND EDITORIAL DECISIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC			Objective.-To determine whether manuscripts from institutions with greater prestige are more likely to be recommended for publication by reviewers and to be accepted for publication. Design.-Retrospective study of reviewers' recommendations and editorial decisions for manuscripts from the United States received at the Journal of Pediatrics between January 1 and July 31, 1992. Manuscripts were Classified as major papers or as brief reports. Institutions were ranked in quintiles according to the monetary value of grants funded by the National Institutes of Health. Reviewers' recommendations were classified as reject, reconsider, or accept, and editorial decisions as accept or reject, without regard to qualifying recommendations. Results.-For the 147 brief reports, lower institutional rank was associated with lower rates of recommendation for acceptance and of selection for publication. For the 258 major papers, however, there was no significant relationship between institutional rank and either the reviewers' recommendations or the acceptance rate. Similar results were found when the manuscripts were divided into five numerically equal groups according to institutional rank. Conclusions.-Major manuscripts from institutions with greater prestige were no more likely to be recommended or accepted for publication than those from institutions with lesser prestige. In contrast, the likelihood of recommendation for acceptance and of selection for publication of brief reports appeared to correlate with the prestige of the institution.	UNIV N CAROLINA,SCH MED,DEPT PEDIAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	GARFUNKEL, JM (corresponding author), UNIV N CAROLINA,JOURNAL PEDIAT,CBN 7230,MED SCH WING C,CHAPEL HILL,NC 27599, USA.							LOCK S, 1986, DIFFICULT BALANCE, P26; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; MERTON RK, 1968, SCIENCE, V159, P56, DOI 10.1126/science.159.3810.56; PETERS DP, 1982, BEHAV BRAIN SCI, V5, P187, DOI 10.1017/S0140525X00011183; YANKAUER A, 1991, AM J PUBLIC HEALTH, V81, P843, DOI 10.2105/AJPH.81.7.843	5	56	57	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					137	138		10.1001/jama.272.2.137	http://dx.doi.org/10.1001/jama.272.2.137			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015125				2022-12-28	WOS:A1994NV42400015
J	SCHULMAN, K; SULMASY, DP; RONEY, D				SCHULMAN, K; SULMASY, DP; RONEY, D			ETHICS, ECONOMICS, AND THE PUBLICATION POLICIES OF MAJOR MEDICAL JOURNALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		BIOETHICS	Objective.-To evaluate aspects of the publication process that may affect the quality of the literature in clinical economics and biomedical ethics, and to learn about the policies of medical journals regarding disclosure of relationships between investigators and research sponsors. Design.-Mail survey. Participants.-Editors in chief of 15 major medical journals. Results.-Twelve editors responded to the survey. Ten reported having statisticians among their editors, while only two had health economists and none had ethicists. Clinicians in the specialty field were almost always the primary reviewers of submissions, while methodologists (statisticians, health economists, or ethicists) were involved less frequently. Journals reported little knowledge of the training of their reviewers in these fields. While nine journals requested disclosure of the financial relationship between author and sponsor, only one inquired whether the sponsor's written approval was required prior to manuscript submission, and only one knew whether there was an independent steering committee for the study. Conclusions.-These findings suggest that the peer review process can be strengthened to improve the quality of the medical literature in clinical economics and biomedical ethics. Journal editors also need to better understand the terms of research sponsorship agreements.	GEORGETOWN UNIV,MED CTR,DIV GEN INTERNAL MED,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,CTR CLIN BIOETH,WASHINGTON,DC 20007	Georgetown University; Georgetown University	SCHULMAN, K (corresponding author), GEORGETOWN UNIV,MED CTR,CLIN ECON RES UNIT,2233 WISCONSIN AVE NW,WASHINGTON,DC 20007, USA.							ADAMS ME, 1992, MED CARE, V30, P231, DOI 10.1097/00005650-199203000-00005; BEAUCHAMP TL, 1982, HASTINGS CENT REP, V12, P13; BRODY BA, 1990, J MED PHILOS, V15, P161, DOI 10.1093/jmp/15.2.161; BRODY BA, 1993, THEOR MED, V14, P211, DOI 10.1007/BF00995163; HILLMAN AL, 1991, NEW ENGL J MED, V324, P1362, DOI 10.1056/NEJM199105093241911; KRAHN M, 1993, MED DECIS MAKING, V13, P4, DOI 10.1177/0272989X9301300103; SOUTHGATE MT, 1987, JAMA-J AM MED ASSOC, V258, P1375; UDVARHELYI S, 1992, ANN INTERN MED, V116, P238; 1993, ANN INTERN MED, V118, P646	9	29	30	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					154	156		10.1001/jama.272.2.154	http://dx.doi.org/10.1001/jama.272.2.154			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015131				2022-12-28	WOS:A1994NV42400021
J	POOLE, CJM; MILLER, S; FILLINGHAM, G				POOLE, CJM; MILLER, S; FILLINGHAM, G			IMMUNITY TO HEPATITIS-B AMONG HEALTH-CARE WORKERS PERFORMING EXPOSURE PRONE PROCEDURES	BRITISH MEDICAL JOURNAL			English	Article									HAMMERSMITH HOSP,OCCUPAT HLTH SERV,LONDON W12 0HS,ENGLAND	Imperial College London	POOLE, CJM (corresponding author), DUDLEY HLTH AUTHOR,CENT CLIN,OCCUPAT HLTH SERV,DUDLEY DY2 7BX,W MIDLANDS,ENGLAND.							ALEXANDER G, 1986, BRIT MED J, V293, P956, DOI 10.1136/bmj.293.6552.956-a; BOXALL EH, 1993, BRIT MED J, V306, P652, DOI 10.1136/bmj.306.6878.652-c; Gupta H L, 1989, J Assoc Physicians India, V37, P618; 1992, IMMUNISATION INFECTI, P114; 1993, PROTECTING HLTH CARE	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					94	95		10.1136/bmj.309.6947.94a	http://dx.doi.org/10.1136/bmj.309.6947.94a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038675	Green Published			2022-12-28	WOS:A1994NW71600018
J	MATHESON, KH; BIGGS, JSG				MATHESON, KH; BIGGS, JSG			OUTCOME OF FLEXIBLE TRAINING IN EAST ANGLIAN REGION	BRITISH MEDICAL JOURNAL			English	Article											MATHESON, KH (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,POSTGRAD DEANS OFF,CAMBRIDGE CB2 2SP,CAMBS,ENGLAND.							JESSOP EG, 1984, PUBLIC HEALTH, V98, P134, DOI 10.1016/S0033-3506(84)80036-0; 1969, REEMPLOYMENT WOMEN D; 1979, OPPORTUNITIES PART T; 1993, FLEXIBLE TRAINING RE	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					29	29		10.1136/bmj.309.6946.29	http://dx.doi.org/10.1136/bmj.309.6946.29			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044065	Green Published			2022-12-28	WOS:A1994NV89100022
J	JAMESON, SC; HOGQUIST, KA; BEVAN, MJ				JAMESON, SC; HOGQUIST, KA; BEVAN, MJ			SPECIFICITY AND FLEXIBILITY IN THYMIC SELECTION	NATURE			English	Article							T-CELL-RECEPTOR; TRANSGENIC MICE; POSITIVE SELECTION; PEPTIDE BINDING; BETA-2-MICROGLOBULIN; THYMOCYTES; EXPRESSION; DEFICIENT; TOLERANCE; ANTIGEN	DURING positive selection, developing thymocytes are rescued from programmed cell death by T-cell receptor (TCR)-mediated recognition of major histocompatibility complex (MHC) molecules(1-3). MHC-bound peptides contribute to this process(4-8). Recently we identified individual MHC-binding peptides which can induce positive selection of a single TCR(9). Here we examine peptide fine specificity in positive selection. These data suggest that a direct TCR-peptide interaction occurs during this event, and strengthens the correlation between selecting peptides and TCR antagonists(9,10). Certain positively selecting peptides are weakly antigenic(9). We demonstrate that thymocytes 'educated' on such a peptide are specifically non-responsive to it and have decreased CD8 expression levels. Similar reduction of CD8 expression on mature T cells converts a TCR agonist into a TCR antagonist. These data indicate that thymocytes may maintain self-tolerance towards a positively selecting ligand by regulating co-receptor expression.			JAMESON, SC (corresponding author), UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195, USA.		Jameson, Stephen C/D-9892-2013	Jameson, Stephen C/0000-0001-9137-1146; Hogquist, Kristin/0000-0001-9963-5687	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019335] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI019335, R01 AI019335-19] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER J, 1993, J IMMUNOL, V150, P1; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; AUPHAN N, 1992, INT IMMUNOL, V4, P1419, DOI 10.1093/intimm/4.12.1419; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HAMMERLING GJ, 1991, IMMUNOL REV, V122, P47, DOI 10.1111/j.1600-065X.1991.tb00596.x; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; MOLLER G, 1993, IMMUNOL REV, V135; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUGIC JN, 1990, NATURE, V344, P65	25	209	209	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					750	752		10.1038/369750a0	http://dx.doi.org/10.1038/369750a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008067	Green Accepted			2022-12-28	WOS:A1994NU58100062
J	MCLATCHIE, G; JENNETT, B				MCLATCHIE, G; JENNETT, B			HEAD-INJURY IN SPORT	BRITISH MEDICAL JOURNAL			English	Article									UNIV SUNDERLAND,SUNDERLAND,DURHAM,ENGLAND; NATL SPORTS MED INST,LONDON,ENGLAND; UNIV GLASGOW,INST NEUROL SCI,GLASGOW,SCOTLAND	University of Sunderland; University of Glasgow	MCLATCHIE, G (corresponding author), HARTLEPOOL GEN HOSP,HARTLEPOOL,CLEVELAND,ENGLAND.								0	17	17	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1620	1624		10.1136/bmj.308.6944.1620	http://dx.doi.org/10.1136/bmj.308.6944.1620			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025432	Green Published			2022-12-28	WOS:A1994NT52800026
J	AUSTOKER, J; SANDERS, D; FOWLER, G				AUSTOKER, J; SANDERS, D; FOWLER, G			CANCER PREVENTION IN PRIMARY-CARE - SMOKING AND CANCER - SMOKING CESSATION	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Smoking is the single most important cause of cancer. The risk of developing cancer is reduced by stopping smoking and decreases substantially after five years. Reduction in smoking must be central to any programme aimed seriously at the prevention of cancer. An individual approach, based in primary care, has the potential to bring about modest but important reductions in risk. Many randomised trials have shown the effectiveness of various smoking cessation interventions in primary care. Given resource limitations in primary care, individual effort should be focused on those at highest risk who are motivated to stop smoking. A population strategy has considerable advantages over the high risk approach as the potential for reducing morbidity and mortality in the whole population is much greater. The government must acknowledge its major responsibility; the outstanding example of its failure to do this is its persistent refusal to ban outright all forms of advertising and promotion of tobacco. There is clear evidence that a ban would contribute to a reduction in smoking prevalence and especially in the uptake of smoking by children.	UNIV OXFORD, WARNEFORD HOSP, DEPT PSYCHIAT, OXFORD OX3 7JX, ENGLAND; UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, IMPERIAL CANC RES FUND, GEN PRACTICE RES GRP, OXFORD OX2 6PE, ENGLAND	University of Oxford; University of Oxford	AUSTOKER, J (corresponding author), UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, CANC RES CAMPAIGN, PRIMARY CARE EDUC RES GRP, OXFORD OX2 6PE, ENGLAND.							DICLEMENTE CC, 1991, J CONSULT CLIN PSYCH, V59, P295, DOI 10.1037/0022-006X.59.2.295; FOWLER G, 1993, PREVENTION GENERAL P, P106; FOWLER G, IN PRESS PREVENTIVE; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882, DOI 10.1001/jama.1988.03720190050031; RAW M, 1994, GUIDELINES SMOKING P; SANDERS D, 1992, PHP DEP PUBLICATION, V6; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; WALD N, 1991, UK SMOKING STATISTIC; 1992, STOPPING SMOKING MAD; 1993, GIVING UP SMOKING DO; [No title captured]; 1993, EUROPEAN CODE CANCER; [No title captured]; 1992, 11 CANC RES CAMP FAC; 1992, EFFECT TOBACCO ADVER	16	37	37	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	1994	308	6942					1478	1482		10.1136/bmj.308.6942.1478	http://dx.doi.org/10.1136/bmj.308.6942.1478			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019283	Green Published			2022-12-28	WOS:A1994NQ22900020
J	HACKNEY, RG				HACKNEY, RG			ABC OF SPORTS MEDICINE - NATURE, PREVENTION, AND MANAGEMENT OF INJURY IN SPORT	BRITISH MEDICAL JOURNAL			English	Article									QUEENS MED CTR,NOTTINGHAM,ENGLAND; ROYAL AIR FORCE,FARNBOROUGH,HANTS,ENGLAND	University of Nottingham	HACKNEY, RG (corresponding author), BRITISH ASSOC SPORT & MED,LONDON,ENGLAND.								0	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1356	1359		10.1136/bmj.308.6940.1356	http://dx.doi.org/10.1136/bmj.308.6940.1356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019228	Green Published			2022-12-28	WOS:A1994NM98900030
J	ARNOW, PM; BLAND, LA; GARCIAHOUCHINS, S; FRIDKIN, S; FELLNER, SK				ARNOW, PM; BLAND, LA; GARCIAHOUCHINS, S; FRIDKIN, S; FELLNER, SK			AN OUTBREAK OF FATAL FLUORIDE INTOXICATION IN A LONG-TERM HEMODIALYSIS UNIT	ANNALS OF INTERNAL MEDICINE			English	Article						HEMODIALYSIS UNITS, HOSPITAL; FLUORIDE POISONING; HEMODIALYSIS; DEIONIZATION SYSTEMS; WATER	HYPERKALEMIA	Objective: To determine the cause of an outbreak of acute illness and death in a long-term hemodialysis unit. Design: A retrospective cohort and case-control study of patients receiving hemodialysis and a laboratory study of a model deionization system to purify water for hemodialysis. Setting: An outpatient hemodialysis unit of a university hospital. Patients: 12 patients who became severely ill after hemodialysis treatment and 20 patients who did not become ill after receiving hemodialysis treatment in the same unit. Measurements: Medical and dialysis unit records were reviewed to identify and characterize cases. Fluids for dialysis were tested for toxic substances, and fluoride was measured in patients' serum. Resistivity and fluoride were measured in effluent from a model deionization system operated in the same way as the system associated with illness. Results: During five consecutive hemodialysis shifts, 12 of 15 patients receiving dialysis treatment in one room became acutely ill, with severe pruritus, multiple nonspecific symptoms, and/or fatal ventricular fibrillation (3 patients). None of 17 patients treated in the adjacent room became ill (P < 0.0001). Death was associated with longer hemodialysis time and increased age compared with other patients who became ill. Serum concentrations of fluoride in the sick patients were markedly increased to as high as 716 mu mol/L, and the source of fluoride was the temporary deionization system used to purify water for hemodialysis only in the affected room. Operation of a model deionization system showed how fluoride was adsorbed and then displaced in a massive efflux. Conclusions: Because deionization systems are used widely in hemodialysis and can cause fatal fluoride intoxication, careful design and monitoring are essential.	CTR DIS CONTROL & PREVENT, HOSP INFECT PROGRAM, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	ARNOW, PM (corresponding author), UNIV CHICAGO HOSP & CLIN, DEPT MED MC5065, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.							ABUELO JG, 1993, SEMIN DIALYSIS, V6, P59, DOI 10.1111/j.1525-139X.1993.tb00257.x; ABUKURAH AR, 1972, J AMER MED ASSOC, V222, P816; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; Arduino MJ, 1989, DIALYSIS TRANSPLANT, V18, P655; ARMSTRONG W D, 1964, J Clin Invest, V43, P555; BALTAZAR RF, 1980, CHEST, V78, P660, DOI 10.1378/chest.78.4.660; BERMAN L, 1973, NEW ENGL J MED, V289, P922; Clifford D., 1990, WATER QUALITY TREATM; FLAHERTY JP, 1993, ANN INTERN MED, V119, P1072, DOI 10.7326/0003-4819-119-11-199312010-00003; FUCHS C, 1975, CLIN CHIM ACTA, V60, P157, DOI 10.1016/0009-8981(75)90121-7; HANES CM, 1990, J DENT RES, V69, P282, DOI 10.1177/00220345900690S110; JOHNSON WJ, 1974, KIDNEY INT, V5, P451, DOI 10.1038/ki.1974.64; KESHAVIAH PR, 1989, REPLACEMENT RENAL FU, P189; KUO HC, 1975, ARCH ORAL BIOL, V20, P235, DOI 10.1016/0003-9969(75)90117-X; LEVIN NW, 1990, CLIN DIALYSIS, P172; LUEHMAN DA, 1989, MANUAL WATER TREATME, P109; MCIVOR M, 1983, AM J CARDIOL, V51, P901, DOI 10.1016/S0002-9149(83)80153-2; MCIVOR ME, 1987, ANN EMERG MED, V16, P1165; MCIVOR ME, 1987, ANN EMERG MED, V16, P777; Murray J. J., 1986, APPROPRIATE USE FLUO, P131; PARSONS V, 1975, BMJ-BRIT MED J, V1, P128, DOI 10.1136/bmj.1.5950.128; SCHIFFL HH, 1980, NEPHRON, V26, P69, DOI 10.1159/000181954; SIDDIQUI JY, 1970, P EUR DIAL TRANS, V7, P110; SNEDECOR GW, 1980, STATISTICAL METHODS, P107; TAVES DR, 1968, T AM SOC ART INT ORG, V14, P412; TEPPERMAN PB, 1980, J OCCUP ENVIRON MED, V22, P691, DOI 10.1097/00043764-198010000-00018; Tokars J I, 1993, ASAIO J, V39, P966, DOI 10.1097/00002480-199310000-00027; VLCHEK DL, 1991, QUALITY ASSURANCE GU; YOLKEN R, 1976, PEDIATRICS, V58, P90; 1993, ANSIAAMI RD51992 ASS, P5; 1980, MMWR-MORBID MORTAL W, V29, P134	31	47	48	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					339	344		10.7326/0003-4819-121-5-199409010-00005	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042823				2022-12-28	WOS:A1994PD70100005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA TO SPONSOR WORKSHOP ON HIV DETECTION DURING WINDOW PERIOD IN DONOR SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					344	344						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028152				2022-12-28	WOS:A1994NY90300006
J	CACALANO, G; LEE, J; KIKLY, K; RYAN, AM; PITTSMEEK, S; HULTGREN, B; WOOD, WI; MOORE, MW				CACALANO, G; LEE, J; KIKLY, K; RYAN, AM; PITTSMEEK, S; HULTGREN, B; WOOD, WI; MOORE, MW			NEUTROPHIL AND B-CELL EXPANSION IN MICE THAT LACK THE MURINE IL-8 RECEPTOR HOMOLOG	SCIENCE			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; OXYGEN METABOLITES; CYTOKINE FAMILY; CLONING; LUNG; ACCUMULATION; ACTIVATION; INHIBITOR; BINDING; INJURY	Interleukin-8 (IL-8) is a preinflammatory cytokine that specifically attracts and activates human neutrophils. A murine gene with a high degree of homology to the two known human IL-8 receptors was cloned and then deleted from the mouse genome by homologous recombination in embryonic stem (ES) cells. These mice, although outwardly healthy, had lymphadenopathy, resulting from an increase in B cells, and splenomegaly, resulting from an increase in metamyelocytes, band, and mature neutrophils. Thus, this receptor may participate in the expansion and development of neutrophils and B cells. This receptor was the major mediator of neutrophil migration to sites of inflammation and may provide a potential therapeutic target in inflammatory disease.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PHARMACOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT ENDOCRINE RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Huang, H/E-9490-2010					BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CERRETTI DP, 1993, GENOMICS, V18, P410, DOI 10.1006/geno.1993.1486; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; COLDITZ I, 1989, AM J PATHOL, V134, P755; DAVEY FR, 1984, CLIN DIAGNOSIS MANAG, P857; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HECHTMAN DH, 1991, J IMMUNOL, V147, P883; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JOHNSON KJ, 1981, J IMMUNOL, V126, P2365; KIKLY K, UNPUB; KIMATA H, 1992, J EXP MED, V176, P1227, DOI 10.1084/jem.176.4.1227; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RAMPART M, 1989, AM J PATHOL, V135, P21; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; TILL GO, 1982, J CLIN INVEST, V69, P1126, DOI 10.1172/JCI110548; WATANABE K, 1993, EUR J BIOCHEM, V214, P267, DOI 10.1111/j.1432-1033.1993.tb17920.x; WATANABE K, 1989, J BIOL CHEM, V264, P18907; WOOD WB, UNPUB	30	556	566	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					682	684		10.1126/science.8036519	http://dx.doi.org/10.1126/science.8036519			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036519				2022-12-28	WOS:A1994NZ53800040
J	ONO, K; TSUJIMOTO, G; SAKAMOTO, A; ETO, K; MASAKI, T; OZAKI, Y; SATAKE, M				ONO, K; TSUJIMOTO, G; SAKAMOTO, A; ETO, K; MASAKI, T; OZAKI, Y; SATAKE, M			ENDOTHELIN-A RECEPTOR MEDIATES CARDIAC INHIBITION BY REGULATING CALCIUM AND POTASSIUM CURRENTS	NATURE			English	Article							GENE-RELATED PEPTIDE; VASOCONSTRICTOR PEPTIDE; CELLS; CLONING; HEART; CDNA; EXPRESSION; SUBTYPES; MYOCYTES; BINDING	VOLTAGE-SENSITIVE ion channels play fundamental roles in the regulation of cardiac function by various neurotransmitters(1,2). Endothelins(3) have strong positive inotropic(4) and chronotropic(5) effects, for,which recent studies have implicated various intracellular mechanisms(6,7). However, very little is known about the underlying ion-channel regulation by the peptide. We report here that endothelin-1 consistently hyperpolarizes the membrane and shortens the duration of the action potential in mammalian atrial myocytes, leading to suppression of electrical excitability of the heart. Endothelin-1, but not endothelin(3), inhibited the L-type calcium current by decreasing cyclic AMP accumulation and activated the muscarinic potassium current by stimulating a pertussis toxin-sensitive GTP-binding protein. Consistent with these results, endothelin-1 strongly reduced the heart rate when it was increased by beta-adrenoceptor stimulation. These effects were blocked by an ET(A) (endothelin-1-selective) receptor-selective antagonist, BQ123 (refs 8-11). The ET(A) receptor-mediated regulation of cardiac ion channels gives new insight into our understanding of the physiological and pathophysiological roles of endothelins in the control of cardiac function.	NATL CHILDRENS MED RES CTR,DIV MOLEC & CELLULAR PHARMACOL,SETAGAYA KU,TOKYO 154,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 60601,JAPAN	National Center for Child Health & Development - Japan; Kyoto University	ONO, K (corresponding author), NATL INST HLTH SCI,DIV CHEM PHARMACOL & PHYTOCHEM,SETAGAYA KU,1-18-1 KAMI YOHGA,TOKYO 158,JAPAN.							ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; FRANCOCERECEDA A, 1990, ACTA PHYSIOL SCAND, V138, P539, DOI 10.1111/j.1748-1716.1990.tb08882.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTZELL HC, 1987, J PHYSIOL-LONDON, V389, P411, DOI 10.1113/jphysiol.1987.sp016663; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HURI S, 1992, ENDOCRINOLOGY, V130, P1885; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA T, 1988, PFLUG ARCH EUR J PHY, V413, P108, DOI 10.1007/BF00581239; ISHIKAWA T, 1991, CIRC RES, V69, P918, DOI 10.1161/01.RES.69.4.918; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; KIM D, 1991, CIRC RES, V69, P250, DOI 10.1161/01.RES.69.1.250; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; ONO K, 1991, J PHYSIOL-LONDON, V436, P195, DOI 10.1113/jphysiol.1991.sp018546; ONO K, 1989, NATURE, V340, P721, DOI 10.1038/340721a0; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; REID JJ, 1991, EUR J PHARMACOL, V194, P173, DOI 10.1016/0014-2999(91)90102-V; REUTER H, 1979, ANNU REV PHYSIOL, V41, P413, DOI 10.1146/annurev.ph.41.030179.002213; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; TANAKA T, 1994, MOL PHARMACOL, V45, P724; TOHSE N, 1990, BRIT J PHARMACOL, V99, P437, DOI 10.1111/j.1476-5381.1990.tb12944.x; VOGELSANG M, 1994, J CARDIOVASC PHARM, V23, P344, DOI 10.1097/00005344-199402000-00025; WENNMALM A, 1991, J PHYSIOL-LONDON, V435, P163, DOI 10.1113/jphysiol.1991.sp018503; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	27	144	144	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					301	304		10.1038/370301a0	http://dx.doi.org/10.1038/370301a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035879				2022-12-28	WOS:A1994NZ22900066
J	WILLCOX, SM; HIMMELSTEIN, DU; WOOLHANDLER, S				WILLCOX, SM; HIMMELSTEIN, DU; WOOLHANDLER, S			INAPPROPRIATE DRUG PRESCRIBING FOR THE COMMUNITY-DWELLING ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL ADMISSION; NURSING-HOME; MEDICATION; FACILITIES; MISUSE; RISK; CARE; LONG	Objective.-To examine the amount of inappropriate drug prescribing for Americans aged 65 years or older living in the community. Design.-Cross-sectional survey of a national probability sample of older adults. Setting.-The 1987 National Medical Expenditure Survey, a national probability sample of the US civilian noninstitutionalized population, with oversampling of some population groups, including the elderly. Subjects.-The 6171 people aged 65 years or older in the National Medical Expenditure Survey sample, using appropriate weighting procedures to produce national estimates. Main Outcome Measures.-Incidence of prescribing 20 potentially inappropriate drugs, using explicit criteria previously developed by 13 United States and Canadian geriatrics experts through a modified Delphi consensus technique. Three cardiovascular drugs identified as potentially inappropriate were analyzed separately since they may be considered appropriate for some noninstitutionalized elderly patients. Results.-A total of 23.5% (95% confidence interval [CI], 22.4% to 24.6%) of people aged 65 years or older living in the community, or 6.64 million Americans (95% CI, 6.28 million to 7.00 million), received at least one of the 20 contraindicated drugs. While 79.6% (95% CI, 77.2% to 82.0%) of people receiving potentially inappropriate medications received only one such drug, 20.4% received two or more. The most commonly prescribed of these drugs were dipyridamole, propoxyphene, amitriptyline, chlorpropamide, diazepam, indomethacin, and chlordiazepoxide, each used by at least half a million people aged 65 years or older. Including the three controversial cardiovascular agents (propranolol, methyldopa, and reserpine) in the list of contraindicated drugs increased the incidence of probably inappropriate medication use to 32% (95% CI, 30.7% to 33.3%), or 9.04 million people (95% CI, 8.64 million to 9.44 million). Conclusion.-Physicians prescribe potentially inappropriate medications for nearly a quarter of all older people living in the community, placing them at risk of drug adverse effects such as cognitive impairment and sedation. Although most previous strategies for improving drug prescribing for the elderly have focused on nursing homes, broader educational and regulatory initiatives are needed.	VICTORIAN HLTH DEPT,MELBOURNE,VIC,AUSTRALIA; HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,CTR NATL HLTH PROGRAM STUDIES,CAMBRIDGE,MA; HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,DEPT MED,CAMBRIDGE,MA 02139	Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University; Cambridge Health Alliance; Cambridge Hospital								AVORN J, 1989, NEW ENGL J MED, V320, P227, DOI 10.1056/NEJM198901263200406; BAUM C, 1984, JAMA-J AM MED ASSOC, V241, P1293; BEARD K, 1992, DRUG AGING, V2, P356, DOI 10.2165/00002512-199202040-00008; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; BEERS MH, 1992, ANN INTERN MED, V117, P684, DOI 10.7326/0003-4819-117-8-684; BENNETT DR, 1993, DRUG EVALUATIONS ANN; BERNSTEIN LR, 1989, MED CARE, V27, P654, DOI 10.1097/00005650-198906000-00008; BLACK AJ, 1984, J ROY COLL PHYS LOND, V18, P40; CADIEUX RJ, 1989, POSTGRAD MED, V86, P179; CHRISCHILLES EA, 1992, ANN INTERN MED, V117, P634, DOI 10.7326/0003-4819-117-8-634; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; GOSNEY M, 1989, HLTH TRENDS, V21, P129; GRAVES EJ, 1989, VITAL HLTH STAT 13, V100; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRYMONPRE RE, 1988, J AM GERIATR SOC, V36, P1092, DOI 10.1111/j.1532-5415.1988.tb04395.x; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; GURWITZ JH, 1990, J AM GERIATR SOC, V38, P542, DOI 10.1111/j.1532-5415.1990.tb02406.x; HARRINGTON C, 1992, GERONTOLOGIST, V32, P822, DOI 10.1093/geront/32.6.822; KOCH HK, 1980, VITAL HLTH STAT 2, V90; LAKSHMANAN MC, 1986, ARCH INTERN MED, V146, P1931, DOI 10.1001/archinte.146.10.1931; LARMOUR I, 1991, Australian Journal of Hospital Pharmacy, V21, P90; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LEXCHIN J, 1991, CAN FAM PHYSICIAN, V37, P109; LINDLEY CM, 1992, AGE AGEING, V21, P294, DOI 10.1093/ageing/21.4.294; MOELLER J, 1989, US DHHS PHS893448 PU; MONTAMAT SC, 1989, NEW ENGL J MED, V321, P303; NOLAN L, 1988, J AM GERIATR SOC, V36, P142, DOI 10.1111/j.1532-5415.1988.tb01785.x; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; WEEDLE PB, 1990, DICP ANN PHARMAC, V24, P533; 1992, ISSUES PHARM DRUG US; 1993, NATIONAL PRESCRIPTIO; 1979, MED CODING MANUAL NA	34	304	313	1	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					292	296		10.1001/jama.272.4.292	http://dx.doi.org/10.1001/jama.272.4.292			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NX806	8028142				2022-12-28	WOS:A1994NX80600031
J	HELDE, KA; WILSON, ET; CRETEKOS, CJ; GRUNWALD, DJ				HELDE, KA; WILSON, ET; CRETEKOS, CJ; GRUNWALD, DJ			CONTRIBUTION OF EARLY CELLS TO THE FATE MAP OF THE ZEBRAFISH GASTRULA	SCIENCE			English	Article							EMBRYO; LINEAGE; BLASTOMERES; MOVEMENTS	Previously, a tissue-specific fate map was compiled for the gastrula stage of the zebrafish embryo, indicating that development subsequent to this stage follows a reproducible pattern. Here it is shown that each early zebrafish blastomere normally contributes to a subset of the gastrula and thus gives rise to a limited array of tissues. However, the final contribution that any early blastomere makes to the fate map in the gastrula cannot be predicted because of variability in both the position of the future dorsoventral axis with respect to the early cleavage blastomeres and the scattering of daughter cells as the gastrula is formed. Therefore, early cell divisions of the zebrafish embryo cannot reproducibly segregate determinants of tissue fates.			HELDE, KA (corresponding author), UNIV UTAH,ECCLES INST HUMAN GENET,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		Cretekos, Chris J/D-8350-2013					ABDELILAH S, IN PRESS NATURE; HO RK, 1993, SCIENCE, V261, P109, DOI 10.1126/science.8316841; KANE DA, 1992, NATURE, V360, P735, DOI 10.1038/360735a0; KANE DA, 1993, DEVELOPMENT, V119, P447; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1986, SCIENCE, V231, P365, DOI 10.1126/science.231.4736.365; KIMMEL CB, 1994, DEVELOPMENT, V120, P265; KIMMEL CB, 1987, DEV BIOL, V124, P269, DOI 10.1016/0012-1606(87)90478-7; KIMMEL CB, 1985, DEV BIOL, V108, P78, DOI 10.1016/0012-1606(85)90010-7; KIMMEL CB, 1985, DEV BIOL, V108, P94, DOI 10.1016/0012-1606(85)90012-0; NUSSLEINVOLHARD C, 1992, DEVELOPMENT, V116, P1021; Oppenheimer JM, 1936, J EXP ZOOL, V72, P409, DOI 10.1002/jez.1400720304; Oppenheimer JM, 1936, J EXP ZOOL, V73, P405, DOI 10.1002/jez.1400730304; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STREHLOW D, 1993, NATURE, V361, P451, DOI 10.1038/361451a0; WARGA RM, 1990, DEVELOPMENT, V108, P569; WETERFIELD M, 1993, ZEBRAFISH BOOK; WILSON ET, 1993, TRENDS GENET, V9, P348, DOI 10.1016/0168-9525(93)90039-K	19	72	74	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					517	520		10.1126/science.8036493	http://dx.doi.org/10.1126/science.8036493			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036493				2022-12-28	WOS:A1994NY21600028
J	MOHLER, KM; SLEATH, PR; FITZNER, JN; CERRETTI, DP; ALDERSON, M; KERWAR, SS; TORRANCE, DS; OTTENEVANS, C; GREENSTREET, T; WEERAWARNA, K; KRONHEIM, SR; PETERSEN, M; GERHART, M; KOZLOSKY, CJ; MARCH, CJ; BLACK, RA				MOHLER, KM; SLEATH, PR; FITZNER, JN; CERRETTI, DP; ALDERSON, M; KERWAR, SS; TORRANCE, DS; OTTENEVANS, C; GREENSTREET, T; WEERAWARNA, K; KRONHEIM, SR; PETERSEN, M; GERHART, M; KOZLOSKY, CJ; MARCH, CJ; BLACK, RA			PROTECTION AGAINST A LETHAL DOSE OF ENDOTOXIN BY AN INHIBITOR OF TUMOR-NECROSIS-FACTOR PROCESSING	NATURE			English	Article							MOLECULAR-CLONING; EMERGING FAMILY; TNF; PURIFICATION; LIGAND; LIPOPOLYSACCHARIDE; INTERLEUKIN-1-BETA; CYTOKINES; PRECURSOR; HOMOLOGY	TUMOUR necrosis factor (tumour necrosis factor-alpha/cachectin) plays a critical role in certain physiological defensive responses but causes severe damage to the host organism when produced in excess(1). There are two forms of tumour necrosis factor, a type II membrane protein of relative molecular mass 26,000 (26K) and a soluble, 17K form generated from the cell-bound protein by proteolytic cleavage(2,3). The two forms of tumour necrosis factor and lymphotoxin-alpha (tumour necrosis factor-beta/lymphotoxin), a related protein, have similar but apparently not identical biological activities(4-6). A therapeutic agent which inhibited the release of tumour necrosis factor, but did not reduce the cell-associated activity or the level of lymphotoxin-alpha, might preserve the benefits of these cytokines while preventing tumour necrosis factor-induced damage. Here we describe a potent inhibitor of tumour necrosis factor processing and report that it protects mice from a lethal dose of endotoxin.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,PEARL RIVER,NY 10965									AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BIRKLAND TP, 1992, J LEUKOCYTE BIOL, V51, P296, DOI 10.1002/jlb.51.3.296; BLACK RA, 1988, J BIOL CHEM, V263, P9437; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; JUE DM, 1990, BIOCHEMISTRY-US, V29, P8371, DOI 10.1021/bi00488a025; KARP SE, 1992, J IMMUNOL, V149, P2076; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KRONHEIM SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P698, DOI 10.1016/0003-9861(92)90629-B; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; LIBBY RT, 1987, DNA-J MOLEC CELL BIO, V6, P221, DOI 10.1089/dna.1987.6.221; MAEDA T, 1983, BIOCHIM BIOPHYS ACTA, V731, P115, DOI 10.1016/0005-2736(83)90404-2; MALISZEWSKI CR, 1988, MOL IMMUNOL, V25, P429, DOI 10.1016/0161-5890(88)90162-9; MOHLER KM, 1993, J IMMUNOL, V151, P1548; ROQUES BP, 1990, TRENDS PHARMACOL SCI, V11, P245; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; 1992, 12TH P AM PEPT S CAM	24	566	598	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					218	220		10.1038/370218a0	http://dx.doi.org/10.1038/370218a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028669				2022-12-28	WOS:A1994NX97100053
J	HJALMARS, U; KULLDORFF, M; GUSTAFSSON, G; GARWICZ, S; ANDERSONGARE, B; BJORK, O; FORESTIER, E; BEHRENDTZ, M; LONNERHOLM, G; MELLANDER, L; WRANNE, L				HJALMARS, U; KULLDORFF, M; GUSTAFSSON, G; GARWICZ, S; ANDERSONGARE, B; BJORK, O; FORESTIER, E; BEHRENDTZ, M; LONNERHOLM, G; MELLANDER, L; WRANNE, L			RISK OF ACUTE CHILDHOOD LEUKEMIA IN SWEDEN AFTER THE CHERNOBYL REACTOR ACCIDENT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To evaluate the risk of acute childhood leukaemia in areas of Sweden contaminated after the Chernobyl reactor accident in April 1986. Design-Population based study of childhood leukaemia diagnosed during 1980-92. Setting-Coordinates for places of residence of all 1.6 million children aged 0-15 years; aerial mapped areas of Sweden heavily contaminated after the Chernobyl accident. Subjects-888 children aged 0-15 years with acute leukaemia diagnosed in Sweden during 1980-92, identified with place of birth and residence at diagnosis. Main outcome measures-Risk of leukaemia in areas contaminated after the Chernobyl accident compared with the rest of Sweden and in the same areas before the accident. Results-During six and a half years of follow up after the accident the odds ratio for acute leukaemia was 0.9 (95% confidence interval 0.6 to 1.4) in highly contaminated areas (greater than or equal to 10 kBq/m(2)) compared with the same areas before the accident. For the subgroup acute lymphoblastic leukaemia in children aged under 5 years at diagnosis the odds ratio was 1.5 (0.8 to 2.6). For all cases diagnosed after May 1986 in highly contaminated areas compared with areas of low contamination the odds ratio was 0.9 (0.7 to 1.3). For acute lymphblastic leukaemia in children aged under 5 years at diagnosis the odds ratio was 1.2 (0.8 to 1.9) in highly contaminated areas compared with areas of low contamination. Dose-response analysis showed no correlation between the degree of contamination and the incidence of childhood leukaemia. Conclusion-There has been no significant increase in the incidence of acute childhood leukaemia in areas of Sweden contaminated after the Chernobyl reactor accident.	UPPSALA UNIV,DEPT STAT,UPPSALA,SWEDEN	Uppsala University	HJALMARS, U (corresponding author), CENT HOSP,DEPT PAEDIAT,S-83183 OSTERSUND,SWEDEN.		Kulldorff, Martin/H-4282-2011					BITHELL JF, 1988, STAT MED, V7, P857, DOI 10.1002/sim.4780070804; Edvarson K, 1991, CHERNOBYL FALLOUT SW, P527; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JOSEPH L, 1981, STATISTICAL METHODS; KINLEN LJ, 1993, BRIT MED J, V306, P1153, DOI 10.1136/bmj.306.6886.1153; Knox E. G., 1987, J SOC RADIOL PROT, V7, P3; PARKIN DM, 1993, EUR J CANCER, V29A, P87, DOI 10.1016/0959-8049(93)90582-Z; PRISYAZHIUK A, 1991, LANCET, V338, P1334, DOI 10.1016/0140-6736(91)92632-C; 1991, INT PROGRAMME HLTH E; 1991, ANN ICRP, V21, P1; 1989, SUMMARY REPORT CONSU	11	48	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					154	157		10.1136/bmj.309.6948.154	http://dx.doi.org/10.1136/bmj.309.6948.154			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044093	Green Published			2022-12-28	WOS:A1994NY22900018
J	STEINBACHER, S; SECKLER, R; MILLER, S; STEIPE, B; HUBER, R; REINEMER, P				STEINBACHER, S; SECKLER, R; MILLER, S; STEIPE, B; HUBER, R; REINEMER, P			CRYSTAL-STRUCTURE OF P22 TAILSPIKE PROTEIN - INTERDIGITATED SUBUNITS IN A THERMOSTABLE TRIMER	SCIENCE			English	Article							TAIL SPIKE PROTEIN; SENSITIVE FOLDING MUTATIONS; MOLECULAR-PROPERTIES; GLOBAL SUPPRESSORS; MUTANT PROTEINS; PHAGE-P22; BACTERIOPHAGE-P22; ENDORHAMNOSIDASE; PATHWAY; INVITRO	The tailspike protein (TSP) of Salmonella typhimurium phage P22 is a part of the apparatus by which the phage attaches to the bacterial host and hydrolyzes the O antigen. It has served as a model system for genetic and biochemical analysis of protein folding. The x-ray structure of a shortened TSP (residues 109 to 666) was determined to a 2.0 angstrom resolution. Each subunit of the homotrimer contains a large parallel beta helix. The interdigitation of the polypeptide chains at the carboxyl termini is important to protrimer formation in the folding pathway and to thermostability of the mature protein.	UNIV REGENSBURG,D-93040 REGENSBURG,GERMANY	University of Regensburg	STEINBACHER, S (corresponding author), MAX PLANCK INST BIOCHEM,STRUKT FORSCH ABT,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Steipe, Boris/ABE-3813-2020	Steipe, Boris/0000-0002-1134-6758				BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P20071; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DANNER M, 1993, EUR J BIOCHEM, V215, P653, DOI 10.1111/j.1432-1033.1993.tb18076.x; DANNER M, UNPUB; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FANE B, 1991, J BIOL CHEM, V266, P11640; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; ISRAEL JV, 1967, P NATL ACAD SCI USA, V57, P284, DOI 10.1073/pnas.57.2.284; IWASHITA S, 1976, EUR J BIOCHEM, V65, P87, DOI 10.1111/j.1432-1033.1976.tb10392.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LEE SC, 1991, J BIOL CHEM, V266, P23191; MAURIDES PA, 1990, GENETICS, V125, P673; MESSERSCHMIDT A, 1990, J APPL CRYSTALLOGR, V23, P436, DOI 10.1107/S0021889890005301; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MESSERSCHMIDT A, 1991, CRYSTALLOGRAPHIC COM, V5, P115; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1992, FEBS LETT, V307, P20, DOI 10.1016/0014-5793(92)80894-M; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SCHWARZ JJ, 1989, J BIOL CHEM, V264, P20112; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	34	274	278	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					383	386		10.1126/science.8023158	http://dx.doi.org/10.1126/science.8023158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023158				2022-12-28	WOS:A1994NW81600037
J	FRYDMAN, J; NIMMESGERN, E; OHTSUKA, K; HARTL, FU				FRYDMAN, J; NIMMESGERN, E; OHTSUKA, K; HARTL, FU			FOLDING OF NASCENT POLYPEPTIDE-CHAINS IN A HIGH-MOLECULAR-MASS ASSEMBLY WITH MOLECULAR CHAPERONES	NATURE			English	Article							T-COMPLEX POLYPEPTIDE-1; ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; STRESS PROTEINS; BINDING-SPECIFICITY; PEPTIDE-BINDING; CENTRAL CAVITY; GROEL; TRANSLOCATION; CELL	The folding of polypeptides emerging from ribosomes was analysed in a mammalian translation system using firefly luciferase as a model protein. The growing polypeptide interacts with a specific set of molecular chaperones, including Hsp70, the DnaJ homologue Hsp40 and the chaperonin TRiC. The ordered assembly of these components on the nascent chain forms a high molecular mass complex that allows the cotranslational formation of protein domains and the completion of folding once the chain is released from the ribosome.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIPHYS PROGRAM,NEW YORK,NY 10021; AICHI CANC CTR,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Aichi Cancer Center			Hartl, F. Ulrich/Y-8206-2019	, judith/0000-0003-2302-6943				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CZERMELY P, 1991, J BIOL CHEM, V266, P4943; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1994, CURR OPIN STRUC BIOL, V4, P117, DOI 10.1016/S0959-440X(94)90069-8; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Harlow E., 1988, ANTIBODIES LABORATOR, P1; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HATTORI H, 1993, J CELL SCI, V104, P629; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAGUS R, 1987, METHOD ENZYMOL, V152, P267; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MARCO S, IN PRESS BIOPHYS J; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; STEWART ML, 1971, P NATL ACAD SCI USA, V68, P97, DOI 10.1073/pnas.68.1.97; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	50	569	582	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					111	117		10.1038/370111a0	http://dx.doi.org/10.1038/370111a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022479				2022-12-28	WOS:A1994NW80400047
J	SCHERER, RW; DICKERSIN, K; LANGENBERG, P				SCHERER, RW; DICKERSIN, K; LANGENBERG, P			FULL PUBLICATION OF RESULTS INITIALLY PRESENTED IN ABSTRACTS - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To estimate the rate of full publication of the results of randomized clinical trials initially presented as abstracts at national ophthalmology meetings in 1988 and 1989; and to combine data from this study with data from similar studies to determine the rate at which abstracts are subsequently published in full and the association between selected study characteristics and full publication. Data Sources.-Ophthalmology abstracts were identified by review of 1988 and 1989 meeting abstracts for the Association for Research in Vision and Ophthalmology and the American Academy of Ophthalmology. Similar studies were identified either from reports contained in our files or through a MEDLINE search, which combined the textword ''abstract'' with ''or'' statements to the Medical Subject Headings ABSTRACTING and INDEXING, CLINICAL TRIALS, PEER REVIEW, PERIODICALS, MEDICAL SOCIETIES, PUBLISHING, MEDLINE, INFORMATION SERVICES, and REGISTRIES. Study Selection.-Ophthalmology abstracts were selected from the meeting proceedings if they reported results from a randomized controlled trial. For the summary study, similar studies were eligible for inclusion if they described followup and subsequent full publication for a cohort of abstracts describing the results of any type of research study. All studies had to have followed up abstracts for at least 24 months to be included. Data Extraction.-Authors of ophthalmology abstracts were contacted by letter to ascertain whether there was subsequent full publication. Other information, including characteristics of the study design possibly related to publication, was taken from the abstract. For the summary study, rates of full publication were taken directly from reported results, as were associations between study factors (ie, ''significant'' results and sample size) and full publication. Data Synthesis.-Sixty-six percent (61/93) of ophthalmology abstracts were published in full. Combined results from 11 studies showed that 51% (1198/2391) of all abstracts were subsequently published in full. Full publication was weakly associated with ''significant'' results and sample size above the median. Conclusions.-Approximately one half of all studies initially presented in abstract form are subsequently published as full-length reports. Most are published in full within 2 years of appearance as abstracts. Full publication may be associated with ''significant'' results and sample size.			SCHERER, RW (corresponding author), UNIV MARYLAND, SCH MED, DEPT EPIDEMIOL & PREVENT MED, 660 W REDWOOD ST, 228 HOWARD HALL, BALTIMORE, MD 21201 USA.		Dickersin, Kay/A-4576-2008		NEI NIH HHS [EY07766] Funding Source: Medline; NATIONAL EYE INSTITUTE [R21EY007766] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; BEGG CB, 1989, J NATL CANCER I, V81, P107, DOI 10.1093/jnci/81.2.107; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1401, DOI 10.1001/jama.263.10.1401; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; DEBELLEFEUILLE C, 1992, ANN ONCOL, V3, P187, DOI 10.1093/oxfordjournals.annonc.a058147; DICKERSIN K, 1993, ANN NY ACAD SCI, V703, P135, DOI 10.1111/j.1749-6632.1993.tb26343.x; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; DICKERSIN K, 1994, HDB RES SYNTHESIS; Dickersin K., 1993, ONLINE J CURR CLIN T, pDoc No 50; DIRK L, 1993, 2ND INT C PEER REV; DUDLEY HAF, 1978, AM J SURG, V135, P458, DOI 10.1016/0002-9610(78)90084-3; EASTERBROOK P, 1987, BRIT MED J, V295, P1347, DOI 10.1136/bmj.295.6609.1347-a; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; GOLDMAN L, 1980, NEW ENGL J MED, V303, P255, DOI 10.1056/NEJM198007313030504; JUZYCH MS, 1991, OPHTHALMOLOGY, V98, P553; JUZYCH MS, 1993, INVEST OPHTH VIS SCI, V34, P1879; KAHN HA, 1989, STATISTICAL METHODS; Lefebvre C., 1993, IDENTIFICATION RANDO; MCCORMICK MC, 1985, AM J DIS CHILD, V139, P122, DOI 10.1001/archpedi.1985.02140040020017; MERANZE J, 1982, ANESTH ANALG, V61, P445; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHUYLER P, 1993, 2ND INT C PEER REV B; YENTIS SM, 1993, CAN J ANAESTH, V40, P632, DOI 10.1007/BF03009700; 1993, CLIN TRIALS METAANAL, V28, P255; 1985, ARCH DIS CHILD, V60, P90	26	337	343	2	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					158	162		10.1001/jama.272.2.158	http://dx.doi.org/10.1001/jama.272.2.158			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015133				2022-12-28	WOS:A1994NV42400023
J	BUCKMAN, R; LEWITH, G				BUCKMAN, R; LEWITH, G			WHAT DOES HOMEOPATHT DO AND HOW	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER	Robert Buckman, a medical oncologist, and George Lewith, a homoeopathic physician, met in Southampton while filming ''Magic or Medicine?,'' a television series of four programmes about what can and might be learnt from the popularity of complementary medicine. In particular, the series showed how the effect of the patient's and the doctor's beliefs affected the relationship between them. The two doctors so enjoyed talking with each other that they carried on their debate in letters to each other over the next year. We think that their exchange merits a wider readership.	CTR STUDY COMPLEMENTARY MED,SOUTHAMPTON SO15 2DT,HANTS,ENGLAND		BUCKMAN, R (corresponding author), TORONTO SUNNYBROOK REG CANC CTR,2075 BAYVIEW AVE,TORONTO M4N 3M5,ON,CANADA.			Lewith, George/0000-0002-2364-3960				BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; Brigo B, 1991, BERL J RES HOM, V1, P98; BUCKMAN R, 1993, MAGIC MED; FERLEY JP, 1989, BRIT J CLIN PHARMACO, V27, P329, DOI 10.1111/j.1365-2125.1989.tb05373.x; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LEWITH G, 1987, COMPLEMENTAYR MED RE, V2, P11; PETO R, 1984, LANCET, V2, P1205; REILLY DT, 1986, LANCET, V2, P881; REILLY DT, 1993, COMPLEMENTARY THE S1, V1, P24; SPIEGEL D, 1989, LANCET, V2, P888	11	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					103	106		10.1136/bmj.309.6947.103	http://dx.doi.org/10.1136/bmj.309.6947.103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038642	Green Published			2022-12-28	WOS:A1994NW71600027
J	HAINES, A; JONES, R				HAINES, A; JONES, R			IMPLEMENTING FINDINGS OF RESEARCH	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; GUIDELINES; INNOVATION; MANAGEMENT; LONDON; TRIALS; CARE	There are unacceptable delays in the implementation of many findings of research. This results in suboptimal care for patients. A number of approaches may be effective in speeding up implementation, including evidence based guidelines, the influence of opinion leaders, and computer based decision support systems. An integrated approach to speeding up this process by means of a number of mechanisms is likely to be most effective. The results of systematic reviews of the research literature should be incorporated into programmes of continuing medical education and clinical audit. Professional associations have an important role to play in ensuring that research based information is included in educational activities and clinical guidelines. Purchasers of health care could promote the uptake of research findings during contract negotiations. Improved methods of informing health care users and the public about evidence of effectiveness could also have an impact. Policy makers should take more account of the results of research when formulating recommendations. Methods of improving the implementation of research findings require further investigation and greater resources devoted to them.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT GEN PRACTICE, LONDON SE11 6SP, ENGLAND	University of London; King's College London	HAINES, A (corresponding author), UCL, WHITTINGTON HOSP, SCH MED, DEPT PRIMARY HLTH CARE, LONDON N19 5NF, ENGLAND.			Haines, Andy/0000-0002-8053-4605				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; BOURDILLON P, 1992, BRIT MED J, V304, P740; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; Chalmers I, 1989, EFFECTIVE CARE PREGN; CHARLTON BG, 1993, LANCET, V342, P99, DOI 10.1016/0140-6736(93)91292-T; DAVEYSMITH G, 1993, BRIT MED J, V306, P1367; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DENNETT KJ, 1987, JAMA-J AM MED ASSOC, V257, P2451; DOMENIGHETTI G, 1988, LANCET, V2, P1470; DONALDSON LJ, 1992, BRIT MED J, V305, P1280, DOI 10.1136/bmj.305.6864.1280; FOWLER G, 1990, BMJ-BRIT MED J, V300, P1318, DOI 10.1136/bmj.300.6735.1318; GRIFFITH CS, 1990, AM J OBSTET GYNECOL, V162, P615, DOI 10.1016/0002-9378(90)90969-E; GRIMES DA, 1993, JAMA-J AM MED ASSOC, V269, P3030, DOI 10.1001/jama.269.23.3030; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUERRANT RL, 1991, NEW ENGL J MED, V325, P327, DOI 10.1056/NEJM199108013250506; HAYNES RB, 1990, ANN INTERN MED, V113, P724, DOI 10.7326/0003-4819-113-9-724; HAYNES RB, 1984, JAMA-J AM MED ASSOC, V251, P61, DOI 10.1001/jama.251.1.61; HUTH EJ, 1989, ANN INTERN MED, V110, P99, DOI 10.7326/0003-4819-110-2-99; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; JONES K, 1991, BRIT J GEN PRACT, V41, P224; KASPER J, 1992, QUAL REV B, V18, P182; KURJI KH, 1984, BMJ-BRIT MED J, V288, P903, DOI 10.1136/bmj.288.6421.903; LAVERICK MD, 1991, BRIT MED J, V303, P549, DOI 10.1136/bmj.303.6802.549; Lock Stephen P., 1991, FUTURE MED J, P127; LOHR KN, 1986, MED CARE S9, V25, pS31; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1988, American Journal of Preventive Medicine, V4, P77; LOMAS J, 1992, 9215 MCM U CTR HLTH; LOMAS J, IN PRESS DISSEMINATI; Long A F, 1992, Qual Health Care, V1, P74, DOI 10.1136/qshc.1.1.74; Menzel H, 1955, PUBLIC OPIN QUART, V19, P337, DOI 10.1086/266584; MOSTELLER F, 1981, SCIENCE, V211, P881, DOI 10.1126/science.6781066; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; Rogers EM., 1983, DIFFUSION INNOVATION; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; SPIEGAL N, 1992, BRIT MED J, V304, P231, DOI 10.1136/bmj.304.6821.231; Stephens R, 1993, Clin Oncol (R Coll Radiol), V5, P211, DOI 10.1016/S0936-6555(05)80231-6; STOCKING B, 1993, MILBANK Q, V71, P497, DOI 10.2307/3350412; STOCKING B, 1992, QUALITY HLTH CARE, V1; VanAmringe M, 1992, QRB Qual Rev Bull, V18, P397; 1993, RES HLTH; 1975, PRINCE; 1992, BRIT MED J, V304, P337; 1993, CLIN AUDIT; 1992, EFFECTIVE HLTH CARE, V1; 1992, ANNOTATED BIBLIO INF; 1993, LANCET, V342, P315; 1993, PREGNANCY CHILDBIRTH	50	251	255	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	1994	308	6942					1488	1492		10.1136/bmj.308.6942.1488	http://dx.doi.org/10.1136/bmj.308.6942.1488			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019284	Green Published			2022-12-28	WOS:A1994NQ22900023
J	SUPER, M; SCHWARZ, MJ; MALONE, G; ROBERTS, T; HAWORTH, A; DERMODY, G				SUPER, M; SCHWARZ, MJ; MALONE, G; ROBERTS, T; HAWORTH, A; DERMODY, G			ACTIVE CASCADE TESTING FOR CARRIERS OF CYSTIC-FIBROSIS GENE	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; CFTR GENE; DNA; PRACTITIONERS; MUTATIONS	Objective-To examine the acceptability, practicability, efficiency, and application of active screening for carriers of the cystic fibrosis gene in the extended families of those in whom the disease is present (cascade screening). Design-Paediatricians and physicians provide details of their affected patients, pedigrees are drawn up, and relatives offered tests after initial contact by the affected nuclear families. Affected patients are genotyped in a laboratory with a special interest in the genetics of cystic fibrosis. Setting-North Western health region. Subjects-Relatives and partners of 607 people with cystic fibrosis.	UNIV MANCHESTER,MANCHESTER M27 1HA,LANCS,ENGLAND	University of Manchester	SUPER, M (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,REG GENET SERV,MANCHESTER M27 1HA,ENGLAND.							BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BURN J, 1993, BRIT MED J, V306, P1558, DOI 10.1136/bmj.306.6892.1558; CASKEY CT, 1990, AM J HUM GENET, V46, P393; DANKS DM, 1965, ANN HUM GENET, V28, P323, DOI 10.1111/j.1469-1809.1965.tb00489.x; FERRIE RM, 1992, AM J HUM GENET, V51, P251; HANDYSIDE AH, NEW ENGL J MED, V905, P92; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; HUBBARD RC, 1992, NEW ENGL J MED, V326, P812, DOI 10.1056/NEJM199203193261207; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LENCH N, 1988, LANCET, V1, P1356; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MODELL M, 1993, BRIT MED J, V307, P849, DOI 10.1136/bmj.307.6908.849; MORRAL N, 1992, HUM GENET, V88, P356; SCHWARZ MJ, 1990, HUM GENET, V85, P428, DOI 10.1007/BF02428298; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SUPER M, 1987, LANCET, V2, P782; SUPER M, 1992, EUR J PEDIATR, V151, P108, DOI 10.1007/BF01958953; SUPER M, 1992, LANCET, V340, P490, DOI 10.1016/0140-6736(92)91816-Q; SUPER M, 1992, J ROY SOC MED, V85, P6; WALD NJ, 1993, LANCET, V342, P1307, DOI 10.1016/0140-6736(93)92403-G; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; 1992, LANCET, V340, P209; 1992, CYSTIC FIBROSIS DNA; 1990, CYSTIC FIBROSIS ADUL	25	63	63	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1462	1467		10.1136/bmj.308.6942.1462	http://dx.doi.org/10.1136/bmj.308.6942.1462			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019278	Green Published			2022-12-28	WOS:A1994NQ22900013
J	TAYLOR, PJ				TAYLOR, PJ			OVERSTATING OVERTREATMENT	BRITISH MEDICAL JOURNAL			English	Note											TAYLOR, PJ (corresponding author), SPECIAL HOSP SERV AUTH,MED SERV,CHARLES HOUSE,LONDON W14 8QH,ENGLAND.							LESTER A, 1989, WOMEN PRISON H WING; LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; MADEN T, 1994, BRIT J PSYCHIAT, V164, P44, DOI 10.1192/bjp.164.1.44; Wilkins J., 1991, CRIMINAL BEHAVIOUR M, V1, P247, DOI DOI 10.1002/cbm.1991.1.issue-3; 1991, MENTALLY INCAPACITAT	5	1	1	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1413	1414		10.1136/bmj.308.6941.1413	http://dx.doi.org/10.1136/bmj.308.6941.1413			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019253	Green Published			2022-12-28	WOS:A1994NP42000018
J	MCCANCE, DR; HANSON, RL; CHARLES, MA; JACOBSSON, LTH; PETTITT, DJ; BENNETT, PH; KNOWLER, WC				MCCANCE, DR; HANSON, RL; CHARLES, MA; JACOBSSON, LTH; PETTITT, DJ; BENNETT, PH; KNOWLER, WC			COMPARISON OF TESTS FOR GLYCATED HEMOGLOBIN AND FASTING AND 2 HOUR PLASMA-GLUCOSE CONCENTRATIONS AS DIAGNOSTIC METHODS FOR DIABETES	BRITISH MEDICAL JOURNAL			English	Article							PIMA-INDIANS; GLYCOSYLATED HEMOGLOBIN; TOLERANCE TEST; SCREENING-TESTS; MELLITUS; BIMODALITY; 2-HOUR; ASSAY; HYPERGLYCEMIA; DISTRIBUTIONS	Objective-To compare the ability of tests measuring two hour plasma glucose, fasting plasma glucose, and glycated haemoglobin concentrations in predicting the specific microvascular complications of non-insulin dependent diabetes mellitus. Design-Cross sectional and longitudinal analysis of the relation between complications and concomitant results of the three tests. Setting-Gila River Indian Community, Arizona. Subjects-Pima Indians (cross sectional, n=960), aged 25 years or above who were not receiving insulin or oral hypoglycaemic treatment at the baseline examination. Main outcome measures-Developement of retinopathy and nephropathy. Results-Cross sectionally, frequency distributions of logarithms of the three sets of results were bimodal, with the prevalence of retinopathy and nephropathy being, respectively, 12.0-26.7 and 3.9-4.2 times as high above as below cut off points which minimised overlap (two hour plasma glucose concentration 12.6mmol/l; fasting plasma glucose concentration 9.3mmol/l; glycated haemoglobin (HbA(1c)) concentration 7.8%). Longitudinally, each of the three measures of glycaemia significantly predicted the development of retinopathy (P<0.0001) and nephropathy (P<0.05). Receiver operating characteristic curves showed that two hour plasma glucose concentration was superior to fasting plasma glucose concentration (P<0.05) for prevalent cases of retinopathy, but otherwise no variable had a significant advantage for detecting incident or prevalent cases of either complication. Conclusions-These findings suggest that determination of glycated haemoglobin or fasting plasma glucose concentrations alone may be acceptable alternatives to measuring glucose concentration two hours after challenge with 75g glucose for the diagnosis of diabetes.	NIDDKD,PHOENIX EPIDEMIOL & CLIN RES BRANCH,DIABET & ARTHRITIS EPIDEMIOL SECT,PHOENIX,AZ 85014; NIAMSD,PHOENIX,AZ 85014	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)			Bennett, Peter/AAH-9605-2021; Charles, Marie Aline/F-8567-2017; Hanson, Robert L/O-3238-2015; Charles, Marie Aline/S-1866-2019	Charles, Marie Aline/0000-0003-4025-4390; Hanson, Robert L/0000-0002-4252-7068; Charles, Marie Aline/0000-0003-4025-4390				ALBUTT EC, 1985, ANN CLIN BIOCHEM, V22, P67, DOI 10.1177/000456328502200106; BENNETT PH, 1984, J CHRON DIS, V37, P653, DOI 10.1016/0021-9681(84)90116-4; BENNETT PH, 1980, 6 P INT C END, P711; DAVIDSON JK, 1986, CLIN DIABETES MELLIT, P108; DODS RF, 1979, CLIN CHEM, V25, P764; ELLIS G, 1984, CLIN CHEM, V30, P1746; ERDREICH LS, 1981, AM J EPIDEMIOL, V114, P649, DOI 10.1093/oxfordjournals.aje.a113236; FAJANS SS, 1959, ANN NY ACAD SCI, V82, P208, DOI 10.1111/j.1749-6632.1959.tb44901.x; FLOCK EV, 1979, DIABETES, V28, P984, DOI 10.2337/diabetes.28.11.984; FORREST RD, 1988, CLIN CHEM, V34, P145; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANSON RL, 1993, ARCH INTERN MED, V153, P2133, DOI 10.1001/archinte.153.18.2133; Hoffman WS, 1937, J BIOL CHEM, V120, P51; JARRETT RJ, 1976, LANCET, V2, P1009; John H., 1922, J METAB RES, V1, P497; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; KUNZELMAN CL, 1989, KIDNEY INT, V35, P681, DOI 10.1038/ki.1989.39; LARKINS RG, 1992, DIABETOLOGIA, V35, P499, DOI 10.1007/BF00400475; LESTER E, 1985, ANN CLIN BIOCHEM, V22, P74, DOI 10.1177/000456328502200107; LIU QZ, 1993, DIABETOLOGIA, V36, P428, DOI 10.1007/BF00402279; MAYER JH, 1950, AM J MED SCI, V219, P161; MENARD L, 1980, CLIN CHEM, V26, P1598; METZ CE, 1984, 8TH P C INF PROC MED, P432; MILLER M, 1968, HYPERGLYCAEMIA PIMA, P89; MODAN M, 1984, AM J EPIDEMIOL, V119, P431, DOI 10.1093/oxfordjournals.aje.a113761; NATHAN DM, 1984, CLIN CHEM, V30, P109; PETTITT DJ, 1980, LANCET, V2, P1050; Raper L R, 1984, Diabetes Res, V1, P19; ROSENTHAL M, 1985, J CHRON DIS, V38, P5, DOI 10.1016/0021-9681(85)90003-7; RUSHFORT.NB, 1971, DIABETES, V20, P756, DOI 10.2337/diab.20.11.756; RUSHFORTH NB, 1975, DIABETES, V24, P538, DOI 10.2337/diabetes.24.6.538; RUSHFORTH NB, 1979, DIABETOLOGIA, V16, P373, DOI 10.1007/BF01223157; SANTIAGO JV, 1978, J CLIN ENDOCR METAB, V47, P578, DOI 10.1210/jcem-47-3-578; Sherwin R S, 1977, Prim Care, V4, P255; SHEVSKY MC, 1923, ARCH INTERN MED, V32, P222; SIMON D, 1985, AM J EPIDEMIOL, V122, P589, DOI 10.1093/oxfordjournals.aje.a114138; SINGER DE, 1988, ANN INTERN MED, V109, P639, DOI 10.7326/0003-4819-109-8-639; STEINBERG AG, 1970, PATHOGENESIS DIABETE, P237; VERILLO A, 1983, DIABETOLOGIA, V24, P391; YEGH HA, 1979, LANCET, V2, P431; ZIMMET P, 1978, DIABETES, V27, P793, DOI 10.2337/diabetes.27.8.793; ZWEIG MH, 1993, CLIN CHEM, V39, P561; 1985, WHO TECH REP SER, V727, P9; 1980, WHO TECH REP SER, V646, P9; 1969, DIABETES, V18, P299; 1989, DIABETES CARE, V12, P588; 1979, DIABETES, V28, P1039	47	389	411	0	30	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1323	1328		10.1136/bmj.308.6940.1323	http://dx.doi.org/10.1136/bmj.308.6940.1323			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019217	Green Published			2022-12-28	WOS:A1994NM98900018
J	DIVNE, C; STAHLBERG, J; REINIKAINEN, T; RUOHONEN, L; PETTERSSON, G; KNOWLES, JKC; TEERI, TT; JONES, TA				DIVNE, C; STAHLBERG, J; REINIKAINEN, T; RUOHONEN, L; PETTERSSON, G; KNOWLES, JKC; TEERI, TT; JONES, TA			THE 3-DIMENSIONAL CRYSTAL-STRUCTURE OF THE CATALYTIC CORE OF CELLOBIOHYDROLASE-I FROM TRICHODERMA-REESEI	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; ENDOGLUCANASE-I; ACTIVE-SITE; X-RAY; CELLULASE; SYNERGISM; QM-9414; DOMAIN; INTACT; OLIGOSACCHARIDES	Cellulose is the major polysaccharide of plants where it plays a predominantly structural role. A variety of highly specialized microorganisms have evolved to produce enzymes that either synergistically or in complexes can carry out the complete hydrolysis of cellulose. The structure of the major cellobiohydrolase, CBHI, of the potent cellulolytic fungus Trichoderma reesei has been determined and refined to 1.8 angstrom resolution. The molecule contains a 40 angstrom long active site tunnel that may account for many of the previously poorly understood macroscopic properties of the enzyme and its interaction with solid cellulose. The active site residues were identified by solving the structure of the enzyme complexed with an oligosaccharide, o-iodobenzyl-1-thio-beta-cellobioside. The three-dimensional structure is very similar to a family of bacterial beta-glucanases with the main-chain topology of the plant legume lectins.	UPPSALA UNIV, CTR BIOMED, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN; VTT BIOTECHNOL & FOOD RES, SF-02044 ESPOO, FINLAND; UNIV UPPSALA, CTR BIOMED, DEPT BIOCHEM, S-75123 UPPSALA, SWEDEN; GLAXO INST MOLEC BIOL SA, CH-1228 PLAN LES OUATES, SWITZERLAND	Uppsala University; VTT Technical Research Center Finland; Uppsala University; GlaxoSmithKline			Teeri, Tuula T/E-7509-2013; Divne, Christina/E-8646-2010; Stahlberg, Jerry/D-4163-2013	Divne, Christina/0000-0002-5805-2693; Stahlberg, Jerry/0000-0003-4059-8580				ABUJA PM, 1988, EUR BIOPHYS J BIOPHY, V15, P339, DOI 10.1007/BF00254721; ANDERSON WF, 1981, J MOL BIOL, V147, P523, DOI 10.1016/0022-2836(81)90398-3; BAILEY MJ, 1981, ENZYME MICROB TECH, V3, P153, DOI 10.1016/0141-0229(81)90076-4; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHANZY H, 1983, FEBS LETT, V153, P113, DOI 10.1016/0014-5793(83)80129-X; CHANZY H, 1985, FEBS LETT, V184, P285, DOI 10.1016/0014-5793(85)80623-2; CLAEYSSENS M, 1989, BIOCHEM J, V261, P819, DOI 10.1042/bj2610819; CLAEYSSENS M, 1990, FEBS LETT, V263, P89, DOI 10.1016/0014-5793(90)80712-R; DAVIES GJ, 1993, NATURE, V365, P362, DOI 10.1038/365362a0; DIVNE C, 1993, J MOL BIOL, V234, P905, DOI 10.1006/jmbi.1993.1640; DURAND H, 1988, ENZYME MICROB TECH, V10, P341, DOI 10.1016/0141-0229(88)90012-9; EDELMAN GM, 1972, P NATL ACAD SCI USA, V69, P2580, DOI 10.1073/pnas.69.9.2580; FAGERSTAM LG, 1980, FEBS LETT, V119, P97, DOI 10.1016/0014-5793(80)81006-4; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; Gritzali M., 1979, HYDROLYSIS CELLULOSE, V181, P237, DOI DOI 10.1021/BA-1979-0181.CH012; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1985, BIO-TECHNOL, V3, P722, DOI 10.1038/nbt0885-722; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOJ PB, 1992, J BIOL CHEM, V267, P25059; IRWIN DC, 1993, BIOTECHNOL BIOENG, V42, P1002, DOI 10.1002/bit.260420811; JKCWLES K, 1988, J CHEM SOC CHEM COMM, P1401; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KONSTANTINIDIS AK, 1993, BIOCHEM J, V291, P883, DOI 10.1042/bj2910883; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; MARLE I, 1993, J CHROMATOGR, V648, P333, DOI 10.1016/0021-9673(93)80415-5; NIDETZKY B, 1994, BIOCHEM J, V298, P705, DOI 10.1042/bj2980705; NIDETZKY B, 1994, ENZYME MICROB TECH, V16, P43, DOI 10.1016/0141-0229(94)90108-2; NIKU-PAAVOLA M-L, 1986, Biotechnology and Applied Biochemistry, V8, P449; NUMMI M, 1983, BIOCHEM J, V215, P677, DOI 10.1042/bj2150677; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PENTTILA M, 1986, GENE, V45, P253, DOI 10.1016/0378-1119(86)90023-5; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SPEZIO M, 1993, BIOCHEMISTRY-US, V32, P9906, DOI 10.1021/bi00089a006; STAHLBERG J, 1993, BIOCHIM BIOPHYS ACTA, V1157, P107, DOI 10.1016/0304-4165(93)90085-M; STAHLBERG J, 1993, CELLULASES OTHER HYD, P273; SUOMINEN PL, 1993, MOL GEN GENET, V241, P523, DOI 10.1007/BF00279894; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; VRSANSKA M, 1992, CARBOHYD RES, V227, P19, DOI 10.1016/0008-6215(92)85058-8; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WOOD TM, 1989, ENZYME SYSTEMS LIGNO, P19; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	47	536	550	1	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 22	1994	265	5171					524	528		10.1126/science.8036495	http://dx.doi.org/10.1126/science.8036495			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036495				2022-12-28	WOS:A1994NY21600030
J	HAIMOV, I; LAUDON, M; ZISAPEL, N; SOUROUJON, M; NOF, D; SHLITNER, A; HERER, P; TZISCHINSKY, O; LAVIE, P				HAIMOV, I; LAUDON, M; ZISAPEL, N; SOUROUJON, M; NOF, D; SHLITNER, A; HERER, P; TZISCHINSKY, O; LAVIE, P			SLEEP DISORDERS AND MELATONIN RHYTHMS IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									TECHNION ISRAEL INST TECHNOL,BRUCE RAPPAPORT FAC MED,SLEEP LAB,IL-31096 HAIFA,ISRAEL; NEURIM PHARMACEUT LTD,TEL AVIV,ISRAEL; TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL; MACCABI PHARMACEUT LTD,TEL AVIV,ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Tel Aviv University			Lavie, Peretz/AAC-2736-2020; Laudon, Moshe/GXH-1907-2022					Dement W, 1985, HDB BIOL AGING, P692; GWINNER E, 1978, J COMP PHYSIOL, V127, P209, DOI 10.1007/BF01350111; Sadeh A., 1989, J AMBUL MONITOR, V2, P209; SHARMA M, 1989, BIOL PSYCHIAT, V25, P305, DOI 10.1016/0006-3223(89)90178-9; WISBERG J, 1990, SLEEP RES, V19, P384	5	246	251	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					167	167		10.1136/bmj.309.6948.167	http://dx.doi.org/10.1136/bmj.309.6948.167			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044096	Green Published			2022-12-28	WOS:A1994NY22900022
J	AGGLETON, P; OREILLY, K; SLUTKIN, G; DAVIES, P				AGGLETON, P; OREILLY, K; SLUTKIN, G; DAVIES, P			RISKING EVERYTHING - RISK BEHAVIOR, BEHAVIOR-CHANGE, AND AIDS	SCIENCE			English	Article							CONDOM PROMOTION; MODEL; HIV; TRANSMISSION; AFRICA; WOMEN; SEX	Inquiry into the determinants of risk-related sexual behavior is important for the development of interventions to reduce the incidence of new cases of human immunodeficiency virus infection. Recent social and behavioral research has revealed much about the individual and social factors influencing risk-taking. Findings from these studies have been important in the development of new educational and community-based interventions for communities at risk in the developed and developing worlds.	UNIV PORTSMOUTH, SCH HLTH STUDIES, PORTSMOUTH, HANTS, ENGLAND	University of Portsmouth	AGGLETON, P (corresponding author), WHO, GLOBAL PROGRAMME AIDS, CH-1211 GENEVA, SWITZERLAND.							ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; ALTMAN D, 1991, AIDS FACING 2ND DECA, P1; Altman D., 1986, AIDS NEW PURITANISM; ANDERSON R M, 1991; ANKRAH EM, 1991, SOC SCI MED, V32, P967, DOI 10.1016/0277-9536(91)90155-6; [Anonymous], 1988, NEW PUBLIC HLTH; Bandura A., 1977, SOCIAL LEARNING THEO, V1; BASSETT MT, 1991, INT J HEALTH SERV, V21, P143, DOI 10.2190/N0NJ-FKXB-CT25-PA09; Becker MH, 1974, HLTH BELIEF MODEL PE; Biberfeld G, 1991, AIDS, V5 Suppl 2, pS129, DOI 10.1097/00002030-199101001-00018; CATANIA JA, 1990, HEALTH EDUC QUART, V17, P53, DOI 10.1177/109019819001700107; CATES W, 1992, NEW ENGL J MED, V327, P492, DOI 10.1056/NEJM199208133270711; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P880; CLEARY PD, 1987, TAKING CARE UNDERSTA, P119, DOI DOI 10.1017/CBO9780511527760.009; DAVIES P, 1991, SOC AS AIDS, P111; Davies P, 1993, SEX GAY MEN AIDS; DEZALDUONDO BO, 1991, J SEX RES, V28, P223, DOI 10.1080/00224499109551607; FEE N, 1993, YOUNG PEOPLE AIDS ST; Fetscherin M, 2008, J ELECTRON COMMER RE, V9, P231; Finger W R, 1991, Netw Res Triangle Park N C, V12, P16; FORD N, 1991, SOC SCI MED, V33, P405, DOI 10.1016/0277-9536(91)90321-3; FORD NJ, 1993, 9TH INT C AIDS BERL; GILADA IS, 1993, WOMEN HIV AIDS, P276; HAYS RB, 1993, 9TH INT C AIDS BERL; Herdt G. H., 1981, GUARDIANS FLUTES IDI; HOLLAND J, 1992, SOC AS AIDS, P142; HUNT CW, 1989, J HEALTH SOC BEHAV, V30, P353, DOI 10.2307/2136985; JOB RFS, 1988, AM J PUBLIC HEALTH, V78, P163, DOI 10.2105/AJPH.78.2.163; KAPLAN BJ, 1993, AIDS EDUC PREV, V5, P294; KATLAMA C, 1993, AIDS, V7, pS185, DOI 10.1097/00002030-199301001-00024; Kippax S., 1993, SUSTAINING SAFE SEX; KREPCHO MA, 1993, J PSYCHOACTIVE DRUGS, V25, P135, DOI 10.1080/02791072.1993.10472243; LAMPTEY P, 1993, 9TH INT C AIDS BERL, P18; Mann J., 1992, AIDS WORLD GLOBAL RE; MANN J, 1992, AIDS WORLD GLOBAL RE, P228; MCKUSICK L, 1985, SEX TRANSM DIS, V12, P229, DOI 10.1097/00007435-198510000-00012; MOULI VC, 1992, ALL AIDS COPPERBELT; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; POLLAK M, 1992, ASSESSING AIDS PREVE, P137; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043; SILVERMAN M, 1992, AIDS PREVENTION ED W, P352; SMALLMANRAYNOR M, 1992, ATLAS AIDS, P210; STIMSON G, 1991, SOC AS AIDS, P225; STIMSON G V, 1991, International Review of Psychiatry, V3, P401, DOI 10.3109/09540269109072146; ULIN PR, 1992, SOC SCI MED, V34, P63, DOI 10.1016/0277-9536(92)90068-2; Weinstein N. D., 1987, TAKING CARE UNDERSTA; WILLIAMS G, 1993, WORK AIDS WORKPLACE; Yeboah-Afari A, 1988, AIDSWATCH, V4, P4; ZWI A, 1993, BRIT MED J, V303, P1527; 1993, HIV DEV AFRICA; 1993, BEHAVIORAL SOCIAL SC, P41; 1993, 1993 WORLD BANK WORL, P99; 1993, GLOBAL AIDS NEWS, V3, P1; 1993, EFFECTIVE APPROACHES; 1994, CURRENT GLOBAL SITUA	56	96	97	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 15	1994	265	5170					341	345		10.1126/science.8023156	http://dx.doi.org/10.1126/science.8023156			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023156				2022-12-28	WOS:A1994NW81600026
J	ALTMAN, DG; GOODMAN, SN				ALTMAN, DG; GOODMAN, SN			TRANSFER OF TECHNOLOGY FROM STATISTICAL JOURNALS TO THE BIOMEDICAL LITERATURE - PAST TRENDS AND FUTURE PREDICTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To investigate the speed of the transfer of new statistical methods into the medical literature and, on the basis of current data, to predict what methods medical journal editors should expect to see in the next decade. Design.-Influential statistical articles were identified and the time pattern of citations in the medical literature was ascertained. In addition, longitudinal studies of the statistical content of articles in medical journals were reviewed. Main Outcome Measures.-Cumulative number of citations in medical journals of each article in the years after publication. Results.-Annual citations show some evidence of decreasing lag times between the introduction of new statistical methods and their appearance in medical journals. Newer technical innovations still typically take 4 to 6 years before they achieve 25 citations in the medical literature. Few methodological advances of the 1980s seem yet to have been widely cited in medical journals. Longitudinal studies indicate a large increase in the use of more complex statistical methods. Conclusions.-Time trends suggest that technology diffusion has speeded up during the last 30 years, although there is still a lag of several years before medical citations begin to accrue. Journals should expect to see more articles using increasingly sophisticated methods. Medical journals may need to modify reviewing procedures to deal with articles using these complex new methods.	JOHNS HOPKINS UNIV, CTR ONCOL, DIV BIOSTAT, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	ALTMAN, DG (corresponding author), IMPERIAL CANC RES FUND, MED STAT LAB, POB 123, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Goodman, Steven/0000-0002-3872-5723				ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; ALTMAN DG, 1991, STAT MED, V10, P1897, DOI 10.1002/sim.4780101206; ALTMAN DG, 1991, J R STAT SOC A STAT, V154, P223, DOI 10.2307/2983040; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Breiman L., 1984, CLASSIFICATION REGRE; CIAMPI A, 1988, J CLIN EPIDEMIOL, V41, P737, DOI 10.1016/0895-4356(88)90160-6; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; CORNFIELD J, 1951, J NATL CANCER I, V11, P1269; COX DR, 1972, J R STAT SOC B, V34, P187; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; EMERSON JD, 1983, NEW ENGL J MED, V309, P709, DOI 10.1056/NEJM198309223091206; Emerson JD, 1992, MED USES STAT, P45; FELSON DT, 1984, ARTHRITIS RHEUM, V27, P1018, DOI 10.1002/art.1780270908; GEMAN S, 1984, IEEE T PATTERN ANAL, V6, P721, DOI 10.1109/TPAMI.1984.4767596; GILKS WR, 1993, J R STAT SOC B, V55, P39; GOLDSTEIN H, 1986, MULTILEVEL MODELS ED; Greenland S., 1987, EVOLUTION EPIDEMIOLO; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hastie TJ., 2017, GEN ADDITIVE MODELS; HAYDEN GF, 1983, PEDIATRICS, V72, P84; HUTH EJ, 1989, B NEW YORK ACAD MED, V65, P647; International Committee of Medical Journal Editors, 1993, JAMA-J AM MED ASSOC, V269, P2282, DOI DOI 10.1001/JAMA.1993.03500170112052; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOTZ S, 1992, BREAKTHROUGHS STATIS, V2; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Ripley B. D., 1993, NETWORKS CHAOS STAT, P40, DOI DOI 10.1007/978-1-4899-3099-6_2; SEGLEN PO, 1991, J INTERN MED, V229, P109, DOI 10.1111/j.1365-2796.1991.tb00316.x; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; WULFF HR, 1987, STAT MED, V6, P3, DOI 10.1002/sim.4780060103; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; ZWEIG MH, 1993, CLIN CHEM, V39, P561; 1951, SCI CITATION INDEX	40	69	71	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					129	132		10.1001/jama.272.2.129	http://dx.doi.org/10.1001/jama.272.2.129			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015123				2022-12-28	WOS:A1994NV42400013
J	WHITELY, WP; RENNIE, D; HAFNER, AW				WHITELY, WP; RENNIE, D; HAFNER, AW			THE SCIENTIFIC COMMUNITY RESPONSE TO EVIDENCE OF FRAUDULENT PUBLICATION - THE SLUTSKY,ROBERT CASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC			Objective.-To determine whether scientists can detect fraudulent results in published research articles and to identify corrective measures that are most effective in purging fraudulent results from the literature. Design.-Retrospective case-control study comparing articles by an author known to have published fraudulent articles, Robert A, Slutsky, MD, to a set of control articles. The number of non-self-citations received by each article during each calendar year (1979 through 1990) was counted. The citation numbers were transformed into scores. Each Slutsky article was assigned a score between 1 and 3 based on the number of citations received by the Slutsky article and each of its assigned control articles. Average citation numbers and scores were tracked for each year during the 11-year study period. Results.-Before Slutsky's work was publicly questioned (1975 to 1985), scientists cited his articles as frequently as they cited control articles. After Slutsky's work was questioned and reports were published in the news media (1985), scientists cited his articles less frequently than they cited control articles. Citations decreased further after the University of California-San Diego published a review of the validity of Slutsky's work in 1987. Citations did not decrease after the appearance of retractions in print or in MEDLINE. Conclusion.-Scientists do not, and probably cannot, identify published articles that are fraudulent. However, when alerted to the presence of fraudulent results in the literature, the scientific community responds by reducing the number of citations of the tainted articles. In the Slutsky case, general news articles and the three reviews published by the University of California-San Diego were most effective and retractions were least effective in purging fraudulent results from the literature.	AMER MED ASSOC,DEPT INFORMAT ANAL,CHICAGO,IL 60610	American Medical Association								ENGLER RL, 1987, NEW ENGL J MED, V317, P1383, DOI 10.1056/NEJM198711263172205; FRIEDMAN PJ, 1990, JAMA-J AM MED ASSOC, V263, P1416; GARFIELD E, 1990, JAMA-J AM MED ASSOC, V263, P1424, DOI 10.1001/jama.263.10.1424; GREENBERG DS, 1986, SCI GOVT REP, V16, P4; LOCKE R, 1986, NATURE, V324, P401, DOI 10.1038/324401a0; MARSHALL E, 1986, SCIENCE, V234, P534, DOI 10.1126/science.3764425; PFEIFER MP, 1990, JAMA-J AM MED ASSOC, V263, P1420, DOI 10.1001/jama.263.10.1420	7	32	33	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					170	173		10.1001/jama.272.2.170	http://dx.doi.org/10.1001/jama.272.2.170			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015137				2022-12-28	WOS:A1994NV42400027
J	NAB, HW; HOP, WCJ; CROMMELIN, MA; KLUCK, HM; VANDERHEIJDEN, LH; COEBERGH, JWW				NAB, HW; HOP, WCJ; CROMMELIN, MA; KLUCK, HM; VANDERHEIJDEN, LH; COEBERGH, JWW			CHANGES IN LONG-TERM PROGNOSIS FOR BREAST-CANCER IN A DUTCH CANCER REGISTRY	BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL; TRENDS; WOMEN; CURABILITY	Objectives-To assess whether the long term survival of patients with breast cancer has changed with time. Design-Population based descriptive study. Setting-Eindhoven Cancer Registry in south east Netherlands. Subjects-2O52 patients with first primary breast cancer diagnosed between 1955 and 1974. Main outcome measures-Overall survival and relative survival. Results-Overall survival was 35% (727 patients) after 10 years, 21% (267) after 20 years, and 15% (25) after 30 years. The corresponding relative survival rates were 43%, 34%, and 34%, respectively. Survival improved from 1955 onwards for all ages and all tumour stages, Improvement was observed in both overall and relative survival. Prognosis was strongly related to the stage at diagnosis in the first 10 years of follow up but independent of stage after 10 years. Survival of patients still alive after 19 years became similar to that of the general female population, Conclusions-Both short and long term survival improved considerably in all age groups. This improvement was most marked for patients who were diagnosed with a localised tumour. Patients who survive for 19 years may be considered cured,	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	NAB, HW (corresponding author), COMPREHENS CANC CTR S,REG BREAST CANC STUDY GRP,POB 231,5600 AE EINDHOVEN,NETHERLANDS.			Coebergh, Jan Willem/0000-0002-2419-3930				ADAMI HO, 1986, JNCI-J NATL CANCER I, V76, P653, DOI 10.1093/jnci/76.4.653; BERKSON J, 1950, P STAFF M MAYO CLIN, V25, P270; BRINKLEY D, 1984, LANCET, V1, P1118; CASCINELLI N, 1991, CANCER-AM CANCER SOC, V68, P427, DOI 10.1002/1097-0142(19910715)68:2<427::AID-CNCR2820680236>3.0.CO;2-Y; CAYGILL CPJ, 1991, TUMORI, V77, P126, DOI 10.1177/030089169107700207; COX DR, 1972, J R STAT SOC B, V34, P187; DANFORTH DN, 1986, J CLIN ONCOL, V4, P655, DOI 10.1200/JCO.1986.4.5.655; DUNCAN W, 1976, BRIT MED J, V2, P781, DOI 10.1136/bmj.2.6039.781; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; HAKULINEN T, 1982, BIOMETRICS, V38, P933, DOI 10.2307/2529873; HAKULINEN T, 1981, ANN CLIN RES S31, V13, P48; HAKULINEN T, 1987, APPL STAT-J ROY ST C, V36, P309; HIBBERD AD, 1983, BRIT MED J, V286, P1777, DOI 10.1136/bmj.286.6380.1777; JOENSUU H, 1991, BRIT MED J, V303, P155, DOI 10.1136/bmj.303.6795.155; LANGLANDS AO, 1979, BRIT MED J, V2, P1247, DOI 10.1136/bmj.2.6200.1247; LAVECCHIA C, 1992, EUR J CANCER, V28A, P927, DOI 10.1016/0959-8049(92)90153-S; MILLER BA, 1993, CA-CANCER J CLIN, V43, P27, DOI 10.3322/canjclin.43.1.27; NAB HW, 1994, EUR J CANCER, V30A, P50, DOI 10.1016/S0959-8049(05)80018-8; NAB HW, 1993, EUR J CANCER, V29A, P1557, DOI 10.1016/0959-8049(93)90294-P; PARKIN DM, 1992, CANCER INVIDENCE 5 C, V6; RUTQVIST LE, 1985, CANCER-AM CANCER SOC, V55, P658, DOI 10.1002/1097-0142(19850201)55:3<658::AID-CNCR2820550331>3.0.CO;2-P; 1992, ATLAS CANCER MORTALI; NIH882789 NCI PUBL, P69	23	26	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					83	86		10.1136/bmj.309.6947.83	http://dx.doi.org/10.1136/bmj.309.6947.83			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038671	Green Published			2022-12-28	WOS:A1994NW71600014
J	CHUNG, JK; GRAMMER, TC; LEMON, KP; KAZLAUSKAS, A; BLENIS, J				CHUNG, JK; GRAMMER, TC; LEMON, KP; KAZLAUSKAS, A; BLENIS, J			PDGF-DEPENDENT AND INSULIN-DEPENDENT PP70(S6K) ACTIVATION MEDIATED BY PHOSPHATIDYLINOSITOL-3-OH KINASE	NATURE			English	Article							GROWTH-FACTOR RECEPTOR; S6 PROTEIN-KINASE; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; 3-KINASE; INHIBITION; P70(S6K); 3,4,5-TRISPHOSPHATE; EXPRESSION; WORTMANNIN	PLATELET-DERIVED growth factor receptor (PDGF-R) phosphorylation at tyrosines 740/751 and insulin receptor phosphorylation of insulin receptor substrate-1 effects the recruitment and activation of phosphatidylinositol-3-OH kinase (PI(3)K)(1-5). Changes in PI(3)K activity correlate with cell growth but its downstream signal transducers are unknown(4,5). Activation of the 70/85K S6 kinases (pp70(S6k)) by serine phosphorylation(6,7) results in 40S ribosomal protein S6 phosphorylation and is important for G1 cell-cycle transition in a variety of cells(8-11). Although receptor tyrosine kinases activate the microtubule-associated protein kinase cascade through SH2-/SH3-adaptor proteins, Sos and c-Ras(12), it is unclear how tyrosine kinases are coupled to the pp70(S6k) phosphorylation cascade. Here we report that PI(3)K mediates PDGF or insulin receptor signalling to pp70(S6k). PI(3)K-mediated activation of pp70(S6k) is independent of conventional protein kinase C isoforms. Additionally, rapamycin blocks pp70(S6k) activation by all mitogens(8-10), without inhibiting PI(3)M, and acts downstream this signalling system.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206	Harvard University; Harvard Medical School; National Jewish Health								ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHEATHAM B, IN PRESS MOL CELL BI; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2354; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUSA M, 1992, J BIOL CHEM, V267, P6905; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TSAI M, 1993, EUR J IMMUNOL, V23, P3286, DOI 10.1002/eji.1830231234; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YANO H, 1993, J BIOL CHEM, V268, P25846	30	687	695	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					71	75		10.1038/370071a0	http://dx.doi.org/10.1038/370071a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015612				2022-12-28	WOS:A1994NV71100062
J	BIKKINA, M; LEVY, D; EVANS, JC; LARSON, MG; BENJAMIN, EJ; WOLF, PA; CASTELLI, WP				BIKKINA, M; LEVY, D; EVANS, JC; LARSON, MG; BENJAMIN, EJ; WOLF, PA; CASTELLI, WP			LEFT-VENTRICULAR MASS AND RISK OF STROKE IN AN ELDERLY COHORT - THE FRAMINGHAM HEART-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERTROPHY; ECHOCARDIOGRAPHY; CRITERIA; DISEASE; EVENTS	Objective.-To evaluate the association of echocardiographically determined left ventricular mass (LVM) with incidence of stroke or transient ischemic attack in an elderly cohort. Design.-Cohort study with a follow-up period of 8 years. Setting.-Population-based sample. Subjects.-Elderly original cohort subjects of the Framingham Heart Study who were free of cerebrovascular disease and atrial fibrillation at the 16th biennial examination and who had adequate echocardiograms. This group consisted of 447 men (mean age, 67.8 years; range, 60 to 90 years) and 783 women (mean age, 69.2 years; range 59 to 90 years). Main Outcome Measures.-Age-adjusted 8 year incidence of stroke was examined as a function of baseline quartiles of LVM-to-height ratio. Proportional hazards regression was used in multivariate analyses to assess risk of stroke as a function of LVM-to-height ratio quartile, adjusting for age, sex, systolic blood pressure, hypertension treatment, diabetes, cigarette smoking, and blood lipid levels. Results.-Among the 1230 subjects eligible, 89 cerebrovascular disease events (62 strokes and 27 transient ischemic attacks) occurred during follow-up. In men, 8-year age-adjusted incidence of cerebrovascular events was 18.4% in the highest quartile of LVM-to-height ratio and 5.2% in the lowest quartile. Corresponding values in women were 12.2% and 2.9%. The hazard ratio for cerebrovascular events comparing highest to lowest quartile of LVM-to-height ratio was 2.72 (95% confidence interval [CI], 1.39 to 5.36) after adjusting for age, sex, systolic blood pressure, hypertension treatment, diabetes, cigarette smoking, and the ratio of total cholesterol to high-density lipoprotein cholesterol. After adjusting for age, sex, and cardiovascular disease risk factors, the hazard ratio for cerebrovascular events was 1.45 (95% CI, 1.17 to 1.80) for each quartile increment of LVM-to-height ratio. Conclusions.-Echocardiographically determined LVM-to-height ratio offers prognostic information beyond that provided by traditional cerebrovascular disease risk factors. Echocardiography provides information that facilitates identification of individuals at high risk for stroke and transient ischemic attack.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY,FRAMINGHAM,MA 01701; NHLBI,BETHESDA,MD; BOSTON UNIV,SCH MED,DIV EPIDEMIOL & PREVENT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DIV CARDIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DIV NEUROL,BOSTON,MA 02118; BETH ISRAEL HOSP,DIV CARDIOL,BOSTON,MA; BETH ISRAEL HOSP,DIV CLIN EPIDEMIOL,BOSTON,MA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center			Benjamin, Emelia/E-7103-2011; Levy, Daniel/ABB-2752-2021	Benjamin, Emelia/0000-0003-4076-2336; Levy, Daniel/0000-0003-1843-8724; Wolf, Philip/0000-0002-3628-301X; Larson, Martin/0000-0002-9631-1254	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-RO1-NS-17950-12] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONOW WS, 1988, AM J CARDIOL, V61, P1130, DOI 10.1016/0002-9149(88)90145-2; BAHEMUKA M, 1987, STROKE, V18, P531, DOI 10.1161/01.STR.18.2.531; BAHEMUKA M, 1988, Q J MED, V67, P467; BENJAMIN EJ, 1992, NEW ENGL J MED, V327, P374, DOI 10.1056/NEJM199208063270602; BHALI JK, 1992, ANN INTERN MED, V117, P831; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CUPPLES LA, 1988, NIH882969 US DEP HLT; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; FROHLICH ED, 1971, CIRCULATION, V44, P446, DOI 10.1161/01.CIR.44.3.446; KANNEL WB, 1987, AM J CARDIOL, V60, P851; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; MILLER JT, 1988, AM HEART J, V116, P1048, DOI 10.1016/0002-8703(88)90158-5; NISHIDE M, 1983, STROKE, V14, P541, DOI 10.1161/01.STR.14.4.541; SALONEN JT, 1982, STROKE, V13, P327, DOI 10.1161/01.STR.13.3.327; SAVAGE DD, 1987, HYPERTENSION, V9, P40; TROY BL, 1972, CIRCULATION, V45, P602, DOI 10.1161/01.CIR.45.3.602; VAZIRI SM, 1994, CIRCULATION, V89, P724, DOI 10.1161/01.CIR.89.2.724; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1975, CEREBRAL VASCULAR DI, P105; WOYTHALER JN, 1983, J AM COLL CARDIOL, V2, P305, DOI 10.1016/S0735-1097(83)80167-3; 1993, MONTHLY VITAL STAT R, V42, P1; 1992, ANN INTERN MED, V116, P6	30	254	259	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					33	36		10.1001/jama.272.1.33	http://dx.doi.org/10.1001/jama.272.1.33			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU485	8007076				2022-12-28	WOS:A1994NU48500026
J	LIU, FY; ALTMAN, S				LIU, FY; ALTMAN, S			DIFFERENTIAL EVOLUTION OF SUBSTRATES FOR AN RNA ENZYME IN THE PRESENCE AND ABSENCE OF ITS PROTEIN COFACTOR	CELL			English	Article							4.5 S-RNA; ESCHERICHIA-COLI; RIBONUCLEASE-P; INVITRO; PRECURSOR; SEQUENCE; MOIETY; MODEL; GENE; LIFE	Selection of substrates for an RNA enzyme, the catalytic subunit of RNAase P from E. coli, has been carried out by simulation of evolution in vitro in the presence and absence of the protein cofactor of the enzyme. In the presence of the protein, substrates resembling precursor tRNAs, which were readily cleaved by the catalytic RNA, were selected in addition to others, with different sequences and structures (one of which resembled the precursor to 4.5S RNA) that were not readily cleaved by the catalytic RNA alone. The ribonucleoprotein enzyme is more versatile than the RNA enzyme, and our results suggest that it and 4.5S RNA may have evolved after ancestral tRNAs.			LIU, FY (corresponding author), YALE UNIV,DEPT BIOL,POB 6666,NEW HAVEN,CT 06520, USA.				NIGMS NIH HHS [GM19422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019422, R01GM019422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; BOTHWELL ALM, 1976, J BIOL CHEM, V251, P7709; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CECH TR, 1993, RNA WORLD, P239; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DEBRUIJN MHL, 1983, EMBO J, V2, P1309, DOI 10.1002/j.1460-2075.1983.tb01586.x; FEDOR M, 1993, BIOCHEMISTRY-US, V31, P12042; Fersht A., 1985, ENZYME STRUCTURE MEC; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GUERRIERTAKADA C, 1989, SCIENCE, V246, P1578, DOI 10.1126/science.2480641; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HSU LM, 1984, J MOL BIOL, V178, P509, DOI 10.1016/0022-2836(84)90236-5; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KAHLE D, 1990, EMBO J, V9, P1929, DOI 10.1002/j.1460-2075.1990.tb08320.x; KOMINE Y, 1994, IN PRESS P NATL ACAD; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Moore M., 1993, RNA WORLD, P303; NOLAN JM, 1993, SCIENCE, V261, P762, DOI 10.1126/science.7688143; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OKIMOTO R, 1990, EMBO J, V9, P3405, DOI 10.1002/j.1460-2075.1990.tb07542.x; PECKMILLER KA, 1991, J MOL BIOL, V221, P1; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1399, DOI 10.1021/bi00172a016; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VIOQUE A, 1988, J MOL BIOL, V202, P835, DOI 10.1016/0022-2836(88)90562-1; YUAN Y, 1994, SCIENCE, V263, P1269, DOI 10.1126/science.8122108	33	72	75	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1093	1100		10.1016/0092-8674(94)90448-0	http://dx.doi.org/10.1016/0092-8674(94)90448-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020097				2022-12-28	WOS:A1994NV42500017
J	ROBINSON, RC; GREY, LM; STAUNTON, D; VANKELECOM, H; VERNALLIS, AB; MOREAU, JF; STUART, DI; HEATH, JK; JONES, EY				ROBINSON, RC; GREY, LM; STAUNTON, D; VANKELECOM, H; VERNALLIS, AB; MOREAU, JF; STUART, DI; HEATH, JK; JONES, EY			THE CRYSTAL-STRUCTURE AND BIOLOGICAL FUNCTION OF LEUKEMIA INHIBITORY FACTOR - IMPLICATIONS FOR RECEPTOR-BINDING	CELL			English	Article								The structure of murine leukemia inhibitory factor (LIF) has been determined by X-ray crystallography at 2.0 Angstrom resolution. The main chain fold conforms to the four alpha-helix bundle topology previously observed for several members of the hematopoietic cytokine family. Of these, LIF shows closest structural homology to granulocyte colony-stimulating factor and growth hormone (GH). Sequence alignments for the functionally related molecules oncostatin M and ciliary neurotrophic factor, when mapped to the LIF structure, indicate regions of conserved surface character. Analysis of the biological function and receptor specificity of a series of human-mouse LIF chimeras implicate two regions of receptor interaction that are located in the fourth helix and the preceding loop. A model for receptor binding based on the structure of the GH ligand-receptor complex requires additional, novel features to account for these data.	UNIV OXFORD, CANC RES CAMPAIGN GROWTH FACTOR GRP, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND	University of Oxford; University of Oxford	ROBINSON, RC (corresponding author), UNIV OXFORD, MOLEC BIOPHYS LAB, REX RICHARDS BLDG, OXFORD OX1 3QU, ENGLAND.		Robinson, Robert/G-9702-2011; Jones, Yvonne/J-2293-2016; Jones, Yvonne/N-8111-2019	Robinson, Robert/0000-0001-6367-6903; Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210; Vankelecom, Hugo/0000-0002-2251-7284				BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; BOULAY JL, 1993, CURR BIOL, V3, P573, DOI 10.1016/0960-9822(93)90002-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruce A. Gregory, 1992, Progress in Growth Factor Research, V4, P157, DOI 10.1016/0955-2235(92)90029-H; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1992, CIBA F SYMP, V167, P245; GODARD A, 1988, BLOOD, V71, P1618; HARLOS K, 1992, J APPL CRYSTALLOGR, V25, P536, DOI 10.1107/S0021889892002656; HEATH JK, 1992, NATURE, V359, P17, DOI 10.1038/359017a0; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JONES EY, 1991, ISOMORPHOUS REPLACEM, P39; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE JC, 1982, J IMMUNOL, V128, P2393; LIU JW, 1992, J BIOL CHEM, V267, P16763; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MEREAU A, 1993, J CELL BIOL, V122, P713, DOI 10.1083/jcb.122.3.713; Metcalf D, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046921; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NICOLA NA, 1993, BIOCHEM BIOPH RES CO, V190, P20, DOI 10.1006/bbrc.1993.1004; NISHIMURA C, 1991, EUR J BIOCHEM, V196, P377, DOI 10.1111/j.1432-1033.1991.tb15827.x; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAMUDZI CT, 1991, J BIOL CHEM, V266, P21791; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENDA T, 1992, EMBO J, V11, P3193, DOI 10.1002/j.1460-2075.1992.tb05396.x; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; STURA EA, 1992, CRYSTALLIZATION NUCL, P99; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; VANDAM M, 1993, J BIOL CHEM, V268, P15285; VANSNICK J, 1988, EUR J IMMUNOL, V18, P193; WALTER MR, 1992, J BIOL CHEM, V267, P20371; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553; WODAWER A, 1992, FEBS LETT, V309, P59; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YIN TG, 1993, J IMMUNOL, V151, P2555; ZURAWSKI SM, 1993, EMBO J, V12, P5113, DOI 10.1002/j.1460-2075.1993.tb06206.x	83	188	194	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	1994	77	7					1101	1116		10.1016/0092-8674(94)90449-9	http://dx.doi.org/10.1016/0092-8674(94)90449-9			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020098				2022-12-28	WOS:A1994NV42500018
J	HOLLAND, BK				HOLLAND, BK			PROSPECTING FOR DRUGS IN ANCIENT TEXTS	NATURE			English	Editorial Material							PENNYROYAL OIL; HEPATOTOXICITY; MENTHOFURAN; GLUTATHIONE; PULEGONE				HOLLAND, BK (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PREVENT MED & COMMUNITY HLTH,NEWARK,NJ 07103, USA.							ATHERTON DJ, 1991, LANCET, V338, P510, DOI 10.1016/0140-6736(91)90580-I; BURTON JL, 1990, LANCET, V336, P1565, DOI 10.1016/0140-6736(90)93326-K; FARNSWORTH NR, 1983, NATURAL PRODUCTS DRU; FELLOWS L, 1992, LANCET, V339, P1330, DOI 10.1016/0140-6736(92)91967-D; FROEHLICH O, 1990, Journal of Agricultural and Food Chemistry, V38, P2057, DOI 10.1021/jf00101a012; GORDON WP, 1987, DRUG METAB DISPOS, V15, P589; GORDON WP, 1982, TOXICOL APPL PHARM, V65, P413, DOI 10.1016/0041-008X(82)90387-8; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; REYNOLDS T, 1991, J NATL CANCER I, V83, P594, DOI 10.1093/jnci/83.9.594; RIDDLE JM, 1992, AM SCI, V80, P226; SULLIVAN JB, 1979, JAMA-J AM MED ASSOC, V242, P2873; THOMASSEN D, 1991, DRUG METAB DISPOS, V19, P997; THOMASSEN D, 1990, J PHARMACOL EXP THER, V253, P567; VILLASENOR IM, 1993, CARCINOGENESIS, V14, P123, DOI 10.1093/carcin/14.1.123	14	46	48	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					702	702		10.1038/369702a0	http://dx.doi.org/10.1038/369702a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008059				2022-12-28	WOS:A1994NU58100027
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION IN PRIMARY-CARE - MELANOMA - PREVENTION AND EARLY DIAGNOSIS .5.	BRITISH MEDICAL JOURNAL			English	Article							PUBLIC-EDUCATION CAMPAIGN; BENIGN PIGMENTED LESIONS; MALIGNANT-MELANOMA; 7-POINT CHECKLIST; SUNBURN	Over the past two decades there has been a rapid rise in the numbers of people developing and dying from malignant melanoma. Sunlight is the main aetiological factor linked with melanoma. Exposure to the sun is a risk factor that can be modified provided that people are aware of the dangers. Health promotion campaigns can play a part in producing such change. General practitioners and practice nurses have an important part to play in providing those most at risk with information and advice about sensible sun exposure and sun protection measures. Campaigns to reduce delay in diagnosis by a combination of professional and public education have been reported from several centres around the world. The effects of these campaigns in reducing the depth distribution of cutaneous malignant melanoma have sometimes been encouraging, but in other instances have shown little effect. Until there is clear evidence that early detection reduces mortality from melanoma, the opportunistic promotion of early detection may not be cost effective and will fail to reach all sections of the community at risk. At the present time, therefore, the emphasis should be on the primary prevention of skin cancer.			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX2 6PE,ENGLAND.							DOHERTY VR, 1988, BRIT MED J, V297, P388, DOI 10.1136/bmj.297.6645.388; DUVIVIER AWP, 1991, CLIN EXP DERMATOL, V16, P344, DOI 10.1111/j.1365-2230.1991.tb00397.x; Elwood J M, 1994, J Med Screen, V1, P22; ELWOOD JM, 1992, CLIN DERMATOL, V10, P41, DOI 10.1016/0738-081X(92)90056-5; GRAHAMBROWN RAC, 1990, BRIT J DERMATOL, V122, P53, DOI 10.1111/j.1365-2133.1990.tb08239.x; HEALSMITH MF, 1994, BRIT J DERMATOL, V130, P48, DOI 10.1111/j.1365-2133.1994.tb06881.x; HERD RM, 1992, BMJ-BRIT MED J, V305, P1476, DOI 10.1136/bmj.305.6867.1476; HIGGINS EM, 1992, CLIN EXP DERMATOL, V17, P313, DOI 10.1111/j.1365-2230.1992.tb00218.x; Hill D, 1993, Eur J Cancer Prev, V2, P447; HILL D, 1992, PREV MED, V21, P654, DOI 10.1016/0091-7435(92)90072-P; JARRETT P, 1993, BRIT MED J, V306, P1448, DOI 10.1136/bmj.306.6890.1448; KEEFE M, 1990, CLIN EXP DERMATOL, V15, P167, DOI 10.1111/j.1365-2230.1990.tb02064.x; KOH H, 1992, PUBLIC HLTH APPROACH, P58; KOH HK, 1992, CLIN DERMATOL, V10, P97, DOI 10.1016/0738-081X(92)90064-6; Mackie R. M., 1989, MALIGNANT MELANOMA G; MACKIE RM, 1990, BRIT MED J, V301, P1005, DOI 10.1136/bmj.301.6759.1005; MACKIE RM, 1992, BRIT MED J, V304, P1012, DOI 10.1136/bmj.304.6833.1012; MACKIE RM, 1992, CLIN DERMATOL, V10, P91, DOI 10.1016/0738-081X(92)90063-5; MARKS R, 1994, BRIT MED J, V308, P75, DOI 10.1136/bmj.308.6921.75; MARKS R, 1992, PUBLIC HLTH APPROACH; MELIA J, 1994, J PUBLIC HEALTH MED, V16, P225, DOI 10.1093/oxfordjournals.pubmed.a042961; MELIA J, 1993, BRIT MED J, V307, P737, DOI 10.1136/bmj.307.6906.737-c; SOBER A, 1992, PUBLIC HLTH APPROACH, P108; WHITEHEAD SM, 1989, BRIT J CANCER, V60, P421, DOI 10.1038/bjc.1989.298; 1993, PLAYSAFE SUN SKIN CA; [No title captured]; 1989, CRC4 CANC RES CAMP F; 1993, MALIGNANT MELANOMA F; 1991, SKIN CANCER SUN YOU	29	55	55	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1682	1686		10.1136/bmj.308.6945.1682	http://dx.doi.org/10.1136/bmj.308.6945.1682			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025464	Green Published			2022-12-28	WOS:A1994NU48300025
J	COUPLAND, RM				COUPLAND, RM			EPIDEMIOLOGIC APPROACH TO SURGICAL-MANAGEMENT OF THE CASUALTIES OF WAR	BRITISH MEDICAL JOURNAL			English	Article							INTERNATIONAL-COMMITTEE; RED-CROSS; FALKLANDS WAR; EXPERIENCE; TRIAGE; INJURIES	The nature of modern conflicts precludes adequate medical care for most people wounded in wars. The traditional military approach of echeloned care for those wounded on the battlefield has limited relevance. I present an alternative, epidemiological approach whereby some affective care may reach many more. For a surgical facility to have a positive impact by using surgical and anaesthetic competence there must be access to the wounded; security for staff and patients; and a functioning hospital infrastructure. These all depend on respect for the first Geneva convention. Early hospital admission for urgent surgery is not so important if there is adequate first aid beforehand. The hospitals of the International Committee of the Red Cross have provided surgical care for thousands of wounded people by fulfilling these conditions. People wounded in modern conflicts would fare better if these priorities were recognised and less emphasis was placed on the more spectacular aspects of surgical care that benefit only a few.			COUPLAND, RM (corresponding author), RED CROSS,INT COMM,DIV MED,AVE PAIX,CH-1202 GENEVA,SWITZERLAND.							BELLAMY RF, 1992, WORLD J SURG, V16, P888, DOI 10.1007/BF02066987; BELLAMY RF, 1984, MIL MED, V149, P55; BOWEN TE, 1988, EMERGENCY WAR SURGER; CLYNE A J, 1955, J R Army Med Corps, V101, P33; COUPLAND RM, 1988, INJURY, V19, P259, DOI 10.1016/0020-1383(88)90041-1; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; COUPLAND RM, 1993, JAMA-J AM MED ASSOC, V270, P624, DOI 10.1001/jama.270.5.624; COUPLAND RM, 1992, INJURY, V23, P507, DOI 10.1016/0020-1383(92)90146-J; Coupland RM, 1993, WAR WOUNDS LIMBS SUR; CUTTING PA, 1992, INJURY, V23, P405, DOI 10.1016/0020-1383(92)90018-N; DANON YL, 1984, ISRAEL J MED SCI, V20, P300; DEWIND CM, 1987, ANN ROY COLL SURG, V69, P193; ESHAYACHAUVIN B, 1992, BRIT J ANAESTH, V68, P221, DOI 10.1093/bja/68.2.221; FRASER I, 1984, BRIT MED J, V289, P1723, DOI 10.1136/bmj.289.6460.1723; GERTSCH, 1987, BRIT J SURG, V74, P831; HARDAWAY RM, 1978, J TRAUMA, V18, P635, DOI 10.1097/00005373-197809000-00004; JACKSON DS, 1983, ANN ROY COLL SURG, V65, P281; LLEWELLYN CH, 1992, WORLD J SURG, V16, P904, DOI 10.1007/BF02066990; MALPASS CP, 1976, BRIT J SURG, V63, P482, DOI 10.1002/bjs.1800630621; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; MELSOM MA, 1975, ANN R COLL SURG ENGL, V56, P287; MUCKART DJJ, 1990, BRIT J SURG, V77, P652, DOI 10.1002/bjs.1800770620; Perrin P, 1991, INT REV RED CROSS, V284, P494; RAUTIO J, 1988, J TRAUMA, V28, P523, DOI 10.1097/00005373-198804000-00019; Rogov M, 1982, ISRAEL J MED SCI, V20, P369; ROZIN R, 1988, INJURY, V19, P193, DOI 10.1016/0020-1383(88)90014-9; ROZIN RR, 1987, J TRAUMA, V27, P656; Ryan J M, 1990, J R Army Med Corps, V136, P27; RYAN JM, 1984, ANN ROY COLL SURG, V66, P195; SMITH AM, 1989, FEB US NAV I P, P40; SMITH MSO, 1981, J R ARMY MED CORPS, V127, P31; TROUWBORST A, 1987, INJURY, V18, P96, DOI 10.1016/0020-1383(87)90181-1; 1986, 1949 GEN CONV AUG 12	33	49	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1693	1697		10.1136/bmj.308.6945.1693	http://dx.doi.org/10.1136/bmj.308.6945.1693			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025468	Green Published			2022-12-28	WOS:A1994NU48300033
J	MILLER, LH; GOOD, MF; MILON, G				MILLER, LH; GOOD, MF; MILON, G			MALARIA PATHOGENESIS	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; FALCIPARUM-INFECTED ERYTHROCYTES; HUMAN CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM; ANTIGENIC VARIATION; P-FALCIPARUM; T-CELLS; SURFACE; PARASITES; INVASION	Malaria is a disease caused by repeated cycles of growth of the parasite Plasmodium in the erythrocyte. Various cellular and molecular strategies allow the parasite to evade the human immune response for many cycles of parasite multiplication. Under certain circumstances Plasmodium infection causes severe anemia or cerebral malaria; the expression of disease is influenced by both parasite and host factors, as exemplified by the exacerbation of disease during pregnancy. This article provides an overview of malaria pathogenesis, synthesizing the recent field, laboratory, and epidemiological data that will lead to the development of strategies to reduce mortality and morbidity.	QUEENSLAND INST MED RES, MALARIA & ARBOVIRUS UNIT, BRISBANE, QLD 4029, AUSTRALIA; INST PASTEUR, F-75724 PARIS 15, FRANCE	QIMR Berghofer Medical Research Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	MILLER, LH (corresponding author), NIAID, MALARIA RES LAB, BETHESDA, MD 20892 USA.							ABDALLA S, 1980, BRIT J HAEMATOL, V46, P171, DOI 10.1111/j.1365-2141.1980.tb05956.x; ADAMS JH, 1990, CELL, V63, P141, DOI 10.1016/0092-8674(90)90295-P; AIKAWA M, 1990, AM J TROP MED HYG, V43, P30, DOI 10.4269/ajtmh.1990.43.30; ALLAN RJ, 1993, INFECT IMMUN, V61, P4772, DOI 10.1128/IAI.61.11.4772-4776.1993; ALPERS M, COMMUNICATION; BAIRD JK, 1991, AM J TROP MED HYG, V45, P65, DOI 10.4269/ajtmh.1991.45.65; BARNWELL JW, 1983, CIBA F SYMP, V94, P117; BARNWELL JW, 1983, INFECT IMMUN, V40, P985, DOI 10.1128/IAI.40.3.985-994.1983; BATE CAW, 1988, IMMUNOLOGY, V64, P227; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633; BRABIN BJ, 1991, WHO APPLIED FIELD RE, V1; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; CARLSON J, 1992, J EXP MED, V176, P1311, DOI 10.1084/jem.176.5.1311; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; CLARK IA, 1994, PARASITOL TODAY, V10, P6, DOI 10.1016/0169-4758(94)90341-7; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; COLLINS WE, UNPUB; CURRIER J, 1992, INT IMMUNOL, V4, P985, DOI 10.1093/intimm/4.9.985; DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753; DOLAN SA, IN PRESS MOL BIOCH P; EYLES DE, 1951, J NATL MALAR SOC, V10, P227; Field J. W., 1937, Transactions of the Royal Society of Tropical Medicine and Hygiene London, V30, P569, DOI 10.1016/S0035-9203(37)90070-1; GALBRAITH RM, 1980, T ROY SOC TROP MED H, V74, P61, DOI 10.1016/0035-9203(80)90012-7; GALINSKI MR, 1992, CELL, V69, P1213, DOI 10.1016/0092-8674(92)90642-P; GEROLD P, 1994, J BIOL CHEM, V269, P2597; GODFREY KM, 1994, BRIT J OBSTET GYNAEC, V101, P398, DOI 10.1111/j.1471-0528.1994.tb11911.x; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; HANDUNNETTI SM, 1992, BLOOD, V80, P2097; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HO M, 1991, INFECT IMMUN, V59, P2135, DOI 10.1128/IAI.59.6.2135-2139.1991; Holder AA, 1981, NATURE, V294, P361, DOI 10.1038/294361a0; HOMMEL M, 1983, J EXP MED, V157, P1137, DOI 10.1084/jem.157.4.1137; HUDSON DE, 1988, J MOL BIOL, V203, P707, DOI 10.1016/0022-2836(88)90204-5; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; JEFFERY GM, 1966, B WORLD HEALTH ORGAN, V35, P873; JONGENEEL CV, 1991, P NATL ACAD SCI USA, V88, P9717, DOI 10.1073/pnas.88.21.9717; Kearney J F, 1992, Curr Top Microbiol Immunol, V182, P81; KEEN JK, IN PRESS MOL BIOCH P; KIDSON C, 1981, P NATL ACAD SCI-BIOL, V78, P5829, DOI 10.1073/pnas.78.9.5829; KWIATKOWSKI D, 1989, CLIN EXP IMMUNOL, V77, P361; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; LANGHORNE J, 1992, IMMUNOL TODAY, V13, P298, DOI 10.1016/0167-5699(92)90041-5; LANGRETH SG, 1985, INFECT IMMUN, V47, P760, DOI 10.1128/IAI.47.3.760-766.1985; LANNERS HN, 1984, Z PARASITENKD, V70, P739, DOI 10.1007/BF00927126; LOOAREESUWAN S, 1985, LANCET, V2, P4, DOI 10.1016/S0140-6736(85)90056-X; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MCGREGOR IA, 1956, BRIT MED J, V2, P686, DOI 10.1136/bmj.2.4994.686; MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517, DOI 10.4269/ajtmh.1984.33.517; MESSER G, 1991, J EXP MED, V173, P209, DOI 10.1084/jem.173.1.209; MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F; MILLER LH, 1969, AM J TROP MED HYG, V18, P860, DOI 10.4269/ajtmh.1969.18.860; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; MILLER LH, 1977, J EXP MED, V146, P277, DOI 10.1084/jem.146.1.277; MOLYNEUX ME, 1989, Q J MED, V71, P441; NEWBOLD CI, 1992, EXP PARASITOL, V75, P281, DOI 10.1016/0014-4894(92)90213-T; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; PASVOL G, 1982, NATURE, V297, P64, DOI 10.1038/297064a0; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PHILLIPS RE, 1986, Q J MED, V58, P305; PLAYFAIR JHL, 1990, IMMUNOL TODAY, V11, P25; POWELL RD, 1972, P HELM SOC WASH, V39, P51; PRUKSAKORN S, 1992, J IMMUNOL, V149, P2729; PRUKSAKORN S, UNPUB; REDMAN CWG, 1993, HUMAN PLACENTA GUIDE; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; ROBERTS DJ, 1993, PARASITOL TODAY, V9, P281, DOI 10.1016/0169-4758(93)90121-U; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; STEKETEE RW, 1994, MALARIA PREVENTION P; THOMAS AW, 1984, MOL BIOCHEM PARASIT, V13, P187, DOI 10.1016/0166-6851(84)90112-9; TURNER G, IN PRESS AM J PATHOL; UDEINYA IJ, 1983, NATURE, V303, P429, DOI 10.1038/303429a0; WALTER PR, 1982, AM J PATHOL, V109, P330; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201; WHITE WI, 1991, INFECT IMMUN, V59, P3547, DOI 10.1128/IAI.59.10.3547-3554.1991; YOUNG NS, 1994, APLASTIC ANEMIA ACQU, P68; ZUCKER JR, COMMUNICATION; [No title captured]	83	440	449	3	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	1994	264	5167					1878	1883		10.1126/science.8009217	http://dx.doi.org/10.1126/science.8009217			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009217				2022-12-28	WOS:A1994NT84700032
J	KLEIN, G				KLEIN, G			EPSTEIN-BARR-VIRUS STRATEGY IN NORMAL AND NEOPLASTIC B-CELLS	CELL			English	Review							LATENT MEMBRANE-PROTEIN; BURKITTS-LYMPHOMA; NASOPHARYNGEAL CARCINOMA; EXPRESSION; EBV; ANTIGENS; IDENTIFICATION; LYMPHOCYTES; PHENOTYPE; OUTGROWTH				KLEIN, G (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN.							ANDERSSON ML, 1991, INT J CANCER, V47, P544, DOI 10.1002/ijc.2910470412; BURROWS SR, 1990, J EXP MED, V171, P345, DOI 10.1084/jem.171.1.345; CONTRERASBRODIN BA, 1991, J GEN VIROL, V72, P3025, DOI 10.1099/0022-1317-72-12-3025; DECAMPOSLIMA PO, IN PRESS J EXP MED; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GAVIOLI R, 1993, J VIROL, V67, P1572, DOI 10.1128/JVI.67.3.1572-1578.1993; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; GREGORY CD, 1987, J IMMUNOL, V139, P313; HENLE G, 1979, EPSTEIN BARR VIRUS, P298; HU LF, 1991, J VIROL, V65, P1558, DOI 10.1128/JVI.65.3.1558-1567.1991; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; KLEIN G, 1976, INT J CANCER, V17, P21, DOI 10.1002/ijc.2910170105; KLEIN G, 1989, GENE CHROMOSOME CANC, V1, P3, DOI 10.1002/gcc.2870010103; LEWIN N, 1988, INT J CANCER, V41, P892, DOI 10.1002/ijc.2910410621; LEWIN N, 1987, INT J CANCER, V39, P472, DOI 10.1002/ijc.2910390411; MASUCCI MG, 1989, J VIROL, V63, P3135, DOI 10.1128/JVI.63.7.3135-3141.1989; MASUCCI MG, 1994, IN PRESS TRENDS MICR; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; NILSSON K, 1982, ADV CANCER RES, V37, P319, DOI 10.1016/S0065-230X(08)60886-6; PALLESEN G, 1993, ADV CANCER RES, V62, P179, DOI 10.1016/S0065-230X(08)60319-X; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; SAMPLE J, 1992, J VIROL, V66, P4654, DOI 10.1128/JVI.66.8.4654-4661.1992; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; WOISETSCHLAEGER M, 1989, P NATL ACAD SCI USA, V86, P6498, DOI 10.1073/pnas.86.17.6498	24	236	242	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					791	793		10.1016/0092-8674(94)90125-2	http://dx.doi.org/10.1016/0092-8674(94)90125-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004668				2022-12-28	WOS:A1994NT33100003
J	KLENERMAN, L				KLENERMAN, L			ABC OF SPORTS MEDICINE - MUSCULOSKELETAL INJURIES IN CHILD ATHLETES	BRITISH MEDICAL JOURNAL			English	Article											KLENERMAN, L (corresponding author), UNIV LIVERPOOL,LIVERPOOL L69 3BX,ENGLAND.								0	15	16	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1556	1559		10.1136/bmj.308.6943.1556	http://dx.doi.org/10.1136/bmj.308.6943.1556			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019317	Green Published			2022-12-28	WOS:A1994NR11000032
J	RANIERI, E; LEWIS, BD; GERACE, RL; RYALL, RG; MORRIS, CP; NELSON, PV; CAREY, WF; ROBERTSON, EF				RANIERI, E; LEWIS, BD; GERACE, RL; RYALL, RG; MORRIS, CP; NELSON, PV; CAREY, WF; ROBERTSON, EF			NEONATAL SCREENING FOR CYSTIC-FIBROSIS USING IMMUNOREACTIVE TRYPSINOGEN AND DIRECT GENE ANALYSIS - 4 YEARS EXPERIENCE	BRITISH MEDICAL JOURNAL			English	Article							MUTATION; DELTA-F508; POPULATION; GENOTYPE	Objective-To assess the performance and impact of a two tier neonatal screening programme for cystic fibrosis based on an initial estimation of immunoreactive trypsinogen followed by direct gene analysis. Design-Four year prospective study of two tier screening strategy. First tier: immunoreactive trypsinogen measured in dried blood spot samples from neonates aged 3-5 days. Second tier: direct gene analysis of cystic fibrosis mutations (Delta F-508, Delta I-506, G(551)D, G(542)X, and R(553)X) in samples with immunoreactive trypsinogen concentrations in highest 1% and in all neonates with meconium ileus or family history of cystic fibrosis. Setting-South Australian Neonatal Screening Programme, Adelaide. Subjects-All 88752 neonates born in South Australia between December 1989 and December 1993. Interventions-Neonates with two identifiable mutations were referred directly for clinical assessment and confirmatory sweat test; infants with only one identifiable mutation were recalled for sweat test at age 3-4 weeks. Parents of neonates identified as carriers of cystic fibrosis mutation were counselled and offered genetic testing. Main outcome measures-Identification of all children with cystic fibrosis in the screened population. Results-Of 1004 (1.13%) neonates with immunoreactive trypsinogen greater than or equal to 99th centile, 912 (90.8%) had no identifiable mutation. 23 neonates were homozygotes or compound heterozygotes; 69 carried one identifiable mutation, of whom six had positive sweat tests. Median age at clinical assessment for the 29 neonates with cystic fibrosis was 3 weeks; six had meconium ileus and two had affected siblings. 63 neonates were identified as carriers of a cystic fibrosis mutation. Extra laboratory costs for measuring immunoreactive trypsinogen and direct gene analysis were $A1.50 per neonate screened. Conclusion-This strategy results in early and accurate diagnosis of cystic fibrosis and performs better than screening strategies based on immunoreactive trypsinogen measurement alone.	WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,STATE NEONATAL SCREENING SERV,ADELAIDE,SA 5006,AUSTRALIA; WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,SPECIAL DIAGNOST LAB,ADELAIDE,SA 5006,AUSTRALIA	Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia	RANIERI, E (corresponding author), WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,STATE SCREENING LAB,ADELAIDE,SA 5006,AUSTRALIA.			Morris, Phillip/0000-0001-8976-619X				[Anonymous], 1983, PEDIATRICS; BOLAND C, 1990, ARCH DIS CHILD, V65, P1240, DOI 10.1136/adc.65.11.1240; CHATFIELD S, 1991, ARCH DIS CHILD-FETAL, V66, P29, DOI 10.1136/adc.66.1_Spec_No.29; CULARD JF, 1994, HUM GENET, V93, P167; Dankert-Roelse J E, 1990, Acta Univ Carol Med (Praha), V36, P99; DANKERTROELSE JE, 1989, J PEDIATR-US, V114, P362, DOI 10.1016/S0022-3476(89)80552-9; Farrell P M, 1992, Adv Pediatr, V39, P35; GIBSON LE, 1959, PEDIATRICS, V23, P545; GREEN MR, 1993, ARCH DIS CHILD, V68, P464, DOI 10.1136/adc.68.4.464; GREGG RG, 1993, AM J HUM GENET, V52, P616; HAMMOND K, 1987, ADV NEONATAL SCREENI, P337; HAMMOND KB, 1991, NEW ENGL J MED, V325, P769, DOI 10.1056/NEJM199109123251104; HEELEY AF, 1992, ANN CLIN BIOCHEM, V29, P361, DOI 10.1177/000456329202900401; HENRY RL, 1990, J PAEDIATR CHILD H, V26, P150, DOI 10.1111/j.1440-1754.1990.tb02413.x; KEREM B, 1989, SCIENCE, V284, P1073; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; KRAMER R, 1977, HELV PAEDIATR ACTA, V32, P107; LAROUCHE D, 1991, LANCET, V339, P55; Mischler E, 1989, Wis Med J, V88, P14; NELSON PV, 1990, MED J AUSTRALIA, V152, P328, DOI 10.5694/j.1326-5377.1990.tb120962.x; RANIERI E, 1991, BRIT MED J, V302, P1237, DOI 10.1136/bmj.302.6787.1237; ROCK MJ, 1990, PEDIATRICS, V85, P1001; ROCK MJ, 1989, PEDIATR PULM, V6, P42, DOI 10.1002/ppul.1950060111; ROSENSTEIN BJ, 1982, JOHNS HOPKINS MED J, V150, P113; RYALL RG, 1993, CLIN CHEM, V39, P224; RYLEY HC, 1992, BRIT MED BULL, V48, P805, DOI 10.1093/oxfordjournals.bmb.a072579; SPENCE WC, 1993, BIOCHEM MED METAB B, V49, P200, DOI 10.1006/bmmb.1993.1022; TLUCZEK A, 1992, J DEV BEHAV PEDIATR, V13, P181; WESLEY AW, 1989, AUST PAEDIATR J, V25, P151; WILCKEN B, 1993, SCREENING, V2, P43	32	52	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1469	1472		10.1136/bmj.308.6942.1469	http://dx.doi.org/10.1136/bmj.308.6942.1469			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019280	Green Published			2022-12-28	WOS:A1994NQ22900016
J	GELMAN, B				GELMAN, B			THE LITTLE PICTURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					417	417						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040961				2022-12-28	WOS:A1994PA27800001
J	DELATTRE, O; ZUCMAN, J; MELOT, T; GARAU, XS; ZUCKER, JM; LENOIR, GM; AMBROS, PF; SHEER, D; TURCCAREL, C; TRICHE, TJ; AURIAS, A; THOMAS, G				DELATTRE, O; ZUCMAN, J; MELOT, T; GARAU, XS; ZUCKER, JM; LENOIR, GM; AMBROS, PF; SHEER, D; TURCCAREL, C; TRICHE, TJ; AURIAS, A; THOMAS, G			THE EWING FAMILY OF TUMORS - A SUBGROUP OF SMALL-ROUND-CELL TUMORS DEFINED BY SPECIFIC CHIMERIC TRANSCRIPTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMITIVE NEUROECTODERMAL TUMORS; PERIPHERAL NEUROEPITHELIOMA; ALVEOLAR RHABDOMYOSARCOMA; CHROMOSOME-TRANSLOCATION; CYTOGENETIC ANALYSIS; GENE FUSION; SARCOMA; BONE; HISTOGENESIS; EXPRESSION	Background. Precise diagnosis of small-round-cell tumors is often a challenge to the pathologist and the clinical oncologist. In Ewing's sarcomas and related peripheral primitive neuroectodermal tumors, a t(11;22) translocation or a (21,22) rearrangement is associated with hybrid transcripts of the EWS gene with the FLI1 or ERG gene. To investigate the diagnostic implication of this observation, we searched for these hybrid transcripts in tumors from patients with clinical and radiologic features of Ewing's sarcoma or peripheral primitive neuroectodermal tumors. Methods. Samples of RNA from 114 tumors were reverse transcribed and subjected to the polymerase chain reaction with primers designed to amplify the relevant chimeric transcripts. All amplified products were sequenced. Results. In-frame hybrid transcripts were observed in 89 cases. A hybrid transcript was found in 83 of 87 cases (95 percent) of Ewing's sarcoma or peripheral primitive neuroectodermal tumors. Samples of RNA from all of 12 tumors that had been proved to be other than Ewing's sarcoma or neuroectodermal tumors had no hybrid transcript. However, 6 of 15 undifferentiated tumors whose type was ambiguous (nonsecreting, poorly differentiated neuroblastoma or undifferentiated sarcoma) contained a hybrid transcript, suggesting that they might have to be reclassified. Conclusions. A subgroup of small-round-cell tumors identified as belonging to the Ewing family of tumors can be defined according to a specific molecular genetic lesion that is detectable by a rapid, reliable, and efficient method. This approach can be applied to small specimens obtained by fine-needle biopsies.	INST CURIE,GENET TUMEURS LAB,INSERM,CONTRAT JEUNE FORMAT 9201,F-75231 PARIS 05,FRANCE; INST CURIE,SERV ONCOL PEDIAT,PARIS,FRANCE; INST CURIE,SERV ANATOMOPATHOL,PARIS,FRANCE; CHILDRENS HOSP,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90027; IMPERIAL CANC RES FUND,HUMAN CYTOGENET LAB,LONDON WC2A 3PX,ENGLAND; CNRS,URA 1462,CYTOGENET CANCEROL LAB,F-06034 NICE,FRANCE; ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,VIENNA,AUSTRIA; INT AGCY RES CANC,F-69372 LYON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Children's Hospital Los Angeles; Cancer Research UK; Centre National de la Recherche Scientifique (CNRS); Saint Anna Children's Hospital; World Health Organization; International Agency for Research on Cancer (IARC)			zucman-rossi, Jessica/B-5098-2009; Sheer, Denise/C-6705-2011; Manara, Maria Cristina/K-3366-2018; j, zucman-rossi/AAV-3594-2021; Scotlandi, Katia/J-9009-2016; Ambros, Peter/AAA-1266-2021	zucman-rossi, Jessica/0000-0002-5687-0334; Sheer, Denise/0000-0001-9067-1796; Manara, Maria Cristina/0000-0001-5686-720X; j, zucman-rossi/0000-0002-5687-0334; Scotlandi, Katia/0000-0001-6114-9499; Ambros, Peter/0000-0002-5507-7211; delattre, olivier/0000-0002-8730-2276	Cancer Research UK [A3585] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; ASKIN FB, 1979, CANCER, V43, P2438, DOI 10.1002/1097-0142(197906)43:6<2438::AID-CNCR2820430640>3.0.CO;2-9; AURIAS A, 1983, NEW ENGL J MED, V309, P496; BARR FG, 1991, GENE CHROMOSOME CANC, V3, P153, DOI 10.1002/gcc.2870030212; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; DEHNER LP, 1993, AM J SURG PATHOL, V17, P1, DOI 10.1097/00000478-199301000-00001; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Ewing, 1921, P NEW YORK PATHOL S, V21, P17; FELLINGER EJ, 1991, AM J PATHOL, V139, P317; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; GORMAN PA, 1991, CANCER GENET CYTOGEN, V51, P13, DOI 10.1016/0165-4608(91)90003-D; HAMILTON G, 1988, CANCER RES, V48, P6127; Horowitz ME, 1993, PRINCIPLES PRACTICE, P795; KISSANE JM, 1983, HUM PATHOL, V14, P773, DOI 10.1016/S0046-8177(83)80300-1; KOVAR H, 1990, ONCOGENE, V5, P1067; LIPINSKI M, 1987, CANCER RES, V47, P183; NASCIMENTO AG, 1980, AM J SURG PATHOL, V4, P29, DOI 10.1097/00000478-198004010-00003; NOGUERA R, 1992, LAB INVEST, V66, P143; PAPPO AS, 1993, HUM PATHOL, V24, P880, DOI 10.1016/0046-8177(93)90138-7; Sambrook J, 1989, MOL CLONING LABORATO; TRICHE TJ, 1993, PRINCIPLES PRACTICE, P115; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	29	810	843	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					294	299		10.1056/NEJM199408043310503	http://dx.doi.org/10.1056/NEJM199408043310503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022439				2022-12-28	WOS:A1994NZ22700003
J	BIAGGIONI, I; ROBERTSON, D; KRANTZ, S; JONES, M; HAILE, V				BIAGGIONI, I; ROBERTSON, D; KRANTZ, S; JONES, M; HAILE, V			THE ANEMIA OF PRIMARY AUTONOMIC FAILURE AND ITS REVERSAL WITH RECOMBINANT ERYTHROPOIETIN	ANNALS OF INTERNAL MEDICINE			English	Article						ANEMIA; AUTONOMIC NERVOUS SYSTEM DISEASES; ERYTHROPOIETIN; ERYTHROPOIESIS; SYMPATHETIC NERVOUS SYSTEM	ORTHOSTATIC HYPOTENSION; RHEUMATOID-ARTHRITIS; NERVOUS-SYSTEM; THERAPY; DISEASE	Objective: To determine if chronic sympathetic deprivation is associated with anemia and a low erythropoietin response. Design: Survey of the prevalence and characteristics of anemia in patients with severe primary autonomic failure. Setting: A referral service for autonomic failure in a tertiary teaching hospital. Patients: 84 patients with primary autonomic failure who had symptomatic orthostatic hypotension. Intervention: Open-label trial with human recombinant erythropoietin. Results: Anemia was present in 32 of 84 patients (38%; 95% Cl, 27% to 50%). Plasma norepinephrine levels, measured in patients standing upright, were lower in the patient group with lower hemoglobin levels. Mean values in 22 patients with a hemoglobin level of less than 120 g/L were as follows: hemoglobin, 108 g/L (range, 87 to 118 g/L); hematocrit, 0.33; corrected reticulocyte counts, 0.008; mean corpuscular volume, 89 fL (89 mu cm(3)); serum iron, 16.5 mu mol/L (92 mu g/dL); total iron binding capacity, 43.3 mu mol/L (242 mu g/dL); ferritin, 184 mu g/L; serum vitamin B-12, 410 pmol/L (556 pg/mL); and serum folate, 22.7 nmol/L (10 ng/mL). No relation was found between serum erythropoietin and blood hemoglobin levels. In seven of nine patients with autonomic failure who had hemoglobin levels less than 120 g/L, serum erythropoietin levels decreased below the 95% confidence interval corresponding to patients with iron deficiency anemia. Therapy with recombinant erythropoietin improved mean hemoglobin levels (from 108 to 133 g/L) in all patients treated (n = 5) at relatively low doses (25 to 50 units/kg body weight, subcutaneously, three times a week). Conclusions: Our data support the hypothesis that the sympathetic nervous system stimulates erythropoiesis in humans because anemia is a frequent occurrence in patients with severe autonomic failure and is associated with a blunted erythropoietin response.	DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37212 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	BIAGGIONI, I (corresponding author), VANDERBILT UNIV, CLIN RES CTR, AA-3228 MCN, NASHVILLE, TN 37232 USA.				NCRR NIH HHS [RR00095] Funding Source: Medline; NHLBI NIH HHS [HL14192, HL 36984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014192] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAER AN, 1987, BRIT J HAEMATOL, V66, P559, DOI 10.1111/j.1365-2141.1987.tb01344.x; BALDWIN JG, 1989, GERIATRICS, V44, P33; BEYNON G, 1977, J PHYSIOL-LONDON, V266, P347, DOI 10.1113/jphysiol.1977.sp011771; BIAGGIONI I, 1993, J CLIN ENDOCR METAB, V76, P580, DOI 10.1210/jc.76.3.580; BIAGGIONI I, 1991, CLIN RES, V39, pA300; BIAGGIONI I, 1990, NEUROLOGY, V40, P370, DOI 10.1212/WNL.40.2.370; BLAGGIONI I, 1993, CLIN AUTON RESW, V3, P207; ECKARDT KU, 1992, AM J PHYSIOL, V263, pF925, DOI 10.1152/ajprenal.1992.263.5.F925; EGRIE JC, 1987, J IMMUNOL METHODS, V99, P235, DOI 10.1016/0022-1759(87)90133-5; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; FINK GD, 1977, J PHARMACOL EXP THER, V202, P199; FINK GD, 1975, J PHARMACOL EXP THER, V193, P176; GOLDSTEIN DS, 1989, ANN NEUROL, V26, P558, DOI 10.1002/ana.410260410; HENRY DH, 1992, ANN INTERN MED, V117, P739, DOI 10.7326/0003-4819-117-9-739; HOELDTKE RD, 1993, NEW ENGL J MED, V329, P611, DOI 10.1056/NEJM199308263290904; JANDELEIT K, 1990, NEPHRON, V56, P220, DOI 10.1159/000186138; LEACH CS, 1985, NASA TM58263 JOHNS S; MEANS RT, 1989, ARTHRITIS RHEUM-US, V32, P638, DOI 10.1002/anr.1780320519; MEANS RT, 1992, BLOOD, V80, P1639; MILLER CB, 1990, NEW ENGL J MED, V322, P1689, DOI 10.1056/NEJM199006143222401; OSTER W, 1990, J CLIN ONCOL, V8, P956, DOI 10.1200/JCO.1990.8.6.956; PETTIT JE, 1980, J NUCL MED, V21, P793; POWERS JS, 1991, J AM GERIATR SOC, V39, P30, DOI 10.1111/j.1532-5415.1991.tb05902.x; TAKAKU F, 1961, NATURE, V191, P500, DOI 10.1038/191500a0; WORKMAN RJ, 1979, J LAB CLIN MED, V93, P847; ZIVNY J, 1983, J PHARMACOL EXP THER, V226, P222	27	150	155	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					181	186		10.7326/0003-4819-121-3-199408010-00004	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017744				2022-12-28	WOS:A1994NY33800004
J	COLLINGE, J; WHITTINGTON, MA; SIDLE, KCL; SMITH, CJ; PALMER, MS; CLARKE, AR; JEFFERYS, JGR				COLLINGE, J; WHITTINGTON, MA; SIDLE, KCL; SMITH, CJ; PALMER, MS; CLARKE, AR; JEFFERYS, JGR			PRION PROTEIN IS NECESSARY FOR NORMAL SYNAPTIC FUNCTION	NATURE			English	Article							INTRAHIPPOCAMPAL TETANUS TOXIN; LONG-TERM POTENTIATION; RAT; HIPPOCAMPUS; INVITRO; DEPRESSION; INDUCTION; RECEPTOR; DISEASE	THE prion diseases are neurodegenerative conditions, transmissible by inoculation, and in some cases inherited as an autosomal dominant disorder. They include Creutzfeldt-Jakob disease in humans and scrapie and bovine spongiform encephalopathy in animals. The prion consists principally of a post-translationally modified form of a host-encoded glycoprotein (PrPc), designated PrPSc (ref. 1); the normal cellular function of PrPc is, however, unknown. Although PrP is highly conserved among mammals and widely expressed in early embryogenesis, mice homozygous for disrupted PrP genes appear developmentally and behaviourally normal(2). PrP is a protein anchored to the neuronal surface by glycosylphosphatidylinositol, suggesting a role in cell signalling or adhesion. Here we report that hippocampal slices from PrP null mice have weakened GABA(A) (gamma-aminobutyric acid type A) receptor-mediated fast inhibition and impaired long-term potentiation. This impaired synaptic inhibition may be involved in the epileptiform activity seen in Creutzfeldt-Jakob disease and we argue that loss of function of PrPc may contribute to the early synaptic loss(3) and neuronal degeneration seen in these diseases.	ST MARYS HOSP,SCH MED,DEPT PHYSIOL & BIOPHYS,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,DEPT NEUROL,LONDON W2 1NY,ENGLAND; UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,ENGLAND	Imperial College London; Imperial College London; University of Bristol	COLLINGE, J (corresponding author), ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,PRION DIS GRP,LONDON W2 1PG,ENGLAND.		Jefferys, John G R/AAF-1164-2021; Smith, Corinne J/A-3170-2009; Jefferys, John/E-6132-2012	Jefferys, John G R/0000-0003-0106-4412; Smith, Corinne J/0000-0003-3364-7946; Jefferys, John/0000-0003-0106-4412; Whittington, Miles Adrian/0000-0002-0247-1362	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; ALLAN RD, 1980, BRIT J PHARMACOL, V70, P609, DOI 10.1111/j.1476-5381.1980.tb09779.x; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRACE HM, 1985, J PHYSIOL-LONDON, V368, P343, DOI 10.1113/jphysiol.1985.sp015861; Brown D A, 1981, Adv Biochem Psychopharmacol, V29, P321; BUELERH, 1992, NATURE, V356, P577; CLINTON J, 1993, NEUROREPORT, V4, P65, DOI 10.1097/00001756-199301000-00017; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; EMPSON RM, 1993, J PHYSIOL-LONDON, V465, P595, DOI 10.1113/jphysiol.1993.sp019695; GROVERLM, 1993, J NEUROPHYSIOL, V69, P1541; HERRON CE, 1985, NEUROSCI LETT, V61, P255, DOI 10.1016/0304-3940(85)90473-2; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; JEFFERYS JGR, 1994, NEUROBIOL DIS, V1, P3; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; SMITH TL, 1985, J PHARMACOL EXP THER, V232, P702; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0	23	664	676	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					295	297		10.1038/370295a0	http://dx.doi.org/10.1038/370295a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035877				2022-12-28	WOS:A1994NZ22900064
J	KHOURY, SJ; WEINER, HL				KHOURY, SJ; WEINER, HL			KAPPA-LIGHT-CHAINS IN SPINAL-FLUID FOR DIAGNOSING MULTIPLE-SCLEROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CEREBROSPINAL-FLUID; NEUROLOGICAL DISEASES				KHOURY, SJ (corresponding author), BRIGHAM & WOMENS HOSP,BOSTON,MA, USA.							BOLLENGIER F, 1978, J CLIN CHEM CLIN BIO, V16, P165; FAGNART OC, 1988, J NEUROIMMUNOL, V19, P119, DOI 10.1016/0165-5728(88)90041-0; GALLO P, 1989, J NEUROL SCI, V94, P241, DOI 10.1016/0022-510X(89)90234-7; LAURENZI MA, 1980, ANN NEUROL, V8, P241, DOI 10.1002/ana.410080304; LINK H, 1987, ITAL J NEUROL SCI S, V6, P57; RUDICK RA, 1986, ARCH NEUROL-CHICAGO, V43, P456, DOI 10.1001/archneur.1986.00520050036018; SINDIC CJM, 1991, J NEUROIMMUNOL, V33, P63, DOI 10.1016/0165-5728(91)90035-6; STANESCU GL, 1991, J CLIN LAB ANAL, V5, P206, DOI 10.1002/jcla.1860050310	8	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					242	243		10.1001/jama.272.3.242	http://dx.doi.org/10.1001/jama.272.3.242			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022046				2022-12-28	WOS:A1994NW18500032
J	LABAND, DN; PIETTE, MJ				LABAND, DN; PIETTE, MJ			A CITATION ANALYSIS OF THE IMPACT OF BLINDED PEER-REVIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC			Objective.-To determine whether articles published in journals using blinded peer review receive significantly more or fewer citations than those published in journals using nonblinded peer review. Design.-Drawing from a sample of 1051 full articles published in 28 economics journals during 1984, we used nonlinear regression and ordered probit techniques to estimate the impact of blinded peer review on citations of these articles in 1985 through 1989. Outcomes.-Citations of articles. Results.-Articles published in journals using blinded peer review were cited significantly more than articles published in journals using nonblinded peer review, controlling for a variety of author, article, and journal attributes. Conclusions.-Nonblinded peer review apparently suffers from type I error to a greater extent than blinded peer review. That is, journals using nonblinded peer review publish a larger fraction of papers that should not have been published than do journals using blinded peer review. When reviewers know the identity of the author(s) of an article, they are able to (and evidently do) substitute particularistic criteria for universalistic criteria in their evaluative process.	ECON RES SERV,TALLAHASSEE,FL; SALISBURY STATE UNIV,DEPT ECON & FINANCE,SALISBURY,MD	University System of Maryland; Salisbury University								HAMILTON DP, 1991, SCIENCE, V251, P25, DOI 10.1126/science.1986409; HAMILTON DP, 1990, SCIENCE, V250, P1331, DOI 10.1126/science.2255902; LABAND DN, 1986, ECON INQ, V24, P173, DOI 10.1111/j.1465-7295.1986.tb01804.x; LIEBOWITZ SJ, 1984, J ECON LIT, V22, P77; 1985, SOCIAL SCI CITATION	5	62	63	1	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					147	149						3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NV424	8015128				2022-12-28	WOS:A1994NV42400018
J	BOREN, T; FALK, P; ROTH, KA; LARSON, G; NORMARK, S				BOREN, T; FALK, P; ROTH, KA; LARSON, G; NORMARK, S			ATTACHMENT OF HELICOBACTER-PYLORI TO HUMAN GASTRIC EPITHELIUM MEDIATED BY BLOOD-GROUP ANTIGENS	SCIENCE			English	Article							GLYCOLIPID RECEPTORS; ULCER DISEASE; BACTERIA; GLYCOSPHINGOLIPIDS	Helicobacter pylori is associated with development of gastritis, gastric ulcers, and adenocarcinomas in humans. The Lewis(b) (Le(b)) blood group antigen mediates H. pylori attachment to human gastric mucosa. Soluble glycoproteins presenting the Le(b) antigen or antibodies to the Le(b) antigen inhibited bacterial binding. Gastric tissue lacking Le(b) expression did not bind H. pylori. Bacteria did not bind to Le(b) antigen substituted with a terminal GalNAcalpha1-3 residue (blood group A determinant), suggesting that the availability of H. pylori receptors might be reduced in individuals of blood group A and B phenotypes, as compared with blood group O individuals.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT CLIN CHEM, S-41345 GOTHENBURG, SWEDEN; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Sahlgrenska University Hospital; University of Gothenburg; Washington University (WUSTL); Washington University (WUSTL)	BOREN, T (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA.		Larson, Göran/AAF-3404-2019	Roth, Kevin/0000-0002-0643-995X	FIC NIH HHS [TW04669-02] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004669] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P5137, DOI 10.1093/nar/20.19.5137; BAENZIGER J, 1974, J BIOL CHEM, V249, P7260; BORIELLO S P, 1981, Journal of Antimicrobial Chemotherapy, V7, P53; CLARKE CA, 1955, BRIT MED J, V2, P643, DOI 10.1136/bmj.2.4940.643; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; DESCAMPS J, 1968, CR ACAD SCI D NAT, V266, P1775; EVANS DG, 1993, J BACTERIOL, V175, P674, DOI 10.1128/JB.175.3.674-683.1993; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FALK P, IN PRESS METHODS ENZ; FAUCHERE JL, 1990, MICROB PATHOGENESIS, V9, P427, DOI 10.1016/0882-4010(90)90061-T; FINNE J, 1989, J BIOL CHEM, V264, P5720; FORMAN D, 1993, LANCET, V341, P1359; GRAHAM DY, 1988, J INFECT DIS, V157, P777, DOI 10.1093/infdis/157.4.777; GRAHAM DY, 1991, J GASTROEN HEPATOL, V6, P105, DOI 10.1111/j.1440-1746.1991.tb01448.x; HANSSON GC, 1985, ANAL BIOCHEM, V146, P158, DOI 10.1016/0003-2697(85)90410-5; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; LARSON G, 1988, J BIOL CHEM, V263, P10790; MARCUS DM, 1989, HUMAN IMMUNOGENETICS, P685; MENTIS A, 1991, EPIDEMIOL INFECT, V106, P221, DOI 10.1017/S0950268800048366; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237, DOI 10.1093/infdis/161.6.1237; SAITOH T, 1991, FEBS LETT, V282, P385, DOI 10.1016/0014-5793(91)80519-9; SAKAMOTO J, 1989, CANCER RES, V49, P745; SHARON N, 1986, LECTINS, P494; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WYATT JI, 1988, J PATHOL, V154, P113, DOI 10.1002/path.1711540203	27	937	980	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1892	1895		10.1126/science.8018146	http://dx.doi.org/10.1126/science.8018146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8018146				2022-12-28	WOS:A1993MM51100042
J	BROOKOFF, D; COOK, CS; WILLIAMS, C; MANN, CS				BROOKOFF, D; COOK, CS; WILLIAMS, C; MANN, CS			TESTING RECKLESS DRIVERS FOR COCAINE AND MARIJUANA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRUG-USE; ALCOHOL; ABSTINENCE; ABUSERS; TRAUMA	Background. Driving under the influence of intoxicating drugs other than alcohol may be an important cause of traffic injuries. We used a rapid urine test to identify reckless drivers who were under the influence of cocaine or marijuana. Methods. We conducted a consecutive-sample study in Memphis, Tennessee, in the summer of 1993. Subjects arrested for reckless driving who were not apparently impaired by alcohol (did not have an odor of alcohol, tested negative on breath analysis, or both) were tested for cocaine and marijuana at the scene of arrest. The results of the drug tests were compared with clinical evaluations of intoxication made at the scene by a police officer. Results. A total of 175 subjects were stopped for reckless driving, and 150 (86 percent) submitted urine samples for drug testing at the scene of arrest. Eighty-eight of the 150 (59 percent) tested positive: 20 (13 percent) for cocaine, 50 (33 percent) for marijuana, and 18 (12 percent) for both drugs. Ninety-four of the 150 tested drivers were clinically considered to be intoxicated, and 80 of them (85 percent) tested positive for cocaine or marijuana. The intoxicated drivers had a broad range of affects and appearances. Nearly half the drivers intoxicated with cocaine performed normally on standard sobriety tests. Conclusions. Over half of the reckless drivers who were not intoxicated with alcohol were found to be intoxicated with other drugs. Toxicologic testing at the scene is a practical means of identifying drivers under the influence of drugs and is a useful adjunct to standard behavioral sobriety testing.	UNIV TENNESSEE,METHODIST HOSP,DEPT EMERGENCY MED,MEMPHIS,TN; MEMPHIS POLICE DEPT,MEMPHIS,TN; MEMPHIS STATE UNIV,DEPT ANTHROPOL,MEMPHIS,TN	University of Tennessee System; University of Tennessee Health Science Center; University of Memphis								BROOKOFF D, 1993, AM J PUBLIC HEALTH, V83, P369, DOI 10.2105/AJPH.83.3.369; BURKE WM, 1990, J CLIN PSYCHIAT, V51, P145; BYCK R, 1977, COCAINE OTHER STIMUL, P629; CHAVKIN W, 1991, JAMA-J AM MED ASSOC, V266, P1556, DOI 10.1001/jama.266.11.1556; DACKIS CA, 1982, AM J PSYCHIAT, V139, P1196; EVANS DG, 1990, DRUG TESTING LAW TEC; FELL JC, 1993, MMWR-MORBID MORTAL W, V42, P605; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; GRANT BF, 1990, DRUG ALCOHOL DEPEN, V25, P97, DOI 10.1016/0376-8716(90)90147-7; KIRBY JM, 1992, SOUTHERN MED J, V85, P800, DOI 10.1097/00007611-199208000-00003; LOWENSTEIN DH, 1987, AM J MED, V83, P841, DOI 10.1016/0002-9343(87)90640-1; LUNDBERG GD, 1986, JAMA-J AM MED ASSOC, V255, P529, DOI 10.1001/jama.255.4.529; MARSDEN ME, 1988, PREV MED, V17, P366, DOI 10.1016/0091-7435(88)90011-4; MARZUK PM, 1990, JAMA-J AM MED ASSOC, V263, P250, DOI 10.1001/jama.263.2.250; MAULL KI, 1984, JAMA-J AM MED ASSOC, V252, P1880, DOI 10.1001/jama.252.14.1880; MOSKOWITZ H, 1976, ACCIDENT ANAL PREV, V8, P45, DOI 10.1016/0001-4575(76)90033-6; MOSKOWITZ H, 1993, 1993 P INT C ALC DRU, P612; PANNER MJ, 1986, HASTINGS CENT REP, V16, P7, DOI 10.2307/3562082; RAFAELSEN OJ, 1973, SCIENCE, V179, P920, DOI 10.1126/science.179.4076.920; REMALEY AT, 1988, CLIN CHEM, V34, P1933; RESNICK RB, 1977, SCIENCE, V195, P696, DOI 10.1126/science.841307; SAYLOR KE, 1992, JAMA-J AM MED ASSOC, V267, P652, DOI 10.1001/jama.267.5.652; SKOLNICK A, 1990, JAMA-J AM MED ASSOC, V263, P3122; WEISS RD, 1988, AM J MED, V85, P879; WIDMARK EMP, 1981, PRINCIPLES APPLICATI; 1985, DHHS ADM851386 DEP H; 1985, JAMA-J AM MED ASSOC, V254, P2618; 1991, DRUNK DRIVING FACTS; 1986, FIELD EVALUATION LOS; 1988, FED REGISTER, V53, P970; 1992, DRUGS CRIME JUSTICE; 1988, USE CONTROLLED SUBST; 1992, DRUG EVALUATION CLAS	33	83	84	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					518	522		10.1056/NEJM199408253310807	http://dx.doi.org/10.1056/NEJM199408253310807			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PD072	8041419				2022-12-28	WOS:A1994PD07200007
J	JOHNSON, AG; NGUYEN, TV; DAY, RO				JOHNSON, AG; NGUYEN, TV; DAY, RO			DO NONSTEROIDAL ANTIINFLAMMATORY DRUGS AFFECT BLOOD-PRESSURE - A METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							TREATED HYPERTENSIVE PATIENTS; MODERATE ESSENTIAL-HYPERTENSION; CORONARY HEART-DISEASE; PROSTAGLANDIN INHIBITION; RENAL-FUNCTION; DOUBLE-BLIND; INDOMETHACIN; SULINDAC; HYDROCHLOROTHIAZIDE; PROPRANOLOL	Purpose: A meta-analysis of randomized trials studying the effect of nonsteroidal anti-inflammatory drugs (NSAIDs) on blood pressure. Data Sources and Study Selection: Eight databases were searched, yielding 38 randomized, placebo-controlled trials and 12 randomized but not placebo-controlled trials (comparing two or more NSAIDs). Data Extraction: Pooled mean treatment effects were computed in each trial for blood pressure, weight, creatinine clearance, plasma renin activity, and daily urinary excretion of sodium and prostaglandins. Meta-analyses of these variables were done for all randomized, controlled trials; for all randomized, uncontrolled trials; and for several subgroups. Data Synthesis: When pooled, NSAIDs elevated supine mean blood pressure by 5.0 mm Hg (95% CI, 1.2 to 8.7 mm Mg) but had no effect on variables other than blood pressure. Nonsteroidal anti-inflammatory drugs antagonized the antihypertensive effect of P-blockers (blood pressure elevation, 6.2 mm Mg; CI, 1.1 to 11.4 mm Hg) more than did vasodilators and diuretics. Among NSAIDs, piroxicam produced the most marked elevation in blood pressure (6.2 mm Mg; CI, 0.8 to 11.5 mm Hg), whereas sulindac and aspirin had the least hypertensive effect. Conclusions: Nonsteroidal anti-inflammatory drugs may elevate blood pressure and antagonize the blood pressure-lowering effect of antihypertensive medication to an extent that may potentially increase hypertension-related morbidity. Although certain NSAIDs and antihypertensive agents could be more likely to produce these effects, the underlying mechanisms require further study.	ST VINCENTS HOSP, SYDNEY, NSW, AUSTRALIA; UNIV NEW S WALES, SYDNEY, NSW, AUSTRALIA	St Vincents Hospital Sydney; University of New South Wales Sydney			Nguyen, Tuan V./AAD-9503-2020; Day, Richard/D-8699-2011	Nguyen, Tuan V./0000-0002-3246-6281; Day, Richard/0000-0002-6045-6937				ABATE MA, 1990, DICP ANN PHARMAC, V24, P810, DOI 10.1177/106002809002400901; ABBOTT EC, 1978, CLIN RES, V26, pA834; ABDELHAQ B, 1987, INT J CLIN PHARM TH, V25, P598; ALVAREZ CR, 1986, J CLIN PHARMACOL, V26, P544; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; Baez M A, 1987, J Hypertens Suppl, V5, pS563; BAUM C, 1985, ARTHRITIS RHEUM, V28, P686, DOI 10.1002/art.1780280613; BECKMANN ML, 1988, HYPERTENSION, V12, P582, DOI 10.1161/01.HYP.12.6.582; BULPITT CJ, 1988, LANCET, V2, P93; CAPPUCCIO FP, 1991, J HYPERTENS, V9, P465, DOI 10.1097/00004872-199105000-00011; CHALMERS JP, 1984, CLIN EXP HYPERTENS A, V6, P1077, DOI 10.3109/10641968409039582; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CINQUEGRANI MP, 1988, CLIN EXP HYPERTENS A, V10, P411, DOI 10.3109/10641968809033901; CINQUEGRANI MP, 1986, CLIN PHARMACOL THER, V39, P564, DOI 10.1038/clpt.1986.97; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COWLEY AJ, 1985, CARDIOVASC RES, V19, P177, DOI 10.1093/cvr/19.3.177; CURB JD, 1985, AM J EPIDEMIOL, V121, P371, DOI 10.1093/oxfordjournals.aje.a114008; DAVIDSON RA, 1989, J AM GERIATR SOC, V37, P861, DOI 10.1111/j.1532-5415.1989.tb02267.x; DAVIES JG, 1988, J INT MED RES, V16, P173, DOI 10.1177/030006058801600302; DAVIS A, 1986, AUST NZ J MED, V16, P537, DOI 10.1111/j.1445-5994.1986.tb02031.x; EBEL D L, 1985, Advances in Therapy, V2, P131; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GERBER JG, 1990, CLIN PHARMACOL THER, V48, P424, DOI 10.1038/clpt.1990.171; GRIFFIN JP, 1986, BRIT J CLIN PHARMACO, V22, pS83, DOI 10.1111/j.1365-2125.1986.tb02988.x; GROSSBERG GT, 1990, J AM GERIATR SOC, V38, P607, DOI 10.1111/j.1532-5415.1990.tb02418.x; GULLNER HG, 1980, AM J MED, V69, P718, DOI 10.1016/0002-9343(80)90437-4; HALABI A, 1989, CARDIOVASC DRUG THER, V3, P441, DOI 10.1007/BF01858116; HARDY BG, 1988, BRIT J CLIN PHARMACO, V26, P557, DOI 10.1111/j.1365-2125.1988.tb05295.x; HOLLIFIELD JW, 1976, SOUTHERN MED J, V69, P1034, DOI 10.1097/00007611-197608000-00022; HURWITZ GA, 1979, CLIN RES, V27, pA234; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; JACKSON SHD, 1983, EUR J CLIN PHARMACOL, V25, P303, DOI 10.1007/BF01037938; KANNEL WB, 1970, J AMER MED ASSOC, V214, P301, DOI 10.1001/jama.214.2.301; KIRCH W, 1989, BRIT J CLIN PHARMACO, V27, pS297, DOI 10.1111/j.1365-2125.1989.tb03495.x; KOOPMANS PP, 1985, CLIN PHARMACOL THER, V37, P625, DOI 10.1038/clpt.1985.100; KOOPMANS PP, 1987, EUR J CLIN PHARMACOL, V31, P553, DOI 10.1007/BF00606629; KOOPMANS PP, 1986, BRIT J CLIN PHARMACO, V21, P417, DOI 10.1111/j.1365-2125.1986.tb05216.x; KOOPMANS PP, 1984, BRIT MED J, V289, P1492, DOI 10.1136/bmj.289.6457.1492; KOOPMANS PP, 1985, PHARM WEEKBLAD, V7, P87; LEWIS RV, 1989, J HUM HYPERTENS, V3, P233; LEWIS RV, 1986, BRIT MED J, V292, P934, DOI 10.1136/bmj.292.6525.934-a; LONDON GM, 1982, NEPHRON, V32, P118, DOI 10.1159/000182830; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAUNUKSELA EL, 1987, ANN CLIN RES, V19, P359; MCKENNEY JM, 1987, DRUG INTEL CLIN PHAR, V21, P517, DOI 10.1177/106002808702100608; MCMAHON FG, 1989, CURR THER RES CLIN E, V45, P143; MILLS EH, 1982, AUST NZ J MED, V12, P478, DOI 10.1111/j.1445-5994.1982.tb03826.x; MOOKERJEE BK, 1975, KIDNEY INT, V8, P441; MOTOLESE M, 1981, EUR J CLIN INVEST, V11, P22; NOWAK J, 1978, ACTA PHYSIOL SCAND, V102, P484, DOI 10.1111/j.1748-1716.1978.tb06097.x; OBrien B., 1984, PATTERNS EUROPEAN DI; OPARIL S, 1987, AM J MED SCI, V294, P395, DOI 10.1097/00000441-198712000-00001; PEDRINELLI R, 1982, EUR J CLIN INVEST, V12, P107, DOI 10.1111/j.1365-2362.1982.tb00946.x; PUDDEY IB, 1985, CLIN SCI, V69, P327, DOI 10.1042/cs0690327; PUGLIESE F, 1984, European Journal of Clinical Investigation, V14, P54; QUILLEY J, 1987, J HYPERTENS, V5, P121, DOI 10.1097/00004872-198702000-00017; RADACK KL, 1987, ANN INTERN MED, V107, P628, DOI 10.7326/0003-4819-107-5-628; REIMANN IW, 1981, CLIN SCI, V61, pS319, DOI 10.1042/cs061319s; REUSE C, 1988, J CLIN PHARMACOL, V28, P312, DOI 10.1002/j.1552-4604.1988.tb03149.x; ROBERTS DG, 1985, CLIN PHARMACOL THER, V38, P258, DOI 10.1038/clpt.1985.168; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; ROSENTHAL R, 1982, PSYCHOL BULL, V92, P500, DOI 10.1037/0033-2909.92.2.500; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SALVETTI A, 1982, CLIN SCI, V63, pS261, DOI 10.1042/cs063261s; SALVETTI A, 1987, CLIN EXP HYPERTENS A, V9, P559, DOI 10.3109/10641968709164224; SALVETTI A, 1984, BRIT J CLIN PHARMACO, V17, pS108, DOI 10.1111/j.1365-2125.1984.tb02442.x; SALVETTI A, 1982, EUR J CLIN PHARMACOL, V22, P197, DOI 10.1007/BF00545214; SALVETTI A, 1983, PROSTAGLANDINS KIDNE, P287; SHAW W, 1987, CLIN PHARMACOL THER, V41, P219; SHURTLEFF D, 1974, US DHEW NIH74599 PUB; SMITH MD, 1985, CURR MED RES OPIN, V9, P388, DOI 10.1185/03007998509109609; STAESSEN J, 1984, J APPL PHYSIOL, V56, P39, DOI 10.1152/jappl.1984.56.1.39; Staessen J, 1983, J Hypertens, V1, P123, DOI 10.1097/00004872-198308000-00003; STEINESS E, 1982, BRIT MED J, V285, P1702, DOI 10.1136/bmj.285.6356.1702-a; SUGIMOTO K, 1989, J CLIN PHARMACOL, V29, P307, DOI 10.1002/j.1552-4604.1989.tb03332.x; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; TRIMARCO B, 1985, AM J CARDIOL, V55, P116, DOI 10.1016/0002-9149(85)90311-X; WACHTER KW, 1988, SCIENCE, V241, P1407, DOI 10.1126/science.3420397; WALT R, 1986, LANCET, V1, P489; WALTER E, 1981, KLIN WOCHENSCHR, V59, P297, DOI 10.1007/BF01478209; WATKINS J, 1980, BRIT MED J, V281, P702, DOI 10.1136/bmj.281.6242.702; WEBSTER J, 1984, BRIT J CLIN PHARMACO, V18, P861, DOI 10.1111/j.1365-2125.1984.tb02556.x; WING LM, 1985, NONSTEROIDAL ANTIINF, P91; WING LMH, 1981, CLIN EXP PHARMACOL P, V8, P537, DOI 10.1111/j.1440-1681.1981.tb00763.x; WONG DG, 1986, LANCET, V1, P997; WRIGHT JT, 1989, CLIN PHARMACOL THER, V46, P440, DOI 10.1038/clpt.1989.162; 1989, 1988 89 ANN REP DE S, P48; 1982, DRUG UTILIZATION US, P17; 1986, BRIT MED J, V292, P614	90	509	536	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					289	300		10.7326/0003-4819-121-4-199408150-00011	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00011			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037411				2022-12-28	WOS:A1994PB10200011
J	LOPRINZI, CL; MICHALAK, JC; QUELLA, SK; OFALLON, JR; HATFIELD, AK; NELIMARK, RA; DOSE, AM; FISCHER, T; JOHNSON, C; KLATT, NE; BATE, WW; ROSPOND, RM; OESTERLING, JE				LOPRINZI, CL; MICHALAK, JC; QUELLA, SK; OFALLON, JR; HATFIELD, AK; NELIMARK, RA; DOSE, AM; FISCHER, T; JOHNSON, C; KLATT, NE; BATE, WW; ROSPOND, RM; OESTERLING, JE			MEGESTROL-ACETATE FOR THE PREVENTION OF HOT FLASHES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROSTATIC-CANCER; BREAST-CANCER; MEDROXYPROGESTERONE ACETATE; ORAL MEDROXYPROGESTERONE; FLUSHES; THERAPY; SYMPTOMS; HORMONE; TRIAL; ORCHIDECTOMY	Background. Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostrate cancer. Pilot trials have suggested that the progestational agent megestrol acetate can ameliorate hot flashes in both groups of patients. Methods. The patients included 97 women with a history of breast cancer and 66 men with prostate cancer who had undergone androgen-deprivation therapy. All patients had experienced bothersome hot flashes (median number per day at base line, 6.1 for the women and 8.4 for the men). After a one-week pretreatment observation period, the patients received megestrol acetate (20 mg twice dally) for four weeks, followed by placebo for four weeks, or vice versa in a double-blind manner as determined by pretreatment randomization. The patients documented the frequency and severity of hot flashes in daily symptom diaries. Results. After four weeks, hot flashes were reduced by 21 percent in the group receiving placebo first and by 85 percent in the group receiving megestrol acetate first (P<0.001). An intention-to-treat analysis of data for all eligible treated patients showed that 74 percent of the megestrol acetate group, as compared with 20 percent of the placebo group, had a decrease of 50 percent or more in the frequency of hot flashes during the first four weeks (P<0.001). The degree of efficacy was similar in men and women. The only side effect was withdrawal menstrual bleeding in women, generally occurring one to two weeks after the megestrol acetate had been discontinued.	MAYO CLIN & MAYO FDN,DEPT UROL,ROCHESTER,MN 55905; SIOUXLAND HEMATOL ONCOL ASSOCIATES,SIOUX CITY,IA; CARLE CANC CTR,COMMUNITY CLIN ONCOL PROGRAM,URBANA,IL; QUAIN & RAMSTAD CLIN,BISMARCK,ND; ST LUKES HOSP,COMMUNITY CLIN ONCOL PROGRAM,FARGO,ND; GRAND FORKS CLIN LTD,GRAND FORKS,ND; IOWA ONCOL RES ASSOC,COMMUNITY CLIN ONCOL PROGRAM,DES MOINES,IA; CREIGHTON UNIV,NEBRASKA ONCOL GRP,OMAHA,NE 68178; UNIV NEBRASKA,MED CTR,OMAHA,NE	Mayo Clinic; Creighton University; University of Nebraska System; University of Nebraska Medical Center	LOPRINZI, CL (corresponding author), MAYO CLIN & MAYO FDN,DEPT ONCOL,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NCI NIH HHS [CA-15083, CA-37404, CA-25224] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015083, U10CA025224, U10CA037404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHT BH, 1981, AM J OBSTET GYNECOL, V139, P631, DOI 10.1016/0002-9378(81)90475-0; ATALA A, 1992, UROLOGY, V39, P108, DOI 10.1016/0090-4295(92)90264-W; BENGHIAT A, 1986, EUR J SURG ONCOL, V12, P43; BERGMANS MGM, 1987, MATURITAS, V9, P227, DOI 10.1016/0378-5122(87)90005-3; BONOMI P, 1985, SEMIN ONCOL, V12, P36; BULLOCK JL, 1975, OBSTET GYNECOL, V46, P165; BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C; CASPER RF, 1985, CLIN ENDOCRINOL, V22, P293, DOI 10.1111/j.1365-2265.1985.tb03243.x; CHARIG CR, 1989, UROLOGY, V33, P175, DOI 10.1016/0090-4295(89)90385-3; CREAGAN ET, 1989, AM J CLIN ONCOL-CANC, V12, P152, DOI 10.1097/00000421-198904000-00013; EATON AC, 1983, LANCET, V2, P1336; ERLIK Y, 1981, MATURITAS, V3, P167, DOI 10.1016/0378-5122(81)90008-6; FELDMAN JM, 1976, ARCH INTERN MED, V136, P606, DOI 10.1001/archinte.136.5.606; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FRODIN T, 1985, PROSTATE, V7, P203, DOI 10.1002/pros.2990070210; GAMBRELL RD, 1982, FERTIL STERIL, V37, P457; GINSBURG J, 1983, BRIT MED J, V287, P262, DOI 10.1136/bmj.287.6387.262; GOLDBERG RM, 1994, J CLIN ONCOL, V12, P155, DOI 10.1200/JCO.1994.12.1.155; HAAS S, 1988, OBSTET GYNECOL, V71, P671; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; LOPRINZI CL, 1992, ONCOLOGY, V49, P46, DOI 10.1159/000227128; LOPRINZI CL, 1993, J CLIN ONCOL, V11, P762, DOI 10.1200/JCO.1993.11.4.762; MARCHANT DJ, 1993, CANCER, V71, P2169, DOI 10.1002/1097-0142(19930315)71:6+<2169::AID-CNCR2820711608>3.0.CO;2-B; MCCALLUM KA, 1989, BRIT J UROL, V64, P507, DOI 10.1111/j.1464-410X.1989.tb05288.x; MISHELL DR, 1987, MENOPAUSE PHYSL PHAR, P199; MORRISON JC, 1980, AM J OBSTET GYNECOL, V138, P99, DOI 10.1016/0002-9378(80)90017-4; NESHEIM BI, 1981, EUR J CLIN PHARMACOL, V20, P413, DOI 10.1007/BF00542092; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; PRIOR JC, 1990, ENDOCR REV, V11, P386, DOI 10.1210/edrv-11-2-386; SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365, DOI 10.1093/oxfordjournals.aje.a121082; SCHIFF I, 1980, JAMA-J AM MED ASSOC, V244, P1443, DOI 10.1001/jama.244.13.1443; Siegel S., 1988, NONPARAMETRIC STAT B; STEINFELD AD, 1980, UROLOGY, V16, P620, DOI 10.1016/0090-4295(80)90575-0; TREMOLLIERES FA, 1992, ACTA ENDOCRINOL-COP, V126, P329, DOI 10.1530/acta.0.1260329; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; WENTZ WB, 1985, SEMIN ONCOL, V12, P23; YOUNG RL, 1990, DRUGS, V40, P220, DOI 10.2165/00003495-199040020-00004; 1967, J COLL GEN PRACTIT, V13, P267	38	345	355	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					347	352		10.1056/NEJM199408113310602	http://dx.doi.org/10.1056/NEJM199408113310602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA374	8028614				2022-12-28	WOS:A1994PA37400002
J	NIGHTINGALE, SL				NIGHTINGALE, SL			COMBINATION TUBERCULOSIS DRUG APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					344	344						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028152				2022-12-28	WOS:A1994NY90300004
J	LIN, S; GAIANO, N; CULP, P; BURNS, JC; FRIEDMANN, T; YEE, JK; HOPKINS, N				LIN, S; GAIANO, N; CULP, P; BURNS, JC; FRIEDMANN, T; YEE, JK; HOPKINS, N			INTEGRATION AND GERM-LINE TRANSMISSION OF A PSEUDOTYPED RETROVIRAL VECTOR IN ZEBRAFISH	SCIENCE			English	Article							LEUKEMIA-VIRUS; CELLS; GENE; MICE	The zebrafish is rapidly becoming a popular model system for the study of vertebrate development because it is ideal for both embryological studies and genetic analysis. To determine if a retroviral vector pseudotyped with the envelope glycoprotein of the vesicular stomatitis virus could infect zebrafish embryos, and in particular, the cells destined to become the germ line, a pseudotyped virus was injected into blastula-stage zebrafish embryos. Fifty-one embryos were allowed to develop and eight transmitted proviral DNA to their progeny. Founders were mosaic, but as expected, transgenic F-1's transmitted proviral DNA in a Mendelian fashion to the F-2 progeny. Transgenic F-1 fish inherited a single integrated provirus, and a single founder could transmit more than one viral integration to its progeny. These results demonstrate that this pantropic pseudotyped vector, originally developed for human gene therapy, will make the use of retroviral vectors in zebrafish possible.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV CALIF SAN DIEGO,SCH MED,DEPT PEDIAT,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,LA JOLLA,CA 92093	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego; University of California System; University of California San Diego			Burns, Jane C/J-6167-2015		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020034] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001855] Funding Source: NIH RePORTER; NCI NIH HHS [CA14051] Funding Source: Medline; NHLBI NIH HHS [HL-01855] Funding Source: Medline; NICHD NIH HHS [HD-20034] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CEPKO CL, 1993, METHOD ENZYMOL, V225, P933; CHEN J, 1994, METH MOL G, V4, P123; CULP P, UNPUB; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GAIANO N, UNPUB; GRIDLEY T, 1987, TRENDS GENET, V3, P162, DOI 10.1016/0168-9525(87)90218-6; GRUNWALD DJ, 1992, GENET RES, V59, P103, DOI 10.1017/S0016672300030317; HUSZAR D, 1991, DEVELOPMENT, V113, P653; JAENISCH R, 1976, P NATL ACAD SCI USA, V73, P1260, DOI 10.1073/pnas.73.4.1260; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; NJOLSTAD PR, 1988, FEBS LETT, V230, P25, DOI 10.1016/0014-5793(88)80634-3; RIGGLEMAN R, UNPUB; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1; VARMUS HE, 1982, SCIENCE, V216, P812, DOI 10.1126/science.6177038; VONMELCHNER H, 1992, GENE DEV, V6, P919, DOI 10.1101/gad.6.6.919; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	21	221	239	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					666	669		10.1126/science.8036514	http://dx.doi.org/10.1126/science.8036514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036514				2022-12-28	WOS:A1994NZ53800034
J	ROSSKY, PJ; SIMON, JD				ROSSKY, PJ; SIMON, JD			DYNAMICS OF CHEMICAL PROCESSES IN POLAR-SOLVENTS	NATURE			English	Review							ELECTRON-TRANSFER REACTIONS; INTRAMOLECULAR PROTON-TRANSFER; CHARGE-TRANSFER REACTIONS; ACTIVATED RATE-PROCESSES; FREE-ENERGY SURFACES; SOLVATION DYNAMICS; MOLECULAR-DYNAMICS; COMPUTER-SIMULATION; QUANTUM SIMULATION; HYDRATED ELECTRON	Understanding solution-phase chemistry requires a microscopic description of the electronic structure of the reacting molecules, and of the complex influence of the solvent medium on the reaction energetics and dynamics. Processes involving reactant charge-transfer are of particular importance in chemistry and biochemistry, and are strongly influenced by polar media. Recent advances in experimental ultrafast laser spectroscopy and in computer simulation are working together to provide insight into the underlying molecular principles governing this class of processes in solution.	UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego	ROSSKY, PJ (corresponding author), UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712, USA.							ALFANO JC, 1993, J CHEM PHYS, V98, P5996, DOI 10.1063/1.464839; ANDO K, 1991, J CHEM PHYS, V95, P5966, DOI 10.1063/1.461618; BADER JS, 1989, CHEM PHYS LETT, V157, P501, DOI 10.1016/S0009-2614(89)87399-3; BADER JS, 1990, J CHEM PHYS, V93, P230, DOI 10.1063/1.459596; BAGCHI B, 1989, ANNU REV PHYS CHEM, V40, P115, DOI 10.1146/annurev.pc.40.100189.000555; BARBARA PF, 1992, SCIENCE, V256, P975, DOI 10.1126/science.256.5059.975; BARBARA PF, 1989, J PHYS CHEM-US, V93, P29, DOI 10.1021/j100338a011; BERGSMA JP, 1987, J CHEM PHYS, V86, P1356, DOI 10.1063/1.452224; BERNE BJ, 1988, J PHYS CHEM-US, V92, P3711, DOI 10.1021/j100324a007; BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243; BLANDAMER MJ, 1970, CHEM REV, V70, P59, DOI 10.1021/cr60263a002; BORGIS D, 1991, J CHEM PHYS, V94, P3619, DOI 10.1063/1.459733; BORGIS D, 1992, J PHYS CHEM-US, V96, P3188, DOI 10.1021/j100187a003; CALEF DF, 1983, J CHEM PHYS, V78, P4145, DOI 10.1063/1.445091; CARMELI B, 1982, PHYS REV LETT, V49, P423, DOI 10.1103/PhysRevLett.49.423; CARTER EA, 1991, J CHEM PHYS, V94, P5961, DOI 10.1063/1.460431; CHANDLER D, 1986, J STAT PHYS, V42, P49, DOI 10.1007/BF01010840; CHANDLER D, 1987, INTRO MODERN STATIST; CHANDRASEKHAR J, 1985, J AM CHEM SOC, V107, P154, DOI 10.1021/ja00287a028; DELBUONO GS, 1991, J CHEM PHYS, V95, P3728, DOI 10.1063/1.460823; EADS DD, 1990, J CHEM PHYS, V93, P1136, DOI 10.1063/1.459177; FIELD MJ, 1990, J COMPUT CHEM, V11, P700, DOI 10.1002/jcc.540110605; FLEMING GR, 1986, J STAT PHYS, V42, P83, DOI 10.1007/BF01010842; FONSECA T, 1991, J PHYS CHEM-US, V95, P2116, DOI 10.1021/j100159a007; FOX MA, 1992, CHEM REV, V92, P365, DOI 10.1021/cr00011a600; FREED KF, 1976, RAD PROCESSES MOL CO; FRISHMAN AM, 1993, J CHEM PHYS, V98, P9532, DOI 10.1063/1.464384; GAUDUEL Y, 1990, J OPT SOC AM B, V7, P1528, DOI 10.1364/JOSAB.7.001528; GROTE RF, 1980, J CHEM PHYS, V73, P2715, DOI 10.1063/1.440485; GRUEBELE M, 1990, PHYS TODAY, V43, P24, DOI 10.1063/1.881233; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; HUSTON SE, 1989, J AM CHEM SOC, V111, P5680, DOI 10.1021/ja00197a027; HWANG JK, 1987, J AM CHEM SOC, V109, P715, DOI 10.1021/ja00237a013; HYNES JT, 1986, J PHYS CHEM-US, V90, P3701, DOI 10.1021/j100407a044; HYNES JT, 1985, ANNU REV PHYS CHEM, V36, P573, DOI 10.1146/annurev.physchem.36.1.573; HYNES JT, 1986, J STAT PHYS, V42, P149, DOI 10.1007/BF01010844; JIMENEZ R, 1994, NATURE, V369, P471, DOI 10.1038/369471a0; JORTNER J, 1976, ELECTRON SOLVENT ANI; KANG TJ, 1990, CHEM PHYS, V149, P81, DOI 10.1016/0301-0104(90)80131-G; KENNEYWALLACE GA, 1982, J PHYS CHEM-US, V86, P2572, DOI 10.1021/j100211a007; KESZEI E, 1993, J CHEM PHYS, V99, P2004, DOI 10.1063/1.465262; KIM YR, 1989, CHEM PHYS, V136, P311, DOI 10.1016/0301-0104(89)80055-2; KIMURA Y, 1994, J PHYS CHEM-US, V98, P3450, DOI 10.1021/j100064a029; KUHARSKI RA, 1988, J CHEM PHYS, V89, P3248, DOI 10.1063/1.454929; LONG FH, 1990, CHEM PHYS LETT, V169, P165, DOI 10.1016/0009-2614(90)85182-C; LONG FH, IN PRESS J PHYS CHEM; LU H, 1990, J OPT SOC AM B, V7, P1511, DOI 10.1364/JOSAB.7.001511; MARCUS RA, 1964, ANNU REV PHYS CHEM, V15, P155, DOI 10.1146/annurev.pc.15.100164.001103; MARONCELLI M, 1991, J CHEM PHYS, V94, P2084, DOI 10.1063/1.459932; MARONCELLI M, 1988, J CHEM PHYS, V89, P5044, DOI 10.1063/1.455649; MARONCELLI M, 1993, J MOL LIQ, V57, P1, DOI 10.1016/0167-7322(93)80045-W; MARONCELLI M, 1994, ULTRAFAST REACTION D, P310; MOUROU G, 1994, ULTRAFAST PHENOMENA; MURPHREY TH, 1993, J CHEM PHYS, V99, P515, DOI 10.1063/1.466218; NADLER W, 1987, J CHEM PHYS, V86, P3906, DOI 10.1063/1.451951; NERIA E, 1992, J CHEM PHYS, V96, P5433, DOI 10.1063/1.462859; NERLA E, 1991, PHYS REV LETT, V67, P1011; PINES E, 1991, J PHYS CHEM-US, V95, P10448, DOI 10.1021/j100178a036; RAO M, 1981, J PHYS CHEM-US, V85, P1498, DOI 10.1021/j150611a010; Reichardt C., 1988, SOLVENTS SOLVENT EFF; Remler DK, 1990, MOL PHYS, V70, P921, DOI 10.1080/00268979000101451; ROSENTHAL SJ, 1991, J CHEM PHYS, V95, P4715, DOI 10.1063/1.461742; ROSSKY PJ, 1988, J PHYS CHEM-US, V92, P4277, DOI 10.1021/j100326a009; ROSSKY PJ, 1985, ANNU REV PHYS CHEM, V36, P321, DOI 10.1146/annurev.physchem.36.1.321; SCHEINER S, 1985, ACCOUNTS CHEM RES, V18, P174, DOI 10.1021/ar00114a003; SCHWARTZ BJ, 1994, J PHYS CHEM-US, V98, P4489, DOI 10.1021/j100068a001; SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505; SHEU WS, 1993, CHEM PHYS LETT, V213, P233, DOI 10.1016/0009-2614(93)85125-8; Simon J. D., 1994, ULTRAFAST DYNAMICS C, DOI [10.1007/978-94-011-0916-1, DOI 10.1007/978-94-011-0916-1]; SIMON JD, 1992, J AM CHEM SOC, V114, P4861, DOI 10.1021/ja00038a061; SMITH TP, 1991, J PHYS CHEM-US, V95, P10465, DOI 10.1021/j100178a038; SUMI H, 1986, J CHEM PHYS, V84, P4894, DOI 10.1063/1.449978; SUTIN N, 1983, PROG INORG CHEM, V30, P441, DOI 10.1002/9780470166314.ch9; TIMONEDA JJI, 1991, J PHYS CHEM-US, V95, P10431, DOI 10.1021/j100178a034; WEAVER MJ, 1992, CHEM REV, V92, P463, DOI 10.1021/cr00011a006; WEBSTER FJ, 1991, PHYS REV LETT, V66, P3172, DOI 10.1103/PhysRevLett.66.3172; WHITNELL RM, 1993, REV COMPUTATIONAL CH, P67; WIESENFELD JM, 1980, CHEM PHYS LETT, V73, P47, DOI 10.1016/0009-2614(80)85199-2; ZHU JJ, 1993, J CHEM PHYS, V98, P5679, DOI 10.1063/1.464883; ZICHI DA, 1989, J PHYS CHEM-US, V93, P6261, DOI 10.1021/j100354a001	80	200	202	1	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					263	269		10.1038/370263a0	http://dx.doi.org/10.1038/370263a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035874				2022-12-28	WOS:A1994NZ22900054
J	SHAHAR, E; FOLSOM, AR; MELNICK, SL; TOCKMAN, MS; COMSTOCK, GW; GENNARO, V; HIGGINS, MW; SORLIE, PD; KO, WJ; SZKLO, M				SHAHAR, E; FOLSOM, AR; MELNICK, SL; TOCKMAN, MS; COMSTOCK, GW; GENNARO, V; HIGGINS, MW; SORLIE, PD; KO, WJ; SZKLO, M			DIETARY N-3 POLYUNSATURATED FATTY-ACIDS AND SMOKING-RELATED CHRONIC OBSTRUCTIVE PULMONARY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; FISH-OIL; SUPPLEMENTATION; EMPHYSEMA; NEUTROPHIL; GENERATION; INVITRO; HEALTH	Background. Fish contain n-3 polyunsaturated fatty acids, principally eicosapentaenoic acid and docosahexaenoic acid, which are known to interfere with the body's inflammatory response and may be of benefit in chronic inflammatory conditions. Methods. We studied the relation between the dietary intake of n-3 fatty acids and chronic obstructive pulmonary disease (COPD) in 8960 current or former smokers participating in a population-based study of atherosclerosis. Intake of fatty acids was estimated with a dietary questionnaire. The presence of COPD was assessed by a questionnaire on respiratory symptoms and by spirometry. Three case definitions of COPD were used: symptoms of chronic bronchitis (667 subjects), physician-diagnosed emphysema reported by the subject (185 subjects), and spirometrically detected COPD (197 subjects). Results. After control for pack-years of smoking, age, sex, race, height, weight, energy intake, and educational level, the combined intake of eicosapentaenoic acid and docosahexaenoic acid was inversely related to the risk of COPD in a quantity-dependent fashion. The adjusted odds ratio for the highest quartile of intake as compared with the lowest quartile was 0.66 for chronic bronchitis (95 percent confidence interval, 0.52 to 0.85; P<0.001 for linear trend across the range of intake values), 0.31 for physician-diagnosed emphysema (95 percent confidence interval, 0.18 to 0.52; P for linear trend, 0.003), and 0.50 for spirometrically detected COPD (95 percent confidence interval, 0.32 to 0.79; P for linear trend, 0.007). Conclusions. A high dietary intake of n-3 fatty acids may protect cigarette smokers against COPD.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; IST NAZL RIC CANC, ENVIRONM EPIDEMIOL SERV, I-16132 GENOA, ITALY; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, BETHESDA, MD 20892 USA; UNIV N CAROLINA, CTR COLLABORAT STUDIES COORDINATING, CHAPEL HILL, NC USA	Johns Hopkins University; University of Genoa; IRCCS AOU San Martino IST; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of North Carolina; University of North Carolina Chapel Hill	SHAHAR, E (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.			Szklo, Moyses/0000-0001-9433-6266	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055016, N01HC055015, N01HC055022] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55022, N01-HC-55015, N01-HC-55016] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; AOKI M, 1989, CHEST, V96, pS343, DOI 10.1378/chest.96.3_Supplement.343S; COMSTOCK GW, 1973, ARCH ENVIRON HEALTH, V27, P143, DOI 10.1080/00039896.1973.10666343; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FISHER M, 1991, WORLD REV NUTR DIET, V66, P245; HEPBURN FN, 1986, J AM DIET ASSOC, V86, P788; HOIDAL JR, 1981, AM REV RESPIR DIS, V123, P85; HOOGSTEDEN HC, 1991, MEDIATORS PULMONARY, P185; JANOFF A, 1983, J APPL PHYSIOL, V55, P285, DOI 10.1152/jappl.1983.55.2.285; KREMER JM, 1987, ANN INTERN MED, V106, P497, DOI 10.7326/0003-4819-106-4-497; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; MACNEE W, 1989, NEW ENGL J MED, V321, P924, DOI 10.1056/NEJM198910053211402; MCGOWAN SE, 1989, NEW ENGL J MED, V321, P968, DOI 10.1056/NEJM198910053211410; NIEWOEHNER DE, 1988, J LAB CLIN MED, V111, P15; SCHWARTZ J, 1990, AM J EPIDEMIOL, V132, P67, DOI 10.1093/oxfordjournals.aje.a115644; SILVERMAN DI, 1990, AM J CARDIOL, V66, P860, DOI 10.1016/0002-9149(90)90367-A; SIMOPOULOS AP, 1991, AM J CLIN NUTR, V54, P438, DOI 10.1093/ajcn/54.3.438; SPERLING RI, 1987, J IMMUNOL, V139, P4186; STENSON WF, 1992, ANN INTERN MED, V116, P609, DOI 10.7326/0003-4819-116-8-609; TOCKMAN MS, 1985, CHRONIC OBSTRUCTIVE, P43; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; ZAKRZEWSKI JT, 1987, PROSTAGLANDINS, V33, P663, DOI 10.1016/0090-6980(87)90033-5; 1990, SAS STAT USERS GUIDE; 1976, COMPOSITION FOODS RA; 1981, FOOD CONSUMPTION STA	30	143	151	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					228	233		10.1056/NEJM199407283310403	http://dx.doi.org/10.1056/NEJM199407283310403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	8015569				2022-12-28	WOS:A1994NY33500003
J	CARLSON, KJ; SKATES, SJ; SINGER, DE				CARLSON, KJ; SKATES, SJ; SINGER, DE			SCREENING FOR OVARIAN-CANCER	ANNALS OF INTERNAL MEDICINE			English	Review							SERUM CA-125 LEVELS; TUMOR-ASSOCIATED ANTIGEN; PELVIC MASSES; PREOPERATIVE EVALUATION; FAMILY HISTORY; PROPHYLACTIC OOPHORECTOMY; POSTMENOPAUSAL WOMEN; EPITHELIAL CARCINOMA; STAGE-I; CA 125	Purpose: To critically review the available evidence for screening asymptomatic women for ovarian cancer with ultrasonography or the CA 125 radioimmunoassay (CA 125) or both. Data Sources: A MEDLINE search of the English-language literature and bibliographies of published studies providing estimates of ovarian cancer risk and test operating characteristics (based on observational studies and meta-analyses) and effectiveness of treatment according to stage of disease (based on randomized trials). Published mathematical models simulating screening for ovarian cancer in specific populations were also included. Death from ovarian cancer and morbidity from surgical procedures were the principal outcomes considered. Results: Age and family history are the most important risk factors for ovarian cancer. Annual screening with CA 125 or ultrasound in women older than 50 years without a family history of ovarian cancer would result in more than 30 false-positive results for every ovarian cancer detected. False-positive tests are likely to require invasive testing, often including laparotomy. There is currently no direct evidence that mortality from ovarian cancer would be decreased by screening. Conclusions: Available evidence does not support either screening of pre- or postmenopausal women without a family history of ovarian cancer or routine screening in women with a family history of ovarian cancer in one or more relatives (without evidence of a hereditary cancer syndrome). Women from a family with the rare hereditary ovarian cancer syndrome are at high risk for the disease and should be referred to a gynecologic oncologist.	HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard Medical School	CARLSON, KJ (corresponding author), MASSACHUSETTS GEN HOSP, CTR MED PRACTICES EVALUAT, BOSTON, MA 02114 USA.							AMOS CI, 1993, CANCER-AM CANCER SOC, V71, P566; AMOS CI, 1992, JAMA-J AM MED ASSOC, V268, P1896, DOI 10.1001/jama.268.14.1896; ANDOLF E, 1986, BRIT J OBSTET GYNAEC, V93, P1286, DOI 10.1111/j.1471-0528.1986.tb07867.x; ANDOLF E, 1990, OBSTET GYNECOL, V75, P106; BENACERRAF BR, 1990, J REPROD MED, V35, P491; BERGMAN A, 1991, OBSTET GYNECOL, V78, P726; BJORKHOLM E, 1982, ACTA RADIOL ONCOL, V21, P413; BOURNE T, 1989, BRIT MED J, V299, P1367, DOI 10.1136/bmj.299.6712.1367; BOURNE TH, 1993, BRIT MED J, V306, P1025, DOI 10.1136/bmj.306.6884.1025; BOURNE TH, 1991, GYNECOL ONCOL, V43, P92, DOI 10.1016/0090-8258(91)90051-6; BRIOSCHI PA, 1987, BRIT J OBSTET GYNAEC, V94, P196, DOI 10.1111/j.1471-0528.1987.tb02353.x; CAMPBELL S, 1990, BRIT J OBSTET GYNAEC, V97, P304, DOI 10.1111/j.1471-0528.1990.tb01806.x; CASAGRANDE JT, 1979, LANCET, V2, P170; CHEN DX, 1988, OBSTET GYNECOL, V72, P23; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CRUICKSHANK DJ, 1987, BRIT J OBSTET GYNAEC, V94, P692, DOI 10.1111/j.1471-0528.1987.tb03177.x; DEPRIEST PD, 1993, GYNECOL ONCOL, V51, P7, DOI 10.1006/gyno.1993.1238; EINHORN N, 1989, ACTA ONCOL, V28, P655, DOI 10.3109/02841868909092288; EINHORN N, 1985, CANCER, V55, P2019, DOI 10.1002/1097-0142(19850501)55:9<2019::AID-CNCR2820550932>3.0.CO;2-2; EINHORN N, 1986, OBSTET GYNECOL, V67, P414; EINHORN N, 1992, OBSTET GYNECOL, V80, P14; FINKLER NJ, 1988, OBSTET GYNECOL, V72, P659; GALLION HH, 1989, CANCER-AM CANCER SOC, V63, P1070, DOI 10.1002/1097-0142(19890315)63:6<1070::AID-CNCR2820630605>3.0.CO;2-F; GOSWAMY RK, 1983, CLIN OBSTET GYNAECOL, V10, P621; GRANBERG S, 1990, GYNECOL ONCOL, V37, P224, DOI 10.1016/0090-8258(90)90337-K; GRIFFITHS CT, 1986, GYNECOL ONCOL, P313; HANKINSON SE, 1992, OBSTET GYNECOL, V80, P708; HARTGE P, 1989, AM J OBSTET GYNECOL, V161, P10, DOI 10.1016/0002-9378(89)90221-4; HEIZISOUER KJ, 1993, JAMA-J AM MED ASSOC, V269, P1123; HERRMANN UJ, 1987, OBSTET GYNECOL, V69, P777; HILDRETH NG, 1981, AM J EPIDEMIOL, V114, P398, DOI 10.1093/oxfordjournals.aje.a113207; HOWE HL, 1984, AM J PUBLIC HEALTH, V74, P560, DOI 10.2105/AJPH.74.6.560; JACOBS I, 1988, LANCET, V1, P268; JACOBS I, 1993, BRIT MED J, V306, P1030, DOI 10.1136/bmj.306.6884.1030; JACOBS I, 1989, HUM REPROD, V4, P1; JACOBS IJ, 1992, OBSTET GYNECOL, V80, P396; KERLIKOWSKE K, 1992, OBSTET GYNECOL, V80, P700; KOCH M, 1989, INT J EPIDEMIOL, V18, P782, DOI 10.1093/ije/18.4.782; KRAMER BS, 1993, CANCER, V71, P589; KURJAK A, 1991, J ULTRAS MED, V10, P295; LAVECCHIA C, 1984, EUR J CANCER CLIN ON, V20, P175, DOI 10.1016/0277-5379(84)90181-0; LYNCH HT, 1991, CANCER GENET CYTOGEN, V53, P161, DOI 10.1016/0165-4608(91)90094-B; LYNCH HT, 1991, CANCER, V67, P1460, DOI 10.1002/1097-0142(19910301)67:5<1460::AID-CNCR2820670534>3.0.CO;2-S; LYNCH HT, 1990, GYNECOL ONCOL, V36, P48, DOI 10.1016/0090-8258(90)90107-V; LYNCH HT, 1987, CANCER GENETICS WOME, P50; MAGGINO T, 1987, European Journal of Gynaecological Oncology, V8, P590; MALKASIAN GD, 1988, AM J OBSTET GYNECOL, V159, P341, DOI 10.1016/S0002-9378(88)80081-4; MCGOWAN L, 1979, GYNECOL ONCOL, V7, P325, DOI 10.1016/0090-8258(79)90111-2; MOGENSEN O, 1989, EUR J CANCER CLIN ON, V25, P1187, DOI 10.1016/0277-5379(89)90413-6; MORROW CP, 1981, GYNECOL OBSTET, P1138; NILOFF JM, 1988, GYNECOLOGICAL DECISI, P192; OCONNELL GJ, 1987, OBSTET GYNECOL, V70, P930; PARAZZINI F, 1992, AM J EPIDEMIOL, V135, P35, DOI 10.1093/oxfordjournals.aje.a116199; PARKER WH, 1993, CLIN OBSTET GYNECOL, V36, P413, DOI 10.1097/00003081-199306000-00020; PATSNER B, 1988, AM J OBSTET GYNECOL, V159, P873, DOI 10.1016/S0002-9378(88)80158-3; PETTERSSON F, 1991, INT J GYNECOL OBSTET, V36, P1, DOI 10.1016/0020-7292(91)90169-6; PITTAWAY DE, 1987, AM J OBSTET GYNECOL, V156, P75, DOI 10.1016/0002-9378(87)90207-9; PULS LE, 1992, GYNECOL ONCOL, V47, P53, DOI 10.1016/0090-8258(92)90075-T; REQUARD CK, 1981, AM J ROENTGENOL, V137, P79, DOI 10.2214/ajr.137.1.79; RODRIGUEZ MH, 1988, AM J OBSTET GYNECOL, V159, P810, DOI 10.1016/S0002-9378(88)80142-X; SASSONE AM, 1991, OBSTET GYNECOL, V78, P70; SCHAPIRA MM, 1993, ANN INTERN MED, V118, P838, DOI 10.7326/0003-4819-118-11-199306010-00002; SCHILDKRAUT JM, 1988, AM J EPIDEMIOL, V128, P456, DOI 10.1093/oxfordjournals.aje.a114994; SCHILTHUIS MS, 1987, BRIT J OBSTET GYNAEC, V94, P202; SCHWARTZ PE, 1991, YALE J BIOL MED, V64, P557; SKATES SJ, 1991, J CLIN EPIDEMIOL, V44, P365, DOI 10.1016/0895-4356(91)90075-K; SOPER JT, 1990, OBSTET GYNECOL, V75, P249; Sox HC, 1987, COMMON DIAGNOSTIC TE; TOBACMAN JK, 1982, LANCET, V2, P795; TZONOU A, 1984, EUR J CANCER CLIN ON, V20, P1045, DOI 10.1016/0277-5379(84)90107-X; VANNAGELL JR, 1991, CANCER, V68, P458, DOI 10.1002/1097-0142(19910801)68:3<458::AID-CNCR2820680303>3.0.CO;2-3; VASILEV SA, 1988, OBSTET GYNECOL, V71, P751; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WYNDER EL, 1969, CANCER, V23, P352, DOI 10.1002/1097-0142(196902)23:2<352::AID-CNCR2820230212>3.0.CO;2-4; YEDEMA C, 1988, INT J CANCER, P61; YOUNG RC, 1990, NEW ENGL J MED, V322, P1021, DOI 10.1056/NEJM199004123221501; ZANABONI F, 1987, GYNECOL ONCOL, V28, P61, DOI 10.1016/S0090-8258(87)80009-4; ZURAWSKI VR, 1988, GYNECOL ONCOL, V30, P7, DOI 10.1016/0090-8258(88)90039-X; ZURAWSKI VR, 1988, INT J CANCER, V42, P677, DOI 10.1002/ijc.2910420507; ZURAWSKI VR, 1990, GYNECOL ONCOL, V36, P299, DOI 10.1016/0090-8258(90)90130-D; 1989, ACOG68 AM COLL OBST; 1989, GUIDE CLIN PREVENTIV, P81; 1988, NCI902789 SURV PROGR	83	103	109	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					124	132		10.7326/0003-4819-121-2-199407150-00009	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017726				2022-12-28	WOS:A1994NW18600009
J	JOHNSTON, JA; KAWAMURA, M; KIRKEN, RA; CHEN, YQ; BLAKE, TB; SHIBUYA, K; ORTALDO, JR; MCVICAR, DW; O'SHEA, JJ				JOHNSTON, JA; KAWAMURA, M; KIRKEN, RA; CHEN, YQ; BLAKE, TB; SHIBUYA, K; ORTALDO, JR; MCVICAR, DW; O'SHEA, JJ			PHOSPHORYLATION AND ACTIVATION OF THE JAK-3 JANUS KINASE IN RESPONSE TO INTERLEUKIN-2	NATURE			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; RECEPTOR-BETA; INTERFERON-ALPHA/BETA; IL-2; SUBUNIT; CHAIN; PATHWAY	LUTERLEUKIN-2 is an autocrine growth factor for T cells(1,2) which also activates other cells including B cells(3) and natural killer cells(4). The subunits of the interleukin-2 receptor (IL-2R) lack intrinsic enzymatic activity, but protein tyrosine phosphorylation is a critical event following ligand binding and src family kinases, such as Lck, are known to be activated by IL-2 (refs 5-9). However, IL-2 signalling can occur in the absence of receptor interaction with Lck, suggesting that other protein tyrosine kinases might be important(10). Here we report that a new member of the Janus family of kinases (Jak-3) is coupled to the IL-2R in human peripheral blood T cells and natural killer cells.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, MOLEC IMMUNOREGULAT LAB, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, PRI DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, ADV BIOSCI LABS INC, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	JOHNSTON, JA (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, EXPTL IMMUNOL LAB, LEUKOCYTE CELL BIOL SECT, FREDERICK, MD 21702 USA.		McVicar, Daniel/G-1970-2015	McVicar, Daniel/0000-0002-1112-5111				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HENRY CS, 1981, NATURE, V291, P335; KAWAMURA M, IN PRESS P NATN ACAD; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1983, P NATL ACAD SCI-BIOL, V80, P6957, DOI 10.1073/pnas.80.22.6957; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TANIGUCHI T, 1988, A REV IMMUN, V4, P69; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	28	546	569	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					151	153		10.1038/370151a0	http://dx.doi.org/10.1038/370151a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022485	Green Submitted			2022-12-28	WOS:A1994NW80400060
J	FRANK, E				FRANK, E			AUTHORS CRITERIA FOR SELECTING JOURNALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC			Objective.-To evaluate authors' methods of selecting the journals to which they submit manuscripts. Design and Setting.-In 1992, all of the active Clinical and research faculty of Stanford University School of Medicine (n=479), Pale Alto, Calif, were sent up to three mailings of a one-page questionnaire. Results.-Our response rate was 63.7% (n=305). On a scale of 1 (unimportant) to 6 (very important), respondents ranked factors affecting initial manuscript submission to a journal in the following descending order (mean values are reported): the journal's prestige, 5.2; the makeup of the journal's readership, 4.8; whether the journal usually publishes articles on the topic, 4.8; the likelihood of manuscript acceptance, 4.4; the size of journal circulation, 4.1; the rapidity of manuscript turnaround, 4.1; the existence of good editors, 3.9; the likelihood of useful reviewer suggestions, 3.4; a history of having published in that journal previously, 3.4; colleagues' recommendations, 3.1; the likelihood of useful biostatistical suggestions, 2.6; the existence of editors who are personally known to the author, 2.1; and the likelihood of press attention, 1.9. For subsequent submissions, the most important factors were the likelihood of manuscript acceptance (5.0) and whether the journal usually publishes articles on the topic (4.7). Conclusions.-Journal prestige, most frequently published journal topics, and readership composition were the most important factors for initial manuscript submissions. For subsequent submissions, more pragmatic variables, such as likelihood of acceptance, gained importance. These findings should help editors make their journals more attractive to potential authors.	EMORY UNIV,SCH MED,DEPT MED,ATLANTA,GA 30303	Emory University	FRANK, E (corresponding author), EMORY UNIV,SCH MED,DEPT FAMILY & PREVENT MED,69 BUTLER ST SE,ATLANTA,GA 30303, USA.			Frank, Erica/0000-0001-7159-5417					0	61	65	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					163	164		10.1001/jama.272.2.163	http://dx.doi.org/10.1001/jama.272.2.163			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015134				2022-12-28	WOS:A1994NV42400024
J	COLLEDGE, WH; CARLTON, MBL; UDY, GB; EVANS, MJ				COLLEDGE, WH; CARLTON, MBL; UDY, GB; EVANS, MJ			DISRUPTION OF C-MOS CAUSES PARTHENOGENETIC DEVELOPMENT OF UNFERTILIZED MOUSE EGGS	NATURE			English	Article							PROTO-ONCOGENE PRODUCT; PROTOONCOGENE PRODUCT; MEIOTIC MATURATION; XENOPUS EGGS; KINASE; GENE; FERTILIZATION; EXPRESSION; ACTIVATION; OOCYTES	THE c-mos proto-oncogene encodes a 37-39K cytoplasmic serine/threonine kinase(1) implicated in the meiotic maturation events during murine spermatogenesis(2) and oogenesis(3-6). In Xenopus, ectopic expression of pp39(mos) can promote both the meiotic maturation of oocytes(7-9) and also arrest the cleavage of blastomeres(10) To elucidate the role of pp39(mos) we have generated homozygous mutant mice by gene targeting in embryonic stem cells(11). These mice are viable and mutant males are fertile, demonstrating that pp39(mos) is not essential for spermatogenesis. In contrast, mutant females, have a reduced fertility because of the failure of mature eggs to arrest during meiosis. c-mos(-1-) oocytes undergo germinal vesicle breakdown and extrusion of both polar bodies followed in some cases by progression into cleavage. Mutant females also develop ovarian cysts. These results demonstrate that a major role for pp39(mos) is to prevent the spontaneous parthenogenetic activation of unfertilized eggs.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,CAMBS,ENGLAND; RUAKURA AGR CTR,HAMILTON,NEW ZEALAND	University of Cambridge; AgResearch - New Zealand	COLLEDGE, WH (corresponding author), UNIV CAMBRIDGE,WELLCOME CRC INST CANC & DEV BIOL,TENNIS COURT RD,CAMBRIDGE CB2 1QR,CAMBS,ENGLAND.		Colledge, William/X-4976-2019	Colledge, William/0000-0002-9603-4429	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Bradley A, 1991, Curr Opin Biotechnol, V2, P823, DOI 10.1016/S0958-1669(05)80114-4; EPPIG JJ, 1993, METHOD ENZYMOL, V225, P77; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOGAN B, 1986, MANIPULATING MOUSE E; KAUFMAN MH, 1986, GAMETE RES, V14, P255, DOI 10.1002/mrd.1120140309; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1988, ONCOGENE, V2, P227; RATCLIFF R, 1993, NAT GENET, V4, P35, DOI 10.1038/ng0593-35; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; Talerman A, 1992, Curr Top Pathol, V85, P165; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEBER M, 1991, DEV BIOL, V148, P393, DOI 10.1016/0012-1606(91)90347-6; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1990, ONCOGENE, V5, P1727	23	403	418	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					65	68		10.1038/370065a0	http://dx.doi.org/10.1038/370065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015609				2022-12-28	WOS:A1994NV71100060
J	SHEVELL, DE; LEU, WM; GILLMOR, CS; XIA, GX; FELDMANN, KA; CHUA, NH				SHEVELL, DE; LEU, WM; GILLMOR, CS; XIA, GX; FELDMANN, KA; CHUA, NH			EMB30 IS ESSENTIAL FOR NORMAL-CELL DIVISION, CELL EXPANSION, AND CELL-ADHESION IN ARABIDOPSIS AND ENCODES A PROTEIN THAT HAS SIMILARITY TO SEC7	CELL			English	Article							YEAST SECRETORY PATHWAY; AUXIN POLAR TRANSPORT; GOLGI-APPARATUS; LETHAL MUTANTS; SACCHAROMYCES-CEREVISIAE; COMPLEX POLYSACCHARIDES; SOMATIC EMBRYOGENESIS; ARRESTED EMBRYOS; BUDDING YEAST; THALIANA	The EMB30 gene is involved in apical-basal pattern formation in the Arabidopsis embryo. Mutations in this locus produce mutants with a wide range of seedling phenotypes, but all of the mutants lack a root and a true hypocotyl. We have cloned the EMB30 gene, and it encodes a protein that has similarity to the yeast Sec7 protein and to two other open reading frames identified in clones from humans and C. elegans. We refer to the region of similarity among these four sequences as the Sec7 domain. The emb30-1 allele has a mutation in the Sec7 domain that alters a residue conserved in all four of these sequences, suggesting that this domain may be important for EMB30 function. Molecular date and microscopy studies of emb30 seedlings presented here indicate that EMB30 affects cell division, elongation, and adhesion and functions in Seedling and adult plants as well as during embryogenic pattern formation.	UNIV ARIZONA,DEPT PLANT SCI,TUCSON,AZ 85721	University of Arizona	SHEVELL, DE (corresponding author), ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.		Gillmor, Stewart/C-1965-2014	Gillmor, Stewart/0000-0003-1009-2167				ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARTON MK, 1993, DEVELOPMENT, V119, P823; BAUS AD, 1986, THEOR APPL GENET, V72, P577, DOI 10.1007/BF00288994; BERGER F, 1994, SCIENCE, V263, P1421, DOI 10.1126/science.263.5152.1421; BIAROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; DEJONG AJ, 1992, PLANT CELL, V4, P425, DOI 10.2307/3869444; DENFERT C, 1992, EMBO J, V11, P4205, DOI 10.1002/j.1460-2075.1992.tb05514.x; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DRIOUICH A, 1993, TRENDS BIOCHEM SCI, V18, P210, DOI 10.1016/0968-0004(93)90191-O; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; FELDMANN KA, 1986, PLANT SCI, V47, P63, DOI 10.1016/0168-9452(86)90011-7; FRANZUSOFF A, 1992, NATURE, V355, P173, DOI 10.1038/355173a0; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; HERTEL R, 1983, PLANTA, V157, P193, DOI 10.1007/BF00405182; Jurgens G, 1991, DEVELOPMENT S, V1, P27; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLIMYUK VI, 1993, PLANT J, V3, P493, DOI 10.1046/j.1365-313X.1993.t01-26-00999.x; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; Lyndon RF, 1990, PLANT DEV CELLULAR B; MANSFIELD SG, 1991, CAN J BOT, V69, P461, DOI 10.1139/b91-063; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; MAYER U, 1993, DEVELOPMENT, V117, P149; MEINKE DW, 1985, THEOR APPL GENET, V69, P543, DOI 10.1007/BF00251102; MEINKE DW, 1991, DEV GENET, V12, P382, DOI 10.1002/dvg.1020120603; MOORE PJ, 1991, J CELL BIOL, V112, P589, DOI 10.1083/jcb.112.4.589; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P493, DOI DOI 10.1111/J.1399-3054.1962.TB08052.X; NAGY F, 1988, PLANT MOL BIOL MANUA, P1; NAIRN CJ, 1988, GENE, V65, P247, DOI 10.1016/0378-1119(88)90461-1; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; OKADA K, 1991, PLANT CELL, V3, P677, DOI 10.1105/tpc.3.7.677; PATTON DA, 1990, AM J BOT, V77, P653, DOI 10.2307/2444811; PATTON DA, 1991, MOL GEN GENET, V227, P337, DOI 10.1007/BF00273921; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RUBERY PH, 1981, ANNU REV PLANT PHYS, V32, P569, DOI 10.1146/annurev.pp.32.060181.003033; SCHIAVO L, 1990, MOL GEN GENET, V223, P385; SCHIAVONE FM, 1987, CELL DIFFER DEV, V21, P53, DOI 10.1016/0045-6039(87)90448-9; SCHNEIDER T, 1989, DEV BIOL, V131, P161, DOI 10.1016/S0012-1606(89)80047-8; SCHWARTZ RM, 1978, ATLAS PROTEIN SEQUEN, V5, P343; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; SVOBODA A, 1987, J BASIC MICROB, V27, P603, DOI 10.1002/jobm.3620271008; VAI M, 1987, EXP CELL RES, V171, P448, DOI 10.1016/0014-4827(87)90176-5; WATSON JC, 1986, METHOD ENZYMOL, V118, P57; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZIMMERMAN JL, 1993, PLANT CELL, V5, P1411, DOI 10.1105/tpc.5.10.1411	54	252	273	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1051	1062		10.1016/0092-8674(94)90444-8	http://dx.doi.org/10.1016/0092-8674(94)90444-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020095				2022-12-28	WOS:A1994NV42500013
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION IN PRIMARY-CARE - DIET AND CANCER .4.	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; VEGETABLES; NUTRITION; FRUIT	Accumulating data indicate that modifications in diet may reduce the risk of cancer by as much as one third and possibly by as much as two thirds. On the basis of the existing evidence, however, it is not possible to be certain which cancers are causally related to diet and what proportion of them are due to specific components of the diet. Diet is currently thought to be a major factor in the aetiology of cancers of the large bowel and stomach, and it may also be important in the aetiology of several other cancers. With the exception of strong and consistent evidence of the protective effect of fruit and vegetables, practical dietary interventions that reduce the risk of cancer are difficult to formulate as, in general, the evidence is theoretical or contradictory and too weak to justify specific intervention. Authoritative guidelines on dietary management in primary care are conspicuously absent because of lack of research. The success of an individual based strategy will depend on adequate education, training, and support being made available to the relevant members of primary care teams.			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX2 6PE,ENGLAND.							BARON JA, 1990, BRIT J GEN PRACT, V40, P137; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BOYD NF, 1993, BRIT J CANCER, V68, P627, DOI 10.1038/bjc.1993.398; BOYLE P, 1993, BASSMORES TXB NUTRIT, P701; BOYLE P, 1994, ONCOL HEAMATOL, V2, P7; DOLL R, 1992, CANCER RES, V52, pS2024; FRANCIS J, 1989, BRIT MED J, V298, P1620, DOI 10.1136/bmj.298.6688.1620; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; MANN JI, 1990, BRIT J GEN PRACT, V40, P418; MODAN B, 1992, LANCET, V340, P162, DOI 10.1016/0140-6736(92)93227-E; RIBOLI E, 1993, INT J CANCER, V55, P531, DOI 10.1002/ijc.2910550402; RIBOLI E, 1992, ANN ONCOL, V3, P783, DOI 10.1093/oxfordjournals.annonc.a058097; ROBERTSON I, 1992, BRIT J GEN PRACT, V42, P469; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; TOMATIS L, 1990, CANCER CAUSES OCCURR; 1992, REPORT NATIONAL FOOD; 1992, HLTH NATION; 1990, WHO TECH REP SER, V797; 1991, CA, V41, P334; 1992, CEC1991 COMM EUR COM; [No title captured]; 1991, AGR UK 1990; 1990, DIET CANCER; 1993, NUTRITION INTERVENTI	24	26	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1610	1614		10.1136/bmj.308.6944.1610	http://dx.doi.org/10.1136/bmj.308.6944.1610			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025430	Green Published			2022-12-28	WOS:A1994NT52800021
J	PHILLIPS, GD; HARRISON, NK; CUMMIN, ARC; WARD, J; SHENOY, VS; NEWEY, V; RITCHIE, D; WILLIAMS, IP; MILLARD, FJC				PHILLIPS, GD; HARRISON, NK; CUMMIN, ARC; WARD, J; SHENOY, VS; NEWEY, V; RITCHIE, D; WILLIAMS, IP; MILLARD, FJC			NEW METHOD FOR MEASURING COMPLIANCE WITH LONG-TERM OXYGEN TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON ST GEORGES HOSP,DEPT MED PHYS,LONDON SW17 0QT,ENGLAND; ST ALBANS HOSP,DEPT CHEST MED,ST ALBANS AL3 5PN,HERTS,ENGLAND	St Georges University London	PHILLIPS, GD (corresponding author), UNIV LONDON ST GEORGES HOSP,CHEST CLIN,LONDON SW17 0QT,ENGLAND.							[Anonymous], 1981, LANCET, V1, P681; Nocturnal Oxygen Therapy Trial Group, 1980, ANN INTERN MED, V93, P391; Williams B, 1991, Health Trends, V23, P166; 1986, DHSS FPN398 DEP HLTH	4	6	6	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1544	1545		10.1136/bmj.308.6943.1544	http://dx.doi.org/10.1136/bmj.308.6943.1544			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019312	Green Published			2022-12-28	WOS:A1994NR11000025
J	AVGERINOS, PC; YANOVSKI, JA; OLDFIELD, EH; NIEMAN, LK; CUTLER, GB				AVGERINOS, PC; YANOVSKI, JA; OLDFIELD, EH; NIEMAN, LK; CUTLER, GB			THE METYRAPONE AND DEXAMETHASONE SUPPRESSION TESTS FOR THE DIFFERENTIAL-DIAGNOSIS OF THE ADRENOCORTICOTROPIN-DEPENDENT CUSHING SYNDROME - A COMPARISON	ANNALS OF INTERNAL MEDICINE			English	Article						METYRAPONE; DEXAMETHASONE; CUSHINGS SYNDROME; CORTICOTROPIN	CORTICOTROPIN-RELEASING HORMONE; STIMULATION TEST; ACTH; CORTISOL	Objective: To develop criteria for interpreting results of the metyrapone test for the differential diagnosis of the adrenocorticotropin (ACTH)-dependent Cushing syndrome and to compare its diagnostic accuracy with that of the high-dose dexamethasone suppression test. Design: Retrospective cohort study. Setting: Inpatient research ward. Patients: 186 patients believed to have the ACTH-dependent Cushing syndrome who had the metyrapone test, the dexamethasone test, and a surgical procedure to remove the source of excessive ACTH. Measurements: The sensitivity, specificity, and diagnostic accuracy were determined for the metyrapone test using urine excretion of hydroxysteroid and plasma levels of 11-deoxycortisol. For the dexamethasone suppression test, urine excretions of 17-hydroxysteroid (17-OHS) and free cortisol were used. Main Results: 156 patients had pituitary disease, 15 had ectopic ACTH secretion, and 15 had no diagnosis after pituitary surgery. Of those 15 patients, 14 were ultimately classified as having pituitary disease on the basis of follow-up, and 1 was found to have ACTH-independent Cushing syndrome. After administration of metyrapone, stimulation of 17-OHS excretion greater than 70% or of a plasma 11-deoxycortisol level greater than 400-fold did not result in the misclassification of any of the patients with surgically confirmed cases of ectopic ACTH secretion. When these criteria were combined, the percentage of correct predictions (122 of 186 [71%; 95% CI, 62% to 79%]) was higher than that for either steroid alone (116 of 186 [62%; CI, 52% to 71 %]) for excretion of 17-OHS and that for plasma 11-deoxycortisol (82 of 186 [44%; CI, 34% to 54%]). When the criteria for both the metyrapone test and the dexamethasone test were combined, the percentage of correct predictions (153 of 186 [82%; CI, 75% to 87%]) was higher than that obtained when the criteria for either test alone were used (P = 0.001). Similar results were found when the 15 patients with indeterminate surgery were assigned to the appropriate group on the basis of follow-up. When the criteria for both the metyrapone and dexamethasone tests were combined to identify patients with the pituitary Cushing syndrome, the sensitivity and diagnostic accuracy improved to 88% and 89%, respectively. Conclusions: The metyrapone test, which can be done in 48 hours, has a sensitivity and specificity for the diagnosis of the Cushing syndrome identical to that of the standard 6-day high-dose dexamethasone suppression test. Combining both tests results in greater accuracy than that obtained with either test alone.	NINCDS, SURG NEUROL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	AVGERINOS, PC (corresponding author), NICHHD, DEV ENDOCRINOL BRANCH, BLDG 10, ROOM 10N262, BETHESDA, MD 20892 USA.			Yanovski, Jack/0000-0001-8542-1637				ARMITAGE P, 1971, STATISTICAL METHODS; BECK JR, 1986, ARCH PATHOL LAB MED, V110, P13; BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; BLUNT SB, 1990, Q J MED, V77, P1113, DOI 10.1093/qjmed/77.2.1113; BROWNLEE KA, 1965, STATISTICAL THEORY M, P262; CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; FLACK MR, 1992, ANN INTERN MED, V116, P211, DOI 10.7326/0003-4819-116-3-211; FORMAN DT, 1978, MANUAL PROCEDURES SE, P135; GARDNER MJ, 1989, BRIT MED J; HOWLETT TA, 1986, CLIN ENDOCRINOL, V24, P699, DOI 10.1111/j.1365-2265.1986.tb01667.x; JEX RK, 1985, AM J SURG, V149, P276; JONES KL, 1990, PEDIATR CLIN N AM, V37, P1313; KAO M, 1975, CLIN CHEM, V21, P1644; KAYE TB, 1990, ANN INTERN MED, V112, P434, DOI 10.7326/0003-4819-76-3-112-6-434; LEINUNG MC, 1990, MAYO CLIN PROC, V65, P1314, DOI 10.1016/S0025-6196(12)62142-9; LIDDLE GW, 1959, J CLIN ENDOCR METAB, V19, P875, DOI 10.1210/jcem-19-8-875; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LORIAUX DL, 1986, CLIN ENDOCRINOL, P167; MAHAJAN DK, 1972, STEROIDS, V20, P609, DOI 10.1016/0039-128X(72)90018-9; MASON A M S, 1972, Clinical Endocrinology, V1, P3, DOI 10.1111/j.1365-2265.1972.tb00374.x; MEIKLE AW, 1969, J CLIN ENDOCR METAB, V29, P1553, DOI 10.1210/jcem-29-12-1553; MILLER DL, 1992, RADIOLOGY, V185, P143, DOI 10.1148/radiology.185.1.1523298; MORRISON DF, 1984, MULTIVARIATE STATIST, P34; NIEMAN LK, 1993, J CLIN ENDOCR METAB, V77, P1308, DOI 10.1210/jc.77.5.1308; NIEMAN LK, 1986, ANN INTERN MED, V105, P862, DOI 10.7326/0003-4819-105-6-862; NUGENT CA, 1965, ARCH INTERN MED, V116, P172, DOI 10.1001/archinte.1965.03870020012006; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; ORTH DN, 1991, NEW ENGL J MED, V325, P957, DOI 10.1056/NEJM199109263251309; PAVLATOS FC, 1965, J AMER MED ASSOC, V193, P720, DOI 10.1001/jama.1965.03090090026005; SILBER RH, 1950, J BIOL CHEM, V185, P923; SILBER RH, 1954, J BIOL CHEM, V21, P262; SINDLER BH, 1983, AM J MED, V74, P657, DOI 10.1016/0002-9343(83)91024-0; STROTT CA, 1968, AM J MED, V44, P97, DOI 10.1016/0002-9343(68)90240-4; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; WEISS ER, 1969, ANN INTERN MED, V71, P941, DOI 10.7326/0003-4819-71-5-941; YANOVSKI JA, 1993, JAMA-J AM MED ASSOC, V269, P2232, DOI 10.1001/jama.269.17.2232; 1983, CAN MED ASSOC J, V129, P947	37	44	44	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					318	327		10.7326/0003-4819-121-5-199409010-00002	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042820				2022-12-28	WOS:A1994PD70100002
J	FISCHMAN, DL; LEON, MB; BAIM, DS; SCHATZ, RA; SAVAGE, MP; PENN, I; DETRE, K; VELTRI, L; RICCI, D; NOBUYOSHI, M; CLEMAN, M; HEUSER, R; ALMOND, D; TEIRSTEIN, PS; FISH, RD; COLOMBO, A; BRINKER, J; MOSES, J; SHAKNOVICH, A; HIRSHFELD, J; BAILEY, S; ELLIS, S; RAKE, R; GOLDBERG, S				FISCHMAN, DL; LEON, MB; BAIM, DS; SCHATZ, RA; SAVAGE, MP; PENN, I; DETRE, K; VELTRI, L; RICCI, D; NOBUYOSHI, M; CLEMAN, M; HEUSER, R; ALMOND, D; TEIRSTEIN, PS; FISH, RD; COLOMBO, A; BRINKER, J; MOSES, J; SHAKNOVICH, A; HIRSHFELD, J; BAILEY, S; ELLIS, S; RAKE, R; GOLDBERG, S			A RANDOMIZED COMPARISON OF CORONARY-STENT PLACEMENT AND BALLOON ANGIOPLASTY IN THE TREATMENT OF CORONARY-ARTERY DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIRECTIONAL ATHERECTOMY; PREVENT RESTENOSIS; FOLLOW-UP; EXPERIENCE; MULTICENTER; ASPIRIN; MODEL; TRIAL	Background. Coronary-stent placement is a new technique in which a balloon-expandable, stainless-steel, slotted tube is implanted at the site of a coronary stenosis. The purpose of this study was to compare the effects of stent placement and standard balloon angioplasty on angiographically detected restenosis and clinical outcomes. Methods. We randomly assigned 410 patients with symptomatic coronary disease to elective placement of a Palmaz-Schatz stent or to standard balloon angioplasty. Coronary angiography was performed at base line, immediately after the procedure, and six months later. Results. The patients who underwent stenting had a higher rate of procedural success than those who underwent standard balloon angioplasty (96.1 percent vs. 89.6 percent, P = 0.011), a larger immediate increase in the diameter of the lumen (1.72+/-0.46 vs. 1.23+/-0.48 mm, P<0.001), and a larger luminal diameter immediately after the procedure (2.49+/-0.43 vs. 1.99+/-0.47 mm, P<0.001). At six months, the patients with stented lesions continued to have a larger luminal diameter (1.74+/-0.60 vs. 1.56+/-0.65 mm, P = 0.007) and a lower rate of restenosis (31.6 percent vs. 42.1 percent, P = 0.046) than those treated with balloon angioplasty. There were no coronary events (death; myocardial infarction; coronary-artery bypass surgery; vessel closure, including stent thrombosis; or repeated angioplasty) in 80.5 percent of the patients in the stent group and 76.2 percent of those in the angioplasty group (P = 0.16). Revascularization of the original target lesion because of recurrent myocardial ischemia was performed less frequently in the stent group than in the angioplasty group (10.2 percent vs. 15.4 percent, P = 0.06). Conclusions. Inselected patients, placement of an intracoronary stent, as compared with balloon angioplasty, results in an improved rate of procedural success, a lower rate of angiographically detected restenosis, a similar rate of clinical events after six months, and a less frequent need for revascularization of the original coronary lesion.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DIV CARDIOL, PHILADELPHIA, PA 19107 USA; WASHINGTON CARDIOL CTR, WASHINGTON, DC USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; SCRIPPS RES INST, LA JOLLA, CA USA; VICTORIA GEN HOSP, HALIFAX B3H 2Y9, NS, CANADA; UNIV PITTSBURGH, PITTSBURGH, PA USA; VANCOUVER GEN HOSP, VANCOUVER, BC, CANADA; KOKURA MEM HOSP, KYUSHU, JAPAN; YALE UNIV, NEW HAVEN, CT USA; ARIZONA HEART INST, PHOENIX, AZ USA; TORONTO GEN HOSP, TORONTO, ON, CANADA; ST LUKES HOSP, HOUSTON, TX USA; CTR CUORE COLUMBUS, MILAN, ITALY; JOHNS HOPKINS UNIV HOSP, BALTIMORE, MD USA; LENOX HILL HOSP, NEW YORK, NY 10021 USA; HOSP UNIV PENN, PHILADELPHIA, PA 19104 USA; UNIV TEXAS SAN ANTONIO, SAN ANTONIO, TX USA; CLEVELAND CLIN FDN, CLEVELAND, OH USA	Jefferson University; Harvard University; Beth Israel Deaconess Medical Center; Scripps Research Institute; Dalhousie University; University of Victoria; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of British Columbia; Kokura Memorial Hospital; Yale University; Arizona Heart Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Johns Hopkins University; Johns Hopkins Medicine; Northwell Health; University of Pennsylvania; Pennsylvania Medicine; University of Texas System; University of Texas at San Antonio (UTSA); Cleveland Clinic Foundation								ADELMAN AG, 1993, NEW ENGL J MED, V329, P228, DOI 10.1056/NEJM199307223290402; BITTL JA, 1992, AM J CARDIOL, V70, P1533, DOI 10.1016/0002-9149(92)90453-6; CORCOS T, 1985, AM HEART J, V109, P926, DOI 10.1016/0002-8703(85)90231-5; DEHMER GJ, 1988, NEW ENGL J MED, V319, P733, DOI 10.1056/NEJM198809223191201; ELLIS SG, 1989, AM HEART J, V117, P777, DOI 10.1016/0002-8703(89)90612-1; ELLIS SG, 1992, CIRCULATION, V86, P1836, DOI 10.1161/01.CIR.86.6.1836; FISCHMAN DL, 1991, J AM COLL CARDIOL, V18, P1445, DOI 10.1016/0735-1097(91)90673-W; FISCHMAN DL, 1993, DEV CARDIOVASC MED, V137, P553; GRUENTZIG AR, 1987, NEW ENGL J MED, V316, P1127, DOI 10.1056/NEJM198704303161805; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; MANCINI GBJ, 1987, CIRCULATION, V75, P452, DOI 10.1161/01.CIR.75.2.452; MANCINI GBJ, 1987, CIRCULATION, V75, P1199; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; PEPINE CJ, 1990, CIRCULATION, V81, P1753, DOI 10.1161/01.CIR.81.6.1753; REIS GJ, 1989, LANCET, V2, P177; SAFIAN RD, 1993, CIRCULATION, V88, P961, DOI 10.1161/01.CIR.88.3.961; SAVAGE M, IN PRESS J AM COLL C; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; THORNTON MA, 1984, CIRCULATION, V69, P721, DOI 10.1161/01.CIR.69.4.721; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; WALLER BF, 1989, J AM COLL CARDIOL, V13, P969, DOI 10.1016/0735-1097(89)90248-9; WHITWORTH HB, 1986, J AM COLL CARDIOL, V8, P1271, DOI 10.1016/S0735-1097(86)80296-0	26	3433	3634	0	173	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					496	501		10.1056/NEJM199408253310802	http://dx.doi.org/10.1056/NEJM199408253310802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD072	8041414	Bronze			2022-12-28	WOS:A1994PD07200002
J	COUCKE, P; VANCAMP, G; DJOYODIHARJO, B; SMITH, SD; FRANTS, RR; PADBERG, GW; DARBY, JK; HUIZING, EH; CREMERS, CWRJ; KIMBERLING, WJ; OOSTRA, BA; VANDEHEYNING, PH; WILLEMS, PJ				COUCKE, P; VANCAMP, G; DJOYODIHARJO, B; SMITH, SD; FRANTS, RR; PADBERG, GW; DARBY, JK; HUIZING, EH; CREMERS, CWRJ; KIMBERLING, WJ; OOSTRA, BA; VANDEHEYNING, PH; WILLEMS, PJ			LINKAGE OF AUTOSOMAL-DOMINANT HEARING-LOSS TO THE SHORT ARM OF CHROMOSOME-1 IN 2 FAMILIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYNDROME TYPE-I; WAARDENBURG SYNDROME; MOLECULAR-CLONING; COLLAGEN GENE; HUMAN GENOME; DEAFNESS; IMPAIRMENT; LOCALIZATION; ALPHA-1(XVI); MUTATIONS	Background. At least half of the cases of profound deafness of early onset are caused by genetic factors, but few of the genetic defects have been identified. This is particularly true of the most common hereditary forms of deafness, which occur in the absence of any associated syndrome. Methods. We studied a large Indonesian family in which hearing loss was inherited in an autosomal dominant pattern. The hearing loss first affects the high frequencies during the teens or 20s and becomes profound within 10 years. To locate the responsible gene, we performed genetic-linkage analysis, using microsatellite markers distributed over the entire genome. We then performed linkage analyses in an American family and a Dutch family with similar patterns of hereditary hearing loss. Results. In the extended Indonesian family, a gene linked to deafness mapped to chromosome Ip, with a multipoint rod score of more than 7. In the American family, deafness was linked to the same locus on chromosome 1p, with a multipoint rod score of more than 5. In the Dutch family, however, this locus was ruled out. The flanking markers D1S255 and D1S211 defined a region of 6 cM on chromosome 1p that is likely to contain the gene associated with deafness in the first two families. Conclusions. In some families with early-onset autosomal dominant hearing loss, the responsible gene is on chromosome 1p.	UNIV ANTWERP, DEPT MED GENET, B-2610 ANTWERP, BELGIUM; UNIV ANTWERP, DEPT OTORHINOLARYNGOL, B-2020 ANTWERP, BELGIUM; PADJADJARAN STATE UNIV, SCH MED, DEPT EAR NOSE & THROAT, BANDUNG, INDONESIA; BOYS TOWN NATL RES HOSP, CTR HEREDITARY COMMUN DISORDERS, BOYS TOWN, NE USA; LEIDEN UNIV, CTR GENET MED, DEPT HUMAN GENET, LEIDEN, NETHERLANDS; ACAD HOSP NIJMEGEN, DEPT NEUROL, NIJMEGEN, NETHERLANDS; ACAD HOSP NIJMEGEN, DEPT EAR NOSE & THROAT, NIJMEGEN, NETHERLANDS; ACAD HOSP UTRECHT, DEPT EAR NOSE & THROAT, UTRECHT, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT CLIN GENET, 3000 DR ROTTERDAM, NETHERLANDS	University of Antwerp; University of Antwerp; Universitas Padjadjaran; Boys Town National Research Hospital; Leiden University; Leiden University - Excl LUMC; Radboud University Nijmegen; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam			Van Camp, Guy/F-3386-2013; Cremers, C.W.R.J./L-4254-2015; Padberg, G.W.A.M./H-8079-2014	Van Camp, Guy/0000-0001-5105-9000; 	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P60DC000982] Funding Source: NIH RePORTER; NIDCD NIH HHS [P60-DC-00982] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BACH I, 1992, AM J HUM GENET, V51, P38; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; CUTICCHIA AJ, 1993, NUCLEIC ACIDS RES, V21, P3003, DOI 10.1093/nar/21.13.3003; FREIMER NB, 1993, AM J HUM GENET, V52, P1102; GUILFORD P, 1994, NAT GENET, V6, P24, DOI 10.1038/ng0194-24; HAGEMAN MJ, 1977, AM J HUM GENET, V29, P468; HUGHES AE, 1993, GENOMICS, V15, P433, DOI 10.1006/geno.1993.1083; Huizing E H, 1966, Acta Otolaryngol, V61, P161, DOI 10.3109/00016486609127053; Huizing E H, 1966, Acta Otolaryngol, V61, P35, DOI 10.3109/00016486609127040; HUIZING EH, 1983, ACTA OTO-LARYNGOL, V95, P620, DOI 10.3109/00016488309139453; HULL R, 1978, HDB CLIN AUDIOLOGY, P426; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; KIMBERLING WJ, 1990, GENOMICS, V7, P245, DOI 10.1016/0888-7543(90)90546-7; KNOWLES JA, 1992, AM J HUM GENET, V51, P905; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LEON PE, 1981, AM J HUM GENET, V33, P209; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; LEWIS RA, 1990, GENOMICS, V7, P250, DOI 10.1016/0888-7543(90)90547-8; MARAZITA ML, 1993, AM J MED GENET, V46, P486, DOI 10.1002/ajmg.1320460504; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; OTT J, 1992, AM J HUM GENET, V51, P283; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PERALA M, 1993, FEBS LETT, V319, P177, DOI 10.1016/0014-5793(93)80062-Y; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; REARDON W, 1992, J MED GENET, V29, P521, DOI 10.1136/jmg.29.8.521; ROBINSON D, 1992, HUM GENET, V90, P316; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; VANDENWIJNGAART WSIM, 1985, AUDIOLOGY, V24, P336; VANDENWIJNGAART WSIM, 1985, AUDIOLOGY, V24, P233; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YAMAGUCHI N, 1992, J BIOCHEM-TOKYO, V112, P856, DOI 10.1093/oxfordjournals.jbchem.a123989	35	106	108	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					425	431		10.1056/NEJM199408183310702	http://dx.doi.org/10.1056/NEJM199408183310702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	8035838	Bronze, Green Published			2022-12-28	WOS:A1994PB50100002
J	OCONNOR, PG; SELWYN, PA; SCHOTTENFELD, RS				OCONNOR, PG; SELWYN, PA; SCHOTTENFELD, RS			MEDICAL-CARE FOR INJECTION-DRUG USERS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NEW-YORK-CITY; METHADONE-MAINTENANCE PROGRAM; SEXUALLY-TRANSMITTED DISEASES; HEPATITIS-C VIRUS; UNITED-STATES; HIV-INFECTION; CONTROLLED TRIAL; SUBSTANCE-ABUSE; HTLV-I; AIDS		YALE UNIV, SCH MED, DEPT PSYCHIAT, NEW HAVEN, CT 06520 USA	Yale University	OCONNOR, PG (corresponding author), YALE UNIV, SCH MED, CTR PRIMARY CARE, DEPT MED, BOX 208025, NEW HAVEN, CT 06520 USA.							[Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1987, JAMA-J AM MED ASSOC, V257, P3110; Ball J.C., 2012, EFFECTIVENESS METHAD; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BATKI SL, 1988, HOSP COMMUNITY PSYCH, V39, P439; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P1; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BRAUN MM, 1990, ARCH INTERN MED, V150, P1913, DOI 10.1001/archinte.150.9.1913; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; CAIFFA WT, 1993, 9TH INT C AIDS 4TH S, P705; CHANG G, 1992, J SUBST ABUSE TREAT, V9, P327, DOI 10.1016/0740-5472(92)90026-K; CHERUBIN CE, 1993, ANN INTERN MED, V119, P1017, DOI 10.7326/0003-4819-119-10-199311150-00009; CHIRGWIN K, 1991, AM J PUBLIC HEALTH, V81, P1576, DOI 10.2105/AJPH.81.12.1576; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DONAHUE JG, 1991, AM J EPIDEMIOL, V134, P1206, DOI 10.1093/oxfordjournals.aje.a116023; ESTEBAN JI, 1989, LANCET, V2, P294; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; FEINGOLD AR, 1990, J ACQ IMMUN DEF SYND, V3, P896; FRAM DH, 1989, J SUBST ABUSE TREAT, V6, P119, DOI 10.1016/0740-5472(89)90039-1; GACHUPINGARCIA A, 1992, AIDS, V6, P843, DOI 10.1097/00002030-199208000-00013; GARCIALEONI ME, 1992, ARCH INTERN MED, V152, P1808, DOI 10.1001/archinte.152.9.1808; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; GERSTEIN DR, 1990, NEW ENGL J MED, V323, P844, DOI 10.1056/NEJM199009203231230; GOUREVITCH MN, 1993, ANN INTERN MED, V118, P350, DOI 10.7326/0003-4819-118-5-199303010-00005; GROVES JE, 1978, NEW ENGL J MED, V298, P883, DOI 10.1056/NEJM197804202981605; HIGGINS ST, 1991, AM J PSYCHIAT, V148, P1218; HOFFMAN CK, 1989, RADIOLOGY, V172, P463, DOI 10.1148/radiology.172.2.2748827; HOUSSET C, 1992, HEPATOLOGY, V15, P578, DOI 10.1002/hep.1840150404; Jaffe J.H., 1990, PHARMACOL BASIS THER, P522; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; KISSNER DG, 1987, AM REV RESPIR DIS, V136, P1250, DOI 10.1164/ajrccm/136.5.1250; Kosten TR, 1992, CLIN GUIDE COCAINE A, P273; KREEK MJ, 1976, NEW ENGL J MED, V294, P1104, DOI 10.1056/NEJM197605132942008; KREEK MJ, 1983, DHHS ADM831281 PUBL, P456; LANDONIO G, 1990, AIDS, V4, P29, DOI 10.1097/00002030-199001000-00004; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LEVINE SR, 1990, NEW ENGL J MED, V323, P699, DOI 10.1056/NEJM199009133231102; LEWIS DC, 1987, JAMA-J AM MED ASSOC, V257, P2945, DOI 10.1001/jama.257.21.2945; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; MIENTJES GH, 1992, AIDS, V6, P207, DOI 10.1097/00002030-199202000-00012; MIENTJES GH, 1992, AIDS, V6, pU525; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; MONFARDINI S, 1989, AIDS, V3, P449, DOI 10.1097/00002030-198907000-00008; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; NEWELL ML, 1992, LANCET, V339, P1007; NOVICK DM, 1984, SOUTHERN MED J, V77, P302, DOI 10.1097/00007611-198403000-00008; NOVICK DM, 1988, J INFECT DIS, V158, P795, DOI 10.1093/infdis/158.4.795; OCONNOR PG, 1992, AM J MED, V93, P382, DOI 10.1016/0002-9343(92)90166-9; OCONNOR PG, 1993, J GEN INTERN MED, V8, P266, DOI 10.1007/BF02600095; OCONNOR PG, 1992, J GEN INTERN MED, V7, P532, DOI 10.1007/BF02599459; OCONNOR PG, 1992, CLIN GUIDE COCAINE A, P241; PAGE JB, 1990, LANCET, V335, P1439, DOI 10.1016/0140-6736(90)91456-K; PENNEYS NS, 1989, SKIN MANIFESTATIONS; Prochaska J. O., 1986, TREATING ADDICTIVE B, P3, DOI DOI 10.1007/978-1-4613-2191-0_; RAO TKS, 1987, NEW ENGL J MED, V316, P1062, DOI 10.1056/NEJM198704233161705; REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337; ROUNSAVILLE BJ, 1991, ARCH GEN PSYCHIAT, V48, P43; ROUNSAVILLE BJ, 1982, ARCH GEN PSYCHIAT, V39, P161; ROUNSAVILLE BJ, 1992, SUBSTANCE ABUSE COMP, P496; RUBIN AM, 1987, HOSP PRACT, V22, P279, DOI 10.1080/21548331.1987.11707703; SAMET JH, 1992, AM J MED, V92, P495, DOI 10.1016/0002-9343(92)90746-X; SAPIRA JD, 1968, AM J MED, V45, P555, DOI 10.1016/0002-9343(68)90172-1; SAWYER RC, 1993, 9TH INT C AIDS 4TH S, P501; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SCHOTTENFELD RS, 1993, J SUBST ABUSE TREAT, V10, P5, DOI 10.1016/0740-5472(93)90092-G; SCHWARTZ EL, 1990, 6TH INT C AIDS SAN F, V3, P194; SEAGE GR, 1993, J ACQ IMMUN DEF SYND, V6, P831; SELWYN PA, 1990, AIDS, V4, P822, DOI 10.1097/00002030-199008000-00022; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P1289, DOI 10.1001/jama.261.9.1289; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1993, PUBLIC HEALTH REP, V108, P492; SELWYN PA, 1993, NEW ENGL J MED, V328, P671; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; SILVERMAN DC, 1993, AM J PSYCHIAT, V150, P705; SLOAND EM, 1992, EUR J HAEMATOL, V48, P168; SMITH AM, 1992, INT J ADDICT, V27, P435, DOI 10.3109/10826089209068752; STALL R, 1986, HEALTH EDUC QUART, V13, P359, DOI 10.1177/109019818601300407; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; STIMMEL B, 1975, JAMA-J AM MED ASSOC, V234, P1135, DOI 10.1001/jama.234.11.1135; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; STRYKER J, 1993, DIMENSIONS HIV PREVE; TONG TG, 1981, ANN INTERN MED, V94, P349, DOI 10.7326/0003-4819-94-3-349; WALSH DC, 1991, NEW ENGL J MED, V325, P775, DOI 10.1056/NEJM199109123251105; WILLIAMS AE, 1988, SCIENCE, V240, P643, DOI 10.1126/science.2896386; WILLIAMS AE, 1989, SCIENCE, V244, P757; WILLOCKS L, 1992, J INFECTION, V24, P37, DOI 10.1016/0163-4453(92)90898-G; 1991, MMWR-MORBID MORTAL W, V40, P27; 1991, MMWR-MORBID MORTAL W, V40, P485; 1993, PRESIDENTS HLTH SECU; 1990, EFFECTIVENESS DRUG A; 1989, FED REGISTER, V54, P8954; 1991, POLICY REPORT PHYSIC; 1994, MMWR-MORBID MORTAL W, V43, P285; 1991, TWIN EPIDEMICS SUBST; 1993, HIV AIDS SURVEIL OCT, P1	102	134	135	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					450	459		10.1056/NEJM199408183310707	http://dx.doi.org/10.1056/NEJM199408183310707			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	8035842				2022-12-28	WOS:A1994PB50100007
J	KEARNEY, RA; EISEN, HJ; WOLF, JE				KEARNEY, RA; EISEN, HJ; WOLF, JE			NONVALVULAR INFECTIONS OF THE CARDIOVASCULAR-SYSTEM	ANNALS OF INTERNAL MEDICINE			English	Review							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; ABDOMINAL AORTIC-ANEURYSM; VASCULAR GRAFT INFECTION; ANTIBIOTIC-PROPHYLAXIS; ENDOCARDIAL PACEMAKER; MYCOTIC-ANEURYSM; ATRIAL-MYXOMA; BACTERIAL-ENDOCARDITIS; LEUKOCYTE SCINTIGRAPHY; SUSTAINED BACTEREMIA	Purpose: To review the risk factors, clinical presentation, diagnosis, and treatment of nonvalvular infections of the cardiovascular system. Data Sources: A MEDLINE search of English-language articles from 1966 to 1993 relating to myocardial abscesses, mural endocarditis, infective endarteritis and mycotic aneurysms, infection of pacemakers and implantable defibrillators, prosthetic vascular graft infections, and infected atrial myxomas; manual review of article bibliographies. Study Selection and Data Extraction: Case series and single reports, prospective and retrospective clinical studies, autopsy studies, and reviews were selected if they contained sufficient information about the prevalence, clinical manifestations, microbiologic features, management, and outcome of nonvalvular cardiovascular infections. Results: Nonvalvular infections of the cardiovascular system most commonly occur on previously damaged endocardium or vascular intima and are usually associated with intravascular devices such as graft material or pacemakers. Rarely, they can involve primary cardiac tumors such as myxomas. Most patients affected are beyond the fifth decade of life. Risk factors include cardiovascular disease, diabetes mellitus, and malignancy. The sexes are affected equally. The clinical presentations of nonvalvular endovascular infections are subtle and diagnoses are difficult to make, often requiring not only a high index of suspicion but also the use of sophisticated radiologic techniques. Hence, for many of these infections, the diagnosis is made late in the course of the infection, and survival rates are poor. Complications include peripheral embolization, cardiac rupture, vascular aneurysm rupture, and pericarditis. Therapy frequently involves surgical intervention in addition to the use of antibiotics. Conclusions: Although uncommon, nonvalvular infections of the cardiovascular system will increase in frequency as the use of implantable devices and prosthetic materials increases in the elderly. Studies are needed to determine the most appropriate diagnostic methods, treatment regimens, and methods for prevention of these infections.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT MED, DIV INFECT DIS, PHILADELPHIA, PA 19107 USA; HOSP UNIV PENN, PHILADELPHIA, PA 19104 USA	Jefferson University; University of Pennsylvania; Pennsylvania Medicine								AACH R, 1972, AM J MED, V53, P233; AKINS EW, 1991, AM J ROENTGENOL, V156, P1155, DOI 10.2214/ajr.156.6.2028858; ALMASSI GH, 1988, J THORAC CARDIOV SUR, V95, P908; AMIN M, 1991, PACE, V14, P152, DOI 10.1111/j.1540-8159.1991.tb05083.x; AUFFERMANN W, 1989, RADIOLOGY, V172, P359, DOI 10.1148/radiology.172.2.2748815; BANDYK DF, 1992, INFECT DIS CLIN N AM, V6, P719; BEELER BA, 1982, HEART LUNG, V11, P152; BENHAIM S, 1992, J NUCL MED, V33, P1486; BENNETT DE, 1967, AM J SURG, V113, P321, DOI 10.1016/0002-9610(67)90273-5; BLUHM G, 1985, ACTA MED SCAND, P1; BLUHM G, 1982, SCAND J THORAC CARD, V16, P65, DOI 10.3109/14017438209100612; BLUHM G, 1984, SCAND J THORAC CARD, V18, P227, DOI 10.3109/14017438409109896; BLUHM G, 1986, PACE, V9, P720, DOI 10.1111/j.1540-8159.1986.tb05421.x; BORBOLA J, 1988, ARCH INTERN MED, V148, P70, DOI 10.1001/archinte.148.1.70; BOUGH EW, 1987, AM HEART J, V113, P1031, DOI 10.1016/0002-8703(87)90071-8; BRYAN CS, 1978, J THORAC CARDIOV SUR, V75, P758; BUCHBINDER NA, 1972, ARCH PATHOL, V93, P435; BUNT TJ, 1983, SURGERY, V93, P733; CAMUS C, 1993, CLIN INFECT DIS, V17, P46, DOI 10.1093/clinids/17.1.46; CATHERWOOD E, 1980, AM J MED, V68, P782, DOI 10.1016/0002-9343(80)90271-5; COHEN TJ, 1991, PACE, V14, P146, DOI 10.1111/j.1540-8159.1991.tb05081.x; CORMAN LC, 1975, JAMA-J AM MED ASSOC, V233, P264, DOI 10.1001/jama.233.3.264; Crislip M A, 1989, Infect Dis Clin North Am, V3, P103; CROFT CH, 1983, AM J CARDIOL, V51, P1650, DOI 10.1016/0002-9149(83)90203-5; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DANIEL WG, 1991, NEW ENGL J MED, V324, P795, DOI 10.1056/NEJM199103213241203; DAVIES OG, 1978, AM J SURG, V136, P96, DOI 10.1016/0002-9610(78)90207-6; DICK H J, 1956, N Y State J Med, V56, P856; DINUBILE MJ, 1986, AM J CARDIOL, V58, P1213, DOI 10.1016/0002-9149(86)90384-X; EICHHORN EJ, 1981, JAMA-J AM MED ASSOC, V246, P2724; ELSHERIF N, 1991, CARDIAC PAICNG ELECT, P750; ESTEBAN A, 1983, CHEST, V84, P104, DOI 10.1378/chest.84.1.104; EWART JM, 1983, AM SURGEON, V49, P37; FINSETH F, 1974, ANN SURG, V179, P8, DOI 10.1097/00000658-197401000-00002; FRANDSEN TM, 1985, AM HEART J, V110, P180, DOI 10.1016/0002-8703(85)90537-X; FREISCHLAG JA, 1989, VASCULAR SURG, V1, P510; Furman R W, 1972, Ann Thorac Surg, V14, P54; Golan J F, 1989, Infect Dis Clin North Am, V3, P247; GOLDSTONE J, 1974, AM J SURG, V128, P225; GOMES MN, 1992, J CARDIOVASC SURG, V33, P684; GOMES MN, 1992, ANN SURG, V215, P435, DOI 10.1097/00000658-199205000-00005; GOODMAN LR, 1989, RADIOLOGY, V170, P447, DOI 10.1148/radiology.170.2.2911667; GOPALAKRISHNA KV, 1977, AM J MED SCI, V274, P329, DOI 10.1097/00000441-197711000-00013; GORODEZKY M, 1974, CHEST, V66, P214, DOI 10.1378/chest.66.2.214; GRAHAM HV, 1976, AM J CARDIOL, V38, P658, DOI 10.1016/S0002-9149(76)80017-3; GRANTHAM RN, 1983, AM J SURG, V146, P811, DOI 10.1016/0002-9610(83)90348-3; Gray L D, 1988, Infect Dis Clin North Am, V2, P779; GUNERATNE F, 1975, NEW YORK STATE J MED, V75, P1766; HARJULA A, 1985, THORAC CARDIOV SURG, V33, P218, DOI 10.1055/s-2007-1014123; HARSHAI Y, 1990, BRIT J PLAST SURG, V43, P307, DOI 10.1016/0007-1226(90)90077-D; HERZOG CA, 1988, AM HEART J, V115, P684, DOI 10.1016/0002-8703(88)90823-X; HONGBARCO P, 1988, ANN THORAC SURG, V46, P97, DOI 10.1016/S0003-4975(10)65863-8; HURST LN, 1986, PACE, V9, P785, DOI 10.1111/j.1540-8159.1986.tb06628.x; IHDE DC, 1978, CANCER, V41, P2364, DOI 10.1002/1097-0142(197806)41:6<2364::AID-CNCR2820410640>3.0.CO;2-W; JADIMAR HA, 1988, EUR HEART J, V9, P110; JAFFE RB, 1975, RADIOLOGY, V116, P291, DOI 10.1148/116.2.291; JARRETT F, 1975, ARCH SURG-CHICAGO, V110, P1281; JOHANSEN K, 1983, ARCH SURG-CHICAGO, V118, P583; JOHNSON JR, 1983, ARCH SURG-CHICAGO, V118, P577; JUSTICH E, 1985, RADIOLOGY, V154, P133, DOI 10.1148/radiology.154.1.3964932; KAEBNICK HW, 1987, SURGERY, V102, P756; KAISER AB, 1978, ANN SURG, V188, P283, DOI 10.1097/00000658-197809000-00003; KARCHMER A, 1992, INFECT DIS, P1374; KARCHMER AW, 1989, INFECTIONS ASS INDWE, P129; KELLY PA, 1988, PACE, V11, P1220, DOI 10.1111/j.1540-8159.1988.tb03975.x; KIM HS, 1978, AM J CLIN PATHOL, V70, P18; KORTLEVE JW, 1980, AM J MED, V68, P395, DOI 10.1016/0002-9343(80)90110-2; KRAMER L, 1985, PACE, V8, P225, DOI 10.1111/j.1540-8159.1985.tb05753.x; KWAAN JHM, 1981, ARCH SURG-CHICAGO, V116, P716; LAMURAGLIA GM, 1989, J VASC SURG, V10, P20, DOI 10.1067/mva.1989.vs0100020; LANG DM, 1988, WESTERN J MED, V149, P334; LAWRENCE PF, 1985, J VASC SURG, V2, P165, DOI 10.1067/mva.1985.avs0020165; LEWIS AB, 1985, J THORAC CARDIOV SUR, V89, P758; LIEKWEG WG, 1977, SURGERY, V81, P335; LORENTZEN JE, 1985, SURGERY, V98, P81; LOW RN, 1990, RADIOLOGY, V175, P157, DOI 10.1148/radiology.175.1.2315475; LOWRY FD, 1983, ANN INTERN MED, V99, P834; MACBETH GA, 1984, J VASC SURG, V1, P750, DOI 10.1067/mva.1984.avs0010750; MAKI DG, 1986, HOSPITAL INFECTIONS, P561; MALONE JM, 1975, SURGERY, V78, P211; MARRIE TJ, 1982, CIRCULATION, V66, P1339, DOI 10.1161/01.CIR.66.6.1339; MCALLISTER H, 1978, ATLAS TUMOR PATHOL, P15; MERZ WG, 1991, MANUAL CLIN MICROBIO, P588; MILDVAN D, 1977, AM J MED SCI, V274, P311, DOI 10.1097/00000441-197711000-00010; MILLS P, 1978, PROG CARDIOVASC DIS, V20, P337, DOI 10.1016/0033-0620(78)90002-6; MORGAN G, 1979, AM J CARDIOL, V44, P221, DOI 10.1016/0002-9149(79)90308-4; MORIARTY JA, 1992, J COMPUT ASSIST TOMO, V16, P941, DOI 10.1097/00004728-199211000-00021; MUNDTH ED, 1969, AM J SURG, V117, P460, DOI 10.1016/0002-9610(69)90004-X; OHARA PJ, 1984, J VASC SURG, V1, P429, DOI 10.1067/mva.1984.avs0010429; OLOFSSON PA, 1988, J VASC SURG, V8, P99, DOI 10.1067/mva.1988.avs0080099; Osler W, 1885, Br Med J, V1, P577; PALANK EA, 1979, AM J CARDIOL, V43, P1238, DOI 10.1016/0002-9149(79)90159-0; PARKER JC, 1980, AM J CLIN PATHOL, V73, P356; PARKHURST GF, 1955, AM J PATHOL, V31, P821; PERSAUD V, 1970, AM J CLIN PATHOL, V53, P832; PLOTKIN GR, 1981, AM J MED SCI, V281, P35, DOI 10.1097/00000441-198101000-00006; POPOVSKY J, 1980, ARCH SURG-CHICAGO, V115, P203; RAAD II, 1992, CLIN INFECT DIS, V15, P197, DOI 10.1093/clinids/15.2.197; RAJPAL RS, 1979, ARCH INTERN MED, V139, P1176, DOI 10.1001/archinte.139.10.1176; REICHLE F A, 1970, Annals of Surgery, V171, P219, DOI 10.1097/00000658-197002000-00009; Reilly D T, 1989, Eur J Vasc Surg, V3, P393, DOI 10.1016/S0950-821X(89)80044-1; RIVERA JV, 1985, CLIN NUCL MED, V10, P814, DOI 10.1097/00003072-198511000-00016; ROGERS EW, 1978, AM J MED, V64, P683, DOI 10.1016/0002-9343(78)90591-0; RUTHERFORD EJ, 1989, J VASC SURG, V10, P193, DOI 10.1067/mva.1989.0100193; RYON DS, 1966, AM J MED SCI, V251, P698, DOI 10.1097/00000441-196606000-00011; SANSON J, 1963, AM HEART J, V66, P301, DOI 10.1016/0002-8703(63)90260-6; SCHNEIDER JA, 1979, ANN THORAC SURG, V27, P185, DOI 10.1016/S0003-4975(10)63267-5; SCHWEIGER MJ, 1980, AM HEART J, V99, P630, DOI 10.1016/0002-8703(80)90738-3; SEABOLD JE, 1983, CLIN NUCL MED, V8, P486, DOI 10.1097/00003072-198310000-00007; SEDWITZ MM, 1987, J VASC SURG, V6, P476, DOI 10.1067/mva.1987.avs0060476; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1368, DOI 10.1056/NEJM198405243102107; Shepard R B, 1971, Am Surg, V37, P691; SMYTH EG, 1989, J ROY SOC MED, V82, P396, DOI 10.1177/014107688908200709; SPRATT KA, 1993, CLIN INFECT DIS, V17, P679; Stengel A, 1923, ARCH INTERN MED, V31, P527, DOI 10.1001/archinte.1923.00110160074005; TAYLOR RL, 1990, PACE, V13, P1352, DOI 10.1111/j.1540-8159.1990.tb04005.x; TYLMAN TA, 1985, SOUTHERN MED J, V78, P1140, DOI 10.1097/00007611-198509000-00028; VOGELZANG RL, 1988, J COMPUT ASSIST TOMO, V12, P109, DOI 10.1097/00004728-198801000-00021; WALSH TJ, 1979, AM J CLIN PATHOL, V71, P640; WILSON SE, 1978, ARCH SURG-CHICAGO, V113, P1163; WINEK RR, 1988, AM J CARDIOVASC PATH, V1, P255; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0; WUNDERLY D, 1990, PACE, V13, P1360, DOI 10.1111/j.1540-8159.1990.tb04007.x; YENER A, 1990, J CARDIOVASC SURG, V31, P587; ZELLER NH, 1975, ARCH INTERN MED, V135, P580, DOI 10.1001/archinte.135.4.580; 1970, NEW ENGL J MED, V28, P1477	126	84	87	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					219	230		10.7326/0003-4819-121-3-199408010-00010	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017749				2022-12-28	WOS:A1994NY33800010
J	EDDY, DM				EDDY, DM			A CONVERSATION WITH MY MOTHER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1669, DOI 10.1001/jama.267.12.1669; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1674; HUMPHRY D, 1991, FINAL EXIT	3	49	51	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					179	181		10.1001/jama.272.3.179	http://dx.doi.org/10.1001/jama.272.3.179			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022025				2022-12-28	WOS:A1994NW18500001
J	AUVINEN, A; HAKAMA, M; ARVELA, H; HAKULINEN, T; RAHOLA, T; SUOMELA, M; SODERMAN, B; RYTOMAA, T				AUVINEN, A; HAKAMA, M; ARVELA, H; HAKULINEN, T; RAHOLA, T; SUOMELA, M; SODERMAN, B; RYTOMAA, T			FALLOUT FROM CHERNOBYL AND INCIDENCE OF CHILDHOOD LEUKEMIA IN FINLAND, 1976-92	BRITISH MEDICAL JOURNAL			English	Article							CANCER	Objective-To assess effects of fallout from Chernobyl on incidence of childhood leukaemia in Finland. Design-Nationwide cohort study. External exposure measured for 455 Finnish municipalities with instruments driven 19000 km throughout the country. Values specific to municipalities corrected for shielding due to houses and fallout from A bomb testing. Internal exposure estimated from whole body measurements on a random sample of 81 children. Mean effective dose for two years after incident calculated from these measurements. Data on childhood leukaemia obtained from Finnish cancer registry and verified through hospitals treating childhood cancers. Setting-Finland, one of the countries most heavily contaminated by the Chernobyl accident; the population was divided into fifths by exposure. Subjects-Children aged 0-14 years in 1976-92. Main outcome measures-Standardised incidence ratio of childhood leukaemia and relative excess risk of childhood leukaemia per mSv. From incidence data of Finnish cancer registry for 1976-85, expected numbers specific to sex and age group (0-4, 5-9, and 10-14 years) were calculated for each municipality for three periods (1976-85, 1986-8, and 1989-92) and pooled as exposure fifths. Dose response was estimated as regression slope of standardised incidence ratios on mean doses for fifths for each period. Results-Population weighted mean effective doses for first two years after the accident were 410 mu Sv for the whole country and 970 mu Sv for the population fifth with the highest dose. In all Finland the incidence of childhood leukaemia did not increase 1976-92. The relative excess risk 1989-92 was not significantly different from zero (7% per mSv; 95% confidence interval -27% to 41%). Conclusions-An important increase in childhood leukaemia can be excluded. Any effect is smaller than eight extra cases per million children per year in Finland. The results are consistent with the magnitude of effect expected.	FINNISH CTR RADIAT & NUCL SAFETY,SF-00101 HELSINKI,FINLAND; UNIV TAMPERE,DEPT PUBL HLTH,SF-33101 TAMPERE,FINLAND; KAROLINSKA INST,CANC EPIDEMIOL UNIT,S-10401 STOCKHOLM,SWEDEN	Radiation & Nuclear Safety Authority (STUK); Tampere University; Karolinska Institutet	AUVINEN, A (corresponding author), FINNISH CANC REGISTRY,LIISANKATU 21B,SF-00170 HELSINKI,FINLAND.		Auvinen, Anssi/AAD-9311-2020; Auvinen, Anssi/AAL-2111-2020	Auvinen, Anssi/0000-0003-1125-4818				[Anonymous], 1988, SOURCES EFFECTS RISK; ARVELA H, 1990, RADIAT PROT DOSIM, V32, P177, DOI 10.1093/oxfordjournals.rpd.a080734; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Finck R., 1991, CHERNOBYL FALLOUT SW, P489; IVANOV EP, 1993, NATURE, V365, P702, DOI 10.1038/365702a0; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; MJONES L, 1986, SSI8622 SWED RAD PRO; PARKIN M, 1992, EUR J CANCER A, V29, P87; RAHOLA T, 1991, STUKA91 FINN CTR RAD; RAHOLA T, 1990, STUKA81 FINN CTR RAD; SAXEN E, 1978, FINNISH CANCER REGIS; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; 1991, BUILDINGS DWELLINGS; 1990, EUR12551 COMM EUR CO; 1992, CANCER SOC FINLAND P, V51	15	51	51	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					151	154		10.1136/bmj.309.6948.151	http://dx.doi.org/10.1136/bmj.309.6948.151			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044092	Green Published			2022-12-28	WOS:A1994NY22900017
J	CHO, YJ; GORINA, S; JEFFREY, PD; PAVLETICH, NP				CHO, YJ; GORINA, S; JEFFREY, PD; PAVLETICH, NP			CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS	SCIENCE			English	Article							WILD-TYPE P53; CELL-CYCLE CHECKPOINT; MUTANT P53; GENE AMPLIFICATION; BINDING DOMAIN; PROTEIN; CONFORMATION; RESOLUTION; CANCER; RECOGNITION	Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.			CHO, YJ (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.			Jeffrey, Philip/0000-0002-4351-5341	NCI NIH HHS [NCI CA08748-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, ONCOGENE, V5, P893; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR V2 1 MANUAL; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P1739; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN M, IN PRESS NUCLEIC ACI; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1992, NATURE, V358, P83; ROULD MR, 1989, PROGRAM DSCALEAD; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; 1979, COLLABORATIVE COMPUT	64	2119	2169	3	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					346	355		10.1126/science.8023157	http://dx.doi.org/10.1126/science.8023157			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023157				2022-12-28	WOS:A1994NW81600027
J	SEVA, C; DICKINSON, CJ; YAMADA, T				SEVA, C; DICKINSON, CJ; YAMADA, T			GROWTH-PROMOTING EFFECTS OF GLYCINE-EXTENDED PROGASTRIN	SCIENCE			English	Article							PANCREATIC-CELL LINE; GASTRIN RECEPTORS; DNA-SYNTHESIS; SOMATOSTATIN; PROLIFERATION; BINDING; CHOLECYSTOKININ; IDENTIFICATION; MECHANISM; TISSUES	Peptide alpha amidation is required to produce some hormones, such as gastrin, from their glycine-extended precursors. This terminal posttranslational processing reaction is thought to be essential for the biological activation of many peptide hormones; only amidated gastrin exerts a physiological effect that results in gastric acid secretion. However, both amidated gastrin and glycine-extended gastrin stimulate proliferation of exocrine pancreatic cell line AR4-2J through selective receptors for the substrate and the product, respectively, of peptide alpha amidation. Thus, the amidation reaction may function as a determinant of the specific biological actions of products derived from prohormones.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PEDIAT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			SEVA, Catherine/O-9166-2014	SEVA, Catherine/0000-0002-4265-7372	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034306, K08DK001903, P30DK034933] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-34306, K08-DK-01903, P30-DK-34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZUMA T, 1987, GASTROENTEROLOGY, V93, P322, DOI 10.1016/0016-5085(87)91022-5; BARDRAM L, 1990, GASTROENTEROLOGY, V98, P1420, DOI 10.1016/0016-5085(90)91071-D; BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU CK, 1987, J CLIN INVEST, V79, P175, DOI 10.1172/JCI112780; CICCOTOSTO GD, 1992, AM J PHYSIOL, V263, pG802, DOI 10.1152/ajpgi.1992.263.5.G802; CONTEAS CN, 1987, P SOC EXP BIOL MED, V184, P307; DELVALLE J, 1989, GASTROENTEROLOGY, V97, P1159, DOI 10.1016/0016-5085(89)91685-5; DELVALLE J, 1987, GASTROENTEROLOGY, V92, P1908, DOI 10.1016/0016-5085(87)90623-8; Edkins JS, 1905, P R SOC LOND B-CONTA, V76, P376, DOI 10.1098/rspb.1905.0029; FOLSCH UR, 1984, CLIN GASTROENTEROL, V13, P679; HILSTED L, 1991, REGUL PEPTIDES, V36, P323, DOI 10.1016/0167-0115(91)90067-Q; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; JOHNSON LR, 1977, ANNU REV PHYSIOL, V39, P135, DOI 10.1146/annurev.ph.39.030177.001031; KOCHMAN ML, 1992, BIOCHEM BIOPH RES CO, V189, P1165, DOI 10.1016/0006-291X(92)92326-S; MATSUMOTO M, 1987, AM J PHYSIOL, V252, pG143, DOI 10.1152/ajpgi.1987.252.1.G143; MATSUMOTO M, 1987, AM J PHYSIOL, V252, pG315, DOI 10.1152/ajpgi.1987.252.3.G315; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PAUWELS S, 1986, J CLIN INVEST, V77, P376, DOI 10.1172/JCI112315; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; REHFELD JF, 1986, J BIOL CHEM, V261, P5832; ROSENQUIST GL, 1979, GASTROINTESTINAL HOR, P769; SCEMAMA JL, 1989, AM J PHYSIOL, V256, pG846, DOI 10.1152/ajpgi.1989.256.5.G846; SCEMAMA JL, 1987, GUT, V28, P233, DOI 10.1136/gut.28.Suppl.233; SETYONOHAN B, 1987, CANCER RES, V47, P1566; SEVA C, 1990, CANCER RES, V50, P5829; SEVA C, UNPUB; SINGH P, 1986, CANCER RES, V46, P1612; SOLOMON TE, 1987, GASTROENTEROLOGY, V92, P429, DOI 10.1016/0016-5085(87)90138-7; SUGANO K, 1987, AM J PHYSIOL, V253, pG502, DOI 10.1152/ajpgi.1987.253.4.G502; SUGANO K, 1985, J BIOL CHEM, V260, P1724; SUGANO K, 1984, DIGEST DIS SCI, V29, P835; VIGUERIE N, 1989, ENDOCRINOLOGY, V124, P1017, DOI 10.1210/endo-124-2-1017; YOO OJ, 1982, P NATL ACAD SCI-BIOL, V79, P1049, DOI 10.1073/pnas.79.4.1049	34	327	340	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					410	412		10.1126/science.8023165	http://dx.doi.org/10.1126/science.8023165			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023165				2022-12-28	WOS:A1994NW81600045
J	STODDARD, JJ; KINDIG, DA; LIBBY, D				STODDARD, JJ; KINDIG, DA; LIBBY, D			GRADUATE MEDICAL-EDUCATION REFORM - SERVICE PROVISION TRANSITION COSTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTANTS; HOUSE STAFF; RESIDENTS; CARE	Objective.-To analyze the potential strategies and costs of house staff substitution under a reformed system of graduate medical education. Design.-An economic model using two scenarios for substitution of house staff (residents and fellows): (1) a lower-cost model under which nonphysician providers assume many house staff responsibilities, but additional aspects of their workload are taken over by staff physicians, nurses, and ancillary personnel; and (2) a higher-cost traditional model that relies more heavily on staff physicians to replace house officers. Setting.-US teaching hospitals. Main Outcome Measures.-Projected net substitution costs of house staff on a per full-time equivalent basis and aggregate national cost estimates of substitution. Results.-Net annual house staff substitution costs were estimated to be $58 000 and $77 000 per replaced full-time equivalent house officer, respectively, under the two scenarios. Assuming elimination of approximately 23 200 house staff under a reformed system, total (net) substitution costs to teaching hospitals were estimated at approximately $1.4 billion to $1.8 billion nationally on an annual basis. Conclusions.-Graduate medical education reform, while likely to result in substantial long-term cost savings, will necessitate transitions in service provision that are likely to generate some new costs in the short term.	UNIV WISCONSIN,SCH MED,HLTH POLICY PROGRAM,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT PEDIAT,MADISON,WI; UNIV WISCONSIN,SCH MED,DEPT PREVENT MED,MADISON,WI; MERITER HOSP,MADISON,WI 53715	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								CLAWSON DK, 1993, ROLES PHYSICIAN ASSI; COHEN J, 1993, NEW ENGL J MED, V328, P1810; DEMOTS H, 1987, AM J CARDIOL, V60, P784, DOI 10.1016/0002-9149(87)91023-X; DUBAYBO BA, 1991, CHEST, V99, P89, DOI 10.1378/chest.99.1.89; Edmunds M W, 1991, Nurse Pract, V16, P49; FALLON HJ, 1992, ANN INTERN MED, V116, P1103, DOI 10.7326/0003-4819-116-12-1103; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; GUNDERSON CH, 1988, NEUROLOGY, V38, P156, DOI 10.1212/WNL.38.1.156; HARRIS CM, 1990, PHYSICIAN ASSISTANTS, V252, P252; HONIGFELD L, 1990, PEDIATRICS, V85, P969; KINDIG DA, 1994, JAMA-J AM MED ASSOC, V272, P37, DOI 10.1001/jama.272.1.37; KNICKMAN JR, 1992, ACAD MED, V67, P429, DOI 10.1097/00001888-199207000-00003; LIEBERMAN DA, 1992, AM J GASTROENTEROL, V87, P940; LUKE R, 1993, AM J MED, V95, P1; LURIE N, 1989, NEW ENGL J MED, V320, P1673, DOI 10.1056/NEJM198906223202507; MAULE WF, 1994, NEW ENGL J MED, V330, P183, DOI 10.1056/NEJM199401203300307; Nichols L M, 1992, Nurs Econ, V10, P343; PERRY HB, 1981, ANN SURG, V193, P132, DOI 10.1097/00000658-198102000-00002; Rogers B, 1989, Nurse Pract, V14, P59; ROSEVELT J, 1984, DIGEST DIS SCI, V29, P161, DOI 10.1007/BF01317059; SHERMAN EA, 1990, PARTICIPATION WOMEN; SILVER HK, 1988, AM J NURS, V88, P1671; SIMMER TL, 1991, MED CARE S, V297, pJS31; SPISSO J, 1990, J TRAUMA, V30, P660, DOI 10.1097/00005373-199006000-00001; STURMANN KM, 1990, ANN EMERG MED, V19, P304, DOI 10.1016/S0196-0644(05)82051-7; THOMPSON TT, 1974, RADIOLOGY, V111, P603, DOI 10.1148/111.3.603; THORPE KE, 1990, JAMA-J AM MED ASSOC, V263, P3177, DOI 10.1001/jama.263.23.3177; WILLIS J, 1993, J AM ACAD PHYSICIAN, V6, P115; 1986, STUDY FINANCING GRAD; 1992, J MACY F ANNUAL REPO; 1992, IMPROVING ACCESS HLT; 1993, PRIMARY CARE WORKFOR; 1993, PHYSICAN PAYMENT REV, P55; 1994, 4TH US DEP HLTH HUM; 1992, ANN SURVEY HOSPITALS; 1993, 1993 COTH SURVEY HOU; 1993, US MED SCH FACULTY 1; 1993, SOCIOECONOMIC CHARAC; 1993, CENSUS REPORT PHYSIC	39	40	40	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					53	58		10.1001/jama.272.1.53	http://dx.doi.org/10.1001/jama.272.1.53			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU485	8007080				2022-12-28	WOS:A1994NU48500030
J	STARK, C; CHRISTIE, P; MARR, AC				STARK, C; CHRISTIE, P; MARR, AC			HOW TO DO IT - RUN AN EMERGENCY HELPLINE	BRITISH MEDICAL JOURNAL			English	Article								Telephone helplines are an effective way of dealing with health related incidents in which large numbers of people need personal counselling or information for reassurance or case finding. Helplinks often have to be set up at short notice, which is labour intensive and makes recruitment of appropriate staff difficult. They should ideally be part of local emergency planning resources. Doctors need to be included in the team organising the helpline to ensure that staff are properly briefed, to determine what data need to be collected, and to deal with specialised queries.	RUCHILL HOSP,COMMUNICABLE DIS & ENVIRONM HLTH SCOTLAND UNIT,GLASGOW G20 9NB,SCOTLAND; DEPT PUBL HLTH,PAISLEY PA2 7BN,RENFREW,SCOTLAND				Stark, Cameron R/D-5874-2017	Stark, Cameron R/0000-0003-1255-7415				1993, AIDS HIV INFECTED HL	1	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					44	45		10.1136/bmj.309.6946.44	http://dx.doi.org/10.1136/bmj.309.6946.44			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044070	Green Published			2022-12-28	WOS:A1994NV89100029
J	CUTFORTH, T; RUBIN, GM				CUTFORTH, T; RUBIN, GM			MUTATIONS IN HSP83 AND CDC37 IMPAIR SIGNALING BY THE SEVENLESS RECEPTOR TYROSINE KINASE IN DROSOPHILA	CELL			English	Article								A highly conserved signal cascade functions subsequent to receptor tyrosine kinase activation. Signaling by the sevenless receptor, required for differentiation of the R7 photoreceptor neuron in Drosophila, is reduced by mutations in E(sev)3A and E(sev)SB. We show here that E(sev)SA is a member of the HspSO family of stress proteins and that E(sev)SB encodes a homolog of the cell cycle control protein Cdc37 from S. cerevisiae. Mutations in E(sev)3B also dominantly enhance mutations in Dmcdc2, the gene encoding the p34 protein kinase that regulates the G2/M transition. Together, these data support a role for HspSO proteins in tyrosine kinase regulation and suggest that signals promoting neuronal differentiation may involve cell cycle control.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	CUTFORTH, T (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.			Rubin, Gerald/0000-0001-8762-8703				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BLACKMAN RK, 1986, J MOL BIOL, V188, P499, DOI 10.1016/S0022-2836(86)80001-8; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BOSCHELLI F, 1993, MOL CELL BIOL, V13, P5112, DOI 10.1128/MCB.13.8.5112; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FARRELLY FW, 1984, J BIOL CHEM, V259, P5745; FERGUSON J, 1986, NUCLEIC ACIDS RES, V14, P6681, DOI 10.1093/nar/14.16.6681; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GLETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAFEN E, 1993, PHILOS T R SOC B, V340, P273, DOI 10.1098/rstb.1993.0068; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; JIMENEZ J, 1990, EMBO J, V9, P3565, DOI 10.1002/j.1460-2075.1990.tb07567.x; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; LEE JK, 1993, J CELL BIOL, V123, P1797, DOI 10.1083/jcb.123.6.1797; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; OCONNOR D, 1981, NUCLEIC ACIDS RES, V9, P5075, DOI 10.1093/nar/9.19.5075; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1985, COLD SPRING HARB SYM, V50, P627, DOI 10.1101/SQB.1985.050.01.076; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REED SI, 1980, GENETICS, V95, P561; ROSE DW, 1989, J BIOL CHEM, V264, P6239; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLITER TJ, 1989, GENETICS, V123, P327; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STERN B, 1993, DEVELOPMENT, V117, P219; STERNBERG PW, 1993, PHILOS T R SOC B, V340, P259, DOI 10.1098/rstb.1993.0066; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOHLWILL AD, 1991, GENETICS, V128, P763; Wolff Tanya, 1993, P1277; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; XU T, 1993, DEVELOPMENT, V117, P1223; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YAMAZAKI M, 1989, NUCLEIC ACIDS RES, V17, P7108, DOI 10.1093/nar/17.17.7108; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	66	256	264	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	1994	77	7					1027	1036		10.1016/0092-8674(94)90442-1	http://dx.doi.org/10.1016/0092-8674(94)90442-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020093				2022-12-28	WOS:A1994NV42500011
J	WEINER, BM; KLECKNER, N				WEINER, BM; KLECKNER, N			CHROMOSOME PAIRING VIA MULTIPLE INTERSTITIAL INTERACTIONS BEFORE AND DURING MEIOSIS IN YEAST	CELL			English	Article								Fluorescence in situ hybridization analysis reveals that homologous chromosomes are paired in yeast cells about to enter meiosis. Fairing involves multiple interstitial interactions, one per similar to 65 kb. These observations exclude several classes of models for somatic/premeiotic pairing. The number of t = 0 pairing interactions is about the same as the number of subsequent meiotic recombination events. As cells enter meiosis, pairing disappears concomitant with DNA replication and then reappears, independent of synaptonemal complex. Mutant phenotypes suggest that formation of an individual meiotic pairing connection does not require a meiosis-specific double-stranded break (DSB). Mutants defective in recombination before or after DSBs exhibit pairing defects. These and other observations can be united by a model in which premeiotic pairing and early meiotic pairing occur by closely related paranemic DNA-DNA interactions between intact duplexes, with early meiotic interactions subsequently converted directly to plectonemic recombination intermediates via DSBs.			WEINER, BM (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GM14729, GM44794] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014729] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALBINI SM, 1987, CHROMOSOMA, V95, P324, DOI 10.1007/BF00293179; ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CAMPBELL AM, 1993, GENE, V135, P147, DOI 10.1016/0378-1119(93)90059-C; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; CHANDLEY AC, 1986, HUM GENET, V72, P50, DOI 10.1007/BF00278817; CHAUHAN KPS, 1968, CHROMOSOMA, V25, P297, DOI 10.1007/BF01183122; COMINGS DE, 1970, NATURE, V227, P451, DOI 10.1038/227451a0; COMINGS DE, 1971, NATURE, V233, P48, DOI 10.1038/233048a0; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; FOGEL S, 1983, YEAST GENETICS FUNDA, P65; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; Jorgensen R., 1992, Agbiotech News and Information, V4, p265N; KLECKNER N, 1991, COLD SH Q B, V56, P729; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KLEIN S, 1994, MYCOTA, V2; KOWALCZYKOWSKI SC, 1994, IN PRESS ANN REV BIO; LAWRENCE JB, 1988, CELL, V52, P51; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; LOIDL J, 1991, CHROMOSOMA, V100, P221, DOI 10.1007/BF00344155; LOIDL J, 1990, GENOME, V33, P759, DOI 10.1139/g90-115; MAGUIRE MP, 1983, J HERED, V74, P93, DOI 10.1093/oxfordjournals.jhered.a109748; McCLINTOCK BARBARA, 1933, ZEITSCHR WISS BIOL ABT B ZEITSCHR ZELLFORSCH U MIKROSK ANAT, V19, P191, DOI 10.1007/BF02462870; MCDERMOTT A, 1971, CAN J GENET CYTOL, V13, P536, DOI 10.1139/g71-079; MCGAVIN S, 1989, J THEOR BIOL, V136, P135, DOI 10.1016/S0022-5193(89)80221-8; Metz CW, 1916, J EXP ZOOL, V21, P213, DOI 10.1002/jez.1400210204; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MOENS PB, 1969, CHROMOSOMA, V28, P1, DOI 10.1007/BF00325986; MOENS PB, 1988, BIOESSAYS, V9, P151, DOI 10.1002/bies.950090503; Moses M. J., 1968, Annual Review of Genetics, V2, P363, DOI 10.1146/annurev.ge.02.120168.002051; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; OLSON MV, 1991, MOL CELLULAR BIOL YE, V1, P1; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Rhoades MM, 1961, CELL, VIII, P1; RILEY R, 1977, PHILOS T R SOC B, V277, P191, DOI 10.1098/rstb.1977.0011; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROSSIGNOL JL, 1994, EXPERIENTIA, V50, P307, DOI 10.1007/BF01924014; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; STACK SM, 1969, NATURE, V222, P1275, DOI 10.1038/2221275a0; STERN H, 1987, P303; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WANDALL A, 1985, CHROMOSOMA, V92, P254, DOI 10.1007/BF00329808; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; WILSON JH, 1979, P NATL ACAD SCI USA, V76, P3641, DOI 10.1073/pnas.76.8.3641; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x; ZICKLER D, 1977, CHROMOSOMA, V61, P289, DOI 10.1007/BF00288615	66	328	332	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	1994	77	7					977	991		10.1016/0092-8674(94)90438-3	http://dx.doi.org/10.1016/0092-8674(94)90438-3			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020104				2022-12-28	WOS:A1994NV42500007
J	EVANS, DB; JAMISON, DT				EVANS, DB; JAMISON, DT			ECONOMICS AND THE ARGUMENT FOR PARASITIC DISEASE-CONTROL	SCIENCE			English	Editorial Material							CHILDREN; AFRICA; MALARIA; COST		UNIV CALIF LOS ANGELES,CTR PACIFIC RIM STUDIES,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	EVANS, DB (corresponding author), UN DEV PROGRAM,WORLD BANK,WHO,SPECIAL PROGRAMME RES & TRAINING TROP DIS,CH-1211 GENEVA 27,SWITZERLAND.							[Anonymous], [No title captured]; BRIEGER WR, 1990, J TROP MED HYG, V93, P106; CALLENDER JEM, 1992, LANCET, V339, P181, DOI 10.1016/0140-6736(92)90246-Y; COOPER BS, 1976, SOC SECUR BULL, V39, P21; GUYATT HL, 1992, PARASITOL TODAY, V8, P397, DOI 10.1016/0169-4758(92)90187-7; JAMISON D, 1992, ENCY ED RES, P399; JAMISON DT, 1993, DIS CONTROL PRIORITI, P3; KORTE R, 1992, SOC SCI MED, V34, P1, DOI 10.1016/0277-9536(92)90060-4; MAX E, 1989, INT J LEPROSY, V57, P476; Mooney G, 1992, EC MED HLTH CARE, V2nd; Murray C. J. L., 1993, DIS CONTROL PRIORITI, P233; OVER M, 1992, HLTH ADULTS DEV WORL, P161; PICARD J, 1993, T ROY SOC TROP MED H, V87, P53, DOI 10.1016/0035-9203(93)90176-Q; Prescott N., 1989, Demography and vector-borne diseases., P155; Psacharopoulos G., 1993, POLICY RES WORKING P, V1067; SHEPARD DS, 1991, TROP MED PARASITOL, V42, P199; STEPHENSON LS, 1989, AM J TROP MED HYG, V41, P445, DOI 10.4269/ajtmh.1989.41.445; 1993, 1993 WORLD BANK WORL	18	5	6	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1866	1867		10.1126/science.8009213	http://dx.doi.org/10.1126/science.8009213			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NT847	8009213				2022-12-28	WOS:A1994NT84700026
J	MULLER, U; STEINHOFF, U; REIS, LFL; HEMMI, S; PAVLOVIC, J; ZINKERNAGEL, RM; AGUET, M				MULLER, U; STEINHOFF, U; REIS, LFL; HEMMI, S; PAVLOVIC, J; ZINKERNAGEL, RM; AGUET, M			FUNCTIONAL-ROLE OF TYPE-I AND TYPE-II INTERFERONS IN ANTIVIRAL DEFENSE	SCIENCE			English	Article							VESICULAR STOMATITIS; ALPHA-INTERFERON; INFLUENZA-VIRUS; MOUSE CELLS; MICE; EXPRESSION; RECEPTOR; GENES; PROTEIN; BETA	Mice lacking the known subunit of the type I interferon (IFN) receptor were completely unresponsive to type I IFNs, suggesting that this receptor chain is essential for type I IFN-mediated signal transduction. These mice showed no overt anomalies but were unable to cope with viral infections, despite otherwise normal immune responses. Comparison of mice lacking either type I or type II IFN receptors showed that, at least in response to some viruses, both IFN systems are essential for antiviral defense and are functionally nonredundant.	UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND; UNIV ZURICH,INST EXPTL IMMUNOL,CH-8057 ZURICH,SWITZERLAND; UNIV ZURICH,INST MED VIROL,CH-8028 ZURICH,SWITZERLAND	University of Zurich; University of Zurich; University of Zurich			Li, Chia Cheng/D-9906-2015; Yang, Chen/G-1379-2010; Reis, Luiz F. L./C-4556-2013; Pavlovic, Jovan/G-9669-2015	Pavlovic, Jovan/0000-0003-4428-2487; Steinhoff, Ulrich/0000-0003-2141-7756; Reis, Luiz/0000-0002-4040-2456				BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; BINDER D, 1991, J IMMUNOL, V146, P4301; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; DEMAEYER E, 1908, INTERFERONS OTHER RE; FAUCONNIER B, 1969, NATURE, V222, P185, DOI 10.1038/222185a0; FLENNIKEN AM, 1988, J VIROL, V62, P3077, DOI 10.1128/JVI.62.9.3077-3083.1988; FLORES I, 1991, J BIOL CHEM, V266, P19875; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOWLER AK, 1980, NATURE, V286, P266, DOI 10.1038/286266a0; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; GRESSER I, 1976, J EXP MED, V144, P1305, DOI 10.1084/jem.144.5.1305; GRESSER I, 1976, J EXP MED, V144, P1316, DOI 10.1084/jem.144.5.1316; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOORE RN, 1984, SCIENCE, V223, P178, DOI 10.1126/science.6606850; MULLER U, UNPUB; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; QUESADA JR, 1984, NEW ENGL J MED, V310, P15, DOI 10.1056/NEJM198401053100104; ROBERTS RM, 1991, PHARMACOL THERAPEUT, V51, P329, DOI 10.1016/0163-7258(91)90064-S; ROOST HP, 1990, EUR J IMMUNOL, V20, P2547, DOI 10.1002/eji.1830201204; RUTHERFORD MN, 1991, NUCLEIC ACIDS RES, V19, P1917, DOI 10.1093/nar/19.8.1917; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STEWART TA, 1993, SCIENCE, V260, P1942, DOI 10.1126/science.8100367; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WEBER H, 1987, EMBO J, V6, P591, DOI 10.1002/j.1460-2075.1987.tb04795.x; WEISS EH, 1984, NATURE, V310, P650, DOI 10.1038/310650a0; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; ZINKERNAGEL RM, 1993, IMMUNOL REV, V131, P199	35	1964	2023	172	449	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1918	1921		10.1126/science.8009221	http://dx.doi.org/10.1126/science.8009221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009221				2022-12-28	WOS:A1994NT84700041
J	VANDERWAL, G; DILLMANN, RJM				VANDERWAL, G; DILLMANN, RJM			EUTHANASIA IN THE NETHERLANDS	BRITISH MEDICAL JOURNAL			English	Article							ASSISTED SUICIDE; FAMILY DOCTORS; LIFE	The practice of euthanasia in the Netherlands is often used as an argument in debates outside the Netherlands-hence a clear description of the Dutch situation is important. This article summarises recent data and discusses conceptual issues and relevant characteristics of the system of health care. Special emphasis is put on regulation, including relevant data on notification and prosecution. Besides the practice of euthanasia the Dutch are confronted with the gaps in reporting of cases to the public prosecutor and the existence of cases of ending a life without an explicit request. Nevertheless, the ''Dutch experiment'' need not inevitably lead down the slippery slope because of the visibility and openness of this part of medical practice. This will lead to increased awareness, more safeguards, and improvement of medical decisions concerning the end of life.	ROYAL DUTCH MED ASSOC,3502 LB UTRECHT,NETHERLANDS; HLTH PROV N HOLLAND,2001 DC HAARLEM,NETHERLANDS									ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; BATTIN MP, 1990, PERSPECT BIOL MED, V34, P73; Bostrom B A, 1989, Issues Law Med, V4, P467; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; DILLMANN RJM, 1994, EUROPEAN J HLTH LAW, V1, P81; FEBER HRG, 1989, NEDERLANDS JURISTEN, V64, P1441; Fenigsen R, 1989, Hastings Cent Rep, V19, P22, DOI 10.2307/3561967; Gomez Carlos F., 1991, REGULATING DEATH EUT; GUNNING KF, 1991, LANCET, V338, P1010, DOI 10.1016/0140-6736(91)91867-T; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; POLLARD BJ, 1991, MED J AUSTRALIA, V154, P613, DOI 10.5694/j.1326-5377.1991.tb121223.x; RIGTER H, 1988, BMJ-BRIT MED J, V297, P1593, DOI 10.1136/bmj.297.6663.1593; RIGTER H, 1989, HASTINGS CENT REP, V19, P31, DOI 10.2307/3561968; van Delden J J, 1992, Ned Tijdschr Geneeskd, V136, P644; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDELDEN JJM, 1993, BIOETHICS, V7, P323, DOI 10.1111/j.1467-8519.1993.tb00222.x; VANDELDEN JJM, 1993, HASTINGS CENT REP, V23, P24, DOI 10.2307/3562919; VANDERMAAS PJ, 1992, HLTH POLICY S1 S2, V22; VANDERWAL G, 1993, BIOETHICS, V7, P330, DOI 10.1111/j.1467-8519.1993.tb00223.x; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; VANDERWAL G, 1992, FAM PRACT, V9, P135, DOI 10.1093/fampra/9.2.135; VANDERWAL G, 1992, EUTHANASIA ASSISTED; VANDERWAL G, IN PRESS J AM GERIAT; VANDERWAL G, 1993, NEDERLANDS JURISTEN, V68, P444; ZYLICZ Z, 1991, LANCET, V338, P1150, DOI 10.1016/0140-6736(91)92010-Y; 1987, BIOETHICS, V1, P163; 1991, MED BESLISSINGEN RON	29	65	65	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1346	1349		10.1136/bmj.308.6940.1346	http://dx.doi.org/10.1136/bmj.308.6940.1346			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NM989	8019226	Green Published			2022-12-28	WOS:A1994NM98900028
J	JOLLIS, JG; ANCUKIEWICZ, M; DELONG, ER; PRYOR, DB; MUHLBAIER, LH; MARK, DB				JOLLIS, JG; ANCUKIEWICZ, M; DELONG, ER; PRYOR, DB; MUHLBAIER, LH; MARK, DB			DISCORDANCE OF DATABASES DESIGNED FOR CLAIMS PAYMENT VERSUS CLINICAL INFORMATION-SYSTEMS - IMPLICATIONS FOR OUTCOMES RESEARCH	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; SURGERY; COMORBIDITIES; MORTALITY; ACCURACY; HEART	Objective: To determine the suitability of insurance claims information for use in clinical outcomes research in ischemic heart disease. Design: Concordance study of two databases. Setting: Tertiary care referral center. Patients: A total of 12 937 consecutive patients hospitalized for cardiac catheterization for suspected ischemic heart disease between July 1985 and May 1990. Interventions: Two-by-two tables were used to compute overall and kappa measures of agreement comparing clinical versus claims data for 12 important predictors of prognosis in patients with ischemic heart disease. Measurements: Kappa statistics (agreement adjusted for chance agreement) were used to quantify agreement rates. Results: Agreement rates between the clinical and claims databases ranged from 0.83 for the diagnosis of diabetes to 0.09 for the diagnosis of unstable angina (kappa values). Claims data failed to identify more than one half of the patients with prognostically important conditions, including mitral insufficiency, congestive heart failure, peripheral vascular disease, old myocardial infarction, hyperlipidemia, cerebrovascular disease, tobacco use, angina, and unstable angina, when compared with the clinical information system. Conclusions: Our results suggest that insurance claims data lack important diagnostic and prognostic information when compared with concurrently collected clinical data in the study of ischemic heart disease. Thus, insurance claims data are not as useful as clinical data for identifying clinically relevant patient groups and for adjusting for risk in outcome studies, such as analyses of hospital mortality.	DUKE UNIV, MED CTR, DEPT COMMUNITY & FAMILY MED, DIV BIOMETRY, DURHAM, NC 27710 USA	Duke University	JOLLIS, JG (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, BOX 3254, DURHAM, NC 27710 USA.		Tao, Youyou/D-2367-2014	Mark, Daniel/0000-0001-6340-8087	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017670] Funding Source: NIH RePORTER; AHRQ HHS [HS-05635, HS-06503] Funding Source: Medline; NHLBI NIH HHS [HL-17670] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN F, 1989, ICD 9 CM CODING HDB; CLINTON JJ, 1991, JAMA-J AM MED ASSOC, V266, P2057, DOI 10.1001/jama.266.15.2057; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; DANS PE, 1985, NEW ENGL J MED, V313, P1131, DOI 10.1056/NEJM198510313131806; DETRE K, 1977, AM J CARDIOL, V40, P212, DOI 10.1016/0002-9149(77)90011-X; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; HLATKY MA, 1988, J AM COLL CARDIOL, V11, P237, DOI 10.1016/0735-1097(88)90086-1; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KENNEDY GT, 1984, AM J CARDIOL, V53, P1000, DOI 10.1016/0002-9149(84)90625-8; KILLIP T, 1981, CIRCULATION, V63, P1; Lohr K N, 1990, Int J Technol Assess Health Care, V6, P263; PRYOR DB, 1989, J AM COLL CARDIOL, V14, P1016, DOI 10.1016/0735-1097(89)90484-1; SCHIFF GD, 1989, ANN INTERN MED, V110, P243, DOI 10.7326/0003-4819-110-3-243_1; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; VANWALRAVEN C, 1990, CAN J CARDIOL, V6, P383; WILLIAMS SV, 1991, JAMA-J AM MED ASSOC, V266, P810, DOI 10.1001/jama.266.6.810; 1977, RELIABILITY HOSPITAL; 1964, DISEASES HEART BLOOD, P114; 1989, CAN J PUBL HLTH, V80, P412; 1991, INT CLASSIFICATION D; 1989, HCFA00700 HLTH CAR F; 1988, HCFA00647 HLTH CAR F; 1987, HCFA01002 HLTH CAR F	27	547	550	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					844	850		10.7326/0003-4819-119-8-199310150-00011	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8018127				2022-12-28	WOS:A1993MB49600011
J	SCHWARTZ, TB				SCHWARTZ, TB			ASK, AND IT SHALL BE GIVEN YOU	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					376	376		10.7326/0003-4819-121-5-199409010-00011	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042828				2022-12-28	WOS:A1994PD70100011
J	SERRUYS, PW; DEJAEGERE, P; KIEMENEIJ, F; MACAYA, C; RUTSCH, W; HEYNDRICKX, G; EMANUELSSON, H; MARCO, J; LEGRAND, V; MATERNE, P; BELARDI, J; SIGWART, U; COLOMBO, A; GOY, JJ; VANDENHEUVEL, P; DELCAN, J; MOREL, MA				SERRUYS, PW; DEJAEGERE, P; KIEMENEIJ, F; MACAYA, C; RUTSCH, W; HEYNDRICKX, G; EMANUELSSON, H; MARCO, J; LEGRAND, V; MATERNE, P; BELARDI, J; SIGWART, U; COLOMBO, A; GOY, JJ; VANDENHEUVEL, P; DELCAN, J; MOREL, MA			A COMPARISON OF BALLOON-EXPANDABLE-STENT IMPLANTATION WITH BALLOON ANGIOPLASTY IN PATIENTS WITH CORONARY-ARTERY DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; RESTENOSIS; MORPHOLOGY; PREVENTION; HEPARIN; PTCA	Background. Balloon-expandable coronary-artery stents were developed to prevent coronary restenosis after coronary angioplasty. These devices hold coronary vessels open at sites that have been dilated. However, it is unknown whether stenting improves longterm angiographic and clinical outcomes as compared with standard balloon angioplasty. Methods. A total of 520 patients with stable angina and a single coronary-artery lesion were randomly assigned to either stent implantation (262 patients) or standard balloon angioplasty (258 patients). The primary clinical end points were death, the occurrence of a cerebrovascular accident, myocardial infarction, the need for coronary-artery bypass surgery, or a second percutaneous intervention involving the previously treated lesion, either at the time of the initial procedure or during the subsequent seven months. The primary angiographic end point was the minimal luminal diameter at follow-up, as determined by quantitative coronary angiography. Results. After exclusions, 52 patients in the stent group (20 percent) and 76 patients in the angioplasty group (30 percent) reached a primary clinical end point (relative risk, 0.68; 95 percent confidence interval, 0.50 to 0.92; P = 0.02). The difference in clinical-event rates was explained mainly by a reduced need for a second coronary angioplasty in the stent group (relative risk, 0.58; 95 percent confidence interval, 0.40 to 0.85; P = 0.005). The mean (+/-SD) minimal luminal diameters immediately after the procedure were 2.48+/-0.39 mm in the stent group and 2.05+/-0.33 mm in the angioplasty group; at follow-up, the diameters were 1.82+/-0.64 mm in the stent group and 1.73+/-0.55 mm in the angioplasty group (P = 0.09), which correspond to rates of restenosis (diameter of stenosis, greater than or equal to 50 percent) of 22 and 32 percent, respectively (P = 0.02). Peripheral vascular complications necessitating surgery, blood transfusion, or both were more frequent after stenting than after balloon angioplasty (13.5 vs. 3.1 percent, P<0.001). The mean hospital stay was significantly longer in the stent group than in the angioplasty group (8.5 vs. 3.1 days, P<0.001). Conclusions. Over seven months of follow-up, the clinical and angiographic outcomes were better in patients who received a stent than in those who received standard coronary angioplasty. However, this benefit was achieved at the cost of a significantly higher risk of vascular complications at the access site and a longer hospital stay.	ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,CTR THORAX,3015 GD ROTTERDAM,NETHERLANDS; ONZE LIEVE VROUW HOSP,AMSTERDAM,NETHERLANDS; UNIV HOSP SAN CARLOS,MADRID,SPAIN; FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,W-1000 BERLIN,GERMANY; ONZE LIEVE VROUWE KLIN,AALST,BELGIUM; SAHLGRENS UNIV HOSP,GOTHENBURG,SWEDEN; CLIN PASTEUR,TOULOUSE,FRANCE; CHU SART TILMAN,LIEGE,BELGIUM; HOP CITADELLE,LIEGE,BELGIUM; INST CARDIOVASC BUENOS AIRES,BUENOS AIRES,DF,ARGENTINA; ROYAL BROMPTON NATL HEART & LUNG INST,LONDON,ENGLAND; CTR CUORE COLUMBUS,MILAN,ITALY; CHU VAUDOIS,LAUSANNE,SWITZERLAND; MIDDELHEIM ZIEKENHUIS,ANTWERP,BELGIUM; HOSP GEN GREGORIO MARANON,MADRID,SPAIN	Erasmus University Rotterdam; Erasmus MC; Onze Lieve Vrouwe Gasthuis Hospital; Hospital Clinico San Carlos; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Sahlgrenska University Hospital; University of Liege; Instituto Cardiovascular de Buenos Aires (ICBA); Imperial College London; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); ZNA Middelheim Hospital; General University Gregorio Maranon Hospital								AMBROSE JA, 1985, J AM COLL CARDIOL, V5, P609, DOI 10.1016/S0735-1097(85)80384-3; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; COHEN DJ, 1993, J AM COLL CARDIOL, V22, P1052, DOI 10.1016/0735-1097(93)90415-W; COHEN DJ, 1994, CIRCULATION, V89, P1859, DOI 10.1161/01.CIR.89.4.1859; DEJAEGERE P, 1993, CURR REV INTERV CARD, V8, P1; DEJAEGERE PPT, 1993, CLIN CARDIOL, V16, P369, DOI 10.1002/clc.4960160503; DEJAEGEREPPT, 1993, AM HART J, V125, P310; DORROS G, 1983, CIRCULATION, V67, P723, DOI 10.1161/01.CIR.67.4.723; ELLIS SG, 1989, AM HEART J, V117, P777, DOI 10.1016/0002-8703(89)90612-1; ELLIS SG, 1989, AM J CARDIOL, V63, P30, DOI 10.1016/0002-9149(89)91071-0; FAXON D, 1992, Journal of the American College of Cardiology, V19, p258A; FISCHMAN DL, 1992, DEV CARDIOVASC MED, V131, P191; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HERMANS WRM, 1992, J AM COLL CARDIOL, V20, P767, DOI 10.1016/0735-1097(92)90171-I; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; PERIN EC, 1990, CIRCULATION, V82, P497; POCOCK SJ, 1982, BIOMETRICS, V38, P153, DOI 10.2307/2530298; RENSING BJ, 1990, AM J CARDIOL, V66, P1039, DOI 10.1016/0002-9149(90)90501-Q; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; SERRAYS PW, 1994, QUANTITATIVE CORONAR; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; THORNTON MA, 1984, CIRCULATION, V69, P721, DOI 10.1161/01.CIR.69.4.721; URBAN P, 1988, BRIT HEART J, V60, P485; 1985, NEW ENGL J MED, V312, P932	26	3661	3914	1	259	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					489	495		10.1056/NEJM199408253310801	http://dx.doi.org/10.1056/NEJM199408253310801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD072	8041413	Green Published, Green Submitted			2022-12-28	WOS:A1994PD07200001
J	GIOVANNUCCI, E; RIMM, EB; STAMPFER, MJ; COLDITZ, GA; ASCHERIO, A; WILLETT, WC				GIOVANNUCCI, E; RIMM, EB; STAMPFER, MJ; COLDITZ, GA; ASCHERIO, A; WILLETT, WC			ASPIRIN USE AND THE RISK FOR COLORECTAL-CANCER AND ADENOMA IN MALE HEALTH-PROFESSIONALS	ANNALS OF INTERNAL MEDICINE			English	Article						ASPIRIN; COLORECTAL NEOPLASMS; ADENOMA; RISK; HEALTH PERSONNEL	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; COLON CANCER; LARGE-BOWEL; INDOMETHACIN TREATMENT; ALCOHOL-CONSUMPTION; INTESTINAL TUMORS; REDUCED RISK; POLYPOSIS; SULINDAC	Objective: To determine whether regular use of aspirin decreases the risk for colorectal cancer. Design: Prospective cohort study. Setting: Male health professionals throughout the United States. Patients: 47 900 male respondents to a mailed questionnaire in 1986, who were 40 to 75 years of age. Measurements: Questionnaires in 1986, 1988, and 1990 about use of aspirin and other variables including occurrence of cancer. Results: 251 new patients were diagnosed with colorectal cancer during the study period. Regular users of aspirin (greater than or equal to 2 times per week) in 1986 had a lower risk for total colorectal cancer (relative risk [RR] = 0.68; 95% CI, 0.52 to 0.92) and advanced (metastatic and fatal) colorectal cancer (RR = 0.51; CI, 0.32 to 0.84) after controlling for age; history of polyp; previous endoscopy; parental history of colorectal cancer; smoking; body mass; physical activity; and intakes of red meat, vitamin E, and alcohol. The incremental association was greater among men who reported regular use of aspirin consistently on subsequent questionnaires. The total number of colorectal adenomas discovered among aspirin users was lower with or without overt or occult fecal blood. Thus, earlier diagnosis and treatment of adenomas did not account for the inverse association between aspirin and cancer. Conclusions: These results support laboratory, clinical, and other epidemiologic evidence that regular use of aspirin is associated with a decreased risk for colorectal cancer.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	GIOVANNUCCI, E (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARON JA, 1991, NEW ENGL J MED, V325, P1644, DOI 10.1056/NEJM199112053252309; GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183; GONZAGA RAF, 1985, LANCET, V1, P751; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; ISOMAKI HA, 1978, J CHRON DIS, V31, P691, DOI 10.1016/0021-9681(78)90071-1; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; LAAKSO M, 1986, J RHEUMATOL, V13, P522; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LOGAN RFA, 1993, BRIT MED J, V307, P285, DOI 10.1136/bmj.307.6899.285; MARNETT LJ, 1992, CANCER RES, V52, P5575; NARISAWA T, 1981, CANCER RES, V41, P1954; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; RIGAU J, 1991, ANN INTERN MED, V115, P952, DOI 10.7326/0003-4819-115-12-952; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Rothman K, 1986, MODERN EPIDEMIOLOGY; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; 1989, CANCER STATISTICS RE	34	681	711	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					241	246		10.7326/0003-4819-121-4-199408150-00001	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037405				2022-12-28	WOS:A1994PB10200001
J	WILLIAMS, BJ				WILLIAMS, BJ			MY NEW IMAGE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					408	408		10.1056/NEJM199408113310620	http://dx.doi.org/10.1056/NEJM199408113310620			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA374	8028638				2022-12-28	WOS:A1994PA37400035
J	ZOHARY, E; SHADLEN, MN; NEWSOME, WT				ZOHARY, E; SHADLEN, MN; NEWSOME, WT			CORRELATED NEURONAL DISCHARGE RATE AND ITS IMPLICATIONS FOR PSYCHOPHYSICAL PERFORMANCE	NATURE			English	Article							VISUAL AREA MT; CORTICAL-NEURONS; SINGLE NEURONS; MONKEY; DISCRIMINATION; MICROSTIMULATION; ORIENTATION; FREQUENCY; STIMULI; MOTION	SINGLE neurone can signal subtle changes in the sensory environment with surprising fidelity, often matching the perceptual sensitivity of trained psychophysical observers This similarity poses an intriguing puzzle: why is psychophysical sensitivity not greater than that of single neurons? Pooling responses across neurons should average out noise in the activity of single cells, leading to substantially improved psychophysical performance. If, however, noise is correlated among these neurons, the beneficial effects of pooling would be diminished(10-12). To assess correlation within a pool, the responses of pairs of neurons were recorded simultaneously during repeated stimulus presentations. We report here that the observed covariation in spike count was relatively weak, the correlation coefficient averaging 0.12. A theoretical analysis revealed, however, that weak correlation can limit substantially the signalling capacity of the pool. In addition, theory suggests a relationship between neuronal responses and psychophysical decisions which may prove useful for identifying cell populations underlying specific perceptual capacities.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Shadlen, Michael Neil/AAL-1870-2020; Newsome, William T./W-7171-2019	Shadlen, Michael/0000-0002-2002-2210				Anderson T. W., 1958, INTRO MULTIVARIATE S; BRADLEY A, 1987, J NEUROPHYSIOL, V57, P755, DOI 10.1152/jn.1987.57.3.755; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; CELEBRINI S, IN PRESS J NEUROSCI; DUBNER R, 1989, J NEUROPHYSIOL, V62, P450, DOI 10.1152/jn.1989.62.2.450; GAWNE TJ, 1993, J NEUROSCI, V13, P2758; Hawken M.J., 1990, P103; JOHNSON KO, 1980, J NEUROPHYSIOL, V43, P1793, DOI 10.1152/jn.1980.43.6.1793; JOHNSON KO, 1979, J NEUROPHYSIOL, V42, P1332, DOI 10.1152/jn.1979.42.5.1332; JOHNSON KO, 1973, J NEUROPHYSIOL, V36, P347, DOI 10.1152/jn.1973.36.2.347; MOUNTCASTLE VB, 1972, J NEUROPHYSIOL, V35, P122, DOI 10.1152/jn.1972.35.1.122; MOUNTCASTLE VB, 1969, J NEUROPHYSIOL, V32, P452, DOI 10.1152/jn.1969.32.3.452; MURASUGI CM, 1993, J NEUROSCI, V13, P1719; NEWSOME WT, 1988, J NEUROSCI, V8, P2201; NEWSOME WT, 1989, NEURAL MECHANISMS VI, P171; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; TOLHURST DJ, 1983, VISION RES, V23, P775, DOI 10.1016/0042-6989(83)90200-6; VANKAN P, 1985, EXPL BRAIN RES, P559; VOGELS R, 1990, J NEUROSCI, V10, P3543; WORGOTTER F, 1986, J NEUROSCI METH, V17, P141, DOI 10.1016/0165-0270(86)90067-1; ZEKI SM, 1974, J PHYSIOL-LONDON, V236, P549, DOI 10.1113/jphysiol.1974.sp010452	22	857	858	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					140	143		10.1038/370140a0	http://dx.doi.org/10.1038/370140a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022482				2022-12-28	WOS:A1994NW80400057
J	DOWNER, SM; CODY, MM; MCCLUSKEY, P; WILSON, PD; ARNOTT, SJ; LISTER, TA; SLEVIN, ML				DOWNER, SM; CODY, MM; MCCLUSKEY, P; WILSON, PD; ARNOTT, SJ; LISTER, TA; SLEVIN, ML			PURSUIT AND PRACTICE OF COMPLEMENTARY THERAPIES BY CANCER-PATIENTS RECEIVING CONVENTIONAL TREATMENT	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine what proportion of oncology patients receiving conventional medical treatment also use complementary treatments; to assess which complementary treatments are the most popular and to assess patients' motivation for using them; to evaluate associated advantages and risks. Design-Postal screening questionnaire followed by semistructured interview. Setting-Two hospitals in inner London. Subjects-600 unselected oncology patients aged 18 or over who had known their diagnosis of cancer for at least three months. Main outcome measures-Prevalence and demography of use of complementary therapies; patients' motivation and expectations of complementary therapies; areas of satisfaction and dissatisfaction associated with conventional and complementary therapies. Results-415 (69%) patients returned the questionnaire. 16% had used complementary therapies. The most popular were healing, relaxation, visualisation, diets, homoeopathy, vitamins, herbalism, and the Bristol approach. Patients using complementary therapies tended to be younger, of higher social class, and female. Three quarters used two or more therapies. Therapies were mostly used for anticipated antitumour effect. Ill effects of diets and herb treatments were described. Satisfaction with both conventional and complementary therapies was high, although diets often caused difficulties. Patients using complementary therapies were less satisfied with conventional treatments, largely because of side effects and lack of hope of cure. Benefits of complementary therapies were mainly psychological. Conclusions-A sizeable percentage of patients receiving conventional treatments for cancer also use complementary therapies. Patient satisfaction with complementary therapies, other than dietary therapies, was high even without the hoped for anticancer effect. Patients reported psychological benefits such as hope and optimism.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND; UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT RADIOTHERAPY,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London			McCluskey, Peter J/H-7607-2013	McCluskey, Peter J/0000-0002-8177-1637				ALDRIDGE D, 1989, BRIT MED J, V299, P1211; BAGENAL FS, 1990, LANCET, V336, P1185; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Dickson A C, 1985, Oncol Nurs Forum, V12, P49; FULDER S, 1982, STATUS COMPLEMENTARY; LERNER IJ, 1984, CANCER, V53, P815, DOI 10.1002/1097-0142(19840201)53:3+<815::AID-CNCR2820531334>3.0.CO;2-U; SIKORA K, 1970, CANCER CARE, V7, P9; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1986, ALTERNATIVE THERAPY	11	245	246	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					86	89		10.1136/bmj.309.6947.86	http://dx.doi.org/10.1136/bmj.309.6947.86			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038672	Green Published			2022-12-28	WOS:A1994NW71600015
J	LAND, MF; LEE, DN				LAND, MF; LEE, DN			WHERE WE LOOK WHEN WE STEER	NATURE			English	Article							COORDINATION	STEERING a car requires visual information from the changing pattern of the road ahead. There are many theories about what features a driver might use(1-3), and recent attempts to engineer self-steering vehicles have sharpened interest in the mechanisms involved(4,5). However, there is little direct information linking steering performance to the driver's direction of gaze(3). We have made simultaneous recordings of steering-wheel angle and drivers' gaze direction during a series of drives along a tortuous road. We found that drivers rely particularly on the 'tangent point' an the inside of each curve, seeking this point 1-2 s before each bend and returning to it throughout the bend. The direction of this point relative to the car's heading predicts the curvature of the road ahead, and we examine the way this information is used.	UNIV EDINBURGH, DEPT PSYCHOL, PERCEPT ACT LABS, EDINBURGH EH8 9JZ, SCOTLAND	University of Edinburgh	LAND, MF (corresponding author), UNIV SUSSEX, SCH BIOL SCI, SUSSEX CTR NEUROSCI, BRIGHTON BN1 9QG, ENGLAND.							BALLARD DH, 1992, PHILOS T R SOC B, V337, P331, DOI 10.1098/rstb.1992.0111; Carpenter RHS, 1988, MOVEMENTS EYES; Dickmanns E. D., 1993, [1993] Proceedings Fourth International Conference on Computer Vision, P608, DOI 10.1109/ICCV.1993.378155; LAND MF, 1992, NATURE, V359, P318, DOI 10.1038/359318a0; LAND MF, 1993, P IEEE SYST MAN CYB, V3, P490; LANDWEHR K, 1991, VISION VEHICLES, V3, P187; LEE DN, 1977, SCAND J PSYCHOL, V18, P224, DOI 10.1111/j.1467-9450.1977.tb00281.x; OKUNO A, 1992, VISION BASED VEHICLE, P222; Raviv D., 1991, Proceedings of the IEEE Workshop on Visual Motion (Cat. No.91TH0390-5), P217, DOI 10.1109/WVM.1991.212804; RIEMERSMA JBJ, 1991, VISION VEHICLES, V3, P163; SERAFIN C, 1993, UMTRI9329163 U MICH; WARREN WH, 1991, J EXP PSYCHOL HUMAN, V17, P28, DOI 10.1037/0096-1523.17.1.28	12	654	672	2	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	1994	369	6483					742	744		10.1038/369742a0	http://dx.doi.org/10.1038/369742a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008066				2022-12-28	WOS:A1994NU58100059
J	YU, P; KOSCOVILBOIS, M; RICHARDS, M; KOHLER, G; LAMERS, MC				YU, P; KOSCOVILBOIS, M; RICHARDS, M; KOHLER, G; LAMERS, MC			NEGATIVE FEEDBACK-REGULATION OF IGE SYNTHESIS BY MURINE CD23	NATURE			English	Article							LOW-AFFINITY RECEPTOR; FC-EPSILON-RII; B-CELLS; T-CELLS; FC-EPSILON-RII/CD23; LYMPHOCYTES; INHIBITION; ACTIVATION; RESPONSES; CLONES	IMMUNOGLOBULIN E is found in nanogram amounts in normal human and mouse serum. It is increased during parasitic infestations(1) and mediates allergy. CD23, the low-affinity receptor for IgE (Fc epsilon RII), has been proposed as an important regulator of IgE synthesis(2-4). The type-II transmembrane lectin(4) CD23 is expressed in the mouse on B cells and follicular dendritic cells. In humans there are two forms of CD23 which differ in their intracellular amino-terminal 6/7 amino acids(4); expression of the A-form corresponds to that of murine CD23, whereas the B-form is also found on T and other haematopoietic cells(4). CD23 has been implicated in cellular adhesion(5), antigen presentation(6), as a growth and differentiation factor for human B, T and plasma cells, and as a signal transduction molecule(7) (reviewed in refs 3, 8). Here we disrupt the gene coding for murine CD23 (ref. 9) to clarify the role of CD23 in vivo and find that B- and T-cell development is normal in these CD23-deficient mice. Immune responses to the helminth Nippostrongylus brasiliensis are unaffected, In contrast, immunization with thymus-dependent antigens leads to increased and sustained specific IgE antibody titres compared with controls. Formation of germinal centres is normal. These results suggest that murine CD23 acts as a negative feedback component of IgE regulation.	MAX PLANCK INST IMMUNBIOL,D-79108 FREIBURG,GERMANY; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; MED BIOL INST,LA JOLLA,CA 92037	Max Planck Society				Yu, Philipp/0000-0003-2629-6690				ADAMCZEWSKI M, 1991, EUR J IMMUNOL, V21, P617, DOI 10.1002/eji.1830210313; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; AYANE MP, 1990, NUCLEIC ACIDS RES, V17, P6722; BERTHO JM, 1991, EUR J IMMUNOL, V21, P1073, DOI 10.1002/eji.1830210433; CAMPBELL KA, 1992, EUR J IMMUNOL, V22, P2107, DOI 10.1002/eji.1830220822; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; FLORESROMO L, 1993, SCIENCE, V261, P1038, DOI 10.1126/science.8351517; GORDON J, 1991, MONOGR ALLERGY CD23, V29; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; HEYMAN B, 1993, EUR J IMMUNOL, V23, P1739, DOI 10.1002/eji.1830230754; KEEGAN AD, 1989, J IMMUNOL, V142, P3868; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; KOLB JP, 1993, J IMMUNOL, V150, P4798; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LEBRUN P, 1987, J IMMUNOL, V139, P1459; LEDERMANN B, 1991, EXP CELL RES, V197, P254, DOI 10.1016/0014-4827(91)90430-3; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LUO H, 1991, J IMMUNOL, V146, P2125; MAEDA K, 1992, J IMMUNOL, V148, P2340; NITSCHKE L, 1993, BIOTECHNIQUES, V14, P914; RAO M, 1987, J IMMUNOL, V138, P1845; RICHARDS ML, 1991, J IMMUNOL, V147, P1067; SAXON A, 1991, J IMMUNOL, V147, P4000; SHERR E, 1989, J IMMUNOL, V142, P481; SINCLAIR NRS, 1983, IMMUNOL TODAY, V4, P35, DOI 10.1016/0167-5699(83)90107-X; STREET NE, 1990, J IMMUNOL, V144, P1629; SUUTTON BJ, 1993, NATURE, V366, P421; SWENDEMAN S, 1987, EMBO J, V6, P1637, DOI 10.1002/j.1460-2075.1987.tb02412.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5	29	196	200	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					753	756		10.1038/369753a0	http://dx.doi.org/10.1038/369753a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008068				2022-12-28	WOS:A1994NU58100063
J	CUMMINGS, P; STANFORD, JL; DALING, JR; WEISS, NS; MCKNIGHT, B				CUMMINGS, P; STANFORD, JL; DALING, JR; WEISS, NS; MCKNIGHT, B			RISK OF BREAST-CANCER IN RELATION TO THE INTERVAL SINCE LAST FULL-TERM PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							INCREASE; AGE	Objective-To examine whether the risk of breast cancer is increased by a recent term pregnancy. Design-Population based case-control study. Setting-Eight areas in the United States. Subjects-Cases were 2279 multiparous women residents of the eight areas aged 25-49 who were diagnosed as having breast cancer during 1980-2. Controls were 2357 multiparous women selected from the same areas by random digit dialling. Main outcome measure-Relative risk of developing breast cancer according to the time interval since last full term pregnancy. Results-The distribution of intervals since the last term pregnancy was similar in cases and controls. Adjusted for age, parity, and age at first term pregnancy, the odds ratios observed for categories of years since the last full term pregnancy were: 0-2 years, odds ratio 1.16 (95% confidence interval 0.84 to 1.59); 3-6 years, odds ratio 1.21 (0.95 to 1.54); 7-9 years, odds ratio 1.04 (0.84 to 1.38); greater than or equal to 10 years, odds ratio 1.00 (reference). Conclusions-Among multiparous women aged 25-49 years there was no association between the risk of breast cancer and the time interval since the last full term pregnancy.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,SEATTLE,WA 98112	University of Washington; University of Washington Seattle					NCI NIH HHS [R35CA39779, R01CA01364, T32CA09168] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009168, R35CA039779] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; Breslow N, 1980, STATISTICAL METHODS, V32; BRUZZI P, 1988, BRIT MED J, V297, P1096, DOI 10.1136/bmj.297.6656.1096; JANERICH DT, 1982, AM J EPIDEMIOL, V116, P737, DOI 10.1093/oxfordjournals.aje.a113462; Kelsey JL, 1983, BREAST GYNECOLOGIC C; LAYDE PM, 1989, J CLIN EPIDEMIOL, V42, P963, DOI 10.1016/0895-4356(89)90161-3; LOGAN WPD, 1953, LANCET, V2, P1199; MACMAHON B, 1973, JNCI-J NATL CANCER I, V50, P21, DOI 10.1093/jnci/50.1.21; VATTEN LJ, 1992, EUR J CANCER, V28A, P1148, DOI 10.1016/0959-8049(92)90476-I; WILLIAMS EMI, 1990, BRIT MED J, V300, P578, DOI 10.1136/bmj.300.6724.578; WINGO PA, 1988, AM J EPIDEMIOL, V128, P206, DOI 10.1093/oxfordjournals.aje.a114942; WINGO PA, 1991, OBSTET GYNECOL, V78, P161; 1983, JAMA-J AM MED ASSOC, V249, P1591; 1986, NEW ENGL J MED, V315, P401	14	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1672	1674		10.1136/bmj.308.6945.1672	http://dx.doi.org/10.1136/bmj.308.6945.1672			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025460	Green Published			2022-12-28	WOS:A1994NU48300019
J	KREZEL, AM; WAGNER, G; SEYMOURULMER, J; LAZARUS, RA				KREZEL, AM; WAGNER, G; SEYMOURULMER, J; LAZARUS, RA			STRUCTURE OF THE RGD PROTEIN DECORSIN - CONSERVED MOTIF AND DISTINCT FUNCTION IN LEECH PROTEINS THAT AFFECT BLOOD-CLOTTING	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; GLYCOPROTEIN-IIB-IIIA; PLATELET-AGGREGATION INHIBITORS; AMINO-ACID-SEQUENCE; RECOMBINANT HIRUDIN; DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURES; ALPHA-THROMBIN; CELL-ADHESION; FACTOR-XA	The structure of the leech protein decorsin, a potent 39-residue antagonist of glycoprotein IIb-IIIa and inhibitor of platelet aggregation, was determined by nuclear magnetic resonance. In contrast to other disintegrins, the Arg-Gly-Asp (RGD)-containing region of decorsin is well defined. The three-dimensional structure of decorsin is similar to that of hirudin, an anticoagulant leech protein that potently inhibits thrombin. Amino acid sequence comparisons suggest that ornatin, another glycoprotein IIb-IIIa antagonist, and antistasin, a potent Factor Xa inhibitor and anticoagulant found in leeches, share the same structural motif. Although decorsin, hirudin, and antistasin all affect the blood clotting process and appear similar in structure, their mechanisms of action and epitopes important for binding to their respective targets are distinct.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; GENENTECH INC, DEPT PROT ENGN, San Francisco, CA 94080 USA	Harvard University; Harvard Medical School; Roche Holding; Genentech								ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; BANG NU, 1992, TRENDS CARDIOVAS MED, V2, P183, DOI 10.1016/1050-1738(92)90047-V; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; CLORE GM, 1987, EMBO J, V6, P529, DOI 10.1002/j.1460-2075.1987.tb04785.x; COLMAN RW, 1994, HEMOSTASIS THROMBOSI, P3; DENNIS MS, 1993, PROTEINS, V15, P312, DOI 10.1002/prot.340150308; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DODT J, 1984, FEBS LETT, V165, P180, DOI 10.1016/0014-5793(84)80165-9; DUNWIDDIE C, 1989, J BIOL CHEM, V264, P16694; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FOLKERS PJM, 1989, BIOCHEMISTRY-US, V28, P2601, DOI 10.1021/bi00432a038; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; HOLM L, 1992, PROTEIN SCI, V1, P1691, DOI 10.1002/pro.5560011217; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KNAPP A, 1992, J BIOL CHEM, V267, P24230; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREZEL AM, UNPUB; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lazarus Robert A., 1993, Current Opinion in Biotechnology, V4, P438, DOI 10.1016/0958-1669(93)90009-L; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARKWARDT F, 1994, THROMB RES, V74, P1, DOI 10.1016/0049-3848(94)90032-9; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; MAZUR P, 1991, EUR J BIOCHEM, V202, P1073, DOI 10.1111/j.1432-1033.1991.tb16472.x; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NUTT E, 1988, J BIOL CHEM, V263, P10162; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SAWYER RT, 1991, BIO-TECHNOL, V9, P513, DOI 10.1038/nbt0691-513; SEEMULLER U, 1986, PROTEINASE INHIBITOR, P337; SENN H, 1993, J MOL BIOL, V232, P907, DOI 10.1006/jmbi.1993.1439; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; SEYMOURULMER J, UNPUB; SOLLNER C, 1994, EUR J BIOCHEM, V219, P937, DOI 10.1111/j.1432-1033.1994.tb18575.x; STEINER V, 1992, BIOCHEMISTRY-US, V31, P2294, DOI 10.1021/bi00123a012; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SZYPERSKI T, 1992, J MOL BIOL, V228, P1206, DOI 10.1016/0022-2836(92)90326-F; SZYPERSKI T, 1992, J MOL BIOL, V228, P1193, DOI 10.1016/0022-2836(92)90325-E; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; VITALI J, 1992, J BIOL CHEM, V267, P17670; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9	48	131	138	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	1994	264	5167					1944	1947		10.1126/science.8009227	http://dx.doi.org/10.1126/science.8009227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009227				2022-12-28	WOS:A1994NT84700049
J	POTAMITIS, T; FOULADI, M; AGGARWAL, RK; JONES, HS; FIELDER, AR				POTAMITIS, T; FOULADI, M; AGGARWAL, RK; JONES, HS; FIELDER, AR			GENERAL-PRACTITIONERS AWARENESS OF DIFFERENT TECHNIQUES OF CATARACT-SURGERY - IMPLICATIONS FOR QUALITY OF CARE	BRITISH MEDICAL JOURNAL			English	Article											POTAMITIS, T (corresponding author), BIRMINGHAM & MIDLAND EYE HOSP,BIRMINGHAM B3 2NS,ENGLAND.							COURTNEY P, 1992, EYE, V6, P487, DOI 10.1038/eye.1992.103; HODGKINS PR, 1992, BRIT J OPHTHALMOL, V76, P323, DOI 10.1136/bjo.76.6.323; MCDONNELL PJ, 1985, OPHTHALMOLOGY, V92, P1208; 1993, HOSPITAL EPISODE STA, V1, P133; 1979, AM J OPHTHALMOL, V88, P45	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1334	1335		10.1136/bmj.308.6940.1334	http://dx.doi.org/10.1136/bmj.308.6940.1334			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019220	Green Published			2022-12-28	WOS:A1994NM98900021
J	BAYNASH, AG; HOSODA, K; GIAID, A; RICHARDSON, JA; EMOTO, N; HAMMER, RE; YANAGISAWA, M				BAYNASH, AG; HOSODA, K; GIAID, A; RICHARDSON, JA; EMOTO, N; HAMMER, RE; YANAGISAWA, M			INTERACTION OF ENDOTHELIN-3 WITH ENDOTHELIN-B RECEPTOR IS ESSENTIAL FOR DEVELOPMENT OF EPIDERMAL MELANOCYTES AND ENTERIC NEURONS	CELL			English	Article							PROTEIN-KINASE-C; PROCESSING ENDOPROTEASES; SUBTILISIN FAMILY; NEURAL CREST; CLONING; CDNA; GENE; MICE; EXPRESSION; CELLS	Defects in the gene encoding the endothelin-B receptor produce aganglionic megacolon and pigmentary disorders in mice and humans. We report that a targeted disruption of the mouse endothelin-3 ligand (EDN3) gene produces a similar recessive phenotype of megacolon and coat color spotting. A natural recessive mutation that results in the same developmental defects in mice, lethal spotting (Is), failed to complement the targeted EDN3 allele. The Is mice carry a point mutation of the EDN3 gene, which replaces the Arg residue at the C-terminus of the inactive intermediate big EDN3 with a Trp residue. This mutation prevents the proteolytic activation of big EDN3 by ECE-1. These findings indicate that interaction of EDN3 with the endothelin-B receptor is essential in the development of neural crest-derived cell lineages. We postulate that defects in the human EDN3 gene may cause Hirschsprung's disease.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; MONTREAL GEN HOSP,DEPT PATHOL,MONTREAL,PQ H3G 1A4,CANADA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; McGill University	BAYNASH, AG (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.			Hammer, Robert E./0000-0001-5487-7551; Emoto, Noriaki/0000-0001-6673-2616				ANDERSON DJ, 1994, FASEB J, V8, P707, DOI 10.1096/fasebj.8.10.8050669; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARINAMI T, 1991, AM J HUM GENET, V48, P990; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BLOCH KD, 1989, J BIOL CHEM, V264, P18156; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; DOUGLAS SA, 1994, TRENDS PHARMACOL SCI, V15, P313, DOI 10.1016/0165-6147(94)90019-1; EIPPER BA, 1993, PROTEIN SCI, V2, P489; FABBRINI MS, 1993, P NATL ACAD SCI USA, V90, P3923, DOI 10.1073/pnas.90.9.3923; Hosoda K, 1994, CELL, V79; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KAPUR RP, 1993, DEVELOPMENT, V117, P993; KOSAKA T, 1994, J BIOCHEM-TOKYO, V116, P443, DOI 10.1093/oxfordjournals.jbchem.a124544; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; Lyon M., 1989, GENETIC VARIANTS STR; MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V164, P74, DOI 10.1016/0006-291X(89)91684-7; MAYER TC, 1977, DEV BIOL, V56, P255, DOI 10.1016/0012-1606(77)90268-8; OHLSTEIN EH, 1994, P NATL ACAD SCI USA, V91, P8052, DOI 10.1073/pnas.91.17.8052; OKADA K, 1993, EUR J BIOCHEM, V218, P493, DOI 10.1111/j.1432-1033.1993.tb18401.x; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; PUFFENBERGER EG, 1994, CELL, V79; RANDALL MD, 1994, LANCET, V344, P832, DOI 10.1016/S0140-6736(94)92819-3; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; ROTHMAN TP, 1993, DEV BIOL, V159, P559, DOI 10.1006/dbio.1993.1264; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SHIBA R, 1992, BIOCHEM BIOPH RES CO, V186, P588, DOI 10.1016/S0006-291X(05)80849-6; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; STEINER DF, 1992, J BIOL CHEM, V267, P23435; SUZUKI N, 1990, BIOCHEM BIOPH RES CO, V169, P809, DOI 10.1016/0006-291X(90)90403-A; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	43	724	745	0	26	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1277	1285		10.1016/0092-8674(94)90018-3	http://dx.doi.org/10.1016/0092-8674(94)90018-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001160				2022-12-28	WOS:A1994PZ86000018
J	ELMORE, JG; FEINSTEIN, AR				ELMORE, JG; FEINSTEIN, AR			GOLDBERGER,JOSEPH - AN UNSUNG HERO OF AMERICAN CLINICAL EPIDEMIOLOGY	ANNALS OF INTERNAL MEDICINE			English	Biographical-Item								Pellagra, a disease rarely seen in developed countries today, was common during the first half of this century in the United States. The disease was initially believed to be infectious, and severe ''pellagraphobia'' left many victims and their families ostracized. This paper calls attention to Joseph Goldberger, an American physician whose remarkable research helped correct the erroneous belief in an infectious cause for pellagra and led to the elimination of pellagra epidemics in the United States.			ELMORE, JG (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, 333 CEDAR ST, POB 208025, NEW HAVEN, CT 06520 USA.							BOLLET AJ, 1992, YALE J BIOL MED, V65, P211; Brim CJ, 1942, ARCH DERMATOL SYPH, V45, P371, DOI 10.1001/archderm.1942.01500080115012; CARPENTER KJ, 1981, FED PROC, V40, P1531; Chittenden RH, 1917, AM J PHYSIOL, V44, P13, DOI 10.1152/ajplegacy.1917.44.1.13; Elvehjem CA, 1937, J AM CHEM SOC, V59, P1767, DOI 10.1021/ja01288a509; Etheridge E.W., 1972, BUTTERFLY CASTE SOCI, V17); GODLBERGER J, 1920, HYGIENIC LABORATORY, V120, P7; Goldberger J, 1918, J AMER MED ASSOC, V71, P944; GOLDBERGER J., 1927, Public Health Reports, V42, P2706, DOI 10.2307/4578558; Goldberger J, 1914, PUBLIC HEALTH REP, V29, P1683, DOI 10.2307/4570920; GOLDBERGER J., 1926, Public Health Reports, V41, P297, DOI 10.2307/4577789; Goldberger J, 1923, PUBLIC HEALTH REP, V38, P2361, DOI 10.2307/4576901; GOLDBERGERJ, 1916, PUBLIC HLTH REP, V31, P3159; GOLDSMITH GA, 1958, AM J CLIN NUTR, V6, P479, DOI 10.1093/ajcn/6.5.479; KELSEY JL, 1986, METHODS OBSERVATIONA; LAVINDER C. H., 1912, Public Health Reports, V27, P2076, DOI 10.2307/4568999; Mausner J, 1985, EPIDEMIOLOGY INTRO T; Mead GH., 1936, SOCIAL PSYCHOL SELEC; Niles GM, 1912, J AMER MED ASSOC, V58, P1341; Roe D.A., 1973, PLAGUE CORN SOCIAL H; Rothman K, 1986, MODERN EPIDEMIOLOGY; SILER J. F., 1914, Journal of the American Medical Association, V62, P8; Siler JF, 1914, ARCH INTERN MED, V14, P293, DOI 10.1001/archinte.1914.00070150006002; Snow J., 1855, MODE COMMUNICATION C; STEWART CP, 1953, TREATISE SCURVY BICE; Sydenstricker Edgar, 1918, PUBLIC HEALTH REP, V33, P2038; Terris M, 1964, GOLDBERGER PELLAGRA; WILDER RM, 1956, JAMA-J AM MED ASSOC, V162, P1539, DOI 10.1001/jama.1956.72970340006010	28	23	23	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					372	375		10.7326/0003-4819-121-5-199409010-00010	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042827				2022-12-28	WOS:A1994PD70100010
J	WALCO, GA; CASSIDY, RC; SCHECHTER, NL				WALCO, GA; CASSIDY, RC; SCHECHTER, NL			PAIN, HURT, AND HARM - THE ETHICS OF PAIN CONTROL IN INFANTS AND CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SICKLE-CELL DISEASE; POSTOPERATIVE ANALGESIA; MORPHINE INFUSION; PEDIATRIC PAIN; ADOLESCENTS; MANAGEMENT; UNDERTREATMENT; PHYSICIANS; EFFICACY; PATIENT		UNIV MED & DENT NEW JERSEY,NEWARK,NJ 07103; LONG ISL JEWISH MED CTR,SCHNEIDER CHILDRENS HOSP,NEW HYDE PK,NY 11042; UNIV CONNECTICUT,CTR HLTH,FARMINGTON,CT 06032	Rutgers State University New Brunswick; Rutgers State University Medical Center; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; University of Connecticut								ANAND K J S, 1987, Anesthesiology (Hagerstown), V67, pA502, DOI 10.1097/00000542-198709001-00502; ANAND KJS, 1987, LANCET, V1, P62; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANAND R, 1987, LANCET, V2, P234; ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; ARUNASALAM K, 1983, ANAESTHESIA, V38, P529; BEASLEY SW, 1987, AUST NZ J SURG, V57, P233, DOI 10.1111/j.1445-2197.1987.tb01346.x; BERDE C, 1990, PEDIATRICS, V86, pS818; BERDE CB, 1991, J PEDIATR-US, V118, P460, DOI 10.1016/S0022-3476(05)82169-9; CHAPMAN CR, 1989, CANCER, V63, P1636; DILWORTH NM, 1987, J PEDIATR SURG, V22, P264, DOI 10.1016/S0022-3468(87)80343-3; Eland JM, 1977, PAIN SOURCE BOOK NUR, P453; Ferrell B R, 1991, J Clin Ethics, V2, P108; Fitzgerald M., 1993, PAIN INFANTS CHILDRE, P11; GRUNAU RVE, 1987, PAIN, V28, P395, DOI 10.1016/0304-3959(87)90073-X; HAMMOND D, 1979, PERSPECT BIOL MED, V23, P152; HAYNES RB, 1984, JAMA-J AM MED ASSOC, V251, P61, DOI 10.1001/jama.251.1.61; ILOWITE NT, 1992, ANN RHEUM DIS, V51, P313; KOREN G, 1985, J PEDIATR-US, V107, P963, DOI 10.1016/S0022-3476(85)80205-5; LEVINE JD, 1982, PAIN, V14, P85, DOI 10.1016/0304-3959(82)90090-2; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MARSHALL RE, 1980, INFANT BEHAV DEV, V3, P1, DOI 10.1016/S0163-6383(80)80003-8; MCCAFFERY M, 1993, PAIN INFANTS CHILDRE, P295; MCGRATH PA, 1987, PAIN, V31, P147, DOI 10.1016/0304-3959(87)90033-9; MCGRATH PJ, 1989, PEDIATR CLIN N AM, V36, P823; MECHANIC D, 1980, J HEALTH SOC BEHAV, V21, P146, DOI 10.2307/2136734; MIASKOWSKI C, 1993, 7TH WORLD C PAIN PAR, P2; MILLER RR, 1978, J CLIN PHARMACOL, V18, P180, DOI 10.1002/j.1552-4604.1978.tb01591.x; Morrison R A, 1991, Pediatr Nurs, V17, P503; Nolan K., 1993, PAIN INFANTS CHILDRE, P123; PEGELOW CH, 1992, CLIN PEDIATR, V31, P211, DOI 10.1177/000992289203100404; PETRIE A, 1967, INDIVIDUALITY PAIN S; SANDLER AN, 1992, ANESTHESIOL CLIN N A, V10, P271; Schechter N, 1993, PAIN INFANTS CHILDRE; SCHECHTER NL, 1986, PEDIATRICS, V77, P11; SCHECHTER NL, 1986, J DEV BEHAV PEDIATR, V7, P350; SCHECHTER NL, 1989, PEDIATR CLIN N AM, V36, P781; SHANNON M, 1989, PEDIATR CLIN N AM, V36, P855; VAMI JW, 1989, PEDIATRICIAN, V16, P56; WALCO GA, 1990, J PEDIATR PSYCHOL, V15, P643, DOI 10.1093/jpepsy/15.5.643; WILLIAMSON PS, 1983, PEDIATRICS, V71, P36; YASTER M, 1988, J PEDIATR-US, V113, P421, DOI 10.1016/S0022-3476(88)80622-X; YASTER M, 1993, PAIN INFANTS CHILDRE, P145; ZELTZER LK, 1990, PEDIATRICS, V86, pS826; 1990, CANCER PAIN RELIEF P; 1992, AHCPR920032 AG HLTH; 1992, PRINCIPLES ANALGESIC; 1993, ACCREDITATION MANUAL	49	136	137	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					541	544		10.1056/NEJM199408253310812	http://dx.doi.org/10.1056/NEJM199408253310812			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PD072	8041423				2022-12-28	WOS:A1994PD07200012
J	MULLER, A				MULLER, A			THE FAMILY CONNECTION	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					301	302		10.7326/0003-4819-121-4-199408150-00012	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037412				2022-12-28	WOS:A1994PB10200012
J	FRISCH, M; OLSEN, JH; BAUTZ, A; MELBYE, M				FRISCH, M; OLSEN, JH; BAUTZ, A; MELBYE, M			BENIGN ANAL LESIONS AND THE RISK OF ANAL CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CROHNS-DISEASE; CARCINOMA	Background. Benign anal lesions are often considered to cause a predisposition to anal cancer. To reexamine this association, we linked national data on hospital discharge and cancer in Denmark. Methods. After making certain exclusions, we used the Danish Central Hospital Discharge Register to identify 68,549 patients hospitalized with benign anal lesions between 1977 and 1989. Through computerized linkage to the Danish Cancer Registry, all incident cases of epidermoid anal cancer and colorectal cancer among these patients were identified. Follow-up for the occurrence of cancer started the month after the date of the first hospital discharge and continued until the patient died (10.6 percent of the sample), emigrated (0.7 percent), or was lost to follow-up (0.04 percent) or until December 31, 1989 (88.6 percent), whichever came first. Results. The median follow-up period was 6.2 years. There were 23 epidermoid anal cancers and 416 colorectal cancers. The overall relative risk of anal cancer (observed vs. expected cases) was 4.4 (95 percent confidence interval, 2.8 to 6.6). The relative risk was 12.0 (95 percent confidence interval, 5.2 to 23.6) within the first year after hospitalization for benign lesions, 4.6 (95 percent confidence interval, 2.3 to 8.3) from one to four years after hospitalization, and 1.8 (95 percent confidence interval, 0.5 to 4.7) five or more years after hospitalization. The risk of colorectal cancer was significantly increased only during the first year after hospitalization (relative risk, 2.6; 95 percent confidence interval, 2.1 to 3.1). Conclusions. There is a strong temporal association between the diagnosis of benign anal lesions and the diagnosis of anal cancer. Although we could not exclude the possibility of a moderate increase in the long-term risk of anal cancer, our data do not support the view that benign anal lesions cause anal cancer.	DANISH CANC SOC, RES CTR, DIV CANC EPIDEMIOL, COPENHAGEN, DENMARK	Danish Cancer Society	FRISCH, M (corresponding author), STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, EPIDEMIOL RES UNIT, 5 ARTILLERIVEJ, DK-2300 COPENHAGEN S, DENMARK.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; Olsen, Jorgen Helge/0000-0001-9633-5662; melbye, mads/0000-0001-8264-6785				BACON HE, 1964, CANCER COLON RECTUM, P332; BRESLOW NE, 1987, IARC SCI PUBL, V82, P65; BROFELDT SA, 1927, ACTA SOC MED FENN DU, V8, P3; BUCKWALTER JA, 1957, ARCH SURG-CHICAGO, V75, P352; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; EWING J, 1940, NEOPLASTIC DISEASES, P726; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; GOULSTON KJ, 1986, LANCET, V2, P261; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; HUGHES LE, 1992, DIS COLON RECTUM, V35, P928, DOI 10.1007/BF02253493; Keyes EL, 1937, ANN SURG, V106, P1046, DOI 10.1097/00000658-193712000-00008; KLINE RJ, 1964, ARCH SURG-CHICAGO, V89, P989; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; Leichman L P, 1990, Curr Probl Cancer, V14, P117; MELBYE M, 1994, LANCET, V343, P636, DOI 10.1016/S0140-6736(94)92636-0; PRESTON DM, 1983, BRIT J SURG, V70, P346, DOI 10.1002/bjs.1800700612; Rosser C., 1931, AM J SURG, V11, P328; Rothman KJ, 1982, CANCER EPIDEMIOLOGY, P15; SLATER G, 1984, ANN SURG, V199, P348, DOI 10.1097/00000658-198403000-00016; Storm H H, 1991, IARC Sci Publ, P220; 1986, VEJLEDNING UDTRAEK	23	42	47	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					300	302		10.1056/NEJM199408043310504	http://dx.doi.org/10.1056/NEJM199408043310504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022440	Bronze			2022-12-28	WOS:A1994NZ22700004
J	STOVER, E; KELLER, AS; COBEY, J; SOPHEAP, S				STOVER, E; KELLER, AS; COBEY, J; SOPHEAP, S			THE MEDICAL AND SOCIAL-CONSEQUENCES OF LAND MINES IN CAMBODIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNATIONAL-COMMITTEE; RED-CROSS; EXPERIENCE; DEPRESSION		NYU,SCH MED,DEPT MED,NEW YORK,NY; AMER RED CROSS,WASHINGTON,DC 20006; AMER REFUGEE COMM,PHNOM PENH,CAMBODIA	New York University; American Red Cross	STOVER, E (corresponding author), PHYSICIANS HUMAN RIGHTS,100 BOYLSTON ST,SUITE 702,BOSTON,MA 02116, USA.							AKESODE FA, 1981, TROP GEOGR MED, V33, P71; ANDERSON K, 1993, HUMAN RIGHTS WATCH P; Becker Elizabeth, 1986, WAR WAS OVER CAMBODI; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; ESHAYACHAUVIN B, 1992, BRIT J ANAESTH, V68, P221, DOI 10.1093/bja/68.2.221; FAZOL R, 1989, J CARDIOVASC SURG, V30, P39; FINE J, 1992, HIDDEN ENEMIES LAND; GARACHON A, 1993, 1993 S ANT MIN MONTR, P93; GEIGER HJ, 1993, JAMA-J AM MED ASSOC, V270, P616; HIRSCHHORN N, 1991, CLIN NEEDS ASSESSMEN, P37; JOHNSON DE, 1981, J TRAUMA, V21, P486; JOHNSON SR, 1981, J BACTERIOL, V146, P632, DOI 10.1128/JB.146.2.632-638.1981; KASHANI JH, 1983, J CLIN PSYCHIAT, V44, P256; KING F, 1992, THESIS LONDON SCH TR; MARTIN ES, 1985, EXPLOSIVE REMNANTS W; MCCOLLOUGH NC, 1992, ORTHOP CLIN N AM, V3, P136; MCGRATH R, 1991, REPORT AFGHANISTAN M; MCGRATH R, 1992, HIDDEN DEATH LAND MI; MCGRATH R, 1993, LAND MINES ANGOLA; MOLLICA RF, 1990, AM J PSYCHIAT, V147, P83; MOLLICA RF, 1993, JAMA-J AM MED ASSOC, V270, P581, DOI 10.1001/jama.270.5.581; Mollica RF, 1988, CLIN GUIDELINES CROS, P262; MYERS H, 1993, CAMBODIA CANT WAIT, P12; MYSLIWIEK E, 1988, PUNISHING POOR INT I, P42; PIERCE RO, 1993, ORTHOPEDICS, V16, P793; RAUTIO J, 1988, J TRAUMA, V28, P523, DOI 10.1097/00005373-198804000-00019; RONE J, 1986, LAND MINES EL SALVAD; Ryan J M, 1988, J R Army Med Corps, V134, P119; RYBARCZYK BD, 1992, ARCH PHYS MED REHAB, V73, P1169; SHUKLA GD, 1982, BRIT J PSYCHIAT, V141, P50, DOI 10.1192/bjp.141.1.50; STOVER E, 1991, LAND MINES CAMBODIA, P59; THOMPSON DM, 1988, INT REHABIL MED, V5, P165; VARNI JW, 1991, ARCH PHYS MED REHAB, V72, P1053; 1990, CAMBODIA SITUATION C; 1980, UNDOCACONF9515 UN NA; 1993, HIDDEN KILLERS GLOBA; 1992, PERVERSE USE TECHNOL; 1994, LANDMINES UPDATE, P7; 1993, NY TIMES        1227, pA16; 1994, DEMINING SITUATION R; 1981, A36613 UN NAT PUBL; 1994, SECURITY REPORT	42	34	34	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					331	336		10.1001/jama.272.5.331	http://dx.doi.org/10.1001/jama.272.5.331			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028149				2022-12-28	WOS:A1994NY90300001
J	WILSON, MA; MCNAUGHTON, BL				WILSON, MA; MCNAUGHTON, BL			REACTIVATION OF HIPPOCAMPAL ENSEMBLE MEMORIES DURING SLEEP	SCIENCE			English	Article							SYNAPTIC ENHANCEMENT; INFORMATION-STORAGE; ASSOCIATIVE MEMORY; UNIT ACTIVITY; PLASTICITY; POTENTIATION; DYNAMICS; RATES	Simultaneous recordings were made from large ensembles of hippocampal ''place cells'' in three rats during spatial behavioral tasks and in slow-wave sleep preceding and following these behaviors. Cells that fired together when the animal occupied particular locations in the environment exhibited an increased tendency to fire together during subsequent sleep, in comparison to sleep episodes preceding the behavioral tasks. Cells that were inactive during behavior, or that were active but had non-overlapping spatial firing, did not show this increase. This effect, which declined gradually during each post-behavior sleep session, may result from synaptic modification during waking experience. Information acquired during active behavior is thus re-expressed in hippocampal circuits during sleep, as postulated by some theories of memory consolidation.	UNIV ARIZONA, DEPT PSYCHOL, TUCSON, AZ 85724 USA; UNIV ARIZONA, DIV NEURAL SYST MEMORY & AGING, TUCSON, AZ 85724 USA	University of Arizona; University of Arizona					NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH046823, R01MH046823] Funding Source: NIH RePORTER; NIMH NIH HHS [MH46823] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; AMIT DJ, 1989, P NATL ACAD SCI USA, V86, P7871, DOI 10.1073/pnas.86.20.7871; BARNES CA, 1985, BEHAV NEUROSCI, V99, P1040, DOI 10.1037/0735-7044.99.6.1040; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; CHROBAK JJ, IN PRESS J NEUROSCI; GERSTEIN GL, 1969, SCIENCE, V164, P828, DOI 10.1126/science.164.3881.828; GIBSON WG, 1992, NEURAL NETWORKS, V5, P645, DOI 10.1016/S0893-6080(05)80042-5; HEBB DO, 1949, ORG BEHAVIOR; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Landfield P. W., 1987, LONG TERM POTENTIATI; LEONARD BJ, 1987, BRAIN RES, V425, P174; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; McClelland J. L., 1992, Society for Neuroscience Abstracts, V18, P1216; MCGAUGH JL, 1972, MEMORY CONSOLIDATION; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MCNAUGHTON BL, 1990, NEUROSCIENCE CONNECT; MCNAUGHTON BL, 1983, NEUROBIOLOGY HIPPOCA, P609; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV, P150; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; PAVLIDES C, 1989, J NEUROSCI, V9, P2907; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; Squire L. R., 1984, MEMORY CONSOLIDATION, P185; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; TREVES A, 1991, NETWORK-COMP NEURAL, V2, P371, DOI 10.1088/0954-898X/2/4/004; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; WOODY CD, 1972, J NEUROPHYSIOL, V35, P230, DOI 10.1152/jn.1972.35.2.230	32	1883	1912	5	171	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 29	1994	265	5172					676	679		10.1126/science.8036517	http://dx.doi.org/10.1126/science.8036517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036517				2022-12-28	WOS:A1994NZ53800038
J	LEVINE, DM; BECKER, DM; BONE, LR; HILL, MN; TUGGLE, MB; ZEGER, SL				LEVINE, DM; BECKER, DM; BONE, LR; HILL, MN; TUGGLE, MB; ZEGER, SL			COMMUNITY-ACADEMIC HEALTH-CENTER PARTNERSHIPS FOR UNDERSERVED MINORITY POPULATIONS - ONE SOLUTION TO A NATIONAL CRISIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERTENSIVE PATIENTS; BLOOD-PRESSURE; CARE REFORM; EDUCATION		JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH NURSING,BALTIMORE,MD; SANDTOWN WINCHESTER HIGH BLOOD PRESSURE CONTROL P,BALTIMORE,MD; HEART BODY & SOUL & CLERGY UNITED RENEWAL E BALTI,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University	LEVINE, DM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,CTR HLTH PROMOT,DIV INTERNAL MED,1830 E MONUMENT ST 8047,BALTIMORE,MD 21205, USA.			Zeger, Scott/0000-0001-8907-1603				BONE LR, 1989, AM J EMERG MED, V7, P16, DOI 10.1016/0735-6757(89)90077-6; LEVINE D, 1992, J ETHNICITY DIS, V2, P296; LEVINE DM, 1979, JAMA-J AM MED ASSOC, V241, P1700, DOI 10.1001/jama.241.16.1700; LEVINE DM, 1990, J HUM HYPERTENS, V4, P317; LEVINE DM, 1992, AM J PREV MED, V8, P319, DOI 10.1016/S0749-3797(18)30799-2; MILES SH, 1993, ACAD MED, V68, P648, DOI 10.1097/00001888-199309000-00002; MORISKY DE, 1983, AM J PUBLIC HEALTH, V73, P153, DOI 10.2105/AJPH.73.2.153; REMINGTON RD, 1988, 88102 I MED PUBL; SHUGARS DA, 1990, US DHHS9150212 PUBL; STILLMAN F, 1993, PREV MED, V2, P335; WRIGHT RA, 1993, JAMA-J AM MED ASSOC, V269, P2544, DOI 10.1001/jama.269.19.2544; 1993, HLTH PROFESSIONS ED; 1994, CHRONIC DISEASE MORB	13	41	41	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					309	311						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NX806	8028145				2022-12-28	WOS:A1994NX80600034
J	GARIBALDI, RA; TRONTELL, MC; WAXMAN, H; HOLBROOK, JH; KANYA, DT; KHOSHBIN, S; THOMPSON, J; CASEY, M; SUBHIYAH, RG; DAVIDOFF, F				GARIBALDI, RA; TRONTELL, MC; WAXMAN, H; HOLBROOK, JH; KANYA, DT; KHOSHBIN, S; THOMPSON, J; CASEY, M; SUBHIYAH, RG; DAVIDOFF, F			THE IN-TRAINING EXAMINATION IN INTERNAL-MEDICINE	ANNALS OF INTERNAL MEDICINE			English	Article							AMERICAN-BOARD; CERTIFYING EXAMINATION; PREDICTIVE-VALIDITY; PERFORMANCES; RESIDENTS; MANPOWER; PROGRAMS; SURGERY; TRENDS	Objective: The In-Training Examination in Internal Medicine (ITE-IM) has been offered to internal medicine trainees annually since 1988 as an instrument for self-assessment. This report outlines the manner in which the test is prepared, reviews the results of annual examinations, and analyzes trends during the past 6 years. Design: Results of each examination were reviewed with regard to the demographic characteristics of persons taking the test, their previous medical training, and their present program affiliations. Results: The number of residents participating in the ITE-IM has increased steadily over the past 6 years. In 1993, more than 12 000 residents from more than 90% of internal medicine training programs in the United States participated in the examination; the percentage of international medical school graduates taking the examination increased from 27% in 1988 to 47% in 1993. Statistical analyses of each examination have shown it to be reliable, internally consistent, and discriminating. Over the past 6 years, graduates of U.S. medical schools have scored consistently higher than those of international medical schools and schools of osteopathic medicine on all annual examinations. However, in 1993, for residents at all levels of training, the differences in scores between graduates of U.S. medical schools and graduates of international medical schools narrowed substantially. From 1988 to 1993, there has been a trend toward tower scores by every cohort on each subsequent examination. The decreases in scores are most pronounced for graduates of U.S. medical school and those of schools of osteopathic medicine. The lower scores may be caused by either an increased level of difficulty in the examination or decreased knowledge among examinees. Conclusions: The ITE-IM is a useful instrument to assess the knowledge base of residents during internal medicine training. It provides residents and program directors with a reliable evaluation of themselves and their programs in comparison to their national peer groups. It also provides objective data to monitor trends over time in residents' scores and relates them to the changing demographic characteristics of trainees and to innovations in the clinical curricula of internal medicine training programs.	ROBERT WOOD JOHNSON MED CTR, NEW BRUNSWICK, NJ USA; ALBERT EINSTEIN MED CTR, PHILADELPHIA, PA USA; AMER COLL PHYSICIANS, PHILADELPHIA, PA USA; NATL BOARD MED EXAMINERS, PHILADELPHIA, PA USA; UNIV UTAH, SALT LAKE CITY, UT USA; BRIGHAM & WOMENS HOSP, BOSTON, MA USA; UNIV KENTUCKY, SCH MED, LEXINGTON, KY 40536 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Yeshiva University; American College of Physicians; Utah System of Higher Education; University of Utah; Harvard University; Brigham & Women's Hospital; University of Kentucky	GARIBALDI, RA (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT MED, ROOM LG-004, FARMINGTON, CT 06030 USA.							ANDERSEN RM, 1990, ANN INTERN MED, V113, P243, DOI 10.7326/0003-4819-113-3-243; ANDERSEN RM, 1992, ANN INTERN MED, V117, P243, DOI 10.7326/0003-4819-117-3-243; BUCKWALTER JA, 1981, J BONE JOINT SURG AM, V63, P1001, DOI 10.2106/00004623-198163060-00018; DONOVAN AJ, 1985, AM COLLEGE SURGERY B, V70, P3; GARIBALDI RA, 1992, CAREERS INTERNAL MED, V1, P12; Geyman J P, 1976, J Fam Pract, V3, P409; GROSSE ME, 1980, ARCH SURG-CHICAGO, V115, P654; HALL JR, 1990, ACAD MED, V65, P475, DOI 10.1097/00001888-199007000-00016; LEIGH TM, 1990, ACAD MED, V65, P454, DOI 10.1097/00001888-199007000-00009; LINN RL, 1989, ED MEASUREMENT, P359; LINN RL, 1989, ED MEASUREMENT, P113; MAHOUR GH, 1986, J PEDIATR SURG, V21, P154; NORCINI JJ, 1989, JAMA-J AM MED ASSOC, V262, P2402, DOI 10.1001/jama.262.17.2402; NORCINI JJ, 1993, J GEN INTERN MED, V8, P82, DOI 10.1007/BF02599989; NORCINI JJ, 1986, JAMA-J AM MED ASSOC, V256, P3367, DOI 10.1001/jama.256.24.3367; RAMSEY PG, 1989, ANN INTERN MED, V110, P719, DOI 10.7326/0003-4819-110-9-719; RUBIN ML, 1969, AM J OPHTHALMOL, V67, P70, DOI 10.1016/0002-9394(69)90010-5; SHEA JA, 1990, ACAD MED, V65, P523, DOI 10.1097/00001888-199008000-00008; 1988, ANN REPORT REFERENCE	19	33	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					117	123		10.7326/0003-4819-121-2-199407150-00008	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017725				2022-12-28	WOS:A1994NW18600008
J	KABA, H; HAYASHI, Y; HIGUCHI, T; NAKANISHI, S				KABA, H; HAYASHI, Y; HIGUCHI, T; NAKANISHI, S			INDUCTION OF AN OLFACTORY MEMORY BY THE ACTIVATION OF A METABOTROPIC GLUTAMATE-RECEPTOR	SCIENCE			English	Article							PREGNANCY BLOCK; BRAIN-FUNCTION; MESSENGER-RNA; RAT-BRAIN; BULB; MODULATION; INHIBITION; SYSTEM	Female mice form an olfactory memory of male pheromones at mating; exposure to the pheromones of a strange male after that mating will block pregnancy. The formation of this memory is mediated by the accessory olfactory system, in which an increase in norepinephrine after mating reduces inhibitory transmission of gamma-aminobutyric acid from the granule cells to the mitral cells. This study shows that the activation of mGluR2, a metabotropic glutamate receptor that suppresses the gamma-aminobutyric acid inhibition of the mitral cells, permits the formation of a specific olfactory memory without the occurrence of mating by infusion of mGluR2 agonists into the female's accessory olfactory bulb. This memory faithfully reflects the memory formed at mating.	KOCHI MED SCH,DEPT PHYSIOL,NANKO KU,KOCHI 783,JAPAN; KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN	Kochi University; Kyoto University			Hayashi, Yasunori/C-2249-2008; Hayashi, Yasunori/AAF-1408-2019	Hayashi, Yasunori/0000-0002-7560-3004; Hayashi, Yasunori/0000-0002-7560-3004; Kaba, Hideto/0000-0002-5187-1995				BRENNAN P, 1990, SCIENCE, V250, P1223, DOI 10.1126/science.2147078; BRENNAN PA, 1992, NEUROSCIENCE, V49, P277, DOI 10.1016/0306-4522(92)90095-J; BRENNAN PA, 1989, NEUROSCIENCE, V33, P463, DOI 10.1016/0306-4522(89)90398-9; BRUCE HM, 1959, NATURE, V184, P105, DOI 10.1038/184105a0; HALASZ N, 1990, VERTEBRATE OLFACTORY; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; JAHR CE, 1982, NATURE, V297, P227, DOI 10.1038/297227a0; KABA H, 1989, NEUROSCIENCE, V32, P657, DOI 10.1016/0306-4522(89)90287-X; KABA H, 1988, NEUROSCIENCE, V25, P1007, DOI 10.1016/0306-4522(88)90053-X; KABA H, 1988, NEUROSCIENCE, V24, P93, DOI 10.1016/0306-4522(88)90314-4; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHISHI H, 1993, J COMP NEUROL, V335, P252, DOI 10.1002/cne.903350209; OHISHI H, 1993, NEUROSCIENCE, V53, P1009, DOI 10.1016/0306-4522(93)90485-X; ROSSER AE, 1985, NEUROSCIENCE, V15, P1141, DOI 10.1016/0306-4522(85)90258-1; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; TROMBLEY PQ, 1992, J NEUROSCI, V12, P3985	19	145	149	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					262	264		10.1126/science.8023145	http://dx.doi.org/10.1126/science.8023145			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023145				2022-12-28	WOS:A1994NV95700045
J	GU, H; MARTH, JD; ORBAN, PC; MOSSMANN, H; RAJEWSKY, K				GU, H; MARTH, JD; ORBAN, PC; MOSSMANN, H; RAJEWSKY, K			DELETION OF A DNA-POLYMERASE-BETA GENE SEGMENT IN T-CELLS USING CELL-TYPE-SPECIFIC GENE TARGETING	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; TRANSGENIC MICE; EXPRESSION; BACTERIOPHAGE-P1; PATHWAYS; REGIONS	Deletion of the promoter and the first exon of the DNA polymerase beta gene (pol beta) in the mouse germ line results in a lethal phenotype. With the use of the bacteriophage-derived, site-specific recombinase Cre in a transgenic approach, the same mutation can be selectively introduced into a particular cellular compartment-in this case, T cells. The impact of the mutation on those cells can then be analyzed because the mutant animals are viable.	UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA; MAX PLANCK INST IMMUNOBIOL, D-79011 FREIBURG, GERMANY	University of British Columbia; University of British Columbia; Max Planck Society	GU, H (corresponding author), UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY.			Rajewsky, Klaus/0000-0002-6633-6370				ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; FRY M, 1983, ENZYMES NUCLEIC ACID, P39; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Gu H.-Q., UNPUB; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; Sambrook J, 1989, MOL CLONING LABORATO; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SAUER B, 1990, New Biologist, V2, P441; Sprent Jonathan, 1993, P75; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; YAMAGUCHI M, 1987, MOL CELL BIOL, V7, P2012, DOI 10.1128/MCB.7.5.2012	21	1110	1265	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	1994	265	5168					103	106		10.1126/science.8016642	http://dx.doi.org/10.1126/science.8016642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016642				2022-12-28	WOS:A1994NV30100036
J	PRUDENT, JR; UNO, T; SCHULTZ, PG				PRUDENT, JR; UNO, T; SCHULTZ, PG			EXPANDING THE SCOPE OF RNA CATALYSIS	SCIENCE			English	Article							LIGANDS; ENZYME; ANTIBODIES; EVOLUTION; LIBRARY; TETRAHYMENA; MOLECULES; SELECTION; RIBOZYME; INVITRO	The basic notions of transition state theory have been exploited in the past to generate highly selective catalysts from the vast library of antibody molecules in the immune system. These same ideas were used to isolate an RNA molecule, from a large library of RNAs, that catalyzes the isomerization of a bridged biphenyl. The RNA-catalyzed reaction displays Michaelis-Menten kinetics with a catalytic rate constant (k(cat)) of 2.8 x 10(-5) per minute and a Michaelis constant (K-m) of 542 mu M; the reaction is competitively inhibited by the planar transition state analog with an inhibition constant (K-i) value of similar to 7 mu M. This approach may provide a general strategy for expanding the scope of RNA catalysis beyond those reactions in which the substrates are nucleic acids or nucleic acid derivatives.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley				Prudent, James/0000-0002-8948-1781	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008352] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08352A] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; Criegee R, 1942, LIEBIGS ANN CHEM, V550, P99; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HALDANE JBS, 1930, ENZYMES, P182; HALL DM, 1950, J CHEM SOC, P711, DOI 10.1039/jr9500000711; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; LEHMAN N, 1993, NATURE, V361, P182, DOI 10.1038/361182a0; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MISLOW K, 1962, J AM CHEM SOC, V84, P1449, DOI 10.1021/ja00867a022; MISLOW K, 1964, J AM CHEM SOC, V86, P1710, DOI 10.1021/ja01063a014; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; REBEK J, 1980, TETRAHEDRON LETT, V21, P2379, DOI 10.1016/S0040-4039(00)93154-X; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEGEL IH, 1975, ENZYME KINETICS, P46; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	32	136	150	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1924	1927						4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009223				2022-12-28	WOS:A1994NT84700043
J	GILBERT, K; MCCARTHY, M				GILBERT, K; MCCARTHY, M			DEATHS OF CYCLISTS IN LONDON 1985-92 - THE HAZARDS OF ROAD TRAFFIC	BRITISH MEDICAL JOURNAL			English	Article							BICYCLE ACCIDENTS; INJURIES	Objective-To determine the characteristics of cyclists and vehicles involved in fatal cycling accidents. Design-Analysis of data routinely collected by police for each accident from January 1985 to December 1992 and held in a national master file (Stats 19) by the Department of Transport. Setting-Greater London, which comprises inner London (12 boroughs and the City of London) and outer London (20 boroughs). Subjects-178 cyclists who died (78 in inner London and 100 in outer London; age range 3-88). Main outcome measures-Associations between characteristics of cyclists, type of vehicle involved, and place of accident. Results-Motor vehicles were involved in 173 deaths. Heavy goods vehicles were involved in 75 deaths (30/100 (30%) in outer London and 45/78 (58%) in inner London); cars in 74 (54/100) (54%) in outer London and 20/78 (26%) in inner London); light goods vehicles in 12/178 (7%); and buses in 6/178 (3%). Thirty five of the people who died were children aged less than or equal to 16. Female cyclists were especially at risk from heavy goods vehicles in inner London (22 deaths), while male cyclists were especially at risk from cars in outer London (50 deaths). Discussion-Cyclists who died in urban areas are more likely to be adults than children. In inner London, in relation to their traffic volume, heavy goods vehicles are estimated to cause 30 times as many cyclists' deaths as cars and five times as many as buses. Until the factors leading to this excess risk are understood, a ban on heavy goods vehicles in urban areas should be considered.	CAMDEN & ISLINGTON HLTH AUTHOR,LONDON NW1 2LJ,ENGLAND				McCarthy, Mark/C-1117-2009					ATKINSON JE, 1983, ACCIDENT ANAL PREV, V15, P137, DOI 10.1016/0001-4575(83)90069-6; DOWNING C, 1985, PEDAL CYCLING ACCIDE; FIFE D, 1983, J TRAUMA, V23, P745, DOI 10.1097/00005373-198308000-00011; FRIEDE AM, 1985, PEDIATR CLIN N AM, V32, P141; Hillman M, 1993, CYCLE HELMETS CASE; HOQUE MM, 1990, ACCIDENT ANAL PREV, V22, P1; JOLY MF, 1989, CAN J PUBLIC HEALTH, V80, P351; Joshi M.S., 1992, HEALTH EDUC J, V51, P188, DOI [https://doi.org/10.1177/001789699205100409, DOI 10.1177/001789699205100409]; MCCARTHY M, 1991, PUBLIC HEALTH, V105, P327, DOI 10.1016/S0033-3506(05)80218-5; NIXON J, 1987, BRIT MED J, V294, P1267, DOI 10.1136/bmj.294.6582.1267; OSTROM M, 1993, INT J EPIDEMIOL, V22, P483, DOI 10.1093/ije/22.3.483; RILEY BS, 1980, SR586 TRANSP ROAD RE; SELBST SM, 1987, AM J DIS CHILD, V141, P140, DOI 10.1001/archpedi.1987.04460020030021; STUTTS JC, 1990, ACCIDENT ANAL PREV, V22, P67, DOI 10.1016/0001-4575(90)90008-9; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; WARD H, 1991, PREVENTING ROAD ACCI; 1994, LONDON AREA TRANSPOR; 1992, FATALITY FACTS 1992; 1991, ROAD ACCIDENTS GREAT; 1988, PEDAL CYCLE ACCIDENT; 1992, LONDON REGION TRANSP; 1992, HLTH NATION; 1992, CYCLING HLTH SAFETY; 1992, REDUCING TRAFFIC INJ; 1992, 1992 DEP TRANSP LOND; 1991, BIKES NOT FUEMS; 1990, ACTION ACCIDENTS UNI	27	27	27	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1534	1537		10.1136/bmj.308.6943.1534	http://dx.doi.org/10.1136/bmj.308.6943.1534			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NR110	8019308	Green Published			2022-12-28	WOS:A1994NR11000020
J	ORCHARD, C				ORCHARD, C			COMPARING HEALTH-CARE OUTCOMES	BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL MORTALITY; SEVERITY; CARE; INFORMATION; SURGERY	Governments are increasingly concerned to compare the quality and effectiveness of healthcare interventions but find this a complex matter. Crude hospital statistics can be dangerously misleading and need adjusting for case mix, but identifying and weighting the patient characteristics which affect prognosis are problematical for conceptual, methodological, and practical reasons. These include the inherently uncertain nature of prognosis itself and the practical difficulties of collecting and quantifying data on the outcomes of interest for specific healthcare interventions and known risk factors such as severity.			ORCHARD, C (corresponding author), NATL HLTH SERV EXECUT,INFORMAT MANAGEMENT GRP,NATL CASEMIX OFF,WINCHESTER SO23 9JA,HANTS,ENGLAND.							BION J, 1993, BRIT MED J, V307, P953, DOI 10.1136/bmj.307.6910.953; BLUMBERG MS, 1991, JAMA-J AM MED ASSOC, V265, P2965; BRADBURY RC, 1991, HEALTH SERV RES, V26, P407; BUCKLAND R, 1993, BRIT MED J, V306, P287, DOI 10.1136/bmj.306.6873.287; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; FELSON DT, 1991, ARTHRITIS RHEUM, V34, P499, DOI 10.1002/art.1780340420; FISHER ES, 1990, EFFECTIVENESS OUTCOM; FRIES JF, 1981, PROGNOSIS CONT OUTCO; GULLIFORD MC, 1992, J EPIDEMIOL COMMUN H, V46, P323, DOI 10.1136/jech.46.4.323; HARTZ AJ, 1992, AM J CARDIOL, V70, P179, DOI 10.1016/0002-9149(92)91272-6; Holland W., 1983, EVALUATION HLTH CARE; Hornbrook M C, 1982, Med Care Rev, V39, P73, DOI 10.1177/107755878203900201; Iezzoni L I, 1992, QRB Qual Rev Bull, V18, P44; IEZZONI LI, 1992, MED CARE, V30, P347, DOI 10.1097/00005650-199204000-00005; IEZZONI LI, 1990, MED CARE, V28, P757, DOI 10.1097/00005650-199009000-00001; IEZZONI LI, 1991, INQUIRY-J HEALTH CAR, V28, P117; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEANING MS, 1993, BRIT MED J, V307, P217, DOI 10.1136/bmj.307.6898.217; McDowell I, 1987, MEASURING HLTH GUIDE; MCKENNA F, 1988, BRIT J EPIDMEIOLO S1, V27, P1; PICKHAM M, 1993, RES HLTH; ROOS NP, 1989, SOC SCI MED, V28, P109, DOI 10.1016/0277-9536(89)90137-8; SILBER JH, 1992, MED CARE, V30, P615, DOI 10.1097/00005650-199207000-00004; 1992, CROSS DESIGN SYNTHES; 1992, LANCET, V340, P944; 1993, LANCET, V341, P573	28	45	46	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1493	1496		10.1136/bmj.308.6942.1493	http://dx.doi.org/10.1136/bmj.308.6942.1493			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NQ229	8019285	Green Published			2022-12-28	WOS:A1994NQ22900024
J	MACGREGOR, JE; CAMPBELL, MK; MANN, EMF; SWANSON, KY				MACGREGOR, JE; CAMPBELL, MK; MANN, EMF; SWANSON, KY			SCREENING FOR CERVICAL INTRAEPITHELIAL NEOPLASIA IN NORTH-EAST SCOTLAND SHOWS FALL IN INCIDENCE AND MORTALITY FROM INVASIVE CANCER WITH CONCOMITANT RISE IN PREINVASIVE DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DYSKARYOSIS; CYTOLOGY; WOMEN; SMEAR; MILD; CARCINOMA; TRENDS	Objective-To assess the effect of screening for cervical intraepithelial neoplasia on the incidence of and mortality from invasive squamous cell carcinoma of cervix in north east Scotland and to discover why cases of invasive cancer still occur. Design-(a) Analysis of data on cases of cervical intraepithelial neoplasia obtained from the cytology data bank; (b) analysis of data on 612 women presenting with invasive squamous cancer during 1968-91, obtained from cancer registry and hospital records; (c) analysis of death rates obtained from the registrar general's (Scotland) annual reports, the Information Services Division of the Home and Health Department (Scotland), and local records for 1974-91; (d) case-control studies on 282 cases of invasive cancer and 108 deaths which occurred in 1982-91. Cases were matched with two controls both for age and for having a negative smear test result at the time of presentation of the case. Setting-North east Scotland (Grampian region, Orkney, and Shetland). Subjects-Women (n=306 608) who had had cervical smear tests between 1960 and 1991. Results-There had been a substantial increase in cases of cervical intraepithelial neoplasia grade III since 1982. The incidence of invasive cancer has fallen since the start of screening in 1960, the fall occurring mainly in the well screened age group 40-69 years. There was a rise in women aged under 40 and over 70. Women with invasive disease seen between 1982 and 1991 mostly presented at stage I. Of these, half were unscreened, one third were poorly screened, 11% were found in retrospect to have had abnormal cells, 3% had recurrence of disease after treatment for cervical intraepithelial neoplasia grade III, and 3% were lost to follow up. Death rates had fallen, most noticeably in women aged 45-64, who had had the opportunity to be screened and rescreened. There was a disturbing rise in deaths among women under 45. Most deaths (65%) occurred in unscreened women. Case-control studies showed that the longer the time and absence of a smear test before presentation the higher was the risk of invasive cancer and of death. Conclusions-Screening has been effective in reducing the incidence of and mortality from cervical cancer in north east Scotland. Most cases and deaths occurred in unscreened women or in those who had had few smears at long intervals, An increase in cases of cervical intraepithelial neoplasia grade III in women screened for the first time occurred during 1982-91.	UNIV ABERDEEN, HARRIS BIRTHRIGHT RES CTR, DEPT PATHOL, ABERDEEN AB9 2ZD, SCOTLAND; GRAMPIAN AREA HLTH BOARD, ABERDEEN, SCOTLAND; ABERDEEN ROYAL HOSP, NHS TRUST, ABERDEEN, SCOTLAND; UNIV ABERDEEN, HARRIS BIRTHRIGHT RES CTR, DEPT GYNAECOL, ABERDEEN, SCOTLAND	University of Aberdeen; University of Aberdeen			Campbell, Marion/ABB-7063-2020					ANDERSON DJ, 1992, BMJ-BRIT MED J, V305, P84, DOI 10.1136/bmj.305.6845.84; ANDERSON GH, 1988, BMJ-BRIT MED J, V296, P975, DOI 10.1136/bmj.296.6627.975; BERKELEY AS, 1980, LANCET, V2, P375; BETHWAITE P, 1992, BRIT J OBSTET GYNAEC, V99, P745, DOI 10.1111/j.1471-0528.1992.tb13877.x; COOK GA, 1984, BRIT J CANCER, V50, P367, DOI 10.1038/bjc.1984.185; COOPER P, 1992, CYTOPATHOLOGY, V3, P331; COPPLESON LW, 1974, AM J OBSTET GYNECOL, V119, P953, DOI 10.1016/0002-9378(74)90013-1; COTTON RE, 1986, BRIT MED J, V292, P799, DOI 10.1136/bmj.292.6523.799-a; CURLING M, 1992, ADV GYNAECOLOGICAL P, P62; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; GRAY M, 1992, GUIDELINES CLIN PRAC; HUSAIN OAN, 1974, J CLIN PATHOL, V27, P935, DOI 10.1136/jcp.27.12.935; ISMAIL SM, 1989, BRIT MED J, V298, P707, DOI 10.1136/bmj.298.6675.707; JHA PKS, 1993, LANCET, V341, P1116, DOI 10.1016/0140-6736(93)93128-N; KIRBY AJ, 1992, LANCET, V339, P828, DOI 10.1016/0140-6736(92)90278-B; LAARA E, 1987, LANCET, V1, P1247; LAWSON JG, 1956, J OBSTET GYNAECOL, V63, P819; MACGREGOR JE, 1993, BRIT J OBSTET GYNAEC, V100, P801, DOI 10.1111/j.1471-0528.1993.tb14301.x; MACGREGOR JE, 1991, BRIT J OBSTET GYNAEC, V98, P6, DOI 10.1111/j.1471-0528.1991.tb10302.x; MACGREGOR JE, 1961, BRIT MED J, V1, P1631; ROBERTSON AJ, 1989, J CLIN PATHOL, V42, P231, DOI 10.1136/jcp.42.3.231; SILCOCKS PBS, 1988, BRIT J OBSTET GYNAEC, V95, P1111, DOI 10.1111/j.1471-0528.1988.tb06787.x; SMITH A, 1988, BRIT MED J, V296, P1670, DOI 10.1136/bmj.296.6637.1670; THOMPSON B, 1993, HLTH ED J, V52, P62; THOMPSON B, 1989, HAVING 1ST BABY EXPE; VANOORTMARSSEN GJ, 1992, BRIT MED J, V305, P449, DOI 10.1136/bmj.305.6851.449; VANWIJNGAARDEN WJ, 1993, BRIT MED J, V306, P967, DOI 10.1136/bmj.306.6883.967; 1992, REGISTRAR GENERAL AN; 1990, GRAMPIAN HLTH BOARD, P14; 1990, FACTS CANCER; 1990, GRAMPIAN HLTH PROFIL	31	97	106	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	1994	308	6941					1407	1411		10.1136/bmj.308.6941.1407	http://dx.doi.org/10.1136/bmj.308.6941.1407			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019250	Green Published			2022-12-28	WOS:A1994NP42000015
J	SETO, E; LEWIS, B; SHENK, T				SETO, E; LEWIS, B; SHENK, T			INTERACTION BETWEEN TRANSCRIPTION FACTORS SP1 AND YY1	NATURE			English	Article							SYNERGISTIC ACTIVATION; INITIATOR; ENHANCER; PROTEIN; DOMAINS; TRANSACTIVATOR; REPRESSION; EXPRESSION; ELEMENTS; INVITRO	A BASAL level of transcription is usually observed when all but a small region of DNA has been deleted from a eukaryotic gene promoter. These promoter elements, which are necessary and sufficient for specific transcription initiation, are referred to as minimal or core promoter elements. One element that is commonly present in a core promoter is the initiator. It has been demonstrated that the presence of Sp1 binding sites can greatly enhance the level of transcription initiation at initiator elements1-4. A binding site for the YY1 transcription factor, located at the initiation site of the adeno-associated virus P5 promoter, functions as an initiator element; a synergistic enhancement of its activity is observed in vitro when upstream Sp1 binding sites are present3. Here we report that this synergistic activation probably occurs through protein-protein interactions.	PRINCETON UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Howard Hughes Medical Institute; Princeton University	SETO, E (corresponding author), UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78245, USA.							BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	20	260	264	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					462	464		10.1038/365462a0	http://dx.doi.org/10.1038/365462a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8003102				2022-12-28	WOS:A1993LZ63300063
J	SEKUL, EA; CUPLER, EJ; DALAKAS, MC				SEKUL, EA; CUPLER, EJ; DALAKAS, MC			ASEPTIC-MENINGITIS ASSOCIATED WITH HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN THERAPY - FREQUENCY AND RISK-FACTORS	ANNALS OF INTERNAL MEDICINE			English	Article						MENINGITIS, ASEPTIC; IMMUNOGLOBULINS; DOSE-RESPONSE RELATIONSHIP DRUG; INJECTIONS, INTRAVENOUS; MIGRAINE	IMMUNE GLOBULIN; CONTROLLED TRIAL; NEUROPATHY; INFUSIONS	Objective: Intravenous immunoglobulin is widely used to treat various autoimmune disorders. After observing instances of aseptic meningitis in treated patients, we studied the frequency and associated risk factors for aseptic meningitis in patients treated with high-dose intravenous immunoglobulin. Design: Retrospective analysis of a prospective cohort study. Setting: Tertiary research referral center. Patients: 54 consecutive patients with various immune-related neuromuscular diseases participating in ongoing therapeutic trials of high-dose (2 g/kg) intravenous immunoglobulin. Measurements: Analysis of patient records for evidence of aseptic meningitis, associated risk factors, penetration of serum IgG into the cerebrospinal fluid, and clearance of cerebrospinal fluid IgG. Results: Of 54 patients, 6 (11%; 95% CI, 4% to 23%) developed aseptic meningitis within 24 hours after completion of the infusions. Symptoms, lasting 3 to 5 days, included severe headache, meningismus, photophobia, and fever. Cerebrospinal fluid showed pleocytosis in 4 patients (leukocyte count as high as 1169 x 10(6)/L in one patient), eosinophilia in 3 patients, and IgG elevation in all patients (as great as 7 times the upper limit of normal in one patient). Repeat cerebrospinal fluid and serum studies after 24 hours showed a 46% cerebrospinal fluid IgG clearance compared with an 11% clearance of serum IgG in one patient. Cerebrospinal fluid cultures were negative. Aseptic meningitis developed in 4 of 8 patients (50%; CI, 16% to 84%) with a history of migraine but in only 2 of 46 (4%; CI, 0.5% to 15%) patients without such a history (P = 0.003). Aseptic meningitis recurred in patients who had migraine despite the use of different commercial intravenous immunoglobulin preparations and slower rates of infusion. Conclusion: Aseptic meningitis develops in patients receiving high-dose intravenous immunoglobulin therapy. patients with a history of migraine are more likely to develop aseptic meningitis while receiving intravenous immunoglobulin therapy, regardless of the type of commercial preparation or the infusion rate. Possible inciting factors include the IgG itself, various stabilizing products within each of the preparations, cytokine release triggered by the therapy, or cerebrovascular sensitivity in migraineurs.	NINCDS, NEUROMUSCULAR DIS SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Cupler, Edward/0000-0003-0958-8931				ACHIRON A, 1992, ARCH NEUROL-CHICAGO, V49, P1233, DOI 10.1001/archneur.1992.00530360031013; ADAIR JC, 1991, NEUROLOGY, V41, P249, DOI 10.1212/WNL.41.2_Part_1.249; ARUSRA E, 1989, CLIN IMMUNOL IMMUNOP, V53, pS170; BALLOW M, 1991, CANCER, V68, P1430, DOI 10.1002/1097-0142(19910915)68:6+<1430::AID-CNCR2820681405>3.0.CO;2-4; BUCKLEY RH, 1980, IMMUNOGLOBULINS CHAR, P3; CASTEELSVANDAELE M, 1990, NEW ENGL J MED, V323, P614; CHAUDHRY V, 1993, ANN NEUROL, V33, P237, DOI 10.1002/ana.410330303; CHEZ M, 1989, NEUROLOGY, V39, P1578, DOI 10.1212/WNL.39.12.1578; CONSTANTINESCU CS, 1993, NEW ENGL J MED, V329, P583, DOI 10.1056/NEJM199308193290820; COOK D, 1990, NEUROLOGY, V40, P212, DOI 10.1212/WNL.40.2.212; CUTLER RWP, 1970, J NEUROL SCI, V10, P259, DOI 10.1016/0022-510X(70)90154-1; DALAKAS MC, 1984, ANN NEUROL, V15, P590, DOI 10.1002/ana.410150612; DALAKAS MC, 1994, NEUROLOGY, V44, P223, DOI 10.1212/WNL.44.2.223; DALAKAS MC, 1994, SEMIN NEUROL, V14, P97, DOI 10.1055/s-2008-1041065; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; DALAKAS MC, 1994, IN PRESS ARCH NEUROL; DWYER JM, 1992, NEW ENGL J MED, V326, P107; Fishman RA, 1992, CEREBROSPINAL FLUID, P198; GELFAND EW, 1984, CLIN IMMUNOL IMMUNOP, V53, P51; GORDON MF, 1990, NEUROLOGY, V40, P163, DOI 10.1212/WNL.40.1.163; KATO E, 1988, JAMA-J AM MED ASSOC, V259, P3269, DOI 10.1001/jama.1988.03720220017011; KREMER I, 1983, NEW ENGL J MED, V308, P1481; Martelletti P, 1991, Acta Neurol (Napoli), V13, P448; Covelli V, 1992, Acta Neurol (Napoli), V14, P313; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; NEWLAND A C, 1991, P15; Raskin N, 1988, HEADACHE; ROBERTON DM, 1988, AUST PAEDIATR J, V24, P174; SCHWARTZ SA, 1990, J CLIN IMMUNOL, V10, P81, DOI 10.1007/BF00918189; SERGENT JS, 1978, JAMA-J AM MED ASSOC, V240, P529; SOUEIDAN SA, 1993, NEUROLOGY, V43, P876, DOI 10.1212/WNL.43.5.876; TAN E, 1993, ARCH NEUROL-CHICAGO, V50, P137, DOI 10.1001/archneur.1993.00540020015010; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; VERARAMIREZ M, 1992, NEUROLOGY, V42, P1636, DOI 10.1212/WNL.42.8.1636-a	34	286	293	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					259	262		10.7326/0003-4819-121-4-199408150-00004	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037406				2022-12-28	WOS:A1994PB10200004
J	KLIKS, SC; WARA, DW; LANDERS, DV; LEVY, JA				KLIKS, SC; WARA, DW; LANDERS, DV; LEVY, JA			FEATURES OF HIV-1 THAT COULD INFLUENCE MATERNAL-CHILD TRANSMISSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-ASSOCIATED RETROVIRUS; V3 LOOP PEPTIDES; VERTICAL TRANSMISSION; INFECTED INDIVIDUALS; TYPE-1 VARIANTS; UNITED-STATES; GP120; MOTHERS; ANTIBODIES	Objective.-To evaluate the biological and serological properties of the human immunodeficiency virus type 1 (HIV-1) for factors potentially involved in the mother-to-child transmission of HIV-1. Design.-Isolates of HIV-1 were recovered from the blood of 12 of 44 nontransmitting mothers and six of eight transmitting mothers and their corresponding infants. These 24 HIV-1 isolates were compared for their biological and immunologic properties to discern any parameters that correlate with vertical transmission of HIV-1. Main Outcome Measures.-Replication capabilities of the above-mentioned HIV-1 isolates in human peripheral blood mononuclear cells (PBMCs), human macrophages, and various T-cell lines and the susceptibilities of the viruses to neutralization or enhancement by anti-HIV-1 antibodies in autologous serum samples from mothers and infants. Setting.-San Francisco Bay Area, California. Participants.-A cohort of 52 HIV-1-infected women and their infants in a prospective study on perinatal HIV transmission by the Bay Area Perinatal AIDS Center. Results.-The viral isolates from the transmitting mothers and their infants differed from the isolates from the nontransmitting mothers in their efficient replication in human PBMCs and in their ability to infect one or more human T-lymphocytic cell lines. All the HIV-1 isolates were able to infect human macrophages with only low-level replication and were unable to form syncytia in the MTP-lymphocytic cells. No correlation between transmission and reactivity of maternal serum samples to the peptide corresponding to the principal neutralization domain of the third hypervariable region of the viral envelope was observed. However, the majority (9/12) of maternal isolates from the nontransmitters were neutralized by their autologous serum samples compared with only two among six in the transmitter group (P<.07). Moreover, five infant isolates were resistant to neutralization by their respective mothers' serum samples, and one was sensitive to infection enhancement by the mother's serum. Another infant isolate was enhanced by his autologous serum. Conclusions.-Viral factors that appeared to correlate with mother-to-child transmission of HIV-1 observed in a small cohort included rapid or high-titered replication in human PBMCs, T-cell line tropism, and resistance to neutralization or a sensitivity to enhancement of infection by the maternal Serum.	UNIV CALIF SAN FRANCISCO,SCH MED,DIV PEDIAT IMMUNOL,SAN FRANCISCO,CA; SAN FRANCISCO GEN HOSP,DEPT OBSTET & GYNECOL,SAN FRANCISCO,CA 94110	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	KLIKS, SC (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143, USA.				NIAID NIH HHS [R01 AI32446-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032446] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASJO B, 1986, LANCET, V2, P660; BROLIDEN PA, 1989, AIDS, V3, P577, DOI 10.1097/00002030-198909000-00004; CASTRO BA, 1988, J CLIN MICROBIOL, V26, P2371, DOI 10.1128/JCM.26.11.2371-2376.1988; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; CHENGMAYER C, 1989, P NATL ACAD SCI USA, V86, P8575, DOI 10.1073/pnas.86.21.8575; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; CHU SY, 1991, PEDIATRICS, V87, P806; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EVANS LA, 1987, J IMMUNOL, V138, P3415; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, LANCET, V2, P1351; GORNY MK, 1992, J VIROL, V66, P7538, DOI 10.1128/JVI.66.12.7538-7542.1992; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HALSEY NA, 1992, J ACQ IMMUN DEF SYND, V5, P153; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HOMSY J, 1988, LANCET, V1, P1285; HOMSY J, 1990, J VIROL, V64, P1437, DOI 10.1128/JVI.64.4.1437-1440.1990; KESSON AM, 1993, J INFECT DIS, V168, P571, DOI 10.1093/infdis/168.3.571; KLIKS SC, 1993, P NATL ACAD SCI USA, V90, P11518, DOI 10.1073/pnas.90.24.11518; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; LALLEMANT M, 1994, LANCET, V343, P1001, DOI 10.1016/S0140-6736(94)90126-0; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LEWIS SH, 1990, LANCET, V335, P565, DOI 10.1016/0140-6736(90)90349-A; LYMAN WD, 1990, AIDS, V4, P917, DOI 10.1097/00002030-199009000-00014; MARKHAM RB, 1994, LANCET, V343, P390, DOI 10.1016/S0140-6736(94)91225-4; MCDOUGAL JS, 1985, J IMMUNOL METHODS, V76, P171, DOI 10.1016/0022-1759(85)90489-2; MOK JYQ, 1989, ARCH DIS CHILD, V64, P1140, DOI 10.1136/adc.64.8.1140; MOORE JP, 1993, AIDS RES HUM RETROV, V9, P209, DOI 10.1089/aid.1993.9.209; PAN LZ, 1987, J INFECT DIS, V155, P626, DOI 10.1093/infdis/155.4.626; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1169; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SAKAMOTO D, 1993, J CELL BIOCH E S, V17, P85; SCARLATTI G, 1993, P NATL ACAD SCI USA, V90, P1721, DOI 10.1073/pnas.90.5.1721; SCARLATTI G, 1993, VIROLOGY, V197, P624, DOI 10.1006/viro.1993.1637; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; STIEHM ER, 1991, J PEDIATR-US, V118, P410, DOI 10.1016/S0022-3476(05)82157-2; TATENO M, 1988, VIROLOGY, V167, P209; TERSMETTE M, 1989, LANCET, V1, P983; TUOFU Z, 1993, SCIENCE, V261, P1179; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; VALENTIN A, 1990, VIROLOGY, V177, P790, DOI 10.1016/0042-6822(90)90551-2; WILLIAMSHERMAN D, 1993, 9TH P INT C AIDS BER, V1, P313; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZIEGLER JB, 1985, LANCET, V1, P896; 1991, LANCET, V337, P253; 1992, LANCET, V339, P1007; 1987, MMWR-MORBID MORTAL W, V36, P35; 1987, MMWR-MORBID MORTAL W, V36, P225	53	101	101	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					467	474		10.1001/jama.272.6.467	http://dx.doi.org/10.1001/jama.272.6.467			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040983				2022-12-28	WOS:A1994PA27800029
J	WHITE, PC				WHITE, PC			MECHANISMS OF DISEASE - DISORDERS OF ALDOSTERONE BIOSYNTHESIS AND ACTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONGENITAL ADRENAL-HYPERPLASIA; APPARENT MINERALOCORTICOID EXCESS; GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; 21-HYDROXYLASE DEFICIENCY; HUMAN HYPERTENSION; ADDISONS-DISEASE; GENETIC-BASIS; RECEPTOR; CYP11B2		CORNELL UNIV,COLL MED,DIV PEDIAT ENDOCRINOL,NEW YORK,NY	Cornell University	WHITE, PC (corresponding author), UNIV TEXAS,SW MED CTR,DIV PEDIAT ENDOCRINOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NIDDK NIH HHS [DK37094, DK42169, DK37867] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042169, R01DK037867, R37DK037867, R01DK037094] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; ARAI K, IN PRESS J CLIN ENDO; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BARBOZA A, 1992, AIDS, V6, P1437, DOI 10.1097/00002030-199212000-00003; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROWN LS, 1991, ENDOCRIN METAB CLIN, V20, P655, DOI 10.1016/S0889-8529(18)30263-9; CURNOW KM, 1993, P NATL ACAD SCI USA, V90, P4552, DOI 10.1073/pnas.90.10.4552; CURNOW KM, 1991, MOL ENDOCRINOL, V5, P1513, DOI 10.1210/mend-5-10-1513; DIMARTINONARDI J, 1987, CLIN ENDOCRINOL, V27, P49, DOI 10.1111/j.1365-2265.1987.tb00838.x; DUCHATELLE P, 1992, MOL CELL BIOCHEM, V114, P27; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; GOMEZSANCHEZ CE, 1988, J CLIN ENDOCR METAB, V67, P444, DOI 10.1210/jcem-67-3-444; GORDON RD, 1992, LANCET, V340, P159, DOI 10.1016/0140-6736(92)93225-C; HANUKOGLU A, 1991, J CLIN ENDOCR METAB, V73, P936, DOI 10.1210/jcem-73-5-936; HORISBERGER JD, 1992, HYPERTENSION, V19, P221, DOI 10.1161/01.HYP.19.3.221; IRONY I, 1990, AM J HYPERTENS, V3, P576, DOI 10.1093/ajh/3.7.576; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; KOMESAROFF P, IN PRESS J CLIN ENDO; KUHNLE U, 1990, J CLIN ENDOCR METAB, V70, P638, DOI 10.1210/jcem-70-3-638; LIFTON RP, 1992, NAT GENET, V2, P66, DOI 10.1038/ng0992-66; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; LIN D, 1991, J CLIN INVEST, V88, P1955, DOI 10.1172/JCI115520; LING BN, 1991, KIDNEY INT, V40, P441, DOI 10.1038/ki.1991.231; MASON AS, 1968, LANCET, V2, P744; MCKENNA TJ, 1991, J CLIN ENDOCR METAB, V73, P952, DOI 10.1210/jcem-73-5-952; MELBY JC, 1991, ENDOCRIN METAB CLIN, V20, P247, DOI 10.1016/S0889-8529(18)30266-4; MIGEON CJ, 1990, PEDIAT ENDOCRINOLOGY, P333; MITSUUCHI Y, 1993, BIOCHEM BIOPH RES CO, V190, P864, DOI 10.1006/bbrc.1993.1128; MOSER HW, 1992, J INHERIT METAB DIS, V15, P645, DOI 10.1007/BF01799621; MOSER HW, 1992, J INHERIT METAB DIS, V15, P918, DOI 10.1007/BF01800233; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NEUFELD M, 1981, MEDICINE, V60, P355, DOI 10.1097/00005792-198109000-00003; NIKKILA H, 1993, J CLIN ENDOCR METAB, V77, P687, DOI 10.1210/jc.77.3.687; OBERFIELD SE, 1981, J CLIN ENDOCR METAB, V53, P158, DOI 10.1210/jcem-53-1-158; PALMER LG, 1992, SEMIN NEPHROL, V12, P37; PASCOE L, 1992, P NATL ACAD SCI USA, V89, P4996, DOI 10.1073/pnas.89.11.4996; PASCOE L, 1992, P NATL ACAD SCI USA, V89, P8327, DOI 10.1073/pnas.89.17.8327; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; QUINN SJ, 1988, ANNU REV PHYSIOL, V50, P409, DOI 10.1146/annurev.ph.50.030188.002205; RHEAUME E, 1992, NAT GENET, V1, P239, DOI 10.1038/ng0792-239; Rogoff J M, 1927, Science, V66, P327, DOI 10.1126/science.66.1710.327; ROSLER A, 1984, J CLIN ENDOCR METAB, V59, P689; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; SCHENKMAN JB, 1993, HDB EXPT PHARM, V105; Selye H, 1950, PHYSL PATHOLOGY EXPO; SIMPSON SA, 1954, EXPERIENTIA, V10, P132, DOI 10.1007/BF02158515; SONINO N, 1987, NEW ENGL J MED, V317, P812, DOI 10.1056/NEJM198709243171307; SPEISER PW, 1991, NEW ENGL J MED, V324, P145, DOI 10.1056/NEJM199101173240302; SPEISER PW, 1992, J CLIN INVEST, V90, P584, DOI 10.1172/JCI115897; STEWART PM, 1987, LANCET, V2, P821; STUHRMANN M, 1991, HUM GENET, V86, P414; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; ULICK S, 1992, J CLIN ENDOCR METAB, V74, P1415, DOI 10.1210/jc.74.6.1415; ULICK S, 1979, J CLIN ENDOCR METAB, V49, P757, DOI 10.1210/jcem-49-5-757; ULICK S, 1990, J CLIN ENDOCR METAB, V71, P1151, DOI 10.1210/jcem-71-5-1151; ULICK S, 1992, J CLIN ENDOCR METAB, V74, P593, DOI 10.1210/jc.74.3.593; WEHLING M, 1993, TRENDS PHARMACOL SCI, V14, P1, DOI 10.1016/0165-6147(93)90104-R; WHITE PC, 1992, J CLIN ENDOCR METAB, V74, P6, DOI 10.1210/jc.74.1.6; WINQVIST O, 1992, LANCET, V339, P1559, DOI 10.1016/0140-6736(92)91829-W; YAMAGUCHI T, 1990, HYPERTENSION, V16, P635, DOI 10.1161/01.HYP.16.6.635; YANASE T, 1991, ENDOCR REV, V12, P91, DOI 10.1210/edrv-12-1-91; ZENNARO MC, IN PRESS J CLIN ENDO	64	148	150	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					250	258						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	8015573				2022-12-28	WOS:A1994NY33500008
J	SCHWARTZ, AB				SCHWARTZ, AB			DIRECT CORTICAL REPRESENTATION OF DRAWING	SCIENCE			English	Article							UNIT-ACTIVITY; MOVEMENTS; KINEMATICS; GEOMETRY; LEECH	How the intention to act results in movement is a fundamental question of brain organization. Recent work has shown that this operation involves the cooperative interaction of large neuronal populations. A population vector method, by transforming neuronal activity to the spatial domain, was used to visualize the motor cortical representation of the hand's trajectory made by rhesus monkeys as they drew spirals. Hand path was accurately reflected by a series of population vectors calculated throughout the task. A psychophysical rule relating speed to curvature, the ''power law,'' was found in this cortical representation. The relative timing between each population vector and the corresponding portion of the movement was variable. The population vectors only preceded the movement in a predictive manner in portions of the spiral where the radius of curvature was greater than 6 centimeters. These results show that the movement trajectory is an important determinant of motor cortical activity and that this aspect of motor cortical activity may contribute only to discrete portions of the drawing movement.			SCHWARTZ, AB (corresponding author), BARROW NEUROL INST,DIV NEUROBIOL,350 W THOMAS RD,PHOENIX,AZ 85013, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026375] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-26375] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAEV KV, 1991, NEUROSCIENCE, V43, P237, DOI 10.1016/0306-4522(91)90431-M; EDELMAN GM, 1978, MINDFUL BRAIN; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; JUNG MW, 1993, HIPPOCAMPUS, V3, P165, DOI 10.1002/hipo.450030209; KALASKA JF, 1992, SCIENCE, V255, P1517, DOI 10.1126/science.1549781; LACQUANITI F, 1983, ACTA PSYCHOL, V54, P115, DOI 10.1016/0001-6918(83)90027-6; LOCKERY SR, 1990, J NEUROSCI, V10, P1811; LUNDBERG A, 1971, EXP BRAIN RES, V12, P317; MASSEY JT, 1992, EXP BRAIN RES, V88, P685; SCHWARTZ AB, 1993, J NEUROPHYSIOL, V70, P28, DOI 10.1152/jn.1993.70.1.28; SCHWARTZ AB, 1992, J NEUROPHYSIOL, V68, P528, DOI 10.1152/jn.1992.68.2.528; VIVIANI P, 1991, J EXP PSYCHOL HUMAN, V17, P198, DOI 10.1037/0096-1523.17.1.198; WANN J, 1988, J EXP PSYCHOL HUMAN, V14, P622, DOI 10.1037/0096-1523.14.4.622; WITTENBERG G, 1992, J NEUROPHYSIOL, V68, P1693, DOI 10.1152/jn.1992.68.5.1693; [No title captured]	16	242	243	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					540	542		10.1126/science.8036499	http://dx.doi.org/10.1126/science.8036499			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NY216	8036499				2022-12-28	WOS:A1994NY21600036
J	DUBOIS, RM				DUBOIS, RM			DIFFUSE LUNG-DISEASE - AN APPROACH TO MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article							CRYPTOGENIC FIBROSING ALVEOLITIS; RESOLUTION COMPUTED-TOMOGRAPHY; CT; APPEARANCES; SURVIVAL; ACCURACY; BIOPSY				DUBOIS, RM (corresponding author), ROYAL BROMPTON HOSP,LONDON SW3 6NP,ENGLAND.							COLLINS CD, IN PRESS CLIN RADIOL; DUBOIS RM, 1987, ADV MED, V23, P21; GILMAN MJ, 1980, AM REV RESPIR DIS, V122, P721, DOI 10.1164/arrd.1980.122.5.721; HANSELL DM, 1991, THORAX, V46, P77, DOI 10.1136/thx.46.2.77; JOHNSON MA, 1989, THORAX, V44, P280, DOI 10.1136/thx.44.4.280; JOHNSTON I, 1990, BRIT MED J, V301, P1017, DOI 10.1136/bmj.301.6759.1017; JOHNSTON IDA, 1993, EUR RESPIR J, V6, P891; LEE JS, 1992, RADIOLOGY, V184, P451, DOI 10.1148/radiology.184.2.1620846; MATHIESON JR, 1989, RADIOLOGY, V171, P111, DOI 10.1148/radiology.171.1.2928513; MULLER NL, 1987, RADIOLOGY, V165, P731; MULLER NL, 1991, AM J ROENTGENOL, V157, P1163; MULLER NL, 1990, AM REV RESPIR DIS, V142, P1206; MULLER NL, 1990, AM REV RESPIR DIS, V142, P1440; PANOS RJ, 1991, IMMUNOLOGICALLY MEDI, P1; SMITH C M, 1990, American Review of Respiratory Disease, V141, pA62; TUKIAINEN P, 1983, THORAX, V38, P349, DOI 10.1136/thx.38.5.349; TUNG KT, 1993, THORAX, V48, P334, DOI 10.1136/thx.48.4.334; TURNERWARWICK M, 1987, AM REV RESPIR DIS, V135, P26; TURNERWARWICK M, 1980, THORAX, V35, P593, DOI 10.1136/thx.35.8.593; TURNERWARWICK M, 1980, THORAX, V35, P171, DOI 10.1136/thx.35.3.171; VENN GE, 1985, THORAX, V40, P931, DOI 10.1136/thx.40.12.931; WEINBERGER SE, 1978, ANN INTERN MED, V89, P459, DOI 10.7326/0003-4819-89-4-459; WELLS AU, 1992, THORAX, V47, P738, DOI 10.1136/thx.47.9.738; WELLS AU, 1993, EUR RESPIR J, V6, P797; WELLS AU, 1993, AM J ROENTGENOL, V161, P1159, DOI 10.2214/ajr.161.6.8249719; WELLS AU, 1993, AM REV RESPIR DIS, V148, P1076, DOI 10.1164/ajrccm/148.4_Pt_1.1076; 1991, MORTALITY STATISTICS	27	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					175	179						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044098				2022-12-28	WOS:A1994NY22900025
J	ALTMAN, DG; CHALMERS, I; HERXHEIMER, A				ALTMAN, DG; CHALMERS, I; HERXHEIMER, A			IS THERE A CASE FOR AN INTERNATIONAL-MEDICAL-SCIENTIFIC-PRESS-COUNCIL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC			Serious abuse of editorial power is rarely publicized, but evidence that it occurs is accumulating. Authors who believe that they have been dealt with unfairly have little possibility of a hearing of their complaint, and cases cannot easily be publicized because of fears of legal action. We describe briefly three cases in which the alleged misdeeds indicate that there were legitimate questions that needed answers. In the first case, an editor republished a previously published article without the authors' permission (but stated the opposite), attacked it in an accompanying editorial, and then denied the authors the right of reply. The other cases concerned a commissioned review article that was plagiarized and an editor with an undisclosed vested interest. An appeal process is needed for authors who think that they are victims of editorial abuse of power. We suggest that the International Committee of Medical Journal Editors turn its attention to editorial misconduct and explore possible procedures for allowing authors' grievances to be heard and for possible sanctions if complaints are upheld. An International Medical Scientific Press Council might be established to produce a code of conduct for editors and a corresponding taxonomy of inappropriate editorial behavior.	NATL HLTH SERV RES & DEV PROGRAMME,COCHRANE CTR,OXFORD,ENGLAND	Cochrane Centre	ALTMAN, DG (corresponding author), IMPERIAL CANC RES FUND,MED STAT LAB,POB 123,61 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							DEWEY ME, 1993, BRIT MED J, V306, P318, DOI 10.1136/bmj.306.6873.318; HERXHEIMER A, 1989, SCIENTIST       0320, P11; HERXHEIMER A, 1989, SCIENTIST       0320, P9; LAFOLLETTE M, 1992, STEALING PRINT; LOCK S, 1993, FRAUD MISCONDUCT SCI; RENNIE D, 1991, BALANCING ACT ESSAYS, P9; 1993, LANCET, V341, P742	7	23	23	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					166	167		10.1001/jama.272.2.166	http://dx.doi.org/10.1001/jama.272.2.166			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015135				2022-12-28	WOS:A1994NV42400025
J	SWEITZER, BJ; CULLEN, DJ				SWEITZER, BJ; CULLEN, DJ			HOW WELL DOES A JOURNALS PEER-REVIEW PROCESS FUNCTION - A SURVEY OF AUTHORS OPINIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		MANUSCRIPTS	Objective.-To evaluate the authors' satisfaction or dissatisfaction with the peer review process of the Journal of Clinical Anesthesia. Design.-Anonymous questionnaires were sent to authors to survey their opinions about specific aspects of the peer review process. Authors were grouped by status of their manuscripts: AR (accept with revision), RR (reject but may resubmit), and RO (reject outright). Participants.-Authors of unsolicited manuscripts submitted in 1991 to 1992. Main Outcome Measures.-Factors that determine authors' satisfaction with the relevancy and benefit of peer review of their manuscript. Results.-Significantly more authors of AR manuscripts responded to our survey than did authors of rejected manuscripts and viewed the review process more favorably. Authors of AR manuscripts were more satisfied with specific aspects of the review process, which led to improvement in their manuscripts. More authors of RR manuscripts believed that our review process improved subsequent manuscript preparation than did authors of accepted manuscripts. Conclusions.-The surveying of authors, important clients of the peer review process, should guide change necessary to better serve our authors and improve peer review.	MASSACHUSETTS GEN HOSP,DEPT ANESTHESIA,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital								BAILAR JC, 1985, NEW ENGL J MED, V312, P654, DOI 10.1056/NEJM198503073121023; BURNHAM JC, 1990, JAMA-J AM MED ASSOC, V263, P1323, DOI 10.1001/jama.263.10.1323; GARFUNKEL JM, 1990, JAMA-J AM MED ASSOC, V263, P1376, DOI 10.1001/jama.263.10.1376; HORROBIN DF, 1990, JAMA-J AM MED ASSOC, V263, P1438, DOI 10.1001/jama.263.10.1438; INGELFINGER FJ, 1974, AM J MED, V56, P686, DOI 10.1016/0002-9343(74)90635-4; LOCK S, 1986, SCHOLARLY PUBL, V17, P302; RENNIE D, 1988, ANN INTERN MED, V109, P181, DOI 10.7326/0003-4819-109-3-181; SCOTT WA, 1974, AM PSYCHOL, V29, P698, DOI 10.1037/h0037631; 1990, JAMA-J AM MED ASSOC, V263, P1317	9	22	22	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					152	153		10.1001/jama.272.2.152	http://dx.doi.org/10.1001/jama.272.2.152			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015130				2022-12-28	WOS:A1994NV42400020
J	RIDDIHOUGH, G				RIDDIHOUGH, G			NO LIMITS ON RESTRICTION	NATURE			English	Note							CRYSTAL-STRUCTURE; ENDONUCLEASE											ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; CHENG X, IN PRESS EMBO J; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; NEWMAN M, 1994, STRUCTURE, V2, P439, DOI 10.1016/S0969-2126(00)00045-9; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; RIDDIHOUGH G, 1994, NATURE, V368, P82, DOI 10.1038/368082a0; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	7	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					78	78		10.1038/370078a0	http://dx.doi.org/10.1038/370078a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015614	Bronze			2022-12-28	WOS:A1994NV71100064
J	BROMWICH, P; COHEN, J; STEWART, I; WALKER, A				BROMWICH, P; COHEN, J; STEWART, I; WALKER, A			DECLINE IN SPERM COUNTS - AN ARTIFACT OF CHANGED REFERENCE RANGE OF NORMAL	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate a reported fall in sperm counts during 1940-90 in relation to the reduced lower reference value of ''normal'' during the same period by assuming the null hypothesis that no change had occurred in the probability distribution of the sperm concentration. Design-Analysis by using various mathematical models of the probability distribution of sperm concentration together with experimental data which supported a model employing a logarithmic distribution.	UNIV WARWICK,CTR ECOSYST ANAL & MANAGEMENT,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND; MIDLAND FERTIL SERV,ALDRIDGE WS9 8LT,STAFFS,ENGLAND; UNIV WARWICK,INST MATH,NONLINEAR SYST LAB,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick; University of Warwick								CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; Cohen J., 1971, Adv comp Physiol Biochem, V4, P267; Feller W., 1957, INTRO PROBABILITY TH; MOORE DS, 1993, INTRO PRACTICE STATI; 1993, HORIZON         1031	5	119	121	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					19	22		10.1136/bmj.309.6946.19	http://dx.doi.org/10.1136/bmj.309.6946.19			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044061	Green Published			2022-12-28	WOS:A1994NV89100016
J	PENNEY, GC; GLASIER, A; TEMPLETON, A				PENNEY, GC; GLASIER, A; TEMPLETON, A			MULTICENTER CRITERION BASED AUDIT OF THE MANAGEMENT OF INDUCED-ABORTION IN SCOTLAND	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL GUIDELINES	Objectives-To assess and improve the quality of care provided to women undergoing induced abortion. Design-Two rounds of prospective, criterion based case note review audit. Setting-Ten NHS gynaecology units throughout Scotland. Subjects-2004 patient episodes of abortion care identified consecutively during two rounds of audit. The first round comprised 967 cases and the second round 1037. Interventions-Dissemination of results from the first round of audit and recommendations for change in the form of a written report and at postgraduate meetings in participating hospitals. Main outcome measures-Improvements in quality of care as assessed against 16 previously agreed criteria, both overall across the 10 study hospitals and within individual hospitals. Results-Overall, four significant improvements occurred: increased availability of early medical abortion, decreased utilisation of surgical abortion at very early gestation, increased use of mifepristone priming before second trimester medical abortion, and increased provision of follow up. At the individual hospital level 42 of 150 elements of care studied were ''close to optimal'' at the time of the first round of audit, rising to 54 at the second round (NS). A total of 31 significant improvements in individual elements of care occurred, but 11 significant deteriorations also occurred (at the P < 0.05 level). Conclusions-The prospective multicentre audit proved feasible and achieved the aims of any form of audit in terms of identifying deficiencies and variations in care. The audit results prompted objective review of local abortion services in participating hospitals. At least for some elements of care in some hospitals significant improvements were detectable.	LOTHIAN HLTH BOARD,FAMILY PLANNING & WELL WOMAN SERV,EDINBURGH EH4 1NL,MIDLOTHIAN,SCOTLAND		PENNEY, GC (corresponding author), ABERDEEN MATERN HOSP,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZD,SCOTLAND.							EMSLIE C, 1993, BRIT MED J, V306, P1728, DOI 10.1136/bmj.306.6894.1728; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Penney G C, 1993, Qual Health Care, V2, P167, DOI 10.1136/qshc.2.3.167; SHAW CD, 1992, AUDIT ACTION, P122; 1992, HLTH BRIEFING, V92; 1993, CLIN GUIDELINES REPO	6	11	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					15	18		10.1136/bmj.309.6946.15	http://dx.doi.org/10.1136/bmj.309.6946.15			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044060	Green Published			2022-12-28	WOS:A1994NV89100014
J	KIMURA, T; NAKAYAMA, K; PENNINGER, J; KITAGAWA, M; HARADA, H; MATSUYAMA, T; TANAKA, N; KAMIJO, R; VILCEK, J; MAK, TW; TANIGUCHI, T				KIMURA, T; NAKAYAMA, K; PENNINGER, J; KITAGAWA, M; HARADA, H; MATSUYAMA, T; TANAKA, N; KAMIJO, R; VILCEK, J; MAK, TW; TANIGUCHI, T			INVOLVEMENT OF THE IRF-1 TRANSCRIPTION FACTOR IN ANTIVIRAL RESPONSES TO INTERFERONS	SCIENCE			English	Article							REGULATORY FACTOR-I; GAMMA SIGNAL-TRANSDUCTION; CONSTITUTIVE EXPRESSION; INDUCIBLE GENES; BINDING PROTEIN; NITRIC-OXIDE; CELL-LINE; INHIBITION; ACTIVATION; ALPHA	The mechanisms underlying interferon (IFN)-induced antiviral states are not well understood. Interferon regulatory factor-1 (IRF-1) is an IFN-inducible transcriptional activator, whereas IRF-2 suppresses IRF-1 action. The inhibition of encephalomyocarditis virus (EMCV) replication by IFN-alpha and especially by IFN-gamma was impaired in cells from mice with a null mutation in the IRF-1 gene (IRF-1(-/-) mice). The IRF-1(-/-) mice were less resistant than normal mice to EMCV infection, as revealed by accelerated mortality and a larger virus titer in target organs. The absence of IRF-1 did not clearly affect replication of two other types of viruses. Thus, IRF-1 is necessary for the antiviral action of IFNs against some viruses, but IFNs activate multiple activation pathways through diverse target genes to induce the antiviral state.	UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,DEPT IMMUNOL & MED BIOPHYS,TORONTO M4X 1K9,ON,CANADA; NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	University of Toronto; University Toronto Affiliates; University Health Network Toronto; New York University; New York University	KIMURA, T (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN.		Kitagawa, Motoo/W-8468-2019; Nakayama, Katsutoshi/AAT-4536-2021; Penninger, Josef M/I-6860-2013; Harada, Hisashi/H-2815-2019	Kitagawa, Motoo/0000-0003-1036-840X; Nakayama, Katsutoshi/0000-0002-0141-7081; Penninger, Josef M/0000-0002-8194-3777; Harada, Hisashi/0000-0001-5993-1289; Kimura, Tohru/0000-0001-9227-0996; Tanaka, Nobuyuki/0000-0002-6373-2220	NCI NIH HHS [R35CA49731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Anderson Sylvia L., 1992, Journal of Interferon Research, V12, pS86; BAIER LJ, 1993, NUCLEIC ACIDS RES, V21, P4830, DOI 10.1093/nar/21.20.4830; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; CONSTANTOULAKIS P, 1993, SCIENCE, V259, P1314, DOI 10.1126/science.7680491; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; Demaeyer E., 1988, INTERFERONS OTHER RE; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FISCHER DG, 1993, SCIENCE, V262, P250, DOI 10.1126/science.8211145; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GLASGOW L A, 1970, Journal of General Physiology, V56, P212, DOI 10.1085/jgp.56.1.212; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HESSEL BA, 1993, EMBO J, V12, P3297; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KERR IM, 1992, J INTERFERON RES, V12, P237, DOI 10.1089/jir.1992.12.237; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MURPHY BR, 1968, J EXP MED, V127, P1035, DOI 10.1084/jem.127.5.1035; NAKAYAMA K, UNPUB; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PENNINGER J, UNPUB; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, IN PRESS CELL; Vilcek J., 1990, HDB EXPT PHARM, V95, P3; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WYNN TA, 1991, J IMMUNOL, V147, P4384; YAMAMOTO HM, UNPUB; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	52	269	275	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1921	1924		10.1126/science.8009222	http://dx.doi.org/10.1126/science.8009222			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009222				2022-12-28	WOS:A1994NT84700042
J	NANCARROW, JK; KREMER, E; HOLMAN, K; EYRE, H; DOGGETT, NA; LEPASLIER, D; CALLEN, DF; SUTHERLAND, GR; RICHARDS, RI				NANCARROW, JK; KREMER, E; HOLMAN, K; EYRE, H; DOGGETT, NA; LEPASLIER, D; CALLEN, DF; SUTHERLAND, GR; RICHARDS, RI			IMPLICATIONS OF FRA16A STRUCTURE FOR THE MECHANISM OF CHROMOSOMAL FRAGILE SITE GENESIS	SCIENCE			English	Article							X-SYNDROME; HUNTINGTONS-DISEASE; MYOTONIC-DYSTROPHY; MENTAL-RETARDATION; MOLECULAR ANALYSIS; UNSTABLE ELEMENT; REPEAT SEQUENCE; FMR1 GENE; DNA; INSTABILITY	Fragile sites are chemically induced nonstaining gaps in chromosomes. Different fragile sites vary in frequency in the population and in the chemistry of their induction. DNA sequences encompassing and including the rare, autosomal, folate-sensitive fragile site, FRA16A, were isolated by positional cloning. The molecular basis of FRA16A was found to be expansion of a normally polymorphic p(CCG), repeat. This repeat was adjacent to a CpG island that was methylated in fragile site-expressing individuals. The FRA16A locus in individuals who do not express the fragile site is not a site of DNA methylation (imprinting), which suggests that the methylation associated with fragile sites may be a consequence and not a cause of their genesis.	WOMENS & CHILDRENS HOSP,CTR GENET MED,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA; LOS ALAMOS NATL LAB,CTR HUMAN GENOME STUDIES,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545; CTR ETUD POLYMORPHISME HUMAIN,F-750101 PARIS,FRANCE	Womens & Childrens Hospital Australia; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory			Sutherland, Grant Robert/D-2606-2012; Kremer, Eric J/D-3734-2013; Callen, David F/G-1975-2012; Richards, Robert/ABE-6423-2020; Kremer, EJ/P-9838-2019	Kremer, EJ/0000-0001-6114-7530; Le Paslier, Denis/0000-0003-4335-9956; Callen, David/0000-0002-6189-9991; Richards, Robert Ian/0000-0002-5978-6453				ASHIZAWA T, 1994, AM J HUM GENET, V54, P414; BRUNNER HG, 1993, AM J HUM GENET, V53, P1016; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GOLDBERG YP, 1993, NAT GENET, V5, P174, DOI 10.1038/ng1093-174; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; JANSEN G, 1993, HUM MOL GENET, V2, P1221, DOI 10.1093/hmg/2.8.1221; KNIGHT SJL, 1993, CELL, V74, P27; KOZMAN H, 1992, GENET LIFE SCI ADV, V11, P229; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LAIRD CD, 1987, GENETICS, V117, P587; LAVEDAN C, 1993, AM J HUM GENET, V52, P875; NANCARROW J, UNPUB; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; RENNIE J, 1993, SCI AM           MAR, P88; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; RICHARDS RI, 1991, J MED GENET, V28, P856, DOI 10.1136/jmg.28.12.856; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; SHERMAN SL, 1986, HUM GENET, V72, P123; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1993, J MED GENET, V30, P978, DOI 10.1136/jmg.30.12.978; TELENIUS H, 1993, HUM MOL GENET, V2, P1535, DOI 10.1093/hmg/2.10.1535; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1992, AM J HUM GENET, V50, P968; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	30	139	141	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1938	1941		10.1126/science.8009225	http://dx.doi.org/10.1126/science.8009225			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009225				2022-12-28	WOS:A1994NT84700047
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION IN PRIMARY-CARE - REDUCING ALCOHOL INTAKE .3.	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; CONSUMPTION; INTERVENTIONS; QUESTIONNAIRE; POPULATION; RISK	Alcohol is second in importance only to smoking as a proved cause of cancer. The risk associated with excessive alcohol consumption can be reduced by adopting national and local population based policies. The population approach is aimed at reducing the level of consumption across the whole population, which contains many modest drinkers. Underlying this approach is the fact that a larger proportion of the total morbidity and mortality attributed to alcohol in a population occurs in modest drinkers, even though individually they are at lower risk. This approach should be complemented by risk reduction initiatives in primary care, focused on high risk individuals. Several studies have shown the efficacy of brief interventions practitioners in patients with consumption. Brief interventions, taking 5 to 10 minutes, use simple assessments to identify those at risk and provide information and advice. Evidence exists that general practitioners underuse opportunities to identify and advise patients about excessive drinking.			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX3 7LF,ENGLAND.							ANDERSON P, 1993, BRIT J GEN PRACT, V43, P386; ANDERSON P, 1991, BRIT MED J, V303, P766, DOI 10.1136/bmj.303.6805.766; ANDERSON P, 1993, ADDICTION, V88, P1493, DOI 10.1111/j.1360-0443.1993.tb03135.x; ANDERSON P, 1993, ADDICTION, V88, pS121, DOI 10.1111/j.1360-0443.1993.tb02170.x; ANDERSON P, 1993, ADDICTION, V88, P170, DOI 10.1111/j.1360-0443.1993.tb00798.x; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; BLOT WJ, 1992, CANCER RES, V52, pS2119; Prochaska J. O., 1986, TREATING ADDICTIVE B, P3, DOI DOI 10.1007/978-1-4613-2191-0_; REID ALA, 1986, BRIT MED J, V293, P735, DOI 10.1136/bmj.293.6549.735; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Scott E, 1991, Drug Alcohol Rev, V10, P313; WALLACE P, 1985, BRIT MED J, V290, P1949, DOI 10.1136/bmj.290.6486.1949; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	30	21	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1549	1552		10.1136/bmj.308.6943.1549	http://dx.doi.org/10.1136/bmj.308.6943.1549			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NR110	8019314	Green Published			2022-12-28	WOS:A1994NR11000028
J	CHALLIS, L; HENWOOD, M				CHALLIS, L; HENWOOD, M			EQUITY IN THE NHS .4. EQUITY IN COMMUNITY CARE	BRITISH MEDICAL JOURNAL			English	Article								The implementation of the NHS and Community Care Act 1990 made local authority social services departments responsible for the organisation and funding of support and care in the community. This development took effect at the same time as a blurring of the boundaries between health and social care. One consequence is that the relevance of equity (a guiding principle of the 1946 National Health Service Act, but relatively lacking from the 1948 National Assistance Act, the foundation of many social services) has come to be more keenly appreciated within personal social services. Equity questions arise in community care over the distribution of public resources between different client groups, income groups, generations, and localities. Moreover, no mechanisms exist to monitor the trends that emerge from different ways that people get access to care. Yet there is a risk that substantial divisive consequences may occur, particularly between generations.			CHALLIS, L (corresponding author), UNIV BATH,SCH SOCIAL SCI,BATH BA2 7AY,AVON,ENGLAND.							[Anonymous], 1989, CM849; GLENDINNING C, 1992, COSTS INFORMAL CARE; HAMNETT C, 1991, INHERITANCE BRITAIN; JUDGE K, 1994, BRIT MED J, V308, P1363, DOI 10.1136/bmj.308.6940.1363; WISTOW G, 1994, RESIDENTIAL CARE WIL; 1982, RISING RIDE DEV SERV; 1981, REPORT STUDY COMMUNI; 1991, FINANCING PRIVATE RE, V2; 1900, CARING PEOPLE COMMUN	9	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1496	1499		10.1136/bmj.308.6942.1496	http://dx.doi.org/10.1136/bmj.308.6942.1496			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NQ229	8019286	Green Published			2022-12-28	WOS:A1994NQ22900025
J	WISELKA, M				WISELKA, M			INFLUENZA - DIAGNOSIS, MANAGEMENT, AND PROPHYLAXIS	BRITISH MEDICAL JOURNAL			English	Article							VACCINATION; INFECTION; LEICESTERSHIRE; IMMUNIZATION; PREVENTION; EPIDEMIC; DISEASE; PROGRAM; PEOPLE; DEATHS				WISELKA, M (corresponding author), LEICESTER ROYAL INFIRM,LEICESTER LE1 5WW,ENGLAND.							ARDEN NH, 1986, OPTIONS CONTROL INFL; Ashley J., 1991, Population Trends, P16; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; CHOMEL JJ, 1989, J VIROL METHODS, V25, P81, DOI 10.1016/0166-0934(89)90102-X; CONNOLLY AM, 1993, BRIT MED J, V306, P1452, DOI 10.1136/bmj.306.6890.1452; HOSKINS TW, 1979, LANCET, V1, P33; JONES A, 1991, POSTGRAD MED J, V67, P988, DOI 10.1136/pgmj.67.793.988; KUBAR OI, 1989, ANTIVIR RES, V11, P313, DOI 10.1016/0166-3542(89)90041-7; KURINCZUK JJ, 1989, BRIT MED J, V299, P367, DOI 10.1136/bmj.299.6695.367; LOURIA DB, 1959, J CLIN INVEST, V38, P213, DOI 10.1172/JCI103789; MARGOLIS KL, 1992, J AM GERIATR SOC, V40, P1021, DOI 10.1111/j.1532-5415.1992.tb04480.x; NGUYENVANTAAM JS, 1994, HLTH TRENDS, V25, P101; NGUYENVANTAM JS, 1992, EPIDEMIOL INFECT, V108, P537, DOI 10.1017/S0950268800050032; Nicholson K G, 1992, Semin Respir Infect, V7, P26; NICHOLSON KG, 1991, BRIT MED J, V302, P425, DOI 10.1136/bmj.302.6774.425; NICHOLSON KG, 1987, VACCINE, V5, P302, DOI 10.1016/0264-410X(87)90156-3; NICHOLSON KG, 1993, BRIT MED J, V306, P974, DOI 10.1136/bmj.306.6883.974; NICHOLSON KG, 1990, BRIT MED J, V301, P617, DOI 10.1136/bmj.301.6753.617; Pachucki C T, 1992, Semin Respir Infect, V7, P46; SHANN F, 1990, LANCET, V335, P898, DOI 10.1016/0140-6736(90)90489-R; SMITH AP, 1993, BRIT MED J, V306, P760, DOI 10.1136/bmj.306.6880.760; TREANOR JJ, 1992, ANN INTERN MED, V117, P625, DOI 10.7326/0003-4819-117-8-625; Van Voris L P, 1992, Semin Respir Infect, V7, P61; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WISELKA MJ, 1992, LANCET, V339, P367; WRIGHT P, 1993, AM J MED GENET, V48, P40, DOI 10.1002/ajmg.1320480110; 1993, INFLUENZA IMMUNISATI	29	60	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1341	1345		10.1136/bmj.308.6940.1341	http://dx.doi.org/10.1136/bmj.308.6940.1341			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019225	Green Published			2022-12-28	WOS:A1994NM98900026
J	GRINSPOON, L; BAKALAR, JB				GRINSPOON, L; BAKALAR, JB			THE WAR ON DRUGS - A PEACE PROPOSAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROHIBITION				GRINSPOON, L (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.							Austin J, 1989, NCCD PRISON POPULATI; DENNIS RJ, 1990, DRUG PROHIBITION CON; DINARDO J, 1991, ARE MARIHUANA ALCOHO; Erickson P. G., 1989, SOCIAL PHARM, V3, P249; GILL AM, 1992, IND LABOR RELAT REV, V45, P419, DOI 10.2307/2524269; GRINSPOON L, 1990, N C J INT LAW COMMER, V15, P505; Grinspoon L., 1993, MARIHUANA FORBIDDEN; HORGAN J, 1990, NEW REPUBLIC    0402, P22; Jolliffe N, 1936, SCIENCE, V83, P306, DOI 10.1126/science.83.2152.306-a; Kolb L, 1924, PUBLIC HEALTH REP, V39, P1179, DOI 10.2307/4577168; LEVINE HG, 1991, MILBANK Q, V69, P461, DOI 10.2307/3350105; MAYES LC, 1992, JAMA-J AM MED ASSOC, V267, P406, DOI 10.1001/jama.267.3.406; Moore M.H., 1981, ALCOHOL PUBLIC POLIC; MOORE MH, 1977, BUY BUST EFFECTIVE R; NADELMANN EA, 1992, DAEDALUS, V121, P85; NADELMANN EA, 1988, FOREIGN POLICY, V70, P83; OMALLEY PM, 1985, NIDA RES MONOGRAPH, V61; POPE HG, 1990, AM J PSYCHIAT, V147, P998; SHEDLER J, 1990, AM PSYCHOL, V45, P612, DOI 10.1037/0003-066X.45.5.612; SINGLE E W, 1989, Journal of Public Health Policy, V10, P456, DOI 10.2307/3342518; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V268, P3177, DOI 10.1001/jama.268.22.3177; TERRIS M, 1967, AM J PUBLIC HEALTH N, V57, P2076, DOI 10.2105/AJPH.57.12.2076; TREBACH AS, 1987, GREAT DRUG WAR; Weil Andrew, 1980, MARRIAGE SUN MOON QU; WILSON JQ, 1990, DRUGS CRIME; WISOTSKY S, 1992, POLICY ANAL, V180; 1989, NATIONAL DRUG CONTRO; 1985, NATIONAL HOUSEHOLD S; 1991, CRIME US; 1992, NATIONAL DRUG CONTRO	30	20	20	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					357	360		10.1056/NEJM199402033300513	http://dx.doi.org/10.1056/NEJM199402033300513			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MU489	8043062				2022-12-28	WOS:A1994MU48900013
J	CONNERS, GP; OCHSENSCHLAGER, DW				CONNERS, GP; OCHSENSCHLAGER, DW			BILATERAL FEMUR FRACTURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											CONNERS, GP (corresponding author), CHILDRENS NATL MED CTR,WASHINGTON,DC 20010, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					512	512						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD072	8041417				2022-12-28	WOS:A1994PD07200005
J	HALL, CB; LONG, CE; SCHNABEL, KC; CASERTA, MT; MCINTYRE, KM; COSTANZO, MA; KNOTT, A; DEWHURST, S; INSEL, RA; EPSTEIN, LG				HALL, CB; LONG, CE; SCHNABEL, KC; CASERTA, MT; MCINTYRE, KM; COSTANZO, MA; KNOTT, A; DEWHURST, S; INSEL, RA; EPSTEIN, LG			HUMAN HERPESVIRUS-6 INFECTION IN CHILDREN - A PROSPECTIVE-STUDY OF COMPLICATIONS AND REACTIVATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; SUBITUM ROSEOLA INFANTUM; CENTRAL-NERVOUS-SYSTEM; EXANTHEM-SUBITUM; IDENTIFICATION; ANTIBODY; MENINGOENCEPHALITIS; TRANSMISSION; PREVALENCE; POLYMERASE	Background. Infect with human herpesvirus-6 (HHV-6) is nearly universal in infancy or early childhood. However, the-course of this infection, its complications, and its potential for persistence or reactivation remain unclear. Methods. We studied infants and children under the age of three years who presented to our emergency department with acute illnesses. Infants and young children without acute illness were studied as controls. HHV-6 infection was identified by blood-mononuclear-cell culture, serologic testing, and the polymerase chain reaction (PCR). Results. No primary HHV-6 infection was found among 582 infants and young children with acute nonfebrile illnesses or among 352 controls without acute illness. Of 1653 infants and young children with acute febrile illnesses, 160 (9.7 percent) had primary HHV-6 infection, as documented by viremia and seroconversion. They ranged in age from 2 weeks to 25 months; 23 percent were under the age of 6 months. HHV-6 infections accounted for 20 percent of 365 visits to the emergency department for febrile illnesses among children 6 to 12 months old. Of the 160 infants and young children with acute HHV-6 infections, 21 (13 percent) were hospitalized, and 21 had seizures. Often the seizures appeared late and were prolonged or recurrent. HHV-6 infections accounted for one third of all febrile seizures in children up to the age of two years. In follow-up studies over a period of one to two years, the HHV-6 genome persisted in blood mononuclear cells after primary infection in 37 of 56 children (66 percent). Reactivation, sometimes with febrile illnesses, was suggested by subsequent increases in antibody titers in 16 percent (30 of 187) and by PCR in 6 percent (17 of 278). No recurrent viremia was detected. Of 41 healthy newborns studied, 12 (29 percent) had the HHV-6 genome in their blood mononuclear cells; nevertheless, 6 of these newborns subsequently had primary HHV-6 infections. Conclusions. In infants and young children HHV-6 infection is a major cause of visits to the emergency department, febrile seizures, and hospitalizations. Perinatal transmission may occur, with possible asymptomatic, transient, or persistent neonatal infection.	UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT NEUROL,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester	HALL, CB (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642, USA.			Epstein, Leon/0000-0003-4264-3867; Dewhurst, Stephen/0000-0001-7729-7920	NCRR NIH HHS [5-MO1-RR-000-44] Funding Source: Medline; NIAID NIH HHS [R01 AI33020-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033020] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ablashi D V, 1991, In Vivo, V5, P193; ASANO Y, 1992, ARCH DIS CHILD, V67, P1484, DOI 10.1136/adc.67.12.1484; ASANO Y, 1990, LANCET, V335, P862, DOI 10.1016/0140-6736(90)90983-C; ASANO Y, 1991, J PEDIATR-US, V118, P891, DOI 10.1016/S0022-3476(05)82200-0; ASANO Y, 1991, NEW ENGL J MED, V324, P634; AUBIN JT, 1992, LANCET, V340, P482, DOI 10.1016/0140-6736(92)91801-E; BERENBERG W, 1949, NEW ENGL J MED, V241, P253, DOI 10.1056/NEJM194908182410701; Breese Jr. BB., 1941, NEW YORK J MED, V41, P1854; BURNSTINE RC, 1959, AMA J DIS CHILD, V98, P144, DOI 10.1001/archpedi.1959.02070020146002; CASERTA MT, 1993, ANNU REV MED, V44, P377, DOI 10.1146/annurev.med.44.1.377; CASERTA MT, 1993, CLIN INFECT DIS, V17, P557; CHANDRAN B, 1992, J MED VIROL, V37, P247, DOI 10.1002/jmv.1890370403; CHERRY JD, 1992, TXB PEDIATRIC INFECT, V2, P1789; CHOU SW, 1993, J LAB CLIN MED, V121, P388; CLEMENS HH, 1945, J PEDIATR-US, V26, P66, DOI 10.1016/S0022-3476(45)80135-X; CONE RW, 1993, NEW ENGL J MED, V329, P156, DOI 10.1056/NEJM199307153290302; Dean A. G., 1990, EPI INFO VERSION 5 W; DEWHURST S, 1993, J CLIN MICROBIOL, V31, P416, DOI 10.1128/JCM.31.2.416-418.1993; DEWHURST S, 1992, VIROLOGY, V190, P490, DOI 10.1016/0042-6822(92)91240-U; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; DUNNE WM, 1992, LANCET, V340, P121; DUNNE WM, 1993, J INFECT DIS, V168, P250, DOI 10.1093/infdis/168.1.250; EFSTATHIOU S, 1992, J GEN VIROL, V73, P1661, DOI 10.1099/0022-1317-73-7-1661; ENDERS G, 1990, INFECTION, V18, P12, DOI 10.1007/BF01644173; HALL CB, 1991, PEDIATR RES, V29, pA173; Huang L M, 1991, J Formos Med Assoc, V90, P579; HUANG LM, 1992, J INFECT DIS, V165, P1163, DOI 10.1093/infdis/165.6.1163; ISHIGURO N, 1990, ACTA PAEDIATR SCAND, V79, P987, DOI 10.1111/j.1651-2227.1990.tb11369.x; KAWAGUCHI S, 1992, PEDIATRICS, V90, P628; KEMPE CH, 1950, J PEDIATR-US, V37, P561, DOI 10.1016/S0022-3476(50)80266-4; KONDO K, 1993, J INFECT DIS, V167, P1197, DOI 10.1093/infdis/167.5.1197; KUSUHARA K, 1992, LANCET, V340, P482, DOI 10.1016/0140-6736(92)91800-N; LINNAVUORI K, 1992, PEDIATRICS, V89, P103; MOLLER K L, 1956, Acta Paediatr, V45, P534, DOI 10.1111/j.1651-2227.1956.tb06912.x; OKADA K, 1993, PEDIATR INFECT DIS J, V12, P204, DOI 10.1097/00006454-199303000-00006; PELLETT PE, 1990, ADV EXP MED BIOL, V278, P9; PELLETT PE, 1993, VIROLOGY, V195, P521, DOI 10.1006/viro.1993.1403; PELLETT PE, 1992, ADV VIRUS RES, V41, P1, DOI 10.1016/S0065-3527(08)60034-2; PORTOLANI M, 1993, J MED VIROL, V39, P146, DOI 10.1002/jmv.1890390211; POSSON DD, 1949, J PEDIATR-US, V35, P235, DOI 10.1016/S0022-3476(49)80239-3; PREZIOSO PJ, 1992, J PEDIATR-US, V120, P921, DOI 10.1016/S0022-3476(05)81962-6; PRUKSANANONDA P, 1992, NEW ENGL J MED, V326, P1445, DOI 10.1056/NEJM199205283262201; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SUGA S, 1992, MICROBIOL IMMUNOL, V36, P495, DOI 10.1111/j.1348-0421.1992.tb02047.x; SUGA S, 1992, J MED VIROL, V38, P278, DOI 10.1002/jmv.1890380409; SUGA S, 1993, ANN NEUROL, V33, P597, DOI 10.1002/ana.410330607; TAKIKAWA T, 1992, LANCET, V340, P1288, DOI 10.1016/0140-6736(92)92989-S; YAMANISHI K, 1992, MICROBIOL IMMUNOL, V36, P551, DOI 10.1111/j.1348-0421.1992.tb02055.x; YAMANISHI K, 1988, LANCET, V1, P1065; YANAGI K, 1990, J INFECT DIS, V161, P153, DOI 10.1093/infdis/161.1.153-a; YOSHIKAWA T, 1991, BLOOD, V78, P1381; YOSHIKAWA T, 1990, PEDIATR INFECT DIS J, V9, P589, DOI 10.1097/00006454-199008000-00013; YOSHIKAWA T, 1992, PEDIATRICS, V89, P888	54	428	449	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					432	438		10.1056/NEJM199408183310703	http://dx.doi.org/10.1056/NEJM199408183310703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	8035839				2022-12-28	WOS:A1994PB50100003
J	BOSS, LP; TOOLE, MJ; YIP, R				BOSS, LP; TOOLE, MJ; YIP, R			ASSESSMENTS OF MORTALITY, MORBIDITY, AND NUTRITIONAL-STATUS IN SOMALIA DURING THE 1991-1992 FAMINE - RECOMMENDATIONS FOR STANDARDIZATION OF METHODS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REFUGEES; DISEASE; MALNUTRITION; RATES; SUDAN	Objectives.-To evaluate the various survey methods used in Somalia between 1991 and early 1993 while assessing documentation of mortality and malnutrition rates and common causes of morbidity and mortality. Data Sources.-Twenty-three population surveys were identified from the Center for Public Health Surveillance for Somalia, the United Nations Children's Fund, and other humanitarian organizations. Study Selection.-Only surveys with defined populations and apparently systematic methodology that focused on mortality, morbidity, and/or nutritional status were included. Results.-Extensive methodological differences were found among the 23 surveys. Target populations and sampling strategies varied widely. Twelve studies were considered not reproducible. Of the 16 studies assessing mortality, only eight assessed cause of death. Use of units of measurement and inclusion of denominators in rate calculations were inconsistent. None of the studies provided confidence intervals around the point estimates of the rates. Of the 11 studies providing information on morbidity, none provided case definitions. And in the 16 studies reporting nutritional status, a variety of measurement methods and definitions of malnutrition were used. Three studies presented information based on mid-upper-arm circumference measurements, and 10 presented weight-for-height data below 70% and 80% of the reference median; only four studies presented z scores.			BOSS, LP (corresponding author), CTR DIS CONTROL & PREVENT, MS F-57, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.							ALLEN P, 1991, INTERAGENCY MOH NUTR; [Anonymous], 1986, B WORLD HEALTH ORGAN, V64, P929; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; BOSS LP, 1987, INT J EPIDEMIOL, V16, P556, DOI 10.1093/ije/16.4.556; BROWN V, 1993, HODDUR SOMALIE IMPAC; DEWAAL A, 1989, POP STUD-J DEMOG, V43, P5, DOI 10.1080/0032472031000143826; GLASS RI, 1980, LANCET, V1, P868; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; MANONCOURT S, 1992, LANCET, V340, P176, DOI 10.1016/0140-6736(92)93252-I; MEIJMAN B, 1993, MED NEWS         AUG, V2, P5; MERCER A, 1993, HLTH SURVEILLANCE RE; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; OREILLY F, 1992, NUTRITIONAL SURVEY B; RUTHERFORD GW, 1985, J TROP PEDIATRICS, V31, P143, DOI 10.1093/tropej/31.3.143; SANDLER RH, 1991, JAMA-J AM MED ASSOC, V266, P638, DOI 10.1001/jama.266.5.638; SEAMAN J, 1978, INT J EPIDEMIOL, V7, P31, DOI 10.1093/ije/7.1.31; SHEARS P, 1987, INT MIGR REV, V21, P783, DOI 10.2307/2546622; TOOLE M J, 1989, Bulletin of the World Health Organization, V67, P381; WOODRUFF BA, 1990, DISASTERS, V14, P151, DOI 10.1111/j.1467-7717.1990.tb01056.x; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; 1993, UNPUB NUTRITION MORT; 1992, MMWR-MORBID MORTAL W, V41, P913; 1992, REPORT CONSULTATION; 1989, MMWR-MORBID MORTAL W, V38, P461; 1989, MMWR-MORBID MORTAL W, V38, P455; 1993, SURVEY RESULTS BELET; 1991, MMWR-MORBID MORTAL W, V40, P443; IN PRESS REPORT SUBC; 1991, MMWR-MORBID MORTAL W, V40, P13; 1992, UNPUB HLTH MORTALITY; 1988, MASURING CHANGE NUTR; 1992, CTR PUBLIC HLTH SURV, V2, P1; 1988, MMWR-MORBID MORTAL W, V37, P641; 1993, UNPUB RESULTS MORBID; 1990, MMWR-MORBID MORTAL W, V39, P707; 1992, MMWR MORB MORT SRR13, V41, P1; 1992, REPORT UNICEF RMO NU; 1990, MMWR-MORBID MORTAL W, V39, P715; 1992, HLTH MORTALITY ASSES; 1993, MMWR-MORBID MORTAL W, V42, P304; UNPUB RESULTS MORBID; 1993, NUTRITION HLTH ASSES; 1993, RESULTS MORBIDITY MO	43	41	41	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					371	376						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028168				2022-12-28	WOS:A1994NY90300029
J	DEHAENELAMBERTZ, G; DEHAENE, S				DEHAENELAMBERTZ, G; DEHAENE, S			SPEED AND CEREBRAL CORRELATES OF SYLLABLE DISCRIMINATION IN INFANTS	NATURE			English	Article							1ST YEAR; PERCEPTION; ATTENTION; BRAIN; LIFE	THE remarkable linguistic abilities of human neonates are well documented(1-5). Young infants can discriminate phonemes even if they are not used in their native language(2-4), an ability which regresses during the first year of life(4,5). This ability to discriminate is often studied by repeating a stimulus for several minutes until some behavioural response of the infant habituates, and later examining whether the response recovers when the stimulus is changed(6). This method, however, does not reveal how fast infants can detect phonetic changes, nor what brain mechanisms are involved. We describe here high-density recordings of event-related potentials in three-month-old infants listening to syllables whose first consonants differed in place of articulation Two processing stages, corresponding to an increasingly refined analysis of the auditory input, were identified and localised to the temporal lobes. A late frontal response to novelty was also observed. The infant brain recognizes a phonetic change in less than 400 ms.	CNRS,SCI COGNIT & PSYCHOLINGUIST LAB,INSERM,F-75270 PARIS 06,FRANCE; EHESS,F-75270 PARIS 06,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	DEHAENELAMBERTZ, G (corresponding author), UNIV OREGON,INST COGNIT & DECIS SCI,EUGENE,OR 97405, USA.		Dehaene, Ghislaine/O-3633-2017	Dehaene, Ghislaine/0000-0003-2221-9081				BERTONCINI J, 1989, BRAIN LANG, V37, P591, DOI 10.1016/0093-934X(89)90113-2; BEST CT, 1988, J EXP PSYCHOL HUMAN, V14, P345, DOI 10.1037/0096-1523.14.3.345; BEST CT, 1982, PERCEPT PSYCHOPHYS, V31, P75, DOI 10.3758/BF03206203; CHI JG, 1977, ANN NEUROL, V1, P86, DOI 10.1002/ana.410010109; Courchesne E, 1983, TUTORIALS EVENT RELA, P329; EIMAS PD, 1971, SCIENCE, V171, P303, DOI 10.1126/science.171.3968.303; EMIAS PD, 1987, CATEGORICAL PERCEPTI, P161; JUSCZYK PW, 1985, MEASUREMENT AUDITION, P195; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; LeMay M., 1984, CEREBRAL DOMINANCE B, P26; MILLS DL, 1993, J COGNITIVE NEUROSCI, V5, P317, DOI 10.1162/jocn.1993.5.3.317; MOLFESE DL, 1991, CEREBRAL LATERALITY, P71; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; Naatanen R, 1983, ADV PSYCHOL, P119, DOI DOI 10.1016/S0166-4115(08)62036-1; NELSON CA, 1992, DEV NEUROPSYCHOL, V8, P119, DOI 10.1080/87565649209540521; NOVAK GP, 1989, ELECTROEN CLIN NEURO, V73, P295, DOI 10.1016/0013-4694(89)90108-9; PERRIN F, 1989, ELECTROEN CLIN NEURO, V72, P184, DOI 10.1016/0013-4694(89)90180-6; Rothbart M. K., 1990, ADV PSYCHOL, V69, P47; SCHERG M, 1990, BESA BRAIN ELECTRICA; TUCKER DM, 1993, ELECTROEN CLIN NEURO, V87, P154, DOI 10.1016/0013-4694(93)90121-B; VARGHAKHADEM F, 1979, BRAIN LANG, V8, P19; WERKER JF, 1984, INFANT BEHAV DEV, V7, P49, DOI 10.1016/S0163-6383(84)80022-3; WITELSON SF, 1973, BRAIN, V96, P641, DOI 10.1093/brain/96.3.641; WOODS DL, 1986, ELECTROEN CLIN NEURO, V65, P447, DOI 10.1016/0168-5597(86)90024-9; [No title captured]	25	235	236	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					292	295		10.1038/370292a0	http://dx.doi.org/10.1038/370292a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NZ229	8035876				2022-12-28	WOS:A1994NZ22900063
J	LAUGHLAN, G; MURCHIE, AIH; NORMAN, DG; MOORE, MH; MOODY, PCE; LILLEY, DMJ; LUISI, B				LAUGHLAN, G; MURCHIE, AIH; NORMAN, DG; MOORE, MH; MOODY, PCE; LILLEY, DMJ; LUISI, B			THE HIGH-RESOLUTION CRYSTAL-STRUCTURE OF A PARALLEL-STRANDED GUANINE TETRAPLEX	SCIENCE			English	Article							TELOMERIC DNA; COMPLEX; OLIGONUCLEOTIDE; SEQUENCE; RNA	Repeat tracts of guanine bases found in DNA and RNA can form tetraplex structures in the presence of a variety of monovalent cations. Evidence suggests that guanine tetraplexes assume important functions within chromosomal telomeres, immunoglobulin switch regions, and the human immunodeficiency virus genome. The structure of a parallel-stranded tetraplex formed by the hexanucleotide d(TG(4)T) and stabilized by sodium cations was determined by x-ray crystallography to 1.2 angstroms resolution. Sharply resolved sodium cations were found between and within planes of hydrogen-bonded guanine quartets, and an ordered groove hydration was observed. Distinct intra- and intermolecular stacking arrangements were adopted by the guanine quartets. Thymine bases were exclusively involved in making extensive lattice contacts.	UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN, NUCL ACID RES GRP, DUNDEE DD1 4HN, SCOTLAND; UNIV YORK, DEPT CHEM, YORK YO1 5DD, N YORKSHIRE, ENGLAND	University of Dundee; University of York - UK	LAUGHLAN, G (corresponding author), UNIV GLASGOW, MRC, VIROL UNIT, CHURCH ST, GLASGOW G11 5JR, SCOTLAND.		Moody, Peter/A-6832-2008	Moody, Peter/0000-0003-1762-9238				ABOULELA F, 1992, NATURE, V360, P280, DOI 10.1038/360280a0; ABOULELA F, IN PRESS J MOL BIOL; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRUNGER AT, 1993, X PLOR SYSTEM XRAY C; CHEONG CJ, 1992, BIOCHEMISTRY-US, V31, P8406, DOI 10.1021/bi00151a003; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KARLE IL, 1974, BIOCHEMISTRY-US, V13, P2155, DOI 10.1021/bi00707a025; KIM J, 1991, NATURE, V351, P331, DOI 10.1038/351331a0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; NAVAZA J, 1990, ACTA CRYSTALLOGR A, V46, P619, DOI 10.1107/S0108767390000290; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PIELES U, 1993, NUCLEIC ACIDS RES, V21, P3191, DOI 10.1093/nar/21.14.3191; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHELDRICK GM, SHELX 93; SMITH FW, 1993, BIOCHEMISTRY-US, V32, P8682, DOI 10.1021/bi00084a040; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WANG Y, 1993, J MOL BIOL, V234, P1171, DOI 10.1006/jmbi.1993.1668; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; WANG Y, 1991, NUCLEIC ACIDS RES, V19, P4619, DOI 10.1093/nar/19.17.4619; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; WANG Y, 1991, J MOL BIOL, V222, P819, DOI 10.1016/0022-2836(91)90513-6; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	29	495	504	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 22	1994	265	5171					520	524		10.1126/science.8036494	http://dx.doi.org/10.1126/science.8036494			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036494	Green Submitted			2022-12-28	WOS:A1994NY21600029
J	ADAL, KA; ANGLIM, AM; PALUMBO, CL; TITUS, MG; COYNER, BJ; FARR, BM				ADAL, KA; ANGLIM, AM; PALUMBO, CL; TITUS, MG; COYNER, BJ; FARR, BM			THE USE OF HIGH-EFFICIENCY PARTICULATE AIR-FILTER RESPIRATORS TO PROTECT HOSPITAL WORKERS FROM TUBERCULOSIS - A COST-EFFECTIVENESS ANALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL TRANSMISSION; HIV-INFECTION; OUTBREAK; PERSONNEL; BACILLI; RISK	Background. After outbreaks of multidrug-resistant tuberculosis, the Centers for Disease Control and Prevention proposed the use of respirators with high-efficiency particulate air filters (HEPA respirators) as part of isolation precautions against tuberculosis, along with a respiratory-protection program for health care workers that includes medical evaluation, training, and tests of the fit of the respirators. Each HEPA respirator costs between $7.51 and $9.08, about 10 times the cost of respirators currently used. Methods. We conducted a cost-effectiveness analysis using data from the University of Virginia Hospital on exposure to patients with tuberculosis and rates at which the purified-protein-derivative (PPD) skin test became positive in hospital workers. The costs of a respiratory-protection program were based on those of an existing program for workers dealing with hazardous substances. Results. During 1992, 11 patients with documented tuberculosis were admitted to our hospital. Eight of 3852 workers (0.2 percent) had PPD tests that became positive. Five of these conversions were believed to be due to the booster phenomenon; one followed unprotected exposure to a patient not yet in isolation; the other two occurred in workers who had never entered a tuberculosis isolation room. These data suggest that it will take more than one year for the use of HEPA respirators to prevent a single conversion of the PPD test. Assuming that one conversion is prevented per year, however, it would take 41 years at our hospital to prevent one case of occupationally acquired tuberculosis, at a cost of $1.3 million to $18.5 million. Conclusions. Given the effectiveness of currently recommended measures to prevent nosocomial transmission of tuberculosis, the addition of HEPA respirators would offer negligible protective efficacy at great cost.	UNIV VIRGINIA, HLTH SCI CTR, CHARLOTTESVILLE, VA 22908 USA	University of Virginia					NIAID NIH HHS [T32AI07046] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007046] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1993, MMWR Recomm Rep, V42, P1; ATUK N O, 1971, Journal of the American Medical Association, V218, P1795, DOI 10.1001/jama.218.12.1795; BARNES PF, 1993, ANN INTERN MED, V119, P400, DOI 10.7326/0003-4819-119-5-199309010-00009; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P718; CRAVEN RB, 1975, ANN INTERN MED, V82, P628, DOI 10.7326/0003-4819-82-5-628; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1993, NEW ENGL J MED, V329, P148; GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RILEY LW, 1993, CLIN INFECT DIS, V17, pS442, DOI 10.1093/clinids/17.Supplement_2.S442; WEISSLER JC, 1993, AM J MED SCI, V305, P52, DOI 10.1097/00000441-199301000-00009; 1993, FED REGISTER, V58, P52810; 1982, B WORLD HEALTH ORGAN, V60, P555; 1991, MMWR-MORBID MORTAL W, V40, P585; 1990, AM REV RESPIR DIS, V142, P725; 1990, AM REV RESPIR DIS, V142, P1470	26	78	81	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					169	173		10.1056/NEJM199407213310306	http://dx.doi.org/10.1056/NEJM199407213310306			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008031				2022-12-28	WOS:A1994NW79700006
J	ZIMMERMAN, GC; GRABSKI, WJ				ZIMMERMAN, GC; GRABSKI, WJ			MALIGNANT-MELANOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											ZIMMERMAN, GC (corresponding author), BROOKE ARMY MED CTR,FT SAM HOUSTON,TX 78234, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					168	168						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008030				2022-12-28	WOS:A1994NW79700005
J	FOSTER, PL; TRIMARCHI, JM				FOSTER, PL; TRIMARCHI, JM			ADAPTIVE REVERSION OF A FRAMESHIFT MUTATION IN ESCHERICHIA-COLI BY SIMPLE BASE DELETIONS IN HOMOPOLYMERIC RUNS	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM; SEQUENCE-ANALYSIS; MISMATCH REPAIR; DNA; HOMOLOG; CANCER; OCCUR	Spontaneous mutations are thought to occur primarily in growing cells. However, spontaneous mutations also arise in nutritionally deprived cells, and in some cases this process appears to be adaptive. Here it is reported that when a Lac(-) strain of Escherichia coli is under selection for lactose use, the spectrum of Lac(+) mutations that arises is different, and simpler, than that arising without selection. Mutations appearing during selection were mainly one-base deletions in runs of iterated bases. Similar mutations occurring in repetitive DNA elements are associated with a variety of human hereditary diseases and are increased in cells that cannot correct heteroduplex DNA.	BOSTON UNIV,SCH MED,BOSTON,MA 02118	Boston University	FOSTER, PL (corresponding author), BOSTON UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02118, USA.			Foster, Patricia/0000-0002-7236-4378; Trimarchi, Jeffrey/0000-0001-7923-1538	NIGMS NIH HHS [R01 GM054084-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054084] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON P, 1981, P NATL ACAD SCI-BIOL, V78, P3113, DOI 10.1073/pnas.78.5.3113; ASAI T, 1994, J BACTERIOL, V176, P1807, DOI 10.1128/jb.176.7.1807-1812.1994; BOE L, 1990, MOL MICROBIOL, V4, P597, DOI 10.1111/j.1365-2958.1990.tb00628.x; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CALOS MP, 1981, J MOL BIOL, V153, P39, DOI 10.1016/0022-2836(81)90525-8; CUPPLES CG, 1990, GENETICS, V125, P275; DRAKE JW, 1991, ANNU REV GENET, V25, P125, DOI 10.1146/annurev.ge.25.120191.001013; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; HALL BG, 1991, GENETICA, V84, P73, DOI 10.1007/BF00116545; HALL BG, 1990, GENETICS, V126, P5; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; HASTINGS PJ, 1992, ENCY IMMUNOLOGY, P602; HIGGINS NP, 1992, TRENDS BIOCHEM SCI, V17, P207, DOI 10.1016/0968-0004(92)90376-K; KUNKEL TA, 1988, BIOCHIM BIOPHYS ACTA, V951, P1, DOI 10.1016/0167-4781(88)90020-6; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Miller J.H., 1972, EXPT MOL GENETICS; MULLERHI.B, 1974, NATURE, V249, P561, DOI 10.1038/249561a0; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PRIVAL MJ, 1992, GENETICS, V132, P303; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; Roth Jurgen, COMMUNICATION; RYAN FJ, 1961, Z VEREBUNGSL, V92, P38, DOI 10.1007/BF01854099; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; STAHL FW, 1992, GENETICS, V132, P865; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; STEELE DF, 1992, GENETICS, V132, P9; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014	35	169	174	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					407	409		10.1126/science.8023164	http://dx.doi.org/10.1126/science.8023164			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023164	Green Accepted			2022-12-28	WOS:A1994NW81600044
J	GODAL, T				GODAL, T			FIGHTING THE PARASITES OF POVERTY - PUBLIC RESEARCH, PRIVATE INDUSTRY, AND TROPICAL DISEASES	SCIENCE			English	Editorial Material											GODAL, T (corresponding author), UNDP,WORLD BANK,WHO,SPECIAL PROGRAMME RES & TRAINING TROP DIS,CH-1211 GENEVA,SWITZERLAND.							ABIOSE A, 1993, LANCET, V341, P130, DOI 10.1016/0140-6736(93)90002-X; HENDERSON RH, 1994, 4TH ANN PUBL HLTH FO; 1994, WKLY EPIDEMIOL REC, V69, P145; 1993, 1993 WORLD BANK WORL, P329; 1990, HLTH RES ESSENTIAL L, P136	5	9	9	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1864	1866		10.1126/science.8009212	http://dx.doi.org/10.1126/science.8009212			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NT847	8009212				2022-12-28	WOS:A1994NT84700025
J	FLANNELLY, G; ANDERSON, D; KITCHENER, HC; MANN, EMF; CAMPBELL, M; FISHER, P; WALKER, F; TEMPLETON, AA				FLANNELLY, G; ANDERSON, D; KITCHENER, HC; MANN, EMF; CAMPBELL, M; FISHER, P; WALKER, F; TEMPLETON, AA			MANAGEMENT OF WOMEN MILD AND MODERATE CERVICAL DYSKARYOSIS	BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; COLPOSCOPY; CYTOLOGY; SMEAR; PATHOLOGY; ACCURACY; ATYPIA	Objective-To compare the outcomes in women with mild and moderate dyskaryosis after increasing periods of surveillance and thereby to define a rational protocol for managing such women. Design-Prospective study with randomisation of women to one of four treatment groups, each with a different period of surveillance; one group in which the women were given immediate treatment and three other groups in which the women were under surveillance for six, 12, and 24 months. Setting-A dedicated colposcopy clinic in Aberdeen, Scotland. Subjects-902 women who presented with a mildly or moderately dyskaryotic smear for the first time. Interventions-Cytological and colposcopic examinations at intervals of six months until the allocated period of surveillance was completed, at which time biopsy was performed. Women with severe dyskaryosis were withdrawn from surveillance and a biopsy was performed. Main outcome measures-The histological findings after punch biopsy or large loop excision of the transformation zone, and the trends in cytological appearances of serial cervical smears. Results-793 women completed the study. In all, 769 women had an adequate final smear, of which 197 were normal cytologically, 328 were still mildly or moderately dyskaryotic, and 244 were severely dyskaryotic. Seventeen of the 67 (25%) women with one repeat smear showing non-dyskaryosis had cervical intraepithelial neoplasia grade III compared with only one of the 31 (3%) women with no dyskaryosis in four repeat cervical smears (P < 0.0001). None of the women had invasive cancer. Of 158 women whose index smear showed mild dyskaryosis and who were allocated to the group under surveillance for two years, only 40 had not defaulted or still had dyskaryotic smears by the end of the two years. Conclusion-Cytological surveillance, although safe, is not an efficient strategy for managing women with mildly abnormal smears. Women with any degree of dyskaryosis in a smear should be referred for colposcopy.	ABERDEEN ROYAL INFIRM,HARRIS BIRTHRIGHT RES CTR,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZB,SCOTLAND; ABERDEEN ROYAL INFIRM,HARRIS BIRTHRIGHT RES CTR,DEPT PATHOL,ABERDEEN AB9 2ZB,SCOTLAND; GRAMPIAN AREA HLTH BOARD,INFORMAT SERV TEAM,ABERDEEN AB9 1RE,SCOTLAND	University of Aberdeen; University of Aberdeen								ANDERSON DJ, 1992, BMJ-BRIT MED J, V305, P84, DOI 10.1136/bmj.305.6845.84; ANDERSON MC, 1991, CURR OBSTET GYNAECOL, V1, P124; BLAND M, 1987, INTRO MED STATISTICS; BUXTON EJ, 1991, BRIT J OBSTET GYNAEC, V98, P1273, DOI 10.1111/j.1471-0528.1991.tb15401.x; CAMPION MJ, 1986, LANCET, V2, P237; COOPER P, 1992, CYTOPATHOLOGY, V3, P331; DUNCAN ID, 1993, GUIDELINES CLIN PRAC; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; FLETCHER A, 1990, BRIT MED J, V301, P641, DOI 10.1136/bmj.301.6753.641; GILES JA, 1988, BRIT MED J, V296, P1099, DOI 10.1136/bmj.296.6629.1099; GILES JA, 1989, BRIT J OBSTET GYNAEC, V96, P1067, DOI 10.1111/j.1471-0528.1989.tb03382.x; JOHNSON N, 1993, LANCET, V342, P91, DOI 10.1016/0140-6736(93)91290-3; JORDAN JA, 1988, BRIT MED J, V297, P6, DOI 10.1136/bmj.297.6640.6; KIRBY AJ, 1992, LANCET, V339, P828, DOI 10.1016/0140-6736(92)90278-B; KITCHENER HC, 1991, BRIT J OBSTET GYNAEC, V98, P1112, DOI 10.1111/j.1471-0528.1991.tb15363.x; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SOUTTER WP, 1990, BRIT MED J, V301, P1335, DOI 10.1136/bmj.301.6764.1335-c; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; WALKER EM, 1986, LANCET, V2, P772	21	111	111	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1399	1403		10.1136/bmj.308.6941.1399	http://dx.doi.org/10.1136/bmj.308.6941.1399			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019248	Green Published			2022-12-28	WOS:A1994NP42000013
J	SOUTTER, WP; FLETCHER, A				SOUTTER, WP; FLETCHER, A			INVASIVE CANCER OF THE CERVIX IN WOMEN WITH MILD DYSKARYOSIS FOLLOWED UP CYTOLOGICALLY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMEAR; COLPOSCOPY; MANAGEMENT; ATYPIA	Mildly dyskaryotic smears are common, and women with such results are often followed up with further cervical smear tests. An important consideration in evaluating this practice would be the annual incidence of invasive cervical cancer. A reanalysis of five previous studies of the cytological follow up of women with mildly abnormal smear test results was undertaken to calculate this incidence. The annual incidence of invasive cancer in these women ranged from 0 to 420 per 100 000 women years. The large studies providing the most precise estimates had annual rates of 143 to 420 per 100 000 women years. This is 16 to 47 times greater than in-women aged 15-34 years in England and Wales. The average rate was 208 per 100 000 women years. Women with mild dyskaryosis are at high risk of developing invasive cervical cancer despite cytological follow up. A full appraisal of the costs and benefits of colposcopy in this situation is urgently required.	LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT STUDIES, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine	SOUTTER, WP (corresponding author), ROYAL POSTGRAD MED SCH, INST OBSTET & GYNAECOL, LONDON W12 0NN, ENGLAND.							ANDERSON DJ, 1992, BMJ-BRIT MED J, V305, P84, DOI 10.1136/bmj.305.6845.84; ANDERSON GH, 1988, BMJ-BRIT MED J, V296, P975, DOI 10.1136/bmj.296.6627.975; BOLGER BS, 1988, BRIT J OBSTET GYNAEC, V95, P1117, DOI 10.1111/j.1471-0528.1988.tb06788.x; COOPER P, 1992, CYTOPATHOLOGY, V3, P331; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; FLETCHER A, 1990, BRIT MED J, V301, P641, DOI 10.1136/bmj.301.6753.641; HIRSCHOWITZ L, 1992, BRIT MED J, V304, P1209, DOI 10.1136/bmj.304.6836.1209; JOHNSON N, 1993, LANCET, V342, P91, DOI 10.1016/0140-6736(93)91290-3; JONES MH, 1992, LANCET, V339, P1440, DOI 10.1016/0140-6736(92)92031-A; KESIC VI, 1993, INT J GYNECOL CANCER, V3, P395, DOI 10.1046/j.1525-1438.1993.03060395.x; KIRBY AJ, 1992, LANCET, V339, P828, DOI 10.1016/0140-6736(92)90278-B; PEARSON SE, 1989, BRIT J OBSTET GYNAEC, V96, P486, DOI 10.1111/j.1471-0528.1989.tb02429.x; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SIGURDSSON K, 1989, INT J CANCER, V43, P1, DOI 10.1002/ijc.2910430102; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; SOUTTER WP, 1992, REPORT WORKSHOP MILD; WALKER EM, 1986, LANCET, V2, P672; WILKINSON C, 1990, BRIT MED J, V300, P440, DOI 10.1136/bmj.300.6722.440; 1990, SERIES MB1, V18; 1987, INTERCOLLEGIATE WORK	20	59	60	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	1994	308	6941					1421	1423		10.1136/bmj.308.6941.1421	http://dx.doi.org/10.1136/bmj.308.6941.1421			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019256	Green Published			2022-12-28	WOS:A1994NP42000022
J	BAYLEY, TJ				BAYLEY, TJ			THE HOSPITAL COMPONENT OF VOCATIONAL-TRAINING FOR GENERAL-PRACTICE - COMMENTARY	BRITISH MEDICAL JOURNAL			English	Article								Trainees and educationalists in general practice have some grounds for suggesting that the hospital component of vocational training should be restructured and teaching improved. However, the implications for other trainees and secondary care have to be considered. Changes that are needed include a curriculum for senior house officers in each specialty; appointment of training consultants with the necessary skills; and a different attitude by everyone towards study leave, including arrangements for funding. The optimum duration of hospital posts for trainees in general practice might be shorter than now, but the effects on others must be considered and competencies guaranteed in a briefer training period. Changes in the regulations for vocational training could help to improve specialist experience if trainees in general practice were allowed to be supernumerary. Alternatively, senior house officer posts for trainees in general practice could be split between secondary and primary care, thus encouraging a broader perspective.			BAYLEY, TJ (corresponding author), FAC MED LIVERPOOL,BUSINESS SUPPORT SECT,POSTGRAD OFF,POB 147,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							BAKER M, 1994, POSTGRAD MED J, V70, P198, DOI 10.1136/pgmj.70.821.198; CRAWLEY HS, 1990, BRIT MED J, V300, P911, DOI 10.1136/bmj.300.6729.911; Grant J., 1992, TRAINING SENIOR HOUS; Styles W, 1993, POSTGRADUATE ED GENE, V4, P202; STYLES WM, 1990, BRIT J GEN PRACT, V40, P401; 1994, NEW DEAL PLAN ACTION; 1993, GENERAL PRACTITIONER; 1993, PALLIATIVE MED CONTE; 1992, PAEDIATRIC COMPONENT; 1994, HOSPITAL DOCTORS TRA	10	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1339	1340		10.1136/bmj.308.6940.1339	http://dx.doi.org/10.1136/bmj.308.6940.1339			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019224	Green Published			2022-12-28	WOS:A1994NM98900025
J	BINCHY, JM; MOLYNEUX, EM; MANNING, J				BINCHY, JM; MOLYNEUX, EM; MANNING, J			ACCIDENTAL INGESTION OF METHADONE BY CHILDREN IN MERSEYSIDE	BRITISH MEDICAL JOURNAL			English	Article									ROYAL LIVERPOOL CHILDRENS HOSP,LIVERPOOL L12 2AP,ENGLAND; WIRRAL HOSP,ARROWE PK L49 5PE,MERSEYSIDE,ENGLAND	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital								ARONOW R, 1973, CLIN TOXICOL, V6, P175, DOI 10.3109/15563657308990515; ARONOW R, 1972, J AMER MED ASSOC, V219, P321, DOI 10.1001/jama.219.3.321; BALTMAN S, 1971, PEDIATRICS, V48, P173; DIMAIO D J, 1973, Journal of Forensic Sciences, V18, P130; SMIALEK JE, 1977, JAMA-J AM MED ASSOC, V238, P2516, DOI 10.1001/jama.238.23.2516	5	61	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1335	1336		10.1136/bmj.308.6940.1335	http://dx.doi.org/10.1136/bmj.308.6940.1335			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019221	Green Published			2022-12-28	WOS:A1994NM98900022
J	SHARFSTEIN, JM; SHARFSTEIN, SS				SHARFSTEIN, JM; SHARFSTEIN, SS			CAMPAIGN CONTRIBUTIONS FROM THE AMERICAN-MEDICAL-POLITICAL-ACTION-COMMITTEE TO MEMBERS OF CONGRESS - FOR OR AGAINST THE PUBLIC-HEALTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The American Medical Political Action Committee (AMPAC), the political arm of the American Medical Association (AMA), contributed $2.4 million to candidates for Congress during the 1989-1990 campaign and $2.9 million during the 1991-1992 campaign. It is not known whether these funds preferentially benefited representatives who supported the AMA's positions on public health issues. Methods. We analyzed AMPAC contributions to members of the House of Representatives during the 1989-1990 and 1991-1992 campaigns according to their votes on three health-related issues: the promotion of tobacco exports, the institution of a mandatory waiting period before a handgun purchase, and the so-called gag rule, which limited physicians' speech on abortion in federally funded clinics. For each issue, we determined whether AMPAC had contributed more on average to opponents or to supporters of the official AMA position. Results. AMPAC contributed more on average to opponents of the AMA positions on all three public health issues. From 1989 to 1992, AMPAC gave significantly larger average contributions to House members who favored tobacco-export promotion than to those who opposed it ($11,549 vs. $9,842, P = 0.04) and contributed significantly less on average to supporters of handgun control than to their opponents ($9,022 vs. $11,250, P = 0.001). During the same period, AMPAC's contributions revealed a marked preference for House members who supported the gag rule over those who opposed it ($10,961 vs. $9,611, P = 0.05). House members who supported the AMA positions on all three votes received an average of $8,800 from AMPAC from 1989 through 1992, whereas members who opposed all three positions received an average of $13,270 (correlation between the number of votes for AMA positions and AMPAC contributions, -0.21; P<0.001). Conclusions. AMPAC's contributions to members of the House of Representatives belie the AMA positions on some important public health issues.	SHEPPARD & ENOCH PRATT HOSP,6501 N CHARLES ST,BALTIMORE,MD 21204; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School								KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; SUGARMAN J, 1991, JAMA-J AM MED ASSOC, V266, P3323, DOI 10.1001/jama.266.23.3323; TODD JS, 1991, COMMUNICATION   0503; 1993, MMWR MORB MORTAL WKL, V42, P645; 1992, WORLD SMOKING HLTH, V17, P10; 1991, C Q WEEKLY REPO 0511, P1226; 1992, JAMA-J AM MED ASSOC, V267, P3067; 1992, AMA POLICY COMPENDIU, P347; 1991, C Q WEEKLY REPO 1123, P3490; 1992, C Q WEEKLY REPO 0704, P1994; 1992, AM MED NEWS     0413, P19	11	20	20	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					32	37		10.1056/NEJM199401063300107	http://dx.doi.org/10.1056/NEJM199401063300107			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8018142	Bronze			2022-12-28	WOS:A1994MP64900007
J	GREENBERG, ER; BARON, JA; TOSTESON, TD; FREEMAN, DH; BECK, GJ; BOND, JH; COLACCHIO, TA; COLLER, JA; FRANKL, HD; HAILE, RW; MANDEL, JS; NIERENBERG, DW; ROTHSTEIN, R; SNOVER, DC; STEVENS, MM; SUMMERS, RW; VANSTOLK, RU				GREENBERG, ER; BARON, JA; TOSTESON, TD; FREEMAN, DH; BECK, GJ; BOND, JH; COLACCHIO, TA; COLLER, JA; FRANKL, HD; HAILE, RW; MANDEL, JS; NIERENBERG, DW; ROTHSTEIN, R; SNOVER, DC; STEVENS, MM; SUMMERS, RW; VANSTOLK, RU			CLINICAL-TRIAL OF ANTIOXIDANT VITAMINS TO PREVENT COLORECTAL ADENOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; COLON-CANCER; RANDOMIZED TRIAL; ASCORBIC-ACID; BETA-CAROTENE; SIGMOID COLON; POLYPS; RISK; DIET; EPIDEMIOLOGY	Background. People who consume a diet high in vegetables and fruits have a lower risk of cancer of the large bowel. Antioxidant vitamins, which are present in vegetables and fruits, have been associated with a diminished risk of cancers at various anatomical sites. We conducted a randomized, controlled clinical trial to test the efficacy of beta carotene and vitamins C and E in preventing colorectal adenoma, a precursor of invasive cancer. Methods. We randomly assigned 864 patients, using a two-by-two factorial design, to four treatment groups, which received placebo, beta carotene (25 mg daily), vitamin C (1 g daily) and vitamin E (400 mg daily), or beta carotene plus vitamins C and E. In order to identify new adenomas, we performed complete colonoscopic examinations in the patients one year and four years after they entered the study. The primary end points for analyses were new adenomas identified after the first of these two follow-up examinations. Results. Patients adhered well to the prescribed regimen, and 751 completed the four-year clinical trial. There was no evidence that either beta carotene or vitamins C and E reduced the incidence of adenomas; the relative risk for beta carotene was 1.01 (95 percent confidence interval, 0.85 to 1.20); for vitamins C and E, it was 1.08 (95 percent confidence interval, 0.91 to 1.29). Neither treatment appeared to be effective in any subgroup of patients or in the prevention of any subtype of polyp defined by size or location. Conclusions. The lack of efficacy of these vitamins argues against the use of supplemental beta carotene and vitamins C and E to prevent colorectal cancer. Although our data do not prove definitively that these antioxidants have no anticancer effect, other dietary factors may make more important contributions to the reduction in the risk of cancer associated with a diet high in vegetables and fruits.	DARTMOUTH HITCHCOCK MED CTR, LEBANON, NH USA; NORRIS COTTON CANC CTR, LEBANON, NH USA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; LAHEY CLIN FDN, BURLINGTON, MA USA; KAISER PERMANENTE MED CTR SUNSET, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA USA; UNIV IOWA, IOWA CITY, IA USA	Dartmouth College; Norris Cotton Cancer Center; Cleveland Clinic Foundation; University of Minnesota System; University of Minnesota Twin Cities; Lahey Hospital & Medical Center; Kaiser Permanente; University of California System; University of California Los Angeles; University of Iowa					NCI NIH HHS [CA23108, CA37287] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA037287, P30CA023108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BLOCK G, 1991, AM J CLIN NUTR, V53, pS270, DOI 10.1093/ajcn/53.1.270S; BLOCK G, 1993, J NATL CANCER I, V85, P846, DOI 10.1093/jnci/85.11.846; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BOSTICK RM, 1993, CANCER RES, V53, P4230; BOYLE P, 1985, INT J CANCER, V36, P9, DOI 10.1002/ijc.2910360103; BUSSEY HJR, 1982, CANCER, V50, P1434, DOI 10.1002/1097-0142(19821001)50:7<1434::AID-CNCR2820500733>3.0.CO;2-F; BYAR DP, 1985, CANCER TREAT REP, V69, P1055; BYERS T, 1992, ANNU REV NUTR, V12, P139, DOI 10.1146/annurev.nu.12.070192.001035; CONOVER W. J, 1980, PRACTICAL NONPARAMET; DECOSSE JJ, 1989, JNCI-J NATL CANCER I, V81, P1290, DOI 10.1093/jnci/81.17.1290; Doll R, 1981, THE CAUSES OF CANCER; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GIOVANNUCCI E, 1992, JNCI-J NATL CANCER I, V84, P91, DOI 10.1093/jnci/84.2.91; GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204; GREENBERG ER, 1991, NEW ENGL J MED, V325, P1324; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HIXSON LJ, 1990, JNCI-J NATL CANCER I, V82, P1769, DOI 10.1093/jnci/82.22.1769; HOFF G, 1986, SCAND J GASTROENTERO, V21, P853, DOI 10.3109/00365528609011130; HOFF G, 1986, SCAND J GASTROENTERO, V21, P199, DOI 10.3109/00365528609034647; KATO I, 1990, JPN J CANCER RES, V81, P1101, DOI 10.1111/j.1349-7006.1990.tb02520.x; KNEKT P, 1991, ANN MED, V23, P3, DOI 10.3109/07853899109147923; KONO S, 1993, JPN J CANCER RES, V84, P13, DOI 10.1111/j.1349-7006.1993.tb02777.x; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIPKIN M, 1988, CANCER RES, V48, P235; LITTLE J, 1993, BRIT J CANCER, V67, P177, DOI 10.1038/bjc.1993.31; LONGNECKER MP, 1992, JNCI-J NATL CANCER I, V84, P430, DOI 10.1093/jnci/84.6.430; MACOUARTMOULIN G, 1987, INT J CANCER, V40, P179, DOI 10.1002/ijc.2910400209; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MCKEOWNEYSSEN G, 1988, CANCER RES, V48, P4701; MORSON BC, 1983, CANCER SURV, V2, P451; NIERENBERG DW, 1985, J CHROMATOGR, V339, P273, DOI 10.1016/S0378-4347(00)84654-X; NIERENBERG DW, 1985, J CHROMATOGR, V345, P275, DOI 10.1016/0378-4347(85)80165-1; PAGANELLI GM, 1992, J NATL CANCER I, V84, P47, DOI 10.1093/jnci/84.1.47; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RONCUCCI L, 1993, DIS COLON RECTUM, V36, P227, DOI 10.1007/BF02053502; SANDLER RS, 1993, JNCI-J NATL CANCER I, V85, P884, DOI 10.1093/jnci/85.11.884; SINHA R, 1992, CANCER EPIDEM BIOMAR, V1, P297; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P427, DOI 10.1007/BF00054304; VANPOPPEL G, 1993, EUR J CANCER, V29A, P1335, DOI 10.1016/0959-8049(93)90087-V; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1983, AM J CLIN NUTR, V38, P559, DOI 10.1093/ajcn/38.4.559; WINAWER SJ, 1992, J NATL CANCER I, V84, P74, DOI 10.1093/jnci/84.2.74; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	48	613	626	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					141	147		10.1056/NEJM199407213310301	http://dx.doi.org/10.1056/NEJM199407213310301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008027				2022-12-28	WOS:A1994NW79700001
J	SPIRO, TE; JOHNSON, GJ; CHRISTIE, MJ; LYONS, RM; MACFARLANE, DE; BLASIER, RB; TREMAINE, MD				SPIRO, TE; JOHNSON, GJ; CHRISTIE, MJ; LYONS, RM; MACFARLANE, DE; BLASIER, RB; TREMAINE, MD			EFFICACY AND SAFETY OF ENOXAPARIN TO PREVENT DEEP VENOUS THROMBOSIS AFTER HIP-REPLACEMENT SURGERY	ANNALS OF INTERNAL MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; UNFRACTIONATED HEPARIN; EXTREME THROMBOCYTOSIS; ORTHOPEDIC-SURGERY; VEIN-THROMBOSIS; PK-10169; INVITRO; DISORDERS; INVIVO; TRIAL	Objective: To determine the most effective and safe dose of enoxaparin to prevent deep venous thrombosis in high-risk surgical patients. Design: A double-blind, randomized, multicenter clinical trial. Setting: Private, university, and government hospitals in the United States. Patients: 572 patients having elective hip replacement surgery, 568 of whom received study medication and had efficacy data available for evaluation. interventions: Patients were randomly assigned to one of three subcutaneous enoxaparin regimens: 10 mg once daily (161 patients); 40 mg once daily (199 patients); and 30 mg every 12 hours (208 patients). Treatment was initiated within 24 hours after surgery and continued for as long as 7 days. Treatment with 10 mg enoxaparin once daily was discontinued prematurely after an interim analysis showed an increased deep venous thrombosis incidence in this treatment group. Measurements: Efficacy was determined by bilateral lower extremity venography, noninvasive vascular imaging methods, or clinical evidence on day 7 of treatment ment or earlier if clinically indicated. Results: Deep venous thrombosis occurred in 25% (40 of 161) of the patients who received 10 mg of enoxaparin once daily; in 14% (27 of 199) of those receiving 40 mg of enoxaparin once daily; and in 11% (22 of 208) in those receiving 30 mg of enoxaparin every 12 hours. The incidence of deep venous thrombosis was significantly higher in patients who received 10 mg of enoxaparin once daily compared with those who received 40 mg of enoxaparin once daily (P = 0.02) or those who received 30 mg of enoxaparin every 12 hours (P < 0.001). The difference between the patients who received 40 mg once daily and those who received 30 mg every 12 hours was not significant. Only two cases of pulmonary embolism were diagnosed, one in patients receiving 40 mg of enoxaparin and one in those receiving 10 mg once daily. The incidence of hemorrhagic complications differed significantly between patients who received 10 mg of enoxaparin once daily (5%, 8 of 161 patients) and those who received 30 mg of enoxaparin every 12 hours (13%, 26 of 208; P < 0.05). Conclusions: After surgery, enoxaparin, 40 mg once daily or 30 mg every 12 hours, is more effective than a regimen of 10 mg once daily to prevent deep venous thrombosis in patients having elective hip replacement surgery. The regimens of 40 mg once daily and 30 mg every 12 hours provided prophylaxis similar to the most effective drug treatments previously reported. The incidence of hemorrhagic episodes with the regimens of 40 mg once daily and 30 mg twice daily,was higher than that observed with 10 mg once daily; however, major hemorrhage occurred in only 4% to 5% of patients receiving the higher-dose regimens. The risk-to-benefit ratio supports the use of enoxaparin as a therapeutic agent to prevent deep venous thrombosis in these patients.	VET AFFAIRS MED CTR, MINNEAPOLIS, MN USA; VANDERBILT UNIV, MED CTR, NASHVILLE, TN USA; HEMATOL & ONCOL ASSOCIATES S TEXAS, SAN ANTONIO, TX USA; ANDERSON ORTHOPAED RES INST, ARLINGTON, TX USA; UNIV IOWA HOSP & CLIN, IOWA CITY, IA USA; UNIV MICHIGAN, ANN ARBOR, MI USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Vanderbilt University; University of Iowa; University of Michigan System; University of Michigan	SPIRO, TE (corresponding author), RHONE POULENC PHARMACEUT INC, CARDIOVASC DIS, 500 ARCOLA RD, COLLEGEVILLE, PA 19426 USA.			Macfarlane, Donald/0000-0001-8785-5690				ABURAHMA AF, 1991, AM J SURG, V162, P175, DOI 10.1016/0002-9610(91)90183-E; AIACH M, 1983, THROMB RES, V31, P611, DOI 10.1016/0049-3848(83)90458-9; ALBRECHTSSON U, 1976, LANCET, V1, P723; BELL WR, 1976, ANN INTERN MED, V85, P155, DOI 10.7326/0003-4819-85-2-155; BETTMANN MA, 1987, RADIOLOGY, V165, P113, DOI 10.1148/radiology.165.1.3306781; BORRIS LC, 1991, ARCH INTERN MED, V151, P1621; BRACE LD, 1986, HAEMOSTASIS, V16, P93; BRESLOW A, 1968, BLOOD, V32, P393, DOI 10.1182/blood.V32.3.393.393; BUCKLEY MM, 1992, DRUGS, V44, P465, DOI 10.2165/00003495-199244030-00010; BUNTING RW, 1991, J BONE JOINT SURG BR, V73, P687, DOI 10.1302/0301-620X.73B4.2071662; BUSS DH, 1985, AM J HEMATOL, V20, P365, DOI 10.1002/ajh.2830200408; CADE JF, 1984, THROMB RES, V35, P613, DOI 10.1016/0049-3848(84)90265-2; CARTER CA, 1993, ANN PHARMACOTHER, V27, P1223, DOI 10.1177/106002809302701013; CARTER CJ, 1982, BLOOD, V59, P1239; COLA C, 1990, AM HEART J, V119, P368, DOI 10.1016/S0002-8703(05)80029-8; COVENTRY MB, 1973, J BONE JOINT SURG AM, VA 55, P1487, DOI 10.2106/00004623-197355070-00016; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; DAWES J, 1986, HAEMOSTASIS, V16, P116; DUKES GE, 1984, ANN INTERN MED, V100, P646, DOI 10.7326/0003-4819-100-5-646; GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; HAAKE DA, 1989, CLIN ORTHOP RELAT R, P212; HARRIS WH, 1974, J BONE JOINT SURG AM, VA 56, P1552, DOI 10.2106/00004623-197456080-00002; HARRIS WH, 1984, J BONE JOINT SURG AM, V66A, P1388, DOI 10.2106/00004623-198466090-00011; HARRIS WH, 1977, NEW ENGL J MED, V297, P1246, DOI 10.1056/NEJM197712082972302; JOHNSON R, 1977, CLIN ORTHOP RELAT R, V127, P123; KRISTIANSEN P, 1981, ACTA RADIOL DIAGN, V22, P577, DOI 10.1177/028418518102200511; LAERUM F, 1981, RADIOLOGY, V140, P651, DOI 10.1148/radiology.140.3.7025090; LECOMPTE T, 1991, LANCET, V338, P1217, DOI 10.1016/0140-6736(91)92090-O; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LENTNER M, 1986, EXPT DESIGN ANAL, P124; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; PADILLA A, 1992, BRIT J HAEMATOL, V82, P406, DOI 10.1111/j.1365-2141.1992.tb06437.x; PEPPER H, 1960, SURG GYNECOL OBSTET, V110, P319; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; PLANES A, 1986, HAEMOSTASIS, V16, P152; PLANES A, 1991, SEMIN THROMB HEMOST, V17, P296; SCURR JH, 1988, BRIT MED J, V297, P28, DOI 10.1136/bmj.297.6640.28; SONNENBLICK M, 1975, BRIT MED J, V3, P77, DOI 10.1136/bmj.3.5975.77; SPIRO TE, 1992, BLOOD S, V80, P167; STAMATAKIS JD, 1977, BRIT MED J, V2, P223, DOI 10.1136/bmj.2.6081.223; TROWBRIDGE A, 1994, CLIN ORTHOP RELAT R, V299, P203; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; VINAZZER H, 1986, HAEMOSTASIS, V16, P106; WALENGA JM, 1985, SEMIN THROMB HEMOST, V11, P17, DOI 10.1055/s-2007-1004353	46	106	107	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					81	89		10.7326/0003-4819-121-2-199407150-00001	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017740				2022-12-28	WOS:A1994NW18600001
J	ROBERTS, JC; FLETCHER, RH; FLETCHER, SW				ROBERTS, JC; FLETCHER, RH; FLETCHER, SW			EFFECTS OF PEER-REVIEW AND EDITING ON THE READABILITY OF ARTICLES PUBLISHED IN ANNALS OF INTERNAL-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC			Objective.-To measure the effect of the peer review and editorial processes on the readability of original articles. Design.-Comparison of manuscripts before and after the peer review and editorial processes. Setting.-Annals of Internal Medicine between March 1 and November 30, 1992. Manuscripts.-One hundred one consecutive manuscripts reporting original research. Measurements.-Assessment of readability by means of two previously validated indexes: the Gunning fog index (units of readability in the fog index roughly correlate to years of education) and the Flesch reading ease score. Each manuscript was analyzed for readability and length on receipt and after it had passed through the peer review and editorial processes. Text and abstracts were analyzed similarly but separately. Mean readability scores were compared by two-tailed t tests for paired observations. Results.-Mean (+/-SD) initial readability scores of manuscripts and abstracts by the Gunning fog index were 17.16+/-1.55 and 16.65+/-2.80, respectively. At publication, scores were 16.85+/-1.42 and 15.64+/-2.42 (P=.0005 and P<.0001 for before-after differences, respectively). By comparison, studies of other print media showed scores of about 11 for the New York Times editorial page and about 18 for a typical legal contract. Similar changes were found for the Flesch scores. The median length. of the manuscripts increased by 2.6% and that of the abstracts by 4.2% during the processes. Conclusions.-The peer review and editorial processes slightly improved the readability of original articles and their abstracts, but both remained difficult to read at publication. Better readability scores may improve readership.	ANNALS INTERNAL MED,EDITORIAL OFF,PHILADELPHIA,PA		ROBERTS, JC (corresponding author), JOHNS HOPKINS BAYVIEW MED CTR,DIV GEN INTERNAL MED,B-2 N,4940 EASTERN AVE,BALTIMORE,MD 21224, USA.							DEAN AG, 1990, EPIINFO 5 0; Flesch R, 1948, J APPL PSYCHOL, V32, P221, DOI 10.1037/h0057532; FLETCHER SW, 1992, J INTERN MED, V232, P223, DOI 10.1111/j.1365-2796.1992.tb00576.x; Gray William, 1935, WHAT MAKES BOOK READ; Gunning R., 1952, TECHNIQUE CLEAR WRIT; Klare G, 1963, MEASUREMENT READABIL; LAROCQUE P, 1993, QUILL            SEP, P36; Severin W. J., 1992, COMMUNICATION THEORI; Stone G., 1987, EXAMINING NEWSPAPERS; Swanson CE, 1948, JOURNALISM QUART, V25, P339, DOI 10.1177/107769904802500402; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W; 1992, SAS RELEASE 6 03; 1990, RIGHTWRITER 4 0; 1993, STUDY MED J READERSH	14	73	74	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					119	121		10.1001/jama.272.2.119	http://dx.doi.org/10.1001/jama.272.2.119			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015120				2022-12-28	WOS:A1994NV42400010
J	DORER, DR; HENIKOFF, S				DORER, DR; HENIKOFF, S			EXPANSIONS OF TRANSGENE REPEATS CAUSE HETEROCHROMATIN FORMATION AND GENE SILENCING IN DROSOPHILA	CELL			English	Article							POSITION EFFECT VARIEGATION; P-ELEMENT TRANSPOSITION; WHITE GENE; MELANOGASTER; EXPRESSION; CHROMOSOME; TRANSVECTION; CHROMATIN; TRANSCRIPTION; INSERTIONS	Closely linked repeats of a Drosophila P transposon carrying a white transgene were found to cause white variegation. Arrays of three or more transgenes produced phenotypes similar to classical heterochromatin-induced position-effect variegation (PEV), and these phenotypes were modified by known modifiers of PEV. This effect on the repeated transgenes was much stronger for a site near centric heterochromatin than it was for a medial site, and it strengthened with increasing copy number. Differences between variegated phenotypes could be accounted for if different topological structures were generated by pairing between closely linked repeat sequences. We propose that pairing of repeats underlies heterochromatin formation and is responsible for diverse gene silencing phenomena in animals and plants.			DORER, DR (corresponding author), FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,DIV BASIC SCI,SEATTLE,WA 98104, USA.			Henikoff, Steven/0000-0002-7621-8685				ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; Bernard J., 1988, EUKARYOTE GENOME DEV, DOI [10.1007/978-94-011-5991-3, DOI 10.1007/978-94-011-5991-3]; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COOLEY L, 1990, P NATL ACAD SCI USA, V87, P3170, DOI 10.1073/pnas.87.8.3170; DANIELS SB, 1993, GENETICS, V133, P623; DAVIS BP, 1988, GENE DEV, V2, P13, DOI 10.1101/gad.2.1.13; EISSENBERG JC, 1991, TRENDS GENET, V7, P335, DOI 10.1016/0168-9525(91)90424-O; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; Ephrussi B, 1944, P NATL ACAD SCI USA, V30, P183, DOI 10.1073/pnas.30.8.183; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; Gans M., 1953, B BIOL FRANCE BELG S, V38, P1; GRIGLIATTI T, 1991, FUNCTIONAL ORG NUCLE, P587; GUBB D, 1990, GENETICS, V126, P167; HAWLEY RS, 1988, GENETICS, V119, P85; HAWLEY RS, 1993, DEV GENET, V13, P440; HENIKOFF S, 1993, CHROMOSOME, P183; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; KASSIS JA, 1991, GENETICS, V128, P751; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KKOPCZYNSKI CC, 1992, J CELL BIOL, V119, P503; LAIRD CD, 1987, GENETICS, V117, P587; LEVIS R, 1982, P NATL ACAD SCI-BIOL, V79, P564, DOI 10.1073/pnas.79.2.564; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Matzke M., 1994, Homologous recombination and gene silencing in plants., P271; Metz CW, 1916, J EXP ZOOL, V21, P213, DOI 10.1002/jez.1400210204; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; Rabl C, 1885, MORPHOL JB, V10, P214; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; ROBERTSON HM, 1988, GENETICS, V118, P461; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SMABROOK J, 1989, MOL CLONING LABORATO; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STUART GW, 1990, DEVELOPMENT, V109, P577; TALBERT PB, 1994, GENETICS, V136, P559; TARTOF KD, 1984, CELL, V37, P869, DOI 10.1016/0092-8674(84)90422-7; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TOWER J, 1993, GENETICS, V133, P347; WAKIMOTO BT, 1990, GENETICS, V125, P141; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; WINES DR, 1992, GENETICS, V131, P683; ZACHAR Z, 1985, COLD SPRING HARB SYM, V50, P337, DOI 10.1101/SQB.1985.050.01.043; ZHANG P, 1993, GENETICS, V133, P361	52	452	473	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					993	1002		10.1016/0092-8674(94)90439-1	http://dx.doi.org/10.1016/0092-8674(94)90439-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020105				2022-12-28	WOS:A1994NV42500008
J	HOLM, C				HOLM, C			COMING UNDONE - HOW TO UNTANGLE A CHROMOSOME	CELL			English	Review							DNA TOPOISOMERASE-II; CHROMATID SEPARATION; MITOSIS; CONDENSATION; ANAPHASE; KINETOCHORE; SEGREGATION; REPLICATION; BEHAVIOR; EXTRACTS		UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego	HOLM, C (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.							ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ALEXANDER SP, 1991, J CELL BIOL, V113, P805, DOI 10.1083/jcb.113.4.805; COMINGS DE, 1966, SCIENCE, V154, P1463, DOI 10.1126/science.154.3755.1463; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; DOWNES CS, 1991, P NATL ACAD SCI USA, V88, P8895, DOI 10.1073/pnas.88.20.8895; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; MCCARROLL RM, 1988, CELL, V54, P503; MCNEILL PA, 1981, J CELL BIOL, V88, P543, DOI 10.1083/jcb.88.3.543; MIYAZAKI WY, 1994, ANN REV GENET, V258; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; NICKLAS RB, 1969, J CELL BIOL, V43, P40, DOI 10.1083/jcb.43.1.40; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SPELL RM, 1994, MOL CELL BIOL, V14, P1465, DOI 10.1128/MCB.14.2.1465; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; VERSHAVSKY A, 1983, MECHANISMS DNA REPLI, P463; WEAVER DT, 1985, CELL, V41, P565, DOI 10.1016/S0092-8674(85)80029-5; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839	27	96	96	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					955	957		10.1016/0092-8674(94)90433-2	http://dx.doi.org/10.1016/0092-8674(94)90433-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020101				2022-12-28	WOS:A1994NV42500002
J	THOMAS, BJ; GUNNING, DA; CHO, J; ZIPURSKY, SL				THOMAS, BJ; GUNNING, DA; CHO, J; ZIPURSKY, SL			CELL-CYCLE PROGRESSION IN THE DEVELOPING DROSOPHILA EYE - ROUGHEX ENCODES A NOVEL PROTEIN REQUIRED FOR THE ESTABLISHMENT OF G1	CELL			English	Article							POLARITY GENE HEDGEHOG; MAMMALIAN FIBROBLASTS; SEVENLESS PROTEIN; G2-M TRANSITION; TYROSINE-KINASE; TGF-BETA; HOMOLOG; RETINA; DIFFERENTIATION; PROLIFERATION	The onset of pattern formation in the developing Drosophila eye is marked by the simultaneous synchronization of all cells in the G1 phase of the cell cycle. These cells will then either commit to another round of cell division or differentiate into neurons. Although cell cycle synchronization occurs in rougher (rux) mutants, cells circumvent G1 and all cells enter S phase, including cells that would normally differentiate. This leads to defects in early steps of pattern formation and cell fate determination. rux is suppressed by mutations in genes that promote cell cycle progression (i.e., cyclin A and string) and enhanced by mutations in genes that promote differentiation (i.e., Ras1 and Star). rux encodes a novel protein of 335 amino acids. We propose that rux functions as a negative regulator of G1 progression in the developing eye.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	THOMAS, BJ (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.							ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ASHBURNER M, DROSOPHILA LABORATOR; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; Cagan Ross Leigh, 1992, P189; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHEYETTE BNR, 1994, NEURON, V12, P1; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GONCZY P, 1994, CELL, V77, P1015, DOI 10.1016/0092-8674(94)90441-3; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1993, CELL, V75, P1; KAFATOS FC, 1991, TRENDS GENET, V7, P155, DOI 10.1016/0168-9525(91)90104-X; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOLODKIN A, 1993, IN PRESS DEVELOPMENT; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Murray A, 1993, CELL CYCLE INTRO; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; WEN ME, 1993, CELL, V74, P1009; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	42	166	170	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1003	1014		10.1016/0092-8674(94)90440-5	http://dx.doi.org/10.1016/0092-8674(94)90440-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020091				2022-12-28	WOS:A1994NV42500009
J	BROWN, EJ; ALBERS, MW; SHIN, TB; ICHIKAWA, K; KEITH, CT; LANE, WS; SCHREIBER, SL				BROWN, EJ; ALBERS, MW; SHIN, TB; ICHIKAWA, K; KEITH, CT; LANE, WS; SCHREIBER, SL			A MAMMALIAN PROTEIN TARGETED BY G1-ARRESTING RAPAMYCIN-RECEPTOR COMPLEX	NATURE			English	Article							P70 S6 KINASE; IMMUNOSUPPRESSANT RAPAMYCIN; INDUCED INHIBITION; LYMPHOCYTES-T; YEAST; IMMUNOPHILIN; ACTIVATION; ARREST; FK506; PROLIFERATION	THE structurally related natural products rapamycin and FK506 bind to the same intracellular receptor, FKBP12, yet the resulting complexes interfere with distinct signalling pathways(1,2). FKBP12- rapamycin inhibits progression through the G1 phase of the cell cycle in osteosarcoma(3), liver(4,5) and T cells(6,7) as well as in yeasts, and interferes with mitogenic signalling pathways that are involved in G1 progressiong(9,10), namely with activation of the protein p70(S6k) (refs 5, 11-13) and cyclin-dependent kinases(3,14-16). Here we isolate a mammalian FKBP-rapamycin-associated protein (FRAP) whose binding to structural variants of rapamycin complexed to FKBP12 correlates with the ability of these ligands to inhibit cell-cycle progression. Peptide sequences from purified bovine FRAP were used to isolate a human cDNA clone that is highly related to the DRR1/TOR1 and DRR2/TOR2 gene products from Saccharomyces cerevisiae(8,17,18). Although it has not been previously demonstrated that either of the DRR/TOR gene products can bind the FKBP-rapamycin complex directly(17,19), these yeast genes have been genetically linked to a rapamycin-sensitive pathway and are thought to encode lipid kinases(17-20).	HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University								ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALBERS MW, 1993, ANN NY ACAD SCI, V696, P54; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FOOR F, 1992, NATURE, V360, P682; FRANCAVILLA A, 1992, HEPATOLOGY, V15, P871, DOI 10.1002/hep.1840150520; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; HAYWARD CM, 1993, J AM CHEM SOC, V115, P9345, DOI 10.1021/ja00073a083; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HULTSCH T, 1992, MOL BIOL CELL, V3, P981, DOI 10.1091/mbc.3.9.981; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORICE WG, 1993, J BIOL CHEM, V268, P3734; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9	27	1583	1691	7	137	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					756	758		10.1038/369756a0	http://dx.doi.org/10.1038/369756a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008069				2022-12-28	WOS:A1994NU58100064
J	JACOBSON, RH; ZHANG, XJ; DUBOSE, RF; MATTHEWS, BW				JACOBSON, RH; ZHANG, XJ; DUBOSE, RF; MATTHEWS, BW			3-DIMENSIONAL STRUCTURE OF BETA-GALACTOSIDASE FROM ESCHERICHIA-COLI	NATURE			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ALPHA-COMPLEMENTATION; WEISSENBERG CAMERA; DIFFRACTION DATA; LACZ GENE; CRYSTALLOGRAPHY; REFINEMENT; EXPRESSION; PROGRAM	THE beta-galactosidase from Escherichia coli was instrumental in the development of the operon model(1), and today is one of the most commonly used enzymes in molecular biology. Here we report the structure of this protein and show that it is a tetramer with 222- point symmetry. The 1,023-amino-acid polypeptide chain(2,3) folds into five sequential domains, with an extended segment at the amino terminus. The participation of this amino-terminal segment in a subunit interface, coupled with the observation that each active site is made up of elements from two different subunits, provides a structural rationale for the phenomenon of alpha-complementation. The structure represents the longest polypeptide chain for which an atomic structure has been determined. Our results show that it is possible successfully to study non-viral protein crystals with unit cell dimensions in excess of 500 Angstrom and with relative molecular masses in the region of 2,000K per asymmetric unit. Non-crystallographic symmetry averaging proved to be a very powerful tool in the structure determination, as has been shown in other contexts(31,32).	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403	University of Oregon; Howard Hughes Medical Institute; University of Oregon; University of Oregon								ADAMS RM, 1994, J BIOL CHEM, V269, P5666; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BUVINGER WE, 1985, J BACTERIOL, V163, P850, DOI 10.1128/JB.163.3.850-857.1985; CELADA F, 1974, BIOCHEMISTRY-US, V13, P5543, DOI 10.1021/bi00724a014; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; FOWLER AV, 1978, J BIOL CHEM, V253, P5521; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; HANCOCK KR, 1991, J BACTERIOL, V173, P3084, DOI 10.1128/JB.173.10.3084-3095.1991; HEINZ DW, 1994, PROTEIN ENG, V7, P301, DOI 10.1093/protein/7.3.301; HENDERSON DR, 1986, CLIN CHEM, V32, P1637; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JACOBSON RH, 1992, J MOL BIOL, V223, P1177, DOI 10.1016/0022-2836(92)90269-P; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGLEY KE, 1975, P NATL ACAD SCI USA, V72, P1254, DOI 10.1073/pnas.72.4.1254; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; RING M, 1990, ARCH BIOCHEM BIOPHYS, V283, P342, DOI 10.1016/0003-9861(90)90652-F; ROSSMANN MG, 1985, NATURE, V317, P153; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SCHMIDT BF, 1989, J BACTERIOL, V171, P625, DOI 10.1128/jb.171.2.625-635.1989; SCHROEDER CJ, 1991, J GEN MICROBIOL, V137, P369, DOI 10.1099/00221287-137-2-369; STOKES HW, 1985, MOL BIOL EVOL, V2, P469; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; Weinstock G M, 1983, Gene Amplif Anal, V3, P27; ZABIN I, 1982, MOL CELL BIOCHEM, V49, P87	32	538	550	2	86	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					761	766		10.1038/369761a0	http://dx.doi.org/10.1038/369761a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008071				2022-12-28	WOS:A1994NU58100066
J	ANDERSON, RM				ANDERSON, RM			MATHEMATICAL STUDIES OF PARASITIC INFECTION AND IMMUNITY	SCIENCE			English	Article							T-CELLS; RESPONSES; MODEL	The techniques that underpin modern molecular biology have been rapidly adopted by those interested in the major parasitic infections of humans. The parasitological literature is full of reports of genes and their amino acid sequences, of molecules, of cell membrane receptors and channels, and of the fine details of the immunological responses mounted by the host to combat infection. Much less enthusiasm has been shown for the mathematical techniques that facilitate the analysis and interpretation of dynamical processes such as transmission, evolution, and the interplay between parasite population growth and immunological responses within the host. Molecular techniques provide enormous opportunities for description, but ultimately, understanding biological systems with the precision that physicists and engineers aspire to in their own fields will require quantitative description of the many rate processes that dictate both an observed pattern and the dynamics of its change.			ANDERSON, RM (corresponding author), UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND.			Anderson, Roy/0000-0002-9528-3175				AGUR Z, 1989, P NATL ACAD SCI USA, V86, P9626, DOI 10.1073/pnas.86.23.9626; ANDERSON R M, 1991; ANDERSON RM, 1985, NATURE, V315, P493, DOI 10.1038/315493a0; ANDERSON RM, 1982, PARASITOLOGY, V85, P411, DOI 10.1017/S0031182000055360; ANDERSON RM, IN PRESS PHILOS T B; ANDERSON RM, 1981, POPULATION BIOL, P249; ANDERSON RW, UNPUB; BABAD HR, IN PRESS EPIDEMIOL I; BUTTERWORTH AE, 1991, PARASITOLOGY, V103, P339, DOI 10.1017/S0031182000059850; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; GUPTA S, IN PRESS P R SOC L B; GUYATT HL, 1993, T ROY SOC TROP MED H, V87, P570, DOI 10.1016/0035-9203(93)90094-7; LEVIN S, 1981, AM NAT, V117, P308, DOI 10.1086/283708; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; MEDLEY GF, IN PRESS PARASITOLOG; MICHAEL E, 1992, PARASITOLOGY, V105, P139, DOI 10.1017/S0031182000073790; NOWAK MA, 1994, P ROY SOC B-BIOL SCI, V255, P81, DOI 10.1098/rspb.1994.0012; NOWAK MA, IN PRESS J THEOR BIO; REMME J, 1986, B WORLD HEALTH ORGAN, V64, P667; Ross R., 1911, PREVENTION MALARIA; SCHWEITZER AN, 1992, P ROY SOC B-BIOL SCI, V247, P107, DOI 10.1098/rspb.1992.0015; SCHWEITZER AN, 1993, PARASITE IMMUNOL, V15, P85, DOI 10.1111/j.1365-3024.1993.tb00588.x; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SWINTON J, UNPUB	25	28	28	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	1994	264	5167					1884	1886		10.1126/science.8009218	http://dx.doi.org/10.1126/science.8009218			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009218				2022-12-28	WOS:A1994NT84700033
J	HYNDMAN, SJ; WILLIAMS, DRR; MERRILL, SL; LIPSCOMBE, JM; PALMER, CR				HYNDMAN, SJ; WILLIAMS, DRR; MERRILL, SL; LIPSCOMBE, JM; PALMER, CR			RATES OF ADMISSION TO HOSPITAL FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							ACUTE CHILDHOOD ASTHMA; TRENDS; CHILDREN; INCREASE; HEALTH; CARE	Objective-To describe trends in hospital admission rates for asthma in England and Wales (1976-85), the East Anglian region (from 1976 to 1991-2), and Wales (1980-90). Design-Descriptive study. Setting-Hospitals in England and Wales; hospitals in the East Anglian Regional Health Authority; hospitals in Wales. Main outcome measures-Hospital admissions for asthma as principal diagnosis in England and Wales (Hospital In-patient Enquiry, 1976-85), for the East Anglian region (Hospital In-patient Enquiry, 1976-7; Hospital Activity Analysis, 1978-86; Regional Information System, 1987-8 to 1991-2), and for Wales (Hospital Activity Analysis, l980-90). Results-Rates for England and Wales as a whole showed a steady upward trend throughout the period examined. Rates in East Anglia, though they were similar to the national trends in the early years, showed a peak in 1985 (for males and females) with some indication of a decline in rates thereafter. Rates for Wales showed an upward trend until 1988 (for both males and females) after which they showed a decline. Conclusions-Interpretation of the East Anglian trends is made more difficult by the change in England in 1987 of the system for the collection of hospital admission data. The fact that the rates for the East Anglian region seem to decline before this change and other considerations suggest that the observed trends, although partly reflecting the disruption of the coding during the changeover in systems, may not be entirely artefactual. The possible roles of diagnostic transfer and changes in the delivery of care, asthma treatment, admission and readmission policies, and the severity and prevalence of asthma in changing admission rates are considered. The changing bends in admission rates for East Anglia and Wales reflect recently published trends for mortality from asthma in England.			HYNDMAN, SJ (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,HLTH SERV RES GRP,UNIV FORVIE SITE,CAMBRIDGE CB2 2SR,CAMBS,ENGLAND.							ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1978, ARCH DIS CHILD, V53, P295, DOI 10.1136/adc.53.4.295; ANDERSON HR, 1980, BRIT MED J, V281, P1191, DOI 10.1136/bmj.281.6249.1191; [Anonymous], 1990, BMJ, V301, P797; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; CARMAN PG, 1990, MED J AUSTRALIA, V152, P23, DOI 10.5694/j.1326-5377.1990.tb124423.x; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P227; CLARK TJH, 1990, OCCURRENCE COST ASTH; GARDNER MJ, 1989, STATISTICS CONFIDENC; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; KHOT A, 1984, BRIT MED J, V289, P235, DOI 10.1136/bmj.289.6439.235; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MITCHELL EA, 1989, EUR RESPIR J, V2, P470; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STORR J, 1988, ARCH DIS CHILD, V63, P774, DOI 10.1136/adc.63.7.774; STRACHAN DP, 1992, BRIT MED J, V304, P819, DOI 10.1136/bmj.304.6830.819; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; 1993, HOSPITAL EPISODE STA, V1; 1980, HOSPITAL INPATIENT E; 1990, BRIT MED J, V301, P651	22	87	87	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1596	1600		10.1136/bmj.308.6944.1596	http://dx.doi.org/10.1136/bmj.308.6944.1596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025425	Green Published			2022-12-28	WOS:A1994NT52800016
J	SAWYER, SM; BOWES, G; PHELAN, PD				SAWYER, SM; BOWES, G; PHELAN, PD			VULVO-VAGINAL CANDIDIASIS IN YOUNG-WOMEN WITH CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article									UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT THORAC MED,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne								BLUM RW, 1991, PEDIATRICIAN, V18, P1010; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; O'Neill S, 1989, Aust Fam Physician, V18, P99; SPARKS JM, 1991, J REPROD MED, V36, P745	4	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1609	1609		10.1136/bmj.308.6944.1609	http://dx.doi.org/10.1136/bmj.308.6944.1609			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025429	Green Published			2022-12-28	WOS:A1994NT52800020
J	JUDGE, K; MAYS, N				JUDGE, K; MAYS, N			ALLOCATING RESOURCES FOR HEALTH AND SOCIAL CARE IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article							CRITIQUE; NHS	The fair allocation of resources for health and social care in relation to the needs of the population in different parts of the United Kingdom has become particularly important since the implementation of the new arrangements for community care in April 1993. These depend on close collaboration between health authorities and local authority social services departments. Yet funding reaches these authorities by different means and according to different criteria. Most health authority funds come through a weighted capitation formula that overemphasises the effects of age, while family health services funding is largely not cash limited and hence demand led, Funds to local authorities for community care are being transferred from the social security budget but on a basis that partly reflects past provision of residential and nursing home care. None of these mechanisms responds to underlying needs that give rise to demands on the health and social care system as a whole, and none makes any attempt to compensate for defects in the others. The solution includes better research and a unified weighted capitation system for all sources of funding.	KINGS FUND INST,HLTH SERV RES,LONDON W2 4HT,ENGLAND									[Anonymous], 1989, CM555; BALARAJAN R, 1987, J EPIDEMIOL COMMUN H, V41, P196, DOI 10.1136/jech.41.3.196; BOYLE S, 1993, PRIMARY HLTH CARE LO; CARRHILL R, 1992, J PUBLIC HEALTH MED, V14, P117; CHALLIS L, IN PRESS BMJ; DIXON J, IN PRESS BMJ; JONES D, 1976, SOC ECON ADMIN, V10, P92, DOI 10.1111/j.1467-9515.1976.tb00105.x; KLEIN R, 1974, NEW SOC         1107, P357; MAYS N, 1989, COMMUNITY MED, V11, P173; NOYCE J, 1974, LANCET, V1, P554; RAFTERY J, 1993, BRIT MED J, V307, P1121, DOI 10.1136/bmj.307.6912.1121; SHELDON TA, 1993, BRIT MED J, V306, P835, DOI 10.1136/bmj.306.6881.835; SHELDON TA, 1992, J ROY STAT SOC A STA, V155, P403, DOI 10.2307/2982891; WHITEHEAD M, 1994, BRIT MED J, V308, P1284, DOI 10.1136/bmj.308.6939.1284; 1991 CENSUS; 1993, HLTH SERVICE INDICAT; 1994, CM2512; 1993, 1994 95 CASH LIMITS	18	26	26	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1363	1366		10.1136/bmj.308.6940.1363	http://dx.doi.org/10.1136/bmj.308.6940.1363			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019229	Green Published			2022-12-28	WOS:A1994NM98900032
J	ROSELL, R; GOMEZCODINA, J; CAMPS, C; MAESTRE, J; PADILLE, J; CANTO, A; MATE, JL; LI, SR; ROIG, J; OLAZABAL, A; CANELA, M; ARIZA, A; SKACEL, Z; MORERAPRAT, J; ABAD, A				ROSELL, R; GOMEZCODINA, J; CAMPS, C; MAESTRE, J; PADILLE, J; CANTO, A; MATE, JL; LI, SR; ROIG, J; OLAZABAL, A; CANELA, M; ARIZA, A; SKACEL, Z; MORERAPRAT, J; ABAD, A			A RANDOMIZED TRIAL COMPARING PREOPERATIVE CHEMOTHERAPY PLUS SURGERY WITH SURGERY ALONE IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-II TRIAL; NEOADJUVANT CHEMOTHERAPY; SURGICAL-TREATMENT; RADIATION-THERAPY; CARCINOMA; SURVIVAL; CISPLATIN; IFOSFAMIDE; MITOMYCIN; RESECTION	Background. The efficacy of surgery for patients with non-small-cell lung cancer is limited, although recent studies suggest that preoperative chemotherapy may improve survival. We conducted a randomized trial to examine the possible benefit of preoperative chemotherapy and surgery for the treatment of patients with non-small-cell lung cancer. Methods. We studied 60 patients (59 men and 1 woman) with stage IIIA non-small-cell lung cancer. The patients were randomly assigned to receive either surgery alone or three courses of chemotherapy (6 mg of mitomycin per square meter of body-surface area, 3 g of ifosfamide per square meter, and 50 mg of cisplatin per square meter) given intravenously at three-week intervals and followed by surgery. All patients received mediastinal radiation after surgery. The resected tumors were evaluated by means of K-ras oncogene analysis and flow cytometry. Results. The median period of survival was 26 months in the patients with chemotherapy plus surgery, as compared with 8 months in the patients treated with surgery alone (P<0.001); the median period of disease-free survival was 20 months in the former group, as compared with 5 months in the latter (P<0.001). The rate of recurrence was 56 percent in the group treated with chemotherapy plus surgery and 74 percent in the group treated with surgery alone. The prevalence of mutated K-ras oncogenes was 15 percent among the patients receiving preoperative chemotherapy and 42 percent among those treated with surgery alone (P = 0.05). Most of the patients treated with chemotherapy plus surgery had tumors that consisted of diploid cells, whereas the patients treated with surgery alone had tumors with aneuploid cells. Conclusions. Preoperative chemotherapy increases the median survival in patients with non-small-cell lung cancer.	HOSP LA FE, DEPT THORAC SURG, VALENCIA, SPAIN; HOSP GEN VALENCIA, DEPT MED ONCOL, VALENCIA, SPAIN; HOSP GEN VALENCIA, DEPT THORAC SURG, VALENCIA, SPAIN; UNIV BARCELONA, HOSP BADALONA GERMANS TRIAS & PUJOL, DEPT THORAC SURG, BARCELONA 7, SPAIN; UNIV BARCELONA, HOSP BADALONA GERMANS TRIAS & PUJOL, DEPT PNEUMOL, BARCELONA 7, SPAIN; UNIV BARCELONA, HOSP BADALONA GERMANS TRIAS & PUJOL, DEPT RADIOL, BARCELONA 7, SPAIN; UNIV BARCELONA, HOSP BADALONA GERMANS TRIAS & PUJOL, DEPT PATHOL, BARCELONA 7, SPAIN; HOSP LA FE, DEPT MED ONCOL, VALENCIA, SPAIN	Hospital Universitari i Politecnic La Fe; Hospital Germans Trias i Pujol; University of Barcelona; Hospital Germans Trias i Pujol; University of Barcelona; Hospital Germans Trias i Pujol; University of Barcelona; Hospital Germans Trias i Pujol; University of Barcelona; Hospital Universitari i Politecnic La Fe	ROSELL, R (corresponding author), UNIV BARCELONA, HOSP GERMANS TRIAS & PUJOL, DEPT MED ONCOL, BOX 72, E-08916 BADALONA, SPAIN.		Herrero, Carlos Camps/L-3073-2017; SANZ, JOSE LUIS MATE/O-3158-2019	Herrero, Carlos Camps/0000-0002-0648-5403; SANZ, JOSE LUIS MATE/0000-0002-4829-3426; Roig, Jordi/0000-0002-5593-7090				BAINS MS, 1991, CHEST, V100, P826, DOI 10.1378/chest.100.3.826; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; BURKES RL, 1992, J CLIN ONCOL, V10, P580, DOI 10.1200/JCO.1992.10.4.580; COTTRELL JJ, 1992, CLIN CHEST MED, V13, P47; CULLEN MH, 1988, BRIT J CANCER, V58, P359, DOI 10.1038/bjc.1988.219; CYBULSKY IJ, 1992, ANN THORAC SURG, V54, P533, DOI 10.1016/0003-4975(92)90449-E; DAUTZENBERG B, 1990, CANCER, V65, P2435, DOI 10.1002/1097-0142(19900601)65:11<2435::AID-CNCR2820651105>3.0.CO;2-2; DESLAURIERS J, 1989, J THORAC CARDIOV SUR, V97, P504; DIXON WJ, 1983, BMDP STATISTICAL SOF, P555; FABER LP, 1989, ANN THORAC SURG, V47, P669, DOI 10.1016/0003-4975(89)90115-X; FOSSELLA FV, 1991, P AN M AM SOC CLIN, V10, P240; GOMEZCODINA J, 1991, EJC SUPPL, V27, pS167; HIDDEMANN W, 1984, CYTOMETRY, V5, P445, DOI 10.1002/cyto.990050502; LODDENKEMPER R, 1983, THORAC CARDIOV SURG, V31, P334, DOI 10.1055/s-2007-1022013; MARTINI N, 1993, ANN THORAC SURG, V55, P1365, DOI 10.1016/0003-4975(93)91072-U; MARTINI N, 1987, SURG CLIN N AM, V67, P1037; MARTINI N, 1988, ANN THORAC SURG, V45, P370, DOI 10.1016/S0003-4975(98)90007-8; MARTINI N, 1992, ANN THORAC SURG, V54, P460, DOI 10.1016/0003-4975(92)90435-7; MITSUDOMI T, 1991, CANCER RES, V51, P4999; MOUNTAIN CF, 1990, CHEST, V97, P1045, DOI 10.1378/chest.97.5.1045; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; MURREN JR, 1991, AM REV RESPIR DIS, V143, P889, DOI 10.1164/ajrccm/143.4_Pt_1.889; NARUKE T, 1988, ANN THORAC SURG, V46, P603, DOI 10.1016/S0003-4975(10)64717-0; PASS HI, 1992, ANN THORAC SURG, V53, P992, DOI 10.1016/0003-4975(92)90373-C; RATTO GB, 1990, J THORAC CARDIOV SUR, V99, P416; ROSELL R, 1993, ONCOGENE, V8, P2407; ROSELL R, 1990, J SURG ONCOL, V45, P124, DOI 10.1002/jso.2930450213; ROSELL R, 1992, P AN M AM SOC CLIN, V11, P287; SKARIN A, 1989, J SURG ONCOL, V40, P266, DOI 10.1002/jso.2930400413; Slebos R J, 1992, Diagn Mol Pathol, V1, P136, DOI 10.1097/00019606-199206000-00007; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STRAUSS GM, 1992, J CLIN ONCOL, V10, P1237, DOI 10.1200/JCO.1992.10.8.1237; WATANABE Y, 1991, ANN THORAC SURG, V51, P253, DOI 10.1016/0003-4975(91)90797-T; WEIDEN PL, 1991, J NATL CANCER I, V83, P266, DOI 10.1093/jnci/83.4.266; YU JM, 1991, CANCER-AM CANCER SOC, V68, P76, DOI 10.1002/1097-0142(19910701)68:1<76::AID-CNCR2820680115>3.0.CO;2-L	35	990	1016	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 20	1994	330	3					153	158		10.1056/NEJM199401203300301	http://dx.doi.org/10.1056/NEJM199401203300301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ863	8043059	Bronze			2022-12-28	WOS:A1994MQ86300001
J	GROMPE, M; STLOUIS, M; DEMERS, SI; ALDHALIMY, M; LECLERC, B; TANGUAY, RM				GROMPE, M; STLOUIS, M; DEMERS, SI; ALDHALIMY, M; LECLERC, B; TANGUAY, RM			SINGLE MUTATION OF THE FUMARYLACETOACETATE HYDROLASE GENE IN FRENCH-CANADIANS WITH HEREDITARY TYROSINEMIA TYPE-I	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DNA; QUEBEC; IDENTIFICATION; DEFICIENT	Background. Hereditary tyrosinemia type I is an autosomal recessive inborn error of metabolism caused by a deficiency of the enzyme fumarylacetoacetate hydrolase. The disorder clusters in the Saguenay-Lac-St.-Jean area of Quebec. In this region, 1 of 1846 newborns is affected and 1 of every 22 persons is thought to be a carrier. Recently, we identified a splice mutation and two nonsense mutations in the fumarylacetoacetate hydrolase gene in two patients from Quebec with tyrosinemia type I. Methods. We used allele-specific-oligonucleotide hybridization to examine the frequency of these three candidate mutations in patients with tyrosinemia type I and in the population of Quebec. Results. The splice mutation was found in 100 percent of patients from the Saguenay-Lac-St.-Jean area and in 28 percent of patients from other regions of the world. Of 25 patients from the Saguenay-Lac-St.-Jean region, 20 (80 percent) were homozygous for this mutation, a guanine-to-adenine change in the splice-donor sequence in intron 12 of the gene, indicating that it causes most cases of tyrosinemia type I in the region. The frequency of carrier status, based on screening of blood spots from newborns, was about 1 per 25 in the Saguenay-Lac-St.-Jean population and about 1 per 66 overall in Quebec. Conclusions. This study identified the most prevalent mutation causing hereditary tyrosinemia in French Canada; it also showed the feasibility of DNA-based testing for carriers in the population at risk.	OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201; CHU LAVAL,CTR RECH,GENET CELLULAIRE & MOLEC LAB,ST FOY,PQ,CANADA	Oregon Health & Science University; Laval University	GROMPE, M (corresponding author), OREGON HLTH SCI UNIV,DEPT MOLEC & MED GENET,MAIL CODE L103,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.			Grompe, Markus/0000-0002-6616-4345	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD028585] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-28585-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGSTERIBBE E, 1990, NUCLEIC ACIDS RES, V18, P1887, DOI 10.1093/nar/18.7.1887; DEBRAEKELEER M, 1990, AM J HUM GENET, V47, P302; DEMERS SI, 1994, AM J HUM GENET, V55, P327; GROMPE M, 1993, HUM MUTAT, V2, P85, DOI 10.1002/humu.1380020205; HARTL DL, 1988, PRIMER POPULATION GE, P7; HECHTMAN P, 1990, AM J HUM GENET, V47, P815; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; John S. W. M., 1992, Human Mutation, V1, P72, DOI 10.1002/humu.1380010112; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; Kvittingen E.A., 1986, SCAND J CLIN LAB I S, V184, P27; KVITTINGEN EA, 1983, PEDIATR RES, V17, P541, DOI 10.1203/00006450-198307000-00005; LABELLE Y, 1993, HUM MOL GENET, V2, P941, DOI 10.1093/hmg/2.7.941; LABERGE C, 1990, AM J HUM GENET, V47, P329; LABERGE C, 1969, AM J HUM GENET, V21, P36; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; LINDSTEDT S, 1992, LANCET, V340, P813, DOI 10.1016/0140-6736(92)92685-9; MITCHELL G, 1990, NEW ENGL J MED, V322, P432, DOI 10.1056/NEJM199002153220704; MITCHELL GA, IN PRESS METABOLIC B, V1; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PARADISK, 1990, AM J HUM GENET, V47, P328; PHANEUF D, 1992, J CLIN INVEST, V90, P1185, DOI 10.1172/JCI115979; PHANEUF D, 1991, AM J HUM GENET, V48, P525; ROZEN R, 1992, AM J MED GENET, V42, P360, DOI 10.1002/ajmg.1320420322; SALT A, 1992, ACTA PAEDIATR, V81, P449, DOI 10.1111/j.1651-2227.1992.tb12270.x; Sambrook J, 1989, MOL CLONING LABORATO; STLOUIS M, 1994, HUM MOL GENET, V3, P69, DOI 10.1093/hmg/3.1.69; TANGUAY RM, 1990, AM J HUM GENET, V47, P308; TANGUAY RM, 1984, ADV GENE TECHNOLOGY, P250; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; WU DY, 1989, DNA-J MOLEC CELL BIO, V8, P135, DOI 10.1089/dna.1.1989.8.135; [No title captured]	31	94	97	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					353	357		10.1056/NEJM199408113310603	http://dx.doi.org/10.1056/NEJM199408113310603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA374	8028615				2022-12-28	WOS:A1994PA37400003
J	PALLAS, DC; FU, H; HAEHNEL, LC; WELLER, W; COLLIER, RJ; ROBERTS, TM				PALLAS, DC; FU, H; HAEHNEL, LC; WELLER, W; COLLIER, RJ; ROBERTS, TM			ASSOCIATION OF POLYOMAVIRUS MIDDLE TUMOR-ANTIGEN WITH 14-3-3-PROTEINS	SCIENCE			English	Article							SMALL T-ANTIGEN; CELLULAR PROTEINS; TRANSFORMATION; PHOSPHATASE-2A; COMPLEXES; FAMILY; CELLS	To carry out its transformation function, the middle tumor antigen (MT) of murine polyomavirus associates with a number of cellular proteins involved in regulation of cell proliferation, including pp60(c-Src), phosphatidylinositol 3-kinase, protein phosphatase 2A, Src homologous and collagen protein and growth factor receptor-binding protein 2. Here, two additional MT-associated proteins were identified as members of the 14-3-3 family of proteins. Yeast homologs of 14-3-3 proteins have recently been shown to play a role in the timing of mitosis. Thus, regulation of 14-3-3 protein function by MT may contribute to the development of neoplasia.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,SHIPLEY INST MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	PALLAS, DC (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115, USA.			Collier, R John/0000-0002-2427-4239	NATIONAL CANCER INSTITUTE [R01CA030002, R29CA045285, P01CA050661, R01CA057327, R37CA030002] Funding Source: NIH RePORTER; NCI NIH HHS [CA50661, CA30002, CA45285, R01 CA057327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, UNPUB; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; MORGAN WC, 1988, J VIROL, V62, P3407, DOI 10.1128/JVI.62.9.3407-3414.1988; PALLAS D, UNPUB; PALLAS DC, 1989, J VIROL, V63, P4533, DOI 10.1128/JVI.63.11.4533-4539.1989; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	16	164	167	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					535	537		10.1126/science.8036498	http://dx.doi.org/10.1126/science.8036498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036498				2022-12-28	WOS:A1994NY21600034
J	PEPPER, A; DELANEY, T; WASHBURN, T; POOLE, D; CHORY, J				PEPPER, A; DELANEY, T; WASHBURN, T; POOLE, D; CHORY, J			DET1, A NEGATIVE REGULATOR OF LIGHT-MEDIATED DEVELOPMENT AND GENE-EXPRESSION IN ARABIDOPSIS, ENCODES A NOVEL NUCLEAR-LOCALIZED PROTEIN	CELL			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; CHLOROPLAST DEVELOPMENT; SACCHAROMYCES-CEREVISIAE; PLANT; SEQUENCE; YEAST; TRANSFORMATION; PATHWAYS; MUTANTS; DNA	The mechanisms by which plants integrate light signals to modify endogenous developmental programs are largely unknown. One candidate for a signal transduction component that may integrate light with developmental pathways is the Arabidopsis DET1 gene product. Here we report the positional cloning of the DET1 locus and show that DET1 is a unique nuclear-localized protein. An analysis of a number of det1 mutants indicates that mutants with partial DET1 activity develop as light-grown plants in the dark. det1 null mutants share this phenotype, but also display severe defects in temporal and spatial regulation of gene expression. These results suggest that DET1 acts in the nucleus to control the cell type-specific expression of light-regulated promoters.			PEPPER, A (corresponding author), SALK INST, PLANT BIOL LAB, SAN DIEGO, CA 92186 USA.		Delaney, Terrence P/A-2947-2008					ABEL S, 1994, P NATL ACAD SCI USA, V91, P326, DOI 10.1073/pnas.91.1.326; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BROWN JWS, 1986, NUCLEIC ACIDS RES, V14, P9549, DOI 10.1093/nar/14.24.9549; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1991, NEW BIOL, V3, P538; CHORY J, 1990, P NATL ACAD SCI USA, V87, P8776, DOI 10.1073/pnas.87.22.8776; CHORY J, 1989, CELL, V58, P991, DOI 10.1016/0092-8674(89)90950-1; CHORY J, 1994, PLANT PHYSIOL, V104, P339, DOI 10.1104/pp.104.2.339; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; LIN S, 1993, PLANT CELL, V5, P109, DOI 10.1105/tpc.5.1.109; Meer I. M. van der, 1993, Control of plant gene expression., P125; MISERA S, 1994, IN PRESS MOL GEN GEN; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rose MD., 1990, METHODS YEAST GENETI; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925; YOUNG JC, 1992, PLANTA, V188, P106, DOI 10.1007/BF00198946	36	242	250	2	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					109	116		10.1016/0092-8674(94)90577-0	http://dx.doi.org/10.1016/0092-8674(94)90577-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033202				2022-12-28	WOS:A1994NX32800013
J	ODOWD, TC; BOURNE, N				ODOWD, TC; BOURNE, N			INVENTING A NEW DIAGNOSTIC-TEST FOR VAGINAL INFECTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BACTERIAL VAGINOSIS; CHLAMYDIA-TRACHOMATIS; WOMEN; FLUID	Bacterial vaginosis, which is underdiagnosed in clinical practice, has a characteristic fishy smell because of production of diamines. This smell is the basis of a visual rapid diagnostic test that is technically simple to perform. The test has been patented in Europe and America, and a licence agreement has been negotiated. This paper describes the process from idea to invention to patenting and licensing. The combined costs of research and patenting were met by a multinational company in return for rights to exploit the patented invention. The process has taken nine years and has needed clinical, scientific, legal, and commercial input to get the test to the marketplace.	UNIV WALES COLL CARDIFF, CARDIFF CF1 3XA, S GLAM, WALES	Cardiff University	ODOWD, TC (corresponding author), TRINITY COLL DUBLIN, DEPT COMMUNITY HLTH & GEN PRACTICE, DUBLIN 2, IRELAND.							[Anonymous], 1977, PATENTS ACT; CHEN KCS, 1982, J INFECT DIS, V145, P337, DOI 10.1093/infdis/145.3.337; DAVIS RH, 1991, Patent No. 2215044; GARDNER HL, 1955, AM J OBSTET GYNECOL, V69, P962, DOI 10.1016/0002-9378(55)90095-8; GRAVETT M G, 1986, Journal of the American Medical Association, V256, P1899, DOI 10.1001/jama.256.14.1899; GRAVETT MG, 1986, OBSTET GYNECOL, V67, P229, DOI 10.1097/00006250-198602000-00013; KROHN MA, 1989, J CLIN MICROBIOL, V27, P1266, DOI 10.1128/JCM.27.6.1266-1271.1989; LARSSON PG, 1992, AM J OBSTET GYNECOL, V166, P100, DOI 10.1016/0002-9378(92)91838-2; MARTIUS J, 1988, OBSTET GYNECOL, V71, P89; MEAD G, 1992, FINANCIAL TIMES 0409, P11; ODOWD TC, 1988, BRIT MED J, V292, P1640; PEARSON H, 1990, COMMERCIAL EXPLOITAT, P1; THOMASON JL, 1988, OBSTET GYNECOL, V71, P67; WATTS DH, 1990, OBSTET GYNECOL, V75, P52; 1992, PREPARE UK PATENT AP; 1992, INTELLECTUAL PROPERT, P1	16	6	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	1994	309	6946					40	42		10.1136/bmj.309.6946.40	http://dx.doi.org/10.1136/bmj.309.6946.40			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044068	Green Published			2022-12-28	WOS:A1994NV89100026
J	HENKEL, T; LING, PD; HAYWARD, SD; PETERSON, MG				HENKEL, T; LING, PD; HAYWARD, SD; PETERSON, MG			MEDIATION OF EPSTEIN-BARR-VIRUS EBNA2 TRANSACTIVATION BY RECOMBINATION SIGNAL-BINDING PROTEIN J(K)	SCIENCE			English	Article							RNA POLYMERASE-II; NUCLEAR ANTIGEN-2; DROSOPHILA HOMOLOG; J-KAPPA; PROMOTER; SEQUENCE; ELEMENT; GENE; DNA; PURIFICATION	The Epstein-Barr virus (EBV) transactivator protein, termed Epstein-Barr virus nuclear antigen 2 (EBNA2), plays a critical role in the regulation of latent viral transcription and in the immortalization of EBV-infected B cells. Unlike most transcription factors, EBNA2 does not bind directly to its cis-responsive DNA element but requires a cellular factor, termed C-promoter binding factor 1 (CBF1). Here, CBF1 was purified and was found to directly interact with EBNA2. CBF1 is identical to a protein thought to be involved in immunoglobulin gene rearrangement, RBPJ(k)appa. Contrary to previous reports, CBF1-RBPJ(k)appa did not bind to the recombination signal sequences but instead bound to sites in the EBV C-promoter and in the CD23 promoter.	TULARIK INC,S SAN FRANCISCO,CA 94080; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R37CA042245, R01CA042245] Funding Source: NIH RePORTER; NCI NIH HHS [CA42245] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAKAWA R, 1993, GENOMICS, V17, P306, DOI 10.1006/geno.1993.1326; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; CORDIER M, 1990, J VIROL, V64, P1002, DOI 10.1128/JVI.64.3.1002-1013.1990; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; HAMAGUCHI Y, 1992, J BIOCHEM-TOKYO, V112, P314, DOI 10.1093/oxfordjournals.jbchem.a123898; HAMAGUCHI Y, 1989, NUCLEIC ACIDS RES, V17, P9015, DOI 10.1093/nar/17.22.9015; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENKEL T, UNPUB; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JIN XW, 1992, J VIROL, V66, P2846, DOI 10.1128/JVI.66.5.2846-2852.1992; KIEFF E, 1990, VIROLOGY, P1889; LIEBERMAN PM, 1989, J VIROL, V63, P3040, DOI 10.1128/JVI.63.7.3040-3050.1989; LING PD, 1993, J VIROL, V67, P2990, DOI 10.1128/JVI.67.6.2990-3003.1993; LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MILLER G, 1990, VIROLOGY, P1921; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SUNG NS, 1991, J VIROL, V65, P2161; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WANG F, 1991, J VIROL, V65, P4101, DOI 10.1128/JVI.65.8.4101-4106.1991; ZIMBERSTROBL U, 1993, EMBO J, V12, P167, DOI 10.1002/j.1460-2075.1993.tb05642.x	24	382	394	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					92	95		10.1126/science.8016657	http://dx.doi.org/10.1126/science.8016657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016657				2022-12-28	WOS:A1994NV30100032
J	MAJEED, FA; CHATURVEDI, N; READING, R; BENSHLOMO, Y				MAJEED, FA; CHATURVEDI, N; READING, R; BENSHLOMO, Y			EQUITY IN THE NHS - MONITORING AND PROMOTING EQUITY IN PRIMARY AND SECONDARY CARE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY HEALTH-CARE; GENERAL-PRACTICE; SOCIOECONOMIC-FACTORS; ETHNIC-DIFFERENCES; CHILD HEALTH; DEPRIVATION; COMMUNITY; SERVICES; ACCESS; AGE	Although need is often assumed to be the most important factor in determining the use of health services, there are many inequities in the provision and use of NHS services in both primary and secondary care. For example, existing data from district child health information services have been combined with census data for small areas to show wide variations in immunisation rates between affluent and deprived areas. Purchasers of health care are already responsible for assessing health needs and evaluating services, and the process of monitoring equity is a logical extension of these activities. Routine data sources used to collect activity data in both primary and secondary care can be used to assess needs for care and monitor how well these needs are met. Purchasers and providers should collaborate to improve the usefulness of these routine data and to develop a framework for monitoring and promoting equity more systematically.	UCL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND; ST GEORGE HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND; NORFOLK & NORWICH HOSP, NORWICH NR1 3SR, NORFOLK, ENGLAND	University of London; University College London; St Georges University London; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital			Ben-Shlomo, Yoav/ABD-2004-2021	Ben-Shlomo, Yoav/0000-0001-6648-3007; Majeed, Azeem/0000-0002-2357-9858	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1988, LANCET, V2, P349; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BAKER R, 1992, BRIT J GEN PRACT, V42, P415; BALARAJAN R, 1989, BRIT MED J, V299, P958, DOI 10.1136/bmj.299.6705.958; BALARAJAN R, 1992, BRIT MED J, V304, P529, DOI 10.1136/bmj.304.6826.529; BENSHLOMO Y, 1992, J EPIDEMIOL COMMUN H, V46, P532, DOI 10.1136/jech.46.5.532; BENSHLOMO Y, IN PRESS J EPIDEMIOL; BOMBARDIER C, 1977, NEW ENGL J MED, V297, P699, DOI 10.1056/NEJM197709292971305; BRAVEMAN P, 1993, JAMA-J AM MED ASSOC, V269, P1285, DOI 10.1001/jama.269.10.1285; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; Carstairs V, 1981, Community Med, V3, P4, DOI 10.1007/BF02549432; Carstairs V., 1991, DEPRIVATION HLTH SCO; DAVIS K, 1981, ANNU REV PUBL HEALTH, V2, P159, DOI 10.1146/annurev.pu.02.050181.001111; DUDLEY NJ, 1992, AGE AGEING, V21, P95, DOI 10.1093/ageing/21.2.95; ELDER AT, 1991, BRIT MED J, V303, P950, DOI 10.1136/bmj.303.6808.950; ENTHOVEN AC, 1991, HEALTH AFFAIR, V10, P60, DOI 10.1377/hlthaff.10.3.60; FINDLAY IN, 1991, BRIT HEART J, V66, P70; FINDLAY IN, 1992, BRIT HEART J, V68, P69; FREEMAN HE, 1993, HEALTH SERV RES, V38, P531; FREEMAN HP, 1993, CANCER, V72, P2834, DOI 10.1002/1097-0142(19931101)72:9+<2834::AID-CNCR2820721512>3.0.CO;2-J; GILLAM SJ, 1989, BRIT MED J, V299, P953, DOI 10.1136/bmj.299.6705.953; GILLAM SJ, 1992, BRIT J GEN PRACT, V42, P54; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; HALFON N, 1993, PEDIATRICS, V91, P56; HOBBS R, 1993, BRIT MED J, V306, P534, DOI 10.1136/bmj.306.6877.534; James J, 1992, HLTH TRENDS, V24, P160; JARMAN B, 1992, BRIT MED J, V305, P1130, DOI 10.1136/bmj.305.6862.1130; JUDGE K, 1994, BRIT MED J, V308, P1363, DOI 10.1136/bmj.308.6940.1363; KEE F, 1993, BRIT MED J, V307, P1305, DOI 10.1136/bmj.307.6915.1305; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; KOGEVINAS M, 1991, J EPIDEMIOL COMMUN H, V45, P216, DOI 10.1136/jech.45.3.216; LEAR JT, 1994, J ROY COLL PHYS LOND, V28, P143; MAJEED A, 1993, BRIT MED J, V306, P1689, DOI 10.1136/bmj.306.6893.1689-a; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MARSH GN, 1988, BRIT MED J, V296, P173, DOI 10.1136/bmj.296.6616.173; MORGAN M, 1983, J EPIDEMIOL COMMUN H, V37, P196, DOI 10.1136/jech.37.3.196; MURRAY SA, 1994, BRIT MED J, V308, P698, DOI 10.1136/bmj.308.6930.698; Old P, 1994, Health Serv J, V104, P28; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; POLLOCK AM, 1993, CRITICAL PUBLIC HLTH, V4, P23; READING R, 1994, BRIT MED J, V308, P1142, DOI 10.1136/bmj.308.6937.1142; READING R, 1993, ARCH DIS CHILD, V68, P626, DOI 10.1136/adc.68.5.626; READING R, 1993, ARCH DIS CHILD, V68, P686, DOI 10.1136/adc.68.5.686; SHAUKAT N, 1993, BRIT MED J, V307, P717, DOI 10.1136/bmj.307.6906.717; SMITH T, 1993, BRIT MED J, V306, P1232, DOI 10.1136/bmj.306.6887.1232; TALBOT RJ, 1991, BRIT MED J, V302, P383, DOI 10.1136/bmj.302.6773.383; Townsend PP., 1988, HLTH DEPRIVATION INE; WALSH SS, 1992, J EPIDEMIOL COMMUN H, V46, P26, DOI 10.1136/jech.46.1.26; WHITEHEAD M, 1994, BRIT MED J, V308, P1284, DOI 10.1136/bmj.308.6939.1284; WOMERSLEY J, 1987, J EPIDEMIOL COMMUN H, V41, P190, DOI 10.1136/jech.41.3.190; 1991, MINIMUM DATA SET MOD	53	44	45	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	1994	308	6941					1426	1429		10.1136/bmj.308.6941.1426	http://dx.doi.org/10.1136/bmj.308.6941.1426			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019258	Green Published			2022-12-28	WOS:A1994NP42000028
J	RAY, WA; GRIFFIN, MR; AVORN, J				RAY, WA; GRIFFIN, MR; AVORN, J			EVALUATING DRUGS AFTER THEIR APPROVAL FOR CLINICAL USE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTI-INFLAMMATORY DRUGS; COST-EFFECTIVENESS; CONTROLLED TRIAL; PEPTIC-ULCER; THERAPY; RISK; OSTEOARTHRITIS; PRESCRIPTION; MISOPROSTOL		HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	RAY, WA (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, NASHVILLE, TN 37232 USA.				NIA NIH HHS [AG09634, AG08812] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009634, P60AG008812, P30AG008812] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1991, Arch Intern Med, V151, P1413; [Anonymous], 1989, NEW ENGL J MED, V321, P406; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; BEAM TR, 1992, CLIN INFECT DIS, V15, pS5, DOI 10.1093/clind/15.Supplement_1.S5; Bloom B S, 1988, Am J Med, V84, P20, DOI 10.1016/0002-9343(88)90250-1; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; CHRISCHILLES EA, 1990, J AM GERIATR SOC, V38, P979, DOI 10.1111/j.1532-5415.1990.tb04419.x; COHN CK, 1990, J CLIN PSYCHIAT, V51, P28; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DRUMMOND MF, 1992, HEALTH AFFAIR, V11, P191, DOI 10.1377/hlthaff.11.4.191; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V264, P41, DOI 10.1001/jama.264.1.41; FAICH GA, 1986, NEW ENGL J MED, V314, P1589, DOI 10.1056/NEJM198606123142427; FEINBERG JL, 1991, CONSULTANT PHARM, V6, P6; FELSON DT, 1992, ANN INTERN MED, V116, P535, DOI 10.7326/0003-4819-116-7-535; FREUND DA, 1992, HEALTH AFFAIR, V11, P202, DOI 10.1377/hlthaff.11.4.202; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GOTZSCHE PC, 1989, DAN MED BULL, V36, P395; Greenberg D S, 1974, N Engl J Med, V290, P1211, DOI 10.1056/NEJM197405232902130; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HILLMAN AL, 1989, ARCH INTERN MED, V149, P2061, DOI 10.1001/archinte.149.9.2061; KENNEDY D, 1978, NEW ENGL J MED, V298, P846, DOI 10.1056/NEJM197804132981511; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; MARSHALL E, 1980, SCIENCE, V207, P853, DOI 10.1126/science.7355265; MURRAY MD, 1990, ANN INTERN MED, V112, P559, DOI 10.7326/0003-4819-112-8-559; NIES A S, 1990, P62; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; POLLARD MR, 1990, HEALTH AFFAIR, V9, P55, DOI 10.1377/hlthaff.9.3.55; PRYOR D, 1990, HEALTH AFFAIR, V9, P101, DOI 10.1377/hlthaff.9.3.101; RAY WA, 1990, HEALTH AFFAIR, V9, P114, DOI 10.1377/hlthaff.9.3.114; REGESTEIN QR, 1984, CLIN GERIATRIC PSYCH, P149; SCHAFFNER W, 1983, JAMA-J AM MED ASSOC, V250, P1728, DOI 10.1001/jama.250.13.1728; SCHONDELMEYER SW, 1990, HEALTH AFFAIR, V9, P131, DOI 10.1377/hlthaff.9.3.131; Silverman Milton, 1974, PILLS PROFITS POLITI; SOMERVILLE K, 1986, LANCET, V1, P462; Sonnefeld S T, 1991, Health Care Financ Rev, V13, P1; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; STOLLEY PD, 1986, J CHRON DIS, V39, P1145, DOI 10.1016/0021-9681(86)90145-1; STOLLEY PD, 1969, J CHRON DIS, V22, P395, DOI 10.1016/0021-9681(69)90003-4; STOLLEY PD, 1970, ANN INTERN MED, V73, P479, DOI 10.7326/0003-4819-73-3-479; TALLEY NJ, 1988, ANN INTERN MED, V108, P865, DOI 10.7326/0003-4819-108-6-865; TEMPLE R, 1989, MED CLIN N AM, V73, P495, DOI 10.1016/S0025-7125(16)30685-X; Temple R J, 1981, Ann N Y Acad Sci, V368, P175, DOI 10.1111/j.1749-6632.1981.tb15447.x; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613; 1992, FACTS GLANCE; 1992, DRUG FACTS COMP; 1980, JOINT COMMISSION PRE; 1992, STAT B METROP INSUR, V73, P25; 1992, J AM GERIATR SOC, V40, P946; 1993, PHARM RD COSTS RISKS	50	115	115	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1993	329	27					2029	2032		10.1056/NEJM199312303292710	http://dx.doi.org/10.1056/NEJM199312303292710			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN573	8018139				2022-12-28	WOS:A1993MN57300010
J	LETOURNEUR, F; GAYNOR, EC; HENNECKE, S; DEMOLLIERE, C; DUDEN, R; EMR, SD; RIEZMAN, H; COSSON, P				LETOURNEUR, F; GAYNOR, EC; HENNECKE, S; DEMOLLIERE, C; DUDEN, R; EMR, SD; RIEZMAN, H; COSSON, P			COATOMER IS ESSENTIAL FOR RETRIEVAL OF DILYSINE-TAGGED PROTEINS TO THE ENDOPLASMIC-RETICULUM	CELL			English	Article							CLATHRIN-COATED VESICLES; ALPHA-PHEROMONE RECEPTOR; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEINS; SECRETORY PATHWAY; POLYACRYLAMIDE GELS; YEAST COATOMER; GOLGI-COMPLEX; BETA-COP; SUBUNIT	Dilysine motifs in cytoplasmic domains of transmembrane proteins are signals for their continuous retrieval from the Golgi back to the endoplasmic reticulum (ER). We describe a system to assess retrieval to the ER in yeast cells making use of a dilysine-tagged Ste2 protein. Whereas retrieval was unaffected in most sec mutants tested (sec7, sec12, sec13, sec16, sec17, sec18, sec19, sec22, and sec23), a defect in retrieval was observed in previously characterized coatomer mutants (sec21-1, sec27-1), as well as in newly isolated retrieval mutants (sec21-2, ret1-1). RET1 was cloned by complementation and found to encode the alpha subunit of coatomer. While temperature-sensitive for growth, the newly isolated coatomer mutants exhibited a very modest defect in secretion at the nonpermissive temperature. Coatomer from beta'-COP (sec27-1) and alpha-COP (ret1-1) mutants, but not from gamma-COP (sec21) mutants, had lost the ability to bind dilysine motifs in vitro. Together, these results suggest that coatomer plays an essential role in retrograde Golgi-to-ER transport and retrieval of dilysine-tagged proteins back to the ER.	UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California Berkeley; University of Basel	LETOURNEUR, F (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487, CH-4005 BASEL, SWITZERLAND.		Duden, Rainer/C-8917-2011; Duden, Rainer/GXH-3206-2022	Riezman, Howard/0000-0003-4680-9422; Letourneur, Francois/0000-0003-2232-6127				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, IN PRESS J BIOL CHEM, V269; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HARTER C, 1993, FEBS LETT, V332, P71, DOI 10.1016/0014-5793(93)80487-F; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; Maniatis T., 1982, MOL CLONING; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	43	679	688	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1199	1207		10.1016/0092-8674(94)90011-6	http://dx.doi.org/10.1016/0092-8674(94)90011-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001155				2022-12-28	WOS:A1994PZ86000011
J	PUFFENBERGER, EG; HOSODA, K; WASHINGTON, SS; NAKAO, K; DEWIT, D; YANAGISAWA, M; CHAKRAVARTI, A				PUFFENBERGER, EG; HOSODA, K; WASHINGTON, SS; NAKAO, K; DEWIT, D; YANAGISAWA, M; CHAKRAVARTI, A			A MISSENSE MUTATION OF THE ENDOTHELIN-B RECEPTOR GENE IN MULTIGENIC HIRSCHSPRUNGS-DISEASE	CELL			English	Article							CHROMOSOMAL ASSIGNMENT; AGANGLIONIC MEGACOLON; FUNCTIONAL EXPRESSION; CLONING; IDENTIFICATION; ORGANIZATION; CDNA; ASSOCIATION; ANTAGONIST; DELETION	Hirschsprung's disease (HSCR) is characterized by an absence of enteric ganglia in the distal colon and a failure of innervation in the gastrointestinal tract. We recently mapped a recessive susceptibility locus (HSCR2) to human chromosome 13q22, which we now demonstrate to be the endothelin-B receptor gene (EDNRB). We identified in HSCR patients a G-->T missense mutation in EDNRB exon 4 that substitutes the highly conserved Trp-276 residue in the fifth transmembrane helix of the G protein-coupled receptor with a Cys residue (W276C). The mutant W276C receptor exhibited a partial impairment of ligand-induced Ca2+ transient levels in transfected cells. The mutation is dosage sensitive, in that W276C homozygotes and heterozygotes have a 74% and a 21% risk, respectively, of developing HSCR. Genotype analysis of patients in a Mennonite pedigree shows HSCR to he a multigenic disorder.	CASE WESTERN RESERVE UNIV,SCH MED,CTR HUMAN GENET,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,CLEVELAND,OH 44106; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; KYOTO UNIV,SCH MED,DEPT MED,DIV 2,KYOTO 606,JAPAN	Case Western Reserve University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Kyoto University	PUFFENBERGER, EG (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,CLEVELAND,OH 44106, USA.			Puffenberger, Erik/0000-0002-6388-9148	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-28088] Funding Source: Medline; NIGMS NIH HHS [T32GM08056] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAI H, 1993, J BIOL CHEM, V268, P3463; ARINAMI T, 1991, AM J HUM GENET, V48, P990; BADNER JA, 1990, AM J HUM GENET, V46, P568; BADNER JA, 1990, AM J MED GENET, V35, P100, DOI 10.1002/ajmg.1320350119; BAYNASH AG, 1994, CELL, V79; BECKER A, 1994, EUR J BIOCHEM, V221, P951, DOI 10.1111/j.1432-1033.1994.tb18810.x; Bergey LL, 1992, PA MENNON HERIT, V15, P9; BOTTANI A, 1991, HUM GENET, V87, P748; CECCHERINI I, 1994, ONCOGENE, V9, P3025; CHAKRAVARTI A, 1992, CYTOGENET CELL GENET, V59, P99, DOI 10.1159/000133212; CLAPHAM DE, 1994, NATURE, V371, P109, DOI 10.1038/371109a0; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; EARLAM RJ, 1972, AM J DIG DIS, V17, P255, DOI 10.1007/BF02232298; EDERY P, 1994, J MED GENET, V31, P602, DOI 10.1136/jmg.31.8.602; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HEYL DL, 1993, PEPTIDE RES, V6, P238; HOSODA K, 1992, J BIOL CHEM, V267, P18797; Hosoda K, 1994, CELL, V79; IKADAI H, 1979, Congenital Anomalies, V19, P31; INAGAKI H, 1991, GASTROENTEROLOGY, V101, P47, DOI 10.1016/0016-5085(91)90458-W; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA K, 1994, P NATL ACAD SCI USA, V91, P4892, DOI 10.1073/pnas.91.11.4892; JACOBSCOHEN RJ, 1987, J COMP NEUROL, V255, P425, DOI 10.1002/cne.902550309; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KAPUR RP, 1993, DEVELOPMENT, V117, P993; KARNE S, 1993, J BIOL CHEM, V268, P19126; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KISS P, 1989, J MED GENET, V26, P793, DOI 10.1136/jmg.26.12.793; KUMAR C, 1994, J BIOL CHEM, V269, P13414; LAIRMORE TC, 1993, P NATL ACAD SCI USA, V90, P492, DOI 10.1073/pnas.90.2.492; LAMONT MA, 1989, J MED GENET, V26, P100, DOI 10.1136/jmg.26.2.100; LANE PW, 1984, J HERED, V75, P435, DOI 10.1093/oxfordjournals.jhered.a109980; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MCCABE L, 1990, AM J MED GENET, V36, P336, DOI 10.1002/ajmg.1320360319; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; REPASKE R, 1985, J VIROL, V54, P764, DOI 10.1128/JVI.54.3.764-772.1985; ROMEO G, 1994, NATURE, V357, P377; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; SOGABE K, 1993, J PHARMACOL EXP THER, V264, P1040; SPARKES RS, 1984, HUM GENET, V68, P258, DOI 10.1007/BF00418397; WILKIE TM, 1993, GENOMICS, V18, P175, DOI 10.1006/geno.1993.1452; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	54	730	797	2	25	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1257	1266		10.1016/0092-8674(94)90016-7	http://dx.doi.org/10.1016/0092-8674(94)90016-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001158				2022-12-28	WOS:A1994PZ86000016
J	HONG, MK; MINTZ, GS; POPMA, JJ; KENT, KM; PICHARD, AD; SATLER, LF; LEON, MB				HONG, MK; MINTZ, GS; POPMA, JJ; KENT, KM; PICHARD, AD; SATLER, LF; LEON, MB			LIMITATIONS OF ANGIOGRAPHY FOR ANALYZING CORONARY ATHEROSCLEROSIS PROGRESSION OR REGRESSION	ANNALS OF INTERNAL MEDICINE			English	Review							HEART-DISEASE MORTALITY; FREQUENCY EPICARDIAL ECHOCARDIOGRAPHY; ARTERY DISEASE; INTRAVASCULAR ULTRASOUND; COMPENSATORY ENLARGEMENT; INTEROBSERVER VARIABILITY; PHYSIOLOGIC SIGNIFICANCE; MYOCARDIAL-INFARCTION; COLESTIPOL-NIACIN; CLINICAL-TRIALS	Purpose: To analyze the utility and limitations of serial coronary angiography for determining atherosclerosis progression and regression. Data Sources: A MEDLINE search of the English-language literature (1966 to January 1994) using the keywords atherosclerosis regression, atherosclerosis progression, lipid reduction therapy, and coronary angiography. Study Selection: Selected articles on the effects of cholesterol reduction and lifestyle modification on angiographic coronary artery disease, on the animal models of atherosclerosis progression and regression, and on the limitations of coronary angiography. Data Extraction: Independent extraction by two authors. Results: Although several studies have reported that the rate of atherosclerosis progression, defined by serial coronary angiography, can be reduced and that luminal diameter can be improved somewhat by aggressive lipid modification, the reported changes are small (0.3 mm or 10% change) and have required a prolonged study duration (range, 1 to 10 years). More importantly, angiography simply does not measure atherosclerosis and cannot assess lesion composition. Angiography also underestimates the extent of atherosclerosis, especially in angiographically normal segments. In addition, difficulties with data acquisition, such as substantial variabilities in serial measurements of percent diameter stenosis and minimal luminal diameters, require large sample sizes to show statistically significant regression, even with computerized quantification. Conclusions: Given its current limitations, serial coronary angiography is not a satisfactory means of detecting atherosclerosis progression or regression.	WASHINGTON HOSP CTR, WASHINGTON, DC 20010 USA	MedStar Washington Hospital Center								AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; ARMSTRONG ML, 1970, CIRC RES, V27, P59, DOI 10.1161/01.RES.27.1.59; ARMSTRONG ML, 1985, ARTERIOSCLEROSIS, V5, P336, DOI 10.1161/01.ATV.5.4.336; ARNETT EN, 1979, ANN INTERN MED, V91, P350, DOI 10.7326/0003-4819-91-3-350; ARNTZENIUS AC, 1985, NEW ENGL J MED, V312, P805, DOI 10.1056/NEJM198503283121301; BASHORE TM, 1991, CIRCULATION, V84, P2383; BLANKENHORN D, 1990, ATHEROSCLER REV, P151; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BLANKENHORN DH, 1991, AM J MED, V90, pS42, DOI 10.1016/0002-9343(91)90036-W; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN BG, 1989, ARTERIOSCLEROSIS, V9, pI81; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CLARKSON TB, 1984, EXP MOL PATHOL, V41, P96, DOI 10.1016/0014-4800(84)90011-X; COHN BA, 1988, AM J EPIDEMIOL, V127, P1143, DOI 10.1093/oxfordjournals.aje.a114908; COY KM, 1991, J AM COLL CARDIOL, V18, P1811, DOI 10.1016/0735-1097(91)90525-E; DAVIES MJ, 1990, CIRCULATION, V82, P38; DEFEYTER PJ, 1991, CIRCULATION, V84, P412, DOI 10.1161/01.CIR.84.1.412; DEROUEN TA, 1977, CIRCULATION, V55, P324, DOI 10.1161/01.CIR.55.2.324; DETRE KM, 1975, CIRCULATION, V52, P979, DOI 10.1161/01.CIR.52.6.979; ELLIS S, 1986, CIRCULATION, V74, P1235, DOI 10.1161/01.CIR.74.6.1235; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GALBRAITH JE, 1978, JAMA-J AM MED ASSOC, V240, P2053, DOI 10.1001/jama.240.19.2053; GIBSON M, 1992, AM J CARDIOL, V69, P1286, DOI 10.1016/0002-9149(92)91222-P; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GRONDIN CM, 1974, CIRCULATION, V49, P703; GURLEY JC, 1992, J AM COLL CARDIOL, V19, P1237, DOI 10.1016/0735-1097(92)90330-P; GUSSENHOVEN EJ, 1989, J AM COLL CARDIOL, V14, P947, DOI 10.1016/0735-1097(89)90471-3; HACKETT D, 1989, AM J CARDIOL, V63, P1517, DOI 10.1016/0002-9149(89)90018-0; HARRISON DG, 1984, CIRCULATION, V69, P1111, DOI 10.1161/01.CIR.69.6.1111; HERMILLER JB, 1992, CIRCULATION, V86, P518; ISNER JM, 1981, CIRCULATION, V63, P1056, DOI 10.1161/01.CIR.63.5.1056; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KAPLAN GA, 1988, AM J EPIDEMIOL, V127, P1131, DOI 10.1093/oxfordjournals.aje.a114907; KEMP HG, 1967, CIRCULATION, V36, P526, DOI 10.1161/01.CIR.36.4.526; KEREN G, 1991, Journal of the American College of Cardiology, V17, p217A; KLOCKE FJ, 1983, J AM COLL CARDIOL, V1, P31, DOI 10.1016/S0735-1097(83)80008-4; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; LIEBSON PR, 1992, AM HEART J, V123, P1643, DOI 10.1016/0002-8703(92)90819-H; MARCUS ML, 1982, AM J CARDIOL, V49, P1699, DOI 10.1016/0002-9149(82)90248-X; MCPHERSON DD, 1991, J AM COLL CARDIOL, V17, P79, DOI 10.1016/0735-1097(91)90707-G; MCPHERSON DD, 1987, NEW ENGL J MED, V316, P304, DOI 10.1056/NEJM198702053160604; MINTZ GS, 1992, CIRCULATION, V86, P1383, DOI 10.1161/01.CIR.86.5.1383; MOHIADDIN RH, 1989, BRIT HEART J, V62, P90; NISSEN SE, 1990, CIRCULATION, V82, P459; NISSEN SE, 1992, AM J CARDIOL, V69, pH18, DOI 10.1016/0002-9149(92)90642-C; NISSEN SE, 1991, CIRCULATION, V84, P437; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; RICHARDSON PD, 1989, LANCET, V2, P941; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SELZER RH, 1989, J CLIN INVEST, V83, P520, DOI 10.1172/JCI113913; SEMPOS C, 1988, AM J PUBLIC HEALTH, V78, P1422, DOI 10.2105/AJPH.78.11.1422; SHERMAN CT, 1986, NEW ENGL J MED, V315, P913, DOI 10.1056/NEJM198610093151501; STCLAIR RW, 1983, PROG CARDIOVASC DIS, V26, P109; STIEL GM, 1989, CIRCULATION, V80, P1603, DOI 10.1161/01.CIR.80.6.1603; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; THOMAS AC, 1986, BRIT HEART J, V55, P129; TOBIS JM, 1991, CIRCULATION, V83, P913, DOI 10.1161/01.CIR.83.3.913; TRACY RE, 1985, VIRCHOWS ARCH A, V405, P411, DOI 10.1007/BF00737168; VLODAVER Z, 1973, CIRCULATION, V47, P162, DOI 10.1161/01.CIR.47.1.162; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WHITE CW, 1984, NEW ENGL J MED, V310, P819, DOI 10.1056/NEJM198403293101304; WIJNS W, 1985, CIRCULATION, V71, P273, DOI 10.1161/01.CIR.71.2.273; WISSLER RW, 1976, ANN NY ACAD SCI, V275, P363, DOI 10.1111/j.1749-6632.1976.tb43368.x; ZARINS CK, 1988, J VASC SURG, V7, P386, DOI 10.1067/mva.1988.avs0070386; ZEIHER AM, 1991, CIRCULATION, V84, P1984, DOI 10.1161/01.CIR.84.5.1984; ZIJLSTRA F, 1987, CIRCULATION, V75, P1154, DOI 10.1161/01.CIR.75.6.1154; ZIR LM, 1976, CIRCULATION, V53, P627, DOI 10.1161/01.CIR.53.4.627	73	36	37	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					348	354		10.7326/0003-4819-121-5-199409010-00007	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042825				2022-12-28	WOS:A1994PD70100007
J	BREWER, RD; MORRIS, PD; COLE, TB; WATKINS, S; PATETTA, MJ; POPKIN, C				BREWER, RD; MORRIS, PD; COLE, TB; WATKINS, S; PATETTA, MJ; POPKIN, C			THE RISK OF DYING IN ALCOHOL-RELATED AUTOMOBILE CRASHES AMONG HABITUAL DRUNK DRIVERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREVENTION; DRINKING	Background. Reports suggest that people who drive while intoxicated by alcohol may do so repeatedly. We hypothesized that persons arrested for driving while impaired might be at increased risk for death in an alcohol-related motor vehicle crash. To evaluate this possibility, we studied the deaths of drivers in alcohol-related motor vehicle accidents in North Carolina over a 10-year period. Methods. We compared drivers who died in motor vehicle crashes from 1980 through 1989 and who had blood alcohol concentrations of at least 20 mg per deciliter (4.3 mmol per liter), referred to as the case drivers, with those who died in crashes but had blood alcohol concentrations below 20 mg per deciliter, referred to as the control drivers. We identified case drivers and control drivers through the state Medical Examiner System. We then searched North Carolina driver-history. files for the five years before each death to identify arrests for driving while impaired. Results. We linked a total of 1646 case drivers and 1474 control drivers to their driver-history files. Case drivers were more likely than control drivers to have been arrested for driving while impaired (26 percent vs. 3 percent). After we controlled for potential confounding variables, case drivers 21 to 34 years of age were 4.3 times more likely (95 percent confidence interval, 2.7 to 6.8) than control drivers to have been arrested for driving while impaired; case drivers 35 years of age or older were 11.7 times more likely (95 percent confidence interval, 6.8 to 20.1). The strength of the association appeared to increase with the number of prior arrests. Case drivers were also more likely than the general population of currently licensed drivers to have been arrested. Conclusions. Arrests for driving while impaired substantially increase the risk of eventual death in an alcohol-related crash. Aggressive intervention in the cases of people arrested for driving while impaired may decrease the likelihood of a future fatal alcohol-related crash.	CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, EPIDEM INTELLIGENCE SERV, ATLANTA, GA USA; N CAROLINA DEPT ENVIRONM HLTH & NAT RESOURCES, INJURY CONTROL SECT, RALEIGH, NC USA; N CAROLINA DEPT ENVIRONM HLTH & NAT RESOURCES, DIV STAT & INFORMAT SERV, RALEIGH, NC USA; UNIV N CAROLINA, HIGHWAY SAFETY RES CTR, CHAPEL HILL, NC USA	Centers for Disease Control & Prevention - USA; University of North Carolina; University of North Carolina Chapel Hill	BREWER, RD (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INJURY PREVENT & CONTROL, DIV UNINTENT INJURY PREVENT, ATLANTA, GA 30341 USA.				PHS HHS [H28/CCH401640011] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREASSON S, 1991, BRIT J ADDICT, V86, P877; ARSTEINKERSLAKE GW, 1985, TYPOLOGICAL ANAL CAL; CLARK CD, 1972, HIT LAB REP, V2, P1; Clark WB, 1991, ALCOHOL AM DRINKING; COLQUITT M, 1987, NEW ENGL J MED, V317, P1262, DOI 10.1056/NEJM198711123172005; DEAN AD, 1991, EPI INFO VERION 5 0; FELL JC, 1989, HEALTH EDUC QUART, V16, P335, DOI 10.1177/109019818901600303; FILKINS LD, 1970, ALCOHOL ABUSE TRAFFI; FINE EW, 1976, ANN NY ACAD SCI, V273, P637, DOI 10.1111/j.1749-6632.1976.tb52938.x; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MAULL KI, 1984, JAMA-J AM MED ASSOC, V252, P1880, DOI 10.1001/jama.252.14.1880; MAULL KI, 1982, SOUTHERN MED J, V75, P794, DOI 10.1097/00007611-198207000-00005; MOSKOWITZ JM, 1989, J STUD ALCOHOL, V50, P54, DOI 10.15288/jsa.1989.50.54; Richman A, 1985, J Stud Alcohol Suppl, V10, P21; SELZER ML, 1969, BEHAV SCI, V14, P1, DOI 10.1002/bs.3830140102; SHORE ER, 1988, EVAL PROGRAM PLANN, V11, P245, DOI 10.1016/0149-7189(88)90020-1; SLEET DA, 1989, HEALTH EDUC QUART, V16, P329, DOI 10.1177/109019818901600302; SMITH PF, 1989, HEALTH EDUC QUART, V16, P345, DOI 10.1177/109019818901600304; SODERSTROM CA, 1992, JAMA-J AM MED ASSOC, V267, P2756, DOI 10.1001/jama.267.20.2756; STERLINGSMITH RS, 1974, PSYCHOSOCIAL ANAL OP; Vaillant G.E., 1995, WISDOM EGO; 1992, NHTSA23 TECHN TRANSF; 1992, DHHS PHS921232 PUBL; 1989, SAS RELEASE 6 03; 1993, MMWR-MORBID MORTAL W, V42, P905; 1992, STATISTICAL ABSTRACT	26	90	93	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					513	517		10.1056/NEJM199408253310806	http://dx.doi.org/10.1056/NEJM199408253310806			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD072	8041418				2022-12-28	WOS:A1994PD07200006
J	OCONNELL, M; MARTENSON, JA; WIEAND, HS; KROOK, JE; MACDONALD, JS; HALLER, DG; MAYER, RJ; GUNDERSON, LL; RICH, TA				OCONNELL, M; MARTENSON, JA; WIEAND, HS; KROOK, JE; MACDONALD, JS; HALLER, DG; MAYER, RJ; GUNDERSON, LL; RICH, TA			IMPROVING ADJUVANT THERAPY FOR RECTAL-CANCER BY COMBINING PROTRACTED-INFUSION FLUOROURACIL WITH RADIATION-THERAPY AFTER CURATIVE SURGERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLORECTAL-CANCER; VENOUS INFUSION; SMALL BOWEL; 5-FLUOROURACIL; CARCINOMA	Background. The combination of radiation therapy and chemotherapy with fluorouracil plus semustine after surgery has been established as an effective approach to decreasing the risk of tumor relapse and improving survival in patients with rectal cancer who are at high risk for relapse or death. We sought to determine whether the efficacy of chemotherapy could be improved by administering fluorouracil by protracted infusion throughout the duration of radiation therapy and whether the omission of semustine would reduce the toxicity and delayed complications of chemotherapy without decreasing its antitumor efficacy. Methods. Six hundred sixty patients with TNM stage II or III rectal cancer received intermittent bolus injections or protracted venous infusions of fluorouracil during postoperative radiation to the pelvis. They also received systemic chemotherapy with semustine plus fluorouracil or with fluorouracil alone in a higher dose, both before and after the pelvic irradiation. Results. With a median follow-up of 46 months among surviving patients, patients who received a protracted infusion of fluorouracil had a significantly increased time to relapse (P = 0.01) and improved survival (P = 0.005). There was no evidence of a beneficial effect in the patients who received semustine plus fluorouracil. Conclusions. A protracted infusion of fluorouracil during pelvic irradiation improved the effect of combined-treatment postoperative adjuvant therapy in patients with high-risk rectal cancer. Semustine plus fluorouracil was not more effective than a higher dose of systemic fluorouracil given alone.	DULUTH CLIN, DULUTH, MN USA; TEMPLE UNIV, SCH MED, PHILADELPHIA, PA USA; UNIV PENN, CTR CANC, PHILADELPHIA, PA USA; DANA FARBER CANC INST, BOSTON, MA USA; MD ANDERSON CANC CTR, HOUSTON, TX USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; University of Texas System; UTMD Anderson Cancer Center	OCONNELL, M (corresponding author), MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA.				NCI NIH HHS [CA-06294, CA-31224, CA-25224] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA006294, P01CA031224, U10CA025224] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1985, NEW ENGL J MED, V312, P1465; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BYFIELD JE, 1982, INT J RADIAT ONCOL, V8, P1923, DOI 10.1016/0360-3016(82)90451-5; COX DR, 1972, J R STAT SOC B, V34, P187; DOUGLASS HO, 1986, NEW ENGL J MED, V315, P1294; GALLAGHER MJ, 1986, INT J RADIAT ONCOL, V12, P1565, DOI 10.1016/0360-3016(86)90279-8; GUNDERSON LL, 1985, INT J RADIAT ONCOL, V11, P1379, DOI 10.1016/0360-3016(85)90255-X; GUNDERSON LL, 1992, TECHNOLOGICAL BASIS, P342; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HANSEN RM, 1989, ONCOLOGY, V46, P245; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; LOKICH JJ, 1989, J CLIN ONCOL, V7, P425, DOI 10.1200/JCO.1989.7.4.425; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARTENSON JA, IN PRESS INT J RAD O; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; OCONNELL M, 1993, P AN M AM SOC CLIN, V12, P190; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; RICH TA, 1985, J CLIN ONCOL, V3, P402, DOI 10.1200/JCO.1985.3.3.402; SEIFERT P, 1975, CANCER-AM CANCER SOC, V36, P123, DOI 10.1002/1097-0142(197507)36:1<123::AID-CNCR2820360108>3.0.CO;2-C; WEINERMAN B, 1992, AM J CLIN ONCOL-CANC, V15, P518, DOI 10.1097/00000421-199212000-00012; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; WOOLLEY PV, 1992, J CLIN ONCOL, V10, P549; 1990, SAS STAT USERS GUIDE, V2	24	892	912	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					502	507		10.1056/NEJM199408253310803	http://dx.doi.org/10.1056/NEJM199408253310803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD072	8041415				2022-12-28	WOS:A1994PD07200003
J	CHAMBERLAND, ME; PETERSEN, LR; MUNN, VP; WHITE, CR; JOHNSON, ES; BUSCH, MP; GRINDON, AJ; KAMEL, H; NESS, PM; SHAFER, AW; ZEGER, G				CHAMBERLAND, ME; PETERSEN, LR; MUNN, VP; WHITE, CR; JOHNSON, ES; BUSCH, MP; GRINDON, AJ; KAMEL, H; NESS, PM; SHAFER, AW; ZEGER, G			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AMONG HEALTH-CARE WORKERS WHO DONATE BLOOD	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; HEALTH PERSONNEL; BLOOD DONORS; BLOOD BANKS; OCCUPATIONAL EXPOSURE	HIV-INFECTION; MEMBERS	Objective: To estimate the prevalence of human immunodeficiency virus (HIV) infection among health care workers who donate blood. Design: Point prevalence survey of blood donors. Setting: 20 U.S. blood centers that participate in an ongoing interview study of HIV-seropositive blood donors. Measurements: Prevalence rates for HIV in persons who reported being health care workers were measured directly for 6 of the 20 blood centers. For the other 14 centers, we derived the numerator from the interview study in the same manner used for the 6 centers; we estimated the denominator using blood collection logs at those centers and extrapolations from the survey completed at the 6 blood centers. Results: Between March 1990 and August 1991, 8519 health care workers donated blood at 6 hospitals and other medical facilities. Three persons were HIV seropositive: Two reported being health care workers and having nonoccupational risk factors for HIV infection; the occupation and other possible risk factors of the third seropositive donor could not be determined. Therefore, the highest overall prevalence of HIV infection among health care worker donors at these 6 centers was 0.04% (3 of 8519; upper limit of 95% CI, 0.1%). We estimated that during the same period, approximately 36 329 health care workers were tested for HIV at all 20 centers. Twenty-seven persons infected with HIV who donated at hospitals were identified; 7 did not return for interviews, so their health care occupations could not be verified. Thus, the highest estimated overall prevalence of HIV infection among health care worker donors at the 20 centers was 0.07% (27 of 36 329; upper limit of CI, 0.1%). Of the 20 known health care worker donors, 11 reported nonoccupational risks for HIV infection; 3 of the remaining 9 health care workers described occupational blood exposures that could have resulted in transmission of HIV. Conclusions: Blood donors can serve as a sentinel cohort when evaluating the risk for occupationally acquired HIV infection. These findings suggest that among the many health care worker donors in this study, HIV infection attributable to occupational exposure was uncommon.	IRWIN MEM BLOOD CTR, SAN FRANCISCO, CA USA; AMER RED CROSS, ATLANTA, GA USA; AMER RED CROSS, PHILADELPHIA, PA USA; AMER RED CROSS, BALTIMORE, MD USA; AMER RED CROSS, DETROIT, MI USA; UNIV CALIF LOS ANGELES HOSP, LOS ANGELES, CA USA	American Red Cross; American Red Cross; American Red Cross; American Red Cross; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	CHAMBERLAND, ME (corresponding author), CTR DIS CONTROL, HOSP INFECT PROGRAM, 1600 CLIFTON RD, MAILSTOP A-07, ATLANTA, GA 30333 USA.							CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; CIESIELSKI CA, 1990, NEW ENGL J MED, V322, P1156; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; GRUNINGER SE, 1992, J AM DENT ASSOC, V123, P57, DOI 10.14219/jada.archive.1992.0075; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; PETERSEN LR, 1990, PUBLIC HEALTH REP, V105, P153; PETERSEN LR, 1991, TRANSFUSION, V31, P698, DOI 10.1046/j.1537-2995.1991.31892023493.x; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V268, P489, DOI 10.1001/jama.268.4.489; 1987, MMWR-MORBID M     S2, V36, pS1; 1993, PHS HIVNCID1193036 D; 1992, HIV AIDS SURVEILLANC	12	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					269	273		10.7326/0003-4819-121-4-199408150-00006	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037407				2022-12-28	WOS:A1994PB10200006
J	SHARP, TW; YIP, R; MALONE, JD				SHARP, TW; YIP, R; MALONE, JD			US MILITARY FORCES AND EMERGENCY INTERNATIONAL HUMANITARIAN ASSISTANCE - OBSERVATIONS AND RECOMMENDATIONS FROM 3 RECENT MISSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STATES HOSPITAL SHIPS; PUBLIC-HEALTH; MORTALITY; POPULATIONS; SOMALIA; REFUGEE; RELIEF; WAR		USN,MED RES INST,BETHESDA,MD; USN,NATL MED CTR,BETHESDA,MD; CTR DIS CONTROL & PREVENT,ATLANTA,GA	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; United States Department of Defense; United States Navy; Centers for Disease Control & Prevention - USA								AUTIER P, 1990, LANCET, V335, P1388; BINA WF, 1993, JAMA-J AM MED ASSOC, V270, P2927, DOI 10.1001/jama.1993.03510240039022; BRADT DA, 1994, JAMA-J AM MED ASSOC, V271, P745, DOI 10.1001/jama.1994.03510340035021; BYRD TR, 1980, MIL MED, V145, P270; Chowdhury M, 1992, CRISIS DEV COPING DI, P101; COBEY JC, 1993, JAMA-J AM MED ASSOC, V270, P632, DOI 10.1001/jama.270.5.632; COBEY JC, 1993, JAMA-J AM MED ASSOC, V269, P986, DOI 10.1001/jama.1993.03500080034013; COULTRIP RL, 1974, MIL MED, V139, P879; CUNY F, 1992, SOLDIERS PEACEKEEPER, P52; DEGOYET CD, 1993, DISASTERS, V17, P169, DOI 10.1111/j.1467-7717.1993.tb01144.x; DUNLAP CJ, 1992, PARAMETERS US ARMY W, V2, P20; GAYDOS JC, 1994, DISASTERS, V18, P48, DOI 10.1111/j.1467-7717.1994.tb00284.x; GAYDOS JC, 1978, MIL MED, V143, P318; HENDERSON AK, 1994, ANN EMERG MED, V23, P726, DOI 10.1016/S0196-0644(94)70306-X; HOOPER RR, 1993, JAMA-J AM MED ASSOC, V270, P621, DOI 10.1001/jama.270.5.621; HUNTINGTON SP, 1993, JOINT FORCE Q, V2, P38; LILLIBRIDGE SR, IN PRESS MIL MED; MALONE JL, 1993, TRAVEL MED INT, V1, P21; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; NUNN S, 1993, OFFICER, V69, P20; SHAW R, 1979, MIL MED, V144, P307; SHEARS P, 1993, DISEASTERS, V171, P66; SOMMER A, 1972, LANCET, V1, P1029; SZULC T, 1994, PARADE          0501, P4; TOOLE MJ, 1993, LANCET, V342, P190, DOI 10.1016/0140-6736(93)92292-2; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1993, LANCET, V341, P1193, DOI 10.1016/0140-6736(93)91013-C; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; VANROOYEN MJ, 1994, JAMA-J AM MED ASSOC, V271, P904, DOI 10.1001/jama.1994.03510360028024; WALKER P, 1992, DISASTERS, V16, P153; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; 1990, LANCET, V336, P845; 1991, FROM SEA PREPARING N, P5; 1991, MMWR-MORBID MORTAL W, V40, P443; 1993, NATIONAL SECURITY ST, P14; 1976, PREVENTIVE MED WORLD, V8; 1992, MMWR-MORBID MORTAL W, V41, P26; 1976, LANCET, V2, P1394; 1994, MULTISERVICE PROCEDU; WHODAP901; 1992, MMWR-MORBID MORTAL W, V41, P1	41	36	36	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					386	390		10.1001/jama.272.5.386	http://dx.doi.org/10.1001/jama.272.5.386			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028171				2022-12-28	WOS:A1994NY90300032
J	GEHRING, WJ; QIAN, YQ; BILLETER, M; FURUKUBOTOKUNAGA, K; SCHIER, AF; RESENDEZPEREZ, D; AFFOLTER, M; OTTING, G; WUTHRICH, K				GEHRING, WJ; QIAN, YQ; BILLETER, M; FURUKUBOTOKUNAGA, K; SCHIER, AF; RESENDEZPEREZ, D; AFFOLTER, M; OTTING, G; WUTHRICH, K			HOMEODOMAIN-DNA RECOGNITION	CELL			English	Review							MAGNETIC-RESONANCE SPECTROSCOPY; HUMAN PROTOONCOGENE PBX1; POU-DOMAIN PROTEIN; ANTENNAPEDIA HOMEODOMAIN; FUNCTIONAL SPECIFICITY; FUSHI-TARAZU; TRANSCRIPTION FACTOR; BINDING SPECIFICITY; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE		ETH HONGGERBERG,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich	GEHRING, WJ (corresponding author), UNIV BASEL,BIOZENTRUM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		Otting, Gottfried/H-8413-2014; Billeter, Martin/A-8293-2010; Resendez-Perez, Diana/AAE-3352-2019	Otting, Gottfried/0000-0002-0563-0146; Resendez-Perez, Diana/0000-0002-4709-7677; Affolter, Markus/0000-0002-5171-0016; Schier, Alexander Franz/0000-0001-7645-5325				AFFOLTER M, 1991, CELL, V64, P879, DOI 10.1016/0092-8674(91)90311-L; AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; BILLETER M, 1990, J MOL BIOL, V214, P183, DOI 10.1016/0022-2836(90)90155-F; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; BILLETER M, 1993, J MOL BIOL, V234, P1094, DOI 10.1006/jmbi.1993.1662; CESKA TA, 1993, EMBO J, V12, P1805, DOI 10.1002/j.1460-2075.1993.tb05828.x; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; De Simone V, 1991, CURR OPIN CELL BIOL, V3, P960, DOI 10.1016/0955-0674(91)90114-E; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FURUKUBOTOKUNAGA K, 1992, GENE DEV, V6, P1082, DOI 10.1101/gad.6.6.1082; FURUKUBOTOKUNAGA K, 1993, P NATL ACAD SCI USA, V90, P6360, DOI 10.1073/pnas.90.13.6360; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P437; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GOULTE C, 1993, J MOL BIOL, V233, P359; GUNTERT P, 1991, J MOL BIOL, V217, P531, DOI 10.1016/0022-2836(91)90755-U; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; KALIONIS B, 1993, MECH DEVELOP, V43, P57, DOI 10.1016/0925-4773(93)90023-Q; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEITING B, 1993, EMBO J, V12, P1797, DOI 10.1002/j.1460-2075.1993.tb05827.x; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OTTING G, 1991, J AM CHEM SOC, V113, P4363, DOI 10.1021/ja00011a068; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; PERCIVALSMITH A, 1990, EMBO J, V11, P382; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; QIAN YQ, 1994, P NATL ACAD SCI USA, V91, P4091, DOI 10.1073/pnas.91.9.4091; QIAN YQ, 1993, J MOL BIOL, V234, P1070, DOI 10.1006/jmbi.1993.1660; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; QIAN YQ, 1994, J MOL BIOL, V238, P333, DOI 10.1006/jmbi.1994.1296; QIAN YQ, 1992, P NATL ACAD SCI USA, V89, P10738, DOI 10.1073/pnas.89.22.10738; QIAN YQ, 1993, J AM CHEM SOC, V115, P1189, DOI 10.1021/ja00056a077; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SCHIER AF, 1993, P NATL ACAD SCI USA, V90, P1450, DOI 10.1073/pnas.90.4.1450; SCHIER AF, 1993, EMBO J, V12, P1111, DOI 10.1002/j.1460-2075.1993.tb05752.x; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SHAKKED Z, 1994, NATURE, V368, P469, DOI 10.1038/368469a0; SLUKA JP, 1990, BIOCHEMISTRY-US, V29, P6551, DOI 10.1021/bi00480a002; SLUKA JP, 1987, SCIENCE, V238, P1129, DOI 10.1126/science.3120311; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUZUKI M, 1993, EMBO J, V12, P3221, DOI 10.1002/j.1460-2075.1993.tb05991.x; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TREISMAN J, 1989, CELL, V59, P553; VERSHON AK, 1993, CELL, V72, P1; WIESCHAUS E, 1986, ROUX ARCH DEV BIOL, V195, P63, DOI 10.1007/BF00444042; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WUTHRICH K, 1992, TRANSCRIPTIONAL REGU, P535; ZENG WL, 1993, DEVELOPMENT, V118, P339	75	688	705	0	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					211	223		10.1016/0092-8674(94)90292-5	http://dx.doi.org/10.1016/0092-8674(94)90292-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044836				2022-12-28	WOS:A1994NZ24200006
J	MOORE, P; HEPWORTH, JT				MOORE, P; HEPWORTH, JT			USE OF PERINATAL AND INFANT HEALTH-SERVICES BY MEXICAN-AMERICAN MEDICAID ENROLLEES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL-CARE; HHANES 1982-84; LOW-INCOME; CHILDREN; ACCULTURATION; ACCESS	Objectives.-Lack of health insurance and a regular source of medical care are barriers affecting use of health services by Mexican Americans. We studied perinatal and infant health service use by Mexican-American women and non-Hispanic white women and their infants enrolled in Arizona's Medicaid program and explored characteristics associated with use of health services. Design.-A descriptive comparative study that used data collected from office records, birth certificates, and household interviews. Setting.-Participants resided in the state's most populous county and were enrolled in the Arizona Health Care Cost Containment System, a health maintenance organization-oriented Medicaid demonstration project. Subjects.-Random sample of 308 Mexican-American mother-infant dyads and 312 non-Hispanic white mother-infant dyads. The women were enrolled before the sixth month of pregnancy and for 60 days post partum; their infants were continuously enrolled throughout their first year. Outcome Measures.-Timing and number of prenatal visits and a modified Kessner Index, postpartum visits, number and purpose of office visits during the infants' first year, and immunizations received. Results.-Mexican Americans averaged fewer prenatal visits than non-Hispanic whites (8.6 vs 10.2 visits) and were less likely to have ''adequate'' care (41.1% vs 52.8%). Both groups of mothers are well below the 68% of women nationally who receive adequate prenatal care. Controlling for important socioeconomic status and cultural characteristics, ethnicity had a strong independent effect on the number of prenatal visits and adequacy of prenatal care. Mexican-American infants made fewer visits (8.2 vs 9.8) and completed fewer age-appropriate immunizations than non-Hispanic whites. Conclusions.-Health insurance and a regular source of care are insufficient conditions for ensuring adequate use of maternal and child health services by Mexican-American Medicaid enrollees. Factors associated with their less frequent use of these preventive health services include higher numbers of children, transportation problems, and less assistance from their support system.			MOORE, P (corresponding author), ARIZONA STATE UNIV,COLL NURSING,TEMPE,AZ 85287, USA.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X	AHRQ HHS [HS 06127] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Aday LA, 1980, HLTH CARE US EQUITAB; ANDERSEN R, 1981, J HEALTH SOC BEHAV, V22, P78, DOI 10.2307/2136370; BARRERA M, 1981, SOCIAL NETWORKS SOCI; CAREY T, 1990, J CLIN EPIDEMIOL, V43, P1213, DOI 10.1016/0895-4356(90)90022-H; COHEN J., 1983, APPL MULTIPLE REGRES, V2; Cuellar I., 1980, HISP J BEHAV SCI, V2, P199, DOI DOI 10.1177/07399863950173001; Davis Susan F., 1992, Morbidity and Mortality Weekly Report, V41, P11; FREUND DA, 1989, HLTH CARE FINANCING, V2, P81; GERGEN PJ, 1988, AM J PUBLIC HEALTH, V78, P1446, DOI 10.2105/AJPH.78.11.1446; GUENDELMAN S, 1990, AM J PUBLIC HEALTH, V80, P61, DOI 10.2105/AJPH.80.Suppl.61; GUYER B, 1990, JAMA-J AM MED ASSOC, V264, P2264, DOI 10.1001/jama.264.17.2264; HEPWORTH J, 1991, NOV AM PUBL HLTH ASS; HUGHES D, 1989, HLTH AM CHILDREN; KRIEGER JW, 1992, AM J PUBLIC HEALTH, V82, P185, DOI 10.2105/AJPH.82.2.185; MILLER CA, 1989, MONITORING CHILDRENS; MOORE P, 1984, PB85243095AS; Olson D. H., 1989, CIRCUMPLEX MODEL FAM; ROBERTS RE, 1991, JAMA-J AM MED ASSOC, V265, P248; ROSENBACH ML, 1989, AM J PUBLIC HEALTH, V79, P1220, DOI 10.2105/AJPH.79.9.1220; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405; SCRIBNER R, 1989, AM J PUBLIC HEALTH, V79, P1263, DOI 10.2105/AJPH.79.9.1263; SOLIS JM, 1990, AM J PUBLIC HEALTH, V80, P11, DOI 10.2105/AJPH.80.Suppl.11; STARFIELD B, 1985, MILBANK FUND Q, V63, P523, DOI 10.2307/3349846; STCLAIR PA, 1990, PUBLIC HEALTH REP, V105, P264; STPETER RF, 1992, JAMA-J AM MED ASSOC, V267, P2760, DOI 10.1001/jama.267.20.2760; TREVINO FM, 1983, US DHHS PH841232 PUB; VENTURA SJ, 1985, PUBLIC HEALTH REP, V100, P647; 1991, CLOSING DECADE ARIZO; 1991, P20 US DEP COMM BUR; 1991, US DHHS PHS9150212 P; 1988, GUIDELINES HLTH SUPE, V2; [No title captured]; 1988, PRENATAL CARE REACHI; 1991, 40 NAT CTR HLTH STAT; 1985, PLAN OPERATION HISPA; 1989, US DHHS PHS891501 10	36	71	72	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					297	304		10.1001/jama.272.4.297	http://dx.doi.org/10.1001/jama.272.4.297			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NX806	8028143				2022-12-28	WOS:A1994NX80600032
J	HATTORI, M; ADACHI, H; TSUJIMOTO, M; ARAI, H; INOUE, K				HATTORI, M; ADACHI, H; TSUJIMOTO, M; ARAI, H; INOUE, K			MILLER-DIEKER LISSENCEPHALY GENE ENCODES A SUBUNIT OF BRAIN PLATELET-ACTIVATING-FACTOR	NATURE			English	Article							FACTOR ACETYLHYDROLASE; FACTOR PAF; CHROMOSOME-17P13; PURIFICATION; RECEPTOR; REPEATS; CLONES; PCR	PLATELET-ACTIVATING factor (PAF) is involved in a variety of biological and pathological processes(1) and PAF acetylhydrolase, which inactivates PAF by removing the acetyl group at the sn-2 position, is widely distributed in plasma and tissue cytosols(2,3). One isoform of PAP acetylhydrolase present in bovine brain cortex is a heterotrimer comprising subunits with relative molecular masses of 45K, 30K and 29K (ref. 4). We have now isolated the complementary DNA for the 45K subunit. Sequence analysis revealed a striking identity (99%) of the subunit with a protein encoded by the causative gene (LIS-1) for MiUer-Dieker lissencephaly(5), a human brain malformation manifested by a smooth cerebral surface and abnormal neuronal migration. This indicates that the LIS-1 gene product is a human homologue of the 45K subunit of intracellular PAF acetylhydrolase. Our results raise the possibility that PAF and PAF acetylhydrolase are important in the formation of the brain cortex during differentiation and development.	SUNTORY INST BIOMED RES,MISHIMA 618,OSAKA,JAPAN	Suntory Holdings Ltd	HATTORI, M (corresponding author), UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN.		Hattori, Mitsuharu/F-3859-2010	Hattori, Mitsuharu/0000-0002-0503-4969				BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; CATALAN RE, 1992, BIOCHEM BIOPH RES CO, V183, P300, DOI 10.1016/0006-291X(92)91643-5; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; ISOLA NR, 1991, BIOTECHNIQUES, V11, P580; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KWIATKOWSKI TJ, 1990, NUCLEIC ACIDS RES, V18, P7191, DOI 10.1093/nar/18.23.7191; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOGOS V, 1990, J NEUROSCI RES, V27, P706, DOI 10.1002/jnr.490270431; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; VANDERNVOORN L, 1992, FEBS LETT, V507, P131	18	434	443	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					216	218		10.1038/370216a0	http://dx.doi.org/10.1038/370216a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028668				2022-12-28	WOS:A1994NX97100052
J	CARRAWAY, KL; CANTLEY, LC				CARRAWAY, KL; CANTLEY, LC			A NEU ACQUAINTANCE FOR ERBB3 AND ERBB4 - A ROLE FOR RECEPTOR HETERODIMERIZATION IN GROWTH SIGNALING	CELL			English	Review							TYROSINE KINASE; TUMOR CELLS; LIGAND; HEREGULIN; DIFFERENTIATION; TRANSDUCTION; PROTEIN		BETH ISRAEL HOSP, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center	CARRAWAY, KL (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014; Otonkoski, Timo/F-1189-2011	Cantley, Lewis C/0000-0002-1298-7653; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1993, J BIOL CHEM, V268, P23860; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GUY PM, 1994, IN PRESS P NATL ACAD; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, IN PRESS MOL CELL BI; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	520	588	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					5	8		10.1016/0092-8674(94)90564-9	http://dx.doi.org/10.1016/0092-8674(94)90564-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033211				2022-12-28	WOS:A1994NX32800002
J	COLAIANNI, LA				COLAIANNI, LA			PEER-REVIEW IN JOURNALS INDEXED IN INDEX-MEDICUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC			Objective.-To determine whether peer review policies are published in English-language journals indexed in Index Medicus and, secondarily, to obtain information on the peer review practices of such journals. Design.-Examined one issue of a sample of all journal titles written in English and indexed in Index Medicus, and all indexed English-language journals in four subject fields. A questionnaire was sent to the editors of journals in the subject fields requesting information on their peer review practices. Setting.-Journals received at the National Library of Medicine. Participants.-Editors of journals in four subject fields. Main Outcome Measure.-Existence of a printed statement of the peer review process for manuscripts. Results.-Although the editors queried in the four subject fields indicated that overall, 56% to 65% of the articles were peer reviewed, clear statements about their peer review practices were not found in half of their journals or in the overall sample. Conclusions.-Editors should publish clear statements of the peer review process followed for each type of article published in their journals.			COLAIANNI, LA (corresponding author), NATL LIB MED,8600 ROCKVILLE PIKE,BETHESDA,MD 20894, USA.							CAELLEIGH AS, 1993, ACAD MED, V68, pS23, DOI 10.1097/00001888-199309000-00030; 1993, UNIFORM REQUIREMENTS	2	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					156	158						3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015132				2022-12-28	WOS:A1994NV42400022
J	NYLENNA, M; RIIS, P; KARLSSON, Y				NYLENNA, M; RIIS, P; KARLSSON, Y			MULTIPLE BLINDED REVIEWS OF THE 2 MANUSCRIPTS - EFFECTS OF REFEREE CHARACTERISTICS AND PUBLICATION LANGUAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		PEER REVIEWERS; ENGLISH	Objective.-To study the association between referee characteristics and their manuscript assessments, the influence of manuscript language on referees' judgments, and the usefulness, quality, and extent of referees' free-text comments. Design.-Two nonauthentic, but realistic, short manuscripts with a number of common methodological flaws were sent to 180 Scandinavian referees. Through randomization, each referee received one of the manuscripts in English and the other manuscript in the national language. A structured assessment of the manuscript quality was expressed on a 5-point scale, and the impact of referee characteristics (age, gender, experience, and so on) was analyzed by multiple linear regression. Main Outcome.-Manuscript quality assessed by referees. Results.-A total of 312 reviews from 156 referees could be used for the study of referee characteristics and language. With increasing experience, the referees gave lower quality scores (P<.05). A tendency toward stricter assessment with younger age was seen (P<.05). No influence of referees' gender, specialty, or nationality was found. For the;test manuscript of the poorest quality, the English version was assessed to be better than the national-language version (P<.05). A total of 159 of 312 reviews included free-text comments applicable for the methodological study. In 54 reviews (34%), no methodological comments accompanied the assessment, and in six reviews they were only incomplete. Wrong sampling unit was mentioned by one fourth of 80 referees. Only one referee mentioned the incorrect use of a parametric test in the analysis of data whose distribution was nonparametric. Conclusions.-Experienced and young referees gave a stricter assessment of the manuscripts than their less experienced and older colleagues. An English version seemed to be accepted more easily than a national-language version of the same manuscript. Most referees spontaneously mentioned the shortcomings of the manuscripts only as part of their overall judgment.	HERLEV UNIV HOSP,DEPT MED C,DK-2730 HERLEV,DENMARK; JOURNAL SWEDISH MED ASSOC,STOCKHOLM,SWEDEN	University of Copenhagen; Herlev & Gentofte Hospital	NYLENNA, M (corresponding author), JOURNAL NORWEGIAN MED ASSOC,FJELLVEIEN 5,N-1324 LYSAKER,NORWAY.							BAKEWELL D, 1992, NATURE, V356, P648, DOI 10.1038/356648a0; EVANS AT, 1993, 2ND INT C PEER REV B; LOCK S, 1990, JAMA-J AM MED ASSOC, V263, P1341, DOI 10.1001/jama.263.10.1341; VANDENBROUCKE JP, 1989, BRIT MED J, V298, P1461; YANKAUER A, 1990, JAMA-J AM MED ASSOC, V263, P1338	5	103	111	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					149	151		10.1001/jama.272.2.149	http://dx.doi.org/10.1001/jama.272.2.149			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015129				2022-12-28	WOS:A1994NV42400019
J	OSWALD, H; PHELAN, PD; LANIGAN, A; HIBBERT, M; BOWES, G; OLINSKY, A				OSWALD, H; PHELAN, PD; LANIGAN, A; HIBBERT, M; BOWES, G; OLINSKY, A			OUTCOME OF CHILDHOOD ASTHMA IN MID-ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article									UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT THORAC MED,MELBOURNE,VIC,AUSTRALIA; ROYAL CHILDRENS HOSP,CTR ADOLESCENT HLTH,MELBOURNE,VIC,AUSTRALIA; UNIV MELBOURNE,DEPT PAEDIAT,MELBOURNE,VIC,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Melbourne								KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321	4	100	102	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					95	96		10.1136/bmj.309.6947.95	http://dx.doi.org/10.1136/bmj.309.6947.95			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038676	Green Published			2022-12-28	WOS:A1994NW71600019
J	HIRSCHMANN, R; SMITH, AB; TAYLOR, CM; BENKOVIC, PA; TAYLOR, SD; YAGER, KM; SPRENGELER, PA; BENKOVIC, SJ				HIRSCHMANN, R; SMITH, AB; TAYLOR, CM; BENKOVIC, PA; TAYLOR, SD; YAGER, KM; SPRENGELER, PA; BENKOVIC, SJ			PEPTIDE-SYNTHESIS CATALYZED BY AN ANTIBODY CONTAINING A BINDING-SITE FOR VARIABLE AMINO-ACIDS	SCIENCE			English	Article							REACTIVITY	Monoclonal antibodies, induced with a phosphonate diester hapten, catalyzed the coupling of p-nitrophenyl esters of N-acetyl valine, leucine, and phenylalanine with tryptophan amide to form the corresponding dipeptides. All possible stereoisomeric combinations of the ester and amide substrates were coupled at comparable rates. The antibodies did not catalyze the hydrolysis of the dipeptide product nor hydrolysis or racemization of the activated esters. The yields of the dipeptides ranged from 44 to 94 percent. The antibodies were capable of multiple turnovers at rates that exceeded the rate of spontaneous ester hydrolysis. This achievement suggests routes toward creating a small number of antibody catalysts for polypeptide syntheses.	UNIV PENN,MONELL CHEM SENSES CTR,DEPT CHEM,RES STRUCT MATTER LAB,PHILADELPHIA,PA 19104; PENN STATE UNIV,DEPT CHEM,UNIV PK,PA 16802	Monell Chemical Senses Center; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	HIRSCHMANN, R (corresponding author), UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104, USA.		Taylor, Carol/B-4841-2012	Taylor, Carol/0000-0002-6262-0796	NIGMS NIH HHS [GM-45611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAHMSER L, 1991, BIOCHEMISTRY-US, V30, P4151; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BENKOVIC SJ, 1992, ANNU REV BIOCHEM, V61, P29; BENOITON NL, 1983, PEPTIDES, V5, pCH4; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; FERSHT AR, 1970, J AM CHEM SOC, V92, P5442, DOI 10.1021/ja00721a024; GREEN BS, 1991, CATALYTIC ANTIBODIES, V159, P139; GUTTE B, 1969, J AM CHEM SOC, V91, P501, DOI 10.1021/ja01030a050; HEARD AL, 1963, J CHEM SOC, V1963, P5807; HIRSCHMANN R, 1969, J AM CHEM SOC, V91, P509; HIRSCHMANN R, UNPUB; HOEGER C, 1989, J CHROMATOGR, V404, P307; JACOBSEN JR, 1992, SCIENCE, V256, P365, DOI 10.1126/science.256.5055.365; Jakubke HD., 1987, PEPTIDES ANAL SYNTHE, V9, P103; KAISER ET, 1989, SCIENCE, V243, P187, DOI 10.1126/science.2492114; KIRBY DA, 1993, J CHROMATOGR, V648, P257, DOI 10.1016/0021-9673(93)83309-G; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOULT J, 1976, J MOL BIOL, V74, P137; NAPPER AD, 1987, SCIENCE, V237, P1041, DOI 10.1126/science.3616626; RIVIER JE, 1978, J LIQ CHROMATOGR, V1, P343, DOI 10.1080/01483917808060004; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; SCHWYZER R, 1966, HELV CHIM ACTA, V49, P134, DOI 10.1002/hlca.660490120; SIEPKE G, 1986, ANGEW CHEM INT EDIT, V25, P535; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STEWART JD, 1993, CHEM SOC REV, V22, P213, DOI 10.1039/cs9932200213	27	395	405	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					234	237		10.1126/science.8023141	http://dx.doi.org/10.1126/science.8023141			4	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023141				2022-12-28	WOS:A1994NV95700037
J	SATO, H; TAKINO, T; OKADA, Y; CAO, J; SHINAGAWA, A; YAMAMOTO, E; SEIKI, M				SATO, H; TAKINO, T; OKADA, Y; CAO, J; SHINAGAWA, A; YAMAMOTO, E; SEIKI, M			A MATRIX METALLOPROTEINASE EXPRESSED ON THE SURFACE OF INVASIVE TUMOR-CELLS	NATURE			English	Article							IV COLLAGENASE; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR; ACTIVATION; FIBROBLASTS; GELATINASE; ASSOCIATION; METASTASIS; CARCINOMA; PRECURSOR	GELATINASE A (type-IV collagenase; M(r) 72,000) is produced by tumour stroma cells and is believed to be crucial for their invasion and metastasis, acting by degrading extracellular matrix macromolecules such as type IV collagen(1-3). An inactive precursor of gelatinase A (pro-gelatinase A) is secreted and activated in invasive tumour tissue(4-7) as a result of proteolysis which is mediated by a fraction of tumour cell membrane that is sensitive to metalloproteinase inhibitors(4,5). Here we report the cloning of the complementary DNA encoding a new matrix metalloproteinase with a potential transmembrane domain. Expression of the gene product on the cell surface induces specific activation of pro-gelatinase A in vitro and enhances cellular invasion of the reconstituted basement membrane. Tumour cells of invasive lung carcinomas, which contain activated forms of gelatinase A, were found to express the transcript and the gene product. The new metalloproteinase may thus trigger invasion by tumour cells by activating pro-gelatinase A on the tumour cell surface.	KANAZAWA UNIV,CANC RES INST,DEPT MOLEC VIROL & ONCOL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT ORAL SURG,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT PATHOL,KANAZAWA,ISHIKAWA 920,JAPAN; FUJI CHEM IND CO LTD,RES INST,DEPT BIOCHEM,TAKAOKA,TOYAMA 933,JAPAN	Kanazawa University; Kanazawa University; Kanazawa University			Okada, Yasunori/B-5550-2014; Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015; TAKINO, Takahisa/D-8460-2015	Okada, Yasunori/0000-0001-9208-4755; 				ALBINI A, 1987, CANCER RES, V47, P3239; AZZAM HS, 1992, CANCER RES, V52, P4540; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BROWN PD, 1990, CANCER RES, V50, P6184; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; BROWN PD, 1993, CLIN EXP METASTAS, V11, P183, DOI 10.1007/BF00114976; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; POULSOM R, 1992, AM J PATHOL, V141, P389; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TEMPLETON NS, 1990, CANCER RES, V50, P5431; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	30	2349	2440	5	107	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					61	65		10.1038/370061a0	http://dx.doi.org/10.1038/370061a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015608				2022-12-28	WOS:A1994NV71100059
J	VARTIAINEN, E; PUSKA, P; PEKKANEN, J; TUOMILEHTO, J; JOUSILAHTI, P				VARTIAINEN, E; PUSKA, P; PEKKANEN, J; TUOMILEHTO, J; JOUSILAHTI, P			CHANGES IN RISK-FACTORS EXPLAIN CHANGES IN MORTALITY FROM ISCHEMIC-HEART-DISEASE IN FINLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NORTH-KARELIA; DECLINE	Objective-To estimate the extent to which changes in the main coronary risk factors (serum cholesterol concentration, blood pressure, and smoking) explain the decline in mortality from ischaemic heart disease and to evaluate the relative importance of change in each of these risk factors. Design-Predicted changes in ischaemic heart disease mortality were calculated by a logistic regression model using the risk factor levels assessed by cross sectional population surveys, in 1972, 1977, 1982, 1987, and 1992. These predicted changes were compared with observed changes in mortality statistics. Setting-North Karelia and Kuopio provinces, Finland. Subjects-14257 men and 14786 women aged 30-59 randomly selected from the national population register. Main outcome measures-Levels of the risk factors and predicted and observed changes in mortality from ischaemic heart disease. Results-The observed changes in the risk factors in the population from 1972 to 1992 predicted a decline in mortality from ischaemic heart disease of 44% (95% confidence interval 37% to 50%) in men and 49% (37% to 59%) in women. The observed decline was 55% (51% to 58%) and 68% (61 to 74) respectively. Conclusion-An assessment of the data on the risk factors for ischaemic heart disease and mortality suggests that most of the decline in mortality from ischaemic heart disease can be explained by changes in the three main coronary risk factors.			VARTIAINEN, E (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, MANNERHEIMINTIE 166, SF-00300 HELSINKI, FINLAND.							ALROOMI KA, 1989, AM J EPIDEMIOL, V129, P503, DOI 10.1093/oxfordjournals.aje.a115161; DWYER T, 1980, INT J EPIDEMIOL, V9, P65, DOI 10.1093/ije/9.1.65; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; JACKSON R, 1987, INT J EPIDEMIOL, V16, P377, DOI 10.1093/ije/16.3.377; NICOLOSI A, 1988, INT J EPIDEMIOL, V17, P766, DOI 10.1093/ije/17.4.766; Ovcarov V K, 1978, World Health Stat Q, V31, P208; PIETINEN P, 1990, LIPIDS HLTH; PUSKA P, 1985, ANNU REV PUBL HEALTH, V6, P147, DOI 10.1146/annurev.pu.06.050185.001051; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; SALONEN JT, 1979, BRIT MED J, V2, P1178, DOI 10.1136/bmj.2.6199.1178; SIGFUSSON N, 1991, BRIT MED J, V302, P1371, DOI 10.1136/bmj.302.6789.1371; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; TAO SC, 1989, INT J EPIDEMIOL, V18, pS159; TUOMILEHTO J, 1986, BRIT MED J, V293, P1068, DOI 10.1136/bmj.293.6554.1068; Uemura K, 1985, World Health Stat Q, V38, P142; UESHIMA H, 1987, AM J EPIDEMIOL, V125, P62, DOI 10.1093/oxfordjournals.aje.a114512; VARTIAINEN E, 1991, INT J EPIDEMIOL, V20, P651, DOI 10.1093/ije/20.3.651; *WHO MONICA PROJ P, 1988, J CLIN EPIDEMIOL, V41, P105, DOI [DOI 10.1016/0895-4356(88)90084-4, 10.1016/0895-4356(88)90084-4]; 1992, MINISTRY AGR FORESTR, V11; 1987, AM J EPIDEMIOL, V1, P95	20	344	351	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	1994	309	6946					23	27		10.1136/bmj.309.6946.23	http://dx.doi.org/10.1136/bmj.309.6946.23			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044063	Green Published			2022-12-28	WOS:A1994NV89100019
J	HILL, ME; MACQUILLAN, G; FORSYTH, M; HEATH, DA				HILL, ME; MACQUILLAN, G; FORSYTH, M; HEATH, DA			CARDIOPULMONARY-RESUSCITATION - WHO MAKES THE DECISION	BRITISH MEDICAL JOURNAL			English	Article									QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; SELLY OAK HOSP,BIRMINGHAM B29 6JD,ENGLAND; UNIV BIRMINGHAM,SCH MED,BIRMINGHAM B15 2TT,ENGLAND	University of Birmingham; University of Birmingham								DOYAL L, 1993, BRIT MED J, V306, P1593, DOI 10.1136/bmj.306.6892.1593; OKEEFE S, 1991, Q J MED, V296, P1005; SCHADE SG, 1989, J MED ETHICS, V15, P186, DOI 10.1136/jme.15.4.186; SMITH EM, 1992, J ROY COLL PHYS LOND, V26, P377	4	41	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1677	1677		10.1136/bmj.308.6945.1677	http://dx.doi.org/10.1136/bmj.308.6945.1677			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025462	Green Published			2022-12-28	WOS:A1994NU48300021
J	WARD, BJ; TATE, PA				WARD, BJ; TATE, PA			ATTITUDES AMONG NHS DOCTORS TO REQUESTS FOR EUTHANASIA	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To explore NHS doctors' attitudes to competent patients' requests for euthanasia and to estimate the proportion of doctors who have taken active steps to hasten a patient's death. Design-Anonymous postal questionnaire, with no possibility of follow up. The survey was conducted from December 1992 to March 1993. Subjects-All (221) general practitioners and 203 hospital consultants in one area of England. Results-273 doctors responded to a question on whether a patient had ever asked them to hasten death. Of these, 163 had been asked to; 124 of these had been asked to take active steps to hasten death; 38 of 119 (32%) of these had complied with such a request (95% confidence interval 23% to 40%). This proportion represented 12% of all those who returned a completed questionnaire and 9% of all those who had been sent a questionnaire (95% confidence interval 6.3% to 11.7%). A larger proportion of the respondents (142/307 (46%)), however, would consider taking active steps to bring about the death of a patient if it was legal to do so. Conclusions-Many doctors face difficult decisions about euthanasia. For the benefit of both patients and doctors euthanasia should be discussed more openly.	UNIV CAMBRIDGE,DEPT ANAT,CAMBRIDGE CB2 3DY,ENGLAND	University of Cambridge								KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; 1988, BRIT MED J, V296, P1376; 1987, ATTITUDES EUTHANASIA	5	112	113	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1332	1334		10.1136/bmj.308.6940.1332	http://dx.doi.org/10.1136/bmj.308.6940.1332			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019219	Green Published			2022-12-28	WOS:A1994NM98900020
J	TEDDER, DG; ASHLEY, R; TYLER, KL; LEVIN, MJ				TEDDER, DG; ASHLEY, R; TYLER, KL; LEVIN, MJ			HERPES-SIMPLEX VIRUS-INFECTION AS A CAUSE OF BENIGN RECURRENT LYMPHOCYTIC MENINGITIS	ANNALS OF INTERNAL MEDICINE			English	Article						HERPES SIMPLEX; MENINGITIS, VIRAL; CEREBROSPINAL FLUID; HERPES GENITALIS; CENTRAL NERVOUS SYSTEM	POLYMERASE CHAIN-REACTION; CEREBROSPINAL-FLUID; MOLLARETS MENINGITIS; GENITAL HERPES; ENCEPHALITIS; TYPE-2; DIAGNOSIS; DNA; HERPESVIRUSES; PATIENT	Objective: To identify the role of herpes simplex virus (HSV) in causing benign recurrent lymphocytic meningitis. Design: Prospective cohort study. Setting: Tertiary referral center. Patients: 20 consecutive patients with a provisional diagnosis of benign recurrent lymphocytic meningitis had cerebrospinal fluid specimens submitted between 1990 and 1993 to the diagnostic virology laboratory. Thirteen patients met our criteria for benign recurrent lymphocytic meningitis. Measurements: Herpes simplex virus DNA was detected in cerebrospinal fluid specimens using the polymerase chain reaction, followed by hybridization with a HSV-specific DNA probe. Herpes simplex virus type 1 and type 2 DNA products were distinguished by digestion with restriction enzymes and analysis by gel electrophoresis. Anti-HSV antibodies in cerebrospinal fluid were detected by immunoblot. Results: The patients had 3 to 9 attacks (mean, 4.6 attacks) of benign recurrent lymphocytic meningitis during periods ranging from 2 to 21 years (mean, 8.4 years). Three of 13 patients had known recurrent genital herpes. Cerebrospinal fluid analysis showed 48 to 1600 cells/mu L, glucose levels of more than 2.22 mmol/L (40 mg/dL), and protein levels of 41 to 240 mg/dL (0.41 to 2.4 g/L). Herpes simplex virus DNA and anti-HSV antibodies were detected in cerebrospinal fluid samples in 11 of 13 patients (84.6%; 95% CI, 55% to 98%). Ten of these 11 patients had HSV type 2 DNA and HSV type 2 antibodies. One patient had HSV type 1 DNA and HSV type 1 antibodies in the cerebrospinal fluid. The remaining two patients had only anti-HSV type 2 antibodies. Conclusions: Herpes simplex virus, predominantly HSV type 2, was the major agent causing benign recurrent lymphocytic meningitis that met our specified diagnostic criteria.	UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT INFECT DIS, DENVER, CO 80262 USA; CHILDRENS HOSP, DENVER, CO 80218 USA; VET AFFAIRS MED CTR, NEUROL SERV 127, DENVER, CO 80220 USA; UNIV WASHINGTON, CHILDRENS HOSP & MED CTR, DEPT LAB MED, VIROL LAB, SEATTLE, WA 98105 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; US Department of Veterans Affairs; Veterans Health Administration (VHA); Seattle Children's Hospital; University of Washington; University of Washington Seattle			Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888	NIAID NIH HHS [AI-20381] Funding Source: Medline; NINDS NIH HHS [NINCDS P1NS32228A] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS032228, R01NS032228] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARCHARD JM, 1992, NEW ENGL J MED, V326, P893; ASHLEY R, 1992, ADV HOST DEFENSE MEC, V8, P201; ASHLEY RL, 1989, CLIN LAB MED, V9, P405, DOI 10.1016/S0272-2712(18)30611-5; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; AURELIUS E, 1993, J MED VIROL, V39, P179, DOI 10.1002/jmv.1890390302; AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BARINGER JR, 1974, NEW ENGL J MED, V291, P828, DOI 10.1056/NEJM197410172911606; BERGER JR, 1991, LANCET, V337, P1360, DOI 10.1016/0140-6736(91)93051-A; BERGSTROM T, 1990, J INFECT DIS, V162, P322, DOI 10.1093/infdis/162.2.322; BERGSTROM T, 1990, SCAND J INFECT DIS, V22, P239, DOI 10.3109/00365549009037909; BRUYN GW, 1962, NEUROLOGY, V12, P745, DOI 10.1212/WNL.12.11.745; COHEN BA, 1992, ANN NEUROL, V32, P295; DAVISON AJ, 1983, J GEN VIROL, V64, P1927, DOI 10.1099/0022-1317-64-9-1927; FREDERIKS JAM, 1978, HDB CLIN NEUROLOGY, V34, P545; GRAMAN PS, 1987, ARCH NEUROL-CHICAGO, V44, P1204, DOI 10.1001/archneur.1987.00520230084023; HERMANS PE, 1972, AM J MED, V52, P128, DOI 10.1016/0002-9343(72)90014-9; KAHLON J, 1987, J INFECT DIS, V155, P38, DOI 10.1093/infdis/155.1.38; KIMURA H, 1991, J INFECT DIS, V164, P289, DOI 10.1093/infdis/164.2.289; KLAPPER PE, 1990, J MED VIROL, V32, P261, DOI 10.1002/jmv.1890320413; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Mollaret MP, 1944, REV NEUROL-FRANCE, V76, P57; MOLLARET P, 1977, REV NEUROL, V133, P225; MOLLARET P, 1952, Bull Mem Soc Med Hop Paris, V68, P946; MOLLARET P, 1945, ANN I PASTEUR PARIS, V71, P1; PAL GS, 1987, BRIT MED J, V295, P367, DOI 10.1136/bmj.295.6594.367; PICARD FJ, 1993, NEUROLOGY, V43, P1722, DOI 10.1212/WNL.43.9.1722; PLUMMER G, 1973, J INFECT DIS, V128, P345, DOI 10.1093/infdis/128.3.345; PRICE RW, 1986, CRC CR REV CL NEUROB, V2, P61; PUCHHAMMERSTOCKL E, 1990, J MED VIROL, V32, P77, DOI 10.1002/jmv.1890320202; ROWLEY AH, 1990, LANCET, V335, P440, DOI 10.1016/0140-6736(90)90667-T; SKOLDENBERG B, 1975, SCAND J INFECT DIS, V7, P227, DOI 10.3109/inf.1975.7.issue-4.01; STALDER H, 1973, NEW ENGL J MED, V289, P1296, DOI 10.1056/NEJM197312132892409; STEEL JG, 1982, ANN NEUROL, V11, P17, DOI 10.1002/ana.410110104; STEVENS JG, 1989, MICROBIOL REV, V53, P318, DOI 10.1128/MMBR.53.3.318-332.1989; STRAUS SE, 1990, PRINCIPLES PRACTICE, P1139; TYLER KL, 1983, ARCH NEUROL-CHICAGO, V40, P42, DOI 10.1001/archneur.1983.04050010062017; VONHOFF DD, 1975, WESTERN J MED, V123, P490; WARREN KG, 1977, LANCET, V2, P637; WHITLEY RJ, 1990, NEW ENGL J MED, V323, P242, DOI 10.1056/NEJM199007263230406; WHITLEY RJ, 1991, INFECTIONS CENTRAL N, P41; YAMAMOTO LJ, 1991, NEW ENGL J MED, V325, P1082, DOI 10.1056/NEJM199110103251507	41	131	134	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					334	338		10.7326/0003-4819-121-5-199409010-00004	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042822				2022-12-28	WOS:A1994PD70100004
J	DUVERNOY, WFC; SMALL, DR				DUVERNOY, WFC; SMALL, DR			FLOPPY MITRAL-VALVE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											DUVERNOY, WFC (corresponding author), PROVIDENCE HOSP,SOUTHFIELD,MI 48075, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					443	443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	8035841				2022-12-28	WOS:A1994PB50100005
J	CAMPOSORTEGA, JA				CAMPOSORTEGA, JA			CELLULAR INTERACTIONS IN THE DEVELOPING NERVOUS-SYSTEM OF DROSOPHILA	CELL			English	Review							ACHAETE-SCUTE COMPLEX; LOOP-HELIX PROTEINS; OF-SPLIT COMPLEX; ORGAN FORMATION; ADJACENT GENES; MELANOGASTER; ENHANCER; NEUROGENESIS; ASENSE; REGION				CAMPOSORTEGA, JA (corresponding author), UNIV COLOGNE,INST ENTWICKLUNGSBIOL,D-50923 COLOGNE,GERMANY.							BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRAND M, 1993, DEVELOPMENT, V119, P1; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; DELIDAKIS C, 1992, P NATL ACAD SCI USA, V89, P8731, DOI 10.1073/pnas.89.18.8731; DELIDAKIS C, 1991, GENETICS, V129, P803; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; KNUST E, 1992, GENETICS, V132, P505; KRAMATSCHEK B, 1994, DEVELOPMENT, V120, P815; OELLERS N, 1994, IN PRESS MOL GEN GEN; PROKOP A, 1991, DEVELOPMENT, V111, P79; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RODRIGUEZ I, 1990, EMBO J, V9, P3583, DOI 10.1002/j.1460-2075.1990.tb07569.x; SCHRONS H, 1992, GENETICS, V132, P481; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606	24	21	21	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					969	975		10.1016/0092-8674(94)90437-5	http://dx.doi.org/10.1016/0092-8674(94)90437-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020103				2022-12-28	WOS:A1994NV42500006
J	CROWTHER, RA; KISELEV, NA; BOTTCHER, B; BERRIMAN, JA; BORISOVA, GP; OSE, V; PUMPENS, P				CROWTHER, RA; KISELEV, NA; BOTTCHER, B; BERRIMAN, JA; BORISOVA, GP; OSE, V; PUMPENS, P			3-DIMENSIONAL STRUCTURE OF HEPATITIS-B VIRUS CORE PARTICLES DETERMINED BY ELECTRON CRYOMICROSCOPY	CELL			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ANTIGENIC DETERMINANTS; CAPSID PARTICLES; MICROSCOPY; PROTEIN; SURFACE; RNA; EXPRESSION; MODEL	Human hepatitis B virus core protein expressed in E. coli assembles into two sizes of particle. We have determined their three-dimensional structures by electron cryomicroscopy and image processing. The large and small particles correspond to triangulation number T = 4 and T = 3 dimer clustered packings, containing 240 and 180 protein subunits, respectively. The local packing of subunits is very similar in the two sizes of particle and shows holes or channels through the shell. The native viral core particle packages RNA and is active in reverse transciption to DNA. The holes we observe may provide access for the necessary small molecules. Shells assembled from the intact core protein contain additional material, probably RNA, which appears as an icosahedrally ordered inner shell in the three-dimensional map.	RUSSIAN ACAD SCI,INST CRYSTALLOG,MOSCOW 117333,RUSSIA; UNIV LATVIA,CTR BIOMED RES & STUDY,RIGA 1065,LATVIA	Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; Latvian Biomedical Research & Study Centre; University of Latvia	CROWTHER, RA (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Pumpens, Paul/A-2163-2008; Bottcher, Bettina/E-9397-2010; Kiselev, Nikolay/H-2534-2014	Bottcher, Bettina/0000-0002-7962-4849; Kiselev, Nikolay/0000-0001-8130-8629	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041449] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41449] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1988, EMBO J, V7, P819, DOI 10.1002/j.1460-2075.1988.tb02880.x; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; BORISOVA G, 1993, J VIROL, V67, P3696, DOI 10.1128/JVI.67.6.3696-3701.1993; BORISOVA GP, 1984, DOKL AKAD NAUK SSSR+, V279, P1245; BORISOVA GP, 1988, DOKL AKAD NAUK SSSR+, V298, P1474; BORISOVA GP, 1989, FEBS LETT, V259, P121, DOI 10.1016/0014-5793(89)81509-1; CHENG RH, 1992, VIROLOGY, V186, P655, DOI 10.1016/0042-6822(92)90032-K; COHEN BJ, 1982, NATURE, V296, P677, DOI 10.1038/296677a0; CROWTHER RA, 1971, PHILOS T ROY SOC B, V261, P2211; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EDMAN JC, 1981, NATURE, V291, P503, DOI 10.1038/291503a0; GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989; HATTON T, 1992, J VIROL, V66, P5232, DOI 10.1128/JVI.66.9.5232-5241.1992; HULL R, 1987, J CELL SCI S, V7, P213; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; METCALF P, 1991, EMBO J, V10, P3129, DOI 10.1002/j.1460-2075.1991.tb04874.x; NASSAL M, 1992, J MOL BIOL, V225, P1013, DOI 10.1016/0022-2836(92)90101-O; Nassal M, 1993, Trends Microbiol, V1, P221, DOI 10.1016/0966-842X(93)90136-F; NASSAL M, 1993, HEPATITS B VIRUS NUC, P41; ONODERA S, 1982, J MED VIROL, V10, P147, DOI 10.1002/jmv.1890100209; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; PRASAD BVV, 1992, J VIROL, V66, P2135, DOI 10.1128/JVI.66.4.2135-2142.1992; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; SALFELD J, 1989, J VIROL, V63, P798, DOI 10.1128/JVI.63.2.798-808.1989; ULRICH R, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P323; VIGERS GPA, 1986, THESIS U CAMBRIDGE; ZHENG J, 1992, J BIOL CHEM, V267, P9422; ZHOU S, 1992, P NATL ACAD SCI USA, V89, P10046, DOI 10.1073/pnas.89.21.10046	28	416	451	4	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					943	950		10.1016/0092-8674(94)90142-2	http://dx.doi.org/10.1016/0092-8674(94)90142-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004680				2022-12-28	WOS:A1994NT33100018
J	LOCKWOOD, DNJ; PASVOL, G				LOCKWOOD, DNJ; PASVOL, G			RECENT ADVANCES IN TROPICAL MEDICINE	BRITISH MEDICAL JOURNAL			English	Article							MYCOBACTERIUM-LEPRAE; VISCERAL LEISHMANIASIS; LEPROSY CONTROL; HIV-INFECTION; BCG VACCINE; ONCHOCERCIASIS; TUBERCULOSIS; ANTIGENS; MALARIA; RESISTANCE				LOCKWOOD, DNJ (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,HARROW HA1 3UJ,MIDDX,ENGLAND.							ABIOSE A, 1993, LANCET, V341, P130, DOI 10.1016/0140-6736(93)90002-X; ALVAR J, 1994, PARASITOL TODAY, V10, P160, DOI 10.1016/0169-4758(94)90270-4; BEADLE C, 1994, LANCET, V343, P564, DOI 10.1016/S0140-6736(94)91520-2; BECXBLEUMINK M, 1992, INT J LEPROSY, V60, P173; BRADLEY JE, 1993, AM J TROP MED HYG, V48, P198, DOI 10.4269/ajtmh.1993.48.198; BRADLEY JE, 1993, PARASITOLOGY, V106, P363, DOI 10.1017/S003118200006710X; BRITTON WJ, 1993, T ROY SOC TROP MED H, V87, P508, DOI 10.1016/0035-9203(93)90066-Y; CONVIT J, 1992, LANCET, V339, P446, DOI 10.1016/0140-6736(92)91056-E; DAFAALLA TH, 1992, CLIN EXP IMMUNOL, V88, P258, DOI 10.1111/j.1365-2249.1992.tb03070.x; DAVIDSON RN, 1994, Q J MED, V87, P75; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DECOCK KM, 1994, TUBERCULOSIS BACK FU, P35; EIGLMEIER K, 1993, MOL MICROBIOL, V7, P197, DOI 10.1111/j.1365-2958.1993.tb01111.x; ELSON LH, 1994, J INFECT DIS, V169, P588, DOI 10.1093/infdis/169.3.588; FEENSTR P, 1993, LEPROSY REV, V64, P89; GILKS CF, 1993, LANCET, V342, P1037, DOI 10.1016/0140-6736(93)92885-W; GILKS CF, 1992, Q J MED, V82, P25; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; HONORE N, 1993, ANTIMICROB AGENTS CH, V37, P414, DOI 10.1128/AAC.37.3.414; HOWARD MK, 1992, T ROY SOC TROP MED H, V86, P35, DOI 10.1016/0035-9203(92)90430-K; KHANOLKARYOUNG S, 1994, CLIN EXP IMMUNOL, V96, P208, DOI 10.1111/j.1365-2249.1994.tb06543.x; LIENHARDT C, 1994, LEPROSY REV, V65, P9; Lockwood D. N. J., 1991, Lancet (British edition), V338, P624, DOI 10.1016/0140-6736(91)90623-W; LOCKWOOD DNJ, 1993, INDIA INT J LUPR, V60, P8; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MABEY D, 1993, LANCET, V341, P153, DOI 10.1016/0140-6736(93)90011-5; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; MILLER RL, 1994, T ROY SOC TROP MED H, V88, P31, DOI 10.1016/0035-9203(94)90484-7; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; OKONGOODERA EA, 1993, T ROY SOC TROP MED H, V87, P423, DOI 10.1016/0035-9203(93)90023-J; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; RAMACHANDRAN CP, 1993, PARASITOL TODAY, V9, P76; SINGLA N, 1993, T ROY SOC TROP MED H, V87, P276, DOI 10.1016/0035-9203(93)90125-A; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V58, P283, DOI 10.1016/0166-6851(93)90050-8; SWOFT CJ, 1993, T ROY SOC TROP MED H, V87, P646; TAYLOR TE, 1993, LANCET, V341, P661, DOI 10.1016/0140-6736(93)90423-E; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W; WHITE NJ, 1992, LANCET, V339, P317, DOI 10.1016/0140-6736(92)91644-N; WIN K, 1992, B WORLD HEALTH ORGAN, V70, P777; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582; ZILJSTRA EE, 1992, T ROY SOC TROP MED H, V86, P505; ZIMMERMAN PA, 1994, J INFECT DIS, V169, P686, DOI 10.1093/infdis/169.3.686	44	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1559	1562		10.1136/bmj.308.6943.1559	http://dx.doi.org/10.1136/bmj.308.6943.1559			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019318	Green Published			2022-12-28	WOS:A1994NR11000033
J	PIETRONI, PC; DEURAYURA, S				PIETRONI, PC; DEURAYURA, S			INFORMAL COMPLAINTS PROCEDURE IN GENERAL-PRACTICE - FIRST YEARS EXPERIENCE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To evaluate the first year's experience of an informal patient complaints system that encourages extensive patient participation. Design-Audit of an informal complaints procedure. Setting-The Marylebone Health Centre, London. Subjects-39 complaints received over the audit period. Main outcome measures-Types of complaints (administrative, about doctors or medical care or both, staff about patients, mixed, other) and resolution of complaints (how complaints were dealt with and their resolution). Results-37 of the 39 complaints were resolved within two weeks. Two complaints sent direct to the family health services authority were resolved (with patients' agreement) by the informal complaints procedure. Conclusions-The informal complaints procedure was more cost effective than the family health services authority system and was comparatively straightforward to implement within the practice without major organisational restructuring. The two way process of the procedure ensured patients received a quick response to complaints and helped morale of health centre staff.	MARYLEBONE HLTH CTR,LONDON NW1 5LT,ENGLAND									CHASE HD, 1991, BRIT J GEN PRACT, V41, P63; OWEN C, 1991, BRIT J GEN PRACT, V41, P113; PANTING G, 1993, MED PROTECTION SOC C, V2, P6; PIETRONI P, 1993, BRIT J GEN PRACT, V43, P341; STUTTE P, 1993, WHAT COMPLAINTS SURV; 1993, E LONDON GP SERVICES; 1993, COPING PATIENT COMPL, P2; 1993, CONNECTION       AUG, P3; 1993, EVIDENCE NHS COMPLAI; 1993, HLTH SERVICE INDICAT	10	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1546	1549		10.1136/bmj.308.6943.1546	http://dx.doi.org/10.1136/bmj.308.6943.1546			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019313	Green Published			2022-12-28	WOS:A1994NR11000027
J	HARDY, LM; HAYNES, BF; VOLBERDING, PA				HARDY, LM; HAYNES, BF; VOLBERDING, PA			GENE-THERAPY FOR HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									DUKE UNIV,SCH MED,ROUNDTABLE DEV DRUGS & VACCINES AGAINST AIDS,DURHAM,NC 27706; SAN FRANCISCO GEN HOSP,AIDS PROGRAM & CLIN ONCOL,SAN FRANCISCO,CA 94110	Duke University; San Francisco General Hospital Medical Center									0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					423	423						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040965				2022-12-28	WOS:A1994PA27800005
J	CALLAHAN, TL; HALL, JE; ETTNER, SL; CHRISTIANSEN, CL; GREENE, MF; CROWLEY, WF				CALLAHAN, TL; HALL, JE; ETTNER, SL; CHRISTIANSEN, CL; GREENE, MF; CROWLEY, WF			THE ECONOMIC-IMPACT OF MULTIPLE-GESTATION PREGNANCIES AND THE CONTRIBUTION OF ASSISTED-REPRODUCTION TECHNIQUES TO THEIR INCIDENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVITRO FERTILIZATION; INTRAFALLOPIAN TRANSFER; INFANT-MORTALITY; UNITED-STATES; BIRTH-WEIGHT; MANAGEMENT; PREVENTION; OVULATION; TRIPLETS; TWINS	Background. Although the medical complications associated with multiple-gestation pregnancies have been well documented, little is known about the effects of such pregnancies on the use of health care resources and the associated costs. This is an important issue because of the increasing use of assisted-reproduction techniques, which commonly result in multiple-gestation pregnancies. Methods. We determined hospital charges and the use of assisted-reproduction techniques (such as induction of ovulation, in vitro fertilization, and gamete intrafallopian transfer) for 13,206 pregnant women (11,986 with singleton pregnancies, 1135 with twin pregnancies, and 85 with more than two fetuses) who were admitted for delivery to Brigham and Women's Hospital, Boston, in 1986 through 1991 and their 14,033 neonates (11,671 singletons, 2144 twins, and 218 resulting from higher-order multiple gestations). Results. After we controlled for variables known to affect hospital charges, the predicted total charges to the family in 1991 for a singleton delivery were $9,845, as compared with $37,947 for twins ($18,974 per baby) and $109,765 for triplets ($36,588 per baby). Assisted-reproduction techniques were used in 2 percent of singleton, 35 percent of twin, and 77 percent of higher-order multiple-gestation pregnancies; such procedures were approximately equally divided between induction of ovulation alone and in vitro fertilization or gamete intrafallopian transfer. Conclusions. Multiple-gestation pregnancies, a high proportion of which result from the use of assisted-reproduction techniques, dramatically increase hospital charges. If all the multiple gestations resulting from assisted-reproduction techniques had been singleton pregnancies, the predicted savings to the health care delivery system in the study hospital alone would have been over $3 million per year. Although assisted reproduction provides tremendous benefits to families with infertility, the increased medical risks entailed by multiple-gestation pregnancies and the associated costs cannot be ignored. We suggest that more attention be paid to approaches to infertility that reduce the likelihood of multiple gestation.	MASSACHUSETTS GEN HOSP,NATL CTR INFERTIL RES,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT OBSTET GYNECOL,BOSTON,MA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Hall, Janet E/F-3516-2019	Hall, Janet E/0000-0003-4644-3061; Christiansen, Cindy/0000-0001-9951-480X	NCRR NIH HHS [MO1-RR-01066] Funding Source: Medline; NICHD NIH HHS [U54-HD-29164] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029164] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERKI SE, 1987, PEDIATRICS, V79, P874; BERKOWITZ RL, 1993, AM J OBSTET GYNECOL, V169, P17, DOI 10.1016/0002-9378(93)90124-2; BOLLEN N, 1991, FERTIL STERIL, V55, P314; BOTTING BJ, 1987, ARCH DIS CHILD, V62, P941, DOI 10.1136/adc.62.9.941; CORSON SL, 1989, FERTIL STERIL, V51, P644; DEMUYLDER X, 1982, ACTA GENET MED GEMEL, V31, P149, DOI 10.1017/S0001566000008230; DUAN N, 1983, J AM STAT ASSOC, V78, P605, DOI 10.2307/2288126; ELSTER AD, 1991, OBSTET GYNECOL, V77, P387; Ewald U, 1991, Int J Technol Assess Health Care, V7 Suppl 1, P155; FAUSER BCJM, 1993, BAILLIERE CLIN OB GY, V7, P309, DOI 10.1016/S0950-3552(05)80133-6; Gennaro S, 1992, Image J Nurs Sch, V24, P191; GILSTRAP LC, 1988, CLIN PERINATOL, V15, P71, DOI 10.1016/S0095-5108(18)30725-5; GRUTZNERKONNECKE H, 1990, ACTA GENET MED GEMEL, V39, P491, DOI 10.1017/S000156600000372X; GUTTMACHER AF, 1953, OBSTET GYNECOL, V2, P22; HARRIS J, 1979, BELL J ECON, V1, P224; HECHT BR, 1993, ASSIST REPROD REV, V3, P75; HOWIE PW, 1988, BMJ-BRIT MED J, V297, P433, DOI 10.1136/bmj.297.6646.433; JACKSONBEECK M, 1983, JAMA-J AM MED ASSOC, V250, P2826, DOI 10.1001/jama.250.20.2826; KETTERLINUS RD, 1990, J ADOLESCENT HEALTH, V11, P423, DOI 10.1016/0197-0070(90)90090-O; KIELY JL, 1992, AM J DIS CHILD, V146, P862, DOI 10.1001/archpedi.1992.02160190094029; LEROY F, 1990, ACTA GENET MED GEMEL, V39, P371, DOI 10.1017/S0001566000005298; LEVENE MI, 1992, BRIT J OBSTET GYNAEC, V99, P607, DOI 10.1111/j.1471-0528.1992.tb13831.x; LIPITZ S, 1989, AM J OBSTET GYNECOL, V161, P1279, DOI 10.1016/0002-9378(89)90683-2; LIPITZ S, 1990, OBSTET GYNECOL, V76, P215; LUKE B, 1992, J REPROD MED, V37, P661; MACLENNAN AH, 1990, LANCET, V335, P267, DOI 10.1016/0140-6736(90)90079-K; MALMSTROM PM, 1990, ACTA GENET MED GEMEL, V39, P507, DOI 10.1017/S0001566000003755; MARTIN KA, 1993, J CLIN ENDOCR METAB, V77, P125, DOI 10.1210/jc.77.1.125; MCCARTHY BJ, 1981, AM J OBSTET GYNECOL, V141, P252; NEWMAN RB, 1989, AM J OBSTET GYNECOL, V161, P547, DOI 10.1016/0002-9378(89)90354-2; NIJS M, 1993, FERTIL STERIL, V59, P1245; POLSON DW, 1987, CLIN ENDOCRINOL, V26, P205, DOI 10.1111/j.1365-2265.1987.tb00778.x; REIN MS, 1990, INT J FERTIL, V35, P154; RESNICK MB, 1986, PEDIATRICS, V78, P820; SCHENKER JG, 1981, FERTIL STERIL, V35, P105; WAPNER RJ, 1990, LANCET, V335, P90, DOI 10.1016/0140-6736(90)90550-O; WEEKES ARL, 1977, BRIT J OBSTET GYNAEC, V84, P161, DOI 10.1111/j.1471-0528.1977.tb12549.x; 1990, BRIT MED J, V300, P1229; 1993, FERTIL STERIL, V59, P956; 1988, INFERTILITY MED SOCI	40	328	332	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					244	249		10.1056/NEJM199407283310407	http://dx.doi.org/10.1056/NEJM199407283310407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NY335	8015572	Bronze			2022-12-28	WOS:A1994NY33500007
J	BRODY, DJ; PIRKLE, JL; KRAMER, RA; FLEGAL, KM; MATTE, TD; GUNTER, EW; PASCHAL, DC				BRODY, DJ; PIRKLE, JL; KRAMER, RA; FLEGAL, KM; MATTE, TD; GUNTER, EW; PASCHAL, DC			BLOOD LEAD LEVELS IN THE US POPULATION - PHASE-1 OF THE 3RD NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES-III, 1988 TO 1991)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; EXPOSURE; CHILDREN; IMPAIRMENT; TOXICOLOGY	Objective.-To determine mean blood lead levels and their sociodemographic correlates in the US population. Design.-Nationally representative cross-sectional health examination survey that included measurements of venous blood lead. Participants.-A total of 13 201 persons aged 1 year and older examined during phase 1 of the third National Health and Nutrition Examination Survey (1988 to 1991). Results.-The overall mean blood lead level for the US population was 0.14 mu mol/L (2.8 mu g/dL). Blood lead levels were consistently higher for younger children than for older children, for older adults than for younger adults, for males than for females, for blacks than for whites, and for central-city residents than for non-central-city residents. Other correlates of higher blood lead levels included low income, low educational attainment, and residence in the Northeast region of the United States, National estimates for children 1 to 5 years of age indicate that 8.9%, or approximately 1.7 million children, have blood lead levels 0.48 mu mol/L (10 mu g/dL) or greater. These levels are high enough to be of health concern under 1991 Centers for Disease Control and Prevention guidelines. Conclusions.-The low overall mean blood lead levels demonstrate a major public health success in primary prevention efforts. However, exposure to lead at levels that may adversely affect the health of children remains a problem especially for those who are minority, urban, and from low-income families. Strategies to identify the most vulnerable risk groups are necessary to further reduce lead exposure in the United States.	CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,LEAD POISONING PREVENT BRANCH,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	BRODY, DJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,6525 BELCREST RD,ROOM 900,HYATTSVILLE,MD 20782, USA.		Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X				[Anonymous], 1988, NATURE EXTENT LEAD P; [Anonymous], 1991, PREVENTING LEAD POIS; BELLINGER DC, 1992, PEDIATRICS, V90, P855; BINDER S, 1991, STRATEGIC PLAN ELIMI; BINNS HJ, 1994, PEDIATRICS, V93, P164; CARTERPOKRAS O, 1990, PUBLIC HEALTH REP, V105, P388; DAVIS JM, 1987, NATURE, V329, P298; DIETRICH KN, 1993, PEDIATRICS, V91, P301; DIETRICH KN, 1993, NEUROTOXICOL TERATOL, V15, P37, DOI 10.1016/0892-0362(93)90043-N; EZZATI TM, 1992, VITAL HLTH STAT 2, V113; FLEGAL KM, 1991, DIABETES CARE, V14, P628, DOI 10.2337/diacare.14.7.628; GELLERT GA, 1993, JAMA-J AM MED ASSOC, V270, P69, DOI 10.1001/jama.270.1.69; GUNTER EW, 1986, HHANES1982 1984 CTR; HUNTER JM, 1977, SOC SCI MED, V11, P691, DOI 10.1016/0037-7856(77)90155-X; Johnson B L, 1993, Ann Epidemiol, V3, P175; LANDRIGAN PJ, 1990, ENVIRON HEALTH PERSP, V89, P61, DOI 10.2307/3430898; MAHAFFEY KR, 1982, NEW ENGL J MED, V307, P573, DOI 10.1056/NEJM198209023071001; MARINO PE, 1990, AM J PUBLIC HEALTH, V80, P1183, DOI 10.2105/AJPH.80.10.1183; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; MUSHAK P, 1989, ENVIRON RES, V50, P11, DOI 10.1016/S0013-9351(89)80046-5; NEEDLEMAN HL, 1981, ANNU REV PUBL HEALTH, V2, P277, DOI 10.1146/annurev.pu.02.050181.001425; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; RIFAI N, 1993, THER DRUG MONIT, V15, P71, DOI 10.1097/00007691-199304000-00001; SCHAFFER SJ, 1994, PEDIATRICS, V93, P159; SCHWARTZ J, 1991, ARCH ENVIRON HEALTH, V46, P300, DOI 10.1080/00039896.1991.9934391; SCHWARTZ J, 1986, PEDIATRICS, V77, P281; SCHWARTZ J, 1987, ARCH ENVIRON HEALTH, V42, P153, DOI 10.1080/00039896.1987.9935814; Sempos CT., 1991, MONITORING DIETARY I, P99; SHAH BV, 1991, SUDAAN USERS MANUAL; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; SILBERGELD EK, 1990, ENVIRON HEALTH PERSP, V89, P49, DOI 10.2307/3430896; SILBERGELD EK, 1992, FASEB J, V6, P3201, DOI 10.1096/fasebj.6.13.1397842; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; TEJEDA DM, 1994, PEDIATRICS, V93, P192; WEITZMAN M, 1993, JAMA-J AM MED ASSOC, V269, P1647, DOI 10.1001/jama.269.13.1647; 1988, CURRENT POPULATI P60, V163; 1993, MMWR-MORBID MORTAL W, V42, P522; 1987, ANN HIST REV FNS PRO; 1990, SAS LANGUAGE REFEREN; 1992, MMWR-MORBID MORTAL W, V41, P715; 1989, CURRENT POPULATI P60, V171; 1991, CURRENT POPULATI P60, V175	43	463	474	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					277	283		10.1001/jama.272.4.277	http://dx.doi.org/10.1001/jama.272.4.277			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NX806	8028140				2022-12-28	WOS:A1994NX80600029
J	BAKKEN, JS; DUMLER, JS; CHEN, SM; ECKMAN, MR; VANETTA, LL; WALKER, DH				BAKKEN, JS; DUMLER, JS; CHEN, SM; ECKMAN, MR; VANETTA, LL; WALKER, DH			HUMAN GRANULOCYTIC EHRLICHIOSIS IN THE UPPER MIDWEST UNITED-STATES - A NEW SPECIES EMERGING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ETIOLOGIC AGENT; CANIS; CHAFFEENSIS; INFECTION; SUSCEPTIBILITY; DIAGNOSIS; SENNETSU; PATIENT; DOGS; EQUI	Objective.-To characterize the clinical presentation and course, laboratory findings, and treatment outcome of 12 patients with human granulocytic ehrlichiosis. Setting.-The 12 patients were male, ranged in age from 29 to 91 years, and contracted their illness in Wisconsin or Minnesota. Methods.-Cases were recognized by the presence of intracytoplasmic inclusions (morulae) in peripheral neutrophils of patients presenting with temperature of 38.5 degrees C or higher, chills, severe headache, and myalgias. All patients had a complete blood cell count and blood chemistry profile. Blood smears were examined by light microscopy. All available paired serum samples were analyzed for presence of indirect fluorescent antibodies against Ehrlichia chaffeensis, Ehrlichia phagocytophila, and Ehrlichia equi Blood samples from 12 patients were subjected to polymerase chain reaction analysis using primers specific for the E phagocytophilal E equi group, primers that include the agent identified in our patients, as well as E chaffeensis. Results.-Varying combinations of leukopenia, anemia, and thrombocytopenia were found in all but one patient. All 12 patients demonstrated morulae in the cytoplasm of neutrophils, but not in mononuclear white blood cells. Serum assays failed to detect antibodies against E chaffeensis, but eight of 10 patients and seven of 10 patients tested had antibody titers of 1:80 or more for E phagocytophila and E equi, respectively. Polymerase chain reaction products obtained with primers for E phagocytophila, E equi, and the granulocytotropic Ehrlichia revealed that seven patients were infected with the same agent. The results of serological assays or polymerase chain reaction strongly suggest that all 12 patients were infected by E phagocytophila, E equi, or a closely related Ehrlichia species. Two of the 12 patients died. The other 10 patients improved rapidly with oral doxycycline treatment. Conclusions.-We believe that all 12 patients have been infected with a granulocytic Ehrlichia species, reflecting a recently described new disease entity. The infective organism appears to be closely related to E phagocytophila and E equi. The geographic domain of human granulocytic ehrlichiosis is currently unknown. This novel granulocytic Ehrlichia species is capable of causing fatal infections in humans. Early detection and treatment with tetracycline drugs appear to offer the best chance for complete recovery.	UNIV MARYLAND, DEPT PATHOL, BALTIMORE, MD 21201 USA; UNIV TEXAS, MED BRANCH, DEPT PATHOL, GALVESTON, TX 77550 USA	University System of Maryland; University of Maryland Baltimore; University of Texas System; University of Texas Medical Branch Galveston	BAKKEN, JS (corresponding author), DULUTH CLIN LTD, INFECT DIS SECT, 400 E 3RD ST, DULUTH, MN 55805 USA.				PHS HHS [R01A131431-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON BE, 1992, J CLIN MICROBIOL, V30, P775, DOI 10.1128/JCM.30.4.775-780.1992; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; ARONSON J, 1990, ANN NY ACAD SCI, V590, P148, DOI 10.1111/j.1749-6632.1990.tb42217.x; BROUQUI P, 1992, ANTIMICROB AGENTS CH, V36, P2799, DOI 10.1128/AAC.36.12.2799; BROUQUI P, 1992, J CLIN MICROBIOL, V30, P1062, DOI 10.1128/JCM.30.5.1062-1066.1992; BROUQUI P, 1990, ANTIMICROB AGENTS CH, V34, P1593, DOI 10.1128/AAC.34.8.1593; CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994; CHEN SM, 1994, AM J TROP MED HYG, V50, P52, DOI 10.4269/ajtmh.1994.50.1.TM0500010052; DAWSON JE, 1990, J INFECT DIS, V162, P91, DOI 10.1093/infdis/162.1.91; DAWSON JE, 1991, J INFECT DIS, V163, P564, DOI 10.1093/infdis/163.3.564; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DONATIEN A., 1935, Bulletin de la Societe de Pathologie Exotique, V28, P418; DUMLER JS, 1993, HUM PATHOL, V24, P391; DUMLER JS, 1991, NEW ENGL J MED, V325, P1109, DOI 10.1056/NEJM199110103251517; DUMLER JS, 1993, CLIN INFECT DIS, V17, P903, DOI 10.1093/clinids/17.5.903; DUMLER JS, 1993, 93RD GEN M AM SOC MI; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; FRENCH JB, 1992, J MED ENTOMOL, V29, P723, DOI 10.1093/jmedent/29.5.723; Fukuda T., 1954, MED BIOL, V32, P200; GILSON I, 1991, WIS MED J, V5, P219; GOLDMAN DP, 1992, AM FAM PHYSICIAN, V46, P199; HAHN JD, 1992, AGFO1013C U MINN DEP; Harkess J R, 1991, Infect Dis Clin North Am, V5, P37; KEEFE TJ, 1982, J AM VET MED ASSOC, V181, P236; LEWIS GE, 1976, VET PARASITOL, V2, P61, DOI 10.1016/0304-4017(76)90053-4; LEWIS GE, 1975, AM J VET RES, V36, P85; MADIGAN JE, 1990, J AM VET MED ASSOC, V196, P1962; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MARTY AM, IN PRESS HUM PATHOL; PADDOCK CD, 1993, NEW ENGL J MED, V329, P1164, DOI 10.1056/NEJM199310143291605; RIKIHISA Y, 1991, CLIN MICROBIOL REV, V4, P286, DOI 10.1128/CMR.4.3.286-308.1991; STUEN S, 1992, RES VET SCI, V52, P211, DOI 10.1016/0034-5288(92)90012-Q; WILSON KH, 1990, J CLIN MICROBIOL, V28, P1942, DOI 10.1128/JCM.28.9.1942-1946.1990; 1990, MMWR MROB MORTAL WKL, V39, P281	35	458	483	2	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					212	218		10.1001/jama.272.3.212	http://dx.doi.org/10.1001/jama.272.3.212			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022040				2022-12-28	WOS:A1994NW18500022
J	MILLER, M; HUTCHINS, GM				MILLER, M; HUTCHINS, GM			HEMOCHROMATOSIS, MULTIORGAN HEMOSIDEROSIS, AND CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							LOW-DENSITY-LIPOPROTEIN; ISCHEMIC-HEART-DISEASE; IRON; RISK; AUTOPSY	Objective.-To examine the prevalence of coronary artery disease (CAD) in autopsies of patients with iron-overload syndromes. Design.-Retrospective autopsy study of CAD in cases of hemochromatosis and multiorgan hemosiderosis. Setting.-Registry of nearly 48 000 autopsies performed at The Johns Hopkins Hospital between 1889 and 1992. Subjects.-One hundred twenty-three subjects were studied. In a 2:1 control-case ratio, 82 controls matched by age, race, and sex were compared with 41 cases with iron overload. Main Outcome Measure.-Severity of CAD. Results.-Pathological description of the coronary arteries were recorded as advanced or severe in 12% of iron-overload cases (n=41) (mean age, 57.6+/-13.2 years) compared with 38% of controls (n=82) (mean age, 57.0+/-13.8 years) (P=.01). The prevalence of three-vessel disease assessed by postmortem coronary arteriography was 11.1% in iron-overload cases (n=18) (mean age, 61.7+/-12.2 years) compared with 33.3% in controls (n=36) (mean age, 61.1+/-12.5 years) (P=.04). The odds ratio of CAD with iron overload was 0.18 (95% confidence interval, 0.04 to 0.73). Conclusions.-Iron overload resulting from hemochromatosis or multiorgan hemosiderosis is not associated with an increased prevalence of CAD.	UNIV MARYLAND,MED SYST,DIV CARDIOL,BALTIMORE,MD 21201; JOHNS HOPKINS MED INST,DEPT PATHOL,DIV AUTOPSY PATHOL,BALTIMORE,MD 21205	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine			Miller, Michael/AGX-6773-2022	Miller, Michael/0000-0002-1679-2095	NHLBI NIH HHS [KO7-HL-02263-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL002263] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCHERIO A, 1994, CIRCULATION, V89, P969, DOI 10.1161/01.CIR.89.3.969; CUTLER DJ, 1980, AM J MED, V69, P923, DOI 10.1016/S0002-9343(80)80020-9; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; GOLDSTEIN JL, 1982, MED CLIN N AM, V66, P335, DOI 10.1016/S0025-7125(16)31424-9; Hennekens CH., 1987, EPIDEMIOLOGY MED CHA, P54; HUTCHINS GM, 1973, JOHNS HOPKINS MED J, V133, P96; KUZUYA M, 1990, BIOCHEM INT, V22, P567; MACDONALD RA, 1960, ARCH INTERN MED, V105, P686, DOI 10.1001/archinte.1960.00270170024004; MCCORD JM, 1991, CIRCULATION, V83, P1112, DOI 10.1161/01.CIR.83.3.1112; MCINTOSH HD, 1991, ERA CARDIOVASCULAR M, P316; MOORE GW, 1984, AM J PATHOL, V115, P36; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SEMPOS CT, 1994, NEW ENGL J MED, V330, P1119, DOI 10.1056/NEJM199404213301604; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9; SULLIVAN JL, 1981, LANCET, V1, P1293; VONRECKLINGHAUS.F, 1889, HEIDELBERG J, V52, P324	17	70	72	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					231	233		10.1001/jama.272.3.231	http://dx.doi.org/10.1001/jama.272.3.231			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022042				2022-12-28	WOS:A1994NW18500025
J	ALTMAN, DG; BLAND, JM				ALTMAN, DG; BLAND, JM			DIAGNOSTIC-TESTS-2 - PREDICTIVE VALUES .4.	BRITISH MEDICAL JOURNAL			English	Note									UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	St Georges University London	ALTMAN, DG (corresponding author), IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND.							ALTMAN DG, 1994, BMJ	1	1162	1194	4	36	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					102	102		10.1136/bmj.309.6947.102	http://dx.doi.org/10.1136/bmj.309.6947.102			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038641	Green Published, Bronze			2022-12-28	WOS:A1994NW71600025
J	HASSAN, W; OLDHAM, R				HASSAN, W; OLDHAM, R			REITERS-SYNDROME AND REACTIVE ARTHRITIS IN HEALTH-CARE WORKERS AFTER VACCINATION	BRITISH MEDICAL JOURNAL			English	Article							HEPATITIS-B VACCINATION				HASSAN, W (corresponding author), LEICESTER ROYAL INFIRM,DEPT RHEUMATOL,LEICESTER LE1 5WW,ENGLAND.							BIASI D, 1993, CLIN EXP RHEUMATOL, V11, P215; HACHULLA E, 1990, J RHEUMATOL, V17, P1250; ROGERSON SJ, 1990, BRIT MED J, V301, P345, DOI 10.1136/bmj.301.6747.345; SVENUNGSSON B, 1994, BRIT MED J, V308, P671, DOI 10.1136/bmj.308.6930.671; 1992, IMMUNISATION INFECTI, P110	5	25	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					94	94		10.1136/bmj.309.6947.94	http://dx.doi.org/10.1136/bmj.309.6947.94			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038674	Green Published			2022-12-28	WOS:A1994NW71600017
J	MURPHY, D; LYNCH, M; MULCAHY, F				MURPHY, D; LYNCH, M; MULCAHY, F			ZIDOVUDINE RELATED ARTHROPATHY	BRITISH MEDICAL JOURNAL			English	Letter											MURPHY, D (corresponding author), ST JAMES HOSP,DUBLIN 8,IRELAND.			Murphy, Deirdre/0000-0001-6074-6718				GELMON K, 1989, AIDS, V3, P555, DOI 10.1097/00002030-198909000-00001; MOORE RD, 1991, ARCH INTERN MED, V151, P981, DOI 10.1001/archinte.151.5.981	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					97	97		10.1136/bmj.309.6947.97	http://dx.doi.org/10.1136/bmj.309.6947.97			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038679	Green Published			2022-12-28	WOS:A1994NW71600021
J	TARDIFF, K; MARZUK, PM; LEON, AC; HIRSCH, CS; STAJIC, M; PORTERA, L; HARTWELL, N				TARDIFF, K; MARZUK, PM; LEON, AC; HIRSCH, CS; STAJIC, M; PORTERA, L; HARTWELL, N			HOMICIDE IN NEW-YORK-CITY - COCAINE USE AND FIREARMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-EXCRETION; UNITED-STATES; RECENT TRENDS; VIOLENCE; HANDGUNS; COUNTY; DEATH; ABUSE; BENZOYLECGONINE; COMPLICATIONS	Objective.-To determine differences between racial/ethnic groups in overall rates of death by homicide, proportion of firearm homicides, and the use of cocaine prior to death. Design.-Descriptive epidemiologic survey of a complete 2-year sample of homicides. Setting.-New York City, NY (population 7 322 564). Subjects.-All residents (N=4298) of New York City who were victims of homicide during 1990 and 1991. Main Outcome Measures.-Using medical examiner data, age- and gender-specific rates of homicide were calculated for African Americans, Latinos, and whites. Separate logistic regression analyses were conducted to examine the association between demographic variables and both recent cocaine use and firearm-related homicides. Results.-Young African-American and Latino men were more likely to be victims of homicide than all other demographic groups. Approximately three fourths of all homicides involved firearms. In the subset of homicide victims dying within 48 hours (n=3890), 31.0% were positive for cocaine metabolites. African Americans (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.2 to 2.1), Latinos (OR, 1.4; 95% CI, 1.1 to 1.9), and victims 25 through 34 years of age (OR, 2.9; 95% CI, 2.5 to 3.5) and 35 through 44 years of age (OR, 2.7; 95% CI, 2.2 to 3.4) were more likely to be positive for cocaine metabolites than other groups. Young males and females were equally likely to have used cocaine before death. Victims 15 through 24 years of age were more likely than other age groups to be killed by a firearm. African Americans (OR, 1.7; 95% CI, 1.3 to 2.3), Latinos (OR, 1.5; 95% CI, 1.2 to 2.0), and Asians (OR, 2.2; 95% CI, 1.4 to 3.6) were more likely than whites to be killed by a firearm. Men (OR, 4.8; 95% CI, 4.0 to 5.9) were more likely than women to be killed by a firearm. There was no association between having used cocaine before death and being killed by a firearm. Conclusions.-The high rates of death by homicide among young African Americans and Latinos may be due to the increased involvement with both cocaine use and firearms. New efforts must be made to decrease cocaine use and firearm availability.	CORNELL UNIV, COLL MED, DEPT PUBL HLTH, NEW YORK, NY USA; OFF CHIEF MED EXAMINER, NEW YORK, NY USA; NYU, SCH MED, DEPT FORENS MED, NEW YORK, NY USA	Cornell University; New York University	TARDIFF, K (corresponding author), CORNELL UNIV, COLL MED,DEPT PSYCHIAT,EPIDEMIOL SECT, 525 E 68TH ST, BOX 147, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-06534] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMBRE J, 1988, J ANAL TOXICOL, V12, P301, DOI 10.1093/jat/12.6.301; AMBRE J, 1985, J ANAL TOXICOL, V9, P241, DOI 10.1093/jat/9.6.241; BAILEY DN, 1989, J FORENSIC SCI, V34, P407; BASELT RC, 1974, DISPOSITION TOXIC DR; BUDD RD, 1989, AM J DRUG ALCOHOL AB, V15, P375, DOI 10.3109/00952998908992798; CALLAHAN CM, 1992, JAMA-J AM MED ASSOC, V267, P3038, DOI 10.1001/jama.267.22.3038; CENTERWALL BS, 1991, AM J EPIDEMIOL, V134, P1245, DOI 10.1093/oxfordjournals.aje.a116027; CENTERWALL BS, 1984, AM J PUBLIC HEALTH, V74, P813, DOI 10.2105/AJPH.74.8.813; Collins JJ, 1985, CRIMINOLOGY, V23, P743, DOI 10.1111/j.1745-9125.1985.tb00372.x; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; Fagan J, 1990, NIDA Res Monogr, V103, P8; FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; FINGERHUT LA, 1990, JAMA-J AM MED ASSOC, V263, P3292, DOI 10.1001/jama.263.24.3292; Gerstein D. R., 1993, PREVENTING DRUG ABUS; Goldstein P.J., 1989, CONTEMP DRUG PROBL, V16, P651; GOLDSTEIN PJ, 1991, J DRUG ISSUES, V21, P345, DOI 10.1177/002204269102100207; GOLDSTEIN PJ, 1985, J DRUG ISSUES, V15, P493, DOI 10.1177/002204268501500406; Goldstein PJ, 1979, PROSTITUTION DRUGS; GRIFFITH EEH, 1989, JAMA-J AM MED ASSOC, V262, P2265, DOI 10.1001/jama.262.16.2265; HAMID A, 1990, CONTEMP DRUG PROBL, V17, P31; HANZLICK R, 1991, JAMA-J AM MED ASSOC, V265, P760, DOI 10.1001/jama.265.6.760; HARRUFF RC, 1988, J FORENSIC SCI, V33, P1231; HOUSER HB, 1991, AM J EPIDEMIOL, V134, P1261, DOI 10.1093/oxfordjournals.aje.a116028; INCIARDI JA, 1990, NATIONAL I DRUG ABUS, V103; JATLOW PI, 1987, CLIN CHEM, V33, pB66; KANDEL DB, 1984, AM J PUBLIC HEALTH, V74, P660, DOI 10.2105/AJPH.74.7.660; KASSIRER JP, 1991, NEW ENGL J MED, V325, P1647, DOI 10.1056/NEJM199112053252311; LILLIEBLANTON M, 1993, JAMA-J AM MED ASSOC, V269, P993, DOI 10.1001/jama.269.8.993; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; LOWENSTEIN DH, 1987, AM J MED, V83, P841, DOI 10.1016/0002-9343(87)90640-1; LOWRY PW, 1988, AM J EPIDEMIOL, V128, P1130; MARZUK PM, 1992, JAMA-J AM MED ASSOC, V267, P2635; MENDOZA R, 1992, HOSP COMMUNITY PSYCH, V43, P677; MESSNER SF, 1986, CRIMINOLOGY, V24, P297, DOI 10.1111/j.1745-9125.1986.tb01497.x; OCARROLL PW, 1991, AM J PUBLIC HEALTH, V81, P576, DOI 10.2105/AJPH.81.5.576; ROGERS JN, 1986, J FORENSIC SCI, V31, P1404; ROPP L, 1992, JAMA-J AM MED ASSOC, V267, P2905, DOI 10.1001/jama.267.21.2905; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; TRENT B, 1991, CAN MED ASSOC J, V145, P1332; WALLACE JE, 1977, J ANAL TOXICOL, V1, P20, DOI 10.1093/jat/1.1.20; WEBSTER DW, 1993, AM J PUBLIC HEALTH, V83, P1604, DOI 10.2105/AJPH.83.11.1604; WETLI CV, 1985, J FORENSIC SCI, V30, P873; Wolfgang M. E., 1967, SUBCULTURE VIOLENCE; ZAHN M, 1989, HOMICIDE 20TH CENTUR, P1; 1993, SMA931980 US DEP MEN; 1993, UNDERSTANDING PREVEN; 1990, VITAL HLTH STAT, V11; 1990, MMWR-MORBID MORTAL W, V39, P869; 1990, TREATING DRUG PROBLE, V1, P220; 1991, MMWR-MORBID MORTAL W, V40, P681	50	58	59	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					43	46		10.1001/jama.272.1.43	http://dx.doi.org/10.1001/jama.272.1.43			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU485	8007078				2022-12-28	WOS:A1994NU48500028
J	YAMADA, T; AHNEN, D; ALPERS, DH; GREENBERG, HB; GRAY, L; JOSCELYN, KB; KAUFFMAN, G; PODOLSKY, DK; RAY, WA; SCHABERG, D; SILVERSTEIN, FE; SIVAK, MV; WILLIAMS, ALB; YOLKEN, R				YAMADA, T; AHNEN, D; ALPERS, DH; GREENBERG, HB; GRAY, L; JOSCELYN, KB; KAUFFMAN, G; PODOLSKY, DK; RAY, WA; SCHABERG, D; SILVERSTEIN, FE; SIVAK, MV; WILLIAMS, ALB; YOLKEN, R			HELICOBACTER-PYLORI IN PEPTIC-ULCER DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The National Institutes of Health Consensus Development Conference on Helicobacter pylori in Peptic Ulcer Disease brought together specialists in gastroenterology, surgery, infectious diseases, epidemiology, and pathology, as well as the public to address the following questions: (1) What is the causal relationship of H pylori to upper gastrointestinal disease? (2) How does one diagnose and eradicate H pylori infection? (3) Does eradication of H pylori infection benefit the patient with peptic ulcer disease? (4) What is the relationship between H pylori infection and gastric malignancy? (5) Which H pylori-infected patients should be treated? (6) What are the most important questions that must be addressed by future research in H pylori infections? Following 1 1/2 days of presentations by experts and discussion by the audience, a consensus panel weighed the evidence and prepared their consensus statement. Among their findings, the consensus panel concluded that (1) ulcer patients with H pylori infection require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation with the illness or on recurrence; (2) the value of treating of nonulcerative dyspepsia patients with H pylori infection remains to be determined; and (3) the interesting relationship between H pylori infection and gastric cancers, requires further exploration.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; DENVER MED CTR,DENVER,CO; WASHINGTON UNIV,SCH MED,DEPT MED,DIV GASTROINTESTINAL,ST LOUIS,MO 63110; STANFORD UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,STANFORD,CA 94305; JOSCELYN MCNAIR & JEFFREY PC,ANN ARBOR,MI; MILTON S HERSHEY MED CTR,DEPT SURG,DIV GEN SURG,HERSHEY,PA; MASSACHUSETTS GEN HOSP,DEPT MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,NASHVILLE,TN 37212; UNIV TENNESSEE,COLL MED,DEPT MED,MEMPHIS,TN; UNIV WASHINGTON,SCH MED,DIV GASTROENTEROL,SEATTLE,WA; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,DIV GASTROENTEROL,CLEVELAND,OH 44106; GEORGE WASHINGTON UNIV,MED CTR,DIV GASTROENTEROL,WASHINGTON,DC 20037; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD	University of Michigan System; University of Michigan; Washington University (WUSTL); Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Massachusetts General Hospital; Vanderbilt University; University of Tennessee System; University of Tennessee Health Science Center; University of Washington; University of Washington Seattle; Case Western Reserve University; George Washington University; Johns Hopkins University			yolken, robert/AAW-2556-2021	Marshall, Barry/0000-0003-4853-5015; greenberg, harry/0000-0002-2128-9080					0	1543	1575	1	75	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					65	69		10.1001/jama.1994.03520010077036	http://dx.doi.org/10.1001/jama.1994.03520010077036			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU485	8007082				2022-12-28	WOS:A1994NU48500032
J	PISACANE, A; IMPAGLIAZZO, N; RUSSO, M; VALIANI, R; MANDARINI, A; FLORIO, C; VIVO, P				PISACANE, A; IMPAGLIAZZO, N; RUSSO, M; VALIANI, R; MANDARINI, A; FLORIO, C; VIVO, P			BREAST-FEEDING AND MULTIPLE-SCLEROSIS	BRITISH MEDICAL JOURNAL			English	Article									OSPED ANTONIO CARDARELLI,DIV NEUROL,NAPLES,ITALY; ASSOC ITALIANA SCLEROSI MULTIPLA,NAPLES,ITALY	Antonio Cardarelli Hospital	PISACANE, A (corresponding author), UNIV NAPLES FEDERICO II,DIPARTIMENTO PEDIAT,VIA PANSINI 5,I-80131 NAPLES,ITALY.							AGRANOFF BW, 1974, LANCET, V2, P1061; FARQUHARSON J, 1992, LANCET, V340, P810, DOI 10.1016/0140-6736(92)92684-8; HANSON LA, 1985, PEDIATRICS, V75, P172; MARTYN CN, 1991, CIBA F SYMP, V156, P93; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302	5	47	49	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1411	1412		10.1136/bmj.308.6941.1411	http://dx.doi.org/10.1136/bmj.308.6941.1411			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019251	Green Published			2022-12-28	WOS:A1994NP42000016
J	COHEN, LS; FRIEDMAN, JM; JEFFERSON, JW; JOHNSON, EM; WEINER, ML				COHEN, LS; FRIEDMAN, JM; JEFFERSON, JW; JOHNSON, EM; WEINER, ML			A REEVALUATION OF RISK OF IN-UTERO EXPOSURE TO LITHIUM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							TERATOGEN UPDATE; PREGNANCY; PHENOTHIAZINES; MALFORMATIONS; WOMEN; MANIA	Objective.-To reevaluate the risk associated with in utero exposure to lithium. Data Sources and Study Selection.-Data were obtained from all published studies, in multiple languages, referenced in MEDLINE, Toxline, and the Lithium Information Center databases. Unpublished studies were not included. The search terms were lithium, pregnancy, teratogen, abnormalities (drug induced), Ebstein's anomaly, and adverse effects. Data Extraction and Synthesis.-In the 1970s a very strong association was suggested between maternal lithium treatment during pregnancy and Ebstein's anomaly of the heart in the offspring. The relative risk for Ebstein's anomaly among such children was estimated to be 400 on the basis of data collected from a registry of voluntarily submitted cases. More recent controlled epidemiologic studies have consistently shown a lower risk. No women who took lithium during pregnancy were found among four case-control studies of Ebstein's anomaly involving 25, 34, 59, and 89 affected children, respectively. In two cohort studies, risk ratios of 3.0 (95% confidence interval [CI], 1.2 to.7.7) and 1.5 (95% CI, 0.4 to 6.8) for all congenital anomalies have been observed. The risk ratios for cardiac malformations in these studies were 7.7 (95% CI 1.5 to 41.2) and 1.2 (95% CI, 0.1 to 18.3), respectively. Conclusion.-While initial information regarding the teratogenic risk of lithium treatment was derived from biased retrospective reports, more recent epidemiologic data indicate that the teratogenic risk of first-trimester lithium exposure is lower than previously suggested. The clinical management of women with bipolar disorder who have childbearing potential should be modified with this revised risk estimate.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1W5,BC,CANADA; DEAN FDN HLTH RES & EDUC,CTR LITHIUM INFORMAT,MADISON,WI; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DANIEL BAUGH INST,DEPT ANAT,PHILADELPHIA,PA 19107; FMC CORP,DEPT TOXICOL,PRINCETON,NJ	University of British Columbia; Jefferson University	COHEN, LS (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PSYCHIAT,CLIN PSYCHOPHARMACOL UNIT,BOSTON,MA 02114, USA.		Kothari, Khyati/B-5008-2014	Friedman, Jan/0000-0002-7482-9570	NIMH NIH HHS [MH-19445] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [T01MH019445] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMSTERDAM JD, 1990, PSYCHOPHARMACOL B, V26, P843; [Anonymous], 1987, PSYCHOPHARMACOLOGY; COHEN LS, 1991, PRACTITIONERS GUIDE, P389; COHEN LS, 1988, AM J PSYCHIAT, V145, P773; COHEN LS, 1989, PSYCHOSOMATICS, V30, P389; CZEIZEL A, 1990, TERATOLOGY, V42, P505, DOI 10.1002/tera.1420420507; DICKE JM, 1989, MED CLIN N AM, V73, P567, DOI 10.1016/S0025-7125(16)30658-7; EDLUND MJ, 1984, COMPR PSYCHIAT, V25, P32, DOI 10.1016/0010-440X(84)90019-1; EDMONDS L D, 1990, Teratology, V41, P551; FAEDDA GL, 1993, ARCH GEN PSYCHIAT, V50, P448; FERNER RE, 1992, LANCET, V339, P869, DOI 10.1016/0140-6736(92)90311-P; JACOBSON SJ, 1992, LANCET, V339, P530, DOI 10.1016/0140-6736(92)90346-5; JEFFERSON JW, 1989, J CLIN PSYCHIAT, V50, P81; JEFFERSON JW, 1987, LITHIUM ENCY CLIN PR, P1; JEFFERSON JW, 1987, ENCY NEUROSCIENCE, P592; JOHNSON EMJ, 1991, LITHIUM BIOL MED NEW, P101; JONES KL, 1989, NEW ENGL J MED, V320, P1661, DOI 10.1056/NEJM198906223202505; KALLEN B, 1988, TERATOLOGY, V38, P597, DOI 10.1002/tera.1420380608; KALLEN B, 1983, ACTA PSYCHIAT SCAND, V68, P134, DOI 10.1111/j.1600-0447.1983.tb06991.x; Kallen B, 1991, LITHIUM BIOL MED NEW, P121; KALLEN B, 1988, EPIDEMIOLOGY HUMAN R, P61; KEHRBERG G, 1991, LITHIUM BIOL MED NEW, P47; KIRKLIN JW, 1986, CARDIAC SURGERY, P889; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; Langman J., 1975, MED EMBRYOLOGY; LINDHOUT D, 1986, LANCET, V1, P329; MARKOVITZ PJ, 1990, PSYCHOSOMATICS, V31, P118, DOI 10.1016/S0033-3182(90)72237-2; MCBRIDE WG, 1961, LANCET, V2, P1358; MILKOVICH L, 1976, AM J OBSTET GYNECOL, V125, P244, DOI 10.1016/0002-9378(76)90601-3; NARS PW, 1977, AM J DIS CHILD, V131, P924, DOI 10.1001/archpedi.1977.02120210102021; NORA JJ, 1974, LANCET, V1, P594; PAFFENBARGER RA, 1982, MOTHERHOOD MENTAL IL; REIFMAN A, 1980, ARCH GEN PSYCHIAT, V37, P385; ROBERT E, 1990, TERATOLOGY, V42, P205, DOI 10.1002/tera.1420420303; ROBERT E, 1988, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V17, P601; ROBERT E, 1982, LANCET, V2, P934; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; RUMEAUROUQUETTE C, 1977, TERATOLOGY, V15, P57, DOI 10.1002/tera.1420150108; SCHOU M, 1973, BMJ-BRIT MED J, V2, P135, DOI 10.1136/bmj.2.5859.135; SIPEK A, 1989, COR VASA, V31, P149; SITLANDMARKEN PA, 1989, J CLIN PSYCHOPHARM, V9, P78; SLONE D, 1977, AM J OBSTET GYNECOL, V128, P486, DOI 10.1016/0002-9378(77)90029-1; SUPPES T, 1991, ARCH GEN PSYCHIAT, V48, P1082; TOHEN M, 1990, ARCH GEN PSYCHIAT, V47, P1106; Weiner ML, 1991, LITHIUM BIOL MED NEW, P81; Weinstein M R, 1976, Drug Inf J, V10, P94; WEINSTEIN MR, 1975, LITHIUM RES THERAPY, P237; ZALSTEIN E, 1990, AM J CARDIOL, V65, P817	49	305	310	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					146	150		10.1001/jama.271.2.146	http://dx.doi.org/10.1001/jama.271.2.146			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ083	8031346				2022-12-28	WOS:A1994MQ08300026
J	LEMP, GF; HIROZAWA, AM; GIVERTZ, D; NIERI, GN; ANDERSON, L; LINDEGREN, ML; JANSSEN, RS; KATZ, M				LEMP, GF; HIROZAWA, AM; GIVERTZ, D; NIERI, GN; ANDERSON, L; LINDEGREN, ML; JANSSEN, RS; KATZ, M			SEROPREVALENCE OF HIV AND RISK BEHAVIORS AMONG YOUNG HOMOSEXUAL AND BISEXUAL MEN - THE SAN-FRANCISCO BERKELEY YOUNG MENS SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To estimate the prevalence of human immunodeficiency virus (HIV) infection and risk behaviors among young homosexual and bisexual men sampled from public venues in San Francisco and Berkeley, Calif. Design.-A survey of 425 young homosexual and bisexual men sampled from 26 locations during 1992 and 1993. Participants were interviewed and blood specimens were drawn and tested for HIV, level of CD4(+) T lymphocytes, and markers of hepatitis B and syphilis. Setting.-Public venues in San Francisco and Berkeley, including street corners and sidewalks, dance clubs, bars, and parks. Population Studied.-Homosexual and bisexual men aged 17 to 22 years. Main Outcome Measures.-Prevalence of HIV infection and risk behaviors. Results.-The HIV seroprevalence was 9.4% (95% confidence interval, 6.8% to 12.6%). The prevalence of markers for hepatitis B was 19.8% (95% confidence interval, 16.1% to 23.9%), and that for syphilis was 1.0% (95% confidence interval, 0.3% to 2.4%). The HIV seroprevalence was significantly higher among African Americans (21.2%) than among other racial/ethnic groups (P=.002). Approximately one third (32.7%) of the participants reported unprotected anal intercourse, and 11.8% reported injecting drug use in the previous 6 months. At the time of interview, 70.0% of the HIV-infected men did not know that they were HIV seropositive, and only 22.5% were receiving medical care for HIV infection. Conclusions.-The prevalence of HIV infection is high among this young population of homosexual and bisexual men, particularly among young African-American men. The high rates of HIV-related risk behaviors suggest a considerable risk for HIV transmission in this population. Prevention programs and health services need to be tailored to address the needs of a new generation of homosexual and bisexual men.	BERKELEY DEPT HLTH & HUMAN SERV, BERKELEY, CA USA; CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV HIV AIDS, ATLANTA, GA 30341 USA	Centers for Disease Control & Prevention - USA	LEMP, GF (corresponding author), SAN FRANCISCO DEPT PUBL HLTH, AIDS OFF, 25 VAN NES AVE, SUITE 500, SAN FRANCISCO, CA 94102 USA.				PHS HHS [U62/CCU906255-03] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		GOLD RS, 1992, AIDS, V6, P1021, DOI 10.1097/00002030-199209000-00017; HAYS RB, 1990, AIDS, V4, P901, DOI 10.1097/00002030-199009000-00011; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; KELLY JA, 1991, J CONSULT CLIN PSYCH, V59, P163, DOI 10.1037/0022-006X.59.1.163; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; MCKUSICK L, 1990, AM J PUBLIC HEALTH, V80, P978, DOI 10.2105/AJPH.80.8.978; SILVESTRE AJ, 1993, AM J PUBLIC HEALTH, V83, P578, DOI 10.2105/AJPH.83.4.578; STALL R, 1992, J ACQ IMMUN DEF SYND, V5, P682; VALDISERRI RO, 1988, AM J PUBLIC HEALTH, V78, P801, DOI 10.2105/AJPH.78.7.801; VANGRIENSVEN GJP, 1989, BMJ-BRIT MED J, V298, P218, DOI 10.1136/bmj.298.6668.218; WATTERS JK, 1989, SOC PROBL, V36, P416, DOI 10.1525/sp.1989.36.4.03a00070; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; WINKELSTEIN W, 1993, 9TH INT C AIDS BERL	13	195	196	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					449	454						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA278	8040980				2022-12-28	WOS:A1994PA27800026
J	VONKORFF, M; BARLOW, W; CHERKIN, D; DEYO, RA				VONKORFF, M; BARLOW, W; CHERKIN, D; DEYO, RA			EFFECTS OF PRACTICE STYLE IN MANAGING BACK PAIN	ANNALS OF INTERNAL MEDICINE			English	Article						PHYSICIANS PRACTICE PATTERNS; BACK PAIN; SELF CARE; COST-BENEFIT ANALYSIS; BED REST	PHYSICIAN EDUCATION INTERVENTION; IMPROVE PRIMARY CARE; DISABILITY; IMPACT	Objective: To assess the effects of a practice style of back pain management consistent with self-care (infrequent prescribing of pain medications and bed rest) on long-term functional outcomes, costs of care, and patient satisfaction. Design: A quasi-experimental observational study in which primary care physicians (n = 44) were categorized according to one of three practice style groups defined by a low, moderate, or high frequency of prescribing pain medications and bed rest for many patients (average, 24 patients per physician). Setting: Primary care practices of a large, staff model health maintenance organization, Group Health Cooperative of Puget Sound. Patients: Consecutive patients with back or neck pain of participating primary care physicians. Patients were interviewed 1 month (n = 1071) and 1 year and 2 years (n = 911) after their index visits. Results: Patients in the three practice style groups rated similarly the quality of medical care received for back pain. Patients treated by physicians who infrequently prescribed pain medications and bed rest were more satisfied with education about back pain. On a scale of 0 to 10, the mean rating of agreement with the statement, ''After your visit with the doctor, you fully understood how to take care of your back problem,'' was 5.6 +/- 3.6 among patients of physicians who frequently prescribed medication and rest and was 6.6 +/- 3.5) among those who infrequently prescribed medication and bed rest. At 1 month, 30% of patients of physicians who infrequently prescribed medications and bed rest were graded as having moderate to severe activity limitation because of back pain, whereas 37% of patients in the moderate group had this grading, and 46% of patients of physicians who frequently prescribed were graded as having moderate to severe activity limitation. Differences in activity limitation by practice style group were no longer evident at 1 or 2 years of follow-up. The total 1-year costs of back care were higher among patients seen by physicians who frequently prescribed bed rest and pain medications (cost, $768 +/- $1592) than among those seen by physicians who infrequently prescribed (cost, $428 +/- $665), due largely to differences in inpatient and specialty care costs. The adjusted difference in costs, after controlling for case-mix variables, was $277 (95% Cl, $85.50 to $471.32). Conclusions: A practice style consistent with back pain self-care yielded similar long-term pain and functional outcomes at lower cost and was associated with higher satisfaction with patient education compared with a practice style characterized by more frequent prescribing of pain medications and bed rest.			VONKORFF, M (corresponding author), GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, 1730 MINOR AVE, SUITE 1600, SEATTLE, WA 98101 USA.			VonKorff, Michael/0000-0001-5386-8477	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006168, P01HS006344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE008773] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS06168, P01 HS06344] Funding Source: Medline; NIDCR NIH HHS [P01 DE08773] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		CHERKIN D, 1991, SPINE, V16, P1168, DOI 10.1097/00007632-199110000-00007; CHERKIN D, 1991, SPINE, V16, P1173, DOI 10.1097/00007632-199110000-00008; CYPRESS BK, 1983, AM J PUBLIC HEALTH, V73, P389, DOI 10.2105/AJPH.73.4.389; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; FORDYCE WE, 1986, J BEHAV MED, V9, P127, DOI 10.1007/BF00848473; FORDYCE WE, 1976, BEHAVIORAL METHODS C; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; LINTON SJ, 1993, PAIN, V54, P353, DOI 10.1016/0304-3959(93)90037-P; Osterweis M., 1987, PAIN DISABILITY CLIN; PHILIPS HC, 1991, BEHAV RES THER, V29, P435, DOI 10.1016/0005-7967(91)90127-O; PHILIPS HC, 1991, BEHAV RES THER, V29, P443, DOI 10.1016/0005-7967(91)90128-P; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROTER DL, 1989, ANNU REV PUBL HEALTH, V10, P163, DOI 10.1146/annurev.pu.10.050189.001115; VONKORFF M, 1993, SPINE, V18, P855, DOI 10.1097/00007632-199306000-00008; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; VONKORFF M, IN PRESS 7TH P WORLD, V2; Waddell G, 1991, Neurosurg Clin N Am, V2, P719; WHITNEY CW, 1992, PAIN, V50, P281, DOI 10.1016/0304-3959(92)90032-7; 1989, SAS USERS GUIDE STAT; 1987, SPINE S1, V12, pS1	23	98	98	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					187	195		10.7326/0003-4819-121-3-199408010-00005	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017745				2022-12-28	WOS:A1994NY33800005
J	LIU, DJ; DAY, LA				LIU, DJ; DAY, LA			PF1 VIRUS STRUCTURE - HELICAL COAT PROTEIN AND DNA WITH PARAXIAL PHOSPHATES	SCIENCE			English	Article							LASER RAMAN-SPECTROSCOPY; FILAMENTOUS BACTERIOPHAGE-PFL; BACTERIAL VIRUS-PF1; NEUTRON-DIFFRACTION; LINEAR DICHROISM; ELECTRON-DENSITY; XF; FD; RESOLUTION; IKE	The helical path of the DNA in filamentous bacteriophage Pf1 was deduced from different kinds of existing structural information, including results from x-ray fiber diffraction. The DNA has the same pitch, 16 angstroms, as the surrounding helix of protein subunits; the rise and rotation per nucleotide are 6.1 angstroms and 132 degrees, respectively; and the phosphates are 2.5 angstroms from the axis. The DNA in Pf1 is, therefore, the most extended and twisted DNA structure known. On the basis of the DNA structure and extensive additional information about the protein, a model of the virion is proposed. In the model, the DNA bases reach out, into the protein, and the lysine and arginine side chains reach in, between the DNA bases, to stabilize the paraxial phosphate charges; the conformation of the protein subunit is combination of alpha and 3(10) helices.			LIU, DJ (corresponding author), PUBL HLTH RES INST CITY NEW YORK INC,455 1ST AVE,NEW YORK,NY 10016, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042286] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42286] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BRYAN RK, 1983, P NATL ACAD SCI-BIOL, V80, P4728, DOI 10.1073/pnas.80.15.4728; CASADEVALL A, 1983, BIOCHEMISTRY-US, V22, P4831, DOI 10.1021/bi00289a033; CASADEVALL A, 1988, BIOCHEMISTRY-US, V27, P3599, DOI 10.1021/bi00410a010; CLACK BA, 1992, BIOPOLYMERS, V32, P795, DOI 10.1002/bip.360320708; CROSS TA, 1983, BIOCHEMISTRY-US, V22, P721, DOI 10.1021/bi00273a002; DAY LA, 1979, NUCLEIC ACIDS RES, V7, P1393, DOI 10.1093/nar/7.6.1393; DAY LA, 1988, ANNU REV BIOPHYS BIO, V17, P509; FRITZSCHE H, 1986, STUD BIOPHYS, V116, P175; GREULICH KO, 1984, BIOCHIM BIOPHYS ACTA, V782, P446, DOI 10.1016/0167-4781(84)90053-8; HILL DF, 1991, J MOL BIOL, V218, P349, DOI 10.1016/0022-2836(91)90717-K; KLUG A, 1958, ACTA CRYSTALLOGR, V11, P199, DOI 10.1107/S0365110X58000517; KOSTRIKIS LG, 1994, BIOCHEMISTRY-US, V33, P1694, DOI 10.1021/bi00173a011; MAKOWSKI L, 1981, J MOL BIOL, V145, P611; MARVIN DA, 1992, PHASE TRANSIT, V39, P45, DOI 10.1080/01411599208203472; MARVIN DA, 1987, J MOL BIOL, V193, P315, DOI 10.1016/0022-2836(87)90222-1; MARZEC CJ, 1988, BIOPHYS J, V53, P425, DOI 10.1016/S0006-3495(88)83119-9; MARZEC CJ, 1993, J BIOMOL STRUCT DYN, V10, P1091, DOI 10.1080/07391102.1993.10508697; MARZEC CJ, UNPUB; NAKASHIMA Y, 1980, J MOL BIOL, V138, P493, DOI 10.1016/S0022-2836(80)80014-3; NAMBUDRIPAD R, 1991, J MOL BIOL, V220, P359, DOI 10.1016/0022-2836(91)90019-3; NAMBUDRIPAD R, 1991, SCIENCE, V252, P1305, DOI 10.1126/science.1925543; NAVE C, 1981, J MOL BIOL, V149, P675, DOI 10.1016/0022-2836(81)90353-3; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; REISBERG SA, 1989, THESIS NEW YORK U; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SHON KJ, 1991, SCIENCE, V252, P1303, DOI 10.1126/science.1925542; STARK W, 1988, J MOL BIOL, V199, P171, DOI 10.1016/0022-2836(88)90387-7; TAKEYA K, 1966, VIROLOGY, V28, P163, DOI 10.1016/0042-6822(66)90317-5; THOMAS GJ, 1983, J MOL BIOL, V165, P321, DOI 10.1016/S0022-2836(83)80260-5; THOMAS GJ, 1988, BIOCHEMISTRY-US, V27, P4350, DOI 10.1021/bi00412a023; THOMAS GJ, 1985, SPECTROCHIM ACTA A, V41, P217, DOI 10.1016/0584-8539(85)80100-8; TORBET J, 1981, BIOPOLYMERS, V20, P2657, DOI 10.1002/bip.1981.360201212; WISEMAN RL, 1977, J MOL BIOL, V116, P607, DOI 10.1016/0022-2836(77)90088-2	34	84	86	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					671	674		10.1126/science.8036516	http://dx.doi.org/10.1126/science.8036516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036516				2022-12-28	WOS:A1994NZ53800036
J	ROGERS, SW; ANDREWS, PI; GAHRING, LC; WHISENAND, T; CAULEY, K; CRAIN, B; HUGHES, TE; HEINEMANN, SF; MCNAMARA, JO				ROGERS, SW; ANDREWS, PI; GAHRING, LC; WHISENAND, T; CAULEY, K; CRAIN, B; HUGHES, TE; HEINEMANN, SF; MCNAMARA, JO			AUTOANTIBODIES TO GLUTAMATE-RECEPTOR GLUR3 IN RASMUSSENS ENCEPHALITIS	SCIENCE			English	Article							BRAIN; EXPRESSION; ACID	Rasmussen's encephalitis is a progressive childhood disease of unknown cause characterized by severe epilepsy, hemiplegia, dementia, and inflammation of the brain. During efforts to raise antibodies to recombinant glutamate receptors (GluRs), behaviors typical of seizures and histopathologic features mimicking Rasmussen's encephalitis were found in two rabbits immunized with GluR3 protein. A correlation was found between the presence of Rasmussen's encephalitis and serum antibodies to GluR3 detected by protein immunoblot analysis and by immunoreactivity to transfected cells expressing GluR3. Repeated plasma exchanges in one seriously ill child transiently reduced serum titers of GluR3 antibodies, decreased seizure frequency, and improved neurologic function. Thus, GluR3 is an autoantigen in Rasmussen's encephalitis, and an autoimmune process may underlie this disease.	UNIV UTAH,HUMAN MOLEC BIOL & GENET PROGRAM,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT NEUROBIOL & ANAT,SALT LAKE CITY,UT 84112; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED NEUROL,DURHAM,NC 27710; UNIV UTAH,DIV HUMAN DEV & AGING,SALT LAKE CITY,UT 84112; SALK INST BIOL STUDIES,LA JOLLA,CA 92037; DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710; YALE UNIV,DEPT OPHTHALMOL,NEW HAVEN,CT 06510; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; VET AFFAIRS MED CTR,DEPT MED NEUROL,DURHAM,NC 27705	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Duke University; Duke University; Utah System of Higher Education; University of Utah; Salk Institute; Duke University; Yale University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	ROGERS, SW (corresponding author), VET AFFAIRS MED CTR,SALT LAKE CITY GERIATR RES EDUC & CLIN CTR,SALT LAKE CITY,UT 84112, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS017771, R29NS030990, R01NS028709] Funding Source: NIH RePORTER; NINDS NIH HHS [NS17771, NS28709, NS30990R29] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERMAN PW, 1981, ANN NY ACAD SCI, V377, P237, DOI 10.1111/j.1749-6632.1981.tb33736.x; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; DAMIAN RT, 1964, AM NAT, V98, P129, DOI 10.1086/282313; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LAXER KD, 1991, CHRONIC ENCEPHALITIS, P135; LEE JC, 1982, HISTOL HISTOPATHOL, P798; LORENZO AV, 1972, AM J PHYSIOL, V223, P268, DOI 10.1152/ajplegacy.1972.223.2.268; NITSCH C, 1986, NEUROSCI LETT, V64, P53, DOI 10.1016/0304-3940(86)90662-2; Oguni H, 1991, CHRONIC ENCEPHALITIS, P7; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; PEYSER J, 1992, INT PEDIATR, V7, P272; RASMUSSEN T, 1958, NEUROLOGY, V8, P435, DOI 10.1212/WNL.8.6.435; Robitaille Y, 1991, CHRONIC ENCEPHALITIS, P79; ROGERS SG, UNPUB; ROGERS SW, 1991, J NEUROSCI, V11, P2713; ROGERS SW, 1992, J NEUROSCI, V12, P4611; STEVENS CF, 1989, NATURE, V342, P620, DOI 10.1038/342620a0; Utley J R, 1990, J Card Surg, V5, P177, DOI 10.1111/j.1540-8191.1990.tb01036.x	21	542	562	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					648	651		10.1126/science.8036512	http://dx.doi.org/10.1126/science.8036512			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036512				2022-12-28	WOS:A1994NZ53800029
J	LEE, HC; AARHUS, R; GRAEFF, R; GURNACK, ME; WALSETH, TF				LEE, HC; AARHUS, R; GRAEFF, R; GURNACK, ME; WALSETH, TF			CYCLIC ADP RIBOSE ACTIVATION OF THE RYANODINE RECEPTOR IS MEDIATED BY CALMODULIN	NATURE			English	Article							SEA-URCHIN EGG; CALCIUM RELEASE; CA2+ RELEASE; MICROSOMES; MODULATION; CHANNEL; BINDING	CYCLIC ADP-ribose (cADPR) is a newly identified nucleotide(1,2) which can release calcium from a variety of cells(3-6), suggesting it is a messenger for mobilizing internal Ca2+ stores. Its cyclic structure has now been confirmed by X-ray crystallography(7). Available results are consistent with it being a modulator of Ca2+-induced Ca2+ releases(8-10). Here we report that sea urchin egg microsomes purified by Percoll gradients lose sensitivity to cADPR, but the response can be restored by a soluble protein in the supernatant. Purification and characterization of the protein indicate that it is calmodulin. It appears to be sensitizing the Ca2+ release mechanism because caffeine and strontium, agonists of Ca2+-induced Ca2+ release, can also mimic calmodulin in conferring cADPR-sensitivity. Although evidence indicates that cADPR may be an activator of the ryanodine receptor(8-10), present results point to the importance of accessory proteins such as calmodulin in modulating its activity.	UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	LEE, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455, USA.		Walseth, Timothy F/F-9518-2010; Lee, Hon Cheung/C-4329-2009; Graeff, Richard Milton/B-3425-2011	Walseth, Timothy F/0000-0003-2558-7859; 				CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1991, J BIOL CHEM, V266, P2276; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; PAYNE ME, 1989, J BIOL CHEM, V262, P8051; SHEN SS, 1989, BIOCHEM BIOPH RES CO, V161, P1100, DOI 10.1016/0006-291X(89)91356-9; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; TAKASAWA S, SCIENCE, V370, P93; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WHITE A, 1993, FEBS LETT, V318, P21	19	209	213	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					307	309		10.1038/370307a0	http://dx.doi.org/10.1038/370307a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035880				2022-12-28	WOS:A1994NZ22900068
J	LAUPACIS, A; WELLS, G; RICHARDSON, WS; TUGWELL, P; GUYATT, GH; BROWMAN, G; COOK, D; GERSTEIN, H; HAYNES, B; HAYWARD, R; LEVINE, M; NISHIKAWA, J; SACKETT, DL; BRILLEDWARDS, P; FARKOUH, M; HOLBROOK, A; JAESCHKE, R; LEE, H; SAUVE, S; MOYER, V; NAYLOR, D; OXMAN, A; PHILBRICK, J; SINCLAIR, J; STROM, BL; TUNIS, S; WILLIAMS, J; WILSON, M				LAUPACIS, A; WELLS, G; RICHARDSON, WS; TUGWELL, P; GUYATT, GH; BROWMAN, G; COOK, D; GERSTEIN, H; HAYNES, B; HAYWARD, R; LEVINE, M; NISHIKAWA, J; SACKETT, DL; BRILLEDWARDS, P; FARKOUH, M; HOLBROOK, A; JAESCHKE, R; LEE, H; SAUVE, S; MOYER, V; NAYLOR, D; OXMAN, A; PHILBRICK, J; SINCLAIR, J; STROM, BL; TUNIS, S; WILLIAMS, J; WILSON, M			USERS GUIDES TO THE MEDICAL LITERATURE .5. HOW TO USE AN ARTICLE ABOUT PROGNOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATRIAL-FIBRILLATION; ALZHEIMERS-DISEASE; NATURAL-HISTORY		MCMASTER UNIV, HLTH SCI CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON L8N 3Z5, ON, CANADA; UNIV OTTAWA, DEPT MED, OTTAWA, ON, CANADA; UNIV OTTAWA, DEPT EPIDEMIOL, OTTAWA, ON, CANADA; UNIV OTTAWA, DEPT COMMUNITY MED, OTTAWA, ON, CANADA; UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Ottawa; University of Ottawa; University of Ottawa; University of Rochester			Tugwell, Peter/AFD-8076-2022; Oxman, Andrew/Y-3004-2019	Tugwell, Peter/0000-0001-5062-0556; Oxman, Andrew/0000-0002-5608-5061				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1992, Lancet, V339, P1; BENNETT JC, 1993, NEW ENGL J MED, V329, P288, DOI 10.1056/NEJM199307223290428; BERGER CJ, 1992, JAMA-J AM MED ASSOC, V268, P1545, DOI 10.1001/jama.268.12.1545; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DOREY F, 1989, J BONE JOINT SURG AM, V71A, P544, DOI 10.2106/00004623-198971040-00010; DRACHMAN DA, 1990, ARCH NEUROL-CHICAGO, V47, P851, DOI 10.1001/archneur.1990.00530080033007; ELLENBERG JH, 1980, JAMA-J AM MED ASSOC, V243, P1337, DOI 10.1001/jama.243.13.1337; KATZ MH, 1993, J GEN INTERN MED, V8, P702, DOI 10.1007/BF02598295; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; LAUPACIS A, 1992, CHEST, V102, pS426, DOI 10.1378/chest.102.4_Supplement.426S; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; MEADOR CK, 1965, NEW ENGL J MED, V272, P92, DOI 10.1056/NEJM196501142720208; MOLLOY DW, 1991, AM J PSYCHIAT, V148, P102; PINCUS T, 1994, ANN INTERN MED, V120, P26, DOI 10.7326/0003-4819-120-1-199401010-00005; STERN Y, 1987, NEUROLOGY, V37, P1649, DOI 10.1212/WNL.37.10.1649; WALSH JS, 1990, ANN INTERN MED, V113, P429, DOI 10.7326/0003-4819-113-6-429; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; 1994, DIAGNOSTIC STATISTIC, P139	19	391	404	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					234	237		10.1001/jama.272.3.234	http://dx.doi.org/10.1001/jama.272.3.234			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022043				2022-12-28	WOS:A1994NW18500026
J	VLADECK, BC				VLADECK, BC			THE CONSUMER INFORMATION STRATEGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VLADECK, BC (corresponding author), HLTH CARE FINANCING ADM,BALTIMORE,MD, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					196	196						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022029				2022-12-28	WOS:A1994NW18500005
J	FEURER, ID; BECKER, GJ; PICUS, D; RAMIREZ, E; DARCY, MD; HICKS, ME				FEURER, ID; BECKER, GJ; PICUS, D; RAMIREZ, E; DARCY, MD; HICKS, ME			EVALUATING PEER REVIEWS - PILOT TESTING OF A GRADING INSTRUMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		PUBLICATION BIAS; RELIABILITY; MANUSCRIPTS	Objective.-To measure the reliability and preliminary validity of a grading instrument for editors to evaluate the quality of peer reviews. Design.-The consecutive sample design included 53 reviews of 23 manuscripts. Reviews were systematically assigned to interrater reliability (n=41; power greater than 0.90 to detect a difference of greater than one point) and preliminary criterion-related validity (n=12) subsamples. Content validity was closely examined. Setting.-Nonclinical. Participants.-Three graders evaluated reliability. One individual examined content validity and two editors tested preliminary criterion-related validity. Intervention (Instrument).-Attributes reflecting two basic dimensions, review content and format, were identified and scored (values are possible points/percent contribution): timeliness, 3/21%; grade sheet, 1/7%; etiquette, 1/7%; sectional narratives, 3/21%; citations, 2/14%; narrative summary, 2/14%; and insights, 2/14%. A scoring guide was provided. Main Outcome Measures.-Statistical analyses used to test the interrater reliability of the total score included the intraclass correlation coefficient and analysis of variance with the expectation to uphold the null hypothesis. Kendall's coefficient of concordance was used to test preliminary criterion-related validity. Results.-The intraclass correlation coefficient was .84 (P<.001) and a lack of difference between mean scores was demonstrated by analysis of variance (P=.46). Content validity was confirmed and preliminary criterion-related validity was indicated (Kendall's coefficient of concordance=.94, P=.038). Conclusions.-The instrument is reliable. Content validation has been completed, and further criterion-related validation is warranted.	BAPTIST HOSP MIAMI,MIAMI VASC INST,MIAMI,FL; JOURNAL VASC & INTERVENT RADIOL,NASHVILLE,TN; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT INST RADIOL,ST LOUIS,MO 63110	Baptist Hospital Miami; Washington University (WUSTL)								Allen M. J., 1979, INTRO MEASUREMENT TH; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1401, DOI 10.1001/jama.263.10.1401; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; CICCHETTI DV, 1980, AM PSYCHOL, V35, P300, DOI 10.1037/0003-066X.35.3.300; GALLAGHER EB, 1991, PEER REV SCI PUBLISH, P153; GARFIELD E, 1990, JAMA-J AM MED ASSOC, V263, P1424, DOI 10.1001/jama.263.10.1424; GARFUNKEL JM, 1990, JAMA-J AM MED ASSOC, V263, P1376, DOI 10.1001/jama.263.10.1376; GARFUNKEL JM, 1990, JAMA-J AM MED ASSOC, V263, P1369, DOI 10.1001/jama.263.10.1369; HARGENS LL, 1990, JAMA-J AM MED ASSOC, V263, P1348, DOI 10.1001/jama.263.10.1348; Keppel G., 1982, DESIGN ANAL RES HDB; Korn D, 1991, PEER REV SCI PUBLISH, P205; MCNABE SM, 1991, PEER REV SCI PUBLISH, P159; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; PEARSON ES, 1951, BIOMETRIKA, V38, P112, DOI 10.1093/biomet/38.1-2.112; PETERS DP, 1982, BEHAV BRAIN SCI, V5, P187, DOI 10.1017/S0140525X00011183; RENNIE D, 1991, PEER REV SCI PUBLISH, P1; SHARP DW, 1990, JAMA-J AM MED ASSOC, V263, P1390; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SOLBERG LI, 1991, PEER REV SCI PUBLISH, P164; Stevens J., 1986, APPLIED MULTIVARIATE; STRAYHORN J, 1993, AM J PSYCHIAT, V150, P947	21	26	26	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					98	100		10.1001/jama.272.2.98	http://dx.doi.org/10.1001/jama.272.2.98			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015141				2022-12-28	WOS:A1994NV42400004
J	BURROWS, NP; RATNAVEL, RC; NORRIS, PG				BURROWS, NP; RATNAVEL, RC; NORRIS, PG			PUSTULAR ERUPTIONS AFTER CHLORPROMAZINE	BRITISH MEDICAL JOURNAL			English	Letter											BURROWS, NP (corresponding author), ADDENBROOKES NATL HLTH SERV TRUST,DEPT DERMATOL,CAMBRIDGE CB2 2QQ,ENGLAND.							BURROWS NP, 1993, HISTOPATHOLOGY, V22, P569, DOI 10.1111/j.1365-2559.1993.tb00178.x; ROUJEAU JC, 1991, ARCH DERMATOL, V127, P1333, DOI 10.1001/archderm.127.9.1333; STAUGHTON RCD, 1984, J ROY SOC MED, V77, P6	3	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					97	97		10.1136/bmj.309.6947.97a	http://dx.doi.org/10.1136/bmj.309.6947.97a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038678	Green Published			2022-12-28	WOS:A1994NW71600022
J	LOCKE, SE; RANSIL, BJ; ZACHARIAE, R; MOLAY, F; TOLLINS, K; COVINO, NA; DANFORTH, D				LOCKE, SE; RANSIL, BJ; ZACHARIAE, R; MOLAY, F; TOLLINS, K; COVINO, NA; DANFORTH, D			EFFECT OF HYPNOTIC SUGGESTION ON THE DELAYED-TYPE HYPERSENSITIVITY RESPONSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL-MEDIATED-IMMUNITY; VARICELLA-ZOSTER VIRUS; SKIN-TEST; GUIDED IMAGERY; MULTI-TEST; MODULATION; RELAXATION; IMMEDIATE; ANTIGENS; SYSTEM	Objective.-To determine whether individuals selected for good general health, high hypnotizability, and the ability to alter skin temperature under hypnotic suggestion can influence the delayed-type hypersensitivity (DTH) response to varicella-zoster (VZ) antigen under hypnotic suggestion. Design.-A blinded clinical trial using a repeated measures design with subjects serving as their own controls. Subjects were randomly assigned to undergo a predetermined sequence of four different experimental conditions, occurring at weekly intervals, with each condition including VZ skin testing: (1) hypnosis with suggestions to enhance the DTH response to VZ antigen; (2) hypnosis with suggestions to suppress the DTH response; (3) hypnosis with suggestions for relaxation only; and (4) skin testing without hypnosis. Setting.-A National Institutes of Health-supported clinical research center in a teaching hospital. Subjects.-A stratified sample of 24 ambulatory, healthy, highly hypnotizable, volunteer college students selected for their above-average ability to alter skin temperature after hypnotic suggestions and their positive baseline responses to VZ antigen. There were 11 males and 13 females with a mean+/-SD age of 22+/-6 years. The mean+/-SD hypnotizability score (Harvard Group Scale of Hypnotic Susceptibility) was 11+/-1. Interventions.-Intradermal skin testing with VZ antigen (Mantoux method) and hypnotic suggestion. Main Outcome Measures.-Areas of induration of the DTH response measured at 24 and 48 hours after injection of antigen. Results.-The area of the DM response was not affected by the experimental interventions. The area of erythema was likewise unaffected.	HARVARD UNIV,SCH MED,BOSTON,MA; BETH ISRAEL HOSP,CHARLES A DANA RES INST,BOSTON,MA 02215; BETH ISRAEL HOSP,HARVARD THORNDIKE LAB,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; AARHUS UNIV,DEPT PSYCHOL,AARHUS,DENMARK; BETH ISRAEL HOSP,DEPT NURSING,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Aarhus University; Harvard University; Beth Israel Deaconess Medical Center	LOCKE, SE (corresponding author), BETH ISRAEL HOSP,DEPT PSYCHIAT,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NCRR NIH HHS [RR-01032] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BABA K, 1987, J CLIN MICROBIOL, V25, P2193, DOI 10.1128/JCM.25.11.2193-2196.1987; BALASCHAK B, 1972, INT J CLIN EXP HYP, V20, P38, DOI 10.1080/00207147208409274; BATES SE, 1979, CANCER, V43, P2306, DOI 10.1002/1097-0142(197906)43:6<2306::AID-CNCR2820430621>3.0.CO;2-K; BERGER R, 1985, POSTGRAD MED J, V61, P137; BERGER R, 1985, POSTGRAD MED J S4, V6, P143; BLACK S, 1963, BRIT MED J, V6, P1649; Brodman K., 1949, CORNELL MED INDEX HL; BURKE BL, 1982, ARCH INTERN MED, V142, P291, DOI 10.1001/archinte.142.2.291; COE WC, 1976, INT J CLIN EXP HYP, V24, P281; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DIAMOND MJ, 1984, AM J CLIN HYPN, V27, P3, DOI 10.1080/00029157.1984.10402582; DUCHATEAU J, 1985, POSTGRAD MED J, V61, P147; DVORAK HF, 1974, LAB INVEST, V31, P111; GROSSMAN J, 1974, J ALLERGY CLIN IMMUN, V55, P268; HALL NRS, 1991, PSYCHONEUROIMMUNOLOG, P1067; HENOCQ E, 1979, LANCET, V1, P674; JEMMOTT JB, 1984, PSYCHOL BULL, V95, P78, DOI 10.1037/0033-2909.95.1.78; JUST M, 1985, POSTGRAD MED J, V61, P129; KAMIYA H, 1977, J INFECT DIS, V136, P784, DOI 10.1093/infdis/136.6.784; KIECOLTGLASER JK, 1992, J CONSULT CLIN PSYCH, V60, P569, DOI 10.1037/0022-006X.60.4.569; KNIKER WT, 1979, ANN ALLERGY, V43, P73; KNIKER WT, 1984, ANN ALLERGY, V52, P75; Kramer E, 1969, Am J Clin Hypn, V11, P175; LARUSSA P, 1985, J INFECT DIS, V152, P869, DOI 10.1093/infdis/152.5.869; LAWRENCE JR, 1982, INT J CLIN EXP HYP, V30, P167; LESOURD B, 1982, CLIN EXP IMMUNOL, V50, P635; LOCKE SE, 1987, ANN NY ACAD SCI, V496, P745, DOI 10.1111/j.1749-6632.1987.tb35841.x; MURPHREE JT, 1979, ANN ALLERGY, V43, P279; PLOTKIN SA, 1985, POSTGRAD MED J, V61, P7; REYHER J, 1976, AM J CLIN HYPN, V19, P103; Sadock, 1989, COMPREHENSIVE TXB PS, P1240; SEYMOUR GE, 1976, J PSYCHOSOM RES, V20, P469, DOI 10.1016/0022-3999(76)90011-8; Shor R. E., 1962, HARVARD GROUP SCALE; SMALL MM, 1969, INT J CLIN EXP HYP, V17, P251, DOI 10.1080/00207146908407248; SMITH GR, 1992, PSYCHOSOMATICS, V33, P444, DOI 10.1016/S0033-3182(92)71949-5; SMITH GR, 1985, ARCH INTERN MED, V145, P2110, DOI 10.1001/archinte.145.11.2110; SMITH GR, 1983, PSYCHOSOM MED, V45, P444; SOKAL J, 1973, NEW ENGL J MED, V293, P501; STEELE RW, 1986, J IMMUNOL METHODS, V86, P213, DOI 10.1016/0022-1759(86)90455-2; STERN D B, 1978, American Journal of Clinical Hypnosis, V21, P109; VANROOD YR, 1993, J BEHAV MED, V16, P163, DOI 10.1007/BF00844891; VONBLOMBERG M, 1978, IMMUNOLOGY, V35, P361; WEITZENHOFFER AM, 1992, STANFORD HYPNOTIC SU; ZACHARIAE R, 1989, ALLERGY, V44, P537, DOI 10.1111/j.1398-9995.1989.tb04198.x; ZACHARIAE R, 1990, PSYCHOTHER PSYCHOSOM, V54, P32, DOI 10.1159/000288374; ZACHARIAE R, 1993, ALLERGY, V48, P6, DOI 10.1111/j.1398-9995.1993.tb02168.x	46	24	24	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					47	52		10.1001/jama.272.1.47	http://dx.doi.org/10.1001/jama.272.1.47			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NU485	8007079				2022-12-28	WOS:A1994NU48500029
J	AMON, A; IRNIGER, S; NASMYTH, K				AMON, A; IRNIGER, S; NASMYTH, K			CLOSING THE CELL-CYCLE CIRCLE IN YEAST - G2 CYCLIN PROTEOLYSIS INITIATED AT MITOSIS PERSISTS UNTIL THE ACTIVATION OF G1 CYCLINS IN THE NEXT CYCLE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; POSITIVE FEEDBACK; S-PHASE; PROTEIN; KINASE; CDC28; CLN1; PHOSPHORYLATION; DEGRADATION	It is thought that DNA replication and mitosis in yeast are triggered by oscillations in the level of G1-specific (CLN1 and CLN2) and G2-specific (CLB1-CLB4) cyclins, which determine the substrate specificity of the CDC28 protein kinase. It is not understood how the time and order of appearance of different cyclin types are determined. We show here that CLB2 proteolysis, which is important for transition from mitosis to G1, is not confined to a narrow window at the end of mitosis as previously thought but continues until reactivation of CDC28 by CLN cyclins toward the end of the subsequent G1 period. Thus, cell cycle-regulated proteolysis prevents accumulation of G2-specific CLB cyclins during G1 and thereby ensures that the CLN-associated forms of the CDC28 kinase are activated without interference from CLB cylins. Accumulation of CLN cyclins leads to inactivation of CLB cyclin proteolysis, which is a precondition for subsequent activation of G2-specific B-type cyclins.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Amon, Angelika/0000-0001-9837-0314; Nasmyth, Kim/0000-0001-7030-4403				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; CHEREST H, 1985, GENE, V34, P269; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; Maniatis T., 1982, MOL CLONING; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MORTIMER RK, 1969, YEASTS, V1, P385; MOUNTAIN HA, 1991, YEAST, V7, P873, DOI 10.1002/yea.320070814; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1991, COLD SPRING HARB SYM, V56, P9; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSE MD, 1990, LABORATORY COURSE MA; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIMCHEN G, 1972, EXP CELL RES, V75, P207, DOI 10.1016/0014-4827(72)90538-1; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x	31	409	412	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1037	1050		10.1016/0092-8674(94)90443-X	http://dx.doi.org/10.1016/0092-8674(94)90443-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020094				2022-12-28	WOS:A1994NV42500012
J	LOWRY, S; COPE, H				LOWRY, S; COPE, H			POSTGRADUATE TRAINING FOR OVERSEAS DOCTORS IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Article								Foreign doctors, other than those from the European Economic Area, who want to train in Britain have to satisfy registration and immigration requirements before they can take up a post. The General Medical Council administers the registration regulations. These are quite separate from the immigration formalities, which are handled by the Home Office. The rules on both are complicated, and doctors should seek advice early to ensure that unnecessary difficulties do not add to the inevitable stresses associated with moving to a new country and working in a strange system.	GEN MED COUNCIL,DIV OVERSEAS REGISTRAT,LONDON W1N 6AE,ENGLAND		LOWRY, S (corresponding author), BRITISH MED ASSOC,DEPT INT,LONDON WC1H 9JP,ENGLAND.							RICHARDS T, 1994, BRIT MED J, V308, P1627, DOI 10.1136/bmj.308.6944.1627; 1985, EMPLOYMENT OVERSEAS; 1993, CONSULTATION PROPOSA	3	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1624	1627		10.1136/bmj.308.6944.1624	http://dx.doi.org/10.1136/bmj.308.6944.1624			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025433	Green Published			2022-12-28	WOS:A1994NT52800027
J	BOUVET, P; WOLFFE, AP				BOUVET, P; WOLFFE, AP			A ROLE FOR TRANSCRIPTION AND FRGY2 IN MASKING MATERNAL MESSENGER-RNA WITHIN XENOPUS-OOCYTES	CELL			English	Article							RNA-BINDING-PROTEINS; MESSENGER-RIBONUCLEOPROTEIN PARTICLES; HISTONE GENE CLUSTERS; POLYMERASE-III; LAEVIS OOCYTES; TRANSLATION; NUCLEAR; EMBRYOS; DNA; IDENTIFICATION	We find that mRNA synthesized within the Xenopus oocyte nucleus is translated with an efficiency 50 times less than that of mRNA injected into the oocyte cytoplasm. For histone H1 mRNA this effect is independent of mRNA splicing, nuclear export, and the promoter driving transcription. The mRNA synthesized in vivo is translationally competent but is masked from the translational machinery in the cytoplasm through association with proteins including frog Y-box protein 2 (FRGY2). We find that overexpression of FRGY2 facilitates the translational repression of mRNA synthesized within Xenopus oocytes. The requirement for transcription to occur in vivo before a translationally repressed state can be established suggests that these two events are functionally coupled in Xenopus oocytes.			BOUVET, P (corresponding author), NICHHD, MOLEC EMBRYOL LAB, BETHESDA, MD 20892 USA.		, Bouvet/AAC-8779-2020	Bouvet, Philippe/0000-0003-4524-2233				ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; ANDREWS MT, 1987, CELL, V51, P445, DOI 10.1016/0092-8674(87)90640-4; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BIENZ M, 1984, EMBO J, V3, P2477, DOI 10.1002/j.1460-2075.1984.tb02159.x; BOUVET P, 1994, MOL CELL BIOL, V14, P1893, DOI 10.1128/MCB.14.3.1893; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CALDWELL DC, 1985, CELL, V42, P691, DOI 10.1016/0092-8674(85)90126-6; CHO H, 1994, IN PRESS GENE; CRAWFORD DR, 1987, DEVELOPMENT, V101, P741; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DELAPENA P, 1987, CELL, V50, P613, DOI 10.1016/0092-8674(87)90034-1; DESCHAMPS S, 1991, FEBS LETT, V282, P110, DOI 10.1016/0014-5793(91)80456-D; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DWORKIN MB, 1985, P NATL ACAD SCI USA, V82, P7636, DOI 10.1073/pnas.82.22.7636; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HARFORD JB, 1990, ENZYME, V44, P28, DOI 10.1159/000468745; HARLAND R, 1988, DEVELOPMENT, V102, P837; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; OLD RW, 1982, NUCLEIC ACIDS RES, V10, P7561, DOI 10.1093/nar/10.23.7561; OSBORNE HB, 1991, EUR J BIOCHEM, V202, P575, DOI 10.1111/j.1432-1033.1991.tb16410.x; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1988, TRENDS BIOCHEM SCI, V13, P483, DOI 10.1016/0968-0004(88)90236-8; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; RUDERMAN JV, 1979, DEV BIOL, V71, P71, DOI 10.1016/0012-1606(79)90083-6; SOMMERVILLE J, 1993, J CELL BIOL, V120, P277, DOI 10.1083/jcb.120.2.277; Spirin A. S., 1966, Current Topics in Developmental Biology, V1, P1; SPIRIN AS, 1969, EUR J BIOCHEM, V10, P20; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WOODLAND HR, 1979, CELL, V18, P165, DOI 10.1016/0092-8674(79)90365-9; WORMINGTON M, 1991, METHOD CELL BIOL, V36, P167	70	175	183	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					931	941		10.1016/0092-8674(94)90141-4	http://dx.doi.org/10.1016/0092-8674(94)90141-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004679				2022-12-28	WOS:A1994NT33100017
J	GOLINO, P; PISCIONE, F; BENEDICT, CR; ANDERSON, HV; CAPPELLIBIGAZZI, M; INDOLFI, C; CONDORELLI, M; CHIARIELLO, M; WILLERSON, JT				GOLINO, P; PISCIONE, F; BENEDICT, CR; ANDERSON, HV; CAPPELLIBIGAZZI, M; INDOLFI, C; CONDORELLI, M; CHIARIELLO, M; WILLERSON, JT			LOCAL EFFECT OF SEROTONIN RELEASED DURING CORONARY ANGIOPLASTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYCLIC FLOW VARIATIONS; VASOCONSTRICTOR ACTIVITY; ARTERIES; INVIVO; MEDIATORS; VASOSPASM; INJURY; DOGS; THROMBOXANE-A2; NITROGLYCERIN	Background. Serotonin is released after the aggregation of platelets, a phenomenon that may occur after coronary angioplasty. We sought to determine whether serotonin is released into the coronary circulation during coronary angioplasty and to assess whether serotonin can affect coronary-artery tone during angioplasty. Methods. Blood samples were drawn from the ascending aorta and the coronary sinus of eight patients scheduled to undergo angioplasty of the left anterior descending or circumflex coronary artery. Samples were obtained before angioplasty and after each balloon dilation. The dimensions of arterial segments distal to the site of dilation were measured angiographically before angioplasty and 5 and 15 minutes after the last dilation in these eight patients and in seven similar patients; the latter group was treated with ketanserin, a serotonin(2)-receptor antagonist, before angioplasty. Results. Before the eight patients underwent angioplasty, their mean (+/-SE) plasma serotonin level in the aorta was 2.5+/-0.7 ng per milliliter and that in the coronary sinus was 2.3+/-0.6 ng per milliliter (P = 0.34). The seretonin level in plasma from the coronary sinus rose significantly, to 31.5+/-13.5, 17.6+/-5.3, and 29.1+/-8.1 ng per milliliter after the first, second, and third dilations, respectively (P = 0.014 for the comparison with preoperative levels). In contrast, the serotonin level in plasma from the ascending aorta did not change. The cross-sectional area of the coronary artery was significantly reduced 5 and 15 minutes after the last dilation (from a preoperative value of 3.7+/-0.5 mm(2) to 2.7+/-0.4 mm(2) 15 minutes after the last dilation; P = 0.011). This vasoconstriction was significantly blunted in the seven patients who received ketanserin (from 3.7+/-0.5 mm(2) before angioplasty to 3.9+/-0.4 mm(2) after 15 minutes) (P = 0.017 for comparison with the eight patients who did not receive ketanserin). Conclusions. Serotonin is released into the coronary circulation during angioplasty, and this vasoactive substance may contribute to the occurrence of vasoconstriction distal to the dilated site. The vasoconstriction is attenuated by ketanserin, a serotonin(2)-receptor antagonist.	UNIV NAPLES,SCH MED 2,DEPT INTERNAL MED,NAPLES,ITALY; UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,HOUSTON,TX; UNIV TEXAS,HLTH SCI CTR,DIV CARDIOL,HOUSTON,TX	University of Naples Federico II; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	GOLINO, P (corresponding author), UNIV NAPLES,SCH MED 2,DIV CARDIOL,VIA SERGIO PANSINI 5,I-80131 NAPLES,ITALY.			GOLINO, Paolo/0000-0002-3590-6983; INDOLFI, Ciro/0000-0003-1241-6487	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL001669] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-1669] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS GA, 1984, THROMB HAEMOSTASIS, V52, P45; ASHTON JH, 1986, CIRCULATION, V73, P572, DOI 10.1161/01.CIR.73.3.572; ASHTON JH, 1987, CIRCULATION, V76, P952, DOI 10.1161/01.CIR.76.4.952; BRUM JM, 1984, CIRCULATION, V70, P1066, DOI 10.1161/01.CIR.70.6.1066; COHEN RA, 1987, CIRC RES, V61, P829, DOI 10.1161/01.RES.61.6.829; CRAGG A, 1983, AM J CARDIOL, V51, P1441, DOI 10.1016/0002-9149(83)90326-0; DORROS G, 1983, CIRCULATION, V67, P723, DOI 10.1161/01.CIR.67.4.723; ELLIS SG, 1988, CIRCULATION, V77, P372, DOI 10.1161/01.CIR.77.2.372; FISCHELL TA, 1988, CIRCULATION, V78, P1323, DOI 10.1161/01.CIR.78.6.1323; FISCHELL TA, 1990, J CLIN INVEST, V86, P575, DOI 10.1172/JCI114747; GOLINO P, 1990, J AM COLL CARDIOL, V15, P718, DOI 10.1016/0735-1097(90)90652-6; GOLINO P, 1989, CIRCULATION, V79, P154, DOI 10.1161/01.CIR.79.1.154; GOLINO P, 1991, NEW ENGL J MED, V324, P641, DOI 10.1056/NEJM199103073241001; HOLLMAN J, 1983, J AM COLL CARDIOL, V2, P1039, DOI 10.1016/S0735-1097(83)80327-1; HOLLMAN J, 1983, CIRCULATION, V68, P725, DOI 10.1161/01.CIR.68.4.725; HUSSAIN MN, 1987, BIOCHEM MED METAB B, V37, P314, DOI 10.1016/0885-4505(87)90042-9; LAM JYT, 1987, CIRCULATION, V75, P243, DOI 10.1161/01.CIR.75.1.243; LAM JYT, 1988, CIRCULATION, V78, P712, DOI 10.1161/01.CIR.78.3.712; LAMPING KG, 1985, CIRC RES, V57, P46, DOI 10.1161/01.RES.57.1.46; MABIN TA, 1985, J AM COLL CARDIOL, V5, P198, DOI 10.1016/S0735-1097(85)80037-1; MCFADDEN EP, 1991, NEW ENGL J MED, V324, P648, DOI 10.1056/NEJM199103073241002; RUBANYI GM, 1987, J AM COLL CARDIOL, V9, P1243, DOI 10.1016/S0735-1097(87)80462-X; SHIMOKAWA H, 1987, CIRC RES, V61, P256, DOI 10.1161/01.RES.61.2.256; SIGAL SL, 1991, ARTERIOSCLER THROMB, V11, P770, DOI 10.1161/01.ATV.11.3.770; SIMPFENDORFER C, 1987, AM J CARDIOL, V59, P267, DOI 10.1016/0002-9149(87)90797-1; SNEDECOR GW, 1980, STATISTICAL METHODS, P291; SPEARS JR, 1983, CIRCULATION, V68, P453, DOI 10.1161/01.CIR.68.2.453; Tousoulis Dimitris, 1993, Journal of the American College of Cardiology, V21, p341A; TSCHOPP TB, 1977, THROMB RES, V11, P619, DOI 10.1016/0049-3848(77)90020-2; VANDENBERG EK, 1989, CIRCULATION, V79, P116, DOI 10.1161/01.CIR.79.1.116; WALLER BF, 1984, AM J CARDIOL, V53, pC42, DOI 10.1016/0002-9149(84)90744-6; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198	32	138	149	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					523	528		10.1056/NEJM199402243300802	http://dx.doi.org/10.1056/NEJM199402243300802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX436	8043066	Bronze			2022-12-28	WOS:A1994MX43600002
J	SORLIE, PD; BACKLUND, E; JOHNSON, NJ; ROGOT, E				SORLIE, PD; BACKLUND, E; JOHNSON, NJ; ROGOT, E			MORTALITY BY HISPANIC STATUS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-DEATH-INDEX; NUTRITION-EXAMINATION-SURVEY; ISCHEMIC HEART-DISEASE; MEXICAN-AMERICANS; CIGARETTE-SMOKING; RISK-FACTORS; HEALTH; WHITES; HHANES; HYPERTENSION	Objective.-To compare all-cause and cause-specific mortality rates between Hispanic and non-Hispanic groups and estimate the effect of family income, place of birth, and place of residence on these rates. Design.-Cohort study using national survey data matched to the National Death Index, with a mortality follow-up period of 9 years. Setting.-The noninstitutionalized population of the United States. Participants.-Approximately 700 000 respondents (aged 25 years or older), including 40 000 Hispanics, to national surveys conducted by the US Bureau of the Census (Current Population Surveys). Outcome Measures.-All causes and underlying cause of death, coded from the death certificate, occurring between 1979 and 1987. Results.-Adjusting for age, Hispanics were shown to have lower mortality from all causes compared with non-Hispanics (standardized rate ratio [SRR], 0.74 for men, 0.82 for women), lower mortality from cancer (SRR, 0.69 for men, 0.61 for women), lower mortality from cardiovascular disease (SRR, 0.65 for men, 0.80 for women), higher mortality from diabetes (SRR, 1.86 for men, 2.38 for women), and higher mortality from homicide (SRR, 3.60 for men). After adjusting for differences in annual family income, the relative mortality ratios were even lower for Hispanics than non-Hispanics. Conclusions.-These data describe, in a large national cohort study, a lower mortality in Hispanics than in non-Hispanics. This mortality is particularly low after adjustment for differences in family income.	BUR CENSUS,SUITLAND,MD		SORLIE, PD (corresponding author), NHLBI,EPIDEMIOL & BIOMETRY PROGRAM,FED BLDG,ROOM 3A10,BETHESDA,MD 20892, USA.							BANG K M, 1990, American Journal of Public Health, V80, P1495, DOI 10.2105/AJPH.80.12.1495; BECKER TM, 1988, CIRCULATION, V78, P302, DOI 10.1161/01.CIR.78.2.302; CALLE EE, 1993, AM J EPIDEMIOL, V137, P235, DOI 10.1093/oxfordjournals.aje.a116664; COULTAS DB, 1988, AM REV RESPIR DIS, V137, P810, DOI 10.1164/ajrccm/137.4.810; FLANDERS WD, 1984, J CHRON DIS, V37, P449, DOI 10.1016/0021-9681(84)90028-6; GERONIMUS AT, 1990, AM J PUBLIC HEALTH, V80, P1437, DOI 10.2105/AJPH.80.12.1437; GINZBERG E, 1991, JAMA-J AM MED ASSOC, V265, P238, DOI 10.1001/jama.265.2.238; HAYNES SG, 1990, AM J PUBLIC HEALTH, V80, P47, DOI 10.2105/AJPH.80.Suppl.47; LEE DJ, 1991, AM J PUBLIC HEALTH, V81, P859, DOI 10.2105/AJPH.81.7.859; Lee E.T., 1992, STATISTICAL METHODS; MARKIDES KS, 1986, PUBLIC HEALTH REP, V101, P253; MITCHELL BD, 1990, AM J EPIDEMIOL, V131, P423, DOI 10.1093/oxfordjournals.aje.a115517; MITCHELL BD, 1991, CIRCULATION, V83, P45, DOI 10.1161/01.CIR.83.1.45; NOVELLO AC, 1991, JAMA-J AM MED ASSOC, V265, P253, DOI 10.1001/jama.265.2.253; PAPPAS G, 1990, AM J PUBLIC HEALTH, V80, P1431, DOI 10.2105/AJPH.80.12.1431; ROGOT E, 1992, NIH923297 PUBL; ROGOT E, 1988, NIH882896 PUBL; ROSENWAIKE I, 1986, INT J EPIDEMIOL, V15, P30, DOI 10.1093/ije/15.1.30; ROSENWAIKE I, 1987, AM J PUBLIC HEALTH, V77, P603, DOI 10.2105/AJPH.77.5.603; ROSENWAIKE L, 1988, PUBLIC HLTH REP, V103, P195; SAMET JM, 1988, AM REV RESPIR DIS, V137, P815, DOI 10.1164/ajrccm/137.4.815; SMITH JC, 1986, PUBLIC HEALTH REP, V101, P265; SOREL JE, 1991, AM J EPIDEMIOL, V134, P370, DOI 10.1093/oxfordjournals.aje.a116099; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STERN MP, 1987, CIRCULATION, V76, P1245, DOI 10.1161/01.CIR.76.6.1245; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; WILLIAMS BC, 1992, AM J PUBLIC HEALTH, V82, P1145, DOI 10.2105/AJPH.82.8.1145; WINKLEBY MA, 1993, AM J EPIDEMIOL, V137, P1365, DOI 10.1093/oxfordjournals.aje.a116646; 1978, 40 US DEP COMM TECHN; 1991, JAMA-J AM MED ASSOC, V265, P248; [No title captured]; 1990, PHS901148 US DEP HLT; 1993, PHS931232 US DEP HLT; 1991, PHS91232 NAT CTR HLT	34	324	326	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2464	2468		10.1001/jama.270.20.2464	http://dx.doi.org/10.1001/jama.270.20.2464			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MG671	8031341				2022-12-28	WOS:A1993MG67100028
J	NAGATAKI, S; SHIBATA, Y; INOUE, S; YOKOYAMA, N; IZUMI, M; SHIMAOKA, K				NAGATAKI, S; SHIBATA, Y; INOUE, S; YOKOYAMA, N; IZUMI, M; SHIMAOKA, K			THYROID-DISEASES AMONG ATOMIC-BOMB SURVIVORS IN NAGASAKI	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NECK IRRADIATION; HODGKINS-DISEASE; RADIATION; CARCINOMA; HEAD; CHILDHOOD; CANCER; THYROGLOBULIN; EXPOSURE; INFANCY	Objective.-To elucidate the current thyroid disease status for the Nagasaki Adult Health Study cohort of the Radiation Effects Research Foundation. Design.-Survey study. Setting.- Nagasaki, Japan. Participants.-Cohort members of the Nagasaki Adult Health Study who received biennial health examinations from October 1984 to April 1987 (n=2856). A total of 2587 subjects remained after exclusion of persons exposed in Hiroshima or in utero and those who were not in Nagasaki at the time of the bombing. Thyroid radiation dose by the dosimetry system established in 1986 was available for 1978 of the 2587 subjects. Main Outcome Measures.-Thyroid diseases were diagnosed using uniform procedures including ultrasonic scanning. The relationship of the prevalence of each thyroid disease with thyroid radiation dose, sex, and age was analyzed using logistic models. Results.-A significant dose-response relationship was observed for solid nodules, which include cancer, adenoma, adenomatous goiter, and nodules without histological diagnosis, and for antibody-positive spontaneous hypothyroidism (autoimmune hypothyroidism) but not for other diseases. The prevalence of solid nodules showed a monotonic dose-response relationship, yet that of autoimmune hypothyroidism displayed a concave dose-response relationship reaching a maximum (+/-SE) level of 0.7 +/- 0.2 Sv. Conclusions.-The present study confirmed the results of previous studies by showing a significant increase in solid nodules with dose to the thyroid and demonstrated for the first time a significant increase in autoimmune disease among atomic bomb survivors. A concave dose-response relationship indicates the necessity for further studies on the effects of relatively low doses of radiation on thyroid disease.	RADIAT EFFECTS RES FDN, NAGASAKI, JAPAN	Radiation Effects Research Foundation - Japan	NAGATAKI, S (corresponding author), NAGASAKI UNIV, SCH MED, DEPT INTERNAL MED 1, SAKAMOTO 1-7-1, NAGASAKI 852, JAPAN.			nagataki, shigenobu/0000-0002-9974-3554				AKIBA S, 1991, 591 RAD EFF RES F RE; DEGROOT L, 1973, JAMA-J AM MED ASSOC, V225, P487, DOI 10.1001/jama.225.5.487; DIXON WJ, 1983, BMDP STATISTICAL SOF; DUFFY BJ, 1950, CANCER, V3, P1018, DOI 10.1002/1097-0142(1950)3:6<1018::AID-CNCR2820030611>3.0.CO;2-H; FAVUS MJ, 1976, NEW ENGL J MED, V294, P1019, DOI 10.1056/NEJM197605062941901; HEGEDUS L, 1983, J CLIN ENDOCR METAB, V56, P260, DOI 10.1210/jcem-56-2-260; HEMPELMANN LH, 1975, J NATL CANCER I, V55, P519, DOI 10.1093/jnci/55.3.519; JOENSUU H, 1986, ACTA RADIOL ONCOL, V25, P167, DOI 10.3109/02841868609136397; JOHNSON KG, 1965, 1065 AT BOMB CAS COM; KAPLAN MM, 1988, J CLIN ENDOCR METAB, V66, P376, DOI 10.1210/jcem-66-2-376; KOTANI T, 1982, CLIN IMMUNOL IMMUNOP, V24, P111, DOI 10.1016/0090-1229(82)90094-0; LESSARD E, 1985, BNL51882 REP; MODAN B, 1974, LANCET, V1, P277; MORIMOTO I, 1987, J NUCL MED, V28, P1115; NAGATAKI S, 1989, LANCET, V2, P385; NAGATAKI S, 1993, 80 YEARS HASHIMOTO D; NELDER JA, 1983, GENERALIZED LINEAR M; NELSON DF, 1978, CANCER-AM CANCER SOC, V42, P2553, DOI 10.1002/1097-0142(197812)42:6<2553::AID-CNCR2820420608>3.0.CO;2-H; OKAJIMA S, 1990, HEALTH PHYS, V58, P591, DOI 10.1097/00004032-199005000-00004; PARKER LN, 1974, ANN INTERN MED, V80, P600, DOI 10.7326/0003-4819-80-5-600; PARKER LN, 1973, J CLIN ENDOCR METAB, V37, P797, DOI 10.1210/jcem-37-5-797; PINCUS RA, 1967, ANN INTERN MED, V66, P1154, DOI 10.7326/0003-4819-66-6-1154; PRAGER D, 1972, CANCER, V29, P458, DOI 10.1002/1097-0142(197202)29:2<458::AID-CNCR2820290232>3.0.CO;2-N; Rasmussen S N, 1974, J Clin Ultrasound, V2, P143, DOI 10.1002/jcu.1870020211; REFETOFF S, 1975, NEW ENGL J MED, V292, P171, DOI 10.1056/NEJM197501232920402; Roesch WC, 1987, US JAPAN JOINT REASS, V1; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHNEIDER AB, 1977, ANN INTERN MED, V86, P29, DOI 10.7326/0003-4819-86-1-29; SHAFER RB, 1975, ARCH INTERN MED, V135, P843, DOI 10.1001/archinte.135.6.843; SLATSTEI.E, 1971, J CLIN ENDOCR METAB, V32, P833, DOI 10.1210/jcem-32-6-833; SOCOLOW EL, 1963, NEW ENGL J MED, V268, P406, DOI 10.1056/NEJM196302212680803; TAMURA K, 1981, CANCER-AM CANCER SOC, V47, P2704, DOI 10.1002/1097-0142(19810601)47:11<2704::AID-CNCR2820471129>3.0.CO;2-G; WOOD JW, 1969, AM J EPIDEMIOL, V89, P4, DOI 10.1093/oxfordjournals.aje.a120914; YOKOYAMA N, 1986, J NUCL MED, V27, P1475	34	109	112	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					364	370		10.1001/jama.272.5.364	http://dx.doi.org/10.1001/jama.272.5.364			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028167				2022-12-28	WOS:A1994NY90300028
J	CARRIER, DR; HEGLUND, NC; EARLS, KD				CARRIER, DR; HEGLUND, NC; EARLS, KD			VARIABLE GEARING DURING LOCOMOTION IN THE HUMAN MUSCULOSKELETAL SYSTEM	SCIENCE			English	Article							MUSCLE; FOOT	Human feet and toes provide a mechanism for changing the gear ratio of the ankle extensor muscles during a running step. A variable gear ratio could enhance muscle performance during constant-speed running by applying a more effective prestretch during landing, while maintaining the muscles near the high-efficiency or high-power portion of the force-velocity curve during takeoff. Furthermore, during acceleration, variable gearing may allow muscle contractile properties to remain optimized despite rapid changes in running speed. Forceplate and kinematic analyses of running steps show low gear ratios at touchdown that increase throughout the contact phase.	PHAROS SYST INC, S CHELMSFORD, MA 01824 USA		CARRIER, DR (corresponding author), BROWN UNIV, DEPT ECOL & EVOLUTIONARY BIOL, PROVIDENCE, RI 02912 USA.							ALEXANDER RMN, 1977, J ZOOL, V183, P125, DOI 10.1111/j.1469-7998.1977.tb04177.x; [Anonymous], 1982, ANAL VERTEBRATE STRU; BIEWENER AA, 1989, SCIENCE, V245, P45, DOI 10.1126/science.2740914; BIEWENER AA, 1993, J BIOMECH, V26, P294; CARRIER DR, 1983, J ZOOL, V201, P27; CARRIER DR, 1980, AM ZOOL, V20, P895; CAVAGNA GA, 1986, AM J PHYSIOL, V251, pC571, DOI 10.1152/ajpcell.1986.251.4.C571; COATES MI, 1990, NATURE, V347, P66, DOI 10.1038/347066a0; GANS C, 1991, J BIOMECH, V24, P53, DOI 10.1016/0021-9290(91)90377-Y; HAYASHI T, 1987, BIOMECHANICS A, V7, P203; HENNIG EM, 1982, J BIOMED ENG, V4, P213, DOI 10.1016/0141-5425(82)90005-X; HILDEBRAND M, 1982, ANAL VERTEBRATE STRU, P417; Hill A. V., 1950, Science Progress London, V38, P209; LORD M, 1986, J BIOMED ENG, V8, P283, DOI 10.1016/0141-5425(86)90060-9; NALBACH G, 1989, J COMP PHYSIOL A, V165, P321, DOI 10.1007/BF00619351; ROME LC, 1988, NATURE, V335, P824, DOI 10.1038/335824a0; Schaeffer Bobb, 1947, AMER MUS NOVITATES, V1356, P1; WISSER A, 1988, ZOOMORPHOLOGY, V107, P359, DOI 10.1007/BF00312219	18	129	131	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					651	653		10.1126/science.8036513	http://dx.doi.org/10.1126/science.8036513			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036513				2022-12-28	WOS:A1994NZ53800030
J	KUCZMARSKI, RJ; FLEGAL, KM; CAMPBELL, SM; JOHNSON, CL				KUCZMARSKI, RJ; FLEGAL, KM; CAMPBELL, SM; JOHNSON, CL			INCREASING PREVALENCE OF OVERWEIGHT AMONG US ADULTS - THE NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEYS, 1960 TO 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; UNITED-STATES ADULTS; WEIGHT-LOSS; ANTHROPOMETRIC MEASUREMENTS; SOCIOECONOMIC-FACTORS; SKINFOLD THICKNESS; SECULAR TRENDS; RISK-FACTORS; OBESITY; WOMEN	Objective.-To examine trends in overweight prevalence and body mass index of the US adult population. Design.-Nationally representative cross-sectional surveys with an in-person interview and a medical examination, including measurement of height and weight. Setting/Participants.-Between 6000 and 13000 adults aged 20 through 74 years examined in each of four separate national surveys during 1960 to 1962 (the first National Health Examination Survey [NHES I]), 1971 to 1974 (the first National Health and Nutrition Examination Survey [NHANES I]), 1976 to 1980 (NHANES II), and 1988 to 1991 (NHANES III phase 1). Results.-In the period 1988 to 1991, 33.4% of US adults 20 years of age or older were estimated to be overweight. Comparisons of the 1988 to 1991 overweight prevalence estimates with data from earlier surveys indicate dramatic increases in all race/sex groups. Overweight prevalence increased 8% between the 1976 to 1980 and 1988 to 1991 surveys. During this period, for adult men and women aged 20 through 74 years, mean body mass index increased from 25.3 to 26.3; mean body weight increased 3.6 kg. Conclusions.-These nationally representative data document a substantial increase in overweight among US adults and support the findings of other investigations that show notable increases in overweight during the past decade. These observations suggest that the Healthy People 2000 objective of reducing the prevalence of overweight US adults to no more than 20% may not be met by the year 2000. Understanding the reasons underlying the increase in the prevalence of overweight in the United States and elucidating the potential consequences in terms of morbidity and mortality present a challenge to our understanding of the, etiology, treatment, and prevention of overweight.	CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, DIV HLTH EXAMINAT STAT, HYATTSVILLE, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)			Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X				ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; [Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; BEGLEY CE, 1991, J AM DIET ASSOC, V91, P1255; BLAIR SN, 1993, ANN INTERN MED, V119, P702, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00015; BRAY GA, 1992, AM J CLIN NUTR, V55, P488, DOI 10.1093/ajcn/55.2.488s; CHUMLEA WC, 1990, AM J CLIN NUTR, V51, pS902, DOI 10.1093/ajcn/51.5.902; CHUNG CS, 1992, AM J PUBLIC HEALTH, V82, P1544, DOI 10.2105/AJPH.82.11.1544; Colditz G A, 1992, Am J Clin Nutr, V55, p503S, DOI 10.1093/ajcn/55.2.503s; Emery E M, 1993, Am J Health Promot, V7, P342; EZZATI RM, 1992, VITAL HLTH STAT 113, V2; FLEGAL KM, 1988, AM J CLIN NUTR, V48, P544, DOI 10.1093/ajcn/48.3.544; FLEGAL KM, 1988, AM J CLIN NUTR, V48, P535, DOI 10.1093/ajcn/48.3.535; FLETCHER SW, 1993, ANN INTERN MED, V119, P764, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00026; FULWOOD R, 1981, VITAL HLTH STAT 224, V11; GOODRICK GK, 1991, J AM DIET ASSOC, V91, P1243; HIGGINS M, 1993, ANN INTERN MED, V119, P758, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00025; HIMES JH, 1994, AM J CLIN NUTR, V59, P307, DOI 10.1093/ajcn/59.2.307; HORM J, 1993, ANN INTERN MED, V119, P672, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00009; JARRETT RJ, 1986, BRIT MED J, V293, P493, DOI 10.1136/bmj.293.6545.493; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KUCZMARSKI R J, 1992, American Journal of Clinical Nutrition, V55, p495S, DOI 10.1093/ajcn/55.2.495s; KUCZMARSKI RJ, 1990, ANTHROPOMETRIC ASSES; KUMANYIKA S, 1993, J AM DIET ASSOC, V93, P416, DOI 10.1016/0002-8223(93)92287-8; KUMANYIKA SK, 1991, ETHNIC DIS, V2, P166; KUSKOWSKAWOLK A, 1989, INT J OBESITY, V13, P441; LEVY AS, 1993, ANN INTERN MED, V119, P661, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00007; LEVY BT, 1988, J FAM PRACTICE, V27, P285; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; Lohman T. G., 1998, ANTROPOMETRIC STANDA; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MARKS GC, 1989, AM J EPIDEMIOL, V130, P578, DOI 10.1093/oxfordjournals.aje.a115372; MAURER KR, 1985, VITAL HLTH STAT 19, V1; MCARTOR RE, 1992, INT J OBESITY, V16, P335; MCDOWELL A, 1981, VITAL HLTH STAT 15, V1; MCGINNIS JM, 1992, MED SCI SPORT EXER, V24, pS196; NAJJAR MF, 1989, VITAL HLTH STAT 239, V11; NAJJAR MF, 1987, VITAL HLTH STAT 238, V11; PAMUK ER, 1993, ANN INTERN MED, V119, P744, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00023; PETITTI DB, 1988, AM J PREV MED, V4, P327, DOI 10.1016/S0749-3797(18)31141-3; PIANI A, 1993, VITAL HLTH STAT 185, V10; PISUNYER FX, 1991, AM J CLIN NUTR, V53, pS1595; PISUNYER FX, 1992, ANN INTERN MED, V55, pS503; RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; SCHOENBORN CA, 1987, EVAL HEALTH PROF, V10, P438, DOI 10.1177/016327878701000405; SCHOENBORN CA, 1988, VITAL HLTH STAT 163, V10; SEIDELL JC, 1992, INT J OBESITY, V16, pS31; SERDULA MK, 1993, ANN INTERN MED, V119, P667, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00008; SHAH BV, 1991, SUDAAN USERS MANUAL; SHAH M, 1991, INT J OBESITY, V15, P499; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; STOUDT HW, 1965, VITAL HLTH STAT 8, V11; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; WEIGLE DS, 1990, WESTERN J MED, V153, P421; White A, 1993, HLTH SURVEY ENGLAND; WIENPAHL J, 1990, J CLIN EPIDEMIOL, V43, P949, DOI 10.1016/0895-4356(90)90078-4; 1973, VITAL HLTH STAT 10, V1; 1993, MMWR-MORBID MORTAL W, V42, P576; 1993, NIH931088 NAT HEART; 1990, SAS STAT USERS GUIDE; 1965, VITAL HLTH STAT 4, V1; 1981, PC801B1 US DEP COMM, V1, pCHB; [No title captured]; 1990, PHS9050212 US DEP HL	64	2145	2181	2	52	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					205	211		10.1001/jama.272.3.205	http://dx.doi.org/10.1001/jama.272.3.205			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022039				2022-12-28	WOS:A1994NW18500021
J	REUVENY, E; SLESINGER, PA; INGLESE, J; MORALES, JM; INIGUEZLLUHI, JA; LEFKOWITZ, RJ; BOURNE, HR; JAN, YN; JAN, LY				REUVENY, E; SLESINGER, PA; INGLESE, J; MORALES, JM; INIGUEZLLUHI, JA; LEFKOWITZ, RJ; BOURNE, HR; JAN, YN; JAN, LY			ACTIVATION OF THE CLONED MUSCARINIC POTASSIUM CHANNEL BY G-PROTEIN BETA-GAMMA-SUBUNITS	NATURE			English	Article							COUPLED RECEPTOR KINASES; K+-CHANNEL; ION CHANNELS; MECHANISM; EXPRESSION; ALPHA; CLONING; CYCLASE; HEART	ACETYLCHOLINE released during parasympathetic stimulation of the vagal nerve slows the heart rate through the activation of muscarinic receptors and subsequent opening of an inwardly rectifying potassium channel(1) The activation of these muscarinic potassium channels is mediated by a pertussis toxin-sensitive heterotrimeric GTP-binding protein (G protein)(2,3). It has not been resolved whether exogenously applied G(alpha)(4,5) or G(beta gamma)(6,7), Or both, activate the channel. Using a heterologous expression system, we have tested the ability of different G protein subunits to activate the cloned muscarinic potassium channel, GIRK1(8,9). We report here that coexpression of GIRK1 with G(beta gamma) but not G(alpha beta gamma) in Xenopus oocytes results in channel activity that persists in the absence of cytoplasmic GTP. This activity is reduced by fusion proteins of the beta-adrenergic receptor kinase and of recombinant G(alpha i)-GDP, both of which are known to interact with G(beta gamma)(10,11). Moreover, application of recombinant G(beta gamma), but not G(alpha i)-GTP-gamma S, activates GIRK1 channels. Thus G(beta gamma) appears to be sufficient for the activation of GIRK1 muscarinic potassium channels.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	REUVENY, E (corresponding author), UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143, USA.		Lefkowitz, Robert/AAW-2649-2021	Jan, Yuh Nung/0000-0003-1367-6299; Iniguez-Lluhi, Jorge/0000-0001-7010-089X; Jan, Lily/0000-0003-3938-8498				BIRNBAUMER L, 1987, NATURE, V327, P21, DOI 10.1038/327021a0; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1989, PFLUG ARCH EUR J PHY, V413, P325, DOI 10.1007/BF00583550; KUROSE H, 1986, J BIOL CHEM, V261, P6423; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; OKABE K, 1991, J GEN PHYSIOL, V97, P1279, DOI 10.1085/jgp.97.6.1279; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; YATANI A, 1990, AM J PHYSIOL, V258, pH1507, DOI 10.1152/ajpheart.1990.258.5.H1507; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	30	432	443	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					143	146		10.1038/370143a0	http://dx.doi.org/10.1038/370143a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022483				2022-12-28	WOS:A1994NW80400058
J	JENKINS, MA; HOPPER, JL; BOWES, G; CARLIN, JB; FLANDER, LB; GILES, GG				JENKINS, MA; HOPPER, JL; BOWES, G; CARLIN, JB; FLANDER, LB; GILES, GG			FACTORS IN CHILDHOOD AS PREDICTORS OF ASTHMA IN ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article							NATURAL-HISTORY; DISEASE; AGE; FOLLOW; BIRTH	Objective-To determine which factors measured in childhood predict asthma in adult life. Design-Prospective study over 25 years of a birth cohort initially studied at the age of 7. Setting-Tasmania, Australia. Subjects-1494 men and women surveyed in 1991-3 when aged 29 to 32 (75% of a random stratified sample from the 1968 Tasmanian asthma survey of children born in 1961 and at school in Tasmania). Main outcome measures-Self reported asthma or wheezy breathing in the previous 12 months (current asthma). Result-Of the subjects with asthma or wheezy breathing by the age of 7, as reported by their parents 25.6% (190/741) reported current asthma as an adult compared with 10.8% (81/753) of subjects without parent reported childhood asthma (P<0.001). Factors measured at the age of 7 that independently predicted current asthma as an adult were being female (odds ratio 1.57; 95% confidence interval 1.19 to 2.08); having a history of eczema (1.45; 1.04 to 2.03); having a low mild forced expiratory flow rate (interquartile odds ratio 1.40; 1.15 to 1.71); having a mother or father with a history of asthma (1.74 (1.23 to 2.47) and 1.68 (1.18 to 2.38) respectively); and having childhood asthma (1.59; 1.10 to 2.29) and, if so, having the first attack after the age of 2 (1.66; 1.17 to 2.36) or having had more than 10 attacks (1.70; 1.17 to 2.48). Conclusion-Children with asthma reported by their parents in 1968 were more likely than not to be free of symptoms as adults. The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult. These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies, and understanding the onset of asthma in adult life.	UNIV MELBOURNE,DEPT PUBL HLTH & COMMUNITY MED,CARLTON,VIC 3053,AUSTRALIA; ROYAL CHILDRENS HOSP,CLIN EPIDEMIOL & BIOSTAT UNIT,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,CTR ADOLESCENT HLTH,PARKVILLE,VIC 3052,AUSTRALIA; ANTICANC COUNCIL VICTORIA,CTR CANC EPIDEMIOL,CARLTON,VIC 3053,AUSTRALIA	University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne			Carlin, John B/B-3492-2012; Carlin, John/AAG-4332-2020; Jenkins, Mark/P-7803-2015	Carlin, John B/0000-0002-2694-9463; Carlin, John/0000-0002-2694-9463; Jenkins, Mark/0000-0002-8964-6160; Flander, Louisa/0000-0003-0824-9364; Giles, Graham/0000-0003-4946-9099				ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; BAKER RJ, 1978, GLIM SYSTEM; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; BURR ML, 1993, MONOGR ALLERGY, V31, P80; DAY NE, 1976, TISSUE ANTIGENS, V8, P109; FLANDER LB, 1983, 111TH P ANN M AM PUB, P181; GIBSON T, 1969, J BIOMECH, V2, P201, DOI 10.1016/0021-9290(69)90032-3; GILES GG, 1984, AUST NZ J MED, V14, P631, DOI 10.1111/j.1445-5994.1984.tb05015.x; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HOPPER JL, 1992, AM J EPIDEMIOL, V136, P1138, DOI 10.1093/oxfordjournals.aje.a116580; HOSMER DW, 1980, APPLIED LOGISTIC REG; Jenkins M A, 1993, Paediatr Perinat Epidemiol, V7, P67, DOI 10.1111/j.1365-3016.1993.tb00602.x; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; KENDALL MG, 1973, ADV THEORY STAT, V2, P231; PETO J, 1980, BANBURY REPORT, V4, P203; PHELAN PD, 1982, RESPIRATORY ILLNESS; Rubio RL, 1988, ALLERGOL IMMUNOPATH, V16, P263; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83, DOI 10.1093/oxfordjournals.aje.a115646; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; STECENKO AA, 1991, AM REV RESPIR DIS, V144, P1008, DOI 10.1164/ajrccm/144.5.1008; STICK SM, 1991, AM REV RESPIR DIS, V144, P1012, DOI 10.1164/ajrccm/144.5.1012	23	189	196	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					90	93		10.1136/bmj.309.6947.90	http://dx.doi.org/10.1136/bmj.309.6947.90			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038673	Green Published			2022-12-28	WOS:A1994NW71600016
J	DOLPH, PJ; MANSONHING, H; YARFITZ, S; COLLEY, NJ; DEER, JR; SPENCER, M; HURLEY, JB; ZUKER, CS				DOLPH, PJ; MANSONHING, H; YARFITZ, S; COLLEY, NJ; DEER, JR; SPENCER, M; HURLEY, JB; ZUKER, CS			AN EYE-SPECIFIC G-BETA SUBUNIT ESSENTIAL FOR TERMINATION OF THE PHOTOTRANSDUCTION CASCADE	NATURE			English	Article							PROTEIN-KINASE-C; GAMMA-SUBUNITS; PHOSPHOLIPASE-C; PHOTORECEPTOR DEACTIVATION; DROSOPHILA PHOTORECEPTORS; ADENYLYL CYCLASE; ALPHA-SUBUNITS; RECEPTORS; TRANSDUCTION; ASSOCIATION	HETEROTRIMERIC G proteins couple various receptors to intracellular effector molecules. Although the role of the G alpha subunit in effector activation, guanine nucleotide exchange and GTP hydrolysis has been well studied(1-4), the cellular functions of the G beta subunits are less well understood(5,6). G beta gamma dimers bind G alpha subunits and anchor them to the membrane for presentation to the receptor(7,9). Tn specific systems, the G beta subunits have also been implicated in direct coupling to ion channels and to effector molecules(10-19). We have isolated Drosophila melanogaster mutants defective in an eye-specific G-protein beta-subunit (G beta e), and show here that the beta-subunit is essential for G-protein-receptor coupling in vivo. Remarkably, G beta mutants are also severely defective in the deactivation of the light response, demonstrating an essential role for the G beta subunit in terminating the active state of this signalling cascade.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of Washington; University of Washington Seattle					NEI NIH HHS [R01 EY008768] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008768] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BLANK JL, 1992, J BIOL CHEM, V267, P23069; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUNG BKK, 1983, J BIOL CHEM, V258, P495; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MINKE B, 1986, MOL MECHANISM PHOTOR, P241; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; RANGANATHAN R, 1991, TRENDS NEUROSCI, V14, P486, DOI 10.1016/0166-2236(91)90060-8; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YARFITZ S, 1991, NEURON, V7, P429, DOI 10.1016/0896-6273(91)90295-B; YARFITZ S, 1988, P NATL ACAD SCI USA, V85, P7134, DOI 10.1073/pnas.85.19.7134; Zuker Charles S., 1992, Current Opinion in Neurobiology, V2, P622, DOI 10.1016/0959-4388(92)90029-K	33	52	53	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					59	61		10.1038/370059a0	http://dx.doi.org/10.1038/370059a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015606				2022-12-28	WOS:A1994NV71100058
J	LINDENSTROM, E; BOYSEN, G; NYBOE, J				LINDENSTROM, E; BOYSEN, G; NYBOE, J			INFLUENCE OF TOTAL CHOLESTEROL, HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL, AND TRIGLYCERIDES ON RISK OF CEREBROVASCULAR-DISEASE - THE COPENHAGEN CITY HEART-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL; CARDIOVASCULAR-DISEASE; FOLLOW-UP; CEREBRAL INFARCTION; STROKE INCIDENCE; CORONARY; MEN; FRAMINGHAM; DENMARK; JAPAN	Objective-To estimate the influence of plasma total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease. Design-The Copenhagen city heart study is a prospective observational survey with two cardiovascular examinations at five year intervals. Non-fasting plasma lipids were measured in participants once at each examination, along with other variables. The Cox regression model was used to establish the effect of the factors recorded on cerebrovascular events of mostly, but not exclusively, ischaemic origin. Subjects-19 698 women and men at least 20 years old, randomly selected after age stratification from an area of central Copenhagen. Main outcome measures-Initial cases of stroke and transient ischaemic attack recorded from hospital records and death certificates from 1976 through 1988. Results-660 non-haemorrhagic and 33 haemorrhagic events were recorded. Total cholesterol was positively associated with risk of non-haemorrhagic events, but only for levels > 8 mmol/l, corresponding to the upper 5% of the distribution in the study population. For lower plasma cholesterol values the relative risk remained nearly constant. Plasma triglyceride concentration was significantly, positively associated with risk of non-haemorrhagic events. The relative risk corresponding to an increase of 1 mmol/l was 1.12 (95% confidence interval 1.07 to 1.16). There was a negative, log linear association between high density lipoprotein cholesterol and risk of non-haemorrhagic events (0.53 (0.34 to 0.83)). There was no indication that the effects of plasma lipids were different in women and men. Conclusions-The pattern of the association between plasma cholesterol and risk of ischaemic cerebrovascular disease was not log linear, and the increased risk was confined to the upper 5% of the cholesterol distribution. Further studies should concentrate on the association between plasma cholesterol and verified haemorrhagic stroke.	RIGSHOSP, COPENHAGEN CITY HEART STUDY, DK-2200 COPENHAGEN N, DENMARK	Rigshospitalet	LINDENSTROM, E (corresponding author), HVIDOVRE UNIV HOSP, DEPT NEUROL, 433, KETTEGARDS ALLE 30, DK-2650 HVIDOVRE, DENMARK.							Appleyard M., 1989, SCAND J SOC MED, V41, P1; ARONOW WS, 1988, ANGIOLOGY, V39, P563, DOI 10.1177/000331978803900701; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BIHARIVARGA M, 1981, ATHEROSCLEROSIS, V40, P337, DOI 10.1016/0021-9150(81)90144-1; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P73; CHEN ZM, 1989, NEW ENGL J MED, V321, P1339; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; Gatchev O, 1993, Ann Epidemiol, V3, P403, DOI 10.1016/1047-2797(93)90068-F; GERTLER MM, 1968, GERIATRICS, V23, P135; GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JAKOBSON T, 1967, ACTA MED SCAND, V182, P233; JENSEN G, 1983, ACTA MED SCAND S682, V214, P18; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1976, CEREBRAL ARTERIAL DI, P1; LINDENSTROM E, 1993, NEUROEPIDEMIOLOGY, V12, P37, DOI 10.1159/000110297; LINDENSTROM E, 1993, NEUROEPIDEMIOLOGY, V12, P43, DOI 10.1159/000110298; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; MEYER JS, 1959, ARCH NEUROL-CHICAGO, V1, P303, DOI 10.1001/archneur.1959.03840030061006; MUI K, 1989, Osaka City Medical Journal, V35, P145; MURAI A, 1981, STROKE, V12, P167, DOI 10.1161/01.STR.12.2.167; NUBIOLA AR, 1981, ARCH NEUROL-CHICAGO, V38, P468, DOI 10.1001/archneur.1981.00510070102026; PATERSON J C, 1960, Can Med Assoc J, V82, P6; PRENTICE RL, 1982, BIOMETRIKA, V69, P331, DOI 10.1093/biomet/69.2.331; QUIZIBLASH N, 1991, BRIT MED J, V303, P605; QUIZIBLASH N, 1992, CEREBROVASC DIS, V2, P127; REED DM, 1990, AM J EPIDEMIOL, V131, P579, DOI 10.1093/oxfordjournals.aje.a115542; ROBINSON RW, 1963, ANN INTERN MED, V59, P180, DOI 10.7326/0003-4819-59-2-180; ROSSNER S, 1978, LANCET, V1, P577; RYU JE, 1992, STROKE, V23, P823, DOI 10.1161/01.STR.23.6.823; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; SIDHARAM R, 1992, NEUROEPIDEMIOLOGY, V11, P24; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STOKES J, 1987, CIRCULATION, V75, P65; STRACHAN D, 1991, J CLIN EPIDEMIOL, V44, P1187, DOI 10.1016/0895-4356(91)90151-X; TAGGART H, 1979, EUR J CLIN INVEST, V9, P219, DOI 10.1111/j.1365-2362.1979.tb00926.x; UESHIMA H, 1980, PREV MED, V9, P722, DOI 10.1016/0091-7435(80)90017-1; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WESTLUND K, 1972, SCAND J CLIN LAB INV, V30, P1; WILHELMSEN L, 1990, CLIN EXP HYPERTENS A, V12, P845, DOI 10.3109/10641969009073504; Wolf P A, 1978, Adv Neurol, V19, P107; WOLF PA, 1986, SEMIN NEUROL, V6, P243, DOI 10.1055/s-2008-1041467; WOO J, 1990, STROKE, V21, P1407, DOI 10.1161/01.STR.21.10.1407; WOO J, 1991, STROKE, V22, P203, DOI 10.1161/01.STR.22.2.203; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460; YATSU FM, 1989, ANN NEUROL, V26, P3, DOI 10.1002/ana.410260102	51	275	290	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	1994	309	6946					11	15		10.1136/bmj.309.6946.11	http://dx.doi.org/10.1136/bmj.309.6946.11			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044059	Green Published			2022-12-28	WOS:A1994NV89100013
J	KURAHASHI, T; LOWE, G; GOLD, GH				KURAHASHI, T; LOWE, G; GOLD, GH			SUPPRESSION OF ODORANT RESPONSES BY ODORANTS IN OLFACTORY RECEPTOR-CELLS	SCIENCE			English	Article							NUCLEOTIDE-GATED CONDUCTANCE; SENSITIVE ADENYLATE-CYCLASE; ADAPTIVE PROPERTIES; TRANSDUCTION; CHANNELS; NEURONS; SALAMANDER; MEMBRANE; CILIA; ACTIVATION	Odorants activate an inward current in vertebrate olfactory receptor cells. Here it is shown, in receptor cells from the newt, that odorants can also suppress this current, by a mechanism that is distinct from inhibition and adaptation. Suppression provides a simple explanation for two seemingly unrelated phenomena: the anomalously long latency of olfactory transduction and the existence of an ''off response'' at the end of a prolonged stimulus. Suppression may influence the perception of odorants by masking odorant responses and by sharpening the odorant specificities of single cells.	MONELL CHEM SENSES CTR,PHILADELPHIA,PA 19104	Monell Chemical Senses Center								ANHOLT RRH, 1987, BIOCHEMISTRY-US, V26, P788, DOI 10.1021/bi00377a020; ARZT AH, 1986, J COMP PHYSIOL A, V158, P479, DOI 10.1007/BF00603794; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAIN WS, 1975, CHEM SENS FLAV, V1, P339, DOI 10.1093/chemse/1.3.339; DIONNE VE, 1992, J GEN PHYSIOL, V99, P415, DOI 10.1085/jgp.99.3.415; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; FIRESTEIN S, 1990, J PHYSIOL-LONDON, V430, P135, DOI 10.1113/jphysiol.1990.sp018286; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; GESTELAND RC, 1965, J PHYSIOL-LONDON, V181, P525, DOI 10.1113/jphysiol.1965.sp007781; GETCHELL TV, 1978, J PHYSIOL-LONDON, V282, P541, DOI 10.1113/jphysiol.1978.sp012480; GETCHELL TV, 1978, J PHYSIOL-LONDON, V282, P521, DOI 10.1113/jphysiol.1978.sp012479; HUQUE T, 1986, BIOCHEM BIOPH RES CO, V137, P36, DOI 10.1016/0006-291X(86)91172-1; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KLEENE SJ, 1991, J MEMBRANE BIOL, V120, P75, DOI 10.1007/BF01868593; KLEENE SJ, 1993, NEURON, V11, P123, DOI 10.1016/0896-6273(93)90276-W; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KOLESNIKOV SS, 1990, FEBS LETT, V266, P96, DOI 10.1016/0014-5793(90)81515-P; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KURAHASHI T, 1991, NEUROREPORT, V2, P5, DOI 10.1097/00001756-199101000-00001; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; KURAHASHI T, 1989, ZOOL SCI, V6, P19; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; LOWE G, 1993, J PHYSIOL-LONDON, V462, P175, DOI 10.1113/jphysiol.1993.sp019550; MENINI A, 1993, J PHYSIOL-LONDON, V468, P1; MICHEL WC, 1991, J NEUROPHYSIOL, V65, P446, DOI 10.1152/jn.1991.65.3.446; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; SHIBUYA TATSUAKI, 1960, JAPANESE JOUR PHYSIOL, V10, P317; SHIRLEY SG, 1986, BIOCHEM J, V240, P605, DOI 10.1042/bj2400605; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SUZUKI N, 1989, CHEM SENSES, V1, P469; TAKAGI SADAYUKI F., 1960, JAPANESE JOUR PHYSIOL, V10, P385; TAKAGI SF, 1959, NATURE, V184, P60, DOI 10.1038/184060a0; ZUFALL F, 1991, P ROY SOC B-BIOL SCI, V246, P225, DOI 10.1098/rspb.1991.0148	46	88	88	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					118	120		10.1126/science.8016645	http://dx.doi.org/10.1126/science.8016645			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016645				2022-12-28	WOS:A1994NV30100040
J	SOMMER, RJ; STERNBERG, PW				SOMMER, RJ; STERNBERG, PW			CHANGES OF INDUCTION AND COMPETENCE DURING THE EVOLUTION OF VULVA DEVELOPMENT IN NEMATODES	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; C-ELEGANS; CELL LINEAGES; FATES	In Caenorhabditis, the vulva is formed in the central body region from three of six equivalent cells and is induced by the gonad. In some nematodes, however, the vulva is located in the posterior body region. Vulval development has been analyzed in three such genera. The same precursor cells give rise to the vulva in Caenorhabditis and in the posterior vulva species, but in the latter the cells first migrate posteriorly. In two such species, the vulva is not induced by the gonad, but instead relies on intrinsic properties of precursor cells. Thus, evolution of organ position involves changes in induction and competence.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology				Sternberg, Paul/0000-0002-7699-0173				AMBROS V, 1987, DEV EVOLUTIONARY PRO; [Anonymous], 2009, COMMUNICATION; BRENNER S, 1974, GENETICS, V77, P71; CHITWOOD BG, 1950, INTRO NEMATOLOGY; CLANDININ T, UNPUB; ELLIS HM, 1985, THESIS MIT; GOULD SJ, 1979, PROC R SOC SER B-BIO, V205, P581, DOI 10.1098/rspb.1979.0086; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; SALSER SJ, 1993, GENE DEV, V7, P1714, DOI 10.1101/gad.7.9.1714; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SMITH JM, 1985, Q REV BIOL, V60, P265, DOI 10.1086/414425; SOMMER R, UNPUB; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1982, DEV BIOL, V93, P181, DOI 10.1016/0012-1606(82)90251-2; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STERNBERG PW, 1993, ANNU REV GENET, V27, P497, DOI 10.1146/annurev.ge.27.120193.002433; SUDHAUS W, 1976, ZOOLOGICA, V43; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WANG BB, 1993, CELL, V74, P43	22	81	89	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					114	118		10.1126/science.8016644	http://dx.doi.org/10.1126/science.8016644			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016644				2022-12-28	WOS:A1994NV30100039
J	KARHUNEN, PJ; ERKINJUNTTI, T; LAIPPALA, P				KARHUNEN, PJ; ERKINJUNTTI, T; LAIPPALA, P			MODERATE ALCOHOL-CONSUMPTION AND LOSS OF CEREBELLAR PURKINJE-CELLS	BRITISH MEDICAL JOURNAL			English	Article							BRAIN ATROPHY; DRINKING; VALIDITY; AUTOPSY; DEGENERATION; NEURONS; LESIONS; DAMAGE; DEATH	Objective-To examine the dose-response effect of alcohol consumption on the number of cerebellar Purkinje cells. Design-A prospective necropsy study combined with detailed reports on use of alcohol from a relative or friend. The number of Purkinje cells was counted in the anterior midsagittal section of the cerebellar vermis, the area of which was measured by computer assisted morphometry. Setting-Department of forensic medicine, University of Helsinki. Subjects-66 men, aged 35 to 69 years, subjected to medicolegal necropsy because of sudden or violent death. The average all year daily alcohol consumption over the year was 0 to 10 g in 17 men, 11 to 80 g in 24 men, and more than 80 g in 25 men. Main outcome measures-Number of Purkinje cells, alcohol consumption. Results-The numbers and density of Purkinje cells in the cross section of vermis showed a consistent but weak decrease with increasing daily alcohol intake but not with age. A wide variation in the cell counts was observed, especially in men drinking more than 80 g, suggesting differences in the susceptibility to effects of alcohol. Compared with men drinking 40 g or less, a long term moderate consumption of an average of 41 to 80 g daily was associated with a significant average loss of 242 (95% confidence interval 45 to 439) Purkinje cells (15.2%) from a mean of 1583 to 1341 cells. In those drinking 81 to 180 g the average loss was 535 (259 to 811) cells (33.4%) to a mean of 1048 cells. The density of cells in the cross section of vermis also fell significantly by 0.9 cell/mm (0.1 to 1.7) when the daily consumption exceeded 40 g and by 1.4 cell/mm (0.3 to 2.5) when the intake was 81 to 180 g. Only three cases (4.5%); in the series showed macroscopical cerebellar atrophy. Conclusion-Long term intake of moderate doses of alcohol daily for 20-30 years may damage the cerebellum before the onset of macroscopical atrophy. Despite distinct individual differences an all year average daily alcohol intake of 41-80 g results in a risk of significant loss of Purkinje cells.	UNIV HELSINKI,DEPT FORENS MED,SF-00300 HELSINKI,FINLAND; UNIV HELSINKI,DEPT NEUROL,MED RES UNIT,HELSINKI,FINLAND	University of Helsinki; University of Helsinki	KARHUNEN, PJ (corresponding author), UNIV TAMPERE,DEPT PUBL HLTH,BIOMETRY UNIT,PL 607,SF-33101 TAMPERE,FINLAND.							ACKER W, 1982, J NEUROL NEUROSUR PS, V45, P984, DOI 10.1136/jnnp.45.11.984; ALTERMAN AI, 1989, ALCOHOL CLIN EXP RES, V13, P799, DOI 10.1111/j.1530-0277.1989.tb00425.x; ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; CALA LA, 1978, AUST NZ J MED, V8, P147, DOI 10.1111/j.1445-5994.1978.tb04502.x; ESTRIN WJ, 1987, ALCOHOL CLIN EXP RES, V11, P372, DOI 10.1111/j.1530-0277.1987.tb01327.x; FULLER RK, 1988, ALCOHOL CLIN EXP RES, V12, P201, DOI 10.1111/j.1530-0277.1988.tb00180.x; GURLING HMD, 1991, BRIT J ADDICT, V86, P151; HARPER C, 1987, BRIT MED J, V294, P534, DOI 10.1136/bmj.294.6571.534; HARPER C, 1988, J NEUROL NEUROSUR PS, V51, P909, DOI 10.1136/jnnp.51.7.909; HILLBOM M, 1986, J NEUROL SCI, V73, P45, DOI 10.1016/0022-510X(86)90062-6; KARHUNEN PJ, 1990, ALCOHOL ALCOHOLISM, V25, P25; KERR JT, 1989, ALCOHOL CLIN EXP RES, V13, P730, DOI 10.1111/j.1530-0277.1989.tb00412.x; MIDANIK LT, 1989, BRIT J ADDICT, V84, P1419; MUURONEN A, 1989, ALCOHOL CLIN EXP RES, V13, P137, DOI 10.1111/j.1530-0277.1989.tb00298.x; PHILLIPS SC, 1987, BRAIN, V110, P301, DOI 10.1093/brain/110.2.301; SAVOLAINEN VT, 1992, ALCOHOL CLIN EXP RES, V16, P661, DOI 10.1111/j.1530-0277.1992.tb00655.x; SAVOLAINEN VT, 1993, ALCOHOL CLIN EXP RES, V17, P1112, DOI 10.1111/j.1530-0277.1993.tb05673.x; SKULLERUD K, 1991, INT J LEGAL MED, V104, P209, DOI 10.1007/BF01369809; SORENSEN TIA, 1989, LIVER, V9, P189; SUN GY, 1985, ALCOHOLISM CLIN EXP, V9, P95; TAVARES MA, 1987, ALCOHOL CLIN EXP RES, V11, P315, DOI 10.1111/j.1530-0277.1987.tb01315.x; THOMSON AD, 1988, HUM TOXICOL, V7, P455, DOI 10.1177/096032718800700513; TORVIK A, 1986, J NEUROL SCI, V75, P43, DOI 10.1016/0022-510X(86)90049-3; TORVIK A, 1982, J NEUROL SCI, V56, P233, DOI 10.1016/0022-510X(82)90145-9; VICTOR M, 1959, ARCH NEUROL-CHICAGO, V1, P579, DOI 10.1001/archneur.1959.03840060001001; VICTOR M, 1978, ADV NEUROLOGY; WATSON CG, 1984, J STUD ALCOHOL, V45, P344, DOI 10.15288/jsa.1984.45.344; 1987, MED CONSEQUENCES ALC, P125	28	76	76	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1663	1667		10.1136/bmj.308.6945.1663	http://dx.doi.org/10.1136/bmj.308.6945.1663			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NU483	8025457	Green Published			2022-12-28	WOS:A1994NU48300016
J	SMITH, LFP				SMITH, LFP			HIGHER PROFESSIONAL-TRAINING IN GENERAL-PRACTICE - PROVISION OF MASTERS-DEGREE COURSES IN THE UNITED-KINGDOM IN 1993	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FAMILY PHYSICIANS; PRACTITIONERS; GRADUATE; PROGRAM	Review of a 1993 survey of the 29 United Kingdom departments of general practice (or equivalent) identified seven master's degree courses available for general practitioners. Up to another 11 are planned within the next five years. Around 50 general practitioners undertake ah such courses at any one time. Possible reasons for this low uptake include cost, lack of flexibility of courses, and the prospect of writing a thesis. Appropriate master's courses are essential to the future development of general practice, and this paper postulates the characteristics of an ''ideal'' course.	UNIV WESTERN ONTARIO, DEPT FAMILY MED, LONDON, ON, CANADA	Western University (University of Western Ontario)								BRENNAN M, 1985, FAM PRACT, V2, P165, DOI 10.1093/fampra/2.3.165; COHEN MD, 1990, ACAD MED, V65, P348, DOI 10.1097/00001888-199005000-00018; Culpepper L, 1991, Fam Med, V23, P10; Curtis P, 1992, Fam Med, V24, P586; FREELING P, 1991, BRIT MED J, V303, P61, DOI 10.1136/bmj.303.6793.61; GRAY DP, 1992, BRIT J GEN PRACT, V42, P29; GRAY DP, 1991, BRIT MED J, V302, P1380, DOI 10.1136/bmj.302.6789.1380; HAINES AP, 1991, BMJ-BRIT MED J, V303, P1213, DOI 10.1136/bmj.303.6812.1213; HARRIS CM, 1989, J ROY COLL GEN PRACT, V39, P313; McGaghie W C, 1990, Fam Med, V22, P196; MCWHINNEY IR, 1966, LANCET, V1, P419; SANGSTER JF, 1990, CAN FAM PHYSICIAN, V36, P1957; STANLEY IM, 1984, J ROY COLL GEN PRACT, V34, P45; STRASSER R, 1992, MED J AUSTRALIA, V157, P181, DOI 10.5694/j.1326-5377.1992.tb137083.x; SWEENEY R, 1993, AM FAM PHYSICIAN, V47, P37; WILLIAMS WO, 1990, BRIT J GEN PRACT, V40, P491; WRIGHT AF, 1991, BRIT J GEN PRACT, V41, P178; 1990, COLLEGE PLAN PRIORIT; 1991, 51 ROYAL COLL GEN PR; 1993, CAREER STRUCTURE ACA; 1985, QUALITY GENERAL PRAC, V2; 1991, UNDERGRADUATE MED ED	22	13	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 25	1994	308	6945					1679	1682		10.1136/bmj.308.6945.1679	http://dx.doi.org/10.1136/bmj.308.6945.1679			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025463	Green Published			2022-12-28	WOS:A1994NU48300024
J	WILLIAMS, BT; NICHOLL, JP				WILLIAMS, BT; NICHOLL, JP			PATIENT CHARACTERISTICS AND CLINICAL CASELOAD OF SHORT-STAY INDEPENDENT HOSPITALS IN ENGLAND AND WALES, 1992-3	BRITISH MEDICAL JOURNAL			English	Article								Objective-To describe and quantify the patients and clinical activities of independent short stay hospitals. Design-Retrospective survey of hospital records for sampled periods of one financial year and comparison with data from 1981 to 1986. Setting-217 independent hospitals in England and Wales, 1992-3. Main outcome measures-Distributions of sex, age groups, and areas of residence of patients, clinical procedures, financial provision. Results-Data were obtained from 201 (93%) hospitals. An estimated 429 172 inpatients (7% more than 1986) and 249 531 day cases (an increase of 154%) from 1986 were treated in the year. The number of overseas patients was half that in 1986. Clinical case mix remained similar to 1986. Abortion remained the commonest procedure (13% v 19% in 1986). Lens operations, heart operations, endoscopies, and non-surgical cases showed the largest increases from 1986. Proportionately more overseas patients had abortions (30% v 12% for England and Wales residents) and they received 41% of coronary artery bypass grafting. Three quarters of the patients were aged 15-64. The proportion of patients aged over 65 had changed little (19% v 17% in 1986). Estimated average bed occupancy was only 48%. Only one in 20 patients was treated under NHS contract; 90% of episodes were funded through private health insurance. Conclusions-The demand for treatment in private hospitals continues to increase despite additional investment in the NHS, but the overseas market is falling. Overall, the range of clinical activity has changed little.			WILLIAMS, BT (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PUBL HLTH MED,MED CARE RES UNIT,SHEFFIELD S10 2RX,ENGLAND.		Nicholl, Jon/B-8257-2008					LAING WA, 1993, PRIVATE MED INSURANC; NICHOLL JP, 1989, BRIT MED J, V298, P243, DOI 10.1136/bmj.298.6668.243; NICHOLL JP, 1989, BRIT MED J, V298, P239, DOI 10.1136/bmj.298.6668.239; WILLIAMS BT, 1984, BRIT MED J, V289, P446, DOI 10.1136/bmj.289.6442.446; 1993, ACUTE HOSPITALS INDE; 1993, ABORTION STATISTI AB; 1994, ABORTION STATISTI AB; 1986, SURVEY ACUTE HOSPITA; 1992, PPI 18, V14; 1993, DIRECTORY INDEPENDEN; 1986, CLASSIFICATION SURGI	11	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1699	1701		10.1136/bmj.308.6945.1699	http://dx.doi.org/10.1136/bmj.308.6945.1699			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025470	Green Published			2022-12-28	WOS:A1994NU48300035
J	PEAT, JK; VANDENBERG, RH; GREEN, WF; MELLIS, CM; LEEDER, SR; WOOLCOCK, AJ				PEAT, JK; VANDENBERG, RH; GREEN, WF; MELLIS, CM; LEEDER, SR; WOOLCOCK, AJ			CHANGING PREVALENCE OF ASTHMA IN AUSTRALIAN CHILDREN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOUSE-DUST MITE; RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; SCHOOLCHILDREN; CHILDHOOD; POPULATION; ALLERGENS; ATOPY; EXPOSURE	Objective-To investigate whether prevalence of asthma in children increased in 10 years. Design-Serial cross sectional studies of two populations of children by means of standard protocol. Setting-Two towns in New South Wales: Belmont (coastal and humid) and Wagga Wagga (inland and dry). Subjects-Children aged 8-10 years: 718 in Belmont and 769 in Wagga Wagga in 1982; 873 in Belmont and 795 in Wagga Wagga in 1992. Main outcome measures-History of respiratory illness recorded by parents in self administered questionnaire; airway hyperresponsiveness by histamine inhalation test; atopy by skin prick tests; counts of house dust mites in domestic dust. Results-Prevalence of wheeze in previous 12 months increased in Belmont, from 10.4% (75/718) in 1982 to 27.6% (240/873) in 1992 (P<0.001), and in Wagga Wagga, from 15.5% (119/769) to 23.1% (183/795) (P<0.001). The prevalence of airway hyperresponsiveness increased twofold in Belmont to 19.8% (173/873) (P<0.001) and 1.4-fold in Wagga Wagga to 18.1% (P<0.05). The prevalence of airway hyperresponsiveness increased mainly in atopic children only, but the prevalence of atopy was unchanged (about 28.5% in Belmont and about 32.5% in Wagga Wagga). Numbers of house dust mites increased 5.5-fold in Belmont and 4.5-fold in Wagga Wagga. Conclusions-We suggest that exposure to higher allergen levels has increased airway abnormalities in atopic children or that mechanisms that protected airways of earlier generations of children have been altered by new environmental factors.	UNIV SYDNEY, DEPT MED, SYDNEY, NSW 2006, AUSTRALIA; ROYAL PRINCE ALFRED HOSP, INST RESP MED, ALLEN & HANBURYS EPIDEMIOL UNIT, SYDNEY, NSW 2050, AUSTRALIA; WESTMEAD HOSP, DEPT COMMUNITY MED, WESTMEAD, NSW 2145, AUSTRALIA	University of Sydney; University of Sydney; University of Sydney								BAUMAN A, 1992, MED J AUSTRALIA, V156, P827, DOI 10.5694/j.1326-5377.1992.tb136992.x; BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; FEATHER IH, 1993, THORAX, V48, P5, DOI 10.1136/thx.48.1.5; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GREEN WF, 1978, CLIN ALLERGY, V8, P135, DOI 10.1111/j.1365-2222.1978.tb00458.x; HABY MM, 1994, EUR RESPIR J, V7, P43, DOI 10.1183/09031936.94.07010043; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; HURRY VM, 1988, AUST NZ J MED, V18, P745, DOI 10.1111/j.1445-5994.1988.tb00173.x; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PEAT JK, 1992, BMJ-BRIT MED J, V305, P1326, DOI 10.1136/bmj.305.6865.1326; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; PEAT JK, 1991, AM REV RESPIR DIS, V144, P663, DOI 10.1164/ajrccm/144.3_Pt_1.663; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; PEAT JK, 1992, SEARCH, V23, P252; PEAT JK, 1994, IN PRESS EUR RESPIR; PECKHAM C, 1978, J EPIDEMIOL COMMUN H, V32, P79, DOI 10.1136/jech.32.2.79; Pepys J., 1975, BRIT J HOSP MED, V14, P412; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; VARJONEN E, 1992, ALLERGY, V47, P243, DOI 10.1111/j.1398-9995.1992.tb00657.x; WOOLCOCK AJ, 1991, EUR RESPIR REV, V1, P243; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; 1985, SAS USERS GUIDE STAT	37	424	427	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 18	1994	308	6944					1591	1596		10.1136/bmj.308.6944.1591	http://dx.doi.org/10.1136/bmj.308.6944.1591			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025424	Green Published			2022-12-28	WOS:A1994NT52800015
J	TANAKA, N; ISHIHARA, M; KITAGAWA, M; HARADA, H; KIMURA, T; MATSUYAMA, T; LAMPHIER, MS; AIZAWA, S; MAK, TW; TANIGUCHI, T				TANAKA, N; ISHIHARA, M; KITAGAWA, M; HARADA, H; KIMURA, T; MATSUYAMA, T; LAMPHIER, MS; AIZAWA, S; MAK, TW; TANIGUCHI, T			CELLULAR COMMITMENT TO ONCOGENE-INDUCED TRANSFORMATION OR APOPTOSIS IS DEPENDENT ON THE TRANSCRIPTION FACTOR IRF-1	CELL			English	Article							REGULATORY FACTOR-I; ACUTE NONLYMPHOCYTIC LEUKEMIA; TUMOR-SUPPRESSOR GENES; ACUTE MYELOID-LEUKEMIA; IFN-INDUCIBLE GENES; INTERFERON SYSTEM; PROTEIN-KINASE; P53 GENE; MALIGNANT TRANSFORMATION; MYELOGENOUS LEUKEMIA	The transcriptional activator interferon regulatory factor 1 (IRF-1) and its antagonistic repressor IRF-2 are regulators of the interferon (IFN) system and of cell growth. Here we report that embryonic fibroblasts (EFs) from mice with a null mutation in the IRF-1 gene (IRF-1(-/-) mice) can be transformed by expression of an activated c-Ha-ras oncogene. This property is not observed in EFs from wild-type or IRF-2(-/-) mice but is still observed in EFs from mice deficient in both genes. The transformed phenotype of ras-expressing IRF-1(-/-) EFs could be suppressed by the expression of the IRF-1 cDNA. Thus, IRF-1 functions as a tumor suppressor. Furthermore, expression of the c-Ha-ras oncogene causes wild-type but not IRF-1(-/-) EFs to undergo apoptosis when combined with a block to cell proliferation or treated by anticancer drugs or ionizing radiation. Hence, IRF-1 may be a critical determinant of oncogene-induced cell transformation or apoptosis.	UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL & MED BIOPHYS,AMGEN INST,TORONTO M4X 1K9,ON,CANADA; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,TSUKUBA,IBARAKI 305,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; RIKEN	TANAKA, N (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADA OKA,SUITA,OSAKA 565,JAPAN.		Harada, Hisashi/H-2815-2019; Kitagawa, Motoo/W-8468-2019	Harada, Hisashi/0000-0001-5993-1289; Kitagawa, Motoo/0000-0003-1036-840X; Tanaka, Nobuyuki/0000-0002-6373-2220; Kimura, Tohru/0000-0001-9227-0996				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BOS JL, 1989, CANCER RES, V49, P4682; BOULTWOOD J, 1993, BLOOD, V82, P2611; Carter Graham, 1992, Critical Reviews in Oncogenesis, V3, P339; CLRKE AR, 1993, NATURE, V362, P849; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Demaeyer E., 1988, INTERFERONS OTHER RE; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FENAUX P, 1991, BLOOD, V78, P1652; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1991, ORIGINS OF HUMAN CANCER, P423; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KASTAN MB, 1991, CANCER RES, V51, P6304; KERIM S, 1990, LEUKEMIA, V4, P12; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEBEAU MM, 1992, CANCER SURV, V15, P143; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUYAMA T, 1993, WATA, V75, P83; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYASHITA K, 1975, CELL, V5, P131, DOI 10.1016/0092-8674(75)90021-5; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUFNER H, 1993, P NATL ACAD SCI USA, V90, P11503; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SEN GC, 1992, J BIOL CHEM, V267, P5017; Shin S, 1979, Methods Enzymol, V58, P370; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; SLINGERLAND JM, 1991, BLOOD, V77, P1500; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; SUGIMOTO K, 1993, BLOOD, V81, P3022; SUGIMOTO K, 1991, BLOOD, V77, P1153; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSUKADA T, 1993, ONCOGENE, V8, P3313; VILCEK J, 1990, PEPTIDE GROWTH FACTO, V2, P3; VOGELSTEIN B, 1992, CELL, V70, P623; WATANABE N, CELL, V83, P93; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERG RA, 1989, CANCER RES, V49, P3713; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1990, P NATL ACAD SCI USA, V88, P532; YAMAMOTO H, 1994, IN PRESS ONCOGENE; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YOSHIDA K, 1988, CANCER RES, V48, P5503; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	92	474	487	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					829	839		10.1016/0092-8674(94)90132-5	http://dx.doi.org/10.1016/0092-8674(94)90132-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004672				2022-12-28	WOS:A1994NT33100008
J	MAIMARIS, C; SUMMERS, CL; BROWNING, C; PALMER, CR				MAIMARIS, C; SUMMERS, CL; BROWNING, C; PALMER, CR			INJURY PATTERNS IN CYCLISTS ATTENDING AN ACCIDENT AND EMERGENCY DEPARTMENT - A COMPARISON OF HELMET WEARERS AND NON-WEARERS	BRITISH MEDICAL JOURNAL			English	Article							PEDAL CYCLISTS; HEAD-INJURIES; BICYCLE	Objectives-To study circumstances of bicycle accidents and nature of injuries sustained and to determine effect of safety helmets on pattern of injuries. Design-Prospective study of patients with cycle related injuries. Setting-Accident and emergency department of teaching hospital. Subjects-1040 patients with complete data presenting to the department in one year with cycle related injuries, of whom 114 had worn cycle helmets when accident occurred. Main outcome measures-Type of accident and nature and distribution of injuries among patients with and without safety helmets. Results-There were no significant differences between the two groups with respect to type of accident or nature and distribution of injuries other than those to the head. Head injury was sustained by 4/114 (4%) of helmet wearers compared with 100/928 (11%) of non-wearers (P=0.023). Significantly more children wore helmets (50/309 (16%)) than did adults (64/731 (9%)) (P<0.001). The incidence of head injuries sustained in accidents involving motor vehicles (52/288 (18%)) was significantly higher than in those not involving motor vehicles (52/754 (7%)) (chi(2)=28.9, P<0.0001). Multiple logistic regression analysis of probability of sustaining a head injury showed that only two variables were significant: helmet use and involvement of a motor vehicle. Mutually adjusted odds ratios showed a risk factor of 2.95 (95% confidence interval 1.95 to 4.47, P<0.0001) for accidents involving a motor vehicle and a protective factor of 3.25 (1.17 to 9.06, P=0.024) for wearing a helmet. Conclusion-The findings suggest an increased risk of sustaining head injury in a bicycle accident when a motor vehicle is involved and confirm protective effect of helmet wearing for any bicycle accident.	UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,CAMBRIDGE CB2 1TN,ENGLAND	University of Cambridge	MAIMARIS, C (corresponding author), ADDENBROOKES HOSP,DEPT ACCID & EMERGENCY,CAMBRIDGE CB2 2QQ,ENGLAND.							Altman DG, 1991, PRACTICAL STATISTICS; BULLJP, 1988, BRIT MED J, V296, P1144; CLEARY J, 1992, CYCLING WEEKLY  1031, P8; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; Everitt B.S., 1992, ANAL CONTINGENCY TAB; FIFE D, 1983, J TRAUMA, V23, P745, DOI 10.1097/00005373-198308000-00011; GUICHON DMP, 1975, J TRAUMA, V15, P504, DOI 10.1097/00005373-197506000-00009; HILMAN M, 1993, CYCLE HELMETS CASE; ILINGWORTH C, 1991, BRIT MED J, V305, P882; KRAUS JF, 1987, AM J PUBLIC HEALTH, V77, P76, DOI 10.2105/AJPH.77.1.76; MCCARTHY M, 1992, BRIT MED J, V305, P881, DOI 10.1136/bmj.305.6858.881; Mills N J, 1990, Br J Sports Med, V24, P55; MILLS PJ, 1989, 200 TRANSP ROAD RES; NIXON J, 1987, BRIT MED J, V294, P1267, DOI 10.1136/bmj.294.6582.1267; PITT WR, 1994, BRIT MED J, V308, P177, DOI 10.1136/bmj.308.6922.177; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; SHARPE JM, 1993, CAMBRIDGESHIRE COUNT; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1351; TRIPPE HR, 1992, BRIT MED J, V305, P843, DOI 10.1136/bmj.305.6858.843; WOOD T, 1988, ACCIDENT ANAL PREV, V20, P177, DOI 10.1016/0001-4575(88)90002-4; 1992, ROAD ACCIDENT STATIS; 1992, STATISTICAL PACKAGE; 1986, ROAD ACCIDENTS GREAT; 1992, CYCLING HLTH SAFETY	25	101	102	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1537	1540		10.1136/bmj.308.6943.1537	http://dx.doi.org/10.1136/bmj.308.6943.1537			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019309	Green Published			2022-12-28	WOS:A1994NR11000021
J	GRINO, JM				GRINO, JM			BN-52021 - A PLATELET-ACTIVATING-FACTOR ANTAGONIST FOR PREVENTING POSTTRANSPLANT RENAL-FAILURE - A DOUBLE-BLIND, RANDOMIZED STUDY	ANNALS OF INTERNAL MEDICINE			English	Note							RAT KIDNEYS; BN-52021				GRINO, JM (corresponding author), HOSP BELLVITGE PRINCEPS ESPANYA, DEPT NEPHROL, C FEIXA LLARGA S-N, E-08907 LHOSPITALET DE LLOBREGAT, SPAIN.							BRAQUET P, 1987, IMMUNOL TODAY, V8, P345, DOI 10.1016/0167-5699(87)90010-7; CAMPBELL MJ, 1988, BRIT MED J, V296, P1454, DOI 10.1136/bmj.296.6634.1454; CONTE JV, 1991, TRANSPLANTATION, V51, P1152, DOI 10.1097/00007890-199106000-00002; GRINO JM, 1992, AM J KIDNEY DIS, V20, P603, DOI 10.1016/S0272-6386(12)70227-5; LOPEZFARRE A, 1988, BIOCHEM BIOPH RES CO, V152, P129, DOI 10.1016/S0006-291X(88)80689-2; ONTELL SJ, 1990, PLATELET ACTIVATING, P419; PIROTZKY E, 1984, KIDNEY INT, V25, P404, DOI 10.1038/ki.1984.31; SCHLONDORFF D, 1986, AM J PHYSIOL, V251, pF1, DOI 10.1152/ajprenal.1986.251.1.F1; TORRAS J, 1993, TRANSPLANT INT, V6, P236, DOI 10.1007/BF00337106; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	10	48	57	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					345	347		10.7326/0003-4819-121-5-199409010-00006	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042824				2022-12-28	WOS:A1994PD70100006
J	KAO, CM; KATZ, L; KHOSLA, C				KAO, CM; KATZ, L; KHOSLA, C			ENGINEERED BIOSYNTHESIS OF A COMPLETE MACROLACTONE IN A HETEROLOGOUS HOST	SCIENCE			English	Article							METHYLMALONYL-COA EPIMERASE; COENZYME-A MUTASE; POLYKETIDE SYNTHASE; SACCHAROPOLYSPORA-ERYTHRAEA; ESCHERICHIA-COLI; STREPTOMYCES-ERYTHREUS; MACROLIDE ANTIBIOTICS; PROPIONIBACTERIUM-SHERMANII; PHYSICOCHEMICAL PROPERTIES; NUCLEOTIDE-SEQUENCE	Macrocyclic polyketides have been subjects of great interest in synthetic and biosynthetic chemistry because of their structural complexity and medicinal activities. With expression of the entire 6-deoxyerythronolide B synthase (DEBS) (10,283 amino acids) in a heterologous host, substantial quantities of 6-deoxyerythronolide B (6dEB), the aglycone of the macrolide antibiotic erythromycin, and 8,8a-deoxyoleandolide, a 14-membered lactone ring identical to 6dEB except for a methyl group side chain in place of an ethyl unit, were synthesized in Streptomyces coelicolor. The biosynthetic strategy utilizes a genetic approach that facilitates rapid structural manipulation of DEBS or other modular polyketide synthases (PKSs), including those found in actinomycetes with poorly developed genetic methods. From a technological viewpoint, this approach should allow the rational design of biosynthetic products and may eventually lead to the generation of diverse polyketide libraries by means of combinatorial cloning of naturally occurring and mutant PKS modules.	STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305; ABBOTT LABS,ANTIINFECT DISCOVERY RES,ABBOTT PK,IL 60064	Stanford University; Abbott Laboratories				Khosla, Chaitan/0000-0001-6529-495X				ALBERSSCHONBERG G, 1981, J AM CHEM SOC, V103, P4216, DOI 10.1021/ja00404a040; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; BIRCH A, 1993, J BACTERIOL, V175, P3511, DOI 10.1128/jb.175.11.3511-3519.1993; BRENDELBERGER G, 1988, ANGEW CHEM INT EDIT, V27, P1089, DOI 10.1002/anie.198810891; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CANE DE, 1983, J AM CHEM SOC, V105, P4110, DOI 10.1021/ja00350a070; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DONADIO S, 1992, GENE, V115, P97, DOI 10.1016/0378-1119(92)90546-2; DORMAN DE, 1976, HELV CHIM ACTA, V59, P2625, DOI 10.1002/hlca.19760590802; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; FU H, IN PRESS BIOCHEMISTR; FU H, 1993, IN PRESS J AM CHEM S, V115, P11671; FULLER JQ, 1983, BIOCHEM J, V213, P643, DOI 10.1042/bj2130643; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hopwood D.A., 1985, GENETIC MANIPULATION; HSIEH YJ, 1994, J BACTERIOL, V176, P714, DOI 10.1128/jb.176.3.714-724.1994; HUNAITI AA, 1984, ANTIMICROB AGENTS CH, V25, P173, DOI 10.1128/AAC.25.2.173; HUNAITI AR, 1982, ARCH BIOCHEM BIOPHYS, V216, P362, DOI 10.1016/0003-9861(82)90222-3; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KATZ L, UNPUB; KIBWAGE IO, 1987, J ANTIBIOT, V40, P1; LEADLAY PF, 1981, BIOCHEM J, V197, P413, DOI 10.1042/bj1970413; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MACNEIL DJ, 1988, J BACTERIOL, V170, P5607, DOI 10.1128/jb.170.12.5607-5612.1988; Maniatis T., 1982, MOL CLONING; MARDSEN AFA, 1994, SCIENCE, V263, P378; MARTIN JR, 1974, J ANTIBIOT, V27, P570, DOI 10.7164/antibiotics.27.570; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL RG, UNPUB; NOURSE JG, 1975, J AM CHEM SOC, V97, P4584, DOI 10.1021/ja00849a021; OCONNOR M, 1989, SCIENCE, V244, P1307, DOI 10.1126/science.2660262; OHagan D., 1991, POLYKETIDE METABOLIT; OMURA S, 1983, J ANTIBIOT, V36, P614, DOI 10.7164/antibiotics.36.614; ONO M, 1983, J ANTIBIOT, V36, P509, DOI 10.7164/antibiotics.36.509; PIEPER R, UNPUB; POSPISIL S, 1983, J ANTIBIOT, V36, P617, DOI 10.7164/antibiotics.36.617; REYNOLDS KA, 1988, J CHEM SOC PERK T 1, P3195, DOI 10.1039/p19880003195; ROBERTS GA, 1993, EUR J BIOCHEM, V214, P305, DOI 10.1111/j.1432-1033.1993.tb17925.x; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SHERMAN MM, 1986, J ANTIBIOT, V39, P1135, DOI 10.7164/antibiotics.39.1135; TAKIGUCHI Y, 1983, J ANTIBIOT, V36, P502, DOI 10.7164/antibiotics.36.502; TUAN JS, 1990, GENE, V90, P21, DOI 10.1016/0378-1119(90)90435-T; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WEBER JM, 1991, SCIENCE, V252, P114, DOI 10.1126/science.2011746; YU TW, 1994, J BACTERIOL, V176, P2627, DOI 10.1128/JB.176.9.2627-2634.1994	49	212	252	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					509	512		10.1126/science.8036492	http://dx.doi.org/10.1126/science.8036492			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036492				2022-12-28	WOS:A1994NY21600025
J	CAELLES, C; HELMBERG, A; KARIN, M				CAELLES, C; HELMBERG, A; KARIN, M			P53-DEPENDENT APOPTOSIS IN THE ABSENCE OF TRANSCRIPTIONAL ACTIVATION OF P53-TARGET GENES	NATURE			English	Article							REPLICATION FACTOR-A; DNA-REPLICATION; THYMOCYTE APOPTOSIS; CELL-DEATH; WILD-TYPE; P53; PROTEIN; MUTANT; TRANSFORMATION; LOCALIZATION	THE tumour suppressor p53 is required to induce programmed cell death (apoptosis) by DNA-damaging agents(1,2). As p53 is a transcriptional activator(3) that mediates gene induction after DNA damage(4), it has been proposed to be a genetic switch that activates apoptosis-mediator genes(5). Here we evaluate the role of p53 in DNA-damage-induced apoptosis by establishing derivatives of GHFT1 cells, that are somatotropic progenitors immortalized by expression of SV40 T-antigen(6), which express a temperature-sensitive p53 mutant(7). In these cells induction of apoptosis by DNA damage depends strictly on p53 function. A shift to the permissive temperature triggers apoptosis following DNA damage, but this is independent of new RNA or protein synthesis. The extent of apoptotic DNA cleavage is directly proportional to the period during which p53 is functional. These results do not support the proposal that p53 is an activator of apoptosis-mediator genes but rather indicate that p53 either represses genes necessary for cell survival(8) or is a component of the enzymatic machinery for apoptotic cleavage or repair of DNA(5).	UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	University of California System; University of California San Diego								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARPER JW, 1993, CELL, V75, P805; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HIBI M, 1993, GENE DEV, V7, P2134; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEVINE AJ, 1993, BIOL CHEM H-S, V374, P227; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAGIMOV N, 1993, ONCOGENE, V8, P1183; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; Wyllie A H, 1992, Semin Immunol, V4, P389; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	852	868	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					220	223		10.1038/370220a0	http://dx.doi.org/10.1038/370220a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028670				2022-12-28	WOS:A1994NX97100054
J	KONDRASHOV, AS				KONDRASHOV, AS			THE ASEXUAL PLOIDY CYCLE AND THE ORIGIN OF SEX	NATURE			English	Article							CELL-FUSION; EVOLUTION; MEIOSIS; AMEBA; DNA; REPRODUCTION; GYMNAMOEBIA; SELECTION; MUTATIONS; ADVANTAGE	SEX involves syngamy (gamete fusion), which doubles the amount of DNA in a cell, and meiosis(1), which halves it. The result is a 'ploidy cycle' of alternating diploid and haploid phases. Asexual reproduction does not require changes of ploidy, and yet asexual forms may have ploidy cycles. Here I show that such cycles lessen the mutation load, compared with permanent diploidy or polyploidy, and are thus likely to evolve in cases where it is always advantageous to have more than one copy of the genome per cell. The asexual ploidy cycle could have facilitated the origin of sex, by providing a means of orderly genetic reduction available immediately after the origin of syngamy.			KONDRASHOV, AS (corresponding author), CORNELL UNIV,ECOL & SYSTEMAT SECT,ITHACA,NY 14853, USA.							AFONKIN SJ, 1986, ARCH PROTISTENKD, V131, P101, DOI 10.1016/S0003-9365(86)80067-7; [Anonymous], 1988, SEX DEATH PROTOZOA H; Bernstein C., 1991, AGING SEX DNA REPAIR; BRUGEROLLE G, 1993, J EUKARYOT MICROBIOL, V40, P616, DOI 10.1111/j.1550-7408.1993.tb06118.x; BYERS TJ, 1986, INT REV CYTOL, V99, P311; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CLEVELAND LR, 1947, SCIENCE, V105, P287, DOI 10.1126/science.105.2724.287; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; DICKSON DPE, 1984, HEREDITY, V53, P717, DOI 10.1038/hdy.1984.129; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; FAN JB, 1991, NUCLEIC ACIDS RES, V19, P1905, DOI 10.1093/nar/19.8.1905; HAIG D, 1993, J THEOR BIOL, V163, P15, DOI 10.1006/jtbi.1993.1104; HASIMOTO T, 1994, MOL BIOL EVOL, V11, P65; HURST LD, 1993, NATURE, V365, P206, DOI 10.1038/365206a0; HURST LD, 1991, J THEOR BIOL, V150, P561, DOI 10.1016/S0022-5193(05)80447-3; KIMURA M, 1966, GENETICS, V54, P1337; KIRKPATRICK M, 1989, NATURE, V339, P300, DOI 10.1038/339300a0; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1994, GENETICS, V137, P311; KONDRASHOV AS, 1982, GENET RES, V40, P325, DOI 10.1017/S0016672300019194; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; LEWIS WM, 1985, AM NAT, V125, P692, DOI 10.1086/284372; MAGUIRE MP, 1992, J THEOR BIOL, V154, P43, DOI 10.1016/S0022-5193(05)80187-0; Margulis L, 1990, HDB PROTOCTISTA; Margulis L, 1986, ORIGINS SEX; MULLER DG, 1967, PLANTA, V75, P39, DOI 10.1007/BF00380838; Raikov I.B., 1989, Progress in Protistology, V3, P21; SERAVIN LN, 1983, TSITOLOGIYA+, V25, P194; SERAVIN LN, 1984, TSITOLOGIYA+, V26, P123; SERAVIN LN, 1985, ZOOL ZH, V64, P1090; WILLUMSEN NBS, 1987, ARCH PROTISTENKD, V134, P303, DOI 10.1016/S0003-9365(87)80002-7; [No title captured]; [No title captured]	34	73	81	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					213	216		10.1038/370213a0	http://dx.doi.org/10.1038/370213a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028667				2022-12-28	WOS:A1994NX97100051
J	ROBERTSON, CM; HAWKINS, MM; KINGSTON, JE				ROBERTSON, CM; HAWKINS, MM; KINGSTON, JE			LATE DEATHS AND SURVIVAL AFTER CHILDHOOD-CANCER - IMPLICATIONS FOR CURE	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY TUMORS	Objectives-To investigate causes of death and survival in subjects who had survived at least five years after diagnosis of childhood cancer; to compare observed mortality with that expected in the general population; and to compare results with a corresponding cohort diagnosed earlier. Design-Retrospective cohort study. Setting-Population based National Register of Childhood Tumours. Subjects-9080 five year survivors of childhood cancer diagnosed in Britain during 1971-85, of whom 793 had died. Comparison with corresponding cohort diagnosed during 1940-70. Main outcome measures-Cause of death established from all available sources of information (including hospital and general practitioner records and postmortem reports) and underlying cause of death coded on death certificate. Results-Of the 781 deaths for which sufficient information was available, death was attributed to recurrent tumour in 578 (74%) cases, treatment related effect in 121 (15%), second primary tumour 52 (7%), and other causes in 30 (4%). Comparison of observed mortality with that expected in the general population indicated a fourfold excess of deaths from non-neoplasic causes. The risk of dying of recurrent tumour in the next 10 years after surviving five years from diagnosis during 1940-70 and 1971-85 fell from 12% to 8%. The risk of dying from a treatment related effect increased slightly from 1% to 2%. Conclusion-Improvements in five year survival after childhood cancer have been accompanied by a reduction in risk of dying from recurrent tumour during the subsequent 10 years and by a slight increase in risk of dying from treatment related effects. The results provide information relevant to decisions concerning balance between effective treatments and their potentially harmful effects.	UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND; ST BARTHOLOMEWS HOSP,LONDON EC1,ENGLAND	University of Oxford								ALASIRI RH, 1992, MED PEDIATR ONCOL, V20, P315, DOI 10.1002/mpo.2950200409; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; Breslow N. E., 1987, STATISTICAL METHODS, VII; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; HAWKINS MM, 1989, ARCH DIS CHILD, V64, P798, DOI 10.1136/adc.64.6.798; HAWKINS MM, 1990, ARCH DIS CHILD, V65, P1356, DOI 10.1136/adc.65.12.1356; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; KINGSTON JE, 1987, BRIT J CANCER, V56, P331, DOI 10.1038/bjc.1987.199; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; NICHOLSON HS, 1994, CANCER, V73, P3094; ODRISCOLL BR, 1990, NEW ENGL J MED, V323, P378, DOI 10.1056/NEJM199008093230604; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROBERTSON CM, 1992, ARCH DIS CHILD, V67, P1378, DOI 10.1136/adc.67.11.1378; STEINHERZ LJ, 1991, JAMA-J AM MED ASSOC, V266, P1672, DOI 10.1001/jama.266.12.1672; STILLER CA, 1990, BRIT J CANCER, V62, P806, DOI 10.1038/bjc.1990.383; [No title captured]; 1965, MANUAL INT STATISTIC	17	95	97	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					162	166		10.1136/bmj.309.6948.162	http://dx.doi.org/10.1136/bmj.309.6948.162			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044095	Green Published			2022-12-28	WOS:A1994NY22900021
J	WARREN, AJ; COLLEDGE, WH; CARLTON, MBL; EVANS, MJ; SMITH, AJH; RABBITTS, TH				WARREN, AJ; COLLEDGE, WH; CARLTON, MBL; EVANS, MJ; SMITH, AJH; RABBITTS, TH			THE ONCOGENIC CYSTEINE-RICH LIM DOMAIN PROTEIN RBTN2 IS ESSENTIAL FOR ERYTHROID DEVELOPMENT	CELL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; EMBRYONIC STEM-CELLS; MOUSE EMBRYO; ERYTHROPOIETIN RECEPTOR; MESSENGER-RNAS; SCL GENE; C-MYC; DIFFERENTIATION; EXPRESSION	The LIM domain protein rbtn2 is associated with T cell acute leukemias. We demonstrate that rbtn2 is a nuclear protein expressed in the erythroid lineage in vivo, and using homologous recombination, we show that it is essential for erythroid development in mice. The homozygous rbtn2 null mutation leads to failure of yolk sac erythropoiesis and embryonic lethality around E10.5. Moreover, in vitro differentiation of yolk sac tissue from homozygous mutant mice and sequentially targeted double-mutant ES cells demonstrates a block to erythroid development. This shows a pivotal role for a LIM domain protein in lineage specification during mammalian development and suggests that RBTN2 and GATA-1 are critical at similar stages of erythroid differentiation.	UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge; University of Cambridge	WARREN, AJ (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Colledge, William/X-4976-2019; Rabbitts, Terence/D-6262-2016	Colledge, William/0000-0002-9603-4429; Rabbitts, Terence/0000-0002-4982-2609	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, ONCOGENE, V3, P691; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHENG JT, 1993, ONCOGENE, V8, P667; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUI DHK, 1975, BRIT J HAEMATOL, V29, P553, DOI 10.1111/j.1365-2141.1975.tb02742.x; CHUI DHK, 1974, DEV BIOL, V40, P256, DOI 10.1016/0012-1606(74)90128-6; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FISCH P, 1993, ONCOGENE, V8, P3271; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GREEN SM, 1989, ONCOGENE, V4, P737; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTER KR, 1983, NUCLEIC ACIDS RES, V11, P6895, DOI 10.1093/nar/11.19.6895; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MOUTHON MA, 1993, BLOOD, V81, P647; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAIMONDI SC, 1993, BLOOD, V81, P2237; RIBEIRO RC, 1991, BLOOD, V78, P466; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; RUSSELL ES, 1968, GENETICS, V58, P259; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SOFRONIEW MV, 1983, HDB CHEM NEUROANATOM, V1, P210; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; WILES MV, 1991, DEVELOPMENT, V111, P259; WULF GM, 1993, EMBO J, V12, P5065, DOI 10.1002/j.1460-2075.1993.tb06200.x; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	65	534	551	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					45	57		10.1016/0092-8674(94)90571-1	http://dx.doi.org/10.1016/0092-8674(94)90571-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033210				2022-12-28	WOS:A1994NX32800007
J	MOHER, D; DULBERG, CS; WELLS, GA				MOHER, D; DULBERG, CS; WELLS, GA			STATISTICAL POWER, SAMPLE-SIZE, AND THEIR REPORTING IN RANDOMIZED CONTROLLED TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		CLINICAL-TRIALS	Objective.-To describe the pattern over time in the level of statistical power and the reporting of sample size calculations in published randomized controlled trials (RCTs) with negative results. Design.-Our study was a descriptive survey. Power to detect 25% and 50% relative differences was calculated for the subset of trials with negative results in which a simple two-group parallel design was used. Criteria were developed both to classify trial results as positive or negative and to identify the primary outcomes. Power calculations were based on results from the primary outcomes reported in the trials. Population.-We reviewed all 383 RCTs published in JAMA, Lancet, and the New England Journal of Medicine in 1975, 1980, 1985, and 1990. Results.-Twenty-seven percent of the 383 RCTs (n=102) were classified as having negative results. The number of published RCTs more than doubled from 1975 to 1990, with the proportion of trials with negative results remaining fairly stable. Of the simple two-group parallel design trials having negative results with dichotomous or continuous primary outcomes (n=70), only 16% and 36% had sufficient statistical power (80%) to detect a 25% or 50% relative difference, respectively. These percentages did not consistently increase overtime. Overall, only 32% of the trials with negative results reported sample size calculations, but the percentage doing so has improved over time from 0% in 1975 to 43% in 1990. Only 20 of the 102 reports made any statement related to the clinical significance of the observed differences. Conclusions.-Most trials with negative results did not have large enough sample sizes to detect a 25% or a 50% relative difference. This result has not changed over time. Few trials discussed whether the observed differences were clinically important. There are important reasons to change this practice. The reporting of statistical power and sample size also needs to be improved.	UNIV OTTAWA,FAC MED,OTTAWA,ON,CANADA; UNIV OTTAWA,FAC HLTH SCI,OTTAWA K1N 6N5,ON,CANADA	University of Ottawa; University of Ottawa	MOHER, D (corresponding author), OTTAWA CIVIC HOSP,LOEB MED RES INST,CLIN EPIDEMIOL UNIT,1053 CARLING AVE,OTTAWA K1Y 4E9,ON,CANADA.			Moher, David/0000-0003-2434-4206				ALTMAN DG, 1980, BRIT MED J, V281, P1336, DOI 10.1136/bmj.281.6251.1336; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; CHALMERS TC, 1993, ONLINE J CURR C 0911; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COOK DJ, 1992, CHEST, V102, pS305; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; Dickersin K, 1993, ONLINE J CURR CLIN T, V31, P4967; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GRANT A, 1989, BRIT J OBSTET GYNAEC, V96, P397, DOI 10.1111/j.1471-0528.1989.tb02412.x; HAYNES RB, 1990, ANN INTERN MED, V113, P69, DOI 10.7326/0003-4819-113-1-69; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; MOSTELLER F, 1980, CONTROL CLIN TRIALS, V1, P37, DOI 10.1016/S0197-2456(80)80006-7; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	15	408	416	1	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					122	124		10.1001/jama.272.2.122	http://dx.doi.org/10.1001/jama.272.2.122			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015121				2022-12-28	WOS:A1994NV42400011
J	HASHIMOTO, N; WATANABE, N; FURUTA, Y; TAMEMOTO, H; SAGATA, N; YOKOYAMA, M; OKAZAKI, K; NAGAYOSHI, M; TAKEDA, N; IKAWA, Y; AIZAWA, S				HASHIMOTO, N; WATANABE, N; FURUTA, Y; TAMEMOTO, H; SAGATA, N; YOKOYAMA, M; OKAZAKI, K; NAGAYOSHI, M; TAKEDA, N; IKAWA, Y; AIZAWA, S			PARTHENOGENETIC ACTIVATION OF OOCYTES IN C-MOS-DEFICIENT MICE	NATURE			English	Article							PROTO-ONCOGENE PRODUCT; MEIOTIC MATURATION; XENOPUS OOCYTES; MOUSE-TISSUES; MEIOSIS-II; EGGS; PROTOONCOGENE; TRANSCRIPTS; EXPRESSION; FEATURES	IN Xenopus the c-mos proto-oncogene product (Mos) is essential for the initiation of oocyte maturation(1), for the progression from meiosis I to meiosis II2,3 and for the second meiotic metaphase arrest, acting as an essential component of the cytostatic factor CSF4,5. Its function in mouse oocytes is unclear(6-9), however, as is the biological significance of c-mos mRNA expression in testes(1,10) and several somatic tissues(1,10,11). We have generated c-mos-deficient mice by gene targeting in embryonic stem cells. These mice grew at the same rate as their wild-type counterparts and reproduction was normal in the males, but the fertility of the females was very low. The c-mos-deficient female mice developed ovarian teratomas at a high frequency. Oocytes from these females matured to the second meiotic metaphase both in vivo and in vitro, but were activated without fertilization. The results indicate that in mice Mos plays a role in the second meiotic metaphase arrest, but does not seem to be essential for the initiation of oocyte maturation, spermatogenesis or somatic cell cycle.	MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; KURUME UNIV,INST LIFE SCI,DIV MOLEC GENET,KURUME,FUKUOKA 830,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT BIOCHEM,TOKYO 113,JAPAN	RIKEN; Kurume University; Tokyo Medical & Dental University (TMDU)			Okazaki, Kenji/H-4393-2012; Watanabe, Nobumoto/N-6959-2015	Watanabe, Nobumoto/0000-0002-2130-1334				DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; EPPIG JJ, 1977, NATURE, V269, P517, DOI 10.1038/269517a0; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO N, 1988, DEV BIOL, V126, P242, DOI 10.1016/0012-1606(88)90135-2; HASHIMOTO N, 1990, DEV GROWTH DIFFER, V32, P197; HERZOG NK, 1989, ONCOGENE, V4, P1307; HOGAN B, 1986, MANIPULATING MOUSE E, V106; INOUE M, 1975, BIOL REPROD, V13, P546, DOI 10.1095/biolreprod13.5.546; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; WOLF DP, 1978, DEV BIOL, V64, P1, DOI 10.1016/0012-1606(78)90056-8; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43	24	394	412	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					68	71		10.1038/370068a0	http://dx.doi.org/10.1038/370068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015610				2022-12-28	WOS:A1994NV71100061
J	BUTCHER, JM; AUSTIN, M; MCGALLIARD, J; BOURKE, RD				BUTCHER, JM; AUSTIN, M; MCGALLIARD, J; BOURKE, RD			LESSON OF THE WEEK - BILATERAL CATARACTS AND GLAUCOMA INDUCED BY LONG-TERM USE OF STEROID EYE DROPS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL LIVERPOOL UNIV HOSP TRUST,DEPT OPHTHALMOL,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND									ARMALY MANSOUR F., 1965, INVEST OPHTHALMOL, V4, P187; DEBNATH SC, 1987, ANN OPHTHALMOL, V19, P435; LAVIN MJ, 1986, BRIT MED J, V292, P1448, DOI 10.1136/bmj.292.6533.1448; LIMAYE SR, 1988, ANN OPHTHALMOL, V20, P225; MAJURE M, 1989, PEDIATR PULM, V6, P260, DOI 10.1002/ppul.1950060409; RENFRO L, 1992, DERMATOL CLIN, V10, P505; ROBERTS DS, 1986, BMJ-BRIT MED J, V292, P1414, DOI 10.1136/bmj.292.6533.1414; Thygesen P, 1955, T AM ACAD OPHTHALMOL, V57, P64; URBAN RC, 1986, SURV OPHTHALMOL, V31, P102, DOI 10.1016/0039-6257(86)90077-9; 1986, BRIT MED J, V292, P1737; BRIT NATIONAL FORMUL, P379	11	34	35	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					43	43		10.1136/bmj.309.6946.43	http://dx.doi.org/10.1136/bmj.309.6946.43			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044069	Green Published			2022-12-28	WOS:A1994NV89100028
J	ROTHFIELD, LI				ROTHFIELD, LI			BACTERIAL CHROMOSOME SEGREGATION	CELL			English	Review							ESCHERICHIA-COLI; TOPOISOMERASE-IV; DNA-REPLICATION; PLASMID PARTITION; P1 PLASMID; PROTEIN; TERMINATION; MUTANT; SITE				ROTHFIELD, LI (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT MICROBIOL,FARMINGTON,CT 06030, USA.							ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; AUSTIN S, 1990, CELL, V60, P351, DOI 10.1016/0092-8674(90)90584-2; AUSTIN SJ, 1988, PLASMID, V20, P1, DOI 10.1016/0147-619X(88)90001-7; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; EZAKI B, 1991, J BACTERIOL, V173, P6643, DOI 10.1128/jb.173.20.6643-6646.1991; FUNNELL BE, 1991, J BIOL CHEM, V266, P14328; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KATO J, 1992, J BIOL CHEM, V267, P25676; KUEMPEL PL, 1989, CELL, V59, P581, DOI 10.1016/0092-8674(89)90001-9; LOUARN JM, 1991, J BACTERIOL, V173, P5097, DOI 10.1128/jb.173.16.5097-5104.1991; LUTTINGER AL, 1991, NEW BIOL, V3, P687; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; ROTHFIELD LI, 1988, MICROBIOL SCI, V5, P182; VINELLA D, 1992, J BACTERIOL, V174, P2388, DOI 10.1128/JB.174.7.2388-2390.1992	19	27	28	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					963	966		10.1016/0092-8674(94)90435-9	http://dx.doi.org/10.1016/0092-8674(94)90435-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020102				2022-12-28	WOS:A1994NV42500004
J	ADAMS, S				ADAMS, S			SHOULD RELATIVES BE ALLOWED TO WATCH RESUSCITATION - A SISTERS EXPERIENCE	BRITISH MEDICAL JOURNAL			English	Article																			0	55	55	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1687	1687		10.1136/bmj.308.6945.1687	http://dx.doi.org/10.1136/bmj.308.6945.1687			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025465	Green Published			2022-12-28	WOS:A1994NU48300026
J	CELANI, MG; RIGHETTI, E; MIGLIACCI, R; ZAMPOLINI, M; ANTONIUTTI, L; GRANDI, FC; RICCI, S				CELANI, MG; RIGHETTI, E; MIGLIACCI, R; ZAMPOLINI, M; ANTONIUTTI, L; GRANDI, FC; RICCI, S			COMPARABILITY AND VALIDITY OF 2 CLINICAL SCORES IN THE EARLY DIFFERENTIAL-DIAGNOSIS OF ACUTE STROKE	BRITISH MEDICAL JOURNAL			English	Article							HEMORRHAGE; INFARCTION	Objective-To compare two available clinical scores for the differential diagnosis of cerebral ischaemia and haemorrhage in acute stroke patients. Design-Prospective, multicentre study of acute stroke patients evaluated with computed tomography and Allen and Siriraj scores; the scores were tested for comparability (kappa statistic) and validity (sensitivity, specificity, positive and negative predictive values, diagnostic gain). The effect of a policy of using Allen and Siriraj scores to determine pathological type of stroke before computed tomography was calculated. Setting-Three hospitals in Italy, all participating in the international stroke trial, with different access facilities to computed tomography. Subjects-231 consecutive patients who were screened in the three hospitals for possible inclusion in the international stroke trial from 1 November 1991 to 31 May 1993. Results-The prevalence of haemorrhage (diagnosed with computed tomography) was 14.7% (95% confidence interval 10.1% to 19.3%). Allen scores were ''uncertain'' in 44 cases and Siriraj scores in 38 cases; in the 164 cases with both the scores in the range of ''certainty'' kappa was 0.72. Sensitivity, specificity, positive and negative predictive values, and diagnostic gain for haemorrhage were 0.38, 0.98, 0.71, 0.91, and 0.58 for Allen scores and 0.61, 0.94, 0.63, 0.93, and 0.48 for Siriraj scores; positive predictive values for infarction were 91% for Allen scores and 93% for Siriraj scores. According to these data, of 1000 patients with acute stroke, 680 would be correctly and 70 wrongly diagnosed as ''ischaemic'' with the Alien score; the figures would be 671 and 48 with Siriraj score. Conclusion-When computed tomography is not immediately available and the clinician wishes to start antithrombotic treatment (or randomise patients in a clinical trial), the Siriraj score (and possibly the Alien score) can be useful to identify patients at low risk of intracerebral haemorrhage.	OSPED CIVILE,DIV MED,CORTONA,ITALY; OSPED MAGGIORE TRIESTE,DIV NEUROL,TRIESTE,ITALY		CELANI, MG (corresponding author), CLIN NEUROL,VIA E DAL POZZO 50,I-06126 PERUGIA,ITALY.		Zampolini, Mauro/B-7749-2009; celani, maria grazia/AAF-4143-2020	celani, maria grazia/0000-0002-0739-4140				Allen CMC, 1983, Q J MED, V208, P515; BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; CELANI MG, 1992, J NEUROL, V239, P411; GARDNER MJ, 1989, CONFIDENCE INTERVAL; LINDELY RI, 1993, 2ND INT C STROK GEN, P20; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SANDERCOCK PAG, 1985, BRIT MED J, V291, P1675, DOI 10.1136/bmj.291.6510.1675	8	34	34	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1674	1676		10.1136/bmj.308.6945.1674	http://dx.doi.org/10.1136/bmj.308.6945.1674			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025461	Green Published			2022-12-28	WOS:A1994NU48300020
J	BARLOWE, C; ORCI, L; YEUNG, T; HOSOBUCHI, M; HAMAMOTO, S; SALAMA, N; REXACH, MF; RAVAZZOLA, M; AMHERDT, M; SCHEKMAN, R				BARLOWE, C; ORCI, L; YEUNG, T; HOSOBUCHI, M; HAMAMOTO, S; SALAMA, N; REXACH, MF; RAVAZZOLA, M; AMHERDT, M; SCHEKMAN, R			COPII - A MEMBRANE COAT FORMED BY SEC PROTEINS THAT DRIVE VESICLE BUDDING FROM THE ENDOPLASMIC-RETICULUM	CELL			English	Article							YEAST SECRETORY PATHWAY; GOLGI TRANSPORT VESICLES; ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; VESICULAR TRANSPORT; BETA-COP; ESCHERICHIA-COLI; COMPLEX; CLATHRIN; ER	In vitro synthesis of endoplasmic reticulum-derived transport vesicles has been reconstituted with washed membranes and th ree soluble proteins (Sar1p, Sec13p complex, and Sec23p complex). Vesicle formation requires GTP but can be driven by nonhydrolyzable analogs such as GMP-PNP. However, GMP-PNP vesicles fail to target and fuse with the Golgi complex whereas GTP vesicles are functional. All the cytosolic proteins required for vesicle formation are retained on GMP-PNP vesicles, while Sar1p dissociates from GTP vesicles. Thin section electron microscopy of purified preparations reveals a uniform population of 60-65 nm vesicles with a 10 nm thick electron dense coat. The subunits of this novel coat complex are molecularly distinct from the constituents of the nonclathrin coatomer involved in intra-Golgi transport. Because the overall cycle of budding driven by these two types of coats appears mechanistically similar, we propose that the coat structures be called COPI and COPII.	UNIV GENEVA, SCH MED, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	BARLOWE, C (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.		Salama, Nina Reda/AAG-2437-2019	Salama, Nina Reda/0000-0003-2762-1424				BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BARLOWE C, J BIOL CHEM, V268, P87393; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; KUGE O, 1993, J CELL BIOL, V123, P1727, DOI 10.1083/jcb.123.6.1727; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	60	1043	1058	0	135	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					895	907		10.1016/0092-8674(94)90138-4	http://dx.doi.org/10.1016/0092-8674(94)90138-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004676				2022-12-28	WOS:A1994NT33100014
J	PIRKLE, JL; BRODY, DJ; GUNTER, EW; KRAMER, RA; PASCHAL, DC; FLEGAL, KM; MATTE, TD				PIRKLE, JL; BRODY, DJ; GUNTER, EW; KRAMER, RA; PASCHAL, DC; FLEGAL, KM; MATTE, TD			THE DECLINE IN BLOOD LEAD LEVELS IN THE UNITED-STATES - THE NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEYS (NHANES)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe trends in blood lead levels for the US population and selected population subgroups during the time period between 1976 and 1991. Design.-Two nationally representative cross-sectional surveys and one cross-sectional survey representing Mexican Americans in the southwestern United States. Setting/Participants.-Participants in two national surveys that included blood lead measurements: the second National Health and Nutrition Examination Survey, 1976 to 1980 (n=9832), and phase 1 of the third National Health and Nutrition Examination Survey, 1988 to 1991 (n=12119). Also, Mexican Americans participating in the Hispanic Health and Nutrition Examination Survey, 1982 to 1984 (n=5682). Results.-The mean blood lead level of persons aged 1 to 74 years dropped 78%, from 0.62 to 0.14 mu mol/L (12.8 to 2.8 mu g/dL). Mean blood lead levels of children aged 1 to 5 years declined 77% (0.66 to 0.15 mu mol/L [13.7 to 3.2 mu g/dL]) for non-Hispanic white children and 72% (0.97 to 0.27 mu mol/L [20.2 to 5.6 mu g/dL]) for non-Hispanic black children. The prevalence of blood lead levels 0.48 mu mol/L (10 mu g/dL) or greater for children aged 1 to 5 years declined from 85.0% to 5.5% for non-Hispanic white children and from 97.7% to 20.6% for non-Hispanic black children. Similar declines were found in population subgroups defined by age, sex, race/ethnicity, income level, and urban status. Mexican Americans also showed similar declines in blood lead levels of a slightly smaller magnitude over a shorter time. Conclusions.-The results demonstrate a substantial decline in blood lead levels of the entire US population and within selected subgroups of the population. The major cause of the observed decline in blood lead levels is most likely the removal of 99.8% of lead from gasoline and the removal of lead from soldered cans. Although these data indicate major progress in reducing lead exposure, they also show that the same sociodemographic factors continue to be associated with higher blood lead levels, including younger age, male sex, non-Hispanic black race/ethnicity, and low income level. Future efforts to remove other lead sources (eg, paint, dust, and soil) are needed but will be more difficult than removing lead from gasoline and soldered cans.	CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,LEAD POISONING PREVENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,HYATTSVILLE,MD 20782	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	PIRKLE, JL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA 30333, USA.		Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X				ADAMS M A, 1991, Chemical Speciation and Bioavailability, V3, P37; ANNEST JL, 1983, NEW ENGL J MED, V308, P1373, DOI 10.1056/NEJM198306093082301; ANNEST JL, 1984, VITAL HLTH STAT 11, V223; [Anonymous], 1988, NATURE EXTENT LEAD P; [Anonymous], 1991, PREVENTING LEAD POIS; BOLGER P M, 1991, Chemical Speciation and Bioavailability, V3, P31; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; CARTERPOKRAS O, 1990, PUBLIC HEALTH REP, V105, P388; EZZATI TM, 1992, VITAL HLTH STAT 2, V113; MAHAFFEY KR, 1982, NEW ENGL J MED, V307, P573, DOI 10.1056/NEJM198209023071001; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; SHAH BV, 1991, SUDAAN USERS MANUAL; [No title captured]; 1990, SAS LANGUAGE VERSION; 1981, LABORATORY PROCEDURE; 1992, FOOD SOFT DRINK CAN; 1991, H15089 US DEP COMM C; 1986, EPA600883028AF REP; 1982, H15080 US DEP COMM C; 1985, VITAL HLTH STAT 1, V19; 1981, VITAL HLTH STAT 1, V15; 1991, Q SUMMARY LEAD PHASE	22	693	715	1	52	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					284	291		10.1001/jama.272.4.284	http://dx.doi.org/10.1001/jama.272.4.284			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX806	8028141				2022-12-28	WOS:A1994NX80600030
J	SLYPER, AH				SLYPER, AH			LOW-DENSITY-LIPOPROTEIN DENSITY AND ATHEROSCLEROSIS - UNRAVELING THE CONNECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-ARTERY DISEASE; FAMILIAL COMBINED HYPERLIPIDEMIA; LDL PARTICLE-SIZE; MYOCARDIAL-INFARCTION; SUBCLASS PHENOTYPES; SUBFRACTIONS; CHOLESTEROL; RISK; APOLIPOPROTEINS; PATTERNS	Objective.-To provide an overview of the relationship between low-density lipoprotein (LDL) density and coronary artery disease and to examine this relationship in terms of lipid peroxidation and the atherogenic remnant hypothesis. Data Sources.-English-language studies and reviews pertaining to LDL composition and size were identified through a MEDLINE search and reference citations. Study Selection.-Clinical studies on the following topics were critically reviewed: (I)the association between LDL density and coronary artery disease, (2) the relationship between LDL density and the levels and composition of other lipoproteins, and (3) the influence of environmental and genetic factors on LDL density. Data Synthesis.-Low-density lipoprotein is a heterogeneous lipoprotein containing many subpopulations identifiable on the basis of density and size. There is an increased prevalence of small, dense LDL particles in coronary artery disease and conditions commonly associated with atherogenesis, such as non-insulin-dependent diabetes mellitus and familial combined hyperlipidemia. Exercise, visceral fat accumulation, and diet influence LDL density. In comparison with buoyant LDL, dense LDL is associated with a more atherogenic type of lipoprotein profile. An important relationship exists between the triglyceride level and the formation of LDL subpopulations. Conclusion.-Unraveling the connection between dense LDL and atherogenesis should provide important insights into the basic mechanisms underlying atherogenesis.			SLYPER, AH (corresponding author), MED COLL WISCONSIN,MACC FUND RES CTR,DEPT PEDIAT,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.							AUSTIN MA, 1988, AM J HUM GENET, V43, P838; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495; AUSTIN MA, 1991, DIABETES METAB REV, V7, P173, DOI 10.1002/dmr.5610070306; AUWERX JH, 1989, ARTERIOSCLEROSIS, V9, P319, DOI 10.1161/01.ATV.9.3.319; BARAKAT HA, 1990, DIABETES, V39, P1527, DOI 10.2337/diabetes.39.12.1527; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P187, DOI 10.1161/01.ATV.12.2.187; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P1410, DOI 10.1161/01.ATV.12.12.1410; CAMPOS H, 1991, ARTERIOSCLER THROMB, V11, P1077, DOI 10.1161/01.ATV.11.4.1077; CHEN YDI, 1991, DIABETES METAB REV, V7, P191, DOI 10.1002/dmr.5610070308; COMINACINI L, 1993, ATHEROSCLEROSIS, V99, P63, DOI 10.1016/0021-9150(93)90051-U; CROUSE JR, 1985, J LIPID RES, V26, P566; DECKELBAUM RJ, 1984, ARTERIOSCLEROSIS, V4, P225, DOI 10.1161/01.ATV.4.3.225; DEURAAF J, 1991, ARTERIOSCLER THROMB, V11, P298; FEINGOLD KR, 1992, ARTERIOSCLER THROMB, V12, P1496, DOI 10.1161/01.ATV.12.12.1496; HUNT SC, 1989, ARTERIOSCLEROSIS, V9, P335, DOI 10.1161/01.ATV.9.3.335; KNIGHT BL, 1986, ATHEROSCLEROSIS, V59, P301, DOI 10.1016/0021-9150(86)90125-5; KRAUSS RM, 1987, AM HEART J, V113, P578, DOI 10.1016/0002-8703(87)90636-3; KRAUSS RM, 1982, J LIPID RES, V23, P97; LAMONFAVA S, 1991, ATHEROSCLEROSIS, V91, P97, DOI 10.1016/0021-9150(91)90191-5; LAMONFAVA S, 1989, J CLIN ENDOCR METAB, V68, P17, DOI 10.1210/jcem-68-1-17; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MCNAMARA JR, 1987, ARTERIOSCLEROSIS, V7, P483, DOI 10.1161/01.ATV.7.5.483; REAVEN GM, 1993, J CLIN INVEST, V92, P141, DOI 10.1172/JCI116541; SCHAEFER EJ, 1987, CIRCULATION, V76, P531; SLYPER AH, 1992, LANCET, V340, P289, DOI 10.1016/0140-6736(92)92368-P; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; TERRY RB, 1989, J CLIN ENDOCR METAB, V68, P191, DOI 10.1210/jcem-68-1-191; THOMPSON GR, 1984, COLOGNE ATHEROSCLERO, V2, P121; TORNVALL P, 1991, ATHEROSCLEROSIS, V90, P67, DOI 10.1016/0021-9150(91)90245-X; TRIBBLE DL, 1992, ATHEROSCLEROSIS, V93, P189, DOI 10.1016/0021-9150(92)90255-F; WILLIAMS PT, 1986, AM J CLIN NUTR, V44, P788, DOI 10.1093/ajcn/44.6.788; WILLIAMS PT, 1986, METABOLISM, V35, P45, DOI 10.1016/0026-0495(86)90094-6; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	35	76	76	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					305	308		10.1001/jama.272.4.305	http://dx.doi.org/10.1001/jama.272.4.305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX806	8028144				2022-12-28	WOS:A1994NX80600033
J	FERRONOVICK, S; JAHN, R				FERRONOVICK, S; JAHN, R			VESICLE FUSION FROM YEAST TO MAN	NATURE			English	Article							INTEGRAL MEMBRANE-PROTEIN; GTP-BINDING PROTEINS; VESICULAR TRANSPORT; NEUROTRANSMITTER RELEASE; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; GOLGI-COMPLEX; TETANUS TOXIN; IN-VITRO; SYNAPTOTAGMIN	Membrane budding and fusion occur in all eukaryotic cells. Their underlying mechanisms have been studied in mammalian neurons and in yeast, a simple eukaryote. The differences between these two systems would suggest that fusion events in yeast and the neuron would operate by different mechanisms, but recent advances indicate that this is not true.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University	FERRONOVICK, S (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL & PHARMACOL,NEW HAVEN,CT 06510, USA.			Jahn, Reinhard/0000-0003-1542-3498				AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BECHERER KA, 1992, EMBL DATA BANK REL, V31, P90395; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; INOUE A, 1992, J BIOL CHEM, V267, P10613; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LINK E, 1993, J BIOL CHEM, V268, P18423; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MCMAHON H, 1993, NATURE, V364, P356; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; PRYER NK, 1992, REV BIOCH, V61, P471; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; WARREN G, 1993, NATURE, V362, P397; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Wood WB, 1988, NEMATODE CAENORHABDI; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; [No title captured]	56	586	594	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					191	193		10.1038/370191a0	http://dx.doi.org/10.1038/370191a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028665				2022-12-28	WOS:A1994NX97100042
J	WILLMAN, CL; BUSQUE, L; GRIFFITH, BB; FAVARA, BE; MCCLAIN, KL; DUNCAN, MH; GILLILAND, DG				WILLMAN, CL; BUSQUE, L; GRIFFITH, BB; FAVARA, BE; MCCLAIN, KL; DUNCAN, MH; GILLILAND, DG			LANGERHANS-CELL HISTIOCYTOSIS (HISTIOCYTOSIS-X) - A CLONAL PROLIFERATIVE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHROMOSOME INACTIVATION; METHYLATION PATTERNS; DENDRITIC CELLS; HUMAN-TUMORS; M27-BETA; ORIGIN; PROBE; POLYMORPHISMS; LESIONS	Background. The lesions of Langerhans'-cell histiocytosis (histiocytosis X), a proliferative histiocytic disorder of unknown cause, contain histiocytes similar in phenotype to dendritic Langerhans' cells. The disease ranges in severity from a fatal leukemia-like disorder to an isolated lytic lesion of bone. Intermediate forms of the disease are usually characterized by multiorgan involvement, diabetes insipidus, and a chronic course. Methods. To determine whether Langerhans' histiocytosis is a polyclonal reactive disease or a clonal disorder, we used X-linked polymorphic DNA probes (HUMARA, PGK, M27 beta[DXS255], and HPRT) to assess clonality in lesional tissues and control leukocytes from 10 female patients with various forms of the disease. Lymphoid clonality was also assessed by analysis of rearrangements at immunoglobulin and T-cell-receptor gene loci. Results. The HUMARA assay detected clonal cells in the lesions of 9 of the 10 patients: 3 patients had acute disseminated disease, 3 had unifocal disease, and 3 had intermediate forms. The percentage of clonal cells closely approximated the percentage of CD1a-positive histiocytes in each lesion. Clonality was also confirmed in two of nine cases with the PGK or M27 beta probe. Extreme constitutional lyonization precluded assessment of clonality in the 10th case. Lymphoid clonality was ruled out in all cases. Conclusions. The detection of clonal histiocytes in all forms of Langerhans'-cell histiocytosis indicates that this disease is probably a clonal neoplastic disorder with highly variable biologic behavior. Thus, genetic mutations that promote clonal expansion of Langerhans' cells or their precursors may now be identified.	UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT PEDIAT,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,CTR MOLEC & CELLULAR DIAGNOST,ALBUQUERQUE,NM 87131; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; ALL CHILDRENS HOSP,DEPT PATHOL & LAB MED,ST PETERSBURG,FL; TEXAS CHILDRENS HOSP,BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	University of New Mexico; University of New Mexico; University of New Mexico; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Baylor College of Medicine	WILLMAN, CL (corresponding author), UNIV NEW MEXICO,SCH MED,CTR CANC,900 CAMINO SALUD NE,ALBUQUERQUE,NM 87131, USA.			McClain, Kenneth/0000-0003-0725-6263				ABRAHAMSON G, 1990, BRIT J HAEMATOL, V74, P371, DOI 10.1111/j.1365-2141.1990.tb02601.x; ALLEN RC, 1992, AM J HUM GENET, V51, P1229; [Anonymous], 1987, LANCET, V1, p[208, 209]; BOYD Y, 1990, GENOMICS, V7, P182, DOI 10.1016/0888-7543(90)90539-7; BROADBENT V, 1984, LANCET, V1, P253; BUSQUE L, 1994, NUCLEIC ACIDS RES, V22, P697, DOI 10.1093/nar/22.4.697; BUSQUE L, 1993, BLOOD, V82, P337; CACHIA PG, 1992, GENOMICS, V14, P70, DOI 10.1016/S0888-7543(05)80285-X; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; FAVARA BE, 1990, LEUKEMIA LYMPHOMA, V2, P141, DOI 10.3109/10428199009053518; FAVARA BE, 1991, SEMIN ONCOL, V18, P3; FEY MF, 1992, J CLIN INVEST, V89, P1438, DOI 10.1172/JCI115733; GALE RE, 1991, BRIT J HAEMATOL, V79, P193, DOI 10.1111/j.1365-2141.1991.tb04521.x; GILLILAND DG, 1991, P NATL ACAD SCI USA, V88, P6848, DOI 10.1073/pnas.88.15.6848; GREENBERGER JS, 1981, MEDICINE, V60, P311, DOI 10.1097/00005792-198109000-00001; HAGE C, 1993, HUM PATHOL, V24, P840, DOI 10.1016/0046-8177(93)90133-2; Hand. A., 1893, ARCH PEDIAT, V10, P673; HODGES E, 1991, BRIT J HAEMATOL, V77, P315, DOI 10.1111/j.1365-2141.1991.tb08577.x; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOMP DM, 1987, NEW ENGL J MED, V316, P747, DOI 10.1056/NEJM198703193161211; KURAHASHI H, 1991, BLOOD, V77, P1161; LAHEY ME, 1962, J PEDIATR-US, V60, P664, DOI 10.1016/S0022-3476(62)80091-2; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEAHY MA, 1993, J INVEST DERMATOL, V101, P642, DOI 10.1111/1523-1747.ep12371669; MCCLAIN K, IN PRESS AM J HEMATO; MIERAU GW, IN PRESS PEDIATR PAT; NEZELOF C, 1973, BIOMEDICINE, V18, P365; NEZELOF C, 1979, CANCER, V44, P1824, DOI 10.1002/1097-0142(197911)44:5<1824::AID-CNCR2820440542>3.0.CO;2-J; STARZL TE, 1984, LANCET, V1, P583; VANDERVALK P, 1984, VIRCHOWS ARCH B, V45, P169; VOGELSTEIN B, 1985, SCIENCE, V227, P642, DOI 10.1126/science.2982210; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WEISS LM, 1986, NEW ENGL J MED, V315, P475, DOI 10.1056/NEJM198608213150802; WEISS LM, 1985, NEW ENGL J MED, V313, P539, DOI 10.1056/NEJM198508293130903; WEISS LM, 1986, HUM PATHOL, V17, P179, DOI 10.1016/S0046-8177(86)80291-X; WILLMAN CL, 1990, CLIN LAB MED, V10, P119, DOI 10.1016/S0272-2712(18)30585-7	36	728	762	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					154	160		10.1056/NEJM199407213310303	http://dx.doi.org/10.1056/NEJM199407213310303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008029				2022-12-28	WOS:A1994NW79700003
J	KLAES, A; MENNE, T; STOLLEWERK, A; SCHOLZ, H; KLAMBT, C				KLAES, A; MENNE, T; STOLLEWERK, A; SCHOLZ, H; KLAMBT, C			THE ETS TRANSCRIPTION FACTORS ENCODED BY THE DROSOPHILA GENE POINTED DIRECT GLIAL-CELL DIFFERENTIATION IN THE EMBRYONIC CNS	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH CONE GUIDANCE; AXON PATHWAYS; NEURONAL DIFFERENTIATION; SPINAL-CORD; MELANOGASTER; MIGRATION; PATTERN; MIDLINE; PROTEIN	The Drosophila gene pointed (pnt) encodes two putative transcription factors (P1 and P2) of the Ets family, which in the embryonic CNS are found exclusively in glial cells. Loss of pnt function leads to poorly differentiated glial cells and a marked decrease in the expression of the neuronal antigen 22C10 in the MP2 neurons, which are known to interact intimately with the pnt(P1)-expressing longitudinal glial cells. Ectopic expression of pnt(P1) RNA forces additional CNS cells to enter the glial differentiation pathway. Interestingly, the additional glial-like cells are often flanked by cells that ectopically express the neuronal antigen 22C10. Therefore, both the pnt loss-of-function as well as the gain-of-function phenotype suggest that glial cells are able to induce 22C10 expression on neighboring neurons. This was further verified by cell transplantation experiments. Thus, pnt is not only required but also sufficient for several aspects of glial differentiation.			KLAES, A (corresponding author), UNIV COLOGNE,INST ENTWICKLUNGSBIOL,D-50923 COLOGNE,GERMANY.		Scholz, Henrike/ABE-1063-2020					BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BOSSING T, 1994, IN PRESS DEVELOPMENT; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPBELL RM, 1993, DEVELOPMENT, V119, P1217; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CANAL I, 1986, J NEUROGENET, V3, P293, DOI 10.3109/01677068609106856; CHOI KW, 1994, NEURON, V12, P423, DOI 10.1016/0896-6273(94)90282-8; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; FISHELL G, 1991, DEVELOPMENT, V113, P755; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; FUJITA CS, 1982, P NATL ACAD SCI USA, V79, P59; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; GIANGRANDE A, 1994, DEVELOPMENT, V120, P523; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; IP TY, 1992, GENE DEV, V6, P1728; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JACOBS JR, 1993, J NEUROBIOL, V24, P611, DOI 10.1002/neu.480240507; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOLODKIN AL, 1994, IN PRESS DEVELOPMENT; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; MENNE TV, 1994, DEVELOPMENT, V120, P123; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAZ E, 1992, DEVELOPMENT, V114, P113; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLZ H, 1993, GENETICS, V135, P455; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SILVER J, 1984, DEV BIOL, V106, P485, DOI 10.1016/0012-1606(84)90248-3; SILVER J, 1982, J COMP NEUROL, V210, P10, DOI 10.1002/cne.902100103; SINGER M, 1979, J COMP NEUROL, V185, P1, DOI 10.1002/cne.901850102; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P389, DOI 10.1007/BF00402872; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; TYTELL M, 1984, BRAIN RES, V324, P223, DOI 10.1016/0006-8993(84)90032-5; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WILSON MA, 1988, DEVELOPMENT, V102, P537; WINBERG ML, 1992, DEVELOPMENT, V115, P903	55	212	214	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					149	160		10.1016/0092-8674(94)90581-9	http://dx.doi.org/10.1016/0092-8674(94)90581-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033206				2022-12-28	WOS:A1994NX32800017
J	LOVLEY, DR; WOODWARD, JC; CHAPELLE, FH				LOVLEY, DR; WOODWARD, JC; CHAPELLE, FH			STIMULATED ANOXIC BIODEGRADATION OF AROMATIC-HYDROCARBONS USING FE(III) LIGANDS	NATURE			English	Article							DENITRIFYING CONDITIONS; AQUIFER MICROORGANISMS; DISSIMILATORY FE(III); MICROBIAL-DEGRADATION; ORGANIC CONTAMINANTS; REDUCING CONDITIONS; HYDROGEN-PEROXIDE; IRON REDUCTION; SHALLOW SAND; GROUNDWATER	CONTAMINATION of ground waters with water-soluble aromatic hydrocarbons, common components of petroleum pollution, often produces anoxic conditions under which microbial degradation of the aromatics is slow(1-7). Oxygen is often added to contaminated ground water to stimulate biodegradation, but this can be technically difficult and expensive(1,5-8). Insoluble Fe(III) oxides, which are generally abundant in shallow aquifers, are alternative potential oxidants, but are difficult for microorganisms to access(9). Here we report that adding organic ligands that bind to Fe(III) dramatically increases its bioavailability, and that in tbe presence of these ligands, rates of degradation of aromatic hydrocarbons in anoxic aquifer sediments are comparable to those in oxic sediments. We find that even benzene, which is notoriously refractory in the absence of oxygen, can be rapidly degraded. Our results suggest that increasing the bioavailability of Fe(III) by adding suitable ligands provides a potential alternative to oxygen addition for the bioremediation of petroleum-contaminated aquifers.	US GEOL SURVEY, DIV WATER RESOURCES, COLUMBIA, SC 29210 USA	United States Department of the Interior; United States Geological Survey	LOVLEY, DR (corresponding author), US GEOL SURVEY, DIV WATER RESOURCES, 430 NATL CTR, RESTON, VA 22092 USA.							ACTON DW, 1992, J CONTAM HYDROL, V9, P325, DOI 10.1016/0169-7722(92)90002-V; ANID PJ, 1993, WATER RES, V27, P685, DOI 10.1016/0043-1354(93)90178-K; ARNOLD RG, 1988, BIOTECHNOL BIOENG, V32, P1081, DOI 10.1002/bit.260320902; BAEDECKER MJ, 1993, APPL GEOCHEM, V8, P569, DOI 10.1016/0883-2927(93)90014-8; BARBARO JR, 1992, J CONTAM HYDROL, V11, P245, DOI 10.1016/0169-7722(92)90019-B; BARKER JF, 1987, GROUND WATER MONIT R, V7, P64, DOI 10.1111/j.1745-6592.1987.tb01063.x; BELLER HR, 1992, APPL ENVIRON MICROB, V58, P786, DOI 10.1128/AEM.58.3.786-793.1992; EDWARDS EA, 1992, APPL ENVIRON MICROB, V58, P2663, DOI 10.1128/AEM.58.8.2663-2666.1992; FLYVBJERG J, 1993, J CONTAM HYDROL, V12, P133, DOI 10.1016/0169-7722(93)90018-N; GILLHAM RW, 1990, GROUND WATER, V28, P858, DOI 10.1111/j.1745-6584.1990.tb01720.x; GRBICGALIC D, 1987, APPL ENVIRON MICROB, V53, P254; HUTCHINS S R, 1991, Environmental Toxicology and Chemistry, V10, P1437, DOI 10.1897/1552-8618(1991)10[1437:OBBUDC]2.0.CO;2; HUTCHINS SR, 1991, ENVIRON SCI TECHNOL, V25, P68, DOI 10.1021/es00013a005; KUHN EP, 1988, APPL ENVIRON MICROB, V54, P490, DOI 10.1128/AEM.54.2.490-496.1988; LEE MD, 1988, CRIT REV ENV CONTR, V18, P29, DOI 10.1080/10643388809388342; LOVLEY DR, 1989, NATURE, V339, P297, DOI 10.1038/339297a0; LOVLEY DR, 1991, MICROBIOL REV, V55, P259, DOI 10.1128/MMBR.55.2.259-287.1991; LOVLEY DR, 1987, APPL ENVIRON MICROB, V53, P2636, DOI 10.1128/AEM.53.11.2636-2641.1987; LOVLEY DR, IN PRESS ENV SCI TEC; LYNGKILDE J, 1992, J CONTAM HYDROL, V10, P291, DOI 10.1016/0169-7722(92)90012-4; MAJOR DW, 1988, GROUND WATER, V26, P8, DOI 10.1111/j.1745-6584.1988.tb00362.x; MORGAN P, 1992, WATER RES, V26, P73, DOI 10.1016/0043-1354(92)90113-I; PARDIECK DL, 1992, J CONTAM HYDROL, V9, P221, DOI 10.1016/0169-7722(92)90006-Z; RODEN EE, 1993, APPL ENVIRON MICROB, V59, P734, DOI 10.1128/AEM.59.3.734-742.1993; SALANITRO JP, 1993, GROUND WATER MONIT R, V13, P150, DOI 10.1111/j.1745-6592.1993.tb00459.x; THOMAS JM, 1989, ENVIRON SCI TECHNOL, V23, P760, DOI 10.1021/es00065a004; VROBLESKY DA, 1994, WATER RESOUR RES, V30, P1561, DOI 10.1029/94WR00067; WILSON BH, 1986, ENVIRON SCI TECHNOL, V20, P997, DOI 10.1021/es00152a005	28	249	264	6	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	1994	370	6485					128	131		10.1038/370128a0	http://dx.doi.org/10.1038/370128a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022480				2022-12-28	WOS:A1994NW80400052
J	HARRIES, M				HARRIES, M			ABC OF SPORTS MEDICINE - PULMONARY LIMITATIONS TO PERFORMANCE IN SPORT	BRITISH MEDICAL JOURNAL			English	Article									BRITISH OLYMP MED CTR,HARROW,MIDDX,ENGLAND		HARRIES, M (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.								0	2	2	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					113	115		10.1136/bmj.309.6947.113	http://dx.doi.org/10.1136/bmj.309.6947.113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038645	Green Published			2022-12-28	WOS:A1994NW71600031
J	CRAIG, AD; BUSHNELL, MC				CRAIG, AD; BUSHNELL, MC			THE THERMAL GRILL ILLUSION - UNMASKING THE BURN OF COLD PAIN	SCIENCE			English	Article							DORSAL HORN; SKIN; CAT; PRIMATE; STIMULATION; RESPONSES; NEURONS; SENSITIVITY; MECHANISMS; AFFERENTS	In Thunberg's thermal grill illusion, first demonstrated in 1896, a sensation of strong, often painful heat is elicited by touching interlaced warm and cool bars to the skin. Neurophysiological recordings from two classes of ascending spinothalamic tract neurons that are sensitive to innocuous or noxious cold showed differential responses to the grill. On the basis of these results, a simple model of central disinhibition, or unmasking, predicted a quantitative correspondence between grill-evoked pain and cold-evoked pain, which was verified psychophysically. This integration of pain and temperature can explain the thermal grill illusion and the burning sensation of cold pain and may also provide a basis for the cold-evoked, burning pain of the classic thalamic pain syndrome.	BARROW NEUROL INST,DIV NEUROSURG,PHOENIX,AZ 85013; UNIV MONTREAL,FAC MED DENT,CTR RECH SCI NEUROL,MONTREAL H3C 3J7,PQ,CANADA; UNIV MONTREAL,FAC MED DENT,DEPT STOMATOL,MONTREAL H3C 3J7,PQ,CANADA	Barrow Neurological Institute; Universite de Montreal; Universite de Montreal	CRAIG, AD (corresponding author), BARROW NEUROL INST,DIV NEUROBIOL,350 W THOMAS RD,PHOENIX,AZ 85013, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007402] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07402] Funding Source: Medline; NINDS NIH HHS [NS25616] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALRUTZ S, 1897, UPPSALA LAKFOREN FOR, V2, P445; BINI G, 1984, PAIN, V18, P239, DOI 10.1016/0304-3959(84)90819-4; BOIVIE J, 1989, PAIN, V37, P173, DOI 10.1016/0304-3959(89)90128-0; BORING EG, 1942, SENSATION PERCEPTION, P504; BROMAGE PR, 1980, PAIN, V9, P145, DOI 10.1016/0304-3959(80)90003-2; BUSHNELL MC, 1989, EXP BRAIN RES, V78, P415; BUSHNELL MC, 1993, SOC NEUR ABSTR, V19, P1573; CHRISTENSEN BN, 1970, J NEUROPHYSIOL, V33, P293, DOI 10.1152/jn.1970.33.2.293; Craig A. D., 1992, Society for Neuroscience Abstracts, V18, P385; CRAIG AD, 1991, J COMP NEUROL, V313, P377, DOI 10.1002/cne.903130212; CRAIG AD, 1985, J PHYSIOL-LONDON, V365, P197, DOI 10.1113/jphysiol.1985.sp015767; CRAIG AD, 1994, BRAIN RES, V636, P233, DOI 10.1016/0006-8993(94)91022-7; CRAIG AD, 1991, BRAIN RES, V558, P93, DOI 10.1016/0006-8993(91)90719-C; CRAIG AD, 1991, PAIN CENTRAL NERVOUS, P157; CRAIG AG, UNPUB; DARIANSMITH I, 1984, HDB PHYSL 1, V3, P879; DOSTROVSKY JO, 1978, J PHYSIOL-LONDON, V277, P29, DOI 10.1113/jphysiol.1978.sp012258; FERRINGTON DG, 1988, J NEUROPHYSIOL, V59, P886, DOI 10.1152/jn.1988.59.3.886; GELDARD FA, 1972, HUMAN SENSES, P359; GEORGOPOULOS AP, 1976, J NEUROPHYSIOL, V39, P71, DOI 10.1152/jn.1976.39.1.71; HARDY JD, 1951, SCIENCE, V114, P149, DOI 10.1126/science.114.2954.149; HELLON R, 1983, HDB PHYSL 2, P659; JEANMONOD D, 1994, NEUROREPORT, V4, P475; JONES SF, 1988, PAIN, V34, P117, DOI 10.1016/0304-3959(88)90156-X; KENSHALO DR, 1982, PAIN, V12, P141, DOI 10.1016/0304-3959(82)90190-7; KRESS M, 1992, J NEUROPHYSIOL, V68, P581, DOI 10.1152/jn.1992.68.2.581; KURU M, 1949, SENSORY PATHS SPINAL; LAMOTTE RH, 1982, BRAIN RES, V244, P279, DOI 10.1016/0006-8993(82)90086-5; LAMOTTE RH, 1978, J NEUROPHYSIOL, V41, P509, DOI 10.1152/jn.1978.41.2.509; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; NORRSELL U, 1989, EXP BRAIN RES, V78, P369; OSGOOD PF, 1990, BRAIN RES, V507, P11, DOI 10.1016/0006-8993(90)90514-C; Perl E. R., 1984, HDB PHYSL 2 1, VIII, P915; STRASSMAN AM, 1993, J NEUROPHYSIOL, V70, P1811, DOI 10.1152/jn.1993.70.5.1811; SUGIURA Y, 1986, SCIENCE, V234, P358, DOI 10.1126/science.3764416; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; TAYLOR DJ, 1993, SOMATOSENS MOT RES, V10, P455, DOI 10.3109/08990229309028850; THURBERG T, 1896, UPPSALA LAKFOREN FOR, V2, P489; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208; WAHREN LK, 1989, PAIN, V38, P313, DOI 10.1016/0304-3959(89)90218-2; Willis William D., 1985, PAIN SYSTEM; YARNITSKY D, 1990, BRAIN, V113, P893, DOI 10.1093/brain/113.4.893	42	301	309	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					252	255		10.1126/science.8023144	http://dx.doi.org/10.1126/science.8023144			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023144				2022-12-28	WOS:A1994NV95700042
J	HERMER, L; SPELKE, ES				HERMER, L; SPELKE, ES			A GEOMETRIC PROCESS FOR SPATIAL REORIENTATION IN YOUNG-CHILDREN	NATURE			English	Article							RATS	DISORIENTED(1-3) rats and non-human primates reorient themselves using geometrical features of the environment(2,4-6). In rats tested in environments with distinctive geometry, this ability is impervious to non-geometric information (such as colours and odours) marking important locations and used in other spatial tasks'. Here we show that adults use both geometric and non-geometric information to reorient themselves, whereas young children, like mature rats, use only geometric information. These findings provide evidence that: (1) humans reorient in accord with the shape of the environment; (2) the young child's reorientation system is impervious to all but geometric information(8), even when non-geometric information is available and is re-presented by the child-such information should improve performance and is used in similar tasks by the oriented child; and (3) the limits of this process are overcome during human development.	CORNELL UNIV,COGNIT STUDIES PROGRAM,ITHACA,NY 14853	Cornell University	HERMER, L (corresponding author), CORNELL UNIV,DEPT PSYCHOL,URIS HALL,ITHACA,NY 14853, USA.							ACREDOLO L, 1978, PSYCHOLOGY, V14, P244; BREMNER JG, 1978, DEV PSYCHOL, V14, P346, DOI 10.1037/0012-1649.14.4.346; CHENG K, 1986, COGNITION, V23, P149, DOI 10.1016/0010-0277(86)90041-7; Fodor J. A, 1983, MODULARITY MIND; Gallistel C. R., 1990, ORG LEARNING; KARMILOFFSMITH A, 1992, EPIGENESIS MIND ESSA, P171; MARGULES J, 1988, ANIM LEARN BEHAV, V16, P404, DOI 10.3758/BF03209379; MATTHEWS BL, 1988, BEHAV NEUROSCI, V102, P35, DOI 10.1037/0735-7044.102.1.35; MITTELSTAEDT ML, 1980, NATURWISSENSCHAFTEN, V67, P566, DOI 10.1007/BF00450672; NEWCOMBE N, 1988, BRIT J DEV PSYCHOL, V6, P376, DOI 10.1111/j.2044-835X.1988.tb01112.x; PICK HL, 1988, BRIT J DEV PSYCHOL, V6, P372, DOI 10.1111/j.2044-835X.1988.tb01111.x; Sprague J. M., 1976, PROGR PSYCHOL, V6, P245; SUZUKI S, 1980, LEARN MOTIV, V11, P1, DOI 10.1016/0023-9690(80)90018-1; Tinklepaugh OL, 1932, J COMP PSYCHOL, V13, P207, DOI 10.1037/h0072368	14	468	479	0	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					57	59		10.1038/370057a0	http://dx.doi.org/10.1038/370057a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NV711	8015605				2022-12-28	WOS:A1994NV71100057
J	OBRIEN, T; HARDIN, S; GREENLEAF, A; LIS, JT				OBRIEN, T; HARDIN, S; GREENLEAF, A; LIS, JT			PHOSPHORYLATION OF RNA-POLYMERASE-II C-TERMINAL DOMAIN AND TRANSCRIPTIONAL ELONGATION	NATURE			English	Article							TATA-BINDING PROTEIN; DROSOPHILA-MELANOGASTER; LARGEST SUBUNIT; HEAT-SHOCK; NONPHOSPHORYLATED FORM; IN-VIVO; 5' END; GENES; INITIATION; COMPLEX	THE carboxy-terminal domain (CTD) of the large subunit of RNA polymerase II is essential in vivo(1-4), and is found in either an unphosphorylated (IIa) or hyperphosphorylated (IIo) form(5,6). The Drosophila uninduced hsp70 and hsp26 genes, and the constitutively expressed beta-1 tubulin and Gapdh-2 genes, contain an RNA polymerase II complex which pauses after synthesizing a short transcript(7-10). We report here that, using an in vivo ultraviolet crosslinking technique(11) and antibodies directed against the IIa and IIo forms of the CTD12, these paused polymerases have an unphosphorylated CTD. For genes containing a 5' paused polymerase, passage of the paused RNA polymerase into an elongationally competent mode in vivo coincides with phosphorylation of the CTD. Also, the level of phosphorylation of the CTD of elongating polymerases is shown not to be related to the level of transcription, but is promoter specific.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Cornell University; Duke University								ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; CADENA DL, 1987, J BIOL CHEM, V262, P12468; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILMOUR D, 1991, METHODS CELL BIOL FU, P369; HACKETT RW, 1983, NUCLEIC ACIDS RES, V11, P7011, DOI 10.1093/nar/11.20.7011; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LIFTON RP, 1977, COLD SPRING HARB SYM, V42, P1047, DOI 10.1101/SQB.1978.042.01.105; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; ROUGVIE A, 1989, THESIS CORNELL U ITH; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WEEKS JR, 1982, J BIOL CHEM, V257, P5884; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	24	299	300	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					75	77		10.1038/370075a0	http://dx.doi.org/10.1038/370075a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015613				2022-12-28	WOS:A1994NV71100063
J	SIMONDS, AK				SIMONDS, AK			FORTNIGHTLY REVIEW - SLEEP STUDIES OF RESPIRATORY-FUNCTION AND HOME RESPIRATORY SUPPORT	BRITISH MEDICAL JOURNAL			English	Review							DOMICILIARY VENTILATION; APNEA; OXIMETRY; MEN				SIMONDS, AK (corresponding author), ROYAL BROMPTON HOSP,SYDNEY ST,LONDON SW3 6NP,ENGLAND.							AMBROGETTI A, 1991, AUST NZ J MED, V21, P863, DOI 10.1111/j.1445-5994.1991.tb01408.x; BYE PTB, 1991, THORAX, V45, P241; DAVIES RJO, 1993, THORAX, V48, P1242, DOI 10.1136/thx.48.12.1242; DOUGLAS NJ, 1992, LANCET, V339, P347, DOI 10.1016/0140-6736(92)91660-Z; ENGELMAN HM, 1993, THORAX, V48, P911; GUILLEMINAULT C, 1993, CHEST, V104, P781, DOI 10.1378/chest.104.3.781; GYULAY S, 1993, AM REV RESPIR DIS, V147, P50, DOI 10.1164/ajrccm/147.1.50; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; HOFFSTEIN V, 1993, SLEEP, V16, P118; LEGER P, 1992, EUR RESPIR REV, V10, P362; MUIR JF, 1993, THORAX, V48, P1264, DOI 10.1136/thx.48.12.1264; OREM J, 1994, SLEEP BREATH, P113; Rechtschaffen A, 1968, NIH PUBLICATION, V204; ROBERT D, 1983, REV FR MAL RESPIR, V11, P923; ROSEN CL, 1992, AM REV RESPIR DIS, V146, P1231, DOI 10.1164/ajrccm/146.5_Pt_1.1231; SERIES F, 1993, ANN INTERN MED, V119, P449, DOI 10.7326/0003-4819-119-6-199309150-00001; SHAPIRO SH, 1992, LANCET, V340, P1425, DOI 10.1016/0140-6736(92)92620-U; SHNEERSON JM, 1991, THORAX, V46, P131, DOI 10.1136/thx.46.2.131; SIMONDS AK, 1993, RESPIRATORY MED RECE, P231; SLOAN EP, 1993, ABC SLEEP DISORDERS, P34; Stradling, 1992, J Sleep Res, V1, P265; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; STRADLING JR, 1993, HDB SLEEP RELATED BR, P56; SULLIVAN CE, 1981, LANCET, V1, P862; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; [No title captured]; 1993, SLEEP APNOEA RELATED; 1989, AM REV RESPIR DIS, V139, P559	28	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					35	40		10.1136/bmj.309.6946.35	http://dx.doi.org/10.1136/bmj.309.6946.35			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044067	Green Published			2022-12-28	WOS:A1994NV89100025
J	WUNDERLE, VM; RAMKISSOON, YD; KWOK, C; KORN, RM; KING, VE; GOODFELLOW, PN				WUNDERLE, VM; RAMKISSOON, YD; KWOK, C; KORN, RM; KING, VE; GOODFELLOW, PN			BREAKPOINT BREAK FOR CONSORTIUM STUDYING ADULT POLYCYSTIC KIDNEY-DISEASE	CELL			English	Review							GENE				WUNDERLE, VM (corresponding author), UNIV CAMBRIDGE,DEPT GENET,DOWNING ST,CAMBRIDGE CB2 3EH,ENGLAND.							BROWN PO, 1994, IN PRESS CURR OPIN G; DALGAARD O. Z., 1957, ACTA MED SCAND SUPPL, V158, P1; European Chromosome 16 Tuberous Sclerosis C., 1993, CELL, V75, P1305; GABOW PA, 1990, AM J KIDNEY DIS, V16, P403, DOI 10.1016/S0272-6386(12)80051-5; GERMINO GG, 1992, GENOMICS, V13, P144, DOI 10.1016/0888-7543(92)90214-D; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; 1994, CELL, V77; 1993, CELL, V72, P971	11	6	7	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					785	786		10.1016/0092-8674(94)90123-6	http://dx.doi.org/10.1016/0092-8674(94)90123-6			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004666				2022-12-28	WOS:A1994NT33100001
J	SMITH, C; ADAM, S				SMITH, C; ADAM, S			PRESENT SYSTEM COULD BE IMPROVED	BRITISH MEDICAL JOURNAL			English	Note									N THAMES REG HLTH AUTH,LONDON W2 3QR,ENGLAND		SMITH, C (corresponding author), PARKSIDE HLTH,LONDON W9 3XZ,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1414	1414		10.1136/bmj.308.6941.1414	http://dx.doi.org/10.1136/bmj.308.6941.1414			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019254	Green Published			2022-12-28	WOS:A1994NP42000019
J	LU, M; CAMPBELL, JL; BOYE, E; KLECKNER, N				LU, M; CAMPBELL, JL; BOYE, E; KLECKNER, N			SEQA - A NEGATIVE MODULATOR OF REPLICATION INITIATION IN ESCHERICHIA-COLI	CELL			English	Article							DNA-BINDING PROTEINS; ESCHERICHIA-COLI; CHROMOSOMAL REPLICATION; DAM METHYLTRANSFERASE; FLOW-CYTOMETRY; GATC SITES; ORIGIN; METHYLATION; GENE; MEMBRANE	In E. coli, replication initiates at a genetically unique origin, oriC. Rapidly growing cells contain multiple oriC copies. Initiation occurs synchronously, once and only once per cell cycle at all origins present. Secondary initiations are prevented by a sequestration process that acts uniquely on newly replicated origins, which are marked because they are hemimethylated at GATC sites. We report the identification of a gene required for sequestration and demonstrate that this gene, seqA, also serves as a negative modulator of the primary initiation process. All previously identified in vivo initiation factors play positive roles. Thus, precise control of replication initiation may involve a balance between positive and negative elements. We suggest that SeqA might be a cooperativity factor, acting to make the replication initiation process dependent upon cooperative interactions among components.	INST CANC RES,DEPT BIOPHYS,N-0310 OSLO,NORWAY		LU, M (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.				NIGMS NIH HHS [GM25326, GM15405] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025326, F32GM015405, R37GM025326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1971, J BACTERIOL, V108, P621, DOI 10.1128/JB.108.2.621-626.1971; ATLUNG T, 1993, J BACTERIOL, V175, P6573; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1992, ANNU REV GENET, V26, P447; BAKKER A, 1989, J BACTERIOL, V171, P5738, DOI 10.1128/jb.171.10.5738-5742.1989; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOYE E, 1991, RES MICROBIOL, V142, P131, DOI 10.1016/0923-2508(91)90020-B; BOYE E, 1991, J BACTERIOL, V173, P4537, DOI 10.1128/JB.173.14.4537-4539.1991; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BOYE E, 1988, BIOCHIM BIOPHYS ACTA, V951, P359, DOI 10.1016/0167-4781(88)90107-8; BOYE E, 1992, DNA REPLICATION CELL, V43, P15; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CAMPBELL JL, 1991, THESIS HARVARD U CAM; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; CHAKRABORTI A, 1992, J BACTERIOL, V174, P7202, DOI 10.1128/jb.174.22.7202-7206.1992; ELLEDGE SJ, 1989, GENE DEV, V3, P185, DOI 10.1101/gad.3.2.185; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; HANSEN EB, 1984, MOL GEN GENET, V196, P387, DOI 10.1007/BF00436184; HANSEN FG, 1991, RES MICROBIOL, V142, P161, DOI 10.1016/0923-2508(91)90025-6; HENDRICKSON WG, 1982, CELL, V30, P915, DOI 10.1016/0092-8674(82)90296-3; HUGHES P, 1984, J MOL BIOL, V176, P155, DOI 10.1016/0022-2836(84)90386-3; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HWANG DS, 1992, J BIOL CHEM, V267, P2209; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; KELTENBERGERGUJ.G, 1978, MOL GEN GENET, V162, P9; KOGOMA T, 1986, J BACTERIOL, V166, P361, DOI 10.1128/jb.166.2.361-363.1986; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; Kornberg A., 1991, DNA REPLICATION; KUSANO T, 1984, J BACTERIOL, V158, P313, DOI 10.1128/JB.158.1.313-316.1984; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LOUARN J, 1984, MOL GEN GENET, V195, P170, DOI 10.1007/BF00332741; MAGEE TR, 1992, EMBO J, V11, P4219, DOI 10.1002/j.1460-2075.1992.tb05516.x; MAHAFFY JM, 1989, J THEOR BIOL, V140, P453, DOI 10.1016/S0022-5193(89)80109-2; MEIJER M, 1979, P NATL ACAD SCI USA, V76, P580, DOI 10.1073/pnas.76.2.580; MESSER W, 1985, EMBO J, V4, P1327, DOI 10.1002/j.1460-2075.1985.tb03780.x; Miller J.H., 1972, EXPT MOL GENETICS; MORRISON DA, 1977, J BACTERIOL, V132, P349, DOI 10.1128/JB.132.1.349-351.1977; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; Radman M., 1980, PROGR ENV MUTAGENESI, P121; REX JH, 1991, J BACTERIOL, V173, P5944, DOI 10.1128/jb.173.19.5944-5953.1991; RUDD KE, 1992, SHORT COURSE BACTERI; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; Sambrook J, 1989, MOL CLONING LABORATO; SAMITT CE, 1989, EMBO J, V8, P989, DOI 10.1002/j.1460-2075.1989.tb03462.x; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SINGER M, 1989, MICROBIOL REV, V53, P1; SKARSTAD K, 1983, J BACTERIOL, V154, P656, DOI 10.1128/JB.154.2.656-662.1983; SKARSTAD K, 1988, J BACTERIOL, V170, P852, DOI 10.1128/jb.170.2.852-858.1988; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SLATER S, 1993, J BACTERIOL, V175, P4260, DOI 10.1128/JB.175.13.4260-4262.1993; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; STORTS DR, 1988, J BACTERIOL, V170, P1541, DOI 10.1128/jb.170.4.1541-1547.1988; THEISEN PW, 1993, MOL MICROBIOL, V10, P575, DOI 10.1111/j.1365-2958.1993.tb00929.x; VINELLA D, 1992, J BACTERIOL, V174, P2388, DOI 10.1128/JB.174.7.2388-2390.1992; ZYSKIND JW, 1986, CELL, V46, P489, DOI 10.1016/0092-8674(86)90873-1	60	414	421	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 6	1994	77	3					413	426		10.1016/0092-8674(94)90156-2	http://dx.doi.org/10.1016/0092-8674(94)90156-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8011018				2022-12-28	WOS:A1994NK97000012
J	LAW, MR; WALD, NJ; THOMPSON, SG				LAW, MR; WALD, NJ; THOMPSON, SG			BY HOW MUCH AND HOW QUICKLY DOES REDUCTION IN SERUM-CHOLESTEROL CONCENTRATION LOWER RISK OF ISCHEMIC-HEART-DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MIDDLE-AGED MEN; CORONARY-ARTERY DISEASE; CARDIOVASCULAR RISK; FOLLOW-UP; MYOCARDIAL-INFARCTION; PRIMARY-PREVENTION; NICOTINIC-ACID; MORTALITY; DIET; TRIAL	Objective-To estimate by how much and how quickly a given reduction in serum cholesterol concentration will reduce the risk of ischaemic heart disease. Design-Data on the incidence of ischaemic heart disease and serum cholesterol concentration were analysed from 10 prospective (cohort) studies, three international studies in different communities, and 28 randomised controlled trials (with mortality data analysed according to allocated treatment to ensure the avoidance of bias). Main outcome measure-Decrease in incidence of ischaemic heart disease or mortality for a 0.6 mmol/l (about 10%) decrease in serum cholesterol concentration. Results-For men results from the cohort studies showed that a decrease of serum cholesterol concentration of 0.6 mmol/l (about 10%) was associated with a decrease in incidence of ischaemic heart disease of 54% at age 40 years, 39% at age 50, 27% at 60, 20% at 70, and 19% at 80. The combined estimate from the three international studies (for ages 55-64 years) was 38% (95% confidence interval 33% to 42%), somewhat greater than the cohort study estimate of 27%. The reductions in incidence of ischaemic heart disease in the randomised trails (for ages 55-64 years) were 7% (0 to 14%) in the first two years, 22% (15% to 28%) from 2.1-5 years, and 25% (15% to 35%) after five years, the last estimate being close to the estimate of 27% for the long term reduction from the cohort studies. The data for women are limited but indicate a similar effect. Conclusions-The results from the cohort studies, international comparisons, and clinical trials are remarkably consistent. The cohort studies, based on half a million men and 18 000 ischaemic heart disease events, estimate that a long term reduction in serum cholesterol concentration of 0.6 mmol/l (10%), which can be achieved by moderate dietary change, lowers the risk of ischaemic heart disease by 50% at age 40, falling to 20% at age 70. The randomised trials, based on 45 000 men and 4000 ischaemic heart disease events show that the full effect of the reduction in risk is achieved by five years.			LAW, MR (corresponding author), ST BARTHOLOMEWS HOSP MED COLL, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					[Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; Begg T B, 1971, Minerva Med, V62, P3469; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BURR ML, 1989, LANCET, V2, P757; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CROUSE JR, 1989, LANCET, V1, P318, DOI 10.1016/S0140-6736(89)91320-2; DAYTON S, 1969, CIRCULATION S2, V39, P1; DETRE KM, 1974, CIRCULATION, V50, P998, DOI 10.1161/01.CIR.50.5.998; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRICK MH, 1984, ANN MED, V251, P351; GOLDBOURT U, 1990, ARTERIOSCLEROSIS, V10, P512, DOI 10.1161/01.ATV.10.4.512; GROSS L, 1973, J AM GERIATR SOC, V21, P552, DOI 10.1111/j.1532-5415.1973.tb01662.x; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2351, DOI 10.1001/jama.256.17.2351; HEADY JA, 1992, LANCET, V340, P1405, DOI 10.1016/0140-6736(92)92588-7; HENRIKSSON P, 1986, BRIT MED J, V293, P413, DOI 10.1136/bmj.293.6544.413; HJERMANN I, 1981, LANCET, V2, P1303; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; KEYS A, 1967, ACTA MED SCAND, V480, P1; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; LAW MR, IN PRESS EUR J CLIN; Leren P, 1966, Acta Med Scand Suppl, V466, P1; LEWIS B, 1981, LANCET, V2, P1310; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MARMORSTON J, 1962, P SOC EXP BIOL MED, V110, P400; MCCAUGHAN D, 1981, ARCH INTERN MED, V141, P1428, DOI 10.1001/archinte.141.11.1428; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MILLER GJ, 1989, ATHEROSCLEROSIS, V78, P19, DOI 10.1016/0021-9150(89)90154-8; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; POCOCK SJ, 1989, BMJ-BRIT MED J, V298, P998, DOI 10.1136/bmj.298.6679.998; PUSKA P, 1983, BRIT MED J, V287, P1840, DOI 10.1136/bmj.287.6408.1840; Reynolds J.E.F., 1989, MARTINDALE EXTRA PHA, V29th; RIFKIND BM, 1979, CIRCULATION, V60, P427; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; ROSENGREN A, 1989, BRIT MED J, V299, P1127, DOI 10.1136/bmj.299.6708.1127; ROSENHAMER G, 1980, ATHEROSCLEROSIS, V37, P129, DOI 10.1016/0021-9150(80)90100-8; SAHNI R, 1991, AM HEART J, V121, P1600, DOI 10.1016/0002-8703(91)90002-Y; SCHOCH HK, 1968, ADV EXP MED BIOL, V4, P405; SHIPLEY MJ, 1991, BRIT MED J, V303, P89, DOI 10.1136/bmj.303.6794.89; SIGFUSSON N, 1991, BRIT MED J, V302, P1371, DOI 10.1136/bmj.302.6789.1371; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; STAMLER J, 1963, JAMA-J AM MED ASSOC, V183, P632; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; Trial of clofibrate in the treatment of ischaemic heart disease, 1971, BRIT MED J, V4, P767, DOI DOI 10.1136/BMJ.4.5790.767; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WATTS GF, 1988, BMJ-BRIT MED J, V296, P235, DOI 10.1136/bmj.296.6617.235; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; 1971, BRIT MED J, V4, P775; 1972, JAMA-J AM MED ASSOC, V220, P996; 1970, JAMA-J AM MED ASSOC, V214, P1303	67	985	1012	0	38	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	1994	308	6925					367	373		10.1136/bmj.308.6925.367	http://dx.doi.org/10.1136/bmj.308.6925.367			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV862	8043072	Green Published			2022-12-28	WOS:A1994MV86200018
J	MARCUS, RH; SARELI, P; POCOCK, WA; BARLOW, JB				MARCUS, RH; SARELI, P; POCOCK, WA; BARLOW, JB			THE SPECTRUM OF SEVERE RHEUMATIC MITRAL-VALVE DISEASE IN A DEVELOPING-COUNTRY - CORRELATIONS AMONG CLINICAL PRESENTATION, SURGICAL PATHOLOGICAL FINDINGS, AND HEMODYNAMIC SEQUELAE	ANNALS OF INTERNAL MEDICINE			English	Article							NATURAL-HISTORY; UNITED-STATES; FEVER; REGURGITATION; PENICILLIN; CARDITIS; PROLAPSE	Objective: To describe the demographic, pathologic, and hemodynamic profiles of patients with severe rheumatic mitral valve disease in a developing country and to assess their relation to uncontrolled rheumatic disease activity. Design: Retrospective, cross-sectional, cohort study. Setting: Tertiary medical center in Soweto, South Africa. Patients: 714 of 737 consecutive black patients, 4 to 73 years old, with pure mitral regurgitation, pure mitral stenosis, or mixed mitral disease who had mitral valve surgery and in whom preoperative and surgical data were concordant. Measurements: Valve lesions were evaluated on the basis of clinical, echocardiographic, hemodynamic, and surgical pathologic data. Active rheumatic carditis was diagnosed according to clinical evidence for concurrent acute rheumatic fever (Jones criteria), macroscopic appearances at surgery, and histologic findings. Results: 219 patients had pure mitral regurgitation, 275 had pure mitral stenosis, and 220 had mixed lesions. Ongoing rheumatic activity was diagnosed in 106 patients with pure regurgitation (47%) and in only 5 patients with pure stenosis (2%). Pure regurgitation was the most common lesion in the first and second decades; the relative prevalence of pure stenosis increased with age. Purely regurgitant valves had pliable, unscarred leaflets (95%), dilated mitral annuli (95%), elongated chordae tendineae (92%), and anterior leaflet prolapse (81%). In contrast, purely stenotic valves had fused leaflet commissures (100%) and rigid leaflets (38%) but no evidence of prolapse. Conclusions: The spectrum of rheumatic mitral valve disease that is hemodynamically severe in developing countries differs from that currently reported in the United States. Severe, pure rheumatic mitral regurgitation is as prevalent as pure stenosis but has an entirely different time course, surgical anatomy, and relation to disease activity, suggesting a separate pathophysiologic mechanism.	UNIV WITWATERSRAND, SCH MED, DEPT MED, JOHANNESBURG 2193, SOUTH AFRICA	University of Witwatersrand								BAILEY C P, 1956, N Y State J Med, V56, P825; BARLOW JB, 1990, S AFR MED J, V78, P181; BARLOW JB, 1975, AM HEART J, V90, P636, DOI 10.1016/0002-8703(75)90229-X; BARLOW JB, 1987, PERSPECTIVES MITRAL, P227; BLAND EF, 1951, CIRCULATION, V4, P836, DOI 10.1161/01.CIR.4.6.836; BORMAN JB, 1961, AM HEART J, V61, P763, DOI 10.1016/0002-8703(61)90460-4; BRAUNWALD E, 1988, HEART DISEASE, P1039; BULKLEY BH, 1975, AM J MED, V59, P457, DOI 10.1016/0002-9343(75)90252-1; CARPENTIER A, 1980, J THORAC CARDIOV SUR, V79, P338; CHERIAN G, 1964, BRIT HEART J, V26, P157; CHESLER E, 1966, S AFR MED J, V40, P99; Clawson BJ, 1940, AM HEART J, V20, P454, DOI 10.1016/S0002-8703(40)90878-X; DUPLESSIS LA, 1969, J THORAC CARDIOV SUR, V58, P730, DOI 10.1016/S0022-5223(19)42553-1; EDWARDS WD, 1978, CIRCULATION, V57, P181, DOI 10.1161/01.CIR.57.1.181; GORDIS L, 1969, J AMER MED ASSOC, V210, P862, DOI 10.1001/jama.210.5.862; GOTSMAN MS, 1973, THORAX, V28, P453, DOI 10.1136/thx.28.4.453; GOTSMAN MS, 1975, AM HEART J, V90, P685, DOI 10.1016/0002-8703(75)90456-1; GROSSMAN W, 1986, CARDIAC CATHETERIZAT, P364; HALL RJ, 1989, DISEASES CARDIAC VAL, P143; JOHN S, 1983, CIRCULATION, V68, P891, DOI 10.1161/01.CIR.68.5.891; KAPLAN EL, 1988, INT J CARDIOL, V21, P3, DOI 10.1016/0167-5273(88)90003-4; Kinsley R H, 1981, Surg Annu, V13, P299; KLIBANOFF E, 1966, J AMER MED ASSOC, V195, P895, DOI 10.1001/jama.195.11.895; LEMBO NJ, 1988, CIRCULATION, V77, P830, DOI 10.1161/01.CIR.77.4.830; MARCUS R, 1989, CIRCULATION S2, V80, P507; MARCUS RH, 1989, AM J CARDIOL, V63, P577, DOI 10.1016/0002-9149(89)90902-8; MASSELL BF, 1988, NEW ENGL J MED, V318, P280, DOI 10.1056/NEJM198802043180504; OLSON LJ, 1987, MAYO CLIN PROC, V62, P22, DOI 10.1016/S0025-6196(12)61522-5; PADMAVATI S, 1978, B WORLD HEALTH ORGAN, V56, P543; SELZER A, 1972, CIRCULATION, V45, P878, DOI 10.1161/01.CIR.45.4.878; SELZER A, 1972, MEDICINE, V51, P337, DOI 10.1097/00005792-197209000-00001; STOLLERMAN GH, 1975, RHEUMATIC FEVER STRE, P127; TOMARU T, 1987, CIRCULATION, V76, P68, DOI 10.1161/01.CIR.76.1.68; TOMPKINS DG, 1972, CIRCULATION, V45, P543, DOI 10.1161/01.CIR.45.3.543; WALLER BF, 1982, AM HEART J, V104, P276, DOI 10.1016/0002-8703(82)90204-6; WHITE PD, 1951, HEART DISEASE, P670; WOOD PH, 1957, DISEASES HEART CIRCU, P517; ZABRISKIE JB, 1985, CIRCULATION, V71, P1077, DOI 10.1161/01.CIR.71.6.1077; 1965, CIRCULATION, V32, P64	39	132	134	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					177	183		10.7326/0003-4819-120-3-199402010-00001	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8043061				2022-12-28	WOS:A1994MU30300001
J	JAIN, JK; MISHELL, DR				JAIN, JK; MISHELL, DR			COMPARISON OF INTRAVAGINAL MISOPROSTOL WITH PROSTAGLANDIN-E(2) FOR TERMINATION OF 2ND-TRIMESTER PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METHYL ANALOG MISOPROSTOL; ABORTION; INDUCTION	Background. The most widely used medical method of terminating second-trimester pregnancy is the intravaginal administration of prostaglandin E(2) (dinoprostone [PGE(2)]). This treatment is highly effective but is associated with severe gastrointestinal side effects and hyperpyrexia. Methods. We conducted a prospective, randomized trial comparing the efficacy and safety of misoprostol, a prostaglandin E(1) analogue (200 mu g intravaginally every 12 hours), with the efficacy and safety of PGE(2) (20 mg intravaginally every 3 hours). The study population included 55 pregnant women between 12 and 22 weeks' gestation who were undergoing termination of pregnancy for either intrauterine fetal death (37 women) or medical or genetic reasons (18 women).	UNIV SO CALIF, SCH MED, DEPT OBSTET & GYNECOL, LOS ANGELES, CA 90033 USA	University of Southern California								ATRASH HK, 1987, AM J OBSTET GYNECOL, V156, P605, DOI 10.1016/0002-9378(87)90061-5; BERGER GS, 1974, AM J OBSTET GYNECOL, V120, P484, DOI 10.1016/0002-9378(74)90626-7; BUGALHO A, 1993, STUD FAMILY PLANN, V24, P319, DOI 10.2307/2939225; BUGALHO A, 1993, GYNECOL OBSTET INVES, V36, P226, DOI 10.1159/000292634; COLLINS PW, 1985, DIGEST DIS SCI, V30, pS114, DOI 10.1007/BF01309395; FLETCHER HM, 1993, BRIT J OBSTET GYNAEC, V100, P641, DOI 10.1111/j.1471-0528.1993.tb14230.x; GARRIS RE, 1989, CLIN PHARMACY, V8, P627; Grimes D A, 1979, Obstet Gynecol Surv, V34, P177, DOI 10.1097/00006254-197903000-00001; MISHELL DR, 1992, MERCK MANUAL DIAGNOS, P1781; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; RABE T, 1987, GEBURTSH FRAUENHEILK, V47, P324, DOI 10.1055/s-2008-1035830; SANCHEZRAMOS L, 1993, OBSTET GYNECOL, V81, P332; SURRAGO EJ, 1982, CONTRACEPTION, V26, P285, DOI 10.1016/0010-7824(82)90076-2; VERMESH M, 1988, OBSTET GYNECOL, V72, P693; ZAR JH, 1984, BIOSTAT ANAL, P126	15	153	154	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					290	293		10.1056/NEJM199408043310502	http://dx.doi.org/10.1056/NEJM199408043310502			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022438				2022-12-28	WOS:A1994NZ22700002
J	KARNI, A; TANNE, D; RUBENSTEIN, BS; ASKENASY, JJM; SAGI, D				KARNI, A; TANNE, D; RUBENSTEIN, BS; ASKENASY, JJM; SAGI, D			DEPENDENCE ON REM-SLEEP OF OVERNIGHT IMPROVEMENT OF A PERCEPTUAL SKILL	SCIENCE			English	Article							PARADOXICAL SLEEP; CORTEX; MEMORY; DISCRIMINATION; CONSOLIDATION; ACETYLCHOLINE; PLASTICITY	Several paradigms of perceptual learning suggest that practice can trigger long-term, experience-dependent changes in the adult visual system of humans. As shown here, performance of a basic visual discrimination task improved after a normal night's sleep. Selective disruption of rapid eye movement (REM) sleep resulted in no performance gain during a comparable sleep interval, although non-REM slow-wave sleep disruption did not affect improvement. On the other hand, deprivation of REM sleep had no detrimental effects on the performance of a similar, but previously learned, task. These results indicate that a process of human memory consolidation, active during sleep, is strongly dependent on REM sleep.	WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; CHAIM SHEBA MED CTR,DEPT NEUROL,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,OSCAR SAGER SLEEP RES LAB,IL-52621 TEL HASHOMER,ISRAEL	Weizmann Institute of Science; Chaim Sheba Medical Center; Chaim Sheba Medical Center			Sagi, Dov/A-5454-2008; Tanne, David/F-2560-2010	Sagi, Dov/0000-0002-8446-9230; Tanne, David/0000-0002-6699-2220				AGNEW HW, 1967, PERCEPT MOTOR SKILL, V24, P851, DOI 10.2466/pms.1967.24.3.851; AHISSAR M, 1993, P NATL ACAD SCI USA, V90, P5718, DOI 10.1073/pnas.90.12.5718; BALL K, 1987, VISION RES, V27, P935; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; CASTALDO V, 1974, PERCEPT MOTOR SKILL, V39, P1023, DOI 10.2466/pms.1974.39.3.1023; CHERNIK DA, 1972, PERCEPT MOTOR SKILL, V34, P283, DOI 10.2466/pms.1972.34.1.283; DUJARDIN K, 1990, PHYSIOL BEHAV, V47, P1271, DOI 10.1016/0031-9384(90)90382-E; EMPSON JAC, 1970, NATURE, V227, P287, DOI 10.1038/227287a0; FIORENTINI A, 1981, VISION RES, V21, P1149, DOI 10.1016/0042-6989(81)90017-1; FISHBEIN W, 1977, BEHAV BIOL, V19, P425, DOI 10.1016/S0091-6773(77)91903-4; FOWLER MJ, 1973, SCIENCE, V179, P302, DOI 10.1126/science.179.4070.302; Hobson J A, 1992, Curr Opin Neurobiol, V2, P759, DOI 10.1016/0959-4388(92)90130-D; HOBSON JA, 1990, J NEUROSCI, V10, P371; HORNE JA, 1984, BIOL PSYCHOL, V18, P165, DOI 10.1016/0301-0511(84)90001-2; JASPER HH, 1971, SCIENCE, V172, P601, DOI 10.1126/science.172.3983.601; JULIANO SL, 1991, P NATL ACAD SCI USA, V88, P780, DOI 10.1073/pnas.88.3.780; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; KARNI A, 1990, Investigative Ophthalmology and Visual Science, V31, P562; KARNI A, 1994, MATURATIONAL WINDOWS; KARNI A, 1992, THESIS WEIZMANN I SC; KOVACS I, COMMUNICATION; LLINAS RR, 1991, NEUROSCIENCE, V44, P521, DOI 10.1016/0306-4522(91)90075-Y; MISHKIN M, 1952, J EXP PSYCHOL, V43, P43, DOI 10.1037/h0061361; MISHKIN M, 1984, NEUROBIOLOGY LEARNIN, P64; MOSES JM, 1975, PSYCHOPHYSIOLOGY, V12, P141, DOI 10.1111/j.1469-8986.1975.tb01264.x; POGGIO T, 1992, SCIENCE, V256, P1018, DOI 10.1126/science.1589770; POLAT U, 1994, MATURATIONAL WINDOWS; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; SHIU LP, 1992, PERCEPT PSYCHOPHYS, V52, P282; SMITH C, 1982, PHYSIOL BEHAV, V29, P469, DOI 10.1016/0031-9384(82)90268-2; SMITH C, 1985, NEUROSCI BIOBEHAV R, V9, P157, DOI 10.1016/0149-7634(85)90042-9; SQUIRE LR, 1987, MEMORY BRAIN, P164; TILLEY AJ, 1978, BIOL PSYCHOL, V6, P293, DOI 10.1016/0301-0511(78)90031-5; Winson J, 1993, Curr Opin Neurobiol, V3, P243, DOI 10.1016/0959-4388(93)90217-M	35	683	703	1	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					679	682		10.1126/science.8036518	http://dx.doi.org/10.1126/science.8036518			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NZ538	8036518				2022-12-28	WOS:A1994NZ53800039
J	HERSCHBACH, BM; ARNAUD, MB; JOHNSON, AD				HERSCHBACH, BM; ARNAUD, MB; JOHNSON, AD			TRANSCRIPTIONAL REPRESSION DIRECTED BY THE YEAST ALPHA-2 PROTEIN IN-VITRO	NATURE			English	Article							MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; POLYMERASE-II; ACTIVATION; DROSOPHILA; BINDS; NUCLEOSOMES; OPERATOR; COMPLEX; DOMAIN	THE alpha 2 protein, a homeodomain protein involved in specifying cell type in the budding yeast Saccharomyces cerevisiae, is a transcriptional repressor(1,2). alpha 2 binds cooperatively with Mcm1, a serum response factor-related protein, to the a-specific gene operator(3-6). The alpha 2-Mcm1 complex in turn recruits Ssn6 and Tup1 to the operator, and we believe that these latter two proteins are responsible for the transcriptional repression(7-9). Placement of the a-specific gene operator in any of a variety of positions upstream of a test promoter leads to repression of that promoter in vivo(9-11). In this respect, the a-specific gene operator resembles a negatively acting enhancer. Here we describe the in vitro reconstitution of this example of negative control from a distance. We observe repression in vitro in the absence of exogenously added activator protein and on templates that lack binding sites for known activator proteins, and we infer that alpha 2-directed repression acts on the general transcription machinery.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	HERSCHBACH, BM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; HERSCHBACH BM, 1993, MOL CELL BIOL, V13, P4029, DOI 10.1128/MCB.13.7.4029; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; JOHNSON AD, 1985, CELL, V53, P927; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; Johnson SL, 1991, THESIS U WASHINGTON; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; MUKAI Y, 1991, MOL CELL BIOL, V11, P3773, DOI 10.1128/MCB.11.7.3773; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; WOONTNER M, 1990, J BIOL CHEM, V265, P8979; WOOTNER M, 1991, MOL CELL BIOL, V11, P4555	30	99	100	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					309	311		10.1038/370309a0	http://dx.doi.org/10.1038/370309a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035881				2022-12-28	WOS:A1994NZ22900069
J	LEE, PR				LEE, PR			IRRADIATION TO PREVENT FOODBORNE ILLNESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US PHS,WASHINGTON,DC	United States Public Health Service									0	12	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					261	261		10.1001/jama.272.4.261	http://dx.doi.org/10.1001/jama.272.4.261			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX806	8028126				2022-12-28	WOS:A1994NX80600004
J	TOFT, AD				TOFT, AD			DRUG-THERAPY - THYROXINE THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BONE-MINERAL DENSITY; THYROTROPIN-RELEASING HORMONE; SUB-CLINICAL HYPOTHYROIDISM; CORONARY HEART-DISEASE; SUBCLINICAL HYPOTHYROIDISM; THYROID-FUNCTION; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; SUBTOTAL THYROIDECTOMY; AUTOIMMUNE-THYROIDITIS				TOFT, AD (corresponding author), ROYAL INFIRM, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND.							ALTHAUS BU, 1988, CLIN ENDOCRINOL, V28, P157, DOI 10.1111/j.1365-2265.1988.tb03651.x; AREM R, 1990, ARCH INTERN MED, V150, P2097, DOI 10.1001/archinte.150.10.2097; AUWERX J, 1986, Q J MED, V60, P737; BEARCROFT CP, 1991, CLIN ENDOCRINOL, V34, P115, DOI 10.1111/j.1365-2265.1991.tb00280.x; BELL GM, 1985, CLIN ENDOCRINOL, V22, P83, DOI 10.1111/j.1365-2265.1985.tb01068.x; BERGHOUT A, 1990, LANCET, V336, P193, DOI 10.1016/0140-6736(90)91730-X; CARON P, 1990, CLIN ENDOCRINOL, V33, P519, DOI 10.1111/j.1365-2265.1990.tb03889.x; CARR D, 1988, CLIN ENDOCRINOL, V28, P325, DOI 10.1111/j.1365-2265.1988.tb01219.x; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; DAVIS LE, 1988, OBSTET GYNECOL, V72, P108; DIAMOND T, 1991, J CLIN ENDOCR METAB, V72, P1184, DOI 10.1210/jcem-72-6-1184; EDMONDS C, 1992, CLIN ENDOCRINOL, V36, P21, DOI 10.1111/j.1365-2265.1992.tb02897.x; FISHER DA, 1991, J CLIN ENDOCR METAB, V72, P523, DOI 10.1210/jcem-72-3-523; FRANKLYN JA, 1993, CLIN ENDOCRINOL, V38, P453, DOI 10.1111/j.1365-2265.1993.tb00339.x; FRANKLYN JA, 1992, LANCET, V340, P9, DOI 10.1016/0140-6736(92)92423-D; FUNG HYM, 1988, BRIT MED J, V296, P241, DOI 10.1136/bmj.296.6617.241; GAM AN, 1991, J ENDOCRINOL INVEST, V14, P451, DOI 10.1007/BF03346838; GRANT DB, 1992, COMMUNITY LAB MED, V1, P152; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; HARDISTY CA, 1984, CLIN ENDOCRINOL, V20, P597, DOI 10.1111/j.1365-2265.1984.tb00109.x; HARVEY RD, 1991, J CLIN ENDOCR METAB, V72, P1189, DOI 10.1210/jcem-72-6-1189; HEDLEY AJ, 1971, LANCET, V1, P455; HEGEDUS L, 1991, CLIN ENDOCRINOL, V35, P235, DOI 10.1111/j.1365-2265.1991.tb03528.x; HOW J, 1980, LANCET, V2, P427; ISEKI M, 1983, J CLIN ENDOCR METAB, V57, P384, DOI 10.1210/jcem-57-2-384; JACKSON HJ, 1981, LANCET, V2, P992; KAPLAN MM, 1992, THYROID, V2, P147, DOI 10.1089/thy.1992.2.147; KASAGI K, 1986, CLIN ENDOCRINOL, V25, P519, DOI 10.1111/j.1365-2265.1986.tb03604.x; KEATING FR, 1961, PROG CARDIOVASC DIS, V3, P364, DOI 10.1016/S0033-0620(61)90004-4; KLEIN RZ, 1990, J PEDIATR-US, V116, P27; KUTTY KM, 1978, J CLIN ENDOCR METAB, V46, P55, DOI 10.1210/jcem-46-1-55; LALLEMAND D, 1983, J PEDIATR-US, V102, P935, DOI 10.1016/S0022-3476(83)80028-6; LARSEN PR, 1982, NEW ENGL J MED, V306, P23; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; LEHMKE J, 1992, CLIN ENDOCRINOL, V36, P511, DOI 10.1111/j.1365-2265.1992.tb02254.x; LESLIE PJ, 1988, BAILLIERE CLIN ENDOC, V2, P653, DOI 10.1016/S0950-351X(88)80058-2; LEVINE HD, 1980, AM J MED, V69, P411, DOI 10.1016/0002-9343(80)90013-3; LITHELL H, 1981, EUR J CLIN INVEST, V11, P3, DOI 10.1111/j.1365-2362.1981.tb01758.x; LUNDSTROM B, 1981, ACTA CHIR SCAND, V147, P645; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MANDEL SJ, 1993, ANN INTERN MED, V119, P492, DOI 10.7326/0003-4819-119-6-199309150-00009; MAZZAFERRI EL, 1987, SEMIN ONCOL, V14, P315; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; MAZZAFERRI EL, 1988, SEMIN ONCOL, V15, pR10; NILSSON G, 1976, ACTA MED SCAND, V200, P63; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; PIOLI G, 1992, ACTA ENDOCRINOL-COP, V126, P238, DOI 10.1530/acta.0.1260238; RIBOT C, 1990, CLIN ENDOCRINOL, V33, P143, DOI 10.1111/j.1365-2265.1990.tb00477.x; RIDGWAY EC, 1981, J CLIN ENDOCR METAB, V53, P1238, DOI 10.1210/jcem-53-6-1238; ROSENTHAL MJ, 1987, JAMA-J AM MED ASSOC, V258, P209, DOI 10.1001/jama.258.2.209; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; SAWERS JSA, 1980, J CLIN ENDOCR METAB, V50, P226, DOI 10.1210/jcem-50-2-226; SNYDER PJ, 1972, J CLIN INVEST, V51, P2077, DOI 10.1172/JCI107014; SOLOMON BL, 1993, THYROID, V3, P17, DOI 10.1089/thy.1993.3.17; SPENCER C, 1987, CLIN CHEM, V33, P1391; SPENCER CA, 1990, J CLIN ENDOCR METAB, V70, P453, DOI 10.1210/jcem-70-2-453; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; STEINBERG AD, 1968, ANN INTERN MED, V68, P338, DOI 10.7326/0003-4819-68-2-338; STOCK JM, 1974, NEW ENGL J MED, V290, P529, DOI 10.1056/NEJM197403072901001; STONE E, 1984, J CLIN ENDOCR METAB, V59, P139, DOI 10.1210/jcem-59-1-139; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; TAKASU N, 1992, NEW ENGL J MED, V326, P513, DOI 10.1056/NEJM199202203260803; TIECHE M, 1981, BRIT HEART J, V46, P202, DOI 10.1136/hrt.46.2.202; TOFT AD, 1975, LANCET, V2, P576; TOFT AD, 1978, BRIT MED J, V2, P1115, DOI 10.1136/bmj.2.6145.1115; TOFT AD, 1978, NEW ENGL J MED, V298, P643, DOI 10.1056/NEJM197803232981202; TOPLISS DJ, 1980, J CLIN ENDOCR METAB, V50, P52, DOI 10.1210/jcem-50-1-52; TUNBRIDGE WMG, 1981, BRIT MED J, V282, P258, DOI 10.1136/bmj.282.6260.258; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P495, DOI 10.1111/j.1365-2265.1977.tb01341.x; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; TZANELA M, 1993, CLIN ENDOCRINOL, V38, P25, DOI 10.1111/j.1365-2265.1993.tb00968.x; WANG YY, 1985, LANCET, V2, P518; WHEATLEY T, 1983, CLIN ENDOCRINOL, V18, P627, DOI 10.1111/j.1365-2265.1983.tb00601.x; YOSHINARI M, 1983, BRIT MED J, V287, P720, DOI 10.1136/bmj.287.6394.720	75	156	168	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					174	180						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008032				2022-12-28	WOS:A1994NW79700007
J	THIEME, T; PIACENTINI, S; DAVIDSON, S; STEINGART, K				THIEME, T; PIACENTINI, S; DAVIDSON, S; STEINGART, K			DETERMINATION OF MEASLES, MUMPS, AND RUBELLA IMMUNIZATION STATUS USING ORAL FLUID SAMPLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIBODIES; HEPATITIS; SALIVA	Objective.-To determine if oral fluid samples can be used to reliably assess protective blood levels of antibodies to measles, mumps, and rubella. Design.-A comparison of matched serum and oral fluid samples from asymptomatic subjects in enzyme-linked immunosorbent assays for measles, mumps, and rubella antibodies. A longitudinal study compared matched serum and oral fluid samples from 11 subjects after measles-mumps-rubella vaccination. Setting.-Five US clinical sites with samples tested at the reporting laboratory. Participants.-A total of 157 asymptomatic subjects including 55 subjects younger than 18 years. Main Outcome Measures and Results.-The presence of antibodies in oral fluid specimens correlated with that in serum with the following levels of sensitivity and specificity: measles, 97% and 100%, respectively; mumps, 94% and 94%, respectively; rubella, 98% and 98%, respectively. Longitudinal studies of subjects after vaccination showed similar seroconversion profiles in oral fluid and serum samples. Conclusion.-Protective blood levels of antibodies to measles, mumps, and rubella can be assessed by means of an oral fluid sample with good reliability.	SW WASHINGTON HLTH DIST,VANCOUVER,WA		THIEME, T (corresponding author), EPITOPE INC,8505 CREEKSIDE PL,BEAVERTON,OR 97005, USA.							AABY P, 1989, B WORLD HEALTH ORGAN, V67, P443; BAGG J, 1991, ARCH ORAL BIOL, V36, P221, DOI 10.1016/0003-9969(91)90089-D; BRANDTZAEG P, 1989, HUMAN SLAVIA CLIN CH, V2; BRANDTZAEG P, 1972, RESISTANCE COMMENSAL; BULL AR, 1989, EPIDEMIOL INFECT, V103, P371, DOI 10.1017/S0950268800030715; CORDEIRO M, 1993, SALIVA DIAGNOSTIC FL, P330; GAUDETTE D, IN PRESS J CLIN IMMU; ORENSTEIN WA, 1990, PEDIATR CLIN N AM, V37, P709; PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1; SUBBARAO EK, 1991, J INFECT DIS, V163, P876, DOI 10.1093/infdis/163.4.876; THIEME T, 1992, J CLIN MICROBIOL, V30, P1076, DOI 10.1128/JCM.30.5.1076-1079.1992; 1991, JAMA-J AM MED ASSOC, V266, P1547	12	26	27	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					219	221		10.1001/jama.272.3.219	http://dx.doi.org/10.1001/jama.272.3.219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022041				2022-12-28	WOS:A1994NW18500023
J	SPERLING, K; PELZ, J; WEGNER, RD; DORRIES, A; GRUTERS, A; MIKKELSEN, M				SPERLING, K; PELZ, J; WEGNER, RD; DORRIES, A; GRUTERS, A; MIKKELSEN, M			SIGNIFICANT INCREASE IN TRISOMY-21 IN BERLIN 9 MONTHS AFTER THE CHERNOBYL REACTOR ACCIDENT - TEMPORAL CORRELATION OR CAUSAL RELATION	BRITISH MEDICAL JOURNAL			English	Article							DOWNS-SYNDROME; RISK; ABNORMALITIES; RADIATION; EUROPE	Objective-To assess whether the increased prevalence of trisomy 21 in West Berlin in January 1987 might have been causally related to exposure to ionising radiation as a result of the Chernobyl reactor accident or was merely a chance event. Design-Analysis of monthly prevalence of trisomy 21 in West Berlin from January 1980 to December 1989. Setting-Confines of West Berlin. Results-Owing to the former ''island'' situation of West Berlin and its well organised health services, ascertainment of trisomy 21 was thought to be almost complete. A cluster of 12 cases occurred in January 1987 as compared with two or three expected. After exclusion of factors that might have explained the increase, including maternal age distribution, only exposure to radiation as a result of the Chernobyl reactor accident remained. In six of seven cases that could be studied cytogenetically the extra chromosome was of maternal origin, confirming that nondisjunction had occurred at about the time of conception. Conclusion-On the basis of two assumptions -(a) that maternal meiosis is an error prone process susceptible to exogenous factors at the time of conception; (b) that owing to the high prevalence of iodine deficiency in Berlin a large amount of iodine-131 would have been accumulated over a short period-it is concluded that the increased prevalence of trisomy 21 in West Berlin in January 1987 was causally related to a short period of exposure to ionising radiation as a result of the Chernobyl reactor accident.	INST GESCHICHTE MED,D-79104 FREIBURG,GERMANY; FREE UNIV BERLIN,KINDERKLIN,D-14059 BERLIN,GERMANY; JOHN F KENNEDY INST,DK-2600 GLOSTRUP,DENMARK	Free University of Berlin	SPERLING, K (corresponding author), FREE UNIV BERLIN,INST HUMAN GENET,D-14059 BERLIN,GERMANY.							ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; ANTONARAKIS SE, 1993, TRENDS GENET, V9, P142, DOI 10.1016/0168-9525(93)90210-9; CZEIZEL A, 1989, HUM GENET, V82, P359; CZEIZEL A, 1988, ACTA MORPHOL HUNG, V36, P63; CZEIZEL AE, 1993, LANCET, V341, P539, DOI 10.1016/0140-6736(93)90293-P; DELANGE F, 1989, B WORLD HEALTH ORGAN, V67, P317; DELANGE F, 1986, BIOL NEONATE, V49, P322, DOI 10.1159/000242547; DEWALS P, 1988, INT J EPIDEMIOL, V17, P230, DOI 10.1093/ije/17.1.230; Diggle P, 1990, TIME SERIES BIOSTATI; DULK H, 1991, EUROCAT REGISTRY DES; FIALKOW PJ, 1970, ANN NY ACAD SCI, V171, P500, DOI 10.1111/j.1749-6632.1970.tb39359.x; GERMAN J, 1968, NATURE, V217, P516, DOI 10.1038/217516a0; HANSMANN I, 1990, TRENDS CHROMOSOME RE, P165; HARJULEHTOMERVAALA T, 1992, MUTAT RES, V275, P81, DOI 10.1016/0921-8734(92)90011-D; HELLER CG, 1963, SCIENCE, V140, P184, DOI 10.1126/science.140.3563.184; HOOK EB, 1989, AM J HUM GENET, V45, P855; JANERICH DT, 1977, LANCET, V1, P515; JORGBLOET PH, 1982, HUM GENET, V62, P134; KALLEN B, 1989, HEREDITAS, V110, P55, DOI 10.1111/j.1601-5223.1989.tb00417.x; KLINE J, 1985, ANEUPLOIDY ETIOLOGY, P149; KOCHUPILLAI N, 1976, NATURE, V262, P60, DOI 10.1038/262060a0; LIENERT GA, 1978, VERTEILUNGSFREIE MET, V2; LINDSTEN J, 1981, TRISOMY, V21, P1195; RAMSAY CN, 1991, BIOMED PHARMACOTHER, V45, P267, DOI 10.1016/0753-3322(91)90028-R; SPERLING K, 1991, BIOMED PHARMACOTHER, V45, P255, DOI 10.1016/0753-3322(91)90026-P; SPERLING K, 1984, MUTATIONS MAN, P128; SPERLING K, 1987, ANN U SARAVIENSIS S, V7, P307; SPERLING K, 1987, ANN U SARAV MED S, V7, P305; STEINMETZ KH, 1987, RADIOAKTIVITATSMESSU, P439; THIEME C, 1989, KINDERARZT, V20, P857; TORFS CP, 1990, AM J HUM GENET, V47, P727; VOGEL F, 1992, HUM GENET, V89, P127; WINTER M, 1986, RADIOAKTIVITAZ BRD S; WITOWSKI R, 1987, Z KLINISCHE MED, V24, P2203; 1985, LANCET, V1, P1289; 1980, SCIENCE, V209, P877	36	74	77	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					158	162		10.1136/bmj.309.6948.158	http://dx.doi.org/10.1136/bmj.309.6948.158			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044094	Green Published			2022-12-28	WOS:A1994NY22900020
J	CAMPBELL, BA; BANTLE, JP; SCHMIDT, BA				CAMPBELL, BA; BANTLE, JP; SCHMIDT, BA			SUCRALFATE AND THE ABSORPTION OF L-THYROXINE	ANNALS OF INTERNAL MEDICINE			English	Letter							LEVOTHYROXINE				CAMPBELL, BA (corresponding author), UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA.							HAVRANKOVA J, 1992, ANN INTERN MED, V117, P445, DOI 10.7326/0003-4819-117-5-445_3; KHAN F, 1993, ANN INTERN MED, V118, P317, DOI 10.7326/0003-4819-118-4-199302150-00027	2	12	12	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					152	152		10.7326/0003-4819-121-2-199407150-00024	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00024			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017736				2022-12-28	WOS:A1994NW18600023
J	CLORE, GM; OMICHINSKI, JG; SAKAGUCHI, K; ZAMBRANO, N; SAKAMOTO, H; APPELLA, E; GRONENBORN, AM				CLORE, GM; OMICHINSKI, JG; SAKAGUCHI, K; ZAMBRANO, N; SAKAMOTO, H; APPELLA, E; GRONENBORN, AM			HIGH-RESOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTIDIMENSIONAL NMR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ISOTOPICALLY ENRICHED PROTEINS; RESTRAINED MOLECULAR-DYNAMICS; MULTIPLE QUANTUM COHERENCE; DNA-BINDING; DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURE; J COUPLINGS; PEPTIDE COMPLEX; LARGER PROTEINS	The three-dimensional structure of the oligomerization domain (residues 319 to 360) of the tumor suppressor p53 has been solved by multidimensional heteronuclear magnetic resonance (NMR) spectroscopy. The domain forms a 20-kilodalton symmetric tetramer with a topology made up from a dimer of dimers. The two primary dimers each comprise two antiparallel helices linked by an antiparallel beta sheet. One beta strand and one helix are contributed from each monomer. The interface between the two dimers forming the tetramer is mediated solely by helix-helix contacts. The overall result is a symmetric, four-helix bundle with adjacent helices oriented antiparallel to each other and with the two antiparallel beta sheets located on opposing faces of the molecule. The tetramer is stabilized not only by hydrophobic interactions within the protein core but also by a number of electrostatic interactions. The implications of the structure of the tetramer for the biological function of p53 are discussed.	NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892; NCI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Clore, G Marius/L-2546-2018; Sakamoto, Hiroshi/A-3181-2011; Zambrano, Nicola/B-9352-2014; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Zambrano, Nicola/0000-0001-9395-3481; Clore, G. Marius/0000-0003-3809-1027; Sakaguchi, Kazuyasu/0000-0002-8434-4171; Gronenborn, Angela M/0000-0001-9072-3525				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1992, J AM CHEM SOC, V114, P6923, DOI 10.1021/ja00043a052; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; CLICHE L, 1990, P NATL ACAD SCI USA, V87, P3240; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DAMICO D, 1992, ONCOGENE, V7, P339; DECASTRO E, 1992, VISP 1 0 USERS GUIDE; DELANO W, 1993, AVS XPLOR USERS MANU; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; GRZESIEK S, 1992, J MAGN RESON, V96, P215, DOI 10.1016/0022-2364(92)90307-S; GRZESIEK S, 1993, J BIOMOL NMR, V3, P487; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN M, 1993, SCIENCE, V262, P1980; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; IKURA M, 1993, SCIENCE, V261, P438; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU FS, 1994, OBSTET GYNECOL, V83, P118; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MIYAMOTO H, 1993, ONCOL RES, V5, P245; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NISHIDA N, 1993, CANCER RES, V53, P368; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; SAKAMOTO H, IN PRESS P NATL ACAD; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; VUISTER GW, 1994, METHOD ENZYMOL, V239, P79; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	69	299	306	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					386	391		10.1126/science.8023159	http://dx.doi.org/10.1126/science.8023159			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023159				2022-12-28	WOS:A1994NW81600038
J	FRIEND, S				FRIEND, S			P53 - A GLIMPSE AT THE PUPPET BEHIND THE SHADOW PLAY	SCIENCE			English	Editorial Material							WILD-TYPE P53; BINDING PROTEIN; MUTATIONS		HARVARD UNIV,SCH MED,BOSTON,MA 02129	Harvard University; Harvard Medical School	FRIEND, S (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129, USA.							[Anonymous], 1961, COLLECTED DIALOGUES; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DUTTA A, 1993, NATURE, V365, P789; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HOLLSTEIN M, IN PRESS NUCLEIC ACI; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LEGROS Y, IN PRESS ONCOGENE; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; PRIVES C, COMMUNICATION; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028	17	151	156	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					334	335		10.1126/science.8023155	http://dx.doi.org/10.1126/science.8023155			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023155				2022-12-28	WOS:A1994NW81600024
J	POLYAK, K; LEE, MH; ERDJUMENTBROMAGE, H; KOFF, A; ROBERTS, JM; TEMPST, P; MASSAGUE, J				POLYAK, K; LEE, MH; ERDJUMENTBROMAGE, H; KOFF, A; ROBERTS, JM; TEMPST, P; MASSAGUE, J			CLONING OF P27(KIP1), A CYCLIN-DEPENDENT KINASE INHIBITOR AND A POTENTIAL MEDIATOR OF EXTRACELLULAR ANTIMITOGENIC SIGNALS	CELL			English	Article							FC-GAMMA-RIII; CELL-CYCLE; GROWTH-FACTOR; TGF-BETA; GENE-EXPRESSION; CDK2 ACTIVITY; G1 CYCLIN; FIBROBLASTS; PROTEIN; PHASE	We cloned p27(Kip1), a cyclin-dependent kinase inhibitor implicated in G1 phase arrest by TGF beta and cell-cell contact. p27(Kip1) associates with cyclin E-Cdk2 complexes in vivo and in vitro, prevents their activation, and inhibits previously activated complexes, and p27(Kip1) overexpression obstructs cell entry into S phase. p27(Kip1) potently inhibits Rb phosphorylation by cyclin E-Cdk2, cyclin A-Cdk2, and cyclin D2-Cdk4. p27(Kip1) is highly conserved and broadly expressed in human tissues, and its mRNA levels are similar in proliferating and quiescent cells. p27(Kip1) has a region of sequence similarity to p21(Cip1/WAF1), the Cdk inhibitor whose transcription is stimulated by p53. A p27(Kip1) peptide corresponding to this region retains Cdk inhibitory activity. We suggest that cell contact, TGF beta, and p53 all restrain cell proliferation through related Cdk inhibitors.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104	Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Center	POLYAK, K (corresponding author), HOWARD HUGHES MED INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.			Erdjument-Bromage, Hediye/0000-0003-0224-3594; Lee, Mong-Hong/0000-0001-8675-8215; Massague, Joan/0000-0001-9324-8408				ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; COCKS BG, 1992, J BIOL CHEM, V267, P12307; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELICONE C, 1994, IN PRESS J CHROMATOG; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; JIANG W, 1993, ONCOGENE, V8, P3447; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	40	2069	2208	3	57	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					59	66		10.1016/0092-8674(94)90572-X	http://dx.doi.org/10.1016/0092-8674(94)90572-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033212				2022-12-28	WOS:A1994NX32800008
J	VAITKUS, PT; HERRMANN, HC; LEWINTER, MM				VAITKUS, PT; HERRMANN, HC; LEWINTER, MM			TREATMENT OF MALIGNANT PERICARDIAL-EFFUSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CARDIAC-TAMPONADE; INTRAPERICARDIAL INSTILLATION; BREAST-CANCER; SUBXIPHOID PERICARDIOTOMY; TETRACYCLINE SCLEROSIS; SURGICAL-MANAGEMENT; CHROMIC PHOSPHATE; CATHETER DRAINAGE; MEDICAL PATIENTS; LUNG-CANCER	Objective.-To discuss the diagnosis and treatment of malignant pericardial effusion and focus on quantitating the success and complication rates of the many treatment modalities and updating recent advances in the field. Data Sources.-English-language publications were identified by a computerized search (MEDLINE) of these key words: cancer, tumor, malignancy, pericardium, and pericardial effusion. This computerized search was supplemented by a manual search of the bibliographies of original research articles and textbooks. Study Selection.-Studies were included if the outcome of patients undergoing treatment for malignant pericardial effusion was reported separately from the outcome of patients with other causes of pericardial effusions. Studies that only reported the combined results of patients with malignant and nonmalignant effusions were excluded.	HOSP UNIV PENN,DIV CARDIOVASC,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine	VAITKUS, PT (corresponding author), UNIV VERMONT,MED CTR HOSP VERMONT,CARDIOL UNIT,111 COLCHESTER AVE,BURLINGTON,VT 05401, USA.							ALCAN KE, 1982, JAMA-J AM MED ASSOC, V247, P1143, DOI 10.1001/jama.247.8.1143; APPELQVIST P, 1982, J SURG ONCOL, V21, P18, DOI 10.1002/jso.2930210105; Berman K, 1984, Conn Med, V48, P701; BINDI M, 1987, TUMORI, V73, P163, DOI 10.1177/030089168707300213; BITRAN JD, 1984, J SURG ONCOL, V27, P42, DOI 10.1002/jso.2930270110; BUCK M, 1987, CANCER, V60, P263, DOI 10.1002/1097-0142(19870715)60:2<263::AID-CNCR2820600225>3.0.CO;2-N; CALLAHAN JA, 1985, AM J CARDIOL, V55, P476, DOI 10.1016/0002-9149(85)90397-2; CAMPBELL PT, 1992, CHEST, V101, P938, DOI 10.1378/chest.101.4.938; CELERMAJER DS, 1991, MED J AUSTRALIA, V154, P19, DOI 10.5694/j.1326-5377.1991.tb112840.x; CHAM WC, 1975, RADIOLOGY, V114, P701, DOI 10.1148/114.3.701; CHANDRARATNA PAN, 1981, CIRCULATION, V63, P197, DOI 10.1161/01.CIR.63.1.197; CHOW WH, 1992, AM HEART J, V124, P1100, DOI 10.1016/0002-8703(92)91006-M; CLARKE DP, 1987, CLIN RADIOL, V38, P119, DOI 10.1016/S0009-9260(87)80005-3; CORMICAN MC, 1990, BRIT HEART J, V63, P61; COURTENAYLUCK N, 1984, LANCET, V1, P1441; DALEY J R, 1992, Journal of the American College of Cardiology, V19, p357A; DAVIS S, 1984, J CLIN ONCOL, V2, P631, DOI 10.1200/JCO.1984.2.6.631; EDOUTE Y, 1990, J SURG ONCOL, V45, P121, DOI 10.1002/jso.2930450212; FIGOLI F, 1987, CANCER CHEMOTH PHARM, V20, P239, DOI 10.1007/BF00570493; FINCHER RME, 1993, AM J MED SCI, V305, P106, DOI 10.1097/00000441-199302000-00009; FIORENTINO MV, 1988, CANCER, V62, P1904, DOI 10.1002/1097-0142(19881101)62:9<1904::AID-CNCR2820620906>3.0.CO;2-U; FRASER RS, 1980, CANCER, V45, P1597; Gatenby R A, 1991, J Vasc Interv Radiol, V2, P151, DOI 10.1016/S1051-0443(91)72490-1; GHOSH SC, 1985, INT SURG, V70, P5; GREGORY JR, 1985, AM J CLIN ONCOL-CANC, V8, P319, DOI 10.1097/00000421-198508000-00009; GUBERMAN BA, 1981, CIRCULATION, V64, P633, DOI 10.1161/01.CIR.64.3.633; HANKINS JR, 1980, ANN THORAC SURG, V30, P465, DOI 10.1016/S0003-4975(10)61298-2; HILL GJ, 1970, CANCER, V26, P81, DOI 10.1002/1097-0142(197007)26:1<81::AID-CNCR2820260110>3.0.CO;2-8; HOCKEN AG, 1964, BRIT MED J, V1, P164, DOI 10.1136/bmj.1.5376.164; IBARRAPEREZ C, 1978, AM SURGEON, V44, P602; IMAMURA T, 1991, CANCER-AM CANCER SOC, V68, P259, DOI 10.1002/1097-0142(19910715)68:2<259::AID-CNCR2820680207>3.0.CO;2-V; Kaetz H W, 1968, Conn Med, V32, P523; KING DT, 1979, ANN CLIN LAB SCI, V9, P18; KOPECKY SL, 1986, AM J CARDIOL, V58, P633, DOI 10.1016/0002-9149(86)90290-0; KRIKORIAN JG, 1978, AM J MED, V65, P808, DOI 10.1016/0002-9343(78)90800-8; LAHAN RJ, 1994, J AM COLL CARDIOL, V21, pA275; LIEDTKE AJ, 1971, AM J MED, V50, P816, DOI 10.1016/0002-9343(71)90190-2; LIEPMAN MK, 1981, J SURG ONCOL, V17, P183, DOI 10.1002/jso.2930170214; LITTLE AG, 1984, SURGERY, V96, P738; LOCK JE, 1984, AM J CARDIOL, V53, P1179, DOI 10.1016/0002-9149(84)90658-1; MACK MJ, 1992, ANN THORAC SURG, V54, P403, DOI 10.1016/0003-4975(92)90428-7; MAHER ER, 1986, AM HEART J, V111, P613, DOI 10.1016/0002-8703(86)90080-3; MARKIEWICZ W, 1986, AM HEART J, V111, P1138, DOI 10.1016/0002-8703(86)90018-9; MARKMAN M, 1985, CANC DRUG DEL, V2, P49, DOI 10.1089/cdd.1985.2.49; MARTINI N, 1977, AM J ROENTGENOL, V128, P639, DOI 10.2214/ajr.128.4.639; MILLAIRE A, 1992, AM HEART J, V124, P1030, DOI 10.1016/0002-8703(92)90988-8; MILLER JI, 1982, ANN THORAC SURG, V34, P40, DOI 10.1016/S0003-4975(10)60850-8; MILLS SA, 1989, J CARDIOVASC SURG, V30, P768; NAGAMINE K, 1990, JPN CIRC J, V54, P1158, DOI 10.1253/jcj.54.1158; NAUNHEIM KS, 1991, EUR J CARDIO-THORAC, V5, P99, DOI 10.1016/1010-7940(91)90007-7; NELSON BE, 1993, J SURG ONCOL, V52, P203, DOI 10.1002/jso.2930520318; O'Bryan R M, 1968, Henry Ford Hosp Med J, V16, P3; OKAMOTO H, 1993, CANCER-AM CANCER SOC, V71, P93, DOI 10.1002/1097-0142(19930101)71:1<93::AID-CNCR2820710115>3.0.CO;2-R; OSUCH JR, 1985, AM SURGEON, V51, P298; PALACIOS IF, 1991, CATHETER CARDIO DIAG, V22, P244, DOI 10.1002/ccd.1810220403; PALATIANOS GM, 1985, CHEST, V88, P30, DOI 10.1378/chest.88.1.30; PARK JS, 1991, CANCER, V67, P76, DOI 10.1002/1097-0142(19910101)67:1<76::AID-CNCR2820670115>3.0.CO;2-6; PATEL AK, 1987, CHEST, V92, P1018, DOI 10.1378/chest.92.6.1018; PECTASIDES D, 1986, BRIT J CANCER, V53, P727, DOI 10.1038/bjc.1986.125; PIEHLER JM, 1985, J THORAC CARDIOV SUR, V90, P506; POSNER MR, 1981, AM J MED, V71, P407, DOI 10.1016/0002-9343(81)90168-6; PRADHAN DJ, 1976, AM SURGEON, V42, P257; PRAGER RL, 1982, ANN THORAC SURG, V34, P6, DOI 10.1016/S0003-4975(10)60844-2; PRIMROSE WR, 1983, CLIN ONCOL, V9, P67; READY A, 1992, LANCET, V339, P1609, DOI 10.1016/0140-6736(92)91874-8; REITKNECHT F, 1985, J SURG ONCOL, V30, P19, DOI 10.1002/jso.2930300107; REYNOLDS PM, 1977, AUST NZ J MED, V7, P169, DOI 10.1111/j.1445-5994.1977.tb04688.x; RIEKE JW, 1988, GYNECOL ONCOL, V31, P338, DOI 10.1016/S0090-8258(88)80013-1; ROSE RG, 1962, J NUCL MED, V3, P323; Rosenthal DS., 1992, HEART DIS TXB CARDIO, P1742; SANTOS GH, 1977, ANN THORAC SURG, V23, P467, DOI 10.1016/S0003-4975(10)64168-9; Sastic J W, 1992, J Laparoendosc Surg, V2, P263, DOI 10.1089/lps.1992.2.263; SHEPHERD FA, 1987, AM J CARDIOL, V60, P1161, DOI 10.1016/0002-9149(87)90411-5; SHINDE SR, 1986, J SURG ONCOL, V32, P96, DOI 10.1002/jso.2930320211; SMITH FE, 1974, CANCER, V33, P47, DOI 10.1002/1097-0142(197401)33:1<47::AID-CNCR2820330110>3.0.CO;2-8; SPRENGELMEYER JT, 1990, J NUCL MED, V31, P2034; SUHRLAND LG, 1965, ARCH INTERN MED, V116, P431, DOI 10.1001/archinte.1965.03870030111019; SULKES A, 1982, J SURG ONCOL, V20, P71, DOI 10.1002/jso.2930200202; TERPENNING M, 1979, P AM ASSOC CANC RES, V20, P286; TERRY LN, 1970, CANCER-AM CANCER SOC, V25, P1003, DOI 10.1002/1097-0142(197005)25:5<1003::AID-CNCR2820250503>3.0.CO;2-W; THURBER DL, 1962, CIRCULATION, V26, P228, DOI 10.1161/01.CIR.26.2.228; ULTMANN JE, 1957, CANCER, V10, P902, DOI 10.1002/1097-0142(195709/10)10:5<902::AID-CNCR2820100507>3.0.CO;2-F; VANBELLE SJP, 1987, INT J CARDIOL, V16, P155, DOI 10.1016/0167-5273(87)90246-4; VANDERGAAST A, 1989, EUR J CANCER CLIN ON, V25, P1505, DOI 10.1016/0277-5379(89)90112-0; VORA AM, 1992, CATHETER CARDIO DIAG, V25, P164, DOI 10.1002/ccd.1810250216; WEI JY, 1978, AM J CARDIOL, V42, P281, DOI 10.1016/0002-9149(78)90911-6; WEISBERGER AS, 1955, JAMA-J AM MED ASSOC, V159, P1704; WOLL PJ, 1987, J ROY SOC MED, V80, P490, DOI 10.1177/014107688708000811; WONG B, 1979, AM J CARDIOL, V44, P1110, DOI 10.1016/0002-9149(79)90176-0; ZIPF R E, 1972, Chest, V62, P593; ZISKIND AA, 1992, J AM COLL CARDIOL, V21, P1	91	170	177	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					59	64		10.1001/jama.272.1.59	http://dx.doi.org/10.1001/jama.272.1.59			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU485	8007081				2022-12-28	WOS:A1994NU48500031
J	KOSHLAND, D				KOSHLAND, D			MITOSIS - BACK TO THE BASICS	CELL			English	Review							MICROTUBULES; INVITRO; CHROMOSOMES; CENTROMERE; PROTEINS				KOSHLAND, D (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,115 W UNIV PKWY,BALTIMORE,MD 21210, USA.							Bajer A. S., 1972, SPINDLE DYNAMICS CHR; BLOOM K, 1993, CELL, V73, P621, DOI 10.1016/0092-8674(93)90242-I; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; EARNSHAW WC, 1989, GENOME, V31, P541, DOI 10.1139/g89-103; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; GORBSKY GJ, 1992, BIOESSAYS, V14, P73, DOI 10.1002/bies.950140202; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KOSHLAND DE, 1993, SCIENCE, V262, P532, DOI 10.1126/science.8211179; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LOMBILLO VA, 1993, MOL BIOL CELL, V4, P118; McIntosh J. Richard, 1994, V13, P413; MIDDLETON K, 1994, IN PRESS P NATL ACAD; NICKLAS RB, 1967, CHROMOSOMA, V21, P17, DOI 10.1007/BF00330545; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; Rose MD, 1993, CURR OPIN CELL BIOL, V5, P105, DOI 10.1016/S0955-0674(05)80015-8; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; Wadsworth P, 1993, CURR OPIN CELL BIOL, V5, P123, DOI 10.1016/S0955-0674(05)80017-1; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	22	42	42	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					951	954		10.1016/0092-8674(94)90432-4	http://dx.doi.org/10.1016/0092-8674(94)90432-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020100				2022-12-28	WOS:A1994NV42500001
J	TZAMARIAS, D; STRUHL, K				TZAMARIAS, D; STRUHL, K			FUNCTIONAL DISSECTION OF THE YEAST CYC8-TUP1 TRANSCRIPTIONAL CO-REPRESSOR COMPLEX	NATURE			English	Article							DNA-BINDING SPECIFICITY; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; GLUCOSE REPRESSION; ACTIVATION DOMAIN; ESCHERICHIA-COLI; SHUTTLE VECTORS; PROTEIN; GENES; PURIFICATION	DNA-BINDING repressor proteins mediate regulation of yeast genes by cell type (Mcm1/alpha 2 and a1/alpha 2), glucose (Mig1) and oxygen (Rox1) (refs 1-4 respectively). An unusual feature of all these regulatory pathways is that transcriptional repression requires two physically associated proteins(5) that do not bind DNA Cyc8(Ssn6) and Tup1. The Cyc8-Tup1 complex has been proposed to be a corepressor that is recruited to target promoters by pathway-specific DNA-binding proteins(6), but the specific functions of the individual proteins are unknown. Here we show that when it is bound upstream of a functional promoter through the LexA DNA-binding domain, Tup1 represses transcription in the absence of Cyc8. Deletion analysis indicates that Tup1 contains at least two non-overlapping transcriptional repression regions with minimal primary sequence similarity, and a separable Cyc8-interaction domain. These Tup1 domains, which do not include the beta-transducin motifs(7), are necessary and partially sufficient for Tup1 function. We suggest that Tup1 performs the repression function of the Cyc8-Tup1 co-repressor complex, and that Cyc8 serves as a link with the pathway-specific DNA-binding proteins.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	30	286	292	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					758	761		10.1038/369758a0	http://dx.doi.org/10.1038/369758a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008070				2022-12-28	WOS:A1994NU58100065
J	REICHERT, LJM; HUYSMANS, FTM; ASSMANN, K; KOENE, RAP; WETZELS, JFM				REICHERT, LJM; HUYSMANS, FTM; ASSMANN, K; KOENE, RAP; WETZELS, JFM			PRESERVING RENAL-FUNCTION IN PATIENTS WITH MEMBRANOUS NEPHROPATHY - DAILY ORAL CHLORAMBUCIL COMPARED WITH INTERMITTENT MONTHLY PULSES OF CYCLOPHOSPHAMIDE	ANNALS OF INTERNAL MEDICINE			English	Article						GLOMERULONEPHRITIS, MEMBRANOUS; CYCLOPHOSPHAMIDE; CHLORAMBUCIL; KIDNEY FAILURE, CHRONIC; NEPHROTIC SYNDROME	CONTROLLED TRIAL; RENAL-FUNCTION; UNTREATED PATIENTS; NATURAL-HISTORY; GLOMERULONEPHRITIS; PREDNISONE; METHYLPREDNISOLONE; IMMUNOSUPPRESSION; PROGNOSIS; THERAPY	Objective: To compare oral chlorambucil and intravenous cyclophosphamide-based drug regimens in the treatment of patients with membranous nephropathy and deteriorating renal function. Design: Randomized study. Setting: University hospital and teaching hospitals. Patients: 18 patients with membranous nephropathy, a nephrotic syndrome, and deteriorating renal function. Intervention: Chlorambucil (0.15 mg/kg body weight per day orally in months 2, 4, and 6) and prednisone (three intravenous pulses of 1 g of methylprednisolone followed by oral prednisone at 0.5 mg/kg per day in months 1, 3, and 5) or intravenous cyclophosphamide (750 mg/m(2) body surface area once every month for 6 months) and methylprednisolone (three intravenous 1-g pulses in months 1,3, and 5). Measurements: Serum creatinine, serum cholesterol, serum albumin, and urinary protein levels. Results: Before treatment, no statistical differences were found between the treatment groups. Six months after treatment was started, serum creatinine levels had decreased in the group treated with chlorambucil, methylprednisolone, and prednisone from a mean of 260 +/- 112 mu mol/L to 186 +/- 74 mu mol/L (P = 0.003) and had increased in the group treated with intravenous cyclophosphamide and methylprednisolone from 218 +/- 85 mu mol/L to 297 +/- 143 mu mol/L (P = 0.02; difference between both groups, P < 0.001). Serum albumin levels increased in both groups by 9 and 6 g/L, respectively, and the urinary. protein/creatinine ratio decreased by 2.6 and 3.1 g/10 mmol, respectively. At the end of follow-up (median, 15 months; range, 6 to 36 months), one patient in the chlorambucil group and four patients in the cyclophosphamide group had reached end-stage renal failure after 36, 12, 12, 18, and 18 months of therapy, respectively. One patient in the intravenous cyclophosphamide group died after 6 months of therapy. Conclusions: Thus far, both oral chlorambucil and oral cyclophosphamide have been shown to be effective in the treatment of patients with membranous nephropathy and deteriorating renal function. Our study shows that intermittent monthly pulses of low-dose cyclophosphamide are ineffective in preserving renal function in such patients.	UNIV NIJMEGEN HOSP, DEPT PATHOL, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen	REICHERT, LJM (corresponding author), UNIV NIJMEGEN HOSP, DEPT MED, DIV NEPHROL, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		Wetzels, Jack F.M./A-1720-2014	Wetzels, Jack F.M./0000-0002-0650-6921				AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BRUNS FJ, 1991, ANN INTERN MED, V114, P725, DOI 10.7326/0003-4819-114-9-725; CAMERON JS, 1979, KIDNEY INT, V15, P88; CAMERON JS, 1990, Q J MED, V74, P133, DOI 10.1093/oxfordjournals.qjmed.a068422; CATTRAN DC, 1989, NEW ENGL J MED, V320, P210, DOI 10.1056/NEJM198901263200403; COGGINS CH, 1979, NEW ENGL J MED, V301, P1301; DAVISON AM, 1984, CLIN NEPHROL, V22, P61; DONADIO JV, 1988, KIDNEY INT, V33, P708, DOI 10.1038/ki.1988.56; Ehrenreich T., 1968, PATHOL ANNU, V3, P145; FALK RJ, 1992, ANN INTERN MED, V116, P438, DOI 10.7326/0003-4819-116-6-438; JINDAL K, 1992, AM J KIDNEY DIS, V19, P61, DOI 10.1016/S0272-6386(12)70204-4; LEWIS EJ, 1993, NEW ENGL J MED, V329, P127, DOI 10.1056/NEJM199307083290211; MACTIER R, 1986, Q J MED, V60, P793; MATHIESON PW, 1988, LANCET, V2, P869; PONTICELLI C, 1992, NEW ENGL J MED, V327, P599, DOI 10.1056/NEJM199208273270904; PONTICELLI C, 1984, NEW ENGL J MED, V310, P946, DOI 10.1056/NEJM198404123101503; SCHIEPPATI A, 1993, NEW ENGL J MED, V329, P85, DOI 10.1056/NEJM199307083290203; SHORT CD, 1987, Q J MED, V65, P929; WEHRMANN M, 1989, CLIN NEPHROL, V31, P67; WEST ML, 1987, KIDNEY INT, V32, P579, DOI 10.1038/ki.1987.247; WETZELS JFM, 1989, LANCET, V1, P211; WILLIAMS PS, 1989, NEPHROL DIAL TRANSPL, V4, P181, DOI 10.1093/oxfordjournals.ndt.a091853	22	57	58	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					328	333		10.7326/0003-4819-121-5-199409010-00003	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042821				2022-12-28	WOS:A1994PD70100003
J	HIBBS, JR; BENNER, L; KLUGMAN, L; SPENCER, R; MACCHIA, I; MELLINGER, AK; FIFE, D				HIBBS, JR; BENNER, L; KLUGMAN, L; SPENCER, R; MACCHIA, I; MELLINGER, AK; FIFE, D			MORTALITY IN A COHORT OF HOMELESS ADULTS IN PHILADELPHIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-CITY; HUMAN-IMMUNODEFICIENCY-VIRUS; MENTAL-HEALTH; DEATH CERTIFICATES; INNER-CITY; TUBERCULOSIS; SHELTERS; ACCURACY; WOMEN; CARE	Background. Homeless people are at high risk for death from many causes, but age-adjusted death rates for well-defined homeless populations have not been determined. Methods. We identified 6308 homeless persons 15 to 74 years of age who were served by one or both of two agencies for the homeless in Philadelphia between January 1, 1985, and December 31, 1988. Using a data base that contained all deaths in Philadelphia and listings of all Philadelphia residents during the same period, we compared the mortality rate for this homeless population with the rate in the general population of Philadelphia. Results. The age-adjusted mortality rate among the homeless was 3.5 times that of Philadelphia's general population (95 percent confidence interval, 2.8 to 4.5). The age-adjusted number of years of potential life lost before the age of 75 years was 3.6 times higher for the homeless people than for the general population (345 vs. 97 years lost per 1000 person-years of observation). Fifty-one of the 96 deaths of homeless persons (53 percent) occurred during the summer months. Mortality rates were higher among the homeless than in the general population for nonwhites, whites, women, and men. Within the homeless cohort, white men and substance abusers had higher mortality rates than other subgroups, but even homeless people not known to be substance abusers had a threefold higher risk of death than members of the general population. Injuries, heart disease, liver disease, poisoning, and ill-defined conditions accounted for 73 percent of all the deaths among the homeless. Conclusions. Homeless adults in Philadelphia have an age-adjusted mortality rate nearly four times that of Philadelphia's general population. White men and substance abusers are at particularly high risk. Matching cohorts of homeless people to death records is a useful way to monitor mortality rates over time, evaluate interventions, and identify subgroups with an increased risk of death.	CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,ATLANTA,GA 30341; PENN DEPT HLTH,BUR EPIDEMIOL,HARRISBURG,PA; PHILADELPHIA OFF MENTAL HLTH MENTAL RETARDAT,PHILADELPHIA,PA; PHILADELPHIA OFF SERV HOMELESS ADULTS,PHILADELPHIA,PA; PHILADELPHIA DEPT PUBL HLTH,DIV DIS CONTROL,PHILADELPHIA,PA; RW JOHNSON PHARMACEUT RES INST,SPRING HOUSE,PA 19477; UNIV PENN,DEPT MED,CLIN EPIDEMIOL UNIT,PHILADELPHIA,PA 19104	Centers for Disease Control & Prevention - USA; Johnson & Johnson; Johnson & Johnson USA; University of Pennsylvania								BASSUK EL, 1991, SCI AM, V265, P66, DOI 10.1038/scientificamerican1291-66; BENNER L, 1991, JUN WORLD PSYCH ASS; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CALSYN RJ, 1990, AM J COMMUN PSYCHOL, V18, P597, DOI 10.1007/BF00938062; CONNELLY J, 1990, PUBLIC HEALTH, V104, P109, DOI 10.1016/S0033-3506(05)80361-0; DOBLIN BH, 1992, JAMA-J AM MED ASSOC, V267, P698, DOI 10.1001/jama.267.5.698; FERENCHICK GS, 1991, AM J MED SCI, V301, P379, DOI 10.1097/00000441-199106000-00004; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; GELBERG L, 1990, ARCH INTERN MED, V150, P2325, DOI 10.1001/archinte.150.11.2325; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P3132; GOLDSTEIN I, 1989, HOMELESSNESS PHILADE, P31; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; Hanzlick R, 1989, J Med Assoc Ga, V78, P205; HASUO Y, 1989, J CLIN EPIDEMIOL, V42, P577, DOI 10.1016/0895-4356(89)90154-6; HETZEL BS, 1986, NEW DEV ANAL MORTALI, P57; HILFIKER D, 1989, JAMA-J AM MED ASSOC, V262, P1375; JOSEPH H, 1990, NIDA RES MG, V93, P210; KINCHEN K, 1991, AM J PUBLIC HEALTH, V81, P1163, DOI 10.2105/AJPH.81.9.1163; KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1085; LAMB HR, 1986, JAMA-J AM MED ASSOC, V256, P498, DOI 10.1001/jama.256.4.498; LEPKOWSKI JM, 1991, J NUTR, V121, P416, DOI 10.1093/jn/121.3.416; LINN LS, 1990, HOSP COMMUNITY PSYCH, V41, P306; MCCORD C, 1990, NEW ENGL J MED, V322, P173, DOI 10.1056/NEJM199001183220306; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; MILES SH, 1992, JAMA-J AM MED ASSOC, V268, P2561, DOI 10.1001/jama.268.18.2561; MORIYAMA IM, 1989, AM J PUBLIC HEALTH, V79, P1349, DOI 10.2105/AJPH.79.10.1349; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PABLOSMENDEZ A, 1990, NEW YORK STATE J MED, V90, P351; PADGETT D, 1990, MED CARE, V28, P805, DOI 10.1097/00005650-199009000-00010; PADGETT DK, 1991, HOSP COMMUNITY PSYCH, V42, P835; PARKER RM, 1991, AM J DIS CHILD, V145, P520, DOI 10.1001/archpedi.1991.02160050046011; PATERSON CM, 1990, BRIT MED J, V301, P263, DOI 10.1136/bmj.301.6746.263; SAMPHIER ML, 1988, J EPIDEMIOL COMMUN H, V42, P138, DOI 10.1136/jech.42.2.138; SUGERMAN ST, 1991, AM J DIS CHILD, V145, P431, DOI 10.1001/archpedi.1991.02160040089014; SUSSER E, 1989, ARCH GEN PSYCHIAT, V46, P845; SUSSER E, 1990, COMMUNITY MENT HLT J, V26, P391, DOI 10.1007/BF00761067; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; WANG EEL, 1991, PEDIATR INFECT DIS J, V10, P130, DOI 10.1097/00006454-199102000-00011; WOOD D, 1991, AM J DIS CHILD, V145, P1109, DOI 10.1001/archpedi.1991.02160100041021; 1991, MMWR-MORBID MORTAL W, V40, P869; 1991, MMWR-MORBID MORTAL W, V40, P877; [No title captured]; 1987, MMWR-MORBID MORTAL W, V36, P297; 1991, MMWR-MORBID MORTAL W, V40, P865; 1989, PENNSYLVANIA VITAL S	46	261	261	1	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					304	309		10.1056/NEJM199408043310506	http://dx.doi.org/10.1056/NEJM199408043310506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NZ227	8022442	Bronze			2022-12-28	WOS:A1994NZ22700006
J	ARIAS, J; ALBERTS, AS; BRINDLE, P; CLARET, FX; SMEAL, T; KARIN, M; FERAMISCO, J; MONTMINY, M				ARIAS, J; ALBERTS, AS; BRINDLE, P; CLARET, FX; SMEAL, T; KARIN, M; FERAMISCO, J; MONTMINY, M			ACTIVATION OF CAMP AND MITOGEN RESPONSIVE GENES RELIES ON A COMMON NUCLEAR FACTOR	NATURE			English	Article							C-JUN; TRANSCRIPTIONAL ACTIVATION; PHOSPHORYLATION; CREB; FOS; PROMOTERS; COMPLEX; KINASE; DOMAIN; BINDS	A NUMBER of Signalling pathways stimulate transcription of target genes through nuclear factors whose activities are primarily regulated by phosphorylation. Cyclic AMP regulates the expression of numerous genes, for example, through the protein kinase-A (PKA)-mediated phosphorylation of transcription factor CREB at Ser133(1,2) Although phosphorylation may stimulate transcriptional activators by modulating their nuclear transport or DNA-binding affinity(3), CREB belongs to a class of proteins whose phosphorylation appears specifically to enhance their trans-activation potential(1,2,4). Recent work describing a phospho-CREB binding protein (CBP)(5) which interacts specifically with the CREB trans-activation domain prompted us to examine whether CBP is necessary for cAMP regulated transcription. We report here that microinjection of an anti-CBP antiserum into fibroblasts can inhibit transcription from a cAMP responsive promoter. Surprisingly, CBP also cooperates with upstream activators such as c-Jun, which are involved in mitogen responsive transcription(6). We propose that CBP is recruited to the promoter through interaction with certain phosphorylated factors, and that CBP may thus play a critical role in the transmission of inductive signals from cell surface receptor to the transcriptional apparatus.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; IMPERIAL CANC RES FUND, TRANSCRIPT LAB, LONDON WC2A 3PX, ENGLAND	University of California System; University of California San Diego; University of California System; University of California San Diego; Cancer Research UK	ARIAS, J (corresponding author), SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Claret, Francois X/R-2104-2016	Claret, Francois X/0000-0003-4629-6495; Brindle, Paul/0000-0001-7172-8478				ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	21	689	705	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 21	1994	370	6486					226	229		10.1038/370226a0	http://dx.doi.org/10.1038/370226a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028671				2022-12-28	WOS:A1994NX97100056
J	BOUVIER, M; WILEY, DC				BOUVIER, M; WILEY, DC			IMPORTANCE OF PEPTIDE AMINO AND CARBOXYL TERMINI TO THE STABILITY OF MHC CLASS-I MOLECULES	SCIENCE			English	Article							HISTOCOMPATIBILITY COMPLEX-MOLECULES; VIRUS MATRIX PROTEIN; VIRAL PEPTIDES; THERMAL-STABILITY; BINDING; HLA-A2; RECOGNITION; ANTIGENS; HLA-B27; IDENTIFICATION	An influenza virus matrix peptide in which either the charged amino or carboxyl terminus was substituted by methyl groups promoted folding of the class I human histocompatibility antigen (HLA-A2). A peptide modified at both termini did not promote stable folding. The thermal stability of HLA-A2 complexed with peptides that did not have either terminus was similar to 22 degrees C lower than that of the control peptide, whereas matrix peptide in which both anchor positions were substituted by alanines had its stability decreased by only 5.5 degrees C. Thus, the conserved major histocompatibility complex class I residues at both ends of the peptide binding site form energetically important sites for binding the termini of short peptides.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Harvard University; Harvard University; Howard Hughes Medical Institute								BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHEN Y, 1994, J IMMUNOL, V152, P2874; COLLINS EJ, UNPUB; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P2085, DOI 10.1002/eji.1830220819; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; Ghosh P., UNPUB; GUO H, UNPUB; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; HECHT MH, 1983, P NATL ACAD SCI-BIOL, V80, P2676, DOI 10.1073/pnas.80.9.2676; Heinrikson R L, 1977, Methods Enzymol, V47, P175; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LATRON F, 1992, SCIENCE, V257, P964, DOI 10.1126/science.1380181; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MORRISON J, 1992, EUR J IMMUNOL, V22, P903, DOI 10.1002/eji.1830220404; OLSEN AC, 1994, EUR J IMMUNOL, V24, P385, DOI 10.1002/eji.1830240218; OSAPAY G, 1991, TECHNIQUES PROTEIN C, V2, P221; PARKER KC, 1992, J IMMUNOL, V149, P3580; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SAITO Y, 1993, J BIOL CHEM, V268, P21309; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SAUMA SY, 1993, HUM IMMUNOL, V37, P252, DOI 10.1016/0198-8859(93)90508-X; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; UTZ U, 1992, J IMMUNOL, V149, P214; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	44	231	239	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 15	1994	265	5170					398	402		10.1126/science.8023162	http://dx.doi.org/10.1126/science.8023162			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023162				2022-12-28	WOS:A1994NW81600041
J	FISHER, M; FRIEDMAN, SB; STRAUSS, B				FISHER, M; FRIEDMAN, SB; STRAUSS, B			THE EFFECTS OF BLINDING ON ACCEPTANCE OF RESEARCH PAPERS BY PEER-REVIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		MEDICAL JOURNALS; PUBLICATION	Objective.-To study whether reviewers aware of author identity are biased in favor of authors with more previous publications. Design.-Randomized controlled trial. Setting.-Editorial office of the Journal of Developmental and Behavioral Pediatrics. Participants.-Two ''blinded'' and two ''nonblinded'' reviewers assigned to 57 consecutive manuscripts submitted between September 1991 and March 1992. Outcome Measures.-Spearman rank correlation coefficients were used to compare the sum of rating scores of 1 to 5 (1, accept; 5, reject) given by the two blinded reviewers, the two nonblinded reviewers, and the editors to the number of articles published previously by the first and senior authors (as determined from requested curricula vitae). Blinded reviewers were sent a questionnaire asking whether they could determine the identity of the authors, how they knew, and whether they thought blinding changed the quality or difficulty of their review. Results.-The Wilcoxon Sign Rank Test disclosed no differences between blinded and nonblinded scores. The number of previous articles by the senior author was significantly correlated (P<.01) with blinded scores (r=-.45) and editors' decisions (r=-.45), but not with nonblinded scores; the number of articles by the first author was correlated (P<.05) with editors' decisions (r=-.35) but not with blinded or nonblinded scores. Fifty (46%) of 108 blinded reviewers correctly guessed the identity of the authors, mostly from self-references and knowledge of the work; 86% believed blinding did not change the quality of their review, and 73% believed it did not change the difficulty of performing a review. Conclusions.-Blinded reviewers and editors in this study, but not nonblinded reviewers, gave better scores to authors with more previous articles. These results suggest that blinded reviewers may provide more unbiased reviews and that nonblinded reviewers may be affected by various types of bias.	MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,DIV ADOLESCENT MED,BRONX,NY 10467; JOURNAL DEV & BEHAV PEDIAT,BALTIMORE,MD	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	FISHER, M (corresponding author), N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT PEDIAT,DIV ADOLESCENT MED,300 COMMUNITY DR,MANHASSET,NY 11030, USA.							BAILAR JC, 1985, NEW ENGL J MED, V312, P654, DOI 10.1056/NEJM198503073121023; BLANK RM, 1991, AM ECON REV, V81, P1041; CECI SJ, 1984, AM PSYCHOL, V39, P1491, DOI 10.1037/0003-066X.39.12.1491; CLEARY JD, 1988, DRUG INTEL CLIN PHAR, V22, P601, DOI 10.1177/106002808802200720; EVANS AT, 1993, 2ND INT C PEER REV B; FEINSTEIN AR, 1986, J CHRON DIS, V39, P491, DOI 10.1016/0021-9681(86)90193-1; GARFUNKEL JM, 1993, 2ND INT C PEER REV B; GILBERT J, 1993, 2ND INT C PEER REV B; Harnad S., 1982, BEHAV BRAIN SCI, V5, P185; KUPFERSMID J, 1988, AM PSYCHOL, V43, P635, DOI 10.1037/0003-066X.43.8.635; LLOYD ME, 1990, J APPL BEHAV ANAL, V23, P539, DOI 10.1901/jaba.1990.23-539; Lock S., 1985, DIFFICULT BALANCE ED; MAHONEY MJ, 1978, COGNITIVE THER RES, V2, P69, DOI 10.1007/BF01172515; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; MCNUTT RA, 1993, 2ND INT C PEER REV B; MORGAN PP, 1984, CAN MED ASSOC J, V131, P1007; PETERS D, 1982, BEHAV BRAIN SCI, V165, P187; RENNIE D, 1990, JAMA-J AM MED ASSOC, V263, P1317, DOI 10.1001/jama.1990.03440100011001; ROBIN ED, 1987, CHEST, V91, P252, DOI 10.1378/chest.91.2.252; ROSENBLATT A, 1980, J SOCIAL SERVICE RES, V3, P383; SHAPIRO S, 1985, J CHRON DIS, V38, P365, DOI 10.1016/0021-9681(85)90082-7; SQUIRES BP, 1990, CAN MED ASSOC J, V142, P279; STRASBURGER VC, 1985, JAMA-J AM MED ASSOC, V254, P1789, DOI 10.1001/jama.254.13.1789; YANKAUER A, 1982, AM J PUBLIC HEALTH, V72, P239, DOI 10.2105/AJPH.72.3.239; Zar J. H, 1984, BIOSTAT ANAL, P176	25	117	118	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					143	146		10.1001/jama.272.2.143	http://dx.doi.org/10.1001/jama.272.2.143			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NV424	8015127				2022-12-28	WOS:A1994NV42400017
J	GILBERT, JR; WILLIAMS, ES; LUNDBERG, GD				GILBERT, JR; WILLIAMS, ES; LUNDBERG, GD			IS THERE GENDER BIAS IN JAMAS PEER-REVIEW PROCESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		PUBLICATION BIAS; SEX	Objective.-To assess whether manuscripts received by JAMA in 1991 possessed differing peer review and manuscript processing characteristics, or had a variable chance of acceptance, associated with the gender of the participants in the peer review process. Design.-Retrospective cohort study of 1851 research articles. Setting.-JAMA editorial office. Participants.-Eight male and five female JAMA editors, 2452 male and 930 female reviewers, and 1698 male and 462 female authors. Main Outcome Measure.-Statistically significant gender bias. Results.-Female editors were assigned manuscripts from female corresponding authors more often than were male editors (P<.001). Female editors used more reviewers per manuscript if sent for other review. Male reviewers assisted male editors more often than female editors, and male reviewers took longer to return manuscripts than did their female counterparts (median, 25 vs 22 days). Content reviewer recommendations were independent of corresponding author and review gender, while male statistical reviewers recommended the highest and lowest categories more frequently than did female statistical reviewers (P<.001). Manuscripts handled by female editors were rejected summarily at higher rates (P<.001). Articles submitted to JAMA in 1991 were not accepted at significantly different rates based on the gender of the corresponding author or the assigned editor (P>.4). Conclusions.-Gender differences exist in editor and reviewer characteristics at JAMA with no apparent effect on the final outcome of the peer review process or acceptance for publication.	STANFORD UNIV,DEPT PUBL POLICY,PALO ALTO,CA 94304; STANFORD UNIV,DEPT BIOL SCI,PALO ALTO,CA 94304	Stanford University; Stanford University								CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; GANNON L, 1992, AM PSYCHOL, V47, P389, DOI 10.1037/0003-066X.47.3.389; HICKS C, 1992, J ADV NURS, V17, P1343, DOI 10.1111/j.1365-2648.1992.tb01857.x; KNOPPERS A, 1989, RES Q EXERCISE SPORT, V60, P159, DOI 10.1080/02701367.1989.10607431; KRONICK DA, 1990, JAMA-J AM MED ASSOC, V263, P1321, DOI 10.1001/jama.263.10.1321; KRONIK JW, 1990, PUBLICATIONS MODERN, V105, P192; LLOYD ME, 1990, J APPL BEHAV ANAL, V23, P539, DOI 10.1901/jaba.1990.23-539; LOCK S, 1986, DIFFICULT BALANCE ED; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; RENNIE D, 1990, JAMA-J AM MED ASSOC, V263, P1317, DOI 10.1001/jama.1990.03440100011001; SHARP DW, 1990, JAMA-J AM MED ASSOC, V263, P1390; SIEGELMAN SS, 1991, RADIOLOGY, V178, P637, DOI 10.1148/radiology.178.3.1994394; SOJKA RE, 1992, RES ETHICS MANUSCRIP, P35	14	121	122	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					139	142		10.1001/jama.272.2.139	http://dx.doi.org/10.1001/jama.272.2.139			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NV424	8015126				2022-12-28	WOS:A1994NV42400016
J	SCHULZ, KF; CHALMERS, I; GRIMES, DA; ALTMAN, DG				SCHULZ, KF; CHALMERS, I; GRIMES, DA; ALTMAN, DG			ASSESSING THE QUALITY OF RANDOMIZATION FROM REPORTS OF CONTROLLED TRIALS PUBLISHED IN OBSTETRICS AND GYNECOLOGY JOURNALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		CLINICAL-TRIALS; BIAS	Objective.-To assess the methodologic quality of approaches used to allocate participants to comparison groups in randomized controlled trials from one medical specialty. Design.-Survey of published, parallel group randomized controlled trials. Data Sources.-All 206 reports with allocation described as randomized from the 1990 and 1991 volumes of four journals of obstetrics and gynecology. Main Outcome Measures.-Direct and indirect measures of the adequacy of randomization and baseline comparisons. Results.-Only 32% of the reports described an adequate method for generating a sequence of random numbers, and only 23% contained information showing that steps had been taken to conceal assignment until the point of treatment allocation. A mere 9% described both sequence generation and allocation concealment. In reports of trials that had apparently used unrestricted randomization, the differences in sample sizes between treatment and control groups were much smaller than would be expected due to chance. In reports of trials in which hypothesis tests had been used to compare baseline characteristics, only 2% of reported test results were statistically significant, lower than the expected rate of 5%. Conclusions.-Proper randomization is required to generate unbiased comparison groups in controlled trials, yet the reports in these journals usually provided inadequate or unacceptable information on treatment allocation. Additional analyses suggest that nonrandom manipulation of comparison groups and selective reporting of baseline comparisons may have occurred.	LONDON SCH HYG & TROP MED,LONDON WC1,ENGLAND; UNITED KINGDOM COCHRANE CTR,OXFORD,ENGLAND; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; Cochrane Centre; University of California System; University of California San Francisco; Cancer Research UK	SCHULZ, KF (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV STD HIV PREVENT,MAILSTOP E-02,ATLANTA,GA 30333, USA.							ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; ALTMAN DG, 1985, STATISTICIAN, V34, P125; BRACKEN MB, 1989, BRIT J OBSTET GYNAEC, V96, P383, DOI 10.1111/j.1471-0528.1989.tb02410.x; CHALMERS I, 1986, CONTROL CLIN TRIALS, V7, P306, DOI 10.1016/0197-2456(86)90038-3; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; Dean A. G., 1990, EPI INFO VERSION 5 W; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; Fisher R. A., 1966, DESIGN EXPT; GRANT A, 1989, BRIT J OBSTET GYNAEC, V96, P397, DOI 10.1111/j.1471-0528.1989.tb02412.x; GRIMES DA, 1991, OBSTET GYNECOL, V78, P703; GRIMES DA, 1992, OBSTET GYNECOL, V79, P137; HILL AB, 1952, NEW ENGL J MED, V247, P113, DOI 10.1056/NEJM195207242470401; KEIRSE MJNC, 1988, ACTA OBSTET GYN SCAN, V67, P731, DOI 10.3109/00016349809004298; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; Meinert CL., 1986, CLIN TRIALS DESIGN C; MOSTELLER F, 1980, CONTROL CLIN TRIALS, V1, P37, DOI 10.1016/S0197-2456(80)80006-7; Pocock SJ., 2013, CLIN TRIALS PRACTICA; ROTHMAN KJ, 1977, CANCER, V39, P1771, DOI 10.1002/1097-0142(197704)39:4+<1771::AID-CNCR2820390803>3.0.CO;2-2; THACKER SB, 1987, AM J OBSTET GYNECOL, V156, P24, DOI 10.1016/0002-9378(87)90197-9; TYSON JE, 1983, J PEDIATR-US, V102, P10, DOI 10.1016/S0022-3476(83)80277-7; WALD N, 1989, BRIT J OBSTET GYNAEC, V96, P389, DOI 10.1111/j.1471-0528.1989.tb02411.x	22	348	364	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					125	128		10.1001/jama.272.2.125	http://dx.doi.org/10.1001/jama.272.2.125			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015122				2022-12-28	WOS:A1994NV42400012
J	MOSMANN, TR				MOSMANN, TR			CYTOKINE PATTERNS DURING THE PROGRESSION TO AIDS	SCIENCE			English	Editorial Material							CYTOTOXIC T-CELL; CD4+; INFECTION; RESPONSES; HELPER; INTERLEUKIN-4; LYMPHOCYTES; INDIVIDUALS; EXPRESSION; PROFILES				MOSMANN, TR (corresponding author), UNIV ALBERTA,DEPT IMMUNOL,MED SCI BLDG,EDMONTON T6G 2H7,AB,CANADA.							ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; ELSE KJ, 1994, J EXP MED, V179, P347, DOI 10.1084/jem.179.1.347; FIRESTEIN GS, 1989, J IMMUNOL, V143, P518; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; KELKER HC, 1992, AIDS RES HUM RETROV, V8, P1355, DOI 10.1089/aid.1992.8.1355; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MOSMANN TR, 1991, IMMUNOL TODAY, V12, P49; PALIARD X, 1988, J IMMUNOL, V141, P849; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	22	93	107	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					193	194		10.1126/science.8023139	http://dx.doi.org/10.1126/science.8023139			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023139				2022-12-28	WOS:A1994NV95700025
J	CHEN, Y; EBRIGHT, YW; EBRIGHT, RH				CHEN, Y; EBRIGHT, YW; EBRIGHT, RH			IDENTIFICATION OF THE TARGET OF A TRANSCRIPTION ACTIVATOR PROTEIN BY PROTEIN-PROTEIN PHOTO-CROSS-LINKING	SCIENCE			English	Article							COLI RNA-POLYMERASE; CAP-DNA COMPLEX; ESCHERICHIA-COLI; ALPHA-SUBUNIT; RECEPTOR PROTEIN; POSITIVE CONTROL; CAMP-CRP; PROMOTER; REGION; MUTATIONS	Here it is shown, with the use of protein-protein photocrosslinking, that the carboxyl-terminal region of the alpha subunit of RNA polymerase (RNAP) is in direct physical proximity to the activating region of the catabolite gene activator protein (CAP) in the ternary complex of the lac promoter, RNAP, and CAP, These results strongly support the proposal that transcription activation by CAP involves protein-protein contact between the carboxyl-terminal region of the alpha subunit and the activating region of CAP.	RUTGERS STATE UNIV, DEPT CHEM, NEW BRUNSWICK, NJ 08855 USA; RUTGERS STATE UNIV, WAKSMAN INST, NEW BRUNSWICK, NJ 08855 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NIGMS NIH HHS [GM41376] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HU JC, 1985, MOL GEN GENET, V199, P7, DOI 10.1007/BF00327502; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; Niu W., UNPUB; OVCHINNIKOV YA, 1977, FEBS LETT, V76, P108, DOI 10.1016/0014-5793(77)80131-2; RUSSO FD, 1992, J BIOL CHEM, V267, P14515; SARIS CJM, 1983, ANAL BIOCHEM, V132, P54, DOI 10.1016/0003-2697(83)90425-6; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929; ZHANG XP, 1992, J BIOL CHEM, V267, P8136; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x; [No title captured]	25	114	117	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	1994	265	5168					90	92		10.1126/science.8016656	http://dx.doi.org/10.1126/science.8016656			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016656				2022-12-28	WOS:A1994NV30100031
J	SHARP, JM				SHARP, JM			ABC OF SPORTS MEDICINE - INFECTIONS IN SPORT	BRITISH MEDICAL JOURNAL			English	Article											SHARP, JM (corresponding author), RUCHILL HOSP,GLASGOW,SCOTLAND.							McLatchie GR, 1993, ESSENTIALS SPORTS ME, P112; WALKER E, 1993, ABC HLTH TRAVEL	2	9	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1702	1706		10.1136/bmj.308.6945.1702	http://dx.doi.org/10.1136/bmj.308.6945.1702			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025471	Green Published			2022-12-28	WOS:A1994NU48300036
J	COLLINS, FH; BESANSKY, NJ				COLLINS, FH; BESANSKY, NJ			VECTOR BIOLOGY AND THE CONTROL OF MALARIA IN AFRICA	SCIENCE			English	Editorial Material							ANOPHELES-GAMBIAE COMPLEX; PARASITE CHITINASE; SALIVARY-GLANDS; TRANSMISSION; SPOROZOITES; POPULATIONS; KENYA				COLLINS, FH (corresponding author), CTR DIS CONTROL & PREVENT,DIV PARASIT DIS,MAILSTOP F22,4770 BUFORD HIGHWAY,CHAMBLEE,GA 30341, USA.							BEIER JC, 1990, J MED ENTOMOL, V27, P570, DOI 10.1093/jmedent/27.4.570; BESANSKY NJ, IN PRESS P NATL ACAD; BRAIG HR, 1994, NATURE, V367, P453, DOI 10.1038/367453a0; CATTANI J, 1993, WHOTDR11 PROGR REP; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; COLUZZI M, 1985, B ZOOL, V52, P45, DOI 10.1080/11250008509440343; COLUZZI M, 1977, NATURE, V266, P832, DOI 10.1038/266832a0; GILLIES MT, 1968, ANOPHELINAE AFRICA S, P127; GILLIES MT, 1987, ANOPHELINAE AFRICA S, P78; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; KIDWELL MG, 1992, PARASITOL TODAY, V8, P325, DOI 10.1016/0169-4758(92)90065-A; Kumar V., 1994, Insect Molecular Biology, V3, P41, DOI 10.1111/j.1365-2583.1994.tb00149.x; MEISTER GA, 1993, GENOME, V36, P1169, DOI 10.1139/g93-155; PASKEWITZ SM, 1989, J PARASITOL, V75, P594, DOI 10.2307/3282911; PASKEWITZ SM, UNPUB; PETRARCA V, 1992, AM J TROP MED HYG, V46, P229, DOI 10.4269/ajtmh.1992.46.229; RIBEIRO JMC, 1994, J MED ENTOMOL, V31, P10, DOI 10.1093/jmedent/31.1.10; ROSENBERG R, 1985, AM J TROP MED HYG, V34, P687, DOI 10.4269/ajtmh.1985.34.687; SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266; SOPER FL, 1949, ANOPHELES GAMBIAE BR; TAYLOR CE, 1993, MED VET ENTOMOL, V7, P351, DOI 10.1111/j.1365-2915.1993.tb00704.x; TOURAY MG, 1992, J EXP MED, V175, P1607, DOI 10.1084/jem.175.6.1607; TOURE YT, UNPUB; ZHENG LB, 1993, SCIENCE, V261, P605, DOI 10.1126/science.8342025	24	75	76	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1874	1875		10.1126/science.8009215	http://dx.doi.org/10.1126/science.8009215			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009215				2022-12-28	WOS:A1994NT84700030
J	SIM, BKL; CHITNIS, CE; WASNIOWSKA, K; HADLEY, TJ; MILLER, LH				SIM, BKL; CHITNIS, CE; WASNIOWSKA, K; HADLEY, TJ; MILLER, LH			RECEPTOR AND LIGAND DOMAINS FOR INVASION OF ERYTHROCYTES BY PLASMODIUM-FALCIPARUM	SCIENCE			English	Article							BINDING ANTIGEN; GLYCOPHORIN-A; MALARIA PARASITES; AMINO-ACID; GLYCOPROTEIN; MEMBRANE; POLYMORPHISM; KNOWLESI; PROTEINS; SEQUENCE	A 175-kilodalton erythrocyte binding protein, EBA-175, of the parasite Plasmodium falciparum mediates the invasion of erythrocytes. The erythrocyte receptor for EBA-175 is dependent on sialic acid. The domain of EBA-175 that binds erythrocytes was identified as region II with the use of truncated portions of EBA-175 expressed on COS cells. Region II, which contains a cysteine-rich motif, and native EBA-175 bind specifically to glycophorin A, but not to glycophorin B, on the erythrocyte membrane. Erythrocyte recognition of EBA-175 requires both sialic acid and the peptide backbone of glycophorin A. The identification of both the receptor and ligand domains may suggest rational designs for receptor blockade and vaccines.	NIH,MALARIA RES LAB,BETHESDA,MD 20892; UNIV LOUISVILLE,DEPT MED,LOUISVILLE,KY 40292; POLISH ACAD SCI,INST IMMUNOL & EXPTL THERAPY,DEPT IMMUNOCHEM,PL-53114 WROCLAW,POLAND	National Institutes of Health (NIH) - USA; University of Louisville; Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences				Chitnis, Chetan/0000-0002-8773-9865; Wasniowska, Kazimiera/0000-0001-7629-2589				ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085; ANSTEE DJ, 1981, SEMIN HEMATOL, V18, P13; BLUMENFELD OO, 1981, P NATL ACAD SCI-BIOL, V78, P747, DOI 10.1073/pnas.78.2.747; BLUMENFELD OO, 1978, P NATL ACAD SCI USA, V75, P2727, DOI 10.1073/pnas.75.6.2727; BREUER WV, 1983, BIOCHIM BIOPHYS ACTA, V755, P263, DOI 10.1016/0304-4165(83)90213-1; CAMUS D, 1985, SCIENCE, V230, P553, DOI 10.1126/science.3901257; CHITNIS CE, IN PRESS J EXP MED; COHEN GH, 1988, J VIROL, V62, P1932, DOI 10.1128/JVI.62.6.1932-1940.1988; DAHR W, 1980, H-S Z PHYSIOL CHEM, V361, P895, DOI 10.1515/bchm2.1980.361.1.895; FURTHMAYR H, 1978, NATURE, V271, P519, DOI 10.1038/271519a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HADLEY TJ, 1987, J CLIN INVEST, V80, P1190, DOI 10.1172/JCI113178; HAYNES JD, 1988, J EXP MED, V167, P1873, DOI 10.1084/jem.167.6.1873; KLOTZ FW, 1992, MOL BIOCHEM PARASIT, V51, P49, DOI 10.1016/0166-6851(92)90199-T; LISOWSKA E, 1987, MOL IMMUNOL, V24, P605, DOI 10.1016/0161-5890(87)90041-1; MILLER LH, 1977, J EXP MED, V146, P277, DOI 10.1084/jem.146.1.277; ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901; PERKINS M, 1981, J CELL BIOL, V90, P563, DOI 10.1083/jcb.90.3.563; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SIM BKL, 1990, J CELL BIOL, V111, P1877, DOI 10.1083/jcb.111.5.1877; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; WARREN L, 1959, J BIOL CHEM, V234, P1971; Wasniowska K, 1985, GLYCOCONJUGATE J, V2, P163; 1989, SAS STAT USERS GUIDE, V2, P1135	24	451	476	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1941	1944		10.1126/science.8009226	http://dx.doi.org/10.1126/science.8009226			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009226				2022-12-28	WOS:A1994NT84700048
J	HOUGHTON, DJ; AITCHISON, FA; WILKINSON, L; WILSON, JA				HOUGHTON, DJ; AITCHISON, FA; WILKINSON, L; WILSON, JA			USE OF SINUS X-RAY-FILMS BY GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL INFIRM,DEPT OTOLARYNGOL HEAD & NECK SURG,GLASGOW G31 2ER,SCOTLAND; ROYAL INFIRM,DEPT RADIOL,GLASGOW G31 2ER,SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh				wilson, janet/0000-0002-6416-5870				FASCENELLI FW, 1969, ARCH OTOLARYNGOL, V90, P98; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; PFLEIDERER AG, 1986, CLIN OTOLARYNGOL, V11, P455, DOI 10.1111/j.1365-2273.1986.tb00151.x; WILSON PS, 1990, J LARYNGOL OTOL, V104, P694, DOI 10.1017/S0022215100113647; 1993, MAKING BEST USE DEPA	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1608	1609		10.1136/bmj.308.6944.1608	http://dx.doi.org/10.1136/bmj.308.6944.1608			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025428	Green Published			2022-12-28	WOS:A1994NT52800019
J	ALTMAN, DG; BLAND, JM				ALTMAN, DG; BLAND, JM			STATISTICS NOTES - DIAGNOSTIC-TESTS-1 - SENSITIVITY AND SPECIFICITY .3.	BRITISH MEDICAL JOURNAL			English	Note									UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	St Georges University London	ALTMAN, DG (corresponding author), IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND.							DRUM DE, 1972, J NUCL MED, V13, P908; Gardner MJ, 1989, STAT CONFIDENCE, P28	2	1352	1392	2	67	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1552	1552		10.1136/bmj.308.6943.1552	http://dx.doi.org/10.1136/bmj.308.6943.1552			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019315	Green Published, Bronze			2022-12-28	WOS:A1994NR11000029
J	WOODALL, CJ; RIDING, MH; GRAHAM, DI; CLEMENTS, GB				WOODALL, CJ; RIDING, MH; GRAHAM, DI; CLEMENTS, GB			SEQUENCES SPECIFIC FOR ENTEROVIRUS DETECTED IN SPINAL-CORD FROM PATIENTS WITH MOTOR-NEURON DISEASE	BRITISH MEDICAL JOURNAL			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; SUPEROXIDE-DISMUTASE; TISSUE	Objective-To investigate the association enteroviruses with motor neurone disease, known as amyotrophic lateral sclerosis. Design-Analysis by enterovirus polymerase chain reaction of wax embedded material from spinal cords taken at necropsy from subjects with motor neurone disease and from age and sex matched controls. Setting-Specimens were collected in the west of Scotland and in London between 1982 and 1992. Results-Sequences specific for a non-poliovirus type enterovirus were detected in spinal cord tissue from subjects with motor neurone disease. Amplification of a 414 base RNA target sequence in the conserved enterovirus 5' untranslated region from wax embedded tissue sections was successful in tissue from eight of 11 cases of sporadic motor neurone disease, one of two cases of familial motor neurone disease, and the one case of poliomyelitis, but not in the six matched controls or one case of antecedent poliomyelitis. In addition, sequences were detected in spinal cords from one monkey infected with wild type poliovirus and one monkey infected with polio vaccine. Comparison of sequences from cases of motor neurone disease with sequences of corresponding regions of the 5' untranslated regions of known picornaviruses showed them to be tightly grouped within the enterovirus genus closely related to coxsackievirus type B but not to polioviruses. Sequences derived from different parts of the spinal cord of the same subjects were identical, but sequences differed between individual subjects. Conclusions-Conserved enteroviral sequences closely related to coxsackie B virus sequences were detectable in spinal cords from subjects with sporadic motor neurone disease and from one subject with possible familial motor neurone disease.	RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,SCOTLAND; UNIV EDINBURGH,ROYAL DICK SCH VET STUDIES,DEPT VET PATHOL,EDINBURGH EH9 1QH,MIDLOTHIAN,SCOTLAND; RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,SCOTTISH SERUM BANK,GLASGOW G20 9NB,LANARK,SCOTLAND; SO GEN HOSP,INST NEUROL SCI,DEPT NEUROPATHOL,GLASGOW G51 4TF,SCOTLAND	University of Edinburgh; University of Glasgow								[Anonymous], 1990, LANCET, V336, P1033; BRAHIC M, 1985, ANN NEUROL, V18, P337, DOI 10.1002/ana.410180311; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; HEIMANPATTERSON TD, 1986, AMYOTROPHIC LATERAL, P85; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; MARTYN CN, 1988, LANCET, V1, P1319, DOI 10.1016/S0140-6736(88)92129-0; MINOR PD, 1990, TOPLEY WILSONS PRINC, V4, P324; NORBY E, 1990, VIROLOGY, P1028; OLDSTONE MBA, 1989, J INFECT DIS, V159, P384, DOI 10.1093/infdis/159.3.384; PALMENBERG AC, 1988, MOL ASPECTS PICORNAV, P211; POSKANZER DC, 1969, MOTOR NEURON DISEASE, P286; ROOS RP, 1980, ARCH NEUROL-CHICAGO, V37, P312, DOI 10.1001/archneur.1980.00500540090016; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; RUECKERT R R, 1990, P507; STANWAY G, 1990, J GEN VIROL, V71, P2483, DOI 10.1099/0022-1317-71-11-2483; VIOLA MV, 1980, ANN NEUROL, V5, P402; WEINER LP, 1980, NEUROLOGY, V30, P1319, DOI 10.1212/WNL.30.12.1319; WOODALL CJ, 1993, J CLIN PATHOL, V46, P276, DOI 10.1136/jcp.46.3.276; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; ZILKHA K J, 1962, Proc R Soc Med, V55, P1028; 1991, PROGRAM MANUAL GCG P	23	73	75	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1541	1543		10.1136/bmj.308.6943.1541	http://dx.doi.org/10.1136/bmj.308.6943.1541			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019310	Green Published			2022-12-28	WOS:A1994NR11000023
J	MOLBAK, K; GOTTSCHAU, A; AABY, P; HOJLYNG, N; INGHOLT, L; DASILVA, APJ				MOLBAK, K; GOTTSCHAU, A; AABY, P; HOJLYNG, N; INGHOLT, L; DASILVA, APJ			PROLONGED BREAST-FEEDING, DIARRHEAL DISEASE, AND SURVIVAL OF CHILDREN IN GUINEA-BISSAU	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROTECTION; DIARRHEAL; COMMUNITY; STATE	Objective-To analyse the impact of breast feeding on diarrhoeal disease and survival in children above 1 year of age in Guinea-Bissau, west Africa. Design-A community study of an open cohort followed up weekly by interviews over 15 months. Data on feeding practices, anthropometry, and survival were recorded for three years. Setting-301 randomly selected houses in a semiurban area in the capital, Bissau. Subjects-849 children aged less than 3 years. Main outcome measures-Incidence and duration of diarrhoea, weight for age, and death of a child. Results-The incidence of diarrhoea was higher in weaned children than in partially breast fed children, both in 1 year olds (relative risk 1.41; 95% confidence interval 1.23 to 1.62) and in 2 year olds (1.67; 1.29 to 2.15). The mean duration of an episode of diarrhoea was 5.3 days in breast fed children compared with 6.3 days in weaned children (P= 0.001). Independent of the age of weaning, a similar increase was found in an analysis comparing, for each child, the rate and duration of diarrhoea one month before and one month after weaning. Children with low weight for age were breast fed longer than the better nourished children (P=0.02). Children aged 12-35 months who were not breast fed had a 3.5 times higher mortality (1.4 to 8.3) than breast fed children. Conclusions-The beneficial effects of breast feeding are not restricted to infancy. Though children who are partially breast fed after infancy may have a lower state of nutrition than the weaned ones, the benefit in terms of lower morbidity may be more important for child survival in places with a high morbidity from diarrhoea and with high mortality.	STATENS SERUM INST, DEPT STAT, DK-2300 COPENHAGEN, DENMARK; STATENS SERUM INST, DEPT INFECT IMMUNOL, PARASITOL LAB, DK-2300 COPENHAGEN, DENMARK; NATL PUBL HLTH LAB, BISSAU, GUINEA BISSAU	Statens Serum Institut; Statens Serum Institut	MOLBAK, K (corresponding author), STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, EPIDEMIOL RES UNIT, DK-2300 COPENHAGEN S, DENMARK.			Aaby, Peter/0000-0001-8331-1389; Molbak, Kare/0000-0002-3100-4990				BRAKOHIAPA LA, 1988, LANCET, V2, P416; BRIEND A, 1988, BRIT MED J, V296, P879, DOI 10.1136/bmj.296.6626.879; BROWN KH, 1989, PEDIATRICS, V83, P31; CLEMENS JD, 1986, AM J EPIDEMIOL, V123, P710, DOI 10.1093/oxfordjournals.aje.a114291; DETTWYLER KA, 1987, SOC SCI MED, V24, P633, DOI 10.1016/0277-9536(87)90306-6; Diarrhoea Kirkwood B., 1991, DIS MORTALITY SUBSAH, P134; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; GOLDMAN AS, 1983, ACTA PAEDIATR SCAND, V72, P133, DOI 10.1111/j.1651-2227.1983.tb09679.x; HABICHT JP, 1986, AM J EPIDEMIOL, V123, P279, DOI 10.1093/oxfordjournals.aje.a114236; HUTTLY SRA, 1987, T ROY SOC TROP MED H, V81, P865, DOI 10.1016/0035-9203(87)90055-1; Jelliffe D. B., 1978, HUMAN MILK MODERN WO; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P497; Mata L J, 1976, Ciba Found Symp, P311; MICHAELSEN KF, 1988, LANCET, V2, P788; MOLBAK K, 1992, T ROY SOC TROP MED H, V86, P216, DOI 10.1016/0035-9203(92)90580-6; MOLBAK K, 1990, PEDIATR INFECT DIS J, V9, P566, DOI 10.1097/00006454-199008000-00008; TANGERMANN RH, 1988, LANCET, V2, P1016, DOI 10.1016/S0140-6736(88)90761-1; VICTORA CG, 1984, AM J CLIN NUTR, V39, P307, DOI 10.1093/ajcn/39.2.307; VICTORA CG, 1987, LANCET, V2, P319; Wyatt R G, 1972, Arch Latinoam Nutr, V22, P629	20	95	99	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	1994	308	6941					1403	1406		10.1136/bmj.308.6941.1403	http://dx.doi.org/10.1136/bmj.308.6941.1403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019249	Green Published			2022-12-28	WOS:A1994NP42000014
J	GOLDEN, JA; LOUIS, DN				GOLDEN, JA; LOUIS, DN			ACUTE BACTERIAL-MENINGITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											GOLDEN, JA (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.			Golden, Jeffrey/0000-0001-9933-5502					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					364	364						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA374	8028617				2022-12-28	WOS:A1994PA37400005
J	ZOLOPA, AR; HAHN, JA; GORTER, R; MIRANDA, J; WLODARCZYK, D; PETERSON, J; PILOTE, L; MOSS, AR				ZOLOPA, AR; HAHN, JA; GORTER, R; MIRANDA, J; WLODARCZYK, D; PETERSON, J; PILOTE, L; MOSS, AR			HIV AND TUBERCULOSIS INFECTION IN SAN-FRANCISCOS HOMELESS ADULTS - PREVALENCE AND RISK-FACTORS IN A REPRESENTATIVE SAMPLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS-DRUG-USERS; NEW-YORK-CITY; UNITED-STATES; SHELTER; WOMEN; MEN; HEALTH; EPIDEMIC; OUTBREAK	Objective.-To determine the prevalence and risk factors for human immunodeficiency virus (HIV) and tuberculosis (TB) infection and investigate the relationship between these two infections in homeless adults. Design.-Cross-sectional study. Setting.-Inner-city shelters and free meal programs. Participants.-A representative sample of 1226 adults (greater than or equal to 18 years) were enrolled from community sites. Main Outcome Measures.-Serum HIV-1 antibody status and tuberculin skin test reactivity. Results.-Human immunodeficiency virus seroprevalence was 8.5% (95% confidence interval [Cl], 7.0% to 10.1%) and the prevalence of TB infection was 32% (95% Cl, 30% to 37%). Nineteen percent of the HIV-seropositive subjects had positive tuberculin skin tests. Independent risk factors for HIV infection included younger age, black race, male homosexual contact, injection drug use, use of injection drugs in shooting galleries, and selling sex. Tuberculosis infection was associated with the duration of homelessness and living in crowded shelters or single-room-occupancy hotels. Injection drug use, a risk factor for HIV, was also a risk factor for TB, with a particularly strong association in women. No evidence of an association between TB and HIV infection was found, even after accounting for anergy. Conclusions.-The homeless population in the United States should be considered a group at high risk for HIV infection and TB. Given the constellation of risk factors present, the high prevalence of infection, and lack of access to medical services, we anticipate that these communicable diseases in this population will represent a growing public health problem.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DIV EPIDEMIOL & MED,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; SAN FRANCISCO DEPT PUBL HLTH,SAN FRANCISCO,CA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco Department of Public Health			Hahn, Judith/J-5813-2014	Hahn, Judith/0000-0002-2697-8264; Pilote, Louise/0000-0002-6159-0628	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004363] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA04363-07] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALLEN DM, 1992, 8TH INT C AIDS AMST, V2, pC297; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; BARRY MA, 1986, PUBLIC HEALTH REP, V101, P487; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BROWN SM, 1974, ARCH INTERN MED, V134, P1001, DOI 10.1001/archinte.134.6.1001; BRUNDNEY K, 1991, AM REV RESPIR DIS, V144, P745; BURNAM MA, 1988, EVALUATION REV, V12, P117, DOI 10.1177/0193841X8801200202; CELENTANO DD, 1991, AM J PUBLIC HEALTH, V81, P1291, DOI 10.2105/AJPH.81.10.1291; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; COATES T, 1990, AIDS 2 DECADE, P38; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; ELBASSEL N, 1991, PUBLIC HEALTH REP, V106, P586; ELLERBROCK TV, 1992, NEW ENGL J MED, V327, P1704, DOI 10.1056/NEJM199212103272402; ENGLE A, 1977, US DHEW HRA771649 PU; ERICKSON JR, 1992, 8TH INT C AIDS AMST, V2, pC297; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; KINSEY AC, 1948, SEXUAL BEHAVIOR HUMA, P638; Knopf SA, 1914, J AMER MED ASSOC, V63, P1720; MARKOWITZ N, 1993, ANN INTERN MED, V119, P185, DOI 10.7326/0003-4819-119-3-199308010-00002; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; MCADAM JM, 1990, SAFETY NET HLTH SOCI, P234; MOSS AR, 1992, BRIT J ADDICT, V87, P467; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PABLOSMENDEZ A, 1990, NEW YORK STATE J MED, V90, P351; REICHMAN LB, 1978, AM REV RESPIR DIS, V117, P705; REICHMAN LB, 1992, NEW ENGL J MED, V326, P703; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SCHIEFFELBEIN CW, 1988, ARCH INTERN MED, V148, P1843, DOI 10.1001/archinte.148.8.1843; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHLAY J, 1992, 8TH INT C AIDS AMST, V2, pC298; SLUTKIN G, 1986, AM REV RESPIR DIS, V134, P1048, DOI 10.1164/arrd.1986.134.5.1048; TERRIS M, 1948, AM J PUBLIC HEALTH, V88, P1061; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; TUBARO E, 1983, J INFECT DIS, V148, P656, DOI 10.1093/infdis/148.4.656; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P1394; 1979, TUBER LUNG DIS, V60, P191; 1991, MMWR-MORBID MORTAL W, V40, P859; 1991, MMWR-MORBID MORTAL W, V40, P869; 1985, MMWR-MORBID MORTAL W, V34, P429; 1993, HIV SEROPREVALENCE R, V4, P7; 1993, HIV SEROPREVALENCE R, V4, P6; 1991, MMWR-MORBID MORTAL W, V40, P865; 1989, MMWR-MORBID MORTAL W, V38, P236; 1992, MMWR-MORBID MORTAL W, V41, P1	49	200	203	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					455	461		10.1001/jama.272.6.455	http://dx.doi.org/10.1001/jama.272.6.455			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA278	8040981				2022-12-28	WOS:A1994PA27800027
J	FUESSL, H				FUESSL, H			ASCARIS-LUMBRICOIDES	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											FUESSL, H (corresponding author), UNIV MUNICH,D-80336 MUNICH,GERMANY.								0	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					303	303						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022441				2022-12-28	WOS:A1994NZ22700005
J	NEWTON, JA; SCHNEPF, GA; WALLACE, MR; LOBEL, HO; KENNEDY, CA; OLDFIELD, EC				NEWTON, JA; SCHNEPF, GA; WALLACE, MR; LOBEL, HO; KENNEDY, CA; OLDFIELD, EC			MALARIA IN US MARINES RETURNING FROM SOMALIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PLASMODIUM-FALCIPARUM; PREVENTION; TRAVELERS; AFRICA	Objective.-To identify malaria in US Marines returning from Somalia and to determine their compliance with chemoprophylaxis. Design.-Case series. Setting.-The US Navy health care system. Patients.-Consecutive sample of 106 US Marines diagnosed with malaria after returning from Somalia in 1993. Main Outcome Measures.-Identification of the incidence and clinical features of imported malaria. Determination of compliance with chemoprophylaxis in this cohort. Results.-As of December 20, 1993, there were 112 cases of imported malaria in 106 US Marine Corps personnel returning from Somalia. Plasmodium vivax accounted for 97 (87%) of 112 malaria cases, and Plasmodium falciparum accounted for eight (7%) of 112 cases. Mixed infection with P vivax and P falciparum was noted in six (5%) of 112 cases, and a single case of Plasmodium malariae was identified. Patients with P falciparum malaria were diagnosed a mean of 20.9 days (range, 1 to 82 days) after returning to the United States compared with 91.8 days (range, 7 to 228 days) for P vivax infection (P<.0001). The self-reported chemoprophylaxis compliance rate was 56%; however, only 45 (50%) of 90 patients were given an optimal chemoprophylaxis regimen. Conclusions.-Noncompliance with personal protective measures and chemoprophylaxis contributed to the largest outbreak of imported malaria in US military personnel since the Vietnam conflict. Since military personnel frequently go on leave after deployment, health care providers throughout the United States must be aware of the presence of imported malaria from Somalia.	USN,MED CTR,DEPT CLIN INVEST,SAN DIEGO,CA 92134; USN,MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,SAN DIEGO,CA; USN HOSP,DEPT INTERNAL MED,CAMP PENDLETON,CA; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy; United States Department of Defense; United States Navy; Centers for Disease Control & Prevention - USA								BARRETT O, 1969, AM J TROP MED HYG, V18, P495, DOI 10.4269/ajtmh.1969.18.495; KEAN BH, 1976, AM J MED, V61, P159, DOI 10.1016/0002-9343(76)90164-9; LACKRITZ EM, 1991, JAMA-J AM MED ASSOC, V265, P383, DOI 10.1001/jama.265.3.383; LOBEL HO, 1985, J INFECT DIS, V152, P613, DOI 10.1093/infdis/152.3.613; LYNK A, 1989, PEDIATR INFECT DIS J, V8, P745, DOI 10.1097/00006454-198911000-00003; OLDFIELD EC, 1993, CLIN INFECT DIS S3, V16, pS131; ROMBO L, 1987, TROP MED PARASITOL, V38, P49; WALLACE MR, 1993, CLIN INFECT DIS, V17, P510, DOI 10.1093/clinids/17.3.510; ZUCKER JR, 1993, INFECT DIS CLIN N AM, V7, P547; 1993, MMWR-MORBID MORTAL W, V42, P524; 1993, MMWR-MORBID MORTAL W, V42, P976; 1991, 1990 CTR DIS CONTR M	12	60	60	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					397	399		10.1001/jama.272.5.397	http://dx.doi.org/10.1001/jama.272.5.397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028173				2022-12-28	WOS:A1994NY90300034
J	NIGHTINGALE, SL				NIGHTINGALE, SL			POSSIBLE ELECTROMAGNETIC-INTERFERENCE PROBLEMS WITH WHEELCHAIRS AND OTHER MEDICAL DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					344	344						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028152				2022-12-28	WOS:A1994NY90300005
J	PELINI, M; BOICE, D; ONEIL, K; LAROCQUE, J				PELINI, M; BOICE, D; ONEIL, K; LAROCQUE, J			GLUCOCEREBROSIDASE TREATMENT OF TYPE-I GAUCHER DISEASE WITH SEVERE PULMONARY INVOLVEMENT	ANNALS OF INTERNAL MEDICINE			English	Note									USN, MED CTR, DIV PULM, PORTSMOUTH, VA 23708 USA	United States Department of Defense; United States Navy								BARTON NW, 1992, J PEDIATR-US, V120, P277, DOI 10.1016/S0022-3476(05)80444-5; BEUTLER E, 1991, BLOOD, V78, P1183; FALLET S, 1992, PEDIATR RES, V31, P496, DOI 10.1203/00006450-199205000-00018; FIGUEROA ML, 1992, NEW ENGL J MED, V327, P1632, DOI 10.1056/NEJM199212033272304; LEE RE, 1988, LAB INVEST, V58, pA54; ROBERTS WC, 1967, CIRCULATION, V35, P783, DOI 10.1161/01.CIR.35.4.783; SCHNEIDER EL, 1977, AM J MED, V63, P475, DOI 10.1016/0002-9343(77)90288-1; THEISE ND, 1990, AM J PEDIAT HEMATOL, V12, P74; ZIMRAN A, 1992, MEDICINE, V71, P337, DOI 10.1097/00005792-199211000-00002	9	21	21	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					196	197		10.7326/0003-4819-121-3-199408010-00006	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017746				2022-12-28	WOS:A1994NY33800006
J	BURD, CG; DREYFUSS, G				BURD, CG; DREYFUSS, G			CONSERVED STRUCTURES AND DIVERSITY OF FUNCTIONS OF RNA-BINDING PROTEINS	SCIENCE			English	Review							SMALL NUCLEAR RIBONUCLEOPROTEIN; STRAND-ANNEALING ACTIVITY; GENE-EXPRESSION REQUIRES; HIGH-AFFINITY BINDING; SPLICING FACTOR U2AF; AMINO-ACID-RESIDUES; ARGININE-RICH MOTIF; REV TRANS-ACTIVATOR; COLD-SHOCK PROTEIN; HNRNP-C-PROTEINS	In eukaryotic cells, a multitude of RNA-binding proteins play key roles in the posttranscriptional regulation of gene expression. Characterization of these proteins has led to the identification of several RNA-binding motifs, and recent experiments have begun to illustrate how several of them bind RNA. The significance of these interactions is reflected in the recent discoveries that several human and other vertebrate genetic disorders are caused by aberrant expression of RNA-binding proteins. The major RNA-binding motifs are described and examples of how they may function are given.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania			Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774; Burd, Christopher/0000-0003-1831-8706				ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; CHRISTENSEN ME, 1988, BIOCHEM BIOPH RES CO, V155, P1278, DOI 10.1016/S0006-291X(88)81279-8; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; COBIANCHI F, 1993, NUCLEIC ACIDS RES, V21, P949, DOI 10.1093/nar/21.4.949; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELLING U, 1991, P NATL ACAD SCI USA, V88, P6234, DOI 10.1073/pnas.88.14.6234; DEUTSCHER SL, 1988, P NATL ACAD SCI USA, V85, P9479, DOI 10.1073/pnas.85.24.9479; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FANG GS, 1992, P NATL ACAD SCI USA, V89, P5447; FRANKLIN NC, 1985, J MOL BIOL, V181, P75, DOI 10.1016/0022-2836(85)90325-0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GHETTI A, 1991, FEBS LETT, V257, P373; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GIBSON TJ, 1993, TRENDS BIOCHEM SCI, V18, P331, DOI 10.1016/0968-0004(93)90068-X; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GOGUEL V, 1993, MOL CELL BIOL, V13, P6841, DOI 10.1128/MCB.13.11.6841; GOLDEN BL, 1993, EMBO J, V12, P4901, DOI 10.1002/j.1460-2075.1993.tb06184.x; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1993, MOL BIOL REP, V18, P73, DOI 10.1007/BF00986759; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HAMY F, 1993, J MOL BIOL, V230, P111, DOI 10.1006/jmbi.1993.1129; HARPER JW, 1991, BIOCHEMISTRY-US, V30, P8060, DOI 10.1021/bi00246a026; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HODGKIN J, 1989, CELL, V56, P905, DOI 10.1016/0092-8674(89)90619-3; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOLLAND SM, 1990, J VIROL, V64, P5966, DOI 10.1128/JVI.64.12.5966-5975.1990; HORABIN JI, 1993, MOL CELL BIOL, V13, P1408, DOI 10.1128/MCB.13.3.1408; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; KARN J, 1992, TRENDS GENET, V8, P365, DOI 10.1016/0168-9525(92)90284-B; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KILEDJIAN M, IN PRESS RNA PROTEIN; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MATUNIS EL, 1994, P NATL ACAD SCI USA, V91, P2781, DOI 10.1073/pnas.91.7.2781; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MIZRACHIKARSCH I, 1993, NUCLEIC ACIDS RES, V21, P2229; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; NANDABALAN K, 1993, CELL, V73, P407, DOI 10.1016/0092-8674(93)90239-M; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; NUSSBAUM RL, IN PRESS METABOLIC B; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; SACHS A, 1993, J BIOL CHEM, V268, P22955; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1991, J MOL BIOL, V219, P577, DOI 10.1016/0022-2836(91)90651-L; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; SCHWEMMLE M, 1989, FEBS LETT, V251, P117, DOI 10.1016/0014-5793(89)81439-5; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1993; SLICE LW, 1992, BIOCHEMISTRY-US, V31, P12062, DOI 10.1021/bi00163a014; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; STEINER G, 1992, J CLIN INVEST, V90, P1061, DOI 10.1172/JCI115921; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUBRAMANIAN T, 1991, EMBO J, V10, P2311, DOI 10.1002/j.1460-2075.1991.tb07768.x; SUROWY CS, 1989, MOL CELL BIOL, V9, P4179, DOI 10.1128/MCB.9.10.4179; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Tafuri Sherrie R., 1993, Trends in Cell Biology, V3, P94, DOI 10.1016/0962-8924(93)90080-K; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WATSON JC, 1991, VIROLOGY, V185, P206, DOI 10.1016/0042-6822(91)90768-7; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; WITTEKIND MW, UNPUB; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x; [No title captured]	138	1731	1795	4	141	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					615	621		10.1126/science.8036511	http://dx.doi.org/10.1126/science.8036511			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036511				2022-12-28	WOS:A1994NZ53800021
J	HENNINGFIELD, JE; KOZLOWSKI, LT; BENOWITZ, NL				HENNINGFIELD, JE; KOZLOWSKI, LT; BENOWITZ, NL			A PROPOSAL TO DEVELOP MEANINGFUL LABELING FOR CIGARETTES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LOW-YIELD CIGARETTES; CARBON-MONOXIDE; NICOTINE; SMOKING; TAR; BLOCKING; EXPOSURE; VENTS		PENN STATE UNIV,COLL HLTH & HUMAN DEV,PROGRAM BIOBEHAV HLTH,UNIV PK,PA 16802; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARMACOL & EXPTL THERAPEUT,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	HENNINGFIELD, JE (corresponding author), NIDA,ADDICT RES CTR,CLIN PHARMACOL BRANCH,POB 5180,BALTIMORE,MD 21224, USA.							BENOWITZ NL, 1986, JAMA-J AM MED ASSOC, V256, P241; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67; BENOWITZ NL, 1986, NEW ENGL J MED, V315, P1310, DOI 10.1056/NEJM198611203152102; BENOWITZ NL, IN PRESS N ENGL J ME; Browne C. L., 1990, DESIGN CIGARETTES; COHEN JB, 1992, J PUBLIC POLICY MARK, V11, P82, DOI 10.1177/074391569201100109; HENNINGFIELD JE, 1984, ADV BEHAV PHARMACOL, V4, P131; KOZLOWSKI LT, 1980, SCIENCE, V209, P1550, DOI 10.1126/science.7433979; KOZLOWSKI LT, 1988, AM J PUBLIC HEALTH, V78, P694, DOI 10.2105/AJPH.78.6.694; KOZLOWSKI LT, 1989, PHARMACOL BIOCHEM BE, V33, P815, DOI 10.1016/0091-3057(89)90476-0; KOZLOWSKI LT, 1981, JAMA-J AM MED ASSOC, V245, P158, DOI 10.1001/jama.245.2.158; KOZLOWSKI LT, 1983, NATIONAL I DRUG ABUS, V48; PILLSBURY HC, 1969, J ASSOC OFF ANA CHEM, V52, P458; SHAPIRO E, 1994, WALL STREET J   0421, pB7; YOUNG JC, 1981, J TOXICOL ENV HEALTH, V7, P801, DOI 10.1080/15287398109530021; 1991, TAR NICOTINE CARBON; 1993, FED REG 4       0106; 1988, DHHS CDC888406 PUBL; 1986, DHHS CDC878398 PUBL	20	36	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					312	314		10.1001/jama.272.4.312	http://dx.doi.org/10.1001/jama.272.4.312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX806	8028146				2022-12-28	WOS:A1994NX80600035
J	MASSAD, S				MASSAD, S			THE REWARD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					270	270						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX806	8028130				2022-12-28	WOS:A1994NX80600011
J	SIMON, R; CARPENTER, R; DOYLE, S; COEN, E				SIMON, R; CARPENTER, R; DOYLE, S; COEN, E			FIMBRIATA CONTROLS FLOWER DEVELOPMENT BY MEDIATING BETWEEN MERISTEM AND ORGAN IDENTITY GENES	CELL			English	Article							FLORAL HOMEOTIC GENES; ANTIRRHINUM-MAJUS; ARABIDOPSIS; TRANSCRIPTION; TRANSPOSON; EXPRESSION; DEFICIENS	Two major classes of genes directing flower development have so far been described: early activated genes regulating meristem identity and later acting genes controlling organ identity. Here, we show that the fimbriata (fim) gene acts between these two classes in a sequence of gene activation. The fim gene, originally described in 1930, was cloned by transposon tagging from Antirrhinum majus and encodes a product with no detectable homology to other proteins. Mutations in fim result in partial homeotic transformations of floral organs and in reduced determinacy of the meristem. Expression and function of fim depends on the activity of meristem identity genes, and fim in turn controls the spatial and temporal expression of organ identity genes. The pattern of fim expression defines a new domain of the floral meristem that changes with time in a complementary manner to those of the meristem identity gene floricaula and the organ identity gene plena.			SIMON, R (corresponding author), JOHN INNES CTR PLANT SCI RES,COLNEY LANE,NORWICH NR4 7UH,NORFOLK,ENGLAND.		Simon, Rudiger/T-6755-2018	Simon, Rudiger/0000-0002-1317-7716				BAUR ERWIN, 1930, ZEITSCHR BOT, V23, P676; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1993, PLANT CELL, V5, P1175, DOI 10.1105/tpc.5.10.1175; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; HARTE C, 1951, Z INDUKT ABSTAMM VER, V83, P392; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x	16	103	106	2	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					99	107		10.1016/0092-8674(94)90576-2	http://dx.doi.org/10.1016/0092-8674(94)90576-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033217				2022-12-28	WOS:A1994NX32800012
J	MOHR, G; CAPRARA, MG; GUO, QB; LAMBOWITZ, AM				MOHR, G; CAPRARA, MG; GUO, QB; LAMBOWITZ, AM			A TYROSYL-TRANSFER-RNA SYNTHETASE CAN FUNCTION SIMILARLY TO AN RNA STRUCTURE IN THE TETRAHYMENA RIBOZYME	NATURE			English	Article							GROUP-I INTRON; SECONDARY STRUCTURE; TERTIARY STRUCTURE; SEQUENCE; CORE; DOMAIN; SITES	GROUP I introns are highly structured RNAs which catalyse their own splicing by guanosine-initiated transesterification reactions(1,2). Their catalytic core is generally stabilized by RNA-RNA interactions within the core and with peripheral RNA structures(3,4). Additionally, some group I introns require proteins for efficient splicing in vivo(5). The Neurospora CYT-18 protein, the mitochondrial tyrosyl-transfer RNA synthetase (mt TyrRS), promotes splicing of the Neurospora mitochondrial large ribosomal RNA (LSU) and other group I introns by stabilizing the catalytically active structure of the intron core(6-8). We report here that CYT-18 functions similarly to a peripheral RNA structure, P5abc, that stabilizes the catalytic core of the Tetrahymena LSU intron. The CYT-18 protein and P5abc RNA bind to overlapping sites in the intron core, inducing similar conformational changes correlated with splicing activity. Our results show that a protein can play the role of an RNA structure in a catalytic RNA, a substitution postulated for the evolution of nuclear pre-messenger RNA introns from self-splicing introns(9,10).	OHIO STATE UNIV, DEPT MOLEC GENET, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR BIOTECHNOL, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University				Mohr, Georg/0000-0002-6411-0685				AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BANERJEE AR, 1993, BIOCHEMISTRY-US, V32, P153, DOI 10.1021/bi00052a021; BEEN MD, 1985, NUCLEIC ACIDS RES, V13, P8389, DOI 10.1093/nar/13.23.8389; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHEMIACK AD, 1990, CELL, V62, P745; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; FLOR PJ, 1989, EMBO J, V8, P3391, DOI 10.1002/j.1460-2075.1989.tb08503.x; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; JAEGER JA, 1990, BIOCHEMISTRY-US, V29, P10147, DOI 10.1021/bi00496a002; JAEGER L, 1991, J MOL BIOL, V221, P1153, DOI 10.1016/0022-2836(91)90925-V; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; KITTLE JD, 1991, GENE DEV, V5, P1009, DOI 10.1101/gad.5.6.1009; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; STREICHER B, 1993, NUCLEIC ACIDS RES, V21, P311; VANDERHORST G, 1991, P NATL ACAD SCI USA, V88, P184, DOI 10.1073/pnas.88.1.184; WILLIAMSON CL, 1987, J BIOL CHEM, V262, P14672; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0	28	105	114	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	1994	370	6485					147	150		10.1038/370147a0	http://dx.doi.org/10.1038/370147a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022484				2022-12-28	WOS:A1994NW80400059
J	WITTHUHN, BA; SILVENNOINEN, O; MIURA, O; LAI, KS; CWIK, C; LIU, ET; IHLE, JN				WITTHUHN, BA; SILVENNOINEN, O; MIURA, O; LAI, KS; CWIK, C; LIU, ET; IHLE, JN			INVOLVEMENT OF THE JAK-3 JANUS KINASE IN SIGNALING BY INTERLEUKIN-2 AND INTERLEUKIN-4 IN LYMPHOID AND MYELOID CELLS	NATURE			English	Article							PROTEIN-TYROSINE KINASE; RECEPTOR GAMMA-CHAIN; ERYTHROPOIETIN RECEPTOR; INTERFERON-ALPHA/BETA; TRANSDUCTION; PHOSPHORYLATION; PATHWAY; FAMILY; IL-2	MANY cytokines function through interaction with receptors of the cytokine receptor superfamily. Although lacking catalytic domains, cytokine receptors couple ligand binding to induction of protein tyrosine phosphorylation. Recent studie(1-10) have shown that one or more of the Janus kinase family members (Jaks) associate with cytokine receptors and are tyrosine phosphorylated and activated following ligand binding. Here we describe a new Jak family kinase, Jak-3, and demonstrate that Jak-3, and to a lesser extent Jak-1, are tyrosine phosphorylated and Jak-3 is activated in the responses to interleukin-2 and interleukin-4 in T cells and myeloid cells. Jak-3 activation requires the serine-rich, membrane-proximal domain of the interleukin-3 receptor beta-chain, but does not require the acidic domain that is required for association and activation of Src family kinases.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV N CAROLINA, SCH MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT BIOL, CHAPEL HILL, NC 27599 USA	St Jude Children's Research Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill			witthuhn, bruce/GSE-3193-2022; Liu, Edison/C-4141-2008	Miura, Osamu/0000-0002-0981-3054				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARTGETSINGER LS, 1993, CELL, V74, P237; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HARPUR AG, 1992, ONCOGENE, V7, P1347; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	30	584	598	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					153	157		10.1038/370153a0	http://dx.doi.org/10.1038/370153a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022486				2022-12-28	WOS:A1994NW80400061
J	ROCHON, PA; GURWITZ, JH; CHEUNG, CM; HAYES, JA; CHALMERS, TC				ROCHON, PA; GURWITZ, JH; CHEUNG, CM; HAYES, JA; CHALMERS, TC			EVALUATING THE QUALITY OF ARTICLES PUBLISHED IN JOURNAL SUPPLEMENTS COMPARED WITH THE QUALITY OF THOSE PUBLISHED IN THE PARENT JOURNAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		RANDOMIZED CONTROL TRIALS; META-ANALYSIS; CLINICAL-TRIALS; SPONSORED SYMPOSIA; DENTAL RESEARCH; METAANALYSIS; PUBLICATION; AGENTS	Objectives.-To determine the relationship between the quality of articles and whether they were published in a supplement or in the parent journal. Data Sources and Study Selection.-All randomized control trials of drug therapies in adults published in the American Journal of Cardiology, the American Journal of Medicine, and the American Heart Journal from January 1990 and obtained in November 1992 by means of a MEDLINE search. A total of 318 abstracts appeared to meet our inclusion criteria, and these articles were obtained and reviewed in further detail. An additional 76 were excluded. Data Extraction.-Three reviewers who were ''blinded'' and thus unaware of supplement status independently assessed the quality of each of the remaining 242 articles according to a standard quality scoring system. Data Synthesis.-Overall, 67 (27.7%) of the articles were published in journal supplements. Article quality scores ranged from 4.2% to 87.5%, with a mean (+/-SD) score of 37.2%+/-13.1%. Quality scores were lower in articles published in journal supplements than in those published in the parent journal (t[240]=2.61, P=.01). The mean quality score for articles published in journal supplements was 33.6%+/-12.8% compared with a score of 38.5%+/-13.1% for articles published in the parent journal. Supplement articles included in their final analysis a smaller proportion of the patients initially randomized (t[75]=2.8, P=.007). Conclusion.-Our findings suggest that randomized control trials published in journal supplements are generally of inferior quality compared with articles published in the parent journal. The review process surrounding the publication of journal supplements should be consistent with that of the parent journal.	UNIV TORONTO,MT SINAI HOSP,DEPT MED,DIV GERIATR MED,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV GERONTOL,PROGRAM ANAL CLIN STRATEGIE,BOSTON,MA 02115; BROCKTON W ROXBURY VET AFFAIRS MED CTR,W LEBANON,NH; METAWORKS INC,W LEBANON,NH	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Harvard University; Brigham & Women's Hospital; Harvard Medical School	ROCHON, PA (corresponding author), UNIV TORONTO,BAYCREST CTR GERIATR CARE,3560 BATHURST ST,N YORK M6A 2E1,ON,CANADA.		Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151	AHRQ HHS [R01 HS-05936] Funding Source: Medline; NIA NIH HHS [K08 AG00510] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS005936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANTCZAK AA, 1986, J PERIODONTAL RES, V21, P305, DOI 10.1111/j.1600-0765.1986.tb01464.x; ANTCZAK AA, 1986, J PERIODONTAL RES, V21, P315, DOI 10.1111/j.1600-0765.1986.tb01465.x; BAUM ML, 1981, NEW ENGL J MED, V305, P795, DOI 10.1056/NEJM198110013051404; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; CAVALLI F, 1993, ANN ONCOL, V4, P99, DOI 10.1093/oxfordjournals.annonc.a058445; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1401, DOI 10.1001/jama.263.10.1401; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; DETSKY AS, 1987, ANN INTERN MED, V107, P195, DOI 10.7326/0003-4819-107-2-195; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; FINUCANE T, 1987, AM J MED, V83, P811, DOI 10.1016/0002-9343(87)90932-6; FINUCANE TE, 1993, NEW ENGL J MED, V328, P1197; GOLDSTEIN P, 1989, BRIT J OBSTET GYNAEC, V96, P265, DOI 10.1111/j.1471-0528.1989.tb02385.x; GOSCHE PC, 1989, CONTROLLED CLIN TRIA, V10, P31; GOZSCHE PC, 1990, DAN MED B, V37, P329; KESSLER DA, 1991, NEW ENGL J MED, V325, P201, DOI 10.1056/NEJM199107183250310; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAM W, 1987, LANCET, V2, P27; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; MASSIE BM, 1993, NEW ENGL J MED, V328, P1196; NAYLOR CD, 1989, GASTROENTEROLOGY, V97, P1038; REITMAN D, 1987, CONTROLLED CLIN TRIA, V8, P2582; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; SACKS HS, 1988, CLIN PHARMACOL THER, V43, P610, DOI 10.1038/clpt.1988.84; SNEDECOR G. E., 1989, STAT METHODS, V8th, P1; SOFFER A, 1982, ARCH INTERN MED, V142, P2074, DOI 10.1001/archinte.1982.00340250032004; SZE PC, 1988, STROKE, V19, P436, DOI 10.1161/01.STR.19.4.436; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; 1990, SPSS INC BASE SYSTEM, P520; 1988, SAS STAT USERS GUIDE, V1, P1029	32	111	112	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					108	113		10.1001/jama.272.2.108	http://dx.doi.org/10.1001/jama.272.2.108			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015117				2022-12-28	WOS:A1994NV42400007
J	BARRETT, JFR; WHITTAKER, PG; WILLIAMS, JG; LIND, T				BARRETT, JFR; WHITTAKER, PG; WILLIAMS, JG; LIND, T			ABSORPTION OF NONHEME IRON FROM FOOD DURING NORMAL-PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							FOLATE SUPPLEMENTS; DIETARY IRON; ZINC	Objective-To determine whether the increased iron demands of pregnancy could be met by increased absorption from dietary sources. Design and setting-longitudinal prospective study in the research unit of a maternity hospital. Subjects-12 normal pregnant women. Interventions-At 12, 24, and 36 weeks' gestation (within one week) and 16-24 weeks after delivery women ate a breakfast of meat, bread, and orange juice (3.2 mg iron), extrinsically labelled with the stable isotope iron-54 (2.8 mg); the stable isotope iron-57 (200 mu g) was given intravenously. Main outcome measures-Serum samples were taken for 10 hours after administration of the isotopes; ratios of the isotopes were measured by inductively coupled plasma mass spectrometry, and the absorption of oral iron was calculated. Results-The geometric mean (95% confidence interval) absorption of iron at 12, 24, and 36 weeks' gestation was 7% (5% to 11%), 36% (28% to 47%), and 66% (57% to 76%) respectively. At 16-24 weeks after delivery the absorption was 11% (6% to 21%). The mean increase in absorption at 36 weeks (compared with that at 12 weeks) was 9.1 times (6.0 to 13.7). One pregnant woman developed iron deficiency anaemia but was otherwise indistinguishable from the others. Conclusions-An increase in the absorption of iron from food is a physiological consequence of normal pregnancy, not the result of developing anaemia during pregnancy, and such an increase is large enough to meet the increased requirements of pregnancy provided that the dietary intake is adequate.	UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT OBSTET & GYNAECOL,NEWCASTLE TYNE NE1 4LP,ENGLAND; UNIV LONDON IMPERIAL COLL SCI & TECHNOL,NERC,ICP MS FACIL,ASCOT SL5 7TE,BERKS,ENGLAND	Newcastle University - UK; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)								BARRETT JFR, IN PRESS CLIN SCI; BJORNRASMUSSEN E, 1976, AM J CLIN NUTR, V26, P1311; BLACK AE, 1986, BRIT J NUTR, V56, P59, DOI 10.1079/BJN19860085; BONNAR J, 1969, LANCET, V1, P457; Bothwell T.H., 1979, IRON METABOLISM MAN; COOK JD, 1991, AM J CLIN NUTR, V54, P717, DOI 10.1093/ajcn/54.4.717; CROFTON RW, 1989, AM J CLIN NUTR, V50, P141, DOI 10.1093/ajcn/50.1.141; DARKE SJ, 1980, BRIT J NUTR, V44, P243, DOI 10.1079/BJN19800037; Gibaldi M., 1982, PHARMACOKINETICS, P145; HAHN PF, 1951, AM J OBSTET GYNECOL, V61, P477, DOI 10.1016/0002-9378(51)91394-4; HAMBIDGE KM, 1987, OBSTET GYNECOL, V70, P593; HEINRICH HC, 1970, IRON DEFICIENCY, P213; HEMMINKI E, 1978, BRIT J OBSTET GYNAEC, V85, P404, DOI 10.1111/j.1471-0528.1978.tb14905.x; HIBBARD BM, 1988, BRIT MED J, V297, P1324, DOI 10.1136/bmj.297.6659.1324; HORN E, 1988, BRIT MED J, V297, P1325, DOI 10.1136/bmj.297.6659.1325; HYTTEN F, 1985, CLIN HAEMATOL, V14, P601; LIND T, 1983, NUTRITION PREGNANCY, P181; MONSEN ER, 1978, AM J CLIN NUTR, V31, P134, DOI 10.1093/ajcn/31.1.134; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PRITCHARD JA, 1970, IRON DEFICIENCY, P173; Ramdath D D, 1989, Nutr Res Rev, V2, P29, DOI 10.1079/NRR19890006; REYNOLDS LG, 1985, S AFR MED J, V67, P680; ROSSANDER L, 1979, AM J CLIN NUTR, V32, P2484, DOI 10.1093/ajcn/32.12.2484; SCHOFIELD C, 1989, BRIT J NUTR, V62, P363, DOI 10.1079/BJN19890037; SOUTHON S, 1989, BRIT J NUTR, V62, P707, DOI 10.1079/BJN19890071; Svanberg B, 1975, Acta Obstet Gynecol Scand Suppl, V48, P43; TAYLOR DJ, 1982, BRIT J OBSTET GYNAEC, V89, P1011, DOI 10.1111/j.1471-0528.1982.tb04656.x; WHITTAKER PG, 1991, BRIT J NUTR, V65, P457, DOI 10.1079/BJN19910104; 1979, 15 DEP HLTH SOC SEC; 1981, GEIGY SCI TABLES; 1991, PURE APPL CHEM, V63, P991; 1972, WHO TECH REP SER, V503, P29; 1993, JAMA-J AM MED ASSOC, V270, P2846; 1990, NUTRITION PREGNANCY, P272	34	115	116	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					79	82		10.1136/bmj.309.6947.79	http://dx.doi.org/10.1136/bmj.309.6947.79			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038670	Green Published			2022-12-28	WOS:A1994NW71600013
J	GRAY, MY; LAZARUS, JH				GRAY, MY; LAZARUS, JH			IRITIS AFTER TREATMENT WITH STREPTOKINASE	BRITISH MEDICAL JOURNAL			English	Letter							ACUTE MYOCARDIAL-INFARCTION				GRAY, MY (corresponding author), LLANDOUGH HOSP NATL HLTH SERV TRUST,PENARTH CF64 2XX,S GLAM,WALES.		Lazarus, John H/H-5108-2017	Lazarus, John H/0000-0001-8852-704X				BELL WR, 1979, NEW ENGL J MED, V301, P1266, DOI 10.1056/NEJM197912063012305; BUCKNALL C, 1988, BRIT HEART J, V59, P9; KINSHUCK D, 1992, BRIT MED J, V305, P1332, DOI 10.1136/bmj.305.6865.1332-c; SCHWEITZER DH, 1991, CARDIOLOGY, V78, P68, DOI 10.1159/000174768	4	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					97	97						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038677				2022-12-28	WOS:A1994NW71600023
J	CLARK, JD; DEHEINZELIN, J; SCHICK, KD; HART, WK; WHITE, TD; WOLDEGABRIEL, G; WALTER, RC; SUWA, G; ASFAW, B; VRBA, E; SELASSIE, YH				CLARK, JD; DEHEINZELIN, J; SCHICK, KD; HART, WK; WHITE, TD; WOLDEGABRIEL, G; WALTER, RC; SUWA, G; ASFAW, B; VRBA, E; SELASSIE, YH			AFRICAN HOMO-ERECTUS - OLD RADIOMETRIC AGES AND YOUNG OLDOWAN ASSEMBLAGES IN THE MIDDLE-AWASH VALLEY, ETHIOPIA	SCIENCE			English	Article							SOUTHERN KENYA RIFT; OLDUVAI-GORGE; OLORGESAILIE; CALIBRATION; TANZANIA; CRANIUM; BODO	Fossils and artifacts recovered from the middle Awash Valley of Ethiopia's Afar depression sample the Middle Pleistocene transition from Home erectus to Home sapiens. Ar/Ar ages, biostratigraphy, and tephrachronology from this area indicate that the Pleistocene Bodo hominid cranium and newer specimens are approximately 0.6 million years old. Only Oldowan chopper and flake assemblages are present in the lower stratigraphic units, but Acheulean bifacial artifacts are consistently prevalent and widespread in directly overlying deposits. This technological transition is related to a shift in sedimentary regime, supporting the hypothesis that Middle Pleistocene Oldowan assemblages represent a behavioral facies of the Acheulean industrial complex.	INST ROYAL SCI NAT BELGIQUE,B-1040 BRUSSELS,BELGIUM; INDIANA UNIV,DEPT ANTHROPOL,BLOOMINGTON,IN 47405; MIAMI UNIV,DEPT GEOL,OXFORD,OH 45056; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; INST HUMAN ORIGINS,CTR GEOCHRONOL,BERKELEY,CA 94709; UNIV TOKYO,FAC SCI,DEPT ANTHROPOL,TOKYO 113,JAPAN; YALE UNIV,DEPT GEOL & GEOPHYS,NEW HAVEN,CT 06511	Indiana University System; Indiana University Bloomington; University System of Ohio; Miami University; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Tokyo; Yale University	CLARK, JD (corresponding author), UNIV CALIF BERKELEY,DEPT ANTHROPOL,HUMAN EVOLUTIONARY STUDIES LAB,BERKELEY,CA 94720, USA.		Klein, Richard G/B-5910-2009; Walter, Robert/AAD-7642-2020	Walter, Robert/0000-0001-8761-5355				Aigner J. S., 1986, ANTHROPOS, V23, P157; Andrews P., 1984, Courier Forschungsinstitut Senckenberg, V69, P167; ASFAW B, 1983, AM J PHYS ANTHROPOL, V61, P367, DOI 10.1002/ajpa.1330610311; ASFAW B, 1992, NATURE, V360, P732, DOI 10.1038/360732a0; BLUMENSCHINE RJ, 1991, J HUM EVOL, V21, P451, DOI 10.1016/0047-2484(91)90095-D; BRAUER G, 1992, J HUM EVOL, V22, P79, DOI 10.1016/0047-2484(92)90032-5; Clark J.D., 1970, PREHISTORY AFRICA; CLARK JD, 1984, NATURE, V307, P423, DOI 10.1038/307423a0; CLARK JD, 1975, AUSTRALOPITHECINES, P608; CLARKE RJ, 1990, J HUM EVOL, V19, P699, DOI 10.1016/0047-2484(90)90004-U; CONROY GC, 1978, NATURE, V275, P67; DEINO A, 1990, J GEOPHYS RES-SOLID, V95, P8453, DOI 10.1029/JB095iB06p08453; DEINO A, 1990, J GEOL, V98, P567, DOI 10.1086/629425; GOWLETT JAJ, 1988, WORLD ARCHAEOL, V20, P13, DOI 10.1080/00438243.1988.9980053; Hay R.L., 1976, GEOLOGY OLDUVAI GORG; Isaac GL, 1977, OLORGESAILIE ARCHAEO; ISAAC GL, 1966, PUBL MUS ARQUEOL, V6, P135; Kalb J.E., 1982, Newsletters on Stratigraphy, V11, P95; KALB JE, 1982, NATURE, V298, P25, DOI 10.1038/298025a0; KALB JE, 1982, NATURE, V298, P17, DOI 10.1038/298017a0; LEAKEY MD, 1971, DEXCAVATIONS BEDS 1, V3; POTTS R, 1989, J HUM EVOL, V18, P477, DOI 10.1016/0047-2484(89)90076-6; Rightmire G. P., 1990, EVOLUTION HOMO ERECT; SAMSON SD, 1987, CHEM GEOL, V66, P27, DOI 10.1016/0168-9622(87)90025-X; Stiles D., 1991, AFR ARCHAEOL REV, V9, P1, DOI DOI 10.1007/BF01117214; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; WALTER RC, 1991, NATURE, V354, P145, DOI 10.1038/354145a0; WHITE TD, 1986, AM J PHYS ANTHROPOL, V69, P503, DOI 10.1002/ajpa.1330690410; WOLDEGABRIEL G, 1992, J FIELD ARCHAEOL, V19, P471, DOI 10.2307/530428; ZHOU JS, 1990, GEOL SOC AM SPEC PAP, V242, P69	30	121	130	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1907	1910		10.1126/science.8009220	http://dx.doi.org/10.1126/science.8009220			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	NT847	8009220				2022-12-28	WOS:A1994NT84700037
J	STRUTHERS, AD				STRUTHERS, AD			10 YEARS OF NATRIURETIC PEPTIDE RESEARCH - A NEW DAWN FOR THEIR DIAGNOSTIC AND THERAPEUTIC USE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANGIOTENSIN-CONVERTING-ENZYME; NEUTRAL ENDOPEPTIDASE INHIBITOR; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; PORCINE BRAIN; HEART-FAILURE; ATRIAL; HYPERTENSION; POLYPEPTIDE; SUPPRESSION				STRUTHERS, AD (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CLIN PHARMACOL, DUNDEE DD1 9SY, SCOTLAND.			Struthers, Allan/0000-0002-2926-2528				ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; BEVAN EG, 1992, J HYPERTENS, V10, P607; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CARGILL R, IN PRESS BR J CLIN P; CHU A, 1989, CIRCULATION, V80, P1627, DOI 10.1161/01.CIR.80.6.1627; DAVIDSON NC, 1994, J HYPERTENS, V12, P329; DAVIS HR, 1992, CIRCULATION, V86, P220; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; HU DCK, 1988, AM J MED SCI, V296, P111, DOI 10.1097/00000441-198808000-00007; ITOH H, 1992, HYPERTENSION, V19, P758, DOI 10.1161/01.HYP.19.6.758; JAMISON RL, 1992, AM J KIDNEY DIS, V20, P519, DOI 10.1016/S0272-6386(12)70269-X; KANGAWA K, 1984, BIOCHEM BIOPH RES CO, V118, P131, DOI 10.1016/0006-291X(84)91077-5; KUGIYAMA K, 1993, CIRCULATION, V88, P521; LANG CC, 1992, J HYPERTENS, V10, P483, DOI 10.1097/00004872-199205000-00012; LANG CC, 1993, AM J CARDIOL, V72, P1083, DOI 10.1016/0002-9149(93)90868-D; LANG CC, 1992, CLIN SCI, V83, P519, DOI 10.1042/cs0830519; LERMAN A, 1993, LANCET, V341, P1105, DOI 10.1016/0140-6736(93)93125-K; LIPKIN D, 1992, J AM SOC NEPHROL, V3, P440; MONOPOLI A, 1991, J HYPERTENS, V9, pS246; MOTWANI JG, 1993, LANCET, V341, P1109, DOI 10.1016/0140-6736(93)93126-L; NAKAO K, 1992, J HYPERTENS, V10, P907; NORTHRIDGE DB, 1989, LANCET, V2, P591; NORTHRIDGE DB, 1991, BR J CLIN PHARM, V32, P645; PACHER R, 1993, EUR HEART J, V14, P273, DOI 10.1093/eurheartj/14.2.273; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; STRUTHERS AD, 1993, BRIT HEART J, V70, P397; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; TANAKA H, 1993, AM J CARDIOL, V72, P128, DOI 10.1016/0002-9149(93)90147-5; VANDENMEIRACKER AH, 1992, J HYPERTENS, V10, P803; WHEELDON NM, 1993, Q J MED, V86, P17; WILKINS MR, 1993, KIDNEY INT, V43, P273, DOI 10.1038/ki.1993.44; YOSHIBAYASHI M, 1993, NEW ENGL J MED, V329, P433, DOI 10.1056/NEJM199308053290614; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	34	61	63	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 18	1994	308	6944					1615	1619		10.1136/bmj.308.6944.1615	http://dx.doi.org/10.1136/bmj.308.6944.1615			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025431	Green Published			2022-12-28	WOS:A1994NT52800023
J	BEHL, C; DAVIS, JB; LESLEY, R; SCHUBERT, D				BEHL, C; DAVIS, JB; LESLEY, R; SCHUBERT, D			HYDROGEN-PEROXIDE MEDIATES AMYLOID-BETA PROTEIN TOXICITY	CELL			English	Article							SUPEROXIDE-GENERATING OXIDASE; FAMILIAL ALZHEIMERS-DISEASE; CENTRAL-NERVOUS-SYSTEM; PRECURSOR PROTEIN; GLUTAMATE TOXICITY; GROWTH-FACTOR; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; CORTICAL-NEURONS; CELLS	Amyloid beta protein (A beta) is a 40-43 amino acid peptide that is associated with plaques in the brains of Alzheimer's patients and is cytotoxic to cultured neurons. Using both primary central nervous system cultures and clonal cell lines, it is shown that a number of antioxidants protect cells from A beta toxicity, suggesting that at least one pathway to A beta cytotoxicity results in free radical damage. A beta causes increased levels of H2O2 and lipid peroxides to accumulate in cells. The H2O2-degrading enzyme catalase protects cells from A beta toxicity. Clonal cell lines selected for their resistance to A beta toxicity also become resistant to the cytolytic action of H2O2. In addition, A beta induces the activity of NF-kappa B, a transcription factor thought to be regulated by oxidative stress. Finally, A beta-induced H2O2 production and A beta toxicity are blocked by reagents that inhibit flavin oxidases, suggesting that A beta activates a member of this class of enzymes. These results show that the cytotoxic action of A beta on neurons results from free radical damage to susceptible cells.			BEHL, C (corresponding author), SALK INST BIOL STUDIES, SAN DIEGO, CA 92186 USA.			Behl, Christian/0000-0001-8453-2378				ABE K, 1990, JPN J PHARMACOL, V53, P221, DOI 10.1254/jjp.53.221; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BAKALKIN GY, 1993, MOL BRAIN RES, V20, P137, DOI 10.1016/0169-328X(93)90119-A; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BEHL C, 1994, BRAIN RES, V645, P253, DOI 10.1016/0006-8993(94)91659-4; BRODIE AE, 1987, BIOCHEM BIOPH RES CO, V148, P120, DOI 10.1016/0006-291X(87)91084-9; BURDON RH, 1993, FREE RADICAL RES COM, V18, P369, DOI 10.3109/10715769309147503; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHOI DW, 1987, J NEUROSCI, V7, P369; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CROSS AR, 1990, FREE RADICAL BIO MED, V8, P71, DOI 10.1016/0891-5849(90)90147-B; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; GLENNER GG, 1988, CELL, V52, P307, DOI 10.1016/S0092-8674(88)80021-7; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Halliwell B., 1989, FREE RADICAL BIO MED, V2nd; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KESTON AS, 1965, ANAL BIOCHEM, V11, P1, DOI 10.1016/0003-2697(65)90034-5; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P7508, DOI 10.1073/pnas.90.16.7508; KIMURA H, 1992, J CELL BIOL, V116, P777, DOI 10.1083/jcb.116.3.777; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOJIMA S, 1993, FEBS LETT, V329, P125, DOI 10.1016/0014-5793(93)80207-B; LEES GJ, 1993, NEUROSCIENCE, V54, P287, DOI 10.1016/0306-4522(93)90254-D; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OLANOW CW, 1992, ANN NEUROL, V32, pS2, DOI 10.1002/ana.410320703; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SANSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SCHUBERT D, 1992, P NATL ACAD SCI USA, V89, P8264, DOI 10.1073/pnas.89.17.8264; Schubert D., 1984, DEV BIOL CULTURED NE; SLATER TF, 1963, BIOCHIM BIOPHYS ACTA, V77, P383, DOI 10.1016/0006-3002(63)90513-4; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; VOGT M, 1963, P NATL ACAD SCI USA, V49, P171, DOI 10.1073/pnas.49.2.171; WOZNIAK A, 1989, IMMUNOLOGY, V68, P359; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	52	1953	2028	0	216	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					817	827		10.1016/0092-8674(94)90131-7	http://dx.doi.org/10.1016/0092-8674(94)90131-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004671				2022-12-28	WOS:A1994NT33100007
J	NOLAN, GP				NOLAN, GP			NF-AT-AP-1 AND REL-BZIP - HYBRID VIGOR AND BINDING UNDER THE INFLUENCE	CELL			English	Review							NF-KAPPA-B; ACTIVATED T-CELLS; TRANSCRIPTION FACTOR; CYCLOSPORINE-A; NUCLEAR FACTOR; DNA-BINDING; JUN; CALCINEURIN; FOS; IDENTIFICATION				NOLAN, GP (corresponding author), STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305, USA.		Nolan, Garry/AAE-7903-2019	Nolan, Garry/0000-0002-8862-9043				BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GUTSCH DE, 1994, MOL CELL BIOL, V14, P1939, DOI 10.1128/MCB.14.3.1939; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORTHROP JP, 1994, IN PRESS NATURE; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964	21	116	117	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					795	798		10.1016/0092-8674(94)90126-0	http://dx.doi.org/10.1016/0092-8674(94)90126-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004669				2022-12-28	WOS:A1994NT33100004
J	PTACEK, LJ; TAWIL, R; GRIGGS, RC; ENGEL, AG; LAYZER, RB; KWIECINSKI, H; MCMANIS, PG; SANTIAGO, L; MOORE, M; FOUAD, G; BRADLEY, P; LEPPERT, MF				PTACEK, LJ; TAWIL, R; GRIGGS, RC; ENGEL, AG; LAYZER, RB; KWIECINSKI, H; MCMANIS, PG; SANTIAGO, L; MOORE, M; FOUAD, G; BRADLEY, P; LEPPERT, MF			DIHYDROPYRIDINE RECEPTOR MUTATIONS CAUSE HYPOKALEMIC PERIODIC PARALYSIS	CELL			English	Article							CHANNEL ALPHA-SUBUNIT; SLOW CALCIUM CURRENT; SKELETAL-MUSCLE; SODIUM-CHANNEL; PARAMYOTONIA-CONGENITA; MUSCULAR DYSGENESIS; GENE; MICE; LINKAGE; DNA	Hypokalemic periodic paralysis (hypoKPP) is an autosomal dominant skeletal muscle disorder manifested by episodic weakness associated with low serum potassium. Genetic linkage analysis has localized the hypoKPP gene to chromosome 1q31-q32 near a dihydropyridine (DHP) receptor gene. This receptor functions as a voltage-gated calcium channel and is also critical for excitation-contraction coupling in a voltage-sensitive and calcium-independent manner. We have characterized patient-specific DHP receptor mutations in 11 probands of 33 independent hypoKPP kindreds that occur at one of two adjacent nucleotides within the same codon and predict substitution of a highly conserved arginine in the S4 segment of domain 4 with either histidine or glycine. In one kindred, the mutation arose de novo. Taken together, these data establish this DHP receptor as the hypoKPP gene. We are unaware of any other human diseases presently known to result from DHP receptor mutations.	UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132; UNIV ROCHESTER,SCH MED,DEPT NEUROL,ROCHESTER,NY 14642; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; MED ACAD WARSAW,DEPT NEUROL,PL-02097 WARSAW,POLAND	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Rochester; Mayo Clinic; University of California System; University of California San Francisco	PTACEK, LJ (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT NEUROL,SALT LAKE CITY,UT 84132, USA.			Griggs, Robert/0000-0001-7988-4854	NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NHGRI NIH HHS [8 R01 HG00367] Funding Source: Medline; NICHD NIH HHS [1 K11 HD00940-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K11HD000940] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000367] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; CASLEY WL, 1992, GENOMICS, V14, P493, DOI 10.1016/S0888-7543(05)80249-6; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHAHINE M, 1994, NEURON, V12, P281, DOI 10.1016/0896-6273(94)90271-2; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EBERS GC, 1991, ANN NEUROL, V30, P810, DOI 10.1002/ana.410300610; ENGEL AG, 1970, MAYO CLIN PROC, V45, P774; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; FONTAINE B, 1994, NAT GENET, V6, P267, DOI 10.1038/ng0394-267; Fontaine B, 1991, Neuromuscul Disord, V1, P235, DOI 10.1016/0960-8966(91)90095-A; GLUECKSOHNWAELS.S, 1963, SCIENCE, V142, P1269, DOI 10.1126/science.142.3597.1269; GOUW L, 1994, IN PRESS NEUROLOGY; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; GREGG RG, 1993, GENOMICS, V15, P107, DOI 10.1006/geno.1993.1017; GRIGGS RC, 1992, HOSP PRACT, V27, P123; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; KNUDSON CM, 1989, J BIOL CHEM, V264, P1345; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LEONARD JP, 1982, EXP NEUROL, V76, P121, DOI 10.1016/0014-4886(82)90106-6; LERCHE H, 1993, J PHYSIOL-LONDON, V470, P13, DOI 10.1113/jphysiol.1993.sp019843; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MCLATCHEY AI, 1992, NAT GENET, V2, P148; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; POWELL JA, 1973, J CELL PHYSIOL, V82, P21, DOI 10.1002/jcp.1040820104; PTACEK LJ, 1993, ANN NEUROL, V33, P300, DOI 10.1002/ana.410330312; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1992, NEURON, V8, P891; PTACEK LJ, 1994, IN PRESS NEUROLOGY; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; RUDEL R, 1984, MUSCLE NERVE, V7, P110, DOI 10.1002/mus.880070205; RUDOLPH JA, 1992, NAT GENET, V2, P1144; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; WROGEMANN K, 1976, LANCET, V27, P672	38	334	352	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					863	868						6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004673				2022-12-28	WOS:A1994NT33100011
J	BARRY, C; FOX, R; STIRRAT, G				BARRY, C; FOX, R; STIRRAT, G			LESSON OF THE WEEK - UPPER ABDOMINAL-PAIN IN PREGNANCY MAY INDICATE PREECLAMPSIA	BRITISH MEDICAL JOURNAL			English	Article							ELEVATED LIVER-ENZYMES; LOW PLATELETS; INTRAVASCULAR COAGULATION; SEVERE PREECLAMPSIA; HELLP SYNDROME; HEMOLYSIS; HYPERTENSION		UNIV BRISTOL,ST MICHAELS HOSP,DEPT OBSTET & GYNAECOL,BRISTOL BS2 8EG,ENGLAND	University of Bristol								AARNOUDSE JG, 1986, BRIT J OBSTET GYNAEC, V93, P145, DOI 10.1111/j.1471-0528.1986.tb07879.x; LAMONT RF, 1983, BRIT J OBSTET GYNAEC, V90, P199, DOI 10.1111/j.1471-0528.1983.tb08608.x; LIM BH, 1991, AUST NZ J OBSTET GYN, V31, P27; MACKENNA J, 1983, OBSTET GYNECOL, V62, P751; MARTIN JN, 1991, AM J OBSTET GYNECOL, V164, P1500, DOI 10.1016/0002-9378(91)91429-Z; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; SIBAI BM, 1986, AM J OBSTET GYNECOL, V155, P501, DOI 10.1016/0002-9378(86)90266-8; SIBAI BM, 1990, AM J OBSTET GYNECOL, V162, P311, DOI 10.1016/0002-9378(90)90376-I; VANDAM PA, 1989, OBSTET GYNECOL, V73, P97; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4	10	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1562	1563		10.1136/bmj.308.6943.1562	http://dx.doi.org/10.1136/bmj.308.6943.1562			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019319	Green Published			2022-12-28	WOS:A1994NR11000034
J	KAUBE, H; MAY, A; DIENER, HC; PFAFFENRATH, V				KAUBE, H; MAY, A; DIENER, HC; PFAFFENRATH, V			SUMATRIPTAN	BRITISH MEDICAL JOURNAL			English	Letter											KAUBE, H (corresponding author), UNIV ESSEN GESAMTHSCH,DEPT NEUROL,D-45122 ESSEN,GERMANY.		Diener, Hans-Christoph/AAF-7275-2019					DIENER HC, 1991, HEADACHE, V31, P205, DOI 10.1111/j.1526-4610.1991.hed3104205.x; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; OSBORNE MJ, 1994, BRIT MED J, V308, P113, DOI 10.1136/bmj.308.6921.113a; 1991, NEW ENGL J MED, V325, P316	4	78	78	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1573	1574		10.1136/bmj.308.6943.1573d	http://dx.doi.org/10.1136/bmj.308.6943.1573d			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019338	Green Published			2022-12-28	WOS:A1994NR11000075
J	FERRANDON, D; ELPHICK, L; NUSSLEINVOLHARD, C; STJOHNSTON, D				FERRANDON, D; ELPHICK, L; NUSSLEINVOLHARD, C; STJOHNSTON, D			STAUFEN PROTEIN ASSOCIATES WITH THE 3'UTR OF BICOID MESSENGER-RNA TO FORM PARTICLES THAT MOVE IN A MICROTUBULE-DEPENDENT MANNER	CELL			English	Article							MESSENGER-RNA LOCALIZATION; EARLY DROSOPHILA EMBRYO; POLE CELL-FORMATION; POSTERIOR DETERMINANT; ANTERIOR LOCALIZATION; SECONDARY STRUCTURE; MOLECULAR ANALYSIS; MATERNAL GENE; PATTERN; OSKAR	Staufen protein is required in order to anchor bicoid (bcd) mRNA at the anterior pole of the Drosophila egg. Here we show that staufen protein colocalizes with bcd mRNA at the anterior, and that this localization depends upon Its association with the mRNA. Upon injection into the embryo, bcd transcripts specifically interact with staufen, and we have mapped the sequences required to three regions of the 3'UTR, each of which is predicted to form a long stem-loop. The resulting staufen-bcd 3'UTR complexes form particles that show a microtubule-dependent localization. Since staufen is also transported with oskar (osk) mRNA during oogenesis, staufen associates specifically with both osk and bcd mRNAs to mediate their localizations, but at two distinct stages of development.	WELLCOME CANC RES CAMPAIGN INST,CAMBRIDGE CB2 1QR,ENGLAND; DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND		FERRANDON, D (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,SPEMANNSTR 35-III,D-72076 TUBINGEN,GERMANY.		St Johnston, Daniel/C-9568-2009	FERRANDON, Dominique/0000-0001-7680-7773; St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; AKUSJARVI G, 1980, P NATL ACAD SCI-BIOL, V77, P2424, DOI 10.1073/pnas.77.5.2424; ALDEN CJ, 1979, J MOL BIOL, V132, P411, DOI 10.1016/0022-2836(79)90268-7; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; DEBRABANDER M, 1986, INT REV CYTOL, V101, P215; DRIEVER W, 1990, DEVELOPMENT, V109, P811; Driever Wolfgang, 1993, P301; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GANS M, 1975, GENETICS, V81, P683; GAVIS ER, 1992, CELL, V71, P310; GOTTLIEB E, 1992, P NATL ACAD SCI USA, V89, P7164, DOI 10.1073/pnas.89.15.7164; KARR TL, 1991, MECH DEVELOP, V34, P101, DOI 10.1016/0925-4773(91)90047-A; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MACDONALD PM, 1993, DEVELOPMENT, V118, P1233; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; NEWMARK PA, 1994, DEVELOPMENT, V120, P1303; PEERY T, 1993, J VIROL, V67, P3534, DOI 10.1128/JVI.67.6.3534-3543.1993; SCHEJTER ED, 1993, ANNU REV CELL BIOL, V9, P67, DOI 10.1146/annurev.cellbio.9.1.67; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SEEGER MA, 1990, EMBO J, V9, P2977, DOI 10.1002/j.1460-2075.1990.tb07490.x; SINGER R H, 1992, Current Opinion in Cell Biology, V4, P15, DOI 10.1016/0955-0674(92)90053-F; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEPHENSON EC, 1987, DEV BIOL, V124, P1, DOI 10.1016/0012-1606(87)90453-2; STEPHENSON EC, 1988, GENE DEV, V2, P1655, DOI 10.1101/gad.2.12a.1655; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	49	350	358	0	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1221	1232		10.1016/0092-8674(94)90013-2	http://dx.doi.org/10.1016/0092-8674(94)90013-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001156				2022-12-28	WOS:A1994PZ86000013
J	HEISS, JD; DOPPMAN, JL; OLDFIELD, EH				HEISS, JD; DOPPMAN, JL; OLDFIELD, EH			RELIEF OF SPINAL-CORD COMPRESSION FROM VERTEBRAL HEMANGIOMA BY INTRALESIONAL INJECTION OF ABSOLUTE ETHANOL	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							PREOPERATIVE EMBOLIZATION; MALFORMATIONS; RADIOTHERAPY; RESECTION; BODY		NIH,WARREN B MAGNUSON CLIN CTR,DEPT RADIOL,BETHESDA,MD	National Institutes of Health (NIH) - USA	HEISS, JD (corresponding author), NINCDS,SURG NEUROL BRANCH,BLDG 10,RM 5D-37,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Heiss, John/AAL-8281-2021	Heiss, John/0000-0002-3890-0165				DJINDJIAN M, 1992, J NEUROSURG, V76, P1025, DOI 10.3171/jns.1992.76.6.1025; DOPPMAN JL, 1983, AM J ROENTGENOL, V140, P773, DOI 10.2214/ajr.140.4.773; EISENSTEIN S, 1986, SPINE, V11, P640, DOI 10.1097/00007632-198607000-00024; FARIA SL, 1985, INT J RADIAT ONCOL, V11, P387, DOI 10.1016/0360-3016(85)90162-2; FIDLER MW, 1990, J BONE JOINT SURG BR, V72, P884, DOI 10.1302/0301-620X.72B5.2211776; FOX MW, 1993, J NEUROSURG, V78, P36, DOI 10.3171/jns.1993.78.1.0036; Galibert P, 1990, Chirurgie, V116, P326; GALIBERT P, 1987, NEUROCHIRURGIE, V33, P166; GLANZMANN C, 1977, STRAHLENTHER ONKOL, V153, P522; GRAHAM JJ, 1984, SPINE, V9, P97, DOI 10.1097/00007632-198401000-00022; GRAY F, 1989, NEUROCHIRURGIE, V35, P267; GROSS CE, 1976, J NEUROSURG, V45, P327, DOI 10.3171/jns.1976.45.3.0327; HEKSTER REM, 1972, NEURORADIOLOGY, V3, P160, DOI 10.1007/BF00341502; HEMMY DC, 1977, J NEUROSURG, V47, P282, DOI 10.3171/jns.1977.47.2.0282; LANG EF, 1960, SURG CLIN N AM, V40, P817; MCALLISTER VL, 1975, BRAIN, V98, P71, DOI 10.1093/brain/98.1.71; MIRRA JM, 1989, BONE TUMORS CLIN RAD, V2, P1335; NICOLA N, 1987, SURG NEUROL, V27, P481, DOI 10.1016/0090-3019(87)90258-8; PICARD L, 1989, NEUROCHIRURGIE, V35, P289; PICARD L, 1989, NEUROCHIRURGIE, V35, P305; RYOPPY S, 1990, J BONE JOINT SURG AM, V72A, P1245, DOI 10.2106/00004623-199072080-00019; Schmorl G, 1971, HUMAN SPINE HLTH DIS; Smith T P, 1993, J Vasc Interv Radiol, V4, P681, DOI 10.1016/S1051-0443(93)71948-X; YAKES WF, 1989, RADIOLOGY, V170, P1059, DOI 10.1148/radiology.170.3.2916057; YANG ZY, 1985, ACTA RADIOL ONCOL, V24, P129, DOI 10.3109/02841868509134375	25	71	75	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					508	511		10.1056/NEJM199408253310804	http://dx.doi.org/10.1056/NEJM199408253310804			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD072	8041416				2022-12-28	WOS:A1994PD07200004
J	LEE, JH; ARCINUE, E; ROSS, BD				LEE, JH; ARCINUE, E; ROSS, BD			ORGANIC OSMOLYTES IN THE BRAIN OF AN INFANT WITH HYPERNATREMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							ABSOLUTE QUANTITATION; WATER; SPECTROSCOPY; METABOLITES		HUNTINGTON MED RES INST, MAGNET RESONANCE SPECT UNIT, PASADENA, CA 91105 USA; HUNTINGTON MEM HOSP, PASADENA, CA USA	Huntington Medical Research Institutes; University of Southern California; Huntington Memorial Hospital								ARIEFF AI, 1973, J CLIN INVEST, V52, P571, DOI 10.1172/JCI107218; ERNST T, 1993, J MAGN RESON SER B, V102, P1, DOI 10.1006/jmrb.1993.1055; FRASER CL, 1987, CLIN DISORDERS FLUID, P1153; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; KREIS R, 1992, RADIOLOGY, V184, P123, DOI 10.1148/radiology.184.1.1319074; KREIS R, 1993, J MAGN RESON SER B, V102, P9, DOI 10.1006/jmrb.1993.1056; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; LIEN YHH, 1994, LIFE SCI, V54, P1507, DOI 10.1016/0024-3205(94)90018-3; LIEN YHH, 1990, J CLIN INVEST, V85, P1427, DOI 10.1172/JCI114587; MICHAELIS T, 1993, 12TH P M SOC MAGN RE, P437; MOATS RA, 1993, BIOCHEM J, V295, P15, DOI 10.1042/bj2950015; MORRISON G, 1987, CLIN DISORDERS FLUID, P481; Ross BD, 1991, NMR BIOMED, V4, P47; VIDEEN J, 1994, 2ND P M SOC MAGN RES, P193; WEBB PG, 1994, MAGNET RESON MED, V31, P365, DOI 10.1002/mrm.1910310404	15	123	126	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					439	442		10.1056/NEJM199408183310704	http://dx.doi.org/10.1056/NEJM199408183310704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	8035840				2022-12-28	WOS:A1994PB50100004
J	DEVINCENZI, I				DEVINCENZI, I			LONGITUDINAL-STUDY OF HUMAN-IMMUNODEFICIENCY-VIRUS TRANSMISSION BY HETEROSEXUAL PARTNERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEXUAL TRANSMISSION; HIV; DISEASE; WOMEN; MEN	Background. Worldwide, the predominant mode of human immunodeficiency virus (HIV) transmission is heterosexual intercourse, but the risk of heterosexual transmission and the effectiveness of measures to prevent it are not well defined. Methods. We conducted a prospective study of HIV-negative subjects whose only risk of HIV infection was a stable heterosexual relationship with an HIV-infected partner. Every six months the subjects were interviewed, tested for HIV, and counseled about safe sexual practices. Results. A total of 304 HIV-negative subjects (196 women and 108 men) were followed for an average of 20 months. During the study, 130 couples (42.8 percent) ended their sexual relationships, most often because of the HIV-infected partner's illness or death. Of the 256 couples who continued to have sexual relations for more than three months after enrollment in the study, only 124 (48.4 percent) used condoms consistently for vaginal and anal intercourse. Among these couples, none of the seronegative partners became infected with HIV, despite a total of about 15,000 episodes of intercourse. Among the 121 couples who used condoms inconsistently, the rate of seroconversion was 4.8 per 100 person-years (95 percent confidence interval, 2.5 to 8.4). Eleven couples refused to answer questions about condom use. The risk of transmission increased with advanced stages of HIV infection in the index partners (P<0.02) and with genital infection in the HIV-negative partners (P<0.04). Withdrawal to avoid ejaculation in the vagina had a protective effect in uninfected women (P<0.02). Conclusions. Consistent use of condoms for heterosexual intercourse is highly effective in preventing the transmission of HIV. Among couples not using condoms regularly, the risk of HIV transmission varies widely.			DEVINCENZI, I (corresponding author), HOP NATL ST MAURICE,EUROPEAN CTR EPIDEMIOL MONITORING AIDS,14 RUE VAL DOSNE,F-94410 ST MAURICE,FRANCE.							ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; CHANCHEE C, 1991, GENITOURIN MED, V67, P173; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2, P739; HAVERKOS HW, 1992, JAMA-J AM MED ASSOC, V268, P1855, DOI 10.1001/jama.1992.03490140063023; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; KAPLAN EH, 1990, J ACQ IMMUN DEF SYND, V3, P55; KEET IPM, 1992, AIDS, V6, P223, DOI 10.1097/00002030-199202000-00014; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; PADIAN NS, 1993, J ACQ IMMUN DEF SYND, V6, P1043; PUDNEY J, 1992, LANCET, V340, P1470, DOI 10.1016/0140-6736(92)92659-4; ROSENBERG MJ, 1992, AM J PUBLIC HEALTH, V82, P1473, DOI 10.2105/AJPH.82.11.1473; SARACCO A, 1993, J ACQ IMMUN DEF SYND, V6, P497; SIDDIQUI NS, 1992, AIDS, V6, P1529, DOI 10.1097/00002030-199212000-00017; SIDDIQUI NS, 1993, AIDS, V7, P444; VOELLER B, 1990, AIDS SEX INTEGRATED, P276; WELLER SC, 1993, SOC SCI MED, V36, P1635, DOI 10.1016/0277-9536(93)90352-5; WILEY JA, 1989, STAT MED, V8, P93, DOI 10.1002/sim.4780080110; 1986, MMWR-MORBID MORTAL W, V35, P334; 1992, BRIT MED J, V304, P809	19	505	512	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					341	346		10.1056/NEJM199408113310601	http://dx.doi.org/10.1056/NEJM199408113310601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA374	8028613				2022-12-28	WOS:A1994PA37400001
J	FRIEDLAND, IR; MCCRACKEN, GH				FRIEDLAND, IR; MCCRACKEN, GH			DRUG-THERAPY - MANAGEMENT OF INFECTIONS CAUSED BY ANTIBIOTIC-RESISTANT STREPTOCOCCUS-PNEUMONIAE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PENICILLIN-RESISTANT; ANTIMICROBIAL RESISTANCE; PNEUMOCOCCAL MENINGITIS; SEROTYPE DISTRIBUTION; SYSTEMIC INFECTIONS; IMIPENEM-CILASTATIN; INVITRO ACTIVITIES; OTITIS-MEDIA; CHILDREN; SUSCEPTIBILITY		UNIV WITWATERSRAND,JOHANNESBURG,SOUTH AFRICA; UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DIV INFECT DIS,DALLAS,TX	University of Witwatersrand; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	FRIEDLAND, IR (corresponding author), BARAGWANATH HOSP,DEPT PEDIAT,PO BERTSHAM,JOHANNESBURG 2013,SOUTH AFRICA.							ASENSI F, 1989, PEDIATR INFECT DIS J, V8, P895, DOI 10.1097/00006454-198912000-00019; ASENSI F, 1993, J CHEMOTHERAPY, V5, P133; BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl_C.31; BARRY B, 1993, 33RD INT C ANT AG CH, P370; BLOCK S, 1993, 33RD INT C ANT AG CH, P311; BLUESTONE CD, 1992, CLIN INFECT DIS, V14, pS197, DOI 10.1093/clinids/14.Supplement_2.S197; BLUMBERG HM, 1989, J INFECT DIS, V160, P725, DOI 10.1093/infdis/160.4.725; BUTLER JC, 1993, 33RD INT C ANT AG CH, P336; CORCORAN GD, 1992, LANCET, V340, P50; DAGAN R, 1993, 33RD INT C ANT AG CH, P336; ESKOLA J, 1992, JAMA-J AM MED ASSOC, V268, P3323, DOI 10.1001/jama.268.23.3323; FELDMAN C, 1985, NEW ENGL J MED, V313, P615, DOI 10.1056/NEJM198509053131006; FENOLL A, 1991, REV INFECT DIS, V13, P56; FREMAUX A, 1992, 32ND INT C ANT AG CH, P280; FRIEDLAND IR, 1992, AM J DIS CHILD, V146, P920, DOI 10.1001/archpedi.1992.02160200042023; FRIEDLAND IR, 1993, ANTIMICROB AGENTS CH, V37, P1630, DOI 10.1128/AAC.37.8.1630; FRIEDLAND IR, 1993, PEDIATR INFECT DIS J, V12, P196, DOI 10.1097/00006454-199303000-00004; FRIEDLAND IR, 1992, LANCET, V339, P405, DOI 10.1016/0140-6736(92)90087-J; FRIEDLAND IR, 1993, LANCET, V342, P240, DOI 10.1016/0140-6736(93)92331-M; FRIEDLAND IR, 1993, PEDIATR INFECT DIS J, V12, P544, DOI 10.1097/00006454-199306000-00024; FRIEDLAND IR, IN PRESS J ANTIMICRO; FUCHS PC, 1991, ANTIMICROB AGENTS CH, V35, P764, DOI 10.1128/AAC.35.4.764; GOULD FK, 1987, J INFECTION, V15, P77, DOI 10.1016/S0163-4453(87)91576-3; JACOBS RF, 1992, CLIN INFECT DIS, V14, P56, DOI 10.1093/clinids/14.1.56; JETTE LP, 1989, J CLIN MICROBIOL, V27, P1; JORGENSEN JH, 1994, J CLIN MICROBIOL, V32, P159, DOI 10.1128/JCM.32.1.159-163.1994; JORGENSEN JH, 1990, ANTIMICROB AGENTS CH, V34, P2075, DOI 10.1128/AAC.34.11.2075; JORGENSENJH, 1993, 33RD INT C ANT AG CH, P167; KLEIMAN MB, 1993, PEDIATR INFECT DIS J, V12, P782, DOI 10.1097/00006454-199309000-00019; KLEIN JO, 1993, PEDIATR INFECT DIS J, V12, P973, DOI 10.1097/00006454-199312000-00001; KLUGMAN KP, 1986, ARCH DIS CHILD, V61, P377, DOI 10.1136/adc.61.4.377; LEE BL, 1991, NEW ENGL J MED, V325, P520; LINARES J, 1992, J ANTIMICROB CHEMOTH, V30, P279, DOI 10.1093/jac/30.3.279; LONKS JR, 1993, ANTIMICROB AGENTS CH, V37, P1742, DOI 10.1128/AAC.37.9.1742; LOZA E, 1992, EUR J CLIN MICROBIOL, V11, P856, DOI 10.1007/BF01960892; MARTON A, 1991, J INFECT DIS, V163, P542, DOI 10.1093/infdis/163.3.542; MASON EO, 1992, ANTIMICROB AGENTS CH, V36, P1703, DOI 10.1128/AAC.36.8.1703; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; MAZZULLI T, 1990, ANTIMICROB AGENTS CH, V34, P467, DOI 10.1128/AAC.34.3.467; MILLAR M, 1991, LANCET, V338, P323, DOI 10.1016/0140-6736(91)90468-5; MOGDASY MC, 1992, PEDIATR INFECT DIS J, V11, P648; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; PARIS MM, 1994, ANTIMICROB AGENTS CH, V38, P1320, DOI 10.1128/AAC.38.6.1320; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SCHAAD UB, 1981, J INFECT DIS, V143, P156, DOI 10.1093/infdis/143.2.156; SHIBL AM, 1992, J ANTIMICROB CHEMOTH, V29, P149, DOI 10.1093/jac/29.2.149; SOARES S, 1993, J INFECT DIS, V168, P158, DOI 10.1093/infdis/168.1.158; SPANGLER SK, 1992, ANTIMICROB AGENTS CH, V36, P856, DOI 10.1128/AAC.36.4.856; TAN TQ, 1993, PEDIATRICS, V92, P761; TAN TQ, 1992, PEDIATRICS, V90, P928; TINKELMAN DG, 1989, AM J DIS CHILD, V143, P938, DOI 10.1001/archpedi.1989.02150200098025; VERHAEGEN J, 1990, EUR J CLIN MICROBIOL, V9, P390, DOI 10.1007/BF01979467; VILADRICH PF, 1988, AM J MED, V84, P839, DOI 10.1016/0002-9343(88)90061-7; WALLACE JF, 1967, J LAB CLIN MED, V70, P408; WEINGARTEN RD, 1990, REV INFECT DIS, V12, P118; WILLETT LD, 1985, AM J DIS CHILD, V139, P1054, DOI 10.1001/archpedi.1985.02140120100037; 1994, MMWR-MORBID MORTAL W, V43, P31; 1994, MMWR-MORBID MORTAL W, V43, P23	58	502	514	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					377	382						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA374	8028618				2022-12-28	WOS:A1994PA37400007
J	ROSENTHAL, N				ROSENTHAL, N			TOOLS OF THE TRADE - RECOMBINANT-DNA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article														Rosenthal, Nadia/0000-0002-7599-7365				LEWIN B, 1993, GENES, V5; WATSON J, 1992, RECOMBINANT DNA SHOR	2	27	27	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					315	317		10.1056/NEJM199408043310508	http://dx.doi.org/10.1056/NEJM199408043310508			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022444				2022-12-28	WOS:A1994NZ22700008
J	GESSNER, BD				GESSNER, BD			MORTALITY-RATES, CAUSES OF DEATH, AND HEALTH-STATUS AMONG DISPLACED AND RESIDENT POPULATIONS OF KABUL, AFGHANISTAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PUBLIC-HEALTH; SOMALIA; WAR	Objective.-To determine the mortality and health effects from the current civil war in Kabul, Afghanistan. Subjects.-One resident population and one displaced population. Design.-Between November 22 and December 16, 1993, we conducted a retrospective, population-based, household survey, interviewing 312 displaced families and 300 resident families. Results.-During the 285 days before the survey, the highest average daily crude mortality rate and the mortality rate for those younger than 5 years (0.9 and 2.6 per 10 000 population per day, respectively) were among residents who had lived at their current location for 10 months or less. The average daily crude mortality rate and the mortality rate for those younger than 5 years were lower among displaced persons (0.6 and 1.9 per 10 000 per day) and lowest among residents who had lived at their current location for more than 10 months (0.5 and 0.6 per 10 000 per day). Overall, the most common cause of death for both groups was gunshot or other war trauma; for children younger than 5 years, deaths resulting from measles, diarrhea, and acute respiratory tract infection predominated. Conclusions.-While provision of basic public health measures would likely decrease mortality among both displaced and resident populations the most urgent health need is for a cessation of hostilities against the civilian population. During humanitarian relief operations, organizations should not focus exclusively on persons identified as displaced.	MED SANS FRONTIERES,PARIS,FRANCE	Doctors Without Borders								Dean A. G., 1990, EPI INFO VERSION 5 W; MANONCOURT S, 1992, LANCET, V340, P176, DOI 10.1016/0140-6736(92)93252-I; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; RITMEIJER K, 1993, MED NEWS MEDECINES S, V3, P72; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TOOLE MJ, 1993, LANCET, V341, P1193, DOI 10.1016/0140-6736(93)91013-C; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; 1990, LANCET, V336, P845; 1993, MMWR-MORBID MORTAL W, V42, P468; 1991, MMWR-MORBID MORTAL W, V40, P443; 1990, MMWR-MORBID MORTAL W, V39, P707; 1993, MMWR-MORBID MORTAL W, V42, P4; 1989, MMWR-MORBID MORTAL W, V38, P848; 1992, MMWR-MORBID MORTAL W, V41, P1	15	26	26	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					382	385		10.1001/jama.272.5.382	http://dx.doi.org/10.1001/jama.272.5.382			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028170				2022-12-28	WOS:A1994NY90300031
J	CHARI, RS; COLLINS, BH; MAGEE, JC; DIMAIO, JM; KIRK, AD; HARLAND, RC; MCCANN, RL; PLATT, JL; MEYERS, WC				CHARI, RS; COLLINS, BH; MAGEE, JC; DIMAIO, JM; KIRK, AD; HARLAND, RC; MCCANN, RL; PLATT, JL; MEYERS, WC			BRIEF REPORT - TREATMENT OF HEPATIC-FAILURE WITH EX-VIVO PIG-LIVER PERFUSION FOLLOWED BY LIVER-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; VET AFFAIRS MED CTR,DURHAM,NC	Duke University; Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Harland, Robert/GLR-7684-2022; Kirk, Allan D./B-6905-2012; Sano, Michael/E-1715-2011	Kirk, Allan/0000-0003-2004-5962; Platt, Jeffrey/0000-0002-4915-0419	NHLBI NIH HHS [HL52297] Funding Source: Medline; NIDDK NIH HHS [DK35490-08] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052297, R37HL052297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035490] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUNA GM, 1973, SURG GYNECOL OBSTET, V137, P741; EISEMAN B, 1965, ANN SURG, V162, P329, DOI 10.1097/00000658-196509000-00003; MEYERS WC, 1990, TXB LIVER BILIARY SU, P56; MUNOZ SJ, 1993, SEMIN LIVER DIS, V13, P395; NYBERG SL, 1992, CRIT CARE MED, V20, P1157, DOI 10.1097/00003246-199208000-00016; OTTO JJ, 1958, SURGERY, V43, P301; PLATT JL, 1991, TRANSPLANTATION, V52, P214, DOI 10.1097/00007890-199108000-00006; PLATT JL, 1990, IMMUNOL TODAY, V11, P450, DOI 10.1016/0167-5699(90)90174-8; TARTER RE, 1991, ARCH INTERN MED, V151, P1521, DOI 10.1001/archinte.151.8.1521; TUNG LC, 1981, ARTIFICIAL LIVER SUP, P274; 1991, MON VITAL STAT REP, V39, P1	11	216	223	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					234	237		10.1056/NEJM199407283310404	http://dx.doi.org/10.1056/NEJM199407283310404			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	8015570				2022-12-28	WOS:A1994NY33500004
J	NEUMANN, PJ; GHARIB, SD; WEINSTEIN, MC				NEUMANN, PJ; GHARIB, SD; WEINSTEIN, MC			THE COST OF A SUCCESSFUL DELIVERY WITH IN-VITRO FERTILIZATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEONATAL INTENSIVE-CARE; LOW-BIRTH-WEIGHT; INVITRO FERTILIZATION; ASSISTED CONCEPTION; MULTIPLE BIRTHS; OVARIAN-CANCER; TRIPLET; PREGNANCIES; INFERTILITY; RISKS	Background. The use of in vitro fertilization has engendered considerable debate about who should have the procedure, whether health insurance should cover the cost, and if so, to what extent. We investigated the cost of a successful delivery with in vitro fertilization. Methods. We calculated the cost per successful delivery with in vitro fertilization (defined as at least one live birth) for a general population of couples undergoing in vitro fertilization and for two subgroups: couples with a diagnosis of tubal disease (who have a better chance of success), and couples in which the woman is over the age of 40 years and the man has a low sperm count (who have a lower chance of success). Information on charges per cycle of in vitro fertilization was obtained from six facilities across the country; delivery rates with this procedure were estimated from the literature. Results. On average, the cost incurred per successful delivery with in vitro fertilization increases from $66,667 for the first cycle of in vitro fertilization to $114,286 by the sixth cycle. The cost increases because with each cycle in which fertilization fails, the probability that a subsequent effort will be successful declines. Sensitivity analyses indicated that the cost per delivery ranges from $44,000 to $211,940. For couples with a better chance of successful in vitro fertilization (i.e., those with a diagnosis of tubal disease), it costs $50,000 per delivery for the first cycle and $72,727 for the sixth. For couples in which the woman is older and there is a diagnosis of male-factor infertility, the cost rises from $160,000 for the first cycle to $800,000 for the sixth. Conclusions. The debate about insurance coverage for in vitro fertilization must take into account ethical judgments and social values. But analyses of costs and cost effectiveness help elucidate the economic implications of using in vitro fertilization and thus inform the policy discussion.	BRIGHAM & WOMENS HOSP, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	NEUMANN, PJ (corresponding author), PROJECT HOPE CTR HLTH AFFAIRS, SUITE 600, 7500 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA.							BLACKMAN JA, 1991, PEDIATR CLIN N AM, V38, P1497; BONNICKSEN AL, 1989, IN VITRO FERTILIZATI; BOTTING BJ, 1987, ARCH DIS CHILD, V62, P941, DOI 10.1136/adc.62.9.941; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; BRANDES JM, 1992, PEDIATRICS, V90, P424; BROMWICH P, 1989, LANCET, V2, P1327; DALTON M, 1989, LANCET, V2, P1327; DEMOUZON J, 1993, FERTIL STERIL, V59, P587; EDWARDS RG, 1989, LANCET, V2, P1328; Ewald U, 1991, Int J Technol Assess Health Care, V7 Suppl 1, P155; GUZICK DS, 1986, FERTIL STERIL, V46, P663; HARTZ SC, 1992, FERTIL STERIL, V57, P15; HERSHLAG A, 1991, FERTIL STERIL, V56, P913; HOWE RS, 1988, FERTIL STERIL, V49, P726; HULL MGR, 1992, BRIT MED J, V304, P1465, DOI 10.1136/bmj.304.6840.1465; JOHANNES CB, 1993, FERTIL STERIL, V59, P250, DOI 10.1016/S0015-0282(16)55656-8; KELLY TE, 1986, CLIN GENETICS GENETI, P218; KINGSLAND CR, 1990, EUR J OBSTET GYN R B, V34, P197, DOI 10.1016/0028-2243(90)90071-8; LEVENE MI, 1992, BRIT J OBSTET GYNAEC, V99, P607, DOI 10.1111/j.1471-0528.1992.tb13831.x; LEVRAN D, 1990, NEW ENGL J MED, V323, P1153, DOI 10.1056/NEJM199010253231701; NEUMANN PJ, 1994, MED CARE, V32, P686, DOI 10.1097/00005650-199407000-00003; PADILLA SL, 1989, FERTIL STERIL, V52, P270; PAGE H, 1989, J ROY SOC MED, V82, P99, DOI 10.1177/014107688908200216; Petrikovsky B M, 1989, Obstet Gynecol Surv, V44, P578, DOI 10.1097/00006254-198908000-00002; SASSOON DA, 1990, OBSTET GYNECOL, V75, P817; SCHENKER JG, 1994, FERTIL STERIL, V61, P411; SEOUD MAF, 1992, FERTIL STERIL, V57, P825; SMITH BH, 1991, BRIT MED J, V302, P127, DOI 10.1136/bmj.302.6769.127; SPIRTAS R, 1993, FERTIL STERIL, V59, P291; TAN SL, 1992, LANCET, V339, P1390, DOI 10.1016/0140-6736(92)91205-M; TRAVERS B, 1992, BRIT MED J, V305, P50, DOI 10.1136/bmj.305.6844.50-c; WAGNER MG, 1989, LANCET, V2, P1027; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1175, DOI 10.1093/oxfordjournals.aje.a116426; 1993, INFERTILITY NATIONAL; 1990, ANN CLIN SPECIFIC RE; 1991, STATE LAWS INFERTILI; 1989, CLIN GYNECOLOGIC END, P611; 1987, 38 OFF TECHN ASS HLT	39	184	184	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					239	243		10.1056/NEJM199407283310406	http://dx.doi.org/10.1056/NEJM199407283310406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	8015571				2022-12-28	WOS:A1994NY33500006
J	ROSENBERG, SM; LONGERICH, S; GEE, P; HARRIS, RS				ROSENBERG, SM; LONGERICH, S; GEE, P; HARRIS, RS			ADAPTIVE MUTATION BY DELETIONS IN SMALL MONONUCLEOTIDE REPEATS	SCIENCE			English	Article							ESCHERICHIA-COLI; FRAMESHIFT MUTATION; MISMATCH REPAIR; TUMOR-CELLS; RECOMBINATION; RECD; GENE; MUTANTS; ORIGIN; CANCER	Adaptive reversion of a +1 frameshift mutation in Escherichia coli, which requires homologous recombination functions, is shown here to occur by -1 deletions in regions of small mononucleotide repeats. This pattern makes improbable recombinational mechanisms for adaptive mutation in which blocks of sequences are transferred into the mutating gene, and it supports mechanisms that use DNA polymerase errors. The pattern appears similar to that of mutations found in yeast cells and in hereditary colon cancer cells that are deficient in mismatch repair. These results suggest a recombinational mechanism for adaptive mutation that functions through polymerase errors that persist as a result of a deficiency in post-synthesis mismatch repair.	UNIV ALBERTA, DEPT GENET, EDMONTON T6G 2E9, AB, CANADA; UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	University of Alberta; University of California System; University of California Berkeley	ROSENBERG, SM (corresponding author), UNIV ALBERTA, FAC MED, DEPT BIOCHEM, EDMONTON T6G 2H7, AB, CANADA.			Rosenberg, Susan M./0000-0003-1444-473X				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; DEMEREC M, 1962, P NATL ACAD SCI USA, V48, P1696, DOI 10.1073/pnas.48.10.1696; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLEACH FS, 1993, CELL, V75, P1215; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; GRAFEN A, 1988, NATURE, V336, P525, DOI 10.1038/336525b0; HALL BG, 1990, GENETICS, V125, P5; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; HASTINGS PJ, 1992, ENCY IMMUNOLOGY, P602; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAYARAMAN R, 1992, J GENET, V71, P23, DOI 10.1007/BF02927873; Luria SE, 1943, GENETICS, V28, P491; MAGNI GE, 1962, GENETICS, V47, P1097; MAIZELS N, 1991, CELL, V48, P359; MCGILL C, 1993, CURR GENET, V23, P430; Miller J.H., 1992, SHORT COURSE BACTERI, P150; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PASZEWSKI A, 1964, NATURE, V204, P809, DOI 10.1038/204809a0; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; ROSENBERG SM, 1991, BIOCHIMIE, V73, P385, DOI 10.1016/0300-9084(91)90105-A; ROTH J, 1992, GENETICS, V132, P865; ROTHENFLUH H, 1993, TODAYS LIFE SCI, V5, P8; STAHL FW, 1989, NATURE, V355, P112; Steele E.J., 1979, SOMATIC SELECTION AD; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STRAUSS BS, 1992, CANCER RES, V52, P249; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THALER DS, 1994, TRENDS ECOL EVOL, V9, P108, DOI 10.1016/0169-5347(94)90208-9; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; THALER DS, 1990, BACTERIAL CHROMOSOME, P445	35	193	199	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					405	407		10.1126/science.8023163	http://dx.doi.org/10.1126/science.8023163			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023163				2022-12-28	WOS:A1994NW81600043
J	LIU, ZP; GILBERT, W				LIU, ZP; GILBERT, W			THE YEAST KEM1 GENE ENCODES A NUCLEASE SPECIFIC FOR G4 TETRAPLEX DNA - IMPLICATION OF IN-VIVO FUNCTIONS FAR THIS NOVEL DNA-STRUCTURE	CELL			English	Article								We have previously reported the identification of a G4-DNA-dependent nuclease from S. cerevisiae that recognizes a tetrastranded G4-DNA structure and cuts in a single-stranded region 5' to the G4 structure. We purify this activity to homogeneity and show it to be the product of the S. cerevisiae KEM1 gene, which is also known as SEP1, DST2, XRN1, and RAR5. Since a homozygous deletion of the KEM1 gene blocks meiotic cells at the 4N stage, the finding of these G4-dependent DNA binding and cleavage activities for the KEM1 gene product supports the hypothesis that G4-DNA may play a role in meiosis.			LIU, ZP (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, BIOL LABS, CAMBRIDGE, MA 02138 USA.							ASHLEY T, 1993, CYTOGENET CELL GENET, V62, P169, DOI 10.1159/000133464; AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; HAMMONDKOSACK MCU, 1992, NUCLEIC ACIDS RES, V20, P231, DOI 10.1093/nar/20.2.231; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KIM JM, 1990, GENETICS, V126, P799; KIPLING D, 1991, NUCLEIC ACIDS RES, V19, P1385, DOI 10.1093/nar/19.7.1385; KLAPHOLZ S, 1980, GENETICS, V96, P567; KRYSTAL G, 1985, ANAL BIOCHEM, V148, P451, DOI 10.1016/0003-2697(85)90252-0; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LIU ZP, 1993, P NATL ACAD SCI USA, V90, P3157, DOI 10.1073/pnas.90.8.3157; Maxam A M, 1980, Methods Enzymol, V65, P499; MERRIL CR, 1979, P NATL ACAD SCI USA, V76, P4335, DOI 10.1073/pnas.76.9.4335; PEARSON AM, 1993, J BIOL CHEM, V268, P3546; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; SEN D, 1992, METHOD ENZYMOL, V211, P191; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; WHITE MA, 1993, P NATL ACAD SCI USA, V90, P6621, DOI 10.1073/pnas.90.14.6621; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	36	151	153	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	1994	77	7					1083	1092		10.1016/0092-8674(94)90447-2	http://dx.doi.org/10.1016/0092-8674(94)90447-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020096				2022-12-28	WOS:A1994NV42500016
J	SIMPSON, L; MASLOV, DA				SIMPSON, L; MASLOV, DA			RNA EDITING AND THE EVOLUTION OF PARASITES	SCIENCE			English	Editorial Material							KINETOPLAST DNA; TRYPANOSOMA-EQUIPERDUM; RIBOSOMAL-RNA; GUIDE RNAS; MITOCHONDRIA; EVANSI; GENE; TRANSCRIPTS; MINICIRCLES; SEQUENCES		UNIV CALIF LOS ANGELES,DEPT MED MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	SIMPSON, L (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT BIOL,LOS ANGELES,CA 90024, USA.							ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BAKER JR, 1973, PARASITIC PROTOZOA; BENNE R, 1992, MOL BIOL REP, V16, P217, DOI 10.1007/BF00419661; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BORST P, 1987, MOL BIOCHEM PARASIT, V23, P31, DOI 10.1016/0166-6851(87)90184-8; BORST P, 1991, TRENDS GENET, V7, P139, DOI 10.1016/0168-9525(91)90374-Y; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CORELL RA, 1993, NUCLEIC ACIDS RES, V21, P4313, DOI 10.1093/nar/21.18.4313; COVELLO PS, 1993, TRENDS GENET, V9, P265, DOI 10.1016/0168-9525(93)90011-6; DERR LK, 1993, NATURE, V361, P170, DOI 10.1038/361170a0; FERNANDES AP, 1993, P NATL ACAD SCI USA, V90, P11608, DOI 10.1073/pnas.90.24.11608; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FRASCH ACC, 1980, BIOCHIM BIOPHYS ACTA, V607, P397, DOI 10.1016/0005-2787(80)90150-1; HAJDUK SL, 1993, FASEB J, V7, P54, DOI 10.1096/fasebj.7.1.8422975; LAKE JA, 1988, P NATL ACAD SCI USA, V85, P4779, DOI 10.1073/pnas.85.13.4779; LAMBRECHT FL, 1980, P AM PHILOS SOC, V124, P367; LANDWEBER LF, 1994, P NATL ACAD SCI USA, V91, P918, DOI 10.1073/pnas.91.3.918; LANDWEBER LF, 1993, NATURE, V363, P179, DOI 10.1038/363179a0; LANDWEBER LF, 1992, BIOSYSTEMS, V28, P41, DOI 10.1016/0303-2647(92)90006-K; LEE ST, 1994, MOL CELL BIOL, V14, P587, DOI 10.1128/MCB.14.1.587; Leger L, 1904, CR SOC BIOL, V56, P615; LUN ZR, 1992, MOL BIOCHEM PARASIT, V50, P189, DOI 10.1016/0166-6851(92)90215-6; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; MASLOV DA, 1994, NATURE, V368, P345, DOI 10.1038/368345a0; MASLOV DL, UNPUB; Minchin EA, 1908, Q J MICROSC SCI, V52, P159; SHU HH, 1993, NUCLEIC ACIDS RES, V21, P2951, DOI 10.1093/nar/21.12.2951; Simpson L, 1993, RNA EDITING ALTERATI, P53; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STUART K, 1993, RNA EDITING ALTERATI, P25; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; THIEMANN O, UNPUB; Vickerman K., 1976, P1; WALLACE FG, 1966, EXP PARASITOL, V18, P124, DOI 10.1016/0014-4894(66)90015-4	35	49	49	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1870	1871		10.1126/science.8009214	http://dx.doi.org/10.1126/science.8009214			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009214				2022-12-28	WOS:A1994NT84700028
J	BRETELER, MMB; CLAUS, JJ; GROBBEE, DE; HOFMAN, A				BRETELER, MMB; CLAUS, JJ; GROBBEE, DE; HOFMAN, A			CARDIOVASCULAR-DISEASE AND DISTRIBUTION OF COGNITIVE FUNCTION IN ELDERLY PEOPLE - THE ROTTERDAM STUDY	BRITISH MEDICAL JOURNAL			English	Article							MINI-MENTAL-STATE; ARTERIAL-DISEASE; SENILE DEMENTIA; POPULATION	Objective-To investigate the distribution of cognitive function in elderly people and to assess the impact of clinical manifestations of atherosclerotic disease on this distribution. Design-Single centre population based cross sectional door to door study. Setting--Ommoord, a suburb of Rotterdam, the Netherlands. Subjects-4971 subjects aged 55 to 94 years. Main outcome measure-Cognitive function as measured by the mini mental state examination. Results-The overall participation rate in the study was 80%. Cognitive test data were available for 90% of the participants. Increasing age and lower educational level were associated with poorer cognitive function. Previous vascular events, presence of plaques in the carotid arteries, and presence of peripheral arterial atherosclerotic disease were associated with worse cognitive performance independent of the effects of age and education. On average the differences were moderate; however, they reflected the net result of a shift of the total population distribution of cognitive function towards lower values. Thereby, they resulted in a considerable increase in the proportion of subjects with scores indicative of dementia. Conclusions-These findings are compatible with the view that atherosclerotic disease accounts for considerable cognitive impairment in the general population.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT NEUROL,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	BRETELER, MMB (corresponding author), ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS.		Grobbee, Diederick/C-7651-2014; Breteler, Monique M.B./J-5058-2014	Grobbee, Diederick/0000-0003-4472-4468; Breteler, Monique M.B./0000-0002-0626-9305				BRAYNE C, 1988, LANCET, V1, P1265; BRAYNE C, 1990, AGE AGEING, V19, P91, DOI 10.1093/ageing/19.2.91; BRETELER MMB, 1992, NEUROEPIDEMIOLOGY, V11, P23, DOI 10.1159/000110957; DEWEY ME, 1990, CASE FINDING DEMENTI; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; HACHINSKI V, 1992, LANCET, V340, P645; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; RAPP PR, 1992, TRENDS NEUROSCI, V15, P340, DOI 10.1016/0166-2236(92)90051-9; ROMAN GC, 1987, JAMA-J AM MED ASSOC, V258, P1782, DOI 10.1001/jama.258.13.1782; Rose G., 1992, STRATEGY PREVENTIVE; Rothman K, 1986, MODERN EPIDEMIOLOGY; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; SCHERR PA, 1988, AM J EPIDEMIOL, V128, P1084; SCHROLL M, 1981, J CHRON DIS, V34, P261, DOI 10.1016/0021-9681(81)90031-X; STEWART RB, 1991, GERONTOLOGY, V37, P2272; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; VOGT MT, 1992, J CLIN EPIDEMIOL, V45, P529, DOI 10.1016/0895-4356(92)90102-S; 1987, SOI1978 NETH CENTR B	20	419	427	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1604	1608		10.1136/bmj.308.6944.1604	http://dx.doi.org/10.1136/bmj.308.6944.1604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025427	Green Published			2022-12-28	WOS:A1994NT52800018
J	MOORE, JK; NEITHERCUT, WD; MELLORS, AS; MANNING, D; MAKIN, CA; JONES, H; ALMAN, RJ; ALBACHARI, M				MOORE, JK; NEITHERCUT, WD; MELLORS, AS; MANNING, D; MAKIN, CA; JONES, H; ALMAN, RJ; ALBACHARI, M			MAKING THE NEW-DEAL FOR JUNIOR DOCTORS HAPPEN	BRITISH MEDICAL JOURNAL			English	Article							PREREGISTRATION HOUSE OFFICERS; THAMES REGIONS; EDUCATION	How can the new deal for juniors be implemented in today's overstretched health service? How do you get clinicians and management to work together? On the Wirral falling house officer morale and recruitment stimulated a new approach, action learning, which proved to be highly successful. Action learning is not a new approach in management terms, but it is rarely used in the health service. Guided by an experienced facilitator, a group of people learn management skills by exploring and resolving practical problems relevant to them. A group of general practitioners and consultants used action learning to teach themselves more about management and at the same time to make changes which addressed many of the junior doctors' difficulties and solved the hospital recruiting problem.	YORKSHIRE HLTH,HARROGATE HG1 5AH,N YORKSHIRE,ENGLAND		MOORE, JK (corresponding author), WIRRAL HOSP NATL HLTH SERV TRUST,WIRRAL L49 5PE,MERSEYSIDE,ENGLAND.							ALLEN I, 1989, BRIT J HOSP MED, V42, P95; DENT THS, 1990, BRIT MED J, V300, P713, DOI 10.1136/bmj.300.6726.713; FIRTHCOZENS J, 1989, BRIT J HOSP MED, V41, P161; GILLARD JH, 1993, BRIT MED J, V307, P1176, DOI 10.1136/bmj.307.6913.1176; GRANT J, 1989, POSTGRAD MED J, V65, P869, DOI 10.1136/pgmj.65.770.869; PAICE E, 1994, BRIT J HOSP MED, V51, P370; Pedler M., 1983, ACTION LEARNING PRAC; ROBERTS J, 1990, BRIT MED J, V302, P225; WILSON DH, 1993, BRIT MED J, V306, P194, DOI 10.1136/bmj.306.6871.194; 1991, JUNIOR DOCTORS NEW D; 1992, RECOMMENDATIONS GENE; 1990, PREREGISTRATION YEAR	12	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1553	1555		10.1136/bmj.308.6943.1553	http://dx.doi.org/10.1136/bmj.308.6943.1553			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019316	Green Published			2022-12-28	WOS:A1994NR11000030
J	PEEL, NFA; BARRINGTON, NA; SMITH, TWD; EASTELL, R				PEEL, NFA; BARRINGTON, NA; SMITH, TWD; EASTELL, R			DISTAL FOREARM FRACTURE AS RISK FACTOR FOR VERTEBRAL OSTEOPOROSIS	BRITISH MEDICAL JOURNAL			English	Article									UNIV SHEFFIELD,DEPT HUMAN METAB & CLIN BIOCHEM,SHEFFIELD,ENGLAND; NO GEN HOSP,DEPT DIAGNOST IMAGING,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; NO GEN HOSP,DEPT ORTHOPAED,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND	University of Sheffield; Northern General Hospital; Northern General Hospital			Eastell, Richard/G-5851-2011	Eastell, Richard/0000-0002-0323-3366				KLEINBAUM DJ, 1978, APPLIED REGRESSION A; OWEN RA, 1982, CLIN ORTHOPAEDICS, V171, P37; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919	4	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1543	1544		10.1136/bmj.308.6943.1543	http://dx.doi.org/10.1136/bmj.308.6943.1543			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019311	Green Published			2022-12-28	WOS:A1994NR11000024
J	LIVINGSTONE, J; AXTON, RA; GILFILLAN, A; MENNIE, M; COMPTON, M; LISTON, WA; CALDER, AA; GORDON, AJ; BROCK, DJH				LIVINGSTONE, J; AXTON, RA; GILFILLAN, A; MENNIE, M; COMPTON, M; LISTON, WA; CALDER, AA; GORDON, AJ; BROCK, DJH			ANTENATAL SCREENING FOR CYSTIC-FIBROSIS - A TRIAL OF THE COUPLE MODEL	BRITISH MEDICAL JOURNAL			English	Article							INFORMATION LEAFLET; NON-PATERNITY; POPULATION; MUTATIONS; CARRIERS	Objective-To assess the delivery and acceptability of antenatal couple screening for cystic fibrosis. Carrier status was notified only when both members of a partnership had cystic fibrosis alleles and therefore a one in four risk of having an affected child. Design-Mouthwash samples were tested when both partners participated. Results were returned only to positive couples. Setting-Two large maternity hospitals in Edinburgh. Subjects-Screening was offered to all couples who booked at one of the two hospitals. Main outcome measures-(a) The take up of screening, carriers and carrier couples identified, take up of prenatal diagnosis, and numbers of affected fetuses detected; (b) questionnaire measures of patient satisfaction and stress. Results-Screening was offered to 8536 couples. 714 (8.4%) were regarded as ineligible, usually because of late booking or absence of a partner. 1900 (24.3%) of the remainder declined screening. Among the 5922 screened couples, four tested positive-that is, both partners were cystic fibrosis heterozygotes. Ah four elected to have prenatal diagnosis. There were three terminations of pregnancy because of an affected fetus, one couple having two successive pregnancies with affected fetuses. The participation rate was 76% for eligible couples (5922/7822) and 69% for all couples (5922/8536). Only 89 screened couples (1.5%) requested information on individual carrier status. No anxiety was detected among a cohort of the screened population, and 99% of questioned participants expressed satisfaction with the concept of couple screening. Conclusions-Antenatal couple screening is a satisfactory and acceptable way of screening for cystic fibrosis and has been adopted as routine in the two trial hospitals.	UNIV EDINBURGH,WESTERN GEN HOSP,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT OBSTET & GYNAECOL,EDINBURGH EH3 9EW,SCOTLAND	University of Edinburgh; University of Edinburgh								BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BROCK DJH, 1991, LANCET, V338, P1151, DOI 10.1016/0140-6736(91)92013-R; FERRIE RM, 1992, AM J HUM GENET, V51, P251; GILFILLAN A, 1994, CLIN CHEM, V40, P197; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; Holland WW, 1990, SCREENING HLTH CARE; HOLLOWAY SH, IN PRESS J MED SCREE; KABACK MM, 1977, TAY SACHS DISEASE SC, P13; LEROUX MG, 1992, LANCET, V340, P607, DOI 10.1016/0140-6736(92)92139-7; LIVINGSTONE J, 1993, CLIN GENET, V43, P57, DOI 10.1111/j.1399-0004.1993.tb04427.x; MACINTYRE S, 1991, LANCET, V338, P869, DOI 10.1016/0140-6736(91)91513-T; MENNIE M, 1993, CLIN GENET, V44, P102; MENNIE ME, 1993, J MED GENET, V30, P543, DOI 10.1136/jmg.30.7.543; MENNIE ME, 1992, J MED GENET, V29, P308, DOI 10.1136/jmg.29.5.308; MENNIE ME, 1993, PRENATAL DIAG, V13, P807, DOI 10.1002/pd.1970130904; MENNIE ME, 1992, LANCET, V340, P14; MODELL B, 1984, CLIN APPROACH THALAS, P354; SHARP DJ, 1988, PSYCHOL MED, V18, P503, DOI 10.1017/S0033291700008047; SHRIMPTON AE, 1991, J MED GENET, V28, P317, DOI 10.1136/jmg.28.5.317; SUPER M, 1992, LANCET, V340, P490, DOI 10.1016/0140-6736(92)91816-Q; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504	22	62	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1459	1462		10.1136/bmj.308.6942.1459	http://dx.doi.org/10.1136/bmj.308.6942.1459			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019277	Green Published			2022-12-28	WOS:A1994NQ22900012
J	STEIN, PD; HULL, RD; RASKOB, G				STEIN, PD; HULL, RD; RASKOB, G			RISKS FOR MAJOR BLEEDING FROM THROMBOLYTIC THERAPY IN PATIENTS WITH ACUTE PULMONARY-EMBOLISM - CONSIDERATION OF NONINVASIVE MANAGEMENT	ANNALS OF INTERNAL MEDICINE			English	Article						PULMONARY EMBOLISM; HEMORRHAGE; THROMBOLYTIC THERAPY; ANGIOGRAPHY; ALTEPLASE	CONTINUOUS INTRAVENOUS HEPARIN; TISSUE PLASMINOGEN-ACTIVATOR; PROXIMAL-VEIN THROMBOSIS; PERFUSION LUNG SCANS; RANDOMIZED TRIAL; SUBCUTANEOUS HEPARIN; VENOUS THROMBOSIS; INITIAL TREATMENT; ALTEPLASE; UROKINASE	Objective: To assess the relative risks for bleeding with thrombolytic therapy in patients who are managed using pulmonary angiograms compared with those managed using noninvasive tests, primarily the ventilation-perfusion lung scan. Design: A decision analysis based on data from other studies. Methods: The risk for major bleeding in patients with pulmonary embolism who receive thrombolytic therapy after a noninvasive diagnosis was assessed from complications of thrombolytic therapy in patients with myocardial infarction, assuming that the same risk ratio for major bleeding when comparing an invasive with a noninvasive approach applied to patients with pulmonary embolism. The risk ratio was 3.3 (95% CI, 1.5 to 9.8) for major bleeding in patients with myocardial infarction. One or more major complications of pulmonary angiography occurred in 1.3% of patients (CI, 0.6% to 1.9%). Results: The average reported risk was 14% (18 of 129 patients) (CI, 7.9% to 20.1%) for major bleeding in patients who had pulmonary angiography before receiving tissue plasminogen activator (tPA). The estimated risk was 4.2% (estimated CI, 1.4% to 9.3%) for major bleeding with tPA after a noninvasive diagnosis of pulmonary embolism. Assuming a risk of 1.3% for major complications from pulmonary angiography, a risk for major hemorrhage of 14.0% for an invasive diagnosis, and a risk of 4.2% for a noninvasive diagnosis, fewer complications would occur with noninvasive management if the prevalence of pulmonary embolism exceeded 21%. Conclusion: Among patients with suspected pulmonary embolism who are candidates for thrombolytic therapy, it is safer to use noninvasive diagnostic tests in many patients.	HENRY FORD HEART & VASC INST, DETROIT, MI USA	Henry Ford Health System								[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1990, CHEST, V97, P528; CALIFF RM, 1988, AM J MED, V85, P353, DOI 10.1016/0002-9343(88)90586-4; DALLAVOLTA S, 1992, J AM COLL CARDIOL, V20, P520, DOI 10.1016/0735-1097(92)90002-5; DOYLE DJ, 1987, ANN INTERN MED, V107, P441, DOI 10.7326/0003-4819-107-4-441; GOLDHABER SZ, 1992, J AM COLL CARDIOL, V20, P24, DOI 10.1016/0735-1097(92)90132-7; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; GOLDHABER SZ, 1988, LANCET, V2, P293; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; HUNT D, 1992, LANCET, V339, P753; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; LEVINE M, 1990, CHEST, V98, P1473, DOI 10.1378/chest.98.6.1473; LEVINE MN, 1992, CHEST, V102, pS364, DOI 10.1378/chest.102.4_Supplement.364S; MARINI C, 1988, RESPIRATION, V54, P162, DOI 10.1159/000195517; PATIL S, 1993, CHEST, V104, P1685, DOI 10.1378/chest.104.6.1685; PINI M, 1990, THROMB HAEMOSTASIS, V64, P222; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P176; STEIN PD, 1993, CHEST, V104, P1472, DOI 10.1378/chest.104.5.1472; STEIN PD, 1993, CHEST, V104, P1468, DOI 10.1378/chest.104.5.1468; STEINPD, 1992, CIRCULATION, V85, P462; STEINPD, 1993, CHEST, V104, P1461; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VERSTRAETE M, 1988, CIRCULATION, V77, P353, DOI 10.1161/01.CIR.77.2.353; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x	28	76	79	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					313	317		10.7326/0003-4819-121-5-199409010-00001	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042819				2022-12-28	WOS:A1994PD70100001
J	ADJORLOLOJOHNSON, G; DECOCK, KM; EKPINI, E; VETTER, KM; SIBAILLY, T; BRATTEGAARD, K; YAVO, D; DOORLY, R; WHITAKER, JP; KESTENS, L; OU, CY; GEORGE, JR; GAYLE, HD				ADJORLOLOJOHNSON, G; DECOCK, KM; EKPINI, E; VETTER, KM; SIBAILLY, T; BRATTEGAARD, K; YAVO, D; DOORLY, R; WHITAKER, JP; KESTENS, L; OU, CY; GEORGE, JR; GAYLE, HD			PROSPECTIVE COMPARISON OF MOTHER-TO-CHILD TRANSMISSION OF HIV-1 AND HIV-2 IN ABIDJAN, IVORY-COAST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; COTE-DIVOIRE; VERTICAL TRANSMISSION; PERINATAL TRANSMISSION; WEST-AFRICA; INFECTION; WOMEN; INFANTS; BISSAU; EPIDEMIOLOGY	Objective.-To compare mother-to-child transmission of human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2, respectively) and to assess the impact of maternal HIV-1 and HIV-2 infections on child survival. Design.-Prospective cohort study. Setting-Maternal and child health center in a lower socioeconomic class district of Abidjan, Ivory Coast. Participants.-A total of 18 099 women delivering between 1990 and 1992 were tested for HIV-1 and HIV-2 antibodies. A cohort of 613 pregnant women and their infants was followed prospectively (138 women reactive to HIV-1, 132 reactive to HIV-2, 69 reactive to both viruses, and 274 HIV-seronegative). Main Outcome Measures.-Rates of perinatal transmission for HIV-1, HIV-2, and both viruses, determined from results of serological and polymerase chain reaction tests on children; survival of infants born to HIV-1-positive, HIV-2-positive, dually reactive, and HIV-seronegative women. Results-Of the 18 099 women tested, 9.4% were reactive to HIV-1 alone, 1.6% to HIV-2 alone, and 1.0% to both viruses. The rate of perinatal transmission of HIV-1 was 24.7% (95% confidence interval [Cl], 15.8% to 33.7%), compared with 1.2% (95% Cl, 0.0% to 3.5%) for HIV-2 (relative risk, 21.3; 95% Cl, 2.9 to 154.3). Overall, 19.0% (95% Cl, 9.0% to 29.0%) of infants of dually reactive women became infected; of the 11 children concerned, 10 were infected with HIV-1 and one with HIV-1 and HIV-2. Infants of HIV-seropositive mothers had a reduced survival; mortality rates were 15.1, 13.0, 6.5, and 3.4 deaths per 100 child-years, respectively, for children of HIV-1-positive, dually reactive, HIV-2-positive, and HIV-seronegative women. Conclusions-The rate of perinatal transmission of HIV-2 (1.2%) was much lower than the rate of perinatal transmission of HIV-1 (24.7%), and this was associated with more favorable survival for infants of HIV-2-infected mothers. Dually reactive women could transmit both viruses, although transmission usually involved HIV-1 only. Public health guidelines should incorporate advice that perinatal transmission of HIV-2 is rare.	PROJET RETRO CI,ABIDJAN,COTE IVOIRE; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341; EMORY UNIV,SCH PUBL HLTH,ATLANTA,GA; INST TROP MED,DEPT IMMUNOL,B-2000 ANTWERP,BELGIUM	Centers for Disease Control & Prevention - USA; Emory University; Institute of Tropical Medicine (ITM)								ANDIMAN WA, 1990, AM J DIS CHILD, V144, P758, DOI 10.1001/archpedi.1990.02150310026020; ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; BLANCHE S, 1994, NEW ENGL J MED, V330, P308, DOI 10.1056/NEJM199402033300502; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DECOCK KM, 1994, BMJ-BRIT MED J, V308, P441, DOI 10.1136/bmj.308.6926.441; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1991, AIDS, V5, pS21; DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083; DELMISTRO A, 1992, J ACQ IMMUN DEF SYND, V5, P19; GABIANO C, 1992, PEDIATRICS, V90, P369; GAYLE HD, 1992, J ACQ IMMUN DEF SYND, V5, P513; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; GNAORE E, 1989, LANCET, V2, P408; HALSEY NA, 1990, JAMA-J AM MED ASSOC, V264, P2088, DOI 10.1001/jama.264.16.2088; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; KANKI PJ, 1987, AIDS, V1, P141; KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006; LEISENRING W, 1992, 8TH INT C AIDS 3RD S; LEPAGE P, 1993, AM J EPIDEMIOL, V137, P589, DOI 10.1093/oxfordjournals.aje.a116716; MATHERON S, 1990, LANCET, V335, P1103, DOI 10.1016/0140-6736(90)92682-8; MORGAN G, 1990, AIDS, V4, P879, DOI 10.1097/00002030-199009000-00008; MOUDOUB Y, 1993, 9TH INT C AIDS AFF 4; NEWELL M-L, 1990, AIDS (London), V4, pS111; NGBICHI JM, 1991, 7TH INT C AIDS FLOR; OBRIEN TR, 1992, JAMA-J AM MED ASSOC, V267, P2775; PEETERS M, 1992, LANCET, V340, P339, DOI 10.1016/0140-6736(92)91407-Y; PEPIN J, 1991, AIDS, V5, P69, DOI 10.1097/00002030-199101000-00010; POULSEN AG, 1989, LANCET, V1, P827, DOI 10.1016/S0140-6736(89)92281-2; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; RYDER RW, 1991, AIDS, V5, pS75; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SIMON F, 1993, AIDS, V7, P1411, DOI 10.1097/00002030-199311000-00002; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; 1992, LANCET, V339, P1007	36	154	164	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					462	466		10.1001/jama.272.6.462	http://dx.doi.org/10.1001/jama.272.6.462			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040982				2022-12-28	WOS:A1994PA27800028
J	DECOCK, KM; EKPINI, E; GNAORE, E; KADIO, A; GAYLE, HD				DECOCK, KM; EKPINI, E; GNAORE, E; KADIO, A; GAYLE, HD			THE PUBLIC-HEALTH IMPLICATIONS OF AIDS RESEARCH IN AFRICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; SEXUALLY-TRANSMITTED DISEASES; HIV-INFECTION; COTE-DIVOIRE; RISK-FACTORS; CROSS-REACTIVITY; CASE-DEFINITION; IVORY-COAST; TRANSMISSION	The human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic has led to greatly increased international collaboration for medical research, mainly epidemiologic in nature, in Africa. Greater understanding of HIV/AIDS has resulted, and considerable training and technology transfer have occurred. However, analytic and descriptive research in countries heavily affected by AIDS has been slow to turn to assessment of interventions, and practical benefits to those countries' public health and policies have lagged behind scientific knowledge. This article considers the public health implications of selected HIV/AIDS research in sub-Saharan Africa and discusses opportunities for interventions and more applied research. Topics covered include HIV testing and its role, surveillance, control of sexually transmitted diseases, the vulnerability of youth and women, tuberculosis, HIV/AIDS care, and the inadequacy of resources currently committed to HIV/AIDS prevention and control in resource-poor countries. Research on HIV/AIDS in Africa has yielded crucial information but now should prioritize interventions and their evaluation. Specific goals that might limit the effects of the HIV/AIDS epidemic in resource-poor countries are achievable given vision, commitment, and resources.	PROJET RETRO CI,ABIDJAN,COTE IVOIRE; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341; NATL AIDS CONTROL PROGRAMME,ABIDJAN,COTE IVOIRE; CHU TREICHVILLE,INFECT DIS SERV,ABIDJAN,COTE IVOIRE	Centers for Disease Control & Prevention - USA								ACKAH A, 1993, 9TH INT C AIDS BERL; ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; AIDS S, 1991, PLUM, V5, pS65; AISU T, 1993, 9TH INT C AIDS BERL; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; ANCELLEPARK R, 1993, LANCET, V341, P441, DOI 10.1016/0140-6736(93)93040-8; ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; [Anonymous], 1993, Wkly Epidemiol Rec, V68, P361; BARRY M, 1988, NEW ENGL J MED, V319, P1083, DOI 10.1056/NEJM198810203191609; BATTER V, 1993, 9TH INT C AIDS BERL; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; BRATTEGAARD K, 1993, AIDS, V7, P883, DOI 10.1097/00002030-199306000-00019; BUEHLER JW, 1993, AIDS, V7, pS73, DOI 10.1097/00002030-199301001-00010; CAMERON D W, 1990, AIDS (London), V4, pS99; CAMERON DW, 1989, LANCET, V2, P403; CHIN J, 1990, AIDS (London), V4, pS277, DOI 10.1097/00002030-199001001-00045; CHIN J, 1990, B WORLD HEALTH ORGAN, V68, P529; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; DECOCK KM, 1991, AIDS, V5, P859, DOI 10.1097/00002030-199107000-00010; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1991, AIDS, V5, pS21; DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083; DECOCK KM, 1993, LANCET, V342, P437, DOI 10.1016/0140-6736(93)92853-L; DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DECOCK KM, 1989, LANCET, V2, P408; DECOCK KM, 1993, AM J PUBLIC HEALTH, V83, P1385, DOI 10.2105/AJPH.83.10.1385; DECOCK KM, 1991, BMJ-BRIT MED J, V303, P1185, DOI 10.1136/bmj.303.6811.1185; DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; DIALLO MO, 1992, AIDS, V6, P581, DOI 10.1097/00002030-199206000-00010; ECKHOLM E, 1991, NY TIMES        1029, pB6; EVANS LA, 1988, LANCET, V2, P1389; GARNETT GP, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90522-R; GAYLE HD, 1992, J ACQ IMMUN DEF SYND, V5, P513; GELBER RD, 1994, EXECUTIVE SUMMARY AC; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; GHIJS P, 1993, 9TH INT C AIDS BERL; GRANT J, 1994, STATE WORLDS CHILDRE, P69; GURTLER LG, 1994, J VIROL, V68, P1581; HEYMANN DL, 1990, AIDS, V4, P469, DOI 10.1097/00002030-199005000-00017; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; LACKRITZ EM, 1993, 9 INT C AIDS BERL; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LAGA M, 1991, AIDS, V5, pS55; LAGA M, IN PRESS AIDS; LEPAGE P, 1993, AM J EPIDEMIOL, V137, P589, DOI 10.1093/oxfordjournals.aje.a116716; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; LUCAS SB, 1994, BRIT MED J, V308, P1531, DOI 10.1136/bmj.308.6943.1531; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MANN J, 1992, AIDS WORLD, P421; MBOUP S, 1991, AIDS, V5, pS93; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; MUREKEZI C, 1993, 9TH INT C AIDS BERL; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; MWINGA AG, 1993, TUBERCULOSIS BACK FU, P166; NELSON AM, 1991, AIDS, V5, P583, DOI 10.1097/00002030-199105000-00018; NTITA I, 1991, AIDS, V5, P437, DOI 10.1097/00002030-199104000-00013; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PIOT P, 1990, J ACQ IMMUN DEF SYND, V3, P403; PIOT P, 1987, J INFECT DIS, V155, P1108, DOI 10.1093/infdis/155.6.1108; PIOT P, 1991, AIDS, V5, pS1; PIOT P, 1990, HDB AIDS PREVENTION, P1; PLUMMER FA, 1991, AIDS, V5, pS169; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; RICHARDS S, IN PRESS TUBER LUNG; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SAVARIT D, 1992, BRIT MED J, V305, P498, DOI 10.1136/bmj.305.6852.498; SCHULZER M, 1992, TUBERCLE LUNG DIS, V73, P52, DOI 10.1016/0962-8479(92)90080-4; SCHUTZ R, 1993, BRIT MED J, V307, P1517, DOI 10.1136/bmj.307.6918.1517; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SHAPIRO HT, 1990, SCIENCE, V250, P609, DOI 10.1126/science.250.4981.609; SPIELBERG F, 1989, LANCET, V1, P580; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; TAMASHIRO H, 1993, LANCET, V342, P87, DOI 10.1016/0140-6736(93)91289-X; TEDDER RS, 1988, LANCET, V2, P927; TEMMERMAN M, 1992, AIDS, V6, P1181, DOI 10.1097/00002030-199210000-00019; TRAOREETTIEGNE V, 1993, 9 INT C AIDS BERL; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; 1993, 1993 WORLD BANK WORL, P103; 1993, HIV AIDS SURVEILLANC; 1986, WKLY EPIDEMIOL REC, V61, P72; 1993, INVESTING HLTH WORLD, P37; 1993, INVESTING HLTH WORLD, P99; 1994, WKLY EPIDEMIOL REC, V69, P5; 1992, MMWR-MORBID MORTAL W, V41, P1	90	29	29	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					481	486		10.1001/jama.272.6.481	http://dx.doi.org/10.1001/jama.272.6.481			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040984				2022-12-28	WOS:A1994PA27800031
J	ICKOVICS, JR; MORRIL, AC; BEREN, SE; WALSH, U; RODIN, J				ICKOVICS, JR; MORRIL, AC; BEREN, SE; WALSH, U; RODIN, J			LIMITED EFFECTS OF HIV COUNSELING AND TESTING FOR WOMEN - A PROSPECTIVE-STUDY OF BEHAVIORAL AND PSYCHOLOGICAL CONSEQUENCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To assess the consequences of human immunodeficiency virus (HIV) counseling and testing for seronegative women in terms of sexual behavior and psychological outcomes. Design.-The design is prospective and longitudinal, using repeated measures. Participants were interviewed at recruitment, 2 weeks later (when tested women received results), and 3 months later. Setting.-Four community health clinics in southern Connecticut; all provide HIV counseling and testing and other specialized and primary health care services. Study Participants.-A sequential sample of women were recruited for two study groups: those seeking HIV counseling and testing (n=152), and a comparison group never tested for HIV (n=78), matched by clinic, race, and age. Main Outcome Measures.-A composite measure of sexual risk was developed, based on sexual activity, condom use, and partner risk factors. Psychometrically valid and reliable measures of general psychological functioning and acquired immunodeficiency syndrome (AIDS)-specific psychological indicators were also used. Results.-Average level of sexual risk was lower for tested than nontested women at all three interviews. For both groups, there was no significant change in sexual risk from baseline to 3-month follow-up. At the individual level, there was no difference in the number of women who decreased or increased sexual risk. For tested women, intrusive thoughts about AIDS and estimated chance of getting AIDS decreased after counseling and testing. Conclusions.-Behavioral and psychological consequences of HIV counseling and testing for women at risk for HIV were limited. These results have implications for further prevention interventions.	YALE UNIV, DEPT PSYCHOL, NEW HAVEN, CT 06520 USA	Yale University	ICKOVICS, JR (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, POB 208025, SHM IE-61 RWJ CLIN SCHOLARS, NEW HAVEN, CT 06520 USA.							ADIB SM, 1991, AIDS, V5, P757, DOI 10.1097/00002030-199106000-00018; ANTONI MH, 1990, PSYCHOSOM MED, V52, P496, DOI 10.1097/00006842-199009000-00002; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; CATANIA JA, 1992, SCIENCE, V258, P1101, DOI 10.1126/science.1439818; COATES TJ, 1988, AM PSYCHOL, V43, P859, DOI 10.1037/0003-066X.43.11.859; COATES TJ, 1987, JAMA-J AM MED ASSOC, V258, P1889, DOI 10.1001/jama.1987.03400140051006; Cohen J., 1988, STATISTICAL POWER AN, DOI DOI 10.1234/12345678; Crandall R., 1973, MEASURES SOCIAL PSYC, P45; Derogatis L R, 1974, Mod Probl Pharmacopsychiatry, V7, P79; DOLL LS, 1990, HEALTH PSYCHOL, V9, P253, DOI 10.1037/0278-6133.9.3.253; FOX R, 1987, AIDS, V1, P241; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; ICKOVICS JR, 1992, HEALTH PSYCHOL, V11, P1, DOI 10.1037/0278-6133.11.1.1; JACOBSEN PB, 1990, J CONSULT CLIN PSYCH, V58, P31, DOI 10.1037/0022-006X.58.1.31; JOSEPH JG, 1987, J APPL SOC PSYCHOL, V17, P231, DOI 10.1111/j.1559-1816.1987.tb00312.x; KELLY JA, 1990, J CONSULT CLIN PSYCH, V58, P117, DOI 10.1037/0022-006X.58.1.117; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; Ostrow D G, 1989, AIDS Educ Prev, V1, P1; PERRY SW, 1990, AIDS, V4, P145, DOI 10.1097/00002030-199002000-00008; RODIN J, 1989, ANNU REV PSYCHOL, V40, P533, DOI 10.1146/annurev.ps.40.020189.002533; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI DOI 10.1515/9781400876136; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P3567, DOI 10.1001/jama.261.24.3567; Siegel S., 1956, NONPARAMETRIC STAT B; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; WENGER NS, 1991, AM J PUBLIC HEALTH, V81, P1580, DOI 10.2105/AJPH.81.12.1580; WENGER NS, 1992, ANN INTERN MED, V117, P905, DOI 10.7326/0003-4819-117-11-905; WIKTOR SZ, 1990, J ACQ IMMUN DEF SYND, V3, P62; WINOKUR A, 1984, BRIT J PSYCHIAT, V144, P395, DOI 10.1192/bjp.144.4.395; 1992, MMWR-MORBID MORTAL W, V41, P613; 1993, HIV AIDS SURVEILLANC; 1988, 1988 PRES COMM HUM I	35	64	64	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					443	448		10.1001/jama.272.6.443	http://dx.doi.org/10.1001/jama.272.6.443			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA278	8040979				2022-12-28	WOS:A1994PA27800025
J	LYNN, JT				LYNN, JT			TRAVEL	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											LYNN, JT (corresponding author), ARTHRITIS AFFILIATES PC, 801 N CASCADE AVE, SUITE 22, COLORADO SPRINGS, CO 80903 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					231	231		10.7326/0003-4819-121-3-199408010-00011	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017750				2022-12-28	WOS:A1994NY33800011
J	DIEKMANN, D; ABO, A; JOHNSTON, C; SEGAL, AW; HALL, A				DIEKMANN, D; ABO, A; JOHNSTON, C; SEGAL, AW; HALL, A			INTERACTION OF RAC WITH P67(PHOX) AND REGULATION OF PHAGOCYTIC NADPH OXIDASE ACTIVITY	SCIENCE			English	Article							GTP-BINDING-PROTEIN; CELL-FREE SYSTEM; RESPIRATORY BURST; ADP-RIBOSYLATION; GENE-PRODUCT; ACTIVATION; COMPONENTS; RHO; CYTOCHROME-B558; TRANSLOCATION	Rho and Rac, two members of the Ras superfamily of guanosine triphosphate (GIP)-binding proteins, regulate a variety of signal transduction pathways in eukaryotic cells. Upon stimulation of phagocytic cells, Rac enhances the activity of the enzyme nicotinamide adenine dinucleotide phosphate (reduced) (NADPH) oxidase, resulting in the production of superoxide radicals. Activation of the NADPH oxidase requires the assembly of a multimolecular complex at the plasma membrane consisting of two integral membrane proteins, gp91(phox) and p2l(phox), and two cytosolic proteins, p67(phox) and p47(phox). Rac1 interacted directly with p67(phox) in GTP-dependent manner. Modified forms of Rac with mutations in the effector site did not stimulate oxidase activity or bind to p67(phox). Thus, p67(phox) appears to be the Rac effector protein in the NADPH oxidase complex.	UCL, CANC RES CAMPAIGN,ONCOGENE & SIGNAL TRANSDUCT GRP, MRC,MOLEC & CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND; UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND; UCL, DEPT MED, LONDON WC1E 6JJ, ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London				Tapon, Dagmar/0000-0003-3837-4764; Segal, Anthony/0000-0001-7602-9043	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1986, J BIOL CHEM, V261, P963; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; JOUAN A, 1993, BIOCHEM BIOPH RES CO, V197, P1296, DOI 10.1006/bbrc.1993.2618; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MORII N, 1992, J BIOL CHEM, V267, P20921; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1992, J BIOL CHEM, V267, P17327; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SELF AJ, 1993, ONCOGENE, V8, P655; SELF AJ, UNPUB; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	32	352	361	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					531	533		10.1126/science.8036496	http://dx.doi.org/10.1126/science.8036496			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036496				2022-12-28	WOS:A1994NY21600032
J	GILLON, R				GILLON, R			MEDICAL-ETHICS - 4 PRINCIPLES PLUS ATTENTION TO SCOPE	BRITISH MEDICAL JOURNAL			English	Article								The ''four principles plus scope'' approach provides a simple, accessible, and culturally neutral approach to thinking about ethical issues in health care. The approach, developed in the United States, is based on four common, basic prima facie moral commitments-respect for autonomy, beneficence, non-maleficence, and justice-plus concern for their scope of application. It offers a common, basic moral analytical framework and a common, basic moral language. Although they do not provide ordered rules, these principles can help doctors and other health care workers to make decisions when reflecting on moral issues that arise at work.			GILLON, R (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,LONDON SW7 1NA,ENGLAND.							ARISTOTLE, 1941, BASIC WORKS ARISTOTL, V3; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; Bobbitt P., 1978, TRAGIC CHOICES; Gillon R, 1986, PHILOS MED ETHICS; HUNTER DJ, 1993, NAHAT8 NAT ASS HLTH; KLEIN R, 1991, BRIT MED J, V302, P1, DOI 10.1136/bmj.302.6767.1; Lloyd, 1994, PRINCIPLES HLTH CARE; McKeon R., 1941, BASIC WORKS ARISTOTL; Williams Alan, 1994, P829	9	448	457	1	126	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					184	188		10.1136/bmj.309.6948.184	http://dx.doi.org/10.1136/bmj.309.6948.184			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	NY229	8044100	Green Published			2022-12-28	WOS:A1994NY22900028
J	CHOI, KW; BENZER, S				CHOI, KW; BENZER, S			ROTATION OF PHOTORECEPTOR CLUSTERS IN THE DEVELOPING DROSOPHILA EYE REQUIRES THE NEMO GENE	CELL			English	Article							PROTEIN-KINASE; IMAGINAL DISKS; NEURAL DEVELOPMENT; PATTERN-FORMATION; SCATTER FACTOR; CELL-DIVISION; RECEPTOR; TYROSINE; RETINA; PHOSPHORYLATION	The Drosophila eye consists of a reiterative hexagonal array of photoreceptor cell clusters, the ommatidia. During normal morphogenesis, the clusters in the dorsal or ventral halves of the disc rotate 90 degrees in opposite directions, forming mirror images across a dorsoventral equator. In the mutant nemo (nmo), there is an initial turning of approximately 45 degrees, but further rotation is blocked. Genetic mosaic analysis indicates that the nmo gene acts upon each cluster as a whole; normal nmo function in one or more photoreceptor cells appears to be sufficient to induce full rotation. The nmo gene sequence encodes a serine/threonine protein kinase homolog, suggesting that the kinase is required to initiate the second step of rotation. In another mutant, roulette, excessive rotation through varying angles occurs in many ommatidia. This defect is suppressed by nmo, indicating that nmo acts upstream in a rotation-regulating pathway.			CHOI, KW (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Choi, Kwang-Wook/C-1707-2011	Choi, Kwang-Wook/0000-0002-8997-3065	NATIONAL EYE INSTITUTE [R01EY009278] Funding Source: NIH RePORTER; NEI NIH HHS [EY0 9278] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABBOTT MK, 1991, GENETICS, V129, P783; ADLER PN, 1987, DEV GENET, V8, P99, DOI 10.1002/dvg.1020080206; BAIROCH A, 1988, NATURE, V331, P22, DOI 10.1038/331022a0; BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BAKER NE, 1992, J NEUROGENET, V8, P85, DOI 10.3109/01677069209084154; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; DEUCHAR EM, 1971, J EMBRYOL EXP MORPH, V25, P189; Dietrich W, 1909, Z WISS ZOOL ABT A, V92, P465; DUERR B, 1993, PLANT CELL, V5, P87, DOI 10.1105/tpc.5.1.87; ENGELS WR, 1986, FOCUS, V8, P6; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; FRISTROM D, 1976, DEV BIOL, V54, P163, DOI 10.1016/0012-1606(76)90296-7; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Gleichauf R, 1936, Z WISS ZOOL ABT A, V148, P1; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; HAMILTON L, 1969, J EMBRYOL EXP MORPH, V22, P253; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HIME G, 1992, DEVELOPMENT, V114, P165; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; ITOH N, 1986, P NATL ACAD SCI USA, V83, P4081, DOI 10.1073/pnas.83.11.4081; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; Sambrook J, 1989, MOL CLONING LABORATO; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEISEN H, 1994, DEVELOPMENT, V120, P347; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WHITE K, 1978, DEV BIOL, V65, P298; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	53	157	159	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					125	136		10.1016/0092-8674(94)90579-7	http://dx.doi.org/10.1016/0092-8674(94)90579-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033204				2022-12-28	WOS:A1994NX32800015
J	KIEHLBAUCH, JA; TAUXE, RV; BAKER, CN; WACHSMUTH, IK				KIEHLBAUCH, JA; TAUXE, RV; BAKER, CN; WACHSMUTH, IK			HELICOBACTER CINAEDI-ASSOCIATED BACTEREMIA AND CELLULITIS IN IMMUNOCOMPROMISED PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article							CAMPYLOBACTER-LIKE ORGANISMS; HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL MEN	Objective: To define the clinical spectrum of illness associated with Helicobacter cinaedi infection in the United States and to determine associated epidemiologic risk factors and optimal laboratory methods for recovery of H. cinaedi. Design: A retrospective epidemiologic study of 23 patients with H. cinaedi-associated illness. Patients: 23 patients with H. cinaedi infection identified between January 1982 and August 1990. Most isolates (22 of 23) were from blood; one was from stool. Results: Ages ranged from 24 to 84 years (mean, 44 years). Eighty-three percent of patients were men; 17% were women. Clinical and laboratory data were obtained from 21 patients. Eighteen patients were febrile (15 required hospitalization); cellulitis was reported in 9 patients. Sixty percent were immunocompromised; 45% were reported to be seropositive for human immunodeficiency virus (HIV). For bacteremic patients, positive blood cultures were detected by a slightly elevated growth index in an automated blood culture system; many hospital laboratories had difficulty isolating the organism. Conclusions: Helicobacter cinaedi appears to cause recurrent cellulitis with fever and bacteremia in immunocompromised hosts. Blood cultures from immunocompromised patients with these symptoms may need special handling to isolate H. cinaedi.			KIEHLBAUCH, JA (corresponding author), CTR DIS CONTROL & PREVENT, FOOD & DIARRHEAL DIS BRANCH, MAILSTOP CO3, ATLANTA, GA 30333 USA.							CIMOLAI N, 1987, J CLIN MICROBIOL, V25, P942, DOI 10.1128/JCM.25.5.942-943.1987; DECKER CF, 1992, CLIN INFECT DIS, V15, P178, DOI 10.1093/clinids/15.1.178-a; FLORES BM, 1985, ANTIMICROB AGENTS CH, V28, P188, DOI 10.1128/AAC.28.2.188; GEBHART CJ, 1989, J CLIN MICROBIOL, V27, P1692, DOI 10.1128/JCM.27.7.1692-1694.1989; GRAYSON ML, 1989, MED J AUSTRALIA, V150, P214; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; LAUGHON BE, 1988, J INFECT DIS, V158, P464, DOI 10.1093/infdis/158.2.464; NG VL, 1987, J CLIN MICROBIOL, V25, P2008, DOI 10.1128/JCM.25.10.2008-2009.1987; PASTERNAK J, 1984, ANN INTERN MED, V101, P339, DOI 10.7326/0003-4819-101-3-339; QUINN TC, 1984, ANN INTERN MED, V101, P187, DOI 10.7326/0003-4819-101-2-187; SACKS LV, 1991, REV INFECT DIS, V13, P1066; VANDAMME P, 1990, J CLIN MICROBIOL, V28, P1016, DOI 10.1128/JCM.28.5.1016-1020.1990	12	101	104	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					90	93		10.7326/0003-4819-121-2-199407150-00002	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00002			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017741				2022-12-28	WOS:A1994NW18600002
J	DOYAL, L; WILSHER, D				DOYAL, L; WILSHER, D			WITHHOLDING AND WITHDRAWING LIFE-SUSTAINING TREATMENT FROM ELDERLY PEOPLE - TOWARDS FORMAL GUIDELINES	BRITISH MEDICAL JOURNAL			English	Article							ETHICS	Clinicians often decide either to withhold or to withdraw lifesaving treatment in elderly patients. Considerable disagreement exists about the circumstances in which such actions can be defended. Debates about the scarcity of resources in the NHS add urgency to the need to resolve this disagreement. Competent elderly patients have a legal and moral right to decide whether to receive life sustaining treatment. Such treatment should not be withheld or withdrawn on the basis of a patient's age alone. Principles for making decisions about Life sustaining treatment in incompetent elderly patients can be defended and should exist as written guidelines.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEP HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London	DOYAL, L (corresponding author), LONDON MED COLL,DEPT HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND.							[Anonymous], 1993, LANCET, V342, P1; ASPLUND K, 1989, STROKE, V20, P1107, DOI 10.1161/01.STR.20.8.1107; Buchanan Allen E., 1989, DECIDING OTHERS ETHI; DOYAL L, 1993, BRIT MED J, V306, P1593, DOI 10.1136/bmj.306.6892.1593; DOYAL L, 1990, J LAW SOC, V17, P1, DOI 10.2307/1409951; DOYAL L, 1994, ARCH DIS CHILD, V70, P66; Doyal L., 1991, THEORY HUMAN NEED, DOI DOI 10.1007/978-1-349-21500-3; Dworkin R., 1993, LIFES DOMINION; EVANS JG, 1989, AGE AGEING, V18, P217, DOI 10.1093/ageing/18.4.217; FRASER M, 1987, DEMENTIA ITS NATURE; Harris J., 1985, VALUE LIFE; Parfit Derek., 1984, REASONS PERSONS; RACHELS J., 1986, END LIFE EUTHANASIA; VOLICER L, 1986, JAMA-J AM MED ASSOC, V256, P2210, DOI 10.1001/jama.256.16.2210; Wicclair M., 1993, ETHICS ELDERLY; WILLIAMS F, 1993, BRIT J HOSP MED, V50, P50; 1994, ENSURING EQUITY QUAL; 1994, REPORT; 1988, LIVING WILL CONSENT; 1994, BUTTERWORTHS MEDICOL, V15, P77	20	36	36	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1689	1692		10.1136/bmj.308.6945.1689	http://dx.doi.org/10.1136/bmj.308.6945.1689			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025466	Green Published			2022-12-28	WOS:A1994NU48300031
J	THOROGOOD, M; MANN, J; APPLEBY, P; MCPHERSON, K				THOROGOOD, M; MANN, J; APPLEBY, P; MCPHERSON, K			RISK OF DEATH FROM CANCER AND ISCHEMIC-HEART-DISEASE IN MEAT AND NONMEAT EATERS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VEGETARIAN DIET; HYPERTENSION; CONSUMPTION; LIPIDS	Objective-To investigate the consequences of a vegetarian diet by examining the 12 year mortality of non-meat eaters and meat eating controls. Design-Prospective observational study in which members of the non-meat eating cohort were asked to nominate friends or relatives as controls. Setting-United Kingdom. Subjects-6115 non-meat eaters identified through the Vegetarian Society of the United Kingdom and the news media (mean (SD) age 38.7 (16.8) years) and 5015 controls who were meat eaters (39.3 (15.4) years). Main outcome measures-Standardised mortality ratios for cancer, ischaemic heart disease, and total mortality in the two cohorts and death rate ratio in the non-meat eaters compared with meat eaters after adjustment for potentially confounding variables. Results-Standardised mortality ratios (taking the value among the general population as 100) for ischaemic heart disease were 51 (95% confidence interval 38 to 66) for meat eaters and 28 (20 to 38) for non-meat eaters (P <0.01). Values for all cancers were 80 (64 to 98) and 50 (39 to 62) for meat eaters and non-meat eaters respectively. After adjustment for the effects of smoking, body mass index, and socioeconomic status death rate ratios in non-meat eaters compared with meat eaters were 0.72 (0.47 to 1.10) for ischaemic heart disease and 0.61 (0.44 to 0.84) for all cancers. Conclusions-The reduced mortality from cancer among those not eating meat is not explained by lifestyle related risk factors, which have a low prevalence among vegetarians. No firm conclusion can be made about deaths from ischaemic heart disease. These data do not justify advice to exclude meat from the diet since there are several attributes of a vegetarian diet apart from not eating meat which might reduce the risk.	UNIV OTAGO, DEPT HUMAN NUTR, DUNEDIN, NEW ZEALAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1E 7HT, ENGLAND; UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX2 6HE, ENGLAND	University of Otago; University of London; London School of Hygiene & Tropical Medicine; University of Oxford								BEILIN LJ, 1993, ANN NY ACAD SCI, V676, P83; BURR ML, 1988, AM J CLIN NUTR, V48, P830, DOI 10.1093/ajcn/48.3.830; CHANGCLAUDE J, 1993, INT J EPIDEMIOL, V22, P228, DOI 10.1093/ije/22.2.228; DIPLOCK AT, 1991, AM J CLIN NUTR, V53, pS189, DOI 10.1093/ajcn/53.1.189Sb; DWYER JT, 1991, ANNU REV NUTR, V11, P61, DOI 10.1146/annurev.nu.11.070191.000425; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; GOLDIN BR, 1981, CANCER RES, V41, P3771; GOODMAN G T, 1984, American Journal of Clinical Nutrition, V40, P949, DOI 10.1093/ajcn/40.4.949; HOSTMARK AT, 1993, PLANT FOOD HUM NUTR, V43, P55, DOI 10.1007/BF01088096; MANN J, 1987, AM J CLIN NUTR, V45, P1202, DOI 10.1093/ajcn/45.5.1202; MANN JI, 1993, HUMAN NUTRITION DIET; MANN JJ, 1987, OXFORD TXB MED, V2; MARGETTS BM, 1986, BRIT MED J, V293, P1468, DOI 10.1136/bmj.293.6560.1468; NAIR P P, 1984, American Journal of Clinical Nutrition, V40, P927, DOI 10.1093/ajcn/40.4.927; PHILLIPS RL, 1980, AM J EPIDEMIOL, V112, P296, DOI 10.1093/oxfordjournals.aje.a112996; SANDERS TAB, 1992, EUR J CLIN NUTR, V46, P823; THOROGOOD M, 1987, BMJ-BRIT MED J, V295, P351, DOI 10.1136/bmj.295.6594.351; THOROGOOD M, 1990, BRIT MED J, V300, P1297, DOI 10.1136/bmj.300.6735.1297	18	125	126	1	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 25	1994	308	6945					1667	1670		10.1136/bmj.308.6945.1667	http://dx.doi.org/10.1136/bmj.308.6945.1667			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025458	Green Published			2022-12-28	WOS:A1994NU48300017
J	ANDERSON, HR; BUTLAND, BK; STRACHAN, DP				ANDERSON, HR; BUTLAND, BK; STRACHAN, DP			TRENDS IN PREVALENCE AND SEVERITY OF CHILDHOOD ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; CHILDREN; HEALTH	Objective-To test the null hypothesis that there has been no change in the prevalence or severity of childhood asthma over recent years. Design-Repeated population prevalence survey with questionnaires completed by parents followed by home interviews with parents. Setting-London borough of Croydon, 1978 and 1991. Subjects-All children in one year of state and private primary schools aged 71/2 to 81/2 years at screening survey. Main outcome measures-Trends in symptoms, acute severe attacks, and chronic disability. Results-For 1978 and 1991 respectively, the response rates were 4147/4763 and 3070/3786, and home interviews were obtained from 273/288 and 319/395 parents of currently wheezy children. Between 1978 and 1991 there were significant relative increases in prevalence ratios in the 12 month prevalence of attacks of wheezing or asthma (1.16; 95% confidence interval 1.02 to 1.31), the one month prevalence of wheezing episodes (1.78; 1.15 to 2.74), and the one month prevalence of night waking (1.81; 1.01 to 3.23) but not in frequent (greater than or equal to 5) attacks over the past year (1.05; 0.79 to 1.40). There were substantial and significant decreases in the 12 month prevalence of absence from school of more than 10 days due to wheezing (0.52; 0.30 to 0.90), any days in bed (0.67; 0.93 to 1.01), and restriction of activities at home (0.51; 0.31 to 0.83) and an equivalent but not significant fall in speech limiting attacks (0.51; 0.24 to 1.11). Conclusion-The small increase in the prevalence of wheezy children and relatively greater increase in persistent wheezing suggests a change in the environmental determinants of asthma. In contrast and paradoxically the frequency of wheezing attacks remains unchanged and there are indications that severe attacks and chronic disability have fallen by about half; this may be due to an improvement in treatment received by wheezy children.			ANDERSON, HR (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Anderson, Hugh R/A-7417-2016	Butland, Barbara/0000-0001-9952-3108				ANDERSON HR, 1983, J EPIDEMIOL COMMUN H, V37, P180, DOI 10.1136/jech.37.3.180; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; ANDERSON HR, 1993, PAEDIATRIC RESPIRATO, V1, P6; ANDERSON HR, 1993, THORAX, V48, P451; AYRES JG, 1993, BRIT J GEN PRACT, V43, P361; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; FLANDERS WD, 1987, J CHRON DIS, V40, P697, DOI 10.1016/0021-9681(87)90106-8; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; STRACHAN DP, 1992, BRIT MED J, V304, P873; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; WHINCUP PH, 1993, ARCH DIS CHILD, V68, P729, DOI 10.1136/adc.68.6.729; 1989, SAS STAT USERS GUIDE, V2, P846	16	196	199	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1600	1604		10.1136/bmj.308.6944.1600	http://dx.doi.org/10.1136/bmj.308.6944.1600			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025426	Green Published			2022-12-28	WOS:A1994NT52800017
J	SAWADA, S; SCARBOROUGH, JD; KILLEEN, N; LITTMAN, DR				SAWADA, S; SCARBOROUGH, JD; KILLEEN, N; LITTMAN, DR			A LINEAGE-SPECIFIC TRANSCRIPTIONAL SILENCER REGULATES CD4 GENE-EXPRESSION DURING T-LYMPHOCYTE DEVELOPMENT	CELL			English	Article							CELL-SPECIFIC ENHANCER; TRANSGENIC MICE; EUKARYOTIC PROMOTERS; HOMEODOMAIN PROTEIN; NEGATIVE REGULATION; DROSOPHILA; REPRESSION; YEAST; ELEMENTS; IDENTIFICATION	During development of T lymphocytes, differential regulation of expression of the CD4 and CD8 glycoproteins is coupled to the choice of one of two pathways of differentiation. Thymocytes that express both of these coreceptors commit to either the helper lineage, shutting off CD8, or the cytotoxic lineage, shutting off CD4. We have used transgenic mice to identify an intronic regulatory region that controls CD4 gene expression during development. This region selectively extinguishes transgene expression in CD4(-)CD8(+), but not CD4(+)CD8(-) nor CD4(+)CD8(+) T cells. It also represses gene expression in CD4-CD8- immature thymocytes, indicating that the CD4 gene is derepressed during differentiation from the CD4(-)CD8(-) to the CD4(+)CD8(+) stage. The negative element(s) is both orientation and position independent and acts also on heterologous regulatory sequences. Its properties are functionally similar to those of silencers described in yeast and in Drosophila, suggesting that we have identified a developmentally regulated vertebrate transcriptional silencer.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	SAWADA, S (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA.							BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; Bienz Mariann, 1992, Current Opinion in Cell Biology, V4, P955, DOI 10.1016/0955-0674(92)90124-U; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BLUM MD, 1993, J EXP MED, V177, P1343, DOI 10.1084/jem.177.5.1343; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; FRELS W I, 1990, New Biologist, V2, P1024; GEORGOPOULOS K, 1988, EMBO J, V7, P2401, DOI 10.1002/j.1460-2075.1988.tb03085.x; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HANNA Z, 1994, MOL CELL BIOL, V14, P1084, DOI 10.1128/MCB.14.2.1084; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HOGAN B, 1986, MANIPULATING MOUSE E, P153; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; ISHIDA I, 1990, P NATL ACAD SCI USA, V87, P3067, DOI 10.1073/pnas.87.8.3067; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KILLEEN N, 1993, PHILOS T ROY SOC B, V342, P25, DOI 10.1098/rstb.1993.0131; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LAUSTER R, 1993, EMBO J, V12, P4615, DOI 10.1002/j.1460-2075.1993.tb06150.x; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MULLER J, 1992, EMBO J, V11, P3653, DOI 10.1002/j.1460-2075.1992.tb05450.x; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; RAICH N, 1992, BLOOD, V79, P861; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; SANDS JF, 1992, INT IMMUNOL, V4, P1183, DOI 10.1093/intimm/4.10.1183; SAWADA S, 1991, MOL CELL BIOL, V11, P5506, DOI 10.1128/MCB.11.11.5506; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SAYRE PH, 1987, P NATL ACAD SCI USA, V84, P2941, DOI 10.1073/pnas.84.9.2941; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X	54	360	368	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					917	929		10.1016/0092-8674(94)90140-6	http://dx.doi.org/10.1016/0092-8674(94)90140-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004678				2022-12-28	WOS:A1994NT33100016
J	NICKENS, HW; READY, TP; PETERSDORF, RG				NICKENS, HW; READY, TP; PETERSDORF, RG			PROJECT-3000 BY 2000 - RACIAL AND ETHNIC DIVERSITY IN US MEDICAL-SCHOOLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MINORITY-STUDENTS; PROFESSIONS; PROGRAM; SCIENCE; FUTURE				NICKENS, HW (corresponding author), ASSOC AMER MED COLL,WASHINGTON,DC 20037, USA.							BUTLER WT, 1991, ACAD MED, V66, P305, DOI 10.1097/00001888-199106000-00001; CARMICHAEL JW, 1988, J NATL MED ASSOC, V80, P1094; COOPER JAD, 1978, J MED EDUC, V53, P776; CULBERT AJ, 1989, EARLY SELECTION PATH; Ein Lewin M, 1994, BALANCING SCALES OPP; Frazier D T, 1991, Physiologist, V34, P44; HAYMAN W, 1988, J COLL SCI TEACH MAR, P375; HUTCHINS EB, 1967, J MED EDUC, V42, P809; MAEROFF GI, 1984, SCH COLLEGE PARTNERS; MERVIS J, 1994, SCIENCE, V264, P496, DOI 10.1126/science.264.5158.496; Nickens H, 1994, MORE MINORITIES HLTH, P1; Nickens H W, 1992, JAMA, V267, P2395, DOI 10.1001/jama.267.17.2390; NICKENS HW, 1992, JAMA-J AM MED ASSOC, V267, P2395; PETERSDORF RG, 1992, ACAD MED, V67, P73, DOI 10.1097/00001888-199202000-00003; PETERSDORF RG, 1990, ACAD MED, V65, P663, DOI 10.1097/00001888-199011000-00001; READY T, 1991, ACAD MED, V66, P181, DOI 10.1097/00001888-199104000-00001; READY T, 1994, MORE MINORITIES HLTH, P29; SLATER M, 1991, ACAD MED, V66, P220, DOI 10.1097/00001888-199104000-00011; SUSSMAN A, 1993, SCI ED PARTNERSHIPS; The Academic Health Center, 2017, DEL SYST DES CHANG H; THOMSON WA, 1991, ACAD MED, V66, P364, DOI 10.1097/00001888-199106000-00013; 1992, PROJECT 3000 2000 TE; 1993, CURRICULUM DIRECTORY; 1994, PROJECT 3000 2000 PR; 1993, MINORITY STUDENTS ME; 1993, 1992 1993 CIT U NEW; 1970, REPORT ASS AM MED CO; 1992, 3RD DEP HLTH HUM SER; 1978, REPORT ASS AM MED CO; 1988, ONE 3RD NATION REPOR, P11; 1993, DIGEST ED STATISTICS, P123; 1990, ED WORKS ACTION PLAN	32	125	125	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					472	476		10.1056/NEJM199408183310712	http://dx.doi.org/10.1056/NEJM199408183310712			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	8035847				2022-12-28	WOS:A1994PB50100012
J	MCIVOR, C; MORTON, J; BRYANT, A; COOKSLEY, WG; DURRANT, S; WALKER, N				MCIVOR, C; MORTON, J; BRYANT, A; COOKSLEY, WG; DURRANT, S; WALKER, N			FATAL REACTIVATION OF PRECORE MUTANT HEPATITIS-B VIRUS-ASSOCIATED WITH FIBROSING CHOLESTATIC HEPATITIS AFTER BONE-MARROW TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Note							INFECTION; ANTIGEN		ROYAL BRISBANE HOSP, BANCROFT CTR, CLIN RES CTR, BRISBANE, QLD 4029, AUSTRALIA	Royal Brisbane & Women's Hospital			Walker, Neal I/E-7039-2011; cooksley, william ge/G-7742-2011; Walker, Neal I/E-7233-2011					ANGUS P, 1993, J GASTROEN HEPATOL, V8, P353, DOI 10.1111/j.1440-1746.1993.tb01527.x; CARMAN WF, 1989, LANCET, V2, P588; CHEN PM, 1990, TRANSPLANTATION, V49, P708, DOI 10.1097/00007890-199004000-00011; FANG JWS, 1993, GASTROENTEROLOGY, V105, P901, DOI 10.1016/0016-5085(93)90910-5; ILAN Y, 1993, HEPATOLOGY, V18, P246, DOI 10.1002/hep.1840180204; LOCASCIULLI A, 1990, BONE MARROW TRANSPL, V6, P25; PARIENTE EA, 1988, DIGEST DIS SCI, V33, P1185, DOI 10.1007/BF01535798; REED EC, 1991, BLOOD, V77, P195; WEBSTER A, 1989, BONE MARROW TRANSPL, V4, P207; YOSHIBA M, 1992, DIGEST DIS SCI, V37, P1253, DOI 10.1007/BF01296569	10	74	75	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					274	275		10.7326/0003-4819-121-4-199408150-00007	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037408				2022-12-28	WOS:A1994PB10200007
J	ROTHMAN, KJ; MICHELS, KB				ROTHMAN, KJ; MICHELS, KB			THE CONTINUING UNETHICAL USE OF PLACEBO CONTROLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; HEART-FAILURE; MAJOR DEPRESSION; CONTROLLED TRIAL; INDUCED NAUSEA; EFFICACY; CHEMOTHERAPY; METOCLOPRAMIDE; ONDANSETRON		HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	ROTHMAN, KJ (corresponding author), BOSTON UNIV, SCH PUBL HLTH, BOSTON, MA 02118 USA.			Rothman, Kenneth/0000-0003-2398-1705				AMSTERDAM JD, 1989, PHARMACOPSYCHIATRY, V22, P137, DOI 10.1055/s-2007-1014596; ANNAS GJ, 1992, NAZI DOCTORS NUREMBE, P331; Annas GJ, 1992, NAZI DOCTORS NUREMBE, P339; BECK TM, 1993, ANN INTERN MED, V118, P407, DOI 10.7326/0003-4819-118-6-199303150-00002; BOWDEN CL, 1994, JAMA-J AM MED ASSOC, V271, P918, DOI 10.1001/jama.271.12.918; BRAUNWALD E, 1991, NEW ENGL J MED, V325, P351, DOI 10.1056/NEJM199108013250508; CARR AA, 1991, J CLIN PHARMACOL, V31, P144, DOI 10.1002/j.1552-4604.1991.tb03698.x; CASSILETH BR, 1980, NEW ENGL J MED, V302, P896, DOI 10.1056/NEJM198004173021605; CITRON ML, 1993, ANN INTERN MED, V118, P470, DOI 10.7326/0003-4819-118-6-199303150-00013; COWLEY AJ, 1993, INT J CARDIOL, V38, P167, DOI 10.1016/0167-5273(93)90176-H; COX R, 1982, CANCER CHEMOTH PHARM, V8, P133, DOI 10.1007/BF00292884; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; CUNNINGHAM D, 1987, BRIT MED J, V295, P250, DOI 10.1136/bmj.295.6592.250; EDGE SB, 1987, AM J CLIN ONCOL-CANC, V10, P257, DOI 10.1097/00000421-198706000-00020; FABRE LF, 1990, J CLIN PSYCHIAT, V51, P55; FABRE LF, 1991, 5TH WORLD C BIOL PSY; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; GANDARA DR, 1992, SEMIN ONCOL, V19, P67; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GRALLA RJ, 1987, MED CLIN N AM, V71, P289, DOI 10.1016/S0025-7125(16)30871-9; GREENE BM, 1985, NEW ENGL J MED, V313, P133, DOI 10.1056/NEJM198507183130301; Grodin MA., 1992, NAZI DOCTORS NUREMBE, P121; HILL AB, 1963, BMJ-BRIT MED J, P1043, DOI 10.1136/bmj.1.5337.1043; JOHNSEN V, 1989, SCAND J RHEUMATOL, V18, P251, DOI 10.3109/03009748909095027; KELBAEK H, 1993, EUR HEART J, V14, P692, DOI 10.1093/eurheartj/14.5.692; KIEV A, 1992, J CLIN PSYCHIAT, V53, P27; PACKER M, 1993, J AM COLL CARDIOL, V22, P65, DOI 10.1016/0735-1097(93)90816-J; RICKELS K, 1992, J CLIN PSYCHIAT, V53, P30; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; SALSBURG DS, 1985, AM STAT, V39, P220, DOI 10.2307/2683942; SAVITZ DA, 1993, REPROD TOXICOL, V7, P95, DOI 10.1016/0890-6238(93)90242-Y; SILVERSTONE T, 1993, INT CLIN PSYCHOPHARM, V7, P133, DOI 10.1097/00004850-199300730-00002; SMITH WT, 1992, J CLIN PSYCHIAT, V53, P36; SPRIET A, 1994, CHOICE COMPARATOR PL; SVETKEY LP, 1988, CURR THER RES CLIN E, V43, P969; Temple R, 1982, DRUG INF J, V10-17, DOI DOI 10.1177/009286158201600102; TORVIK D, 1986, BRIT J CLIN PHARMACO, V21, pS69, DOI 10.1111/j.1365-2125.1986.tb02856.x; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; TUGWELL P, 1990, LANCET, V335, P1051, DOI 10.1016/0140-6736(90)92630-Z; WALKER AM, 1986, AM J PUBLIC HEALTH, V76, P556, DOI 10.2105/AJPH.76.5.556; WILLIAMS HJ, 1988, ARTHRITIS RHEUM, V31, P702, DOI 10.1002/art.1780310602; 1988, GUIDELINES CLIN EVAL; 1987, FOOD DRUGS, V21	43	492	499	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					394	398		10.1056/NEJM199408113310611	http://dx.doi.org/10.1056/NEJM199408113310611			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA374	8028622				2022-12-28	WOS:A1994PA37400011
J	KLASSEN, TP; FELDMAN, ME; WATTERS, LK; SUTCLIFFE, T; ROWE, PC				KLASSEN, TP; FELDMAN, ME; WATTERS, LK; SUTCLIFFE, T; ROWE, PC			NEBULIZED BUDESONIDE FOR CHILDREN WITH MILD-TO-MODERATE CROUP	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; RANDOMIZED DOUBLE-BLIND; RACEMIC EPINEPHRINE; LARYNGOTRACHEITIS; DEXAMETHASONE	Background. Although recent evidence has strongly supported the use of glucocorticoid therapy in children hospitalized with croup, the benefit of this therapy in children with less severe croup has not been documented. This randomized, double-blind trial compared a nebulized glucocorticoid, budesonide, with placebo in outpatients with mild-to-moderate croup. Methods. Children three months to five years of age were eligible for the study if their croup scores fell in the mild-to-moderate range (scores of 2 to 7 out of a possible 17). The patients were randomly assigned to receive either 2 mg (4 ml) of nebulized budesonide (27 children) or 4 ml of nebulized normal saline (27 children); they were then assessed hourly for up to four hours by investigators who were unaware of the assigned treatments. Results. The median croup score at entry into the study was 4 in both groups. At the final study assessment, the median score was significantly lower in the budesonide group than in the placebo group (1 vs. 3, P = 0.005). The patients in the budesonide group were discharged from the emergency department significantly earlier than those in the placebo group (P = 0.002). One week after enrollment, 21 patients assigned to placebo had received dexamethasone, as compared with 15 patients assigned to budesonide (P = 0.10), and 7 patients assigned to placebo had been admitted to the hospital, as compared with 1 patient assigned to budesonide (P = 0.05). Conclusions. We conclude that nebulized budesonide leads to a prompt and important clinical improvement in children with mild-to-moderate croup who come to the emergency department.	JOHNS HOPKINS UNIV,DEPT PEDIAT,BALTIMORE,MD 21218; UNIV OTTAWA,DEPT PEDIAT,OTTAWA K1N 6N5,ON,CANADA; SCARBOROUGH GRACE HOSP,SCARBOROUGH,ON,CANADA	Johns Hopkins University; University of Ottawa; Scarborough Hospital								CHERRY JD, 1979, J PEDIATR-US, V94, P352, DOI 10.1016/S0022-3476(79)80883-5; CORKEY CWB, 1981, CRIT CARE MED, V9, P587, DOI 10.1097/00003246-198108000-00007; DENNY FW, 1983, PEDIATRICS, V71, P871; EDEN AN, 1967, J AMER MED ASSOC, V200, P403, DOI 10.1001/jama.200.5.403; EDEN AN, 1964, PEDIATRICS, V33, P768; ELLULMICALLEF R, 1983, BRIT J CLIN PHARMACO, V15, P419, DOI 10.1111/j.1365-2125.1983.tb01524.x; ERLANSSON M, 1989, INFLAMMATION, V13, P693, DOI 10.1007/BF00914313; GUYATT GH, 1992, J CLIN EPIDEMIOL, V45, P1341, DOI 10.1016/0895-4356(92)90194-R; HUSBY S, 1993, ARCH DIS CHILD, V68, P352, DOI 10.1136/adc.68.3.352; JAMES JA, 1969, AM J DIS CHILD, V117, P511, DOI 10.1001/archpedi.1969.02100030513003; JOHANSSON SA, 1982, EUR J CLIN PHARMACOL, V22, P523, DOI 10.1007/BF00609625; KAIRYS SW, 1989, PEDIATRICS, V83, P683; KOREN G, 1983, AM J DIS CHILD, V137, P941, DOI 10.1001/archpedi.1983.02140360005002; KUUSELA AL, 1988, ACTA PAEDIATR SCAND, V77, P99, DOI 10.1111/j.1651-2227.1988.tb10606.x; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEIPZIG B, 1979, J PEDIATR-US, V94, P194, DOI 10.1016/S0022-3476(79)80821-5; LENTNER C, 1982, GEIGY SCI TABLES, V2, P26; MARTENSSON B, 1960, Acta Otolaryngol Suppl, V158, P62; MILLERLARSSON A, 1990, AGENTS ACTIONS, V29, P127, DOI 10.1007/BF01964740; MUHLENDAHL KE, 1982, HELV PAEDIATR ACTA, V37, P431; NOVIK A, 1960, Acta Otolaryngol Suppl, V158, P20; SKOLNIK NS, 1989, AM J DIS CHILD, V143, P1045, DOI 10.1001/archpedi.1989.02150210079022; SKOWRON PN, 1966, CAN MED ASSOC J, V94, P528; SMITH DS, 1989, J PEDIATR-US, V115, P256, DOI 10.1016/S0022-3476(89)80074-5; SUPER DM, 1989, J PEDIATR-US, V115, P323, DOI 10.1016/S0022-3476(89)80095-2; SUSSMAN S, 1964, PEDIATRICS, V34, P851; TIBBALLS J, 1992, LANCET, V340, P745, DOI 10.1016/0140-6736(92)92293-O; WESTLEY CR, 1978, AM J DIS CHILD, V132, P484, DOI 10.1001/archpedi.1978.02120300044008; 1989, LANCET, V2, P1134	29	100	102	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					285	289		10.1056/NEJM199408043310501	http://dx.doi.org/10.1056/NEJM199408043310501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022437	Bronze			2022-12-28	WOS:A1994NZ22700001
J	STUBBLEFIELD, PG; GRIMES, DA				STUBBLEFIELD, PG; GRIMES, DA			SEPTIC ABORTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MATERNAL MORTALITY; 1ST-TRIMESTER ABORTION; MONOCLONAL-ANTIBODY; CONTROLLED TRIAL; UNITED-STATES; DOUBLE-BLIND; HEALTH; SHOCK; CONSEQUENCES		UNIV CALIF SAN FRANCISCO, DEPT OBSTET GYNECOL & REPROD SCI, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	STUBBLEFIELD, PG (corresponding author), MAINE MED CTR, DEPT OBSTET & GYNECOL, 22 BRAMHALL ST, PORTLAND, ME 04102 USA.							[Anonymous], 1993, MMWR Recomm Rep, V42, P1; ATRASH HK, 1990, CONT OB GYN, V35, P58; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BURKMAN RT, 1977, AM J OBSTET GYNECOL, V128, P556, DOI 10.1016/0002-9378(77)90041-2; BURNHILL MS, 1985, J REPROD MED, V30, P610; CATES W, 1978, AM J OBSTET GYNECOL, V132, P211, DOI 10.1016/0002-9378(78)90926-2; CATES W, 1976, FAM PLANN PERSPECT, V8, P86, DOI 10.2307/2133995; Cates W Jr, 1976, Adv Plan Parent, V11, P106; DARJ E, 1987, OBSTET GYNECOL, V70, P755; DUFF P, 1987, CLIN OBSTETRICS, P785; EXLEY AR, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91337-A; FARO S, 1992, INFECTIONS ABORTION, P41; FAUVEAU V, 1988, B WORLD HEALTH ORGAN, V66, P643; GRIM PS, 1990, JAMA-J AM MED ASSOC, V263, P2216; GRIMES DA, 1981, OBSTET GYNECOL, V57, P739; HAKIMELAHI E, 1990, OBSTET GYNECOL, V76, P129; HENSHAW SK, 1993, C ST GYN OB, V5, P31; HERN MW, 1984, ABORTION PRACTICE; JEWETT JF, 1973, NEW ENGL J MED, V288, P107; KAMPIKAHO A, 1991, E AFR MED J, V68, P624; KONJE JC, 1992, INT J GYNECOL OBSTET, V37, P193, DOI 10.1016/0020-7292(92)90380-2; KOONIN LM, 1992, MMWR-MORBID MORTAL W, V41, P16; LAGUARDIA KD, 1990, OBSTET GYNECOL, V75, P27; LARSSON PG, 1992, AM J OBSTET GYNECOL, V166, P100, DOI 10.1016/0002-9378(92)91838-2; LAST JM, 1980, MAXCYROSENAU PUBLIC, P3; LEVALLOIS P, 1988, AM J OBSTET GYNECOL, V158, P100, DOI 10.1016/0002-9378(88)90787-9; LISKIN LS, 1980, POPULATION REPORTS F, pF105; MAHLER H, 1987, LANCET, V1, P668; Natanson C, 1989, J Cardiothorac Anesth, V3, P215, DOI 10.1016/S0888-6296(89)93026-3; OKONOFUA FE, 1992, TROP DOCT, V22, P75, DOI 10.1177/004947559202200209; Pardo F, 1991, REV COLOMB OBSTET GI, V42, P287, DOI [10.18597/rcog.939, DOI 10.18597/RCOG.939]; PEDUZZI P, 1987, NEW ENGL J MED, V317, P659; POLGAR S, 1976, FAM PLANN PERSPECT, V8, P125, DOI 10.2307/2133634; POPOV AA, 1991, STUD FAMILY PLANN, V22, P368, DOI 10.2307/1966450; ROSENFIELD A, 1985, LANCET, V2, P83; SAI FT, 1989, INT J GYNECOL OBST S, V3, P103; STEDMAN TL, 1966, STEDMANS MED DICT, P4; STEPHENSON P, 1992, AM J PUBLIC HEALTH, V82, P1328, DOI 10.2105/AJPH.82.10.1328; Stubblefield PG, 1991, OBSTET NORMAL PROBLE, P1303; STUBBLEFIELD PG, 1978, CURR PROB OBST GYN F, V2, P1; SUSSER M, 1992, AM J PUBLIC HEALTH, V82, P1323, DOI 10.2105/AJPH.82.10.1323; SWEET RL, 1990, INFECT DIS, P229; TOURE B, 1992, INT J GYNECOL OBSTET, V37, P89, DOI 10.1016/0020-7292(92)90487-4; VILLARREAL J, 1989, INT J GYNECOL OBSTET, P51; Vincent J L, 1991, Infect Dis Clin North Am, V5, P807; WINKLER CL, 1991, OBSTET GYNECOL, V77, P297, DOI 10.1097/00006250-199102000-00028; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1993, JAMA-J AM MED ASSOC, V269, P82; 1992, JAMA-J AM MED ASSOC, V268, P3231	49	45	50	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					310	314		10.1056/NEJM199408043310507	http://dx.doi.org/10.1056/NEJM199408043310507			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022443				2022-12-28	WOS:A1994NZ22700007
J	MARFIN, AA; MOORE, J; COLLINS, C; BIELLIK, R; KATTEL, U; TOOLE, MJ; MOORE, PS				MARFIN, AA; MOORE, J; COLLINS, C; BIELLIK, R; KATTEL, U; TOOLE, MJ; MOORE, PS			INFECTIOUS-DISEASE SURVEILLANCE DURING EMERGENCY RELIEF TO BHUTANESE REFUGEES IN NEPAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MENINGOCOCCAL MENINGITIS; DEVELOPING-COUNTRIES; MORTALITY TRENDS; VERBAL AUTOPSY; PUBLIC-HEALTH; POPULATIONS; THAILAND; SOMALIA; VALIDATION; INTERVIEWS	Objective.-To implement simplified infectious disease surveillance and epidemic disease control during the relocation of Bhutanese refugees to Nepal. Design.-Longitudinal observation study of mortality and morbidity. Setting.-Refugee health units in six refugee camps housing 73 500 Bhutanese refugees in the eastern tropical lowland between Nepal and India. Interventions.-Infectious disease surveillance and community-based programs to promote vitamin A supplementation, measles vaccination, oral rehydration therapy, and early use of antibiotics to treat acute respiratory infection. Main Outcome Measures.-Crude mortality rate, mortality rate for children younger than 5 years, and cause-specific mortality. Results.-Crude mortality rates up to 1.15 deaths per 10 000 persons per day were reported during the first 6 months of surveillance The leading causes of death were measles, diarrhea, and acute respiratory infections. Surveillance data were used to institute changes in public health management including measles vaccination, vitamin A supplementation, and control programs for diarrhea and acute respiratory infections and to ensure rapid responses to cholera, Shigella dysentery, and meningoencephalitis. Within 4 months of establishing disease control interventions, crude mortality rates were reduced by 75% and were below emergency levels. Conclusions.-Simple, sustainable disease surveillance in refugee populations is essential during emergency relief efforts. Data can be used to direct community-based public health interventions to control common infectious diseases and reduce high mortality rates among refugees while placing a minimal burden on health workers.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VECTOR BORNE INFECT DIS, FT COLLINS, CO USA; SAVE CHILDREN FUND UNITED KINGDOM, LONDON, ENGLAND; WHO, Kathmandu, NEPAL; CTR DIS CONTROL & PREVENT, INT HLTH PROGRAM OFF, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA; Save the Children; World Health Organization; Centers for Disease Control & Prevention - USA			Moore, Patrick/GVR-8294-2022; Moore, Patrick S./F-3960-2011	Moore, Patrick S./0000-0002-8132-858X				BANG AT, 1992, B WORLD HEALTH ORGAN, V70, P499; COCHI SL, 1987, INT J EPIDEMIOL, V16, P91, DOI 10.1093/ije/16.1.91; DESENCLOS JC, 1990, INT J EPIDEMIOL, V19, P367, DOI 10.1093/ije/19.2.367; ELIAS CJ, 1990, AM J PUBLIC HEALTH, V80, P824, DOI 10.2105/AJPH.80.7.824; GLASS RI, 1980, LANCET, V1, P868; HAKEWILL PA, 1991, TROP DOCT, V21, P24, DOI 10.1177/00494755910210S106; KALTER HD, 1991, INT J EPIDEMIOL, V20, P193, DOI 10.1093/ije/20.1.193; KALTER HD, 1990, INT J EPIDEMIOL, V19, P380, DOI 10.1093/ije/19.2.380; KLAUCKE DN, 1988, MMWR S5, V37, P1; MANONCOURT S, 1992, LANCET, V340, P176, DOI 10.1016/0140-6736(92)93252-I; MOORE PS, 1990, B WORLD HEALTH ORGAN, V68, P587; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; OGAWA S, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P37; PACQUEMARGOLIS S, 1990, SOC SCI MED, V31, P585, DOI 10.1016/0277-9536(90)90094-9; TOOLE M J, 1989, Bulletin of the World Health Organization, V67, P381; TOOLE MJ, 1988, J TROP PEDIATRICS, V34, P218, DOI 10.1093/tropej/34.5.218; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TOOLE MJ, 1992, LANCET, V339, P1214, DOI 10.1016/0140-6736(92)91143-V; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; TOOLE MJ, 1992, MMWR-MORBID MORTAL W, V41, P1; 1978, LAY REPORTING HLTH I	22	31	31	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					377	381		10.1001/jama.272.5.377	http://dx.doi.org/10.1001/jama.272.5.377			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028169				2022-12-28	WOS:A1994NY90300030
J	RUSSEL, M				RUSSEL, M			PHAGE ASSEMBLY - A PARADIGM FOR BACTERIAL VIRULENCE FACTOR EXPORT	SCIENCE			English	Editorial Material							GENERAL SECRETORY PATHWAY; PSEUDOMONAS-AERUGINOSA; OUTER-MEMBRANE; PROTEIN SECRETION; ESCHERICHIA-COLI; SHIGELLA-FLEXNERI; GATED CHANNEL; COMPONENTS; BIOGENESIS; CLUSTER				RUSSEL, M (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.							AKRIM M, 1993, MOL MICROBIOL, V10, P431, DOI 10.1111/j.1365-2958.1993.tb02674.x; ALLAOUI A, 1993, MOL MICROBIOL, V7, P59, DOI 10.1111/j.1365-2958.1993.tb01097.x; ARLAT M, 1991, MOL PLANT MICROBE IN, V4, P593, DOI 10.1094/MPMI-4-593; BALLY M, 1992, MOL MICROBIOL, V6, P1121, DOI 10.1111/j.1365-2958.1992.tb01550.x; BAUER DW, 1991, IN PRESS MOL PLANT M; BERGMAN T, 1994, J BACTERIOL, V176, P2619, DOI 10.1128/JB.176.9.2619-2626.1994; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BORTOLIGERMAN I, 1994, MOL MICROBIOL, V11, P545, DOI 10.1111/j.1365-2958.1994.tb00335.x; CORNELIS GR, 1992, MOL BIOL BACTERIAL I, P231; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; GROISMAN EA, 1993, EMBO J, V12, P3779, DOI 10.1002/j.1460-2075.1993.tb06056.x; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; HE SY, 1993, CELL, V73, P1255, DOI 10.1016/0092-8674(93)90354-S; KAZMIERCZAK BI, 1994, J MOL BIOL, V238, P187, DOI 10.1006/jmbi.1994.1280; KORNACKER MG, 1990, MOL MICROBIOL, V4, P1101, DOI 10.1111/j.1365-2958.1990.tb00684.x; LAUER P, 1993, MOL MICROBIOL, V8, P357, DOI 10.1111/j.1365-2958.1993.tb01579.x; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; MARTIN PR, 1993, MOL MICROBIOL, V9, P857, DOI 10.1111/j.1365-2958.1993.tb01744.x; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; PUGSLEY AP, 1992, P NATL ACAD SCI USA, V89, P12058, DOI 10.1073/pnas.89.24.12058; PUGSLEY AP, 1993, MOL MICROBIOL, V10, P665, DOI 10.1111/j.1365-2958.1993.tb00938.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; PUGSLEY AP, 1994, MOL MICROBIOL, V12, P287; PY B, 1991, FEMS MICROBIOL LETT, V79, P315, DOI [10.1016/0378-1097(91)90105-J, 10.1111/j.1574-6968.1991.tb04548.x]; REEVES PJ, 1994, MOL MICROBIOL, V12, P445, DOI 10.1111/j.1365-2958.1994.tb01033.x; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; RUSSEL M, 1989, J VIROL, V63, P3284, DOI 10.1128/JVI.63.8.3284-3295.1989; RUSSEL M, 1991, MOL MICROBIOL, V5, P1607, DOI 10.1111/j.1365-2958.1991.tb01907.x; RUSSEL M, 1993, J BACTERIOL, V175, P3998, DOI 10.1128/JB.175.13.3998-4007.1993; RUSSEL M, 1993, J MOL BIOL, V231, P689, DOI 10.1006/jmbi.1993.1320; RUSSEL M, 1992, J MOL BIOL, V227, P453, DOI 10.1016/0022-2836(92)90900-5; RUSSEL M, 1993, IN PRESS MOL MICROBI; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; TOMB JF, 1991, GENE, V104, P1, DOI 10.1016/0378-1119(91)90457-M; TURNER LR, 1993, J BACTERIOL, V175, P4962, DOI 10.1128/JB.175.16.4962-4969.1993; WEI ZM, 1993, J BACTERIOL, V175, P7958, DOI 10.1128/JB.175.24.7958-7967.1993; WEINER L, 1994, P NATL ACAD SCI USA, V91, P2191, DOI 10.1073/pnas.91.6.2191; WHITCHURCH CB, 1993, MOL MICROBIOL, V10, P233; ZYCHLINSKY A, 1994, MOL MICROBIOL, V11, P619, DOI 10.1111/j.1365-2958.1994.tb00341.x	40	90	94	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					612	614		10.1126/science.8036510	http://dx.doi.org/10.1126/science.8036510			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036510				2022-12-28	WOS:A1994NZ53800020
J	AOSAKI, T; GRAYBIEL, AM; KIMURA, M				AOSAKI, T; GRAYBIEL, AM; KIMURA, M			EFFECT OF THE NIGROSTRIATAL DOPAMINE SYSTEM ON ACQUIRED NEURAL RESPONSES IN THE STRIATUM OF BEHAVING MONKEYS	SCIENCE			English	Article							TERM SYNAPTIC DEPRESSION; PARKINSONS-DISEASE; PREFRONTAL CORTEX; RAT NEOSTRIATUM; NEURONS; PHYSIOLOGY; DEPLETION; LESIONS; ANATOMY; MATRIX	Dysfunction of the nigrostriatal dopamine system results in marked disorders of movement such as occur in Parkinson's disease. Functions of this dopamine-containing projection system were examined in monkeys trained in a classical conditioning task, and the effects of striatal dopamine depletion were tested. Unilateral dopamine loss substantially reduced the acquired sensory responsiveness of striatal neurons monitored electrophysiologically. This effect was ipsilateral and selective, and could be reversed by apomorphine. These results suggest that the primate nigrostriatal system modulates expression of neuronal response plasticity in the striatum during sensorimotor learning.	OSAKA UNIV,FAC HLTH & SPORT SCI,TOYONAKA,OSAKA 560,JAPAN; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Osaka University; Massachusetts Institute of Technology (MIT)				Graybiel, Ann/0000-0002-4326-7720	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025529] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS25529] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AOSAKI T, UNPUB; AOSAKI T, IN PRESS; APICELLA P, 1991, EXP BRAIN RES, V84, P672; ARTIEDA J, 1992, BRAIN, V115, P199, DOI 10.1093/brain/115.1.199; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BLOOM FE, 1979, NEUROSCIENCES 4TH ST, P51; BROCHTIE JM, 1991, MOV DISORD, V6, P133; CALABRESI P, 1992, NEUROSCI LETT, V142, P95, DOI 10.1016/0304-3940(92)90628-K; CALABRESI P, 1992, J NEUROSCI, V12, P4224; CARLI M, 1985, NATURE, V313, P679, DOI 10.1038/313679a0; COOLS AR, 1984, J NEUROL NEUROSUR PS, V47, P443, DOI 10.1136/jnnp.47.5.443; FLOWERS KA, 1976, BRAIN, V99, P269, DOI 10.1093/brain/99.2.269; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; GRAYBIEL AM, 1987, P NATL ACAD SCI USA, V84, P303, DOI 10.1073/pnas.84.1.303; Hornykiewicz O., 1966, BIOCH PHARM BASAL GA, P171; KAWAGUCHI Y, 1992, J NEUROPHYSIOL, V67, P1669, DOI 10.1152/jn.1992.67.6.1669; KIMURA M, 1990, EXP BRAIN RES, V82, P672; KIMURA M, 1984, P NATL ACAD SCI-BIOL, V81, P4998, DOI 10.1073/pnas.81.15.4998; KOOB GF, 1989, NEUROSCI BIOBEHAV R, V13, P135, DOI 10.1016/S0149-7634(89)80022-3; LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145; LJUNGBERG T, 1993, J NEUROSCI, V13, P900; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; Mishkin M., 1984, NEUROBIOL LEARN MEM, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553; MOORE RY, 1978, ANNU REV NEUROSCI, V1, P129, DOI 10.1146/annurev.ne.01.030178.001021; NAKAMURA T, 1988, BRAIN RES, V474, P327; SAINTCYR JA, 1988, BRAIN, V111, P941, DOI 10.1093/brain/111.4.941; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1385, DOI 10.1152/jn.1990.63.6.1385; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1401, DOI 10.1152/jn.1990.63.6.1401; SCHULTZ W, 1982, PROG NEUROBIOL, V18, P121, DOI 10.1016/0301-0082(82)90015-6; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; VONVOIGTLANDER PF, 1973, NEUROPHARMACOLOGY, V12, P451, DOI 10.1016/0028-3908(73)90061-0; WILSON CJ, 1990, J NEUROSCI, V10, P508	33	306	309	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					412	415		10.1126/science.8023166	http://dx.doi.org/10.1126/science.8023166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023166				2022-12-28	WOS:A1994NW81600046
J	JOSEPH, CL				JOSEPH, CL			SMALL SACRIFICES	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											JOSEPH, CL (corresponding author), VET AFFAIRS MED CTR, GERONTOL SECT 111NHCUV, POB 1035, PORTLAND, OR 97207 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					143	143		10.7326/0003-4819-121-2-199407150-00012	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017729				2022-12-28	WOS:A1994NW18600012
J	LATTERICH, M; SCHEKMAN, R				LATTERICH, M; SCHEKMAN, R			THE KARYOGAMY GENE KAR2 AND NOVEL PROTEINS ARE REQUIRED FOR ER-MEMBRANE FUSION	CELL			English	Article							TRANSPORT VESICLE FORMATION; ENDOPLASMIC-RETICULUM; NUCLEAR-FUSION; SECRETORY PATHWAY; TRANSMEMBRANE PROTEIN; GOLGI-APPARATUS; YEAST; TRANSLOCATION; RECONSTITUTION; BINDING	We have developed assays using cells and isolated membranes to identify factors mediating fusion of the ER-nuclear membrane network in yeast. When cells containing distinctly tagged ER-nuclear envelops membranes are observed during mating, the markers of both parental membranes become colocalized in a process sharing a genetic requirement with karyogamy. Using isolated membranes, we find that fusion between ER compartments requires ATP, but not cytosol, Sec17p (alpha-SNAP), or Sec18p (NSF), the latter two being required at the fusion step in vesicular transport. Proteins tightly associated with the ER membrane are essential for fusion, as is Kar2p (BiP), an ER lumenal hsp70 homolog. BiP may activate an ER-localized fusogen, allowing nuclear fusion and karyogamy in yeast.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	LATTERICH, M (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.							ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BERLIN V, 1991, METHOD ENZYMOL, V194, P774; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BYERS B, 1982, MOL BIOL YEAST SACCH, P59; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ESMON B, 1984, J BIOL CHEM, V259, P322; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KAISER CA, 1990, MOL CELL BIOL, V10, P3163, DOI 10.1128/MCB.10.6.3163; KURIHARA LJ, 1994, IN PRESS J CELL BIOL; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MORI K, 1993, CELL, V74, P743; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; REXACH M, 1994, IN PRESS J CELL BIOL; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROSE MD, 1991, ANNU REV MICROBIOL, V45, P539; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROSE MD, 1986, MOL CELL BIOL, V6, P3490, DOI 10.1128/MCB.6.10.3490; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROSE MD, 1990, METHDOS YEAST GENETI; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WATKINS JD, 1993, J BIOL CHEM, V268, P5182; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124	59	99	99	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					87	98		10.1016/0092-8674(94)90575-4	http://dx.doi.org/10.1016/0092-8674(94)90575-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033215				2022-12-28	WOS:A1994NX32800011
J	PUETT, DW; GRIFFIN, MR				PUETT, DW; GRIFFIN, MR			PUBLISHED TRIALS OF NONMEDICINAL AND NONINVASIVE THERAPIES FOR HIP AND KNEE OSTEOARTHRITIS	ANNALS OF INTERNAL MEDICINE			English	Review							ANTIRHEUMATIC DRUG TRIALS; ELECTRICAL NERVE-STIMULATION; DOUBLE-BLIND TRIAL; RHEUMATOID-ARTHRITIS; OSTEO-ARTHRITIS; ELDERLY PERSONS; CLINICAL-TRIALS; PEPTIC-ULCER; PAIN; EXERCISE	Purpose: To review the efficacy of nonmedicinal, noninvasive therapies in hip and knee osteoarthritis. Data Sources: Search of English-language literature from 1966 through 1993 using MEDLINE by cross-referencing ''osteoarthritis'' (therapy subheadings) with ''controlled trial,'' ''comparative study,'' or ''trial(s).'' Study Selection: Fifteen controlled trials of diathermy (deep heat), exercise, acupuncture, transcutaneous electrical nerve stimulation, topically applied capsaicin, low-energy laser, and pulsed electromagnetic fields were found. No experimental studies of superficial heat and cold, orthotic devices, vibration, or weight loss were identified. Results: Exercise reduces pain and improves function in patients with osteoarthritis of the knee. No support exists in the literature for pre-exercise ultrasound treatment. Single, well-designed studies suggest that topically applied capsaicin and laser treatment reduce pain associated with knee osteoarthritis. Data on the other three therapies were sparse (transcutaneous electrical nerve stimulation, pulsed electromagnetic fields) or inconsistent (acupuncture). Conclusions: More data are needed to determine the optimal exercise regimen for treating knee osteoarthritis and to evaluate the role of topical capsaicin, laser therapy, acupuncture, transcutaneous electrical nerve stimulation, and pulsed electromagnetic fields. No data specifically address the role of any of these therapies in hip osteoarthritis.	VANDERBILT UNIV, DEPT PREVENT MED, NASHVILLE, TN 37232 USA	Vanderbilt University					NIA NIH HHS [1 R01AG10566-01AZ] Funding Source: Medline; FDA HHS [FD-U-000073] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010566] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); FDA HHS; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEALS CA, 1985, J RHEUMATOL, V12, P458; BELLAMY N, 1992, J RHEUMATOL, V19, P451; BELLAMY N, 1992, J RHEUMATOL, V19, P444; BELLAMY N, 1992, J RHEUMATOL, V19, P436; BLAIR SN, 1992, ANNU REV PUBL HEALTH, V13, P99, DOI 10.1146/annurev.pu.13.050192.000531; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BUNNING RD, 1991, SEMIN ARTHRITIS RHEU, V21, P33, DOI 10.1016/0049-0172(91)90038-2; Chamberlain M A, 1982, Int Rehabil Med, V4, P101; CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x; Davis G C, 1990, Arthritis Care Res, V3, P127, DOI 10.1002/art.1790030304; DEAL CL, 1991, CLIN THER, V13, P383; ELKAYAM O, 1991, J RHEUMATOL, V18, P1799; Falconer J, 1992, Arthritis Care Res, V5, P29, DOI 10.1002/art.1790050108; FARGASBABJAK A, 1989, CLIN J PAIN, V5, P137, DOI 10.1097/00002508-198906000-00002; FELSON DT, 1992, ANN INTERN MED, V116, P535, DOI 10.7326/0003-4819-116-7-535; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P365; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GAW AC, 1975, NEW ENGL J MED, V293, P375, DOI 10.1056/NEJM197508212930803; GHOSH P, 1991, J RHEUMATOL, V18, P161; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HICKS JE, 1992, OSTEOARTHRITIS DIAGN, P427; Jan M H, 1991, J Formos Med Assoc, V90, P1008; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; KUDOH C, 1989, LASER THER, V1, P63; LAWRENCE RC, 1989, J RHEUMATOL, V16, P427; LEWIS D, 1984, ANN RHEUM DIS, V43, P47, DOI 10.1136/ard.43.1.47; LUNDEBERG T, 1984, PAIN, V20, P25, DOI 10.1016/0304-3959(84)90808-X; MEENAN RF, 1982, J RHEUMATOL, V9, P785; MINOR MA, 1989, ARTHRITIS RHEUM, V32, P1396, DOI 10.1002/anr.1780321108; MINOR MA, 1988, J RHEUMATOL, V15, P905; MULLEN PD, 1987, J RHEUMATOL, V14, P33; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, pR7; SASAKI T, 1987, CLIN ORTHOP RELAT R, P181; STELIAN J, 1992, J AM GERIATR SOC, V40, P23, DOI 10.1111/j.1532-5415.1992.tb01824.x; Svarcova J, 1987, Scand J Rheumatol Suppl, V67, P83; TAYLOR P, 1981, PAIN, V11, P233, DOI 10.1016/0304-3959(81)90008-7; TODD PA, 1990, DRUGS, V40, P91, DOI 10.2165/00003495-199040010-00006; TROCK DH, 1993, J RHEUMATOL, V20, P456; VIRUS RM, 1979, LIFE SCI, V25, P1273, DOI 10.1016/0024-3205(79)90392-8; WALKER J, 1983, NEUROSCI LETT, V43, P339, DOI 10.1016/0304-3940(83)90211-2	41	164	168	1	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					133	140		10.7326/0003-4819-121-2-199407150-00010	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017727				2022-12-28	WOS:A1994NW18600010
J	SPEIR, E; MODALI, R; HUANG, ES; LEON, MB; SHAWL, F; FINKEL, T; EPSTEIN, SE				SPEIR, E; MODALI, R; HUANG, ES; LEON, MB; SHAWL, F; FINKEL, T; EPSTEIN, SE			POTENTIAL ROLE OF HUMAN CYTOMEGALOVIRUS AND P53 INTERACTION IN CORONARY RESTENOSIS	SCIENCE			English	Article							CELLULAR TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; NUCLEAR ANTIGEN; PROTEIN; VIRUS; EXPRESSION; CARCINOMA; PROLIFERATION; ANTIBODY	A subset of patients who have undergone coronary angioplasty develop restenosis, a vessel renarrowing characterized by excessive proliferation of smooth muscle cells (SMCs). Of 60 human restenosis lesions examined, 23 (38 percent) were found to have accumulated high amounts of the tumor suppressor protein p53, and this correlated with the presence of human cytomegalovirus (HCMV) in the lesions. SMCs grown from the lesions expressed HCMV protein IE84 and high amounts of p53. HCMV infection of cultured SMCs enhanced p53 accumulation, which correlated temporally with IE84 expression. IE84 also bound to p53 and abolished its ability to transcriptionally activate a reporter gene. Thus, HCMV, and IE84-mediated inhibition of p53 function, may contribute to the development of restenosis.	BIOSERVE BIOTECHNOL LTD,LAUREL,MD 20707; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; WASHINGTON HOSP CTR,WASHINGTON CARDIOL CTR,DIV CARDIOL,WASHINGTON,DC 20010; WASHINGTON ADVENTIST HOSP,DEPT CARDIOL,TAKOMA PK,MD 20912	University of North Carolina; University of North Carolina Chapel Hill; MedStar Washington Hospital Center	SPEIR, E (corresponding author), NIH,CARDIOL BRANCH,BLDG 10,BETHESDA,MD 20892, USA.							ALBRECHT T, 1993, FRONTIERS VIROLOGY, V2, pCH19; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; BENNETT WP, 1991, ONCOGENE, V6, P101; FABRICANT CG, 1978, J EXP MED, V148, P335, DOI 10.1084/jem.148.1.335; FINKEL T, 1993, J BIOL CHEM, V268, P5; GUMERLOCK PH, 1991, CANCER RES, V51, P1632; GUREVICH I, 1992, HEART LUNG, V21, P85; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; HUANG ES, 1993, FRONTIERS VIROLOGY, V2, P247; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEMSTROM KB, 1993, J CLIN INVEST, V92, P549, DOI 10.1172/JCI116622; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MELNICK JL, 1993, FRONTIERS VIROLOGY, V2, pCH4; MIDGLEY CA, 1992, J CELL SCI, V101, P183; NELSON JA, 1984, J VIROL, V49, P109, DOI 10.1128/JVI.49.1.109-115.1984; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SPEIR E, 1992, CIRCULATION, V86, P538, DOI 10.1161/01.CIR.86.2.538; SPEIR E, 1992, CIRC RES, V71, P251, DOI 10.1161/01.RES.71.2.251; SPEIR E, UNPUB; STENBERG RM, 1989, J VIROL, V63, P2699, DOI 10.1128/JVI.63.6.2699-2708.1989; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TSUKADA T, 1987, AM J PATHOL, V126, P51; TUMILOWICZ JJ, 1985, J VIROL, V56, P839, DOI 10.1128/JVI.56.3.839-845.1985; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	32	672	713	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					391	394		10.1126/science.8023160	http://dx.doi.org/10.1126/science.8023160			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023160				2022-12-28	WOS:A1994NW81600039
J	MAGGI, E; MAZZETTI, M; RAVINA, A; ANNUNZIATO, F; DECARLI, M; PICCINNI, MP; MANETTI, R; CARBONARI, M; PESCE, AM; DELPRETE, G; ROMAGNANI, S				MAGGI, E; MAZZETTI, M; RAVINA, A; ANNUNZIATO, F; DECARLI, M; PICCINNI, MP; MANETTI, R; CARBONARI, M; PESCE, AM; DELPRETE, G; ROMAGNANI, S			ABILITY OF HIV TO PROMOTE A T(H)1 TO T(H)0 SHIFT AND TO REPLICATE PREFERENTIALLY IN T(H)2 AND T(H)0 CELLS	SCIENCE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4+ T-CELLS; LYMPHOKINE ACTIVITIES; CYTOKINE PRODUCTION; SELECTIVE DEFECT; LYMPHOCYTES-T; HELPER; ACTIVATION; INFECTION; PROFILES	Both interferon gamma (IFN-gamma) produced by T helper 1 (T(H)1) lymphocytes and interleukin-4 (IL-4) produced by T(H)2 lymphocytes were reduced in either bulk circulating mononuclear cells or mitogen-induced CD4(+) T cell clones from the peripheral blood of individuals infected with human immunodeficiency virus (HIV). There was a preferential reduction in clones producing IL-4 and IL-5 in the advanced phases of infection. However, enhanced proportions of CD4(+) T cell clones producing both T(H)1-type and T(H)2-type cytokines (T(H)0 clones) were generated from either skin-infiltrating T cells that had been activated in vivo or peripheral blood T cells stimulated by antigen in vitro when cells were isolated from HIV-infected individuals. All T(H)2 and most T(H)0 clones supported viral replication, although viral replication was not detected in any of the T(H)1 clones infected in vitro with HIV. These results suggest that HIV (i) does not induce a definite T(H)1 to T(H)2 switch, but can favor a shift to the T(H)0 phenotype in response to recall antigens, and (ii) preferentially replicates in CD4(+) T cells producing T(H)2-type cytokines (T(H)2 and T(H)0).	UNIV FLORENCE,DIV CLIN IMMUNOL & ALLERGY,FLORENCE,ITALY; UNIV ROMA LA SAPIENZA,DIV CLIN IMMUNOL & ALLERGY,ROME,ITALY	University of Florence; Sapienza University Rome			Maggi, Enrico/AAA-8045-2019; Annunziato, Francesco/C-1155-2013	Maggi, Enrico/0000-0002-1824-3583; Annunziato, Francesco/0000-0001-8798-7589				AMELSEN JC, 1991, IMMUNOL TODAY, V12, P102; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; CARBONARI M, 1993, TRENDS GENET, V9, P42; CHEHIMI J, IN PRESS J EXP MED; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; FAHEY JL, 1984, AM J MED, V76, P95, DOI 10.1016/0002-9343(84)90756-3; GENDELMAN HE, 1990, J EXP MED, V172, P1433, DOI 10.1084/jem.172.5.1433; GRAZLOSI C, COMMUNICATION; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MACCHIA D, 1993, NATURE, V363, P464, DOI 10.1038/363464a0; MACCHIA D, 1991, J IMMUNOL, V146, P3414; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P1039, DOI 10.1089/aid.1992.8.1039; MAGGI E, 1987, EUR J IMMUNOL, V17, P1685, DOI 10.1002/eji.1830171202; MAGGI E, 1988, EUR J IMMUNOL, V18, P1045, DOI 10.1002/eji.1830180712; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MANETTI R, IN PRESS REV IMMUNOL; MARGOLICK JB, 1985, J CLIN INVEST, V76, P709, DOI 10.1172/JCI112025; MORETTA A, 1983, J EXP MED, V158, P571, DOI 10.1084/jem.158.2.571; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PALIARD X, 1990, J IMMUNOL, V144, P849; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROMAGNANI S, 1989, CLIN IMMUNOL IMMUNOP, V50, P13; ROMAGNANI S, IN PRESS IMMUNOL REV; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; STREET NE, 1990, J IMMUNOL, V144, P1629; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188	36	473	489	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					244	248		10.1126/science.8023142	http://dx.doi.org/10.1126/science.8023142			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023142				2022-12-28	WOS:A1994NV95700040
J	CAPRON, M; CAPRON, A				CAPRON, M; CAPRON, A			IMMUNOGLOBULIN-E AND EFFECTOR-CELLS IN SCHISTOSOMIASIS	SCIENCE			English	Editorial Material							DOWN-REGULATION; HUMAN IGE; MANSONI; RESISTANCE; IMMUNITY; REINFECTION; ASSOCIATION; ANTIBODIES; RESPONSES; CERCARIAE		UNIV LILLE,FAC MED,LILLE,FRANCE; UNIV LILLE,FAC PHARM,LILLE,FRANCE	Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille	CAPRON, M (corresponding author), INST PASTEUR,CTR IMMUNOL & BIOL PARASITAIRE,INSERM,U167,F-59000 LILLE,FRANCE.							CAPRON A, 1985, ANNU REV IMMUNOL, V3, P455, DOI 10.1146/annurev.iy.03.040185.002323; CAPRON A, 1986, IMMUNOL TODAY, V7, P15, DOI 10.1016/0167-5699(86)90184-2; CAPRON A, 1992, P INT C IMMUNOL, V14, P739; Capron M, 1991, Monogr Allergy, V29, P63; CAULADABENEDETTI Z, 1991, J IMMUNOL, V146, P1655; DELGADO V, 1990, PARASITE IMMUNOL, V12, P15, DOI 10.1111/j.1365-3024.1990.tb00933.x; DLUBUCQUOI S, 1994, J EXP MED, V179, P703; DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622; DUVAUXMIRET O, 1992, P NATL ACAD SCI USA, V89, P778, DOI 10.1073/pnas.89.2.778; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; GRZYCH JM, 1993, J IMMUNOL, V150, P527; GRZYCH JM, 1991, J IMMUNOL, V146, P1322; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; PEARCE EJ, 1991, EXP PARASITOL, V73, P110, DOI 10.1016/0014-4894(91)90014-N; RIHET P, 1991, EUR J IMMUNOL, V21, P2679, DOI 10.1002/eji.1830211106; ROBERTS M, 1993, INFECT IMMUN, V61, P4984, DOI 10.1128/IAI.61.12.4984-4993.1993; SHER A, 1991, J IMMUNOL, V147, P2713; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; VERWAERDE C, 1987, J IMMUNOL, V138, P4441; VERWAERDE C, 1986, SCAND J IMMUNOL, V24, P509, DOI 10.1111/j.1365-3083.1986.tb02165.x	21	140	145	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1876	1877		10.1126/science.8009216	http://dx.doi.org/10.1126/science.8009216			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009216				2022-12-28	WOS:A1994NT84700031
J	LETTERIO, JJ; GEISER, AG; KULKARNI, AB; ROCHE, NS; SPORN, MB; ROBERTS, AB				LETTERIO, JJ; GEISER, AG; KULKARNI, AB; ROCHE, NS; SPORN, MB; ROBERTS, AB			MATERNAL RESCUE OF TRANSFORMING GROWTH-FACTOR-BETA-1 NULL MICE	SCIENCE			English	Article							FACTOR-BETA; EXPRESSION; MOUSE; RATS; LYMPHOCYTES; ANTIBODIES; DISEASE; ANTIGEN	Maternal sources of transforming growth factor-beta 1 (TGF-beta 1) are shown here to contribute to the normal appearance and perinatal survival of TGF-beta 1 null newborn mice. Labeled TGF-beta 1 crossed the placenta and was recovered intact from various tissues after oral administration to mouse pups. TGF beta-1 protein was also detected in cells recovered from breast milk. In immunohistochemical analyses, TGF-beta 1 null embryos and null newborn pups born to TGF-beta 1 heterozygotes stained positive for TGF-beta 1, whereas those born to a null female were negative and had severe cardiac abnormalities. These results suggest an important role for maternal sources of TGF-beta 1 during development and, more generally, provide evidence for maternal rescue of targeted gene disruption in the fetus.	NINCDS,DEV & METAB NEUROL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	LETTERIO, JJ (corresponding author), NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892, USA.							ABRAHAMSON DR, 1981, J CELL BIOL, V91, P270, DOI 10.1083/jcb.91.1.270; ADENIYIJONES SCA, 1987, J IMMUNOL, V138, P1408; BOTTAZZO GF, 1985, NEW ENGL J MED, V313, P353, DOI 10.1056/NEJM198508083130604; Brambell FWR., 1970, N HOLL RES MONOGR FR, V18; CELADA A, 1993, J EXP MED, V177, P691, DOI 10.1084/jem.177.3.691; COX DA, 1991, EUR J BIOCHEM, V197, P353, DOI 10.1111/j.1432-1033.1991.tb15918.x; DANIELPOUR D, 1993, J IMMUNOL METHODS, V158, P17, DOI 10.1016/0022-1759(93)90254-5; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DRESSER DW, 1990, J REPROD IMMUNOL, V18, P293, DOI 10.1016/0165-0378(90)90050-G; ERICKSON HP, 1993, J CELL BIOL, V120, P1079, DOI 10.1083/jcb.120.5.1079; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; GEISER AG, 1993, P NATL ACAD SCI USA, V90, P9944, DOI 10.1073/pnas.90.21.9944; HANAFUSA T, 1983, LANCET, V2, P1111; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LETTERIO JJ, UNPUB; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLAN FA, 1991, DEVELOPMENT, V111, P131; POPLIKER M, 1987, DEV BIOL, V119, P38, DOI 10.1016/0012-1606(87)90204-1; ROBERTS A, 1990, PEPTIDE GROWTH FACTO, V1, pCH8; SEELIG LL, 1981, TRANSPLANTATION, V32, P308, DOI 10.1097/00007890-198110000-00010; SEELIG LL, 1987, J REPROD IMMUNOL, V10, P285, DOI 10.1016/0165-0378(87)90031-3; SHIMAMURA M, 1994, BLOOD, V83, P926, DOI 10.1182/blood.V83.4.926.bloodjournal834926; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; STACH RM, 1993, J EXP MED, V17, P841; TOKUYAMA H, 1989, CELL BIOL INT REP, V13, P251, DOI 10.1016/0309-1651(89)90147-1; WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932; 1992, MOL REPROD DEV, V32	29	441	460	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1936	1938		10.1126/science.8009224	http://dx.doi.org/10.1126/science.8009224			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009224				2022-12-28	WOS:A1994NT84700046
J	ROMEO, R; POL, S; BERTHELOT, P; BRECHOT, C				ROMEO, R; POL, S; BERTHELOT, P; BRECHOT, C			ERADICATION OF HEPATITIS-C VIRUS-RNA AFTER ALPHA-INTERFERON THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note							LIVER-DISEASE; HCV; MULTICENTER; VIREMIA; SERUM		CHU NECKER, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	ROMEO, R (corresponding author), UNIV MILAN, INST INTERNAL MED, VIA PACE 9, I-20122 MILAN, ITALY.			Romeo, Raffaella/0000-0002-7858-4670				ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRILLANTI S, 1993, LANCET, V341, P464, DOI 10.1016/0140-6736(93)90210-8; BROUWER JT, 1993, HEPATOLOGY, V18, pA110; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; GIL B, 1993, HEPATOLOGY, V18, P1050; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; NOUSBAUM JB, 1993, HEPATOLOGY, V18, pA88; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; ROMEO R, 1993, TRANSFUSION, V33, P629, DOI 10.1046/j.1537-2995.1993.33893342742.x; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3	11	67	67	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					276	277		10.7326/0003-4819-121-4-199408150-00008	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00008			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037409				2022-12-28	WOS:A1994PB10200008
J	LONGSTRETH, WT; NELSON, LM; KOEPSELL, TD; VANBELLE, G				LONGSTRETH, WT; NELSON, LM; KOEPSELL, TD; VANBELLE, G			SUBARACHNOID HEMORRHAGE AND HORMONAL FACTORS IN WOMEN - A POPULATION-BASED CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						SUBARACHNOID HEMORRHAGE; HORMONE REPLACEMENT THERAPY, POSTMENOPAUSAL; MENSTRUATION; ESTROGENS	ORAL-CONTRACEPTIVES; CIGARETTE-SMOKING; REPLACEMENT THERAPY; RISK-FACTORS; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN; PROXY RESPONDENTS; FOLLOW-UP; STROKE; HYPERTENSION	Objective: To determine the degree to which endogenous and exogenous hormonal factors influence the risk for subarachnoid hemorrhage in women. Design: A population-based case-control study. Setting: King County, Washington. Participants: 103 women with an incident, spontaneous subarachnoid hemorrhage and 2 age- and sex-matched controls per case-patient who were identified through random-digit dialing. Measurements: Information on exposures was collected during in-person interviews of case-patients, controls, and their surrogates. Results: Premenopausal women, especially those without a history of smoking or hypertension, were at a reduced risk for subarachnoid hemorrhage compared with age-matched postmenopausal women (odds ratio, 0.24; 95% CI, 0.09 to 0.68). The use of hormone replacement therapy was associated with a reduced risk (odds ratio, 0.47; CI, 0.26 to 0.86); the reduction was significantly greater in women who had smoked than in those that had never smoked. Of the 23 premenopausal case-patients, 74% were either menstruating when hemorrhaging occurred or had had their last menstrual period 21 or more days before hemorrhaging compared with the expected 43% (difference, 31%; CI, 4% to 58%). Conclusions: Premenopausal women are at reduced risk for subarachnoid hemorrhage, especially those without a history of smoking or hypertension. Hormone replacement therapy reduced the risk only in postmenopausal women who had ever smoked. Among women still menstruating, the risk for hemorrhage was greatest in the perimenstrual period.	UNIV WASHINGTON, SCH MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT ENVIRONM HLTH, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Nelson, Lorene M/D-1305-2011		NINDS NIH HHS [R01 NS22690] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022690] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAM S, 1981, BRIT MED J, V282, P1277, DOI 10.1136/bmj.282.6272.1277; BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; BOLOGNIA JL, 1989, MATURITAS, V11, P295, DOI 10.1016/0378-5122(89)90026-1; BONITA R, 1986, STROKE, V17, P831, DOI 10.1161/01.STR.17.5.831; BOURNE T, 1990, LANCET, V335, P1470, DOI 10.1016/0140-6736(90)91505-5; BRASS LM, 1990, J CARDIOVASC TECHNOL, V9, P68; BRINCAT M, 1983, BRIT MED J, V287, P1337, DOI 10.1136/bmj.287.6402.1337; DAVIES OL, 1980, STATISTICAL METHODS, V1; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FISCH IR, 1977, JAMA-J AM MED ASSOC, V237, P2499, DOI 10.1001/jama.237.23.2499; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; GANGAR KF, 1991, LANCET, V338, P839; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; GILL JS, 1987, CLIN SCI, V73, pP57; HANDA H, 1983, STROKE, V14, P857, DOI 10.1161/01.STR.14.6.857; HEYMAN A, 1976, NEUROLOGY, V26, P358; KNEKT P, 1991, J CLIN EPIDEMIOL, V44, P933, DOI 10.1016/0895-4356(91)90056-F; Lind T, 1979, Br J Obstet Gynaecol, V86 Suppl 3, P1, DOI 10.1111/j.1471-0528.1979.tb16232.x; LINDEGARD B, 1987, ACTA NEUROL SCAND, V76, P37, DOI 10.1111/j.1600-0404.1987.tb03541.x; LONGSTRETH WT, 1985, STROKE, V16, P377, DOI 10.1161/01.STR.16.3.377; LONGSTRETH WT, 1992, STROKE, V23, P1242, DOI 10.1161/01.STR.23.9.1242; LONGSTRETH WT, 1993, NEUROLOGY, V43, P712, DOI 10.1212/WNL.43.4.712; MARSHALL JC, 1989, ENDOCRINOLOGOY, P1940; MASHCHAK CA, 1985, J REPROD MED, V30, P805; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NELSON LM, 1994, EPIDEMIOLOGY, V5, P204, DOI 10.1097/00001648-199403000-00011; NELSON LM, 1990, EPIDEMIOL REV, V12, P71, DOI 10.1093/oxfordjournals.epirev.a036063; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; POULTER NR, 1991, ADV CONTRACEPTION S3, V7, P65; PRENTICE RL, 1987, ADV CANCER RES, V49, P285, DOI 10.1016/S0065-230X(08)60801-5; PRENTICE RL, 1988, AM J EPIDEMIOL, V127, P213, DOI 10.1093/oxfordjournals.aje.a114797; ROBINSON RW, 1977, NEW ENGL J MED, V86, P597; ROBISON LL, 1984, AM J EPIDEMIOL, V120, P164, DOI 10.1093/oxfordjournals.aje.a113866; SARREL PM, 1990, MATURITAS, V12, P287, DOI 10.1016/0378-5122(90)90008-T; SHAMMA F, 1992, Neurology, V42, P272; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STOBER T, 1985, J NEUROL, V232, P67, DOI 10.1007/BF00313903; THOROGOOD M, 1990, BRIT J FAMILY PLANNI, V0016; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; TORNER JC, 1984, SEMIN NEUROL, V4, P354, DOI 10.1055/s-2008-1041565; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WALKER AM, 1988, AM J EPIDEMIOL, V127, P905, DOI 10.1093/oxfordjournals.aje.a114893; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; WREN BG, 1992, MED J AUSTRALIA, V157, P204, DOI 10.5694/j.1326-5377.1992.tb137091.x; 1982, JAMA-J AM MED ASSOC, V247, P633	45	142	144	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					168	173		10.7326/0003-4819-121-3-199408010-00002	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017743				2022-12-28	WOS:A1994NY33800002
J	FORD, JC; ALKHODAIRY, F; FOTOU, E; SHELDRICK, KS; GRIFFITHS, DJF; CARR, AM				FORD, JC; ALKHODAIRY, F; FOTOU, E; SHELDRICK, KS; GRIFFITHS, DJF; CARR, AM			14-3-3-PROTEIN HOMOLOGS REQUIRED FOR THE DNA-DAMAGE CHECKPOINT IN FISSION YEAST	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE; KINASE-C; GENE; CLONING; REPLICATION; THIAMINE; MITOSIS; REPAIR; FAMILY	During the cell cycle, DNA is replicated and segregated equally into two daughter cells. The DNA damage checkpoint ensures that DNA damage is repaired before mitosis is attempted. Genetic studies of the fission yeast Schizosaccharomyces pombe have identified two genes, rad24 and rad25, that are required for this checkpoint. These genes encode 14-3-3 protein homologs that together provide a function that is essential for cell proliferation. In addition, S. pombe rad24 null mutants, and to a lesser extent rad25 null mutants, enter mitosis prematurely, which indicates that 14-3-3 proteins have a role in determining the timing of mitosis.	UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,ENGLAND	University of Sussex				Carr, Antony Michael/0000-0002-2028-2389				AITKEN A, 1990, NATURE, V344, P594; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MURRAY JM, 1992, NUCLEIC ACIDS RES, V20, P2673, DOI 10.1093/nar/20.11.2673; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SHELDRICK KS, 1993, BIOESSAYS, V15, P775, DOI 10.1002/bies.950151202; SHELDRICK KS, UNPUB; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	23	319	325	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					533	535		10.1126/science.8036497	http://dx.doi.org/10.1126/science.8036497			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036497				2022-12-28	WOS:A1994NY21600033
J	PEREIRA, L; LEVRAN, O; RAMIREZ, F; LYNCH, JR; SYKES, B; PYERITZ, RE; DIETZ, HC				PEREIRA, L; LEVRAN, O; RAMIREZ, F; LYNCH, JR; SYKES, B; PYERITZ, RE; DIETZ, HC			A MOLECULAR APPROACH TO THE STRATIFICATION OF CARDIOVASCULAR RISK IN FAMILIES WITH MARFANS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONNECTIVE-TISSUE; FIBRILLIN GENES; MISSENSE MUTATION; CALCIUM-BINDING; SYNDROME LOCUS; CHROMOSOME-15; DIAGNOSIS; LINKAGE; DISORDER; SEQUENCE	Background. The fibrillin gene encodes a protein in the extracellular matrix, and this protein is widely distributed in elastic tissues. The fibrillin gene is the site of mutations causing Marfan's syndrome. This disorder shows a high degree of clinical variability both between and within families. Each family appears to have a unique mutation in the fibrillin gene, which precludes the routine use of mutation screening for presymptomatic diagnosis of the disorder. The goal of this study was to develop a widely applicable method of molecular diagnosis. Methods. We used three newly characterized intragenic sites of normal DNA repeat-sequence variation (i.e., polymorphisms) as markers to follow the inheritance pattern of specific copies (alleles) of the fibrillin gene in multiple kindreds with various clinical features of Marfan's syndrome. Results. The polymorphic markers allowed identification of the particular copy of the fibrillin gene that cosegregated with Marfan's syndrome in 13 of the 14 families tested. In 11 families a definite presymptomatic diagnosis of Marfan's syndrome could be made in family members who had only equivocal manifestations of the disorder. In two other families, some family members demonstrated either classic Marfan's syndrome or a milder but closely related phenotype. The copy of the fibrillin gene that cosegregated with classic Marfan's syndrome was not inherited by family members with the latter, atypical, form of the disease. These milder phenotypes, previously diagnosed as Marfan's syndrome, were not associated with aortic involvement. Conclusions, These results document the usefulness of novel polymorphic DNA repeat sequences in the presymptomatic diagnosis of Marfan's syndrome. Our findings also demonstrate that the various clinical phenotypes seen in selected families may be due not to single fibrillin mutations, but rather to different genetic alterations. These findings underscore the need for a modification of the current diagnostic criteria for Marfan's syndrome in order to achieve accurate risk assessment.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,HEADINGTON,OXON,ENGLAND; ALLEGHENY SINGER RES INST,DEPT HUMAN GENET,PITTSBURGH,PA 15212; JOHNS HOPKINS UNIV,SCH MED,DIV PEDIAT CARDIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,BALTIMORE,MD 21205	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Oxford; Johns Hopkins University; Johns Hopkins University			Pyeritz, Reed/A-1364-2010; Pereira, Lygia V/C-1049-2012	Pereira, Lygia V/0000-0002-0002-725X	NCRR NIH HHS [RR-007722] Funding Source: Medline; NHLBI NIH HHS [HL-02815, HL-35877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035877] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BOILEAU C, 1993, AM J HUM GENET, V53, P46; CLARK BA, 1991, NUCLEIC ACIDS RES, V19, P4309, DOI 10.1093/nar/19.15.4309; Dietz Harry C., 1992, Human Mutation, V1, P366, DOI 10.1002/humu.1380010504; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DIETZ HC, 1992, J CLIN INVEST, V89, P1674, DOI 10.1172/JCI115766; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; GLESBY MJ, 1989, JAMA-J AM MED ASSOC, V262, P523, DOI 10.1001/jama.262.4.523; GODFREY M, 1993, AM J HUM GENET, V53, P472; GOTT VL, 1991, ANN THORAC SURG, V52, P38, DOI 10.1016/0003-4975(91)91414-Q; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; KAINULAINEN K, 1992, P NATL ACAD SCI USA, V89, P5917, DOI 10.1073/pnas.89.13.5917; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; KAINULAINEN K, 1991, AM J HUM GENET, V49, P662; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SARFARAZI M, 1992, J MED GENET, V29, P75, DOI 10.1136/jmg.29.2.75; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; TSIPOURAS P, 1991, P NATL ACAD SCI USA, V88, P4486, DOI 10.1073/pnas.88.10.4486; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1; [No title captured]	30	100	106	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					148	153		10.1056/NEJM199407213310302	http://dx.doi.org/10.1056/NEJM199407213310302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008028	Bronze			2022-12-28	WOS:A1994NW79700002
J	WEI, N; CHAMOVITZ, DA; DENG, XW				WEI, N; CHAMOVITZ, DA; DENG, XW			ARABIDOPSIS COP9 IS A COMPONENT OF A NOVEL SIGNALING COMPLEX MEDIATING LIGHT CONTROL OF DEVELOPMENT	CELL			English	Article							GENE-EXPRESSION; REGULATED DEVELOPMENT; HYPOCOTYL ELONGATION; PROTEIN; PHYTOCHROME; MUTANTS; ENCODES	Environmental light signals are sensed by multiple families of photoreceptors and transduced by largely unknown mechanisms to regulate plant development. In this report, genetic analysis suggested that light signals perceived by both phytochromes and a blue light receptor converge to repress the action of Arabidopsis COP9 in suppressing seedling photomorphogenesis. Molecular cloning of the gene revealed that COP9 encodes a novel protein of 197 amino acids whose expression is not regulated by light. COP9 functions as a large (>560 kDa) complex(es) that is probably subjected to light modulation. In addition, COP8 and COP11 are required for either the COP9 complex formation or its stability. Therefore COP9, together with COP8 and COP11, defines a novel signaling step in mediating light control of plant development.			WEI, N (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520, USA.		Deng, Xing Wang/ABF-4107-2020; Chamovitz, Daniel/S-5021-2019	Chamovitz, Daniel/0000-0002-2815-2909				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ANG LH, 1994, PLANT CELL, V6, P613, DOI 10.1105/tpc.6.5.613; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1992, DEVELOPMENT, V115, P337; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; GLASS DB, 1986, J BIOL CHEM, V261, P2987; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; Kendrick RE, 1993, PHOTOMORPHOGENESIS P; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; LISCUM E, 1991, PLANT CELL, V3, P685, DOI 10.1105/tpc.3.7.685; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MISERA S, 1994, IN PRESS MOL GEN GEN; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; ROMERO LC, 1993, P NATL ACAD SCI USA, V90, P1465, DOI 10.1073/pnas.90.4.1465; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; WEI N, 1992, PLANT CELL, V4, P1507, DOI 10.1105/tpc.4.12.1507; WEI N, 1994, PLANT CELL, V6, P629, DOI 10.1105/tpc.6.5.629; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757	25	286	304	0	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					117	124		10.1016/0092-8674(94)90578-9	http://dx.doi.org/10.1016/0092-8674(94)90578-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033203				2022-12-28	WOS:A1994NX32800014
J	MENG, J; WYSS, AR; DAWSON, MR; ZHAI, RJ				MENG, J; WYSS, AR; DAWSON, MR; ZHAI, RJ			PRIMITIVE FOSSIL RODENT FROM INNER-MONGOLIA AND ITS IMPLICATIONS FOR MAMMALIAN PHYLOGENY	NATURE			English	Article							GUINEA-PIG	THE evolutionary origin of rodents is obscured by the group's sudden and highly transformed first appearance in the fossil record(1,2) in the latest Paleocene. We report here the discovery of nearly complete dental remains of an extraordinary new primitive rodent from strata of transitional Paleocene-Eocene age in Inner Mongolia, China. The strikingly conservative morphological features of this taxon, Tribosphenomys minutus, gen. et sp. nov., substantially modify previous ideas about the ancestral rodent morphotype, which in turn has important implications for understanding the origin of rodents and their relationship to other eutherian mammals. This new fossil, in conjunction with recent morphological(3) and molecular(4,5) evidence confirming rodent monophyly, indicates the need for a reassessment of phylogenetic affinities among gliriform eutherians. Our results indicate a sister-group position of the new taxon to other rodents, and support the alliance of lagomorphs (rabbits) and rodents (cohort Glires). They also suggest the paraphyly of an extinct assemblage, the 'Eurymylidae', and reveal an unexpectedly complex pattern of character evolution near the ancestry of Rodentia.	INST VERTEBRATE PALEONTOL & PALEOANTHROPOL, BEIJING, PEOPLES R CHINA; UNIV CALIF SANTA BARBARA, DEPT GEOL SCI, SANTA BARBARA, CA 93106 USA; CARNEGIE MUSEUM NAT HIST, VERTEBRATE PALEONTOL SECT, PITTSBURGH, PA 15213 USA	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; University of California System; University of California Santa Barbara	MENG, J (corresponding author), AMER MUSEUM NAT HIST, DEPT VERTEBRATE PALEONTOL, CENT PK W & 79TH ST, NEW YORK, NY 10024 USA.							ARCHIBALD JD, 1987, CENOZOIC MAMMALS N A, P25; Butler PM., 1985, EVOLUTIONARY RELATIO, P381; DASHZEVEG D, 1988, PALAEONTOLOGY, V31, P129; DASHZEVEG D, 1987, P K NED AKAD B PHYS, V90, P133; DASHZEVEG D, 1990, Acta Zoologica Cracoviensia, V33, P11; DASHZEVEG D, 1990, Acta Zoologica Cracoviensia, V33, P37; DASHZEVEG D, 1988, J GEOL SOC LONDON, V145, P473, DOI 10.1144/gsjgs.145.3.0473; Dawson M. R., 1984, SPECIAL PUBLICATION, V9, P138; Flynn L.J., 1986, AM MUS NOVIT, V2841, P1; GRAUR D, 1991, NATURE, V351, P649, DOI 10.1038/351649a0; Hartenberger J.L., 1985, EVOLUTIONARY RELATIO, P1; HONEYCUTT RL, 1993, ANNU REV ECOL SYST, V24, P279, DOI 10.1146/annurev.es.24.110193.001431; Krishtalka L., 1987, P77; Li C., 1985, EVOLUTIONARY RELATIO, P35; Li C.-K., 1987, Current Mammalogy, V1, P97; LI CK, 1993, MAMMAL PHYLOGENY : PLACENTALS, P151; LI CK, 1989, NATURAL HIST MUSEUM, V33, P179; LI WH, 1992, J HERED, V83, P174, DOI 10.1093/oxfordjournals.jhered.a111188; Luckett W. P., 1993, Journal of Mammalian Evolution, V1, P127, DOI 10.1007/BF01041591; Luckett WP, 1985, EVOLUTIONARY RELATIO, P685; MARTIGNETTI JA, 1993, P NATL ACAD SCI USA, V90, P9698, DOI 10.1073/pnas.90.20.9698; McKenna Malcolm C., 1993, Journal of Vertebrate Paleontology, V13, p50A; NOVACEK MJ, 1985, EVOLUTIONARY RELATIO, P59; RUSSELL D E, 1987, Memoires du Museum National d'Histoire Naturelle Serie C Sciences de la Terre, V52, P1; STEHLIN HG, 1951, SCHWEIZ PALEONT ABH, V67, P1; SWOFFORD DL, 1993, PAUP 311; TONG YS, IN PRESS ANN CARNEGI; VONKOENIGSWALD W, 1985, EVOLUTIONARY RELATIO, P403; WOOD ALBERT E., 1962, TRANS AMER PHIL SOC, V52, P1; [No title captured]	30	69	77	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					134	136		10.1038/370134a0	http://dx.doi.org/10.1038/370134a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022481				2022-12-28	WOS:A1994NW80400054
J	ABBY, M; MASSEY, MD; GALANDIUK, S; POLK, HC				ABBY, M; MASSEY, MD; GALANDIUK, S; POLK, HC			PEER-REVIEW IS AN EFFECTIVE SCREENING PROCESS TO EVALUATE MEDICAL MANUSCRIPTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		PUBLICATION	Objective.-To measure the effectiveness of peer review as a screening process to evaluate medical manuscripts. Design.-Retrospective. Setting.-The editorial office of the American Journal of Surgery (AJS). Method.-A MEDLINE search was conducted of publications from 1984 to 1992 for manuscripts that were identical or similar to those rejected by AJS between January and December 1989. Manuscripts that were submitted to AJS by foreign authors were excluded because of the presumed difficulty in tracking foreign-language publications. Main Outcome Measures.-The percentage of manuscripts rejected by AJS that were subsequently published in journals indexed by MEDLINE, the time from rejection to ultimate publication, and the journal of publication. The reasons for rejection were also documented. We assumed that the majority of rejected manuscripts would be published within 3 years after rejection. Results.-One hundred twenty-five manuscripts submitted by North American authors were rejected by AJS in 1989, and 62% were not subsequently published in another core medical journal during the study period. The average duration between rejection and later publication was 17 months. Of those manuscripts subsequently published, 54% appeared in general surgical journals, including 12% that were revised, reevaluated, and later accepted by AJS. Twenty-nine percent of the rejected manuscripts were published in specialty medical journals, 10% in state and local journals, and the remainder in general medical journals. Twenty-eight percent of the authors of rejected manuscripts had previously and subsequently published manuscripts on very similar subjects. Conclusions.-Our data indicate that the review process serves as a sieve and influences whether manuscripts are published in core medical journals. This was demonstrated by the fact that rejected manuscripts often were not published in other indexed medical journals.	UNIV LOUISVILLE,SCH MED,DEPT SURG,LOUISVILLE,KY 40292; REED ELSEVIER MED PUBLISHERS USA,AMER JOURNAL SURG,BELLE MEAD,NJ	University of Louisville; Reed Elsevier								ABT HA, 1988, PUBL ASTRON SOC PAC, V100, P506, DOI 10.1086/132198; BAILAR JC, 1985, NEW ENGL J MED, V312, P654, DOI 10.1056/NEJM198503073121023; CHEW FS, 1991, AM J ROENTGENOL, V156, P627, DOI 10.2214/ajr.156.3.1899764; GARFIELD E, 1988, SCI J CITATION REPOR, P19; Garvey W.D., 1979, COMMUNICATION ESSENC, P280; Lock S., 1985, DIFFICULT BALANCE ED; RELMAN AS, 1978, COPING BIOMEDICAL LI, P54; STOSSEL TP, 1990, ETHICS POLICY SCI PU, P268; WALDRON T, 1992, BRIT MED J, V304, P1029, DOI 10.1136/bmj.304.6833.1029; Whitman N, 1985, Fam Med, V17, P26; WILLIAMSON JW, 1986, MED USE STATISTICS, P370; WILSON JD, 1978, J CLIN INVEST, V58, P1697; YENTIS SM, 1993, CAN J ANAESTH, V40, P632, DOI 10.1007/BF03009700; 1993, LIST J INDEXED INDEX; 1993, ULRICHS INT PERIODIC	15	34	34	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					105	107		10.1001/jama.272.2.105	http://dx.doi.org/10.1001/jama.272.2.105			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015116				2022-12-28	WOS:A1994NV42400006
J	CHO, MK; BERO, LA				CHO, MK; BERO, LA			INSTRUMENTS FOR ASSESSING THE QUALITY OF DRUG STUDIES PUBLISHED IN THE MEDICAL LITERATURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To develop valid and reliable instruments to assess the methodologic quality and clinical relevance of drug studies. Design.-We developed an instrument to assess the methodologic quality of articles reporting clinical research and an instrument to measure nonmethodologic measures of quality, such as clinical relevance, generalizability, and adherence to ethical standards. Each instrument was pretested by seven independent, masked reviewers and modified based on interrater agreement and content validity of individual items. We determined correlational validity of the final methodologic quality instrument by comparing quality scores assigned to 10 articles by means of our instrument and a previously published one. Participants.-Clinical drug studies published in symposium proceedings and peer reviewed biomedical literature. Main Outcome Measures.-Interrater reliability of overall quality scores, measured by intraclass correlation (r) and Kendall's coefficient of concordance (W), and interrater reliability of individual items, by percentage agreement. Main Results.-The interrater reliability of the pretest methodologic quality instrument was high (r=.89 [95% confidence interval, .73 to .96]; W=0.64). Correlational validity of the final instrument was suggested by the high degree of concordance with another previously published one (W=0.74). The interrater reliability of the pretest clinical relevance instrument was moderate (r=.41 [95% confidence interval, .18 to .64]; W=0.47). Reviewers confirmed the content validity of both instruments. Conclusions.-The two instruments we developed, one measuring methodologic quality and one measuring clinical relevance of articles reporting clinical research, are reliable, valid, and applicable to a variety of research designs.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DIV CLIN PHARM, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, DEPT VET AFFAIRS, CTR HLTH CARE EVALUAT, PALO ALTO, CA USA; STANFORD UNIV, DEPT HLTH RES & POLICY, STANFORD, CA 94305 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	CHO, MK (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, INST HLTH POLICY STUDIES, 1388 SUTTER ST, 11TH FLOOR, SAN FRANCISCO, CA 94109 USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				ANDREW E, 1990, EUR J RADIOL, V10, P92, DOI 10.1016/0720-048X(90)90114-Q; ANDREW E, 1984, ACTA RADIOL DIAGN, V25, P55, DOI 10.1177/028418518402500111; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BAILAR JC, 1988, ANN INTERN MED, V108, P266, DOI 10.7326/0003-4819-108-2-266; BERLIN JA, 1993, 2ND INT C PEER REV B; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; COOPER GS, 1989, J GEN INTERN MED, V4, P232, DOI 10.1007/BF02599530; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; DETSKY AS, 1987, ANN INTERN MED, V107, P195, DOI 10.7326/0003-4819-107-2-195; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; FEURER I, 1993, 2ND INT C PEER REV B; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; Haggard E.A., 1958, INTRACLASS CORRELATI; HEMMINKI E, 1982, METHOD INFORM MED, V21, P81; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; MCREYNOLDS P, 1971, AM PSYCHOL, V26, P400, DOI 10.1037/h0037937; SCOTT WA, 1974, AM PSYCHOL, V29, P698, DOI 10.1037/h0037631; Siegel S., 1988, NONPARAMETRIC STAT B; SPITZER WO, 1990, CLIN INVEST MED, V13, P17; WOLFF WM, 1970, AM PSYCHOL, V25, P636, DOI 10.1037/h0029770; 1979, CAN MED ASS J, V121, P1193; 1990, OFFICES DRUG EVALUAT	25	140	142	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					101	104		10.1001/jama.272.2.101	http://dx.doi.org/10.1001/jama.272.2.101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015115				2022-12-28	WOS:A1994NV42400005
J	FISHER, P; WARD, A				FISHER, P; WARD, A			MEDICINE IN EUROPE .8. COMPLEMENTARY MEDICINE IN EUROPE	BRITISH MEDICAL JOURNAL			English	Article							ALTERNATIVE MEDICINE; PRACTITIONERS	Complementary or unconventional treatments are used by many doctors and other therapists throughout Europe, The major forms are acupuncture, homoeopathy, manual therapy or manipulation, and phytotherapy or herbal medicine. The relative popularity of therapies differs between countries, but public demand is strong and growing. Regulation of practitioners varies widely: in most countries only registered health professionals may practice, but in the United Kingdom practice is virtually unregulated. Germany and some Scandinavian countries have intermediate systems. Legal reforms are in progress in the Netherlands and the United Kingdom. European institutions are starting to influence the development of complementary medicine. Harmonisation of training and regulation of practitioners is the challenge for the future.			FISHER, P (corresponding author), ROYAL LONDON HOMOEOPATH HOSP,GREAT ORMOND ST,LONDON WC1N 3HR,ENGLAND.							ANDERSON E, 1988, J R COLL GEN PRACT, V38, P511; BOUCHAYER F, 1991, COMPLEMENTARY MED EU; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FULDER S, 1981, STATUS COMPLEMENTARY; FULDER SJ, 1985, LANCET, V2, P542; HALPERN S, 1985, HLTH SOCIAL SER 0606, P702; HUGGON T, 1990, J ALTERNATIVE CO JAN; KNIPSCHILD P, 1990, SOC SCI MED, V31, P625, DOI 10.1016/0277-9536(90)90099-E; MATTHIESSEN P, 1992, MATERIALIEN GESUNDHE, V21; PIETRONI PC, 1992, BRIT MED J, V305, P564, DOI 10.1136/bmj.305.6853.564; RASMUSSEN N, 1991, COMPLEMENTARY MED EU; REILLY DT, 1983, BRIT MED J, V287, P337, DOI 10.1136/bmj.287.6388.337; SERMEUS G, 1991, COMPLEMENTARY MED EU; SWAYNE JMD, 1989, J ROY COLL GEN PRACT, V39, P503; VANDIJK P, 1993, GENEWIJZEN NEDERLAND; VASKILAMPI T, 1991, COMPLEMENTARY MED EU; VISSER J, 1991, COMPLEMENTARY MED EU; WHARTON R, 1986, BRIT MED J, V292, P1498, DOI 10.1136/bmj.292.6534.1498; 1989, TIMES           1113; 1992, OFFICIAL J EURO 1013; 1992, DOCTOR          0716, P17; 1992, EEC MARKET HOMOEOPAT; 1989, REPORT ALTERNATIVE M; 1993, COMPLEMENTARY MED NE; 1993, HOMEOPATHIE 1993; 1993, COMPLEMENTARY THERAP; 1992, REGULATON PRACTITION	27	496	512	1	44	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					107	111		10.1136/bmj.309.6947.107	http://dx.doi.org/10.1136/bmj.309.6947.107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038643	Green Published			2022-12-28	WOS:A1994NW71600028
J	GRAZIOSI, C; PANTALEO, G; GANTT, KR; FORTIN, JP; DEMAREST, JF; COHEN, OJ; SEKALY, RP; FAUCI, AS				GRAZIOSI, C; PANTALEO, G; GANTT, KR; FORTIN, JP; DEMAREST, JF; COHEN, OJ; SEKALY, RP; FAUCI, AS			LACK OF EVIDENCE FOR THE DICHOTOMY OF T(H)1 AND T(H)2 PREDOMINANCE IN HIV-INFECTED INDIVIDUALS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL CLONES; INTERFERON-GAMMA PRODUCTION; MESSENGER-RNA EXPRESSION; CYTOKINE PRODUCTION; IFN-GAMMA; HELPER CELL; SCHISTOSOMA-MANSONI; GENE-EXPRESSION; HOMOSEXUAL MEN	A switch from a T helper 1 (T(H)1) cytokine phenotype to a T(H)2 phenotype has been proposed as a critical element in the progression of human immunodeficiency virus (HIV) disease. Here, constitutive cytokine expression was analyzed in unfractionated and sorted cell populations isolated from peripheral blood and lymph nodes of HIV-infected individuals at different stages of disease. Expression of interleukin-2 (IL-2) and IL-4 was barely detectable (or undetectable) regardless of the stage of disease. CD8(+) cells expressed large amounts of interferon gamma and IL-10, and the levels of these cytokines remained stably high throughout the course of infection. Furthermore, similar patterns of cytokine expression were observed after stimulation in vitro of purified CD4(+) T cell populations obtained from HIV-infected individuals at different stages of disease. These results indicate that a switch from the T(H)1 to the T(H)2 cytokine phenotype does not occur during the progression of HIV disease.	INST RECH CLIN MONTREAL,IMMUNOL LAB,MONTREAL H2W 1R7,PQ,CANADA; UNIV MONTREAL,DEPT MICROBIOL & IMMUNOL,MONTREAL H3C 3J7,PQ,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3T 1E2,PQ,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University	GRAZIOSI, C (corresponding author), NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892, USA.		Pantaleo, Giuseppe/K-6163-2016; graziosi, cecilia/M-1882-2019					ABRAMS DI, 1984, ANN INTERN MED, V100, P801, DOI 10.7326/0003-4819-100-6-801; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; BANSAL AS, 1993, IMMUNOLOGY, V80, P652; BARNES PF, 1990, J IMMUNOL, V145, P149; BOYLE MJ, 1993, CLIN EXP IMMUNOL, V92, P100; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DELPRETE G, 1993, J IMMUNOL, V150, P353; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; DING L, 1992, J IMMUNOL, V148, P3133; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; ELSE JK, 1994, J EXP MED, V179, P347; EMILIE D, 1990, J CLIN INVEST, V86, P148, DOI 10.1172/JCI114678; FAN J, 1993, J IMMUNOL, V151, P5031; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; GOUGEON ML, 1991, CR ACAD SCI III-VIE, V312, P529; GRAZIOSI C, 1993, CURRENT PROTOCOLS IM, V5; GROUX H, 1993, EUR J IMMUNOL, V23, P1623, DOI 10.1002/eji.1830230734; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HARPAZ R, 1992, J CLIN INVEST, V90, P515, DOI 10.1172/JCI115889; KARP CL, 1993, J CLIN INVEST, V91, P1644, DOI 10.1172/JCI116372; LABRECQUE N, 1993, J EXP MED, V177, P1735, DOI 10.1084/jem.177.6.1735; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LUCEY DR, 1990, AIDS RES HUM RETROV, V6, P427, DOI 10.1089/aid.1990.6.427; MAGGI E, 1991, J IMMUNOL, V146, P1169; MAGGI E, COMMUNICATION; MAHANTY S, 1992, J IMMUNOL, V148, P3567; MALEFYT RD, 1991, J EXP MED, V174, P915; MARGOLICK JB, 1985, J CLIN INVEST, V76, P709, DOI 10.1172/JCI112025; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MOAETTA A, 1983, J EXP MED, V157, P743; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mshana R N, 1991, J Clin Lab Immunol, V34, P131; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, J NIH RES, V5, P68; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SIELING PA, 1993, J IMMUNOL, V150, P5501; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; TSICOPOULOS A, 1992, J IMMUNOL, V148, P2058; VIEIRA P, 1991, P NATL ACAD SCI USA, V88, P1172, DOI 10.1073/pnas.88.4.1172; WESTERMANN J, 1993, J IMMUNOL, V150, P3843; WYNN TA, 1993, J IMMUNOL, V151, P1430; YAMAMURA M, 1992, J IMMUNOL, V149, P1470; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582; ZWINGENBERGER K, 1991, SCAND J IMMUNOL, V34, P243, DOI 10.1111/j.1365-3083.1991.tb01543.x; ZWINGENBERGER K, 1990, CLIN IMMUNOL IMMUNOP, V57, P242, DOI 10.1016/0090-1229(90)90038-R	59	425	432	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					248	252		10.1126/science.8023143	http://dx.doi.org/10.1126/science.8023143			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023143				2022-12-28	WOS:A1994NV95700041
J	VINCENT, JP; LAWRENCE, PA				VINCENT, JP; LAWRENCE, PA			DROSOPHILA WINGLESS SUSTAINS ENGRAILED EXPRESSION ONLY IN ADJOINING CELLS - EVIDENCE FROM MOSAIC EMBRYOS	CELL			English	Article							SEGMENT-POLARITY GENE; FUSHI-TARAZU; PROTEIN; PARASEGMENTS; EPIDERMIS; SECRETION; PATTERN; WNT-1	The wingless protein is secreted, but it is not known whether it acts only on cells near to its site of synthesis or whether it has a longer range. Here, we use mosaic Drosophila embryos to estimate the range of wingless as it acts to maintain expression of the engrailed gene. We find that expression of engrailed is often sustained in those wingless(-) cells that are located near a wildtype patch of tissue, but this is not invariably so. Also, the numbers of cells maintaining engrailed expression are small. From these findings, we argue that wing less-expressing cells sustain engrailed expression only in adjoining cells. The wingless gene is also needed for maintenance of its own expression; using mosaics, we find that the range of this action is short as well.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology				Lawrence, Peter/0000-0002-9554-8268				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; CRICK FHC, 1975, SCIENCE, V189, P340, DOI 10.1126/science.806966; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FOE VE, 1989, DEVELOPMENT, V107, P1; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; LAWRENCE PA, 1989, DEVELOPMENT, V107, P847; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1993, DEVELOPMENT, V119, P971; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; VINCENT JP, 1994, IN PRESS DEV BIOL; ZALOKAR M, 1971, P NATL ACAD SCI USA, V68, P1539, DOI 10.1073/pnas.68.7.1539	37	54	54	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					909	915		10.1016/0092-8674(94)90139-2	http://dx.doi.org/10.1016/0092-8674(94)90139-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004677				2022-12-28	WOS:A1994NT33100015
J	CZEIZEL, AE; KODAJ, I; LENZ, W				CZEIZEL, AE; KODAJ, I; LENZ, W			SMOKING DURING PREGNANCY AND CONGENITAL LIMB DEFICIENCY	BRITISH MEDICAL JOURNAL			English	Article							MATCHED CASE-CONTROL; MULTIVARIATE-ANALYSIS; REDUCTION DEFECTS; HUNGARY; FAMILY	Objective-To examine genetic and environmental factors in the origin of isolated congenital limb deficiencies. Design-Case-control study with questionnaire at a family interview of cases of isolated congenital Limb deficiencies (six types), negative controls (matched for age, sex, and place of residence), and positive controls (cases of sentinel anomalies). Setting-The database of the Hungarian Congenital Abnormality Registry, 1975-84, complemented by three other sources of ascertainment (1 575 904 births). Subjects-537 case-control pairs; 392 positive controls. Main outcome measures-smoking during pregnancy, congenital limb deficiencies. Results-The adjusted rate of smoking during pregnancy was significantly higher in the mothers of cases of terminal transverse defect (relative odds 1.48; 95% confidence interval 0.98 to 2.23; P=0.017). This finding supports the hypothesis of vascular disruption as a cause of congenital limb deficiency. Conclusions-Maternal smoking during pregnancy raises the relative odds for terminal transverse limb deficiencies.	NATL INST HYG,DEPT HUMAN GENET & TERATOL,WHO,COLLABORATING CTR COMMUNITY CONTROL HEREDITARY DI,BUDAPEST,HUNGARY; STATE HOSP,DEPT OBSTET & GYNAECOL,BUDAPEST,HUNGARY; UNIV MUNSTER,INST HUMAN GENET,W-4400 MUNSTER,GERMANY	World Health Organization; University of Munster								ARO T, 1984, INT J EPIDEMIOL, V13, P459, DOI 10.1093/ije/13.4.459; ARO T, 1983, EARLY HUM DEV, V9, P49, DOI 10.1016/0378-3782(83)90101-9; BRESLOW NE, 1978, AM J EPIDEMIOL, V108, P299, DOI 10.1093/oxfordjournals.aje.a112623; CZEIZEL A, 1991, Acta Morphologica Hungarica, V39, P229; CZEIZEL A, 1989, MUTAT RES, V212, P3, DOI 10.1016/0027-5107(89)90017-1; CZEIZEL A, 1988, World Health Statistics Quarterly, V41, P219; CZEIZEL A, 1980, ACTA MORPHOL HUNG, V28, P177; CZEIZEL AE, 1993, J MED GENET, V30, P593, DOI 10.1136/jmg.30.7.593; CZEIZEL AE, 1993, TERATOLOGY, V48, P323, DOI 10.1002/tera.1420480405; CZEIZEL AE, 1993, AM J MED GENET, V46, P372, DOI 10.1002/ajmg.1320460406; CZEIZEL AE, 1993, AM J MED GENET, V46, P427, DOI 10.1002/ajmg.1320460416; CZEIZEL AE, 1993, CLIN GENET, V44, P32; CZEIZEL AE, 1992, ACTA MORPHOL HUNG, V40, P49; EVANS JA, 1994, IN PRESS AM J MED; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; HARLOW SD, 1989, AM J EPIDEMIOL, V33, P159; HOLFORD TR, 1978, AM J EPIDEMIOL, V107, P245, DOI 10.1093/oxfordjournals.aje.a112531; HOYME HE, 1982, J PEDIATR-US, V101, P839, DOI 10.1016/S0022-3476(82)80343-0; KOBOR J, 1988, Orvosi Hetilap, V129, P21; KULLANDER S, 1971, ACTA OBSTET GYN SCAN, V50, P83, DOI 10.3109/00016347109157292; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LOWE CR, 1959, BRIT MED J, V2, P673, DOI 10.1136/bmj.2.5153.673; MACKENZIE SG, 1989, AM J EPIDEMIOL, V129, P65, DOI 10.1093/oxfordjournals.aje.a115125; MASTROIACOVO P, 1991, LANCET, V337, P1091, DOI 10.1016/0140-6736(91)91735-D; MENGES RW, 1970, ENVIRON RES, V3, P285, DOI 10.1016/0013-9351(70)90022-8; OAKLEY A, 1990, J BIOSOC SCI, V22, P477, DOI 10.1017/S0021932000018885; OLSEN J, 1988, SCAND J SOC MED, V16, P49, DOI 10.1177/140349488801600108; SHIONO PH, 1986, TERATOLOGY, V34, P65, DOI 10.1002/tera.1420340109	28	67	71	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1473	1476		10.1136/bmj.308.6942.1473	http://dx.doi.org/10.1136/bmj.308.6942.1473			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019281	Green Published			2022-12-28	WOS:A1994NQ22900017
J	DOWNEY, GP; GABRIEL, G; DEERY, ARS; CROW, J; WALKER, PG				DOWNEY, GP; GABRIEL, G; DEERY, ARS; CROW, J; WALKER, PG			MANAGEMENT OF FEMALE PRISONERS WITH ABNORMAL CERVICAL CYTOLOGY	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; MOGHISSI KS, 1968, AM J OBSTET GYNECOL, V100, P607, DOI 10.1016/S0002-9378(15)33386-X; WILL M, 1970, Scottish Medical Journal, V15, P219	3	17	18	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1412	1413		10.1136/bmj.308.6941.1412	http://dx.doi.org/10.1136/bmj.308.6941.1412			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019252	Green Published			2022-12-28	WOS:A1994NP42000017
J	KELLY, CP; POTHOULAKIS, C; LAMONT, JT				KELLY, CP; POTHOULAKIS, C; LAMONT, JT			CLOSTRIDIUM-DIFFICILE COLITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ANTIBIOTIC-ASSOCIATED COLITIS; PSEUDO-MEMBRANOUS COLITIS; TOXIN-A-RECEPTOR; PSEUDOMEMBRANOUS COLITIS; ENZYME-IMMUNOASSAY; HOSPITAL ENVIRONMENT; CONTROLLED TRIAL; RABBIT ILEUM; VANCOMYCIN; DIARRHEA		BOSTON UNIV,MED CTR,EVANS MEM DEPT CLIN RES,GASTROENTEROL SECT,BOSTON,MA 02215	Boston University								BARTLETT JG, 1978, NEW ENGL J MED, V298, P531, DOI 10.1056/NEJM197803092981003; BENDER BS, 1986, LANCET, V2, P11, DOI 10.1016/S0140-6736(86)92559-6; BOLTON RP, 1986, GUT, V27, P1169, DOI 10.1136/gut.27.10.1169; BORRIELLO SP, 1990, ANN MED, V22, P61, DOI 10.3109/07853899009147244; BRADLEY SJ, 1988, AM SURGEON, V54, P329; BRICELAND LL, 1988, AM J HOSP PHARM, V45, P122, DOI 10.1093/ajhp/45.1.122; BROOKS SE, 1992, INFECT CONT HOSP EP, V13, P98; BUGGY BP, 1987, J CLIN GASTROENTEROL, V9, P155, DOI 10.1097/00004836-198704000-00009; DEGIROLAMI PC, 1992, J CLIN MICROBIOL, V30, P1085, DOI 10.1128/JCM.30.5.1085-1088.1992; DIPERSIO JR, 1991, J CLIN MICROBIOL, V29, P2724, DOI 10.1128/JCM.29.12.2724-2730.1991; DOERN GV, 1992, J CLIN MICROBIOL, V30, P2042, DOI 10.1128/JCM.30.8.2042-2046.1992; EGLOW R, 1992, J CLIN INVEST, V90, P822, DOI 10.1172/JCI115957; FEKETY R, 1981, AM J MED, V70, P906, DOI 10.1016/0002-9343(81)90553-2; Hall IC, 1935, AM J DIS CHILD, V49, P390, DOI 10.1001/archpedi.1935.01970020105010; HECHT G, 1988, J CLIN INVEST, V82, P1516, DOI 10.1172/JCI113760; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; JOHNSON S, 1990, AM J MED, V88, P137, DOI 10.1016/0002-9343(90)90462-M; JOHNSON S, 1992, ANN INTERN MED, V117, P297, DOI 10.7326/0003-4819-117-4-297; KAATZ GW, 1988, AM J EPIDEMIOL, V127, P1289, DOI 10.1093/oxfordjournals.aje.a114921; KEIGHLEY MRB, 1978, BRIT MED J, V2, P1667, DOI 10.1136/bmj.2.6153.1667; KELLY CP, 1992, GASTROENTEROLOGY, V102, P35, DOI 10.1016/0016-5085(92)91781-X; KELLY CP, 1993, GASTROINTESTINAL PHA, P199; KLEINFELD DI, 1988, J INFECT DIS, V157, P389, DOI 10.1093/infdis/157.2.389; LARSON HE, 1978, LANCET, V1, P1063; LARSON HE, 1977, BRIT MED J, V1, P1246, DOI 10.1136/bmj.1.6071.1246; LARSON HE, 1982, J INFECT DIS, V146, P727, DOI 10.1093/infdis/146.6.727; LEUNG DYM, 1991, J PEDIATR-US, V118, P633, DOI 10.1016/S0022-3476(05)83393-1; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; LYERLY DM, 1991, J CLIN MICROBIOL, V29, P2639, DOI 10.1128/JCM.29.11.2639-2642.1991; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; MILLER PD, 1990, CELL IMMUNOL, V126, P155, DOI 10.1016/0008-8749(90)90308-E; NOLAN NPM, 1987, GUT, V28, P1467, DOI 10.1136/gut.28.11.1467; Peterson LR, 1990, CLOSTRIDIUM DIFFICIL, P115; POTHOULAKIS C, 1988, J CLIN INVEST, V81, P1741, DOI 10.1172/JCI113514; POTHOULAKIS C, 1991, J CLIN INVEST, V88, P119, DOI 10.1172/JCI115267; PRICE AB, 1977, J CLIN PATHOL, V30, P1, DOI 10.1136/jcp.30.1.1; RIEGLER M, 1993, GASTROENTEROLOGY, V104, pA770; SEAL D, 1987, EUR J CLIN MICROBIOL, V6, P51, DOI 10.1007/BF02097191; SURAWICZ CM, 1989, AM J GASTROENTEROL, V84, P1285; TABAQCHALI S, 1990, REV INFECT DIS, V12, pS192; TEASLEY DG, 1983, LANCET, V2, P1043; TEDESCO F, 1978, LANCET, V2, P226; TEDESCO FJ, 1985, AM J GASTROENTEROL, V80, P867; TEDESCO FJ, 1982, AM J GASTROENTEROL, V77, P220; TEDESCO FJ, 1974, ANN INTERN MED, V81, P429, DOI 10.7326/0003-4819-81-4-429; TEDESCO FJ, 1982, GASTROENTEROLOGY, V83, P1259; TRIADAFILOPOULOS G, 1991, GASTROENTEROLOGY, V101, P685, DOI 10.1016/0016-5085(91)90526-Q; TRIADAFILOPOULOS G, 1987, GASTROENTEROLOGY, V93, P273, DOI 10.1016/0016-5085(87)91014-6; TVEDE M, 1989, LANCET, V1, P1156; VISCIDI R, 1983, J INFECT DIS, V148, P93, DOI 10.1093/infdis/148.1.93; YOUNG G, 1986, GASTROENTEROLOGY, V90, P1098, DOI 10.1016/0016-5085(86)90914-5	51	914	974	1	82	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	1994	330	4					257	262		10.1056/NEJM199401273300406	http://dx.doi.org/10.1056/NEJM199401273300406			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR496	8043060				2022-12-28	WOS:A1994MR49600006
J	KLINKENBERGKNOL, EC; FESTEN, HPM; JANSEN, JBMJ; LAMERS, CBHW; NELIS, F; SNEL, P; LUCKERS, A; DEKKERS, CPM; HAVU, N; MEUWISSEN, M				KLINKENBERGKNOL, EC; FESTEN, HPM; JANSEN, JBMJ; LAMERS, CBHW; NELIS, F; SNEL, P; LUCKERS, A; DEKKERS, CPM; HAVU, N; MEUWISSEN, M			LONG-TERM TREATMENT WITH OMEPRAZOLE FOR REFRACTORY REFLUX ESOPHAGITIS - EFFICACY AND SAFETY	ANNALS OF INTERNAL MEDICINE			English	Article						GASTRITIS, ATROPHIC; ENTEROCHROMAFFIN CELLS; GASTROESOPHAGEAL REFLUX; OMEPRAZOLE; ESOPHAGITIS	HIGH-DOSE RANITIDINE; ENTEROCHROMAFFIN-LIKE CELLS; DOUBLE-BLIND; EROSIVE ESOPHAGITIS; CHRONIC GASTRITIS; SERUM GASTRIN; ULCER DISEASE; FOLLOW-UP; 40 MG; MULTICENTER	Objective: To evaluate the long-term efficacy and safety of omeprazole in patients with gastroesophageal reflux disease resistant to treatment with histamine-2 (H-2)-receptor antagonists. Design: Cohort analytic study with a mean follow-up of 48 months (range, 36 to 64 months). Setting: Patients receiving ambulatory care from referral centers. Patients: 91 patients with gastroesophageal reflux disease resistant to treatment with an H-2-receptor antagonist but subsequently responsive to 40 mg of omeprazole daily. Intervention: Open maintenance therapy consisting of 20 mg of omeprazole daily in 86 patients and 40 mg daily in 5 patients. Outcome Measures: Endoscopy to assess healing; side effects, laboratory values, fasting serum gastrin level, and gastric corpus biopsies to assess safety. Results: Esophagitis recurred in 47% of the patients receiving 20 mg of omeprazole daily, but all rehealed after the dose was doubled. Seven of 40 patients (18%) had a second relapse after a mean follow-up time of 24 months (range, 9 to 36 months) that was successfully treated with a further 20-mg dose increment for a mean period of 36 months (range, 6 to 39 months). Median gastrin levels increased initially from 60 ng/L before study entry to 162 ng/L (P < 0.01) with treatment and reached a plateau during maintenance treatment. Very high gastrin levels (>500 ng/L) were observed in a subgroup (11%) of patients. The incidence of micronodular hyperplasia increased from 2.5% of the patients at first biopsy to 20% at the last biopsy (P = 0.001), with a corresponding progression of gastritis to subatrophic or atrophic gastritis from less than 1% to 25% (P < 0.001), which was more pronounced in patients with very high serum gastrin levels. Conclusions: Maintenance therapy with omeprazole was effective for at least 5 years in patients with gastroesophageal reflux disease resistant to treatment with H-2-receptor antagonists. Treatment was accompanied by a persistent increase in serum gastrin levels and an increase of micronodular argyrophil cell hyperplasia and subatrophic or atrophic gastritis.	SOPHIA HOSP, DEPT GASTROENTEROL, 8025 AB ZWOLLE, NETHERLANDS; SLOTERVAART HOSP, DEPT GASTROENTEROL, 1066 EC AMSTERDAM, NETHERLANDS; ST IGNATIUS HOSP, DEPT GASTROENTEROL, 4818 CK BREDA, NETHERLANDS; GROOTE ZIENKENGASTHUIS, SHERTOGENBOSCH, NETHERLANDS; LEIDEN STATE UNIV, LEIDEN, NETHERLANDS; JACOBUS HOSP, ZWIJNDRECHT, NETHERLANDS; CATHOLIC UNIV NIJMEGEN, NIJMEGEN, NETHERLANDS; ASTRA RES CTR AB, S-15185 SODERTALJE, SWEDEN	Slotervaart Hospital; Leiden University; Leiden University - Excl LUMC; Radboud University Nijmegen	KLINKENBERGKNOL, EC (corresponding author), FREE UNIV AMSTERDAM HOSP, DEPT GASTROENTEROL, POB 7057, 1007 MB AMSTERDAM, NETHERLANDS.							BARDHAN KD, 1990, GUT, V31, P745, DOI 10.1136/gut.31.7.745; BRUNNER G, 1988, DIGESTION, V39, P80, DOI 10.1159/000199610; CHING C K, 1990, Gastroenterology, V98, pA30; CREUTZFELDT W, 1992, DIGESTION, V51, P76, DOI 10.1159/000200920; DEHN TCB, 1990, GUT, V31, P509, DOI 10.1136/gut.31.5.509; DENT J, 1988, GASTROENTEROL INT S1, V1, P847; DENT J, 1990, AUG INT WORLD C GAST; FELLENIUS E, 1981, NATURE, V290, P159, DOI 10.1038/290159a0; FIASSE R, 1990, ACTA GASTRO-ENT BELG, V53, P573; FRESTON JW, 1992, DIGESTION, V51, P102, DOI 10.1159/000200923; HAKANSON R, 1986, DIGESTION, V35, P23, DOI 10.1159/000199380; HAMEETEMAN W, 1986, AM J GASTROENTEROL, V81, P764; HAVELUND T, 1988, BRIT MED J, V296, P89, DOI 10.1136/bmj.296.6615.89; HAVU N, 1991, SCAND J GASTROENTERO, V26, P90, DOI 10.3109/00365529109103993; HILL ADK, 1991, GULLET, V1, P81; JANSEN JBMJ, 1990, GASTROENTEROLOGY, V99, P621, DOI 10.1016/0016-5085(90)90946-X; JOHNSON LR, 1988, PHYSIOL REV, V68, P456, DOI 10.1152/physrev.1988.68.2.456; KEKKI M, 1980, SCAND J GASTROENTERO, V15, P651, DOI 10.3109/00365528009181511; KLINKENBERGKNOL EC, 1987, LANCET, V1, P349; KOOP H, 1991, DIGEST DIS SCI, V36, P552, DOI 10.1007/BF01297018; KOOP H, 1990, ALIMENT PHARM THERAP, V4, P593; LAMBERTS R, 1993, GASTROENTEROLOGY, V104, P1356, DOI 10.1016/0016-5085(93)90344-C; LAMERS C, 1976, THESIS NIJMEGEN; LEE FI, 1988, AM J GASTROENTEROL, V83, P914; LUNDELL L, 1991, SCAND J GASTROENTERO, V26, P248, DOI 10.3109/00365529109025038; LUNDELL L, 1990, ALIMENT PHARM THERAP, V4, P145; MAAROOS HI, 1985, SCAND J GASTROENTERO, V20, P198, DOI 10.3109/00365528509089657; MARCIANODAMORE DA, 1990, J CLIN GASTROENTEROL, V12, P616, DOI 10.1097/00004836-199012000-00003; PORRO GB, 1990, GUT, V31, pA1189; SACHS L, 1984, APPLIED STATISTICS H; SANDMARK S, 1988, SCAND J GASTROENTERO, V23, P625, DOI 10.3109/00365528809093923; SAVARY M, 1977, OESOPHAGUS; SIPPONEN P, 1990, SCAND J GASTROENTERO, V25, P513, DOI 10.3109/00365529009095523; SIRINEK KR, 1985, AM J SURG, V149, P35, DOI 10.1016/S0002-9610(85)80006-4; SOLCIA E, 1989, SCAND J GASTROENTERO, V24, P129, DOI 10.3109/00365528909091260; SOLCIA E, 1988, DIGESTION, V41, P185, DOI 10.1159/000199786; SONTAG SJ, 1992, GASTROENTEROLOGY, V102, P109, DOI 10.1016/0016-5085(92)91790-B; TIELEMANS Y, 1989, GASTROENTEROLOGY, V96, P723; VANTRAPPEN G, 1988, DIGEST DIS SCI, V33, P523, DOI 10.1007/BF01798351; VIGNERI S, 1993, ACTA GASTROENTEROL S, V56, P147; VILLAKO K, 1991, SCAND J GASTROENTERO, V26, P135, DOI 10.3109/00365529109104000; ZEITOUN P, 1989, GASTROEN CLIN BIOL, V13, P457; 1991, EUR J GASTROEN HEPAT, V3, P511	43	411	415	2	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					161	167		10.7326/0003-4819-121-3-199408010-00001	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017742				2022-12-28	WOS:A1994NY33800001
J	RUBIN, RA; KOWALSKI, TE; KHANDELWAL, M; MALET, PF				RUBIN, RA; KOWALSKI, TE; KHANDELWAL, M; MALET, PF			URSODIOL FOR HEPATOBILIARY DISORDERS	ANNALS OF INTERNAL MEDICINE			English	Review							PRIMARY BILIARY-CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; URSODEOXYCHOLIC ACID TREATMENT; VERSUS-HOST DISEASE; CHOLESTEROL GALLSTONE DISEASE; TOTAL PARENTERAL-NUTRITION; INTRA-HEPATIC CHOLESTASIS; CHRONIC ACTIVE HEPATITIS; PLACEBO-CONTROLLED TRIAL; REDUCES ACUTE REJECTION	Purpose: To explain the rationale supporting the use of ursodiol (ursodeoxycholic acid) for the treatment of patients with cholesterol gallstones and chronic liver diseases and to describe the results obtained in clinical trials. Data Sources: Personal databases of the authors and MEDLINE were used to identify relevant English-language articles. Study Selection: Randomized controlled trials evaluating ursodiol for the treatment of patients with cholesterol gallstones and chronic liver diseases were emphasized. Data Synthesis: Ursodiol is at least as effective as chenodiol (chenodeoxycholic acid) for the dissolution of cholesterol gallstones and is associated with fewer adverse effects. Ursodiol desaturates bile, solubilizing cholesterol from the stone surface. The diameter of the largest stone is the most important determinant of successful dissolution. Dissolution with ursodiol is effective for approximately 30% to 50% of stones smaller than 20 mm in diameter, with the best results for small, buoyant stones. A meta-analysis of randomized trials with ursodiol found that the dissolution rate was 37% for patients treated with ursodiol at doses of more than 7 mg/kg per day or of more than 500 mg/d for at least 6 months. Maintenance therapy is effective for prevention of gallstone recurrence. Ursodiol also improves biochemical markers of cholestasis and inflammation when used to treat cholestatic liver diseases. By displacing potentially hepatotoxic bile salts, it appears to interrupt the cycle of cholestatic injury. It may also exert hepatoprotective membrane-stabilizing or immunomodulatory effects (or both). Improvements in laboratory variables are limited to the treatment period, with relapses after withdrawal of therapy. Pruritus may be markedly relieved in individual patients treated with ursodiol. Conclusions: Ursodiol is a safe and effective therapy for the treatment of patients with cholesterol gallstones. Although treatment with ursodiol leads to improvement in biochemical markers for cholestatic liver diseases, whether it alters the natural history of these disorders is the subject of ongoing trials.	JEFFERSON MED COLL, PHILADELPHIA, PA USA; UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	Jefferson University; University of Pennsylvania			Rubin, Raymond/AAI-2579-2021		AHRQ HHS [AHCPR HS 06481] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABEI M, 1993, GASTROENTEROLOGY, V104, P539; ANGELICO M, 1990, J CLIN GASTROENTEROL, V12, P656, DOI 10.1097/00004836-199012000-00012; BACHRACH WH, 1982, DIGEST DIS SCI, V27, P737, DOI 10.1007/BF01393771; BATTA AK, 1993, AM J GASTROENTEROL, V88, P691; BATTEZZATI PM, 1993, J HEPATOL, V17, P332, DOI 10.1016/S0168-8278(05)80214-4; BELLENTANI S, 1989, J HEPATOL, V8, P7, DOI 10.1016/0168-8278(89)90155-4; BEUERS U, 1992, HEPATOLOGY, V16, P707, DOI 10.1002/hep.1840160315; BOLONDI L, 1985, GUT, V26, P734, DOI 10.1136/gut.26.7.734; BOWYER BA, 1985, JPEN-PARENTER ENTER, V9, P11, DOI 10.1177/014860718500900111; BRUCKSTEIN AH, 1990, ARCH INTERN MED, V150, P960, DOI 10.1001/archinte.150.5.960; BRUGGE WR, 1992, GASTROENTEROLOGY, V102, pA303; CALMUS Y, 1990, HEPATOLOGY, V11, P12, DOI 10.1002/hep.1840110104; CALMUS Y, 1992, GASTROENTEROLOGY, V103, P617, DOI 10.1016/0016-5085(92)90855-S; Carey M C, 1992, Prog Liver Dis, V10, P139; CAREY MC, 1988, GASTROENTEROLOGY, V95, P508, DOI 10.1016/0016-5085(88)90513-6; CHAPMAN RW, 1988, GUT, V29, P422, DOI 10.1136/gut.29.4.422; CHAPMAN RWG, 1980, GUT, V21, P870, DOI 10.1136/gut.21.10.870; CHAZOUILLERES O, 1990, J HEPATOL, V11, P120, DOI 10.1016/0168-8278(90)90281-U; CHRISTENSEN E, 1985, GASTROENTEROLOGY, V89, P1084, DOI 10.1016/0016-5085(85)90213-6; COLOMBO C, 1992, HEPATOLOGY, V15, P677, DOI 10.1002/hep.1840150421; COLOMBO C, 1992, HEPATOLOGY, V16, P924, DOI 10.1002/hep.1840160412; COMBES B, 1993, HEPATOLOGY, V18, pA175, DOI 10.1016/0270-9139(93)92227-Q; COOPER AD, 1991, GASTROENTEROL CLIN N, V20, P21; CORRIGAN OI, 1980, J PHARM SCI, V69, P869, DOI 10.1002/jps.2600690739; COTTING J, 1990, GUT, V31, P918, DOI 10.1136/gut.31.8.918; CROSIGNANI A, 1991, HEPATOLOGY, V13, P339, DOI 10.1016/0270-9139(91)92450-M; DANZINGER RG, 1972, NEW ENGL J MED, V286, P1, DOI 10.1056/NEJM197201062860101; DECAESTECKER JS, 1991, GUT, V32, P1061, DOI 10.1136/gut.32.9.1061; DELEON MP, 1980, ITAL J GASTROENTEROL, V12, P17; DOLGIN SM, 1981, NEW ENGL J MED, V304, P808, DOI 10.1056/NEJM198104023041402; DONOVAN JM, 1991, GASTROENTEROL CLIN N, V20, P47; ERLINGER S, 1984, HEPATOLOGY, V4, P308, DOI 10.1002/hep.1840040222; FEDOROWSKI T, 1977, GASTROENTEROLOGY, V73, P1131; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; FESTI D, 1990, GASTROENTEROLOGY, V99, P1779, DOI 10.1016/0016-5085(90)90487-L; FISHER RL, 1989, GASTROENTEROL CLIN N, V18, P645; FORGACS IC, 1984, GASTROENTEROLOGY, V87, P299; FREILICH HS, 1986, GASTROENTEROLOGY, V91, P713, DOI 10.1016/0016-5085(86)90643-8; FRIED RH, 1992, ANN INTERN MED, V116, P624, DOI 10.7326/0003-4819-116-8-624; FRIGERIO G, 1979, CURR THER RES CLIN E, V26, P214; FRIMAN S, 1992, TRANSPLANT P, V24, P389; FRIMAN S, 1992, TRANSPLANT P, V24, P344; FROMM H, 1983, GASTROENTEROLOGY, V85, P1257; GALLE PR, 1990, HEPATOLOGY, V12, P486, DOI 10.1002/hep.1840120307; GASKIN KJ, 1988, NEW ENGL J MED, V318, P340, DOI 10.1056/NEJM198802113180602; GHENT CN, 1987, AM J GASTROENTEROL, V82, P117; GREIM H, 1972, GASTROENTEROLOGY, V63, P846; GULDUTUNA S, 1993, GASTROENTEROLOGY, V104, P1736; HADZIYANNIS SJ, 1989, HEPATOLOGY, V10, P580; HAY DW, 1990, SEMIN LIVER DIS, V10, P159, DOI 10.1055/s-2008-1040470; HERTZ R, 1976, SCAND J GASTROENTERO, V11, P741; HEUMAN DM, 1991, GASTROENTEROLOGY, V100, P203, DOI 10.1016/0016-5085(91)90602-H; HEUMAN DM, 1991, HEPATOLOGY, V14, P920, DOI 10.1002/hep.1840140527; HOLZBACH RT, 1991, GASTROENTEROL CLIN N, V20, P67; INNES GK, 1988, TRANSPLANTATION, V45, P749, DOI 10.1097/00007890-198804000-00017; IWAMURA K, 1980, HEPATO-GASTROENTEROL, V27, P26; JONES EA, 1990, HEPATOLOGY, V11, P884, DOI 10.1002/hep.1840110526; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAKIS G, 1978, GASTROENTEROLOGY, V75, P595; KAPLAN MM, 1987, NEW ENGL J MED, V316, P521, DOI 10.1056/NEJM198702263160907; KAPLAN MM, 1991, SEMIN LIVER DIS, V11, P56, DOI 10.1055/s-2008-1040423; KAPLAN MM, 1986, NEW ENGL J MED, V315, P1448, DOI 10.1056/NEJM198612043152304; KITANI K, 1982, LIFE SCI, V30, P515, DOI 10.1016/0024-3205(82)90264-8; KLINTMALM GBG, 1989, HEPATOLOGY, V10, P978, DOI 10.1002/hep.1840100615; KNAPP AB, 1987, GASTROENTEROLOGY, V92, P513, DOI 10.1016/0016-5085(87)90150-8; KONERU B, 1993, HEPATOLOGY, V18, pA336, DOI 10.1016/0270-9139(93)92866-X; Lamont J T, 1992, Prog Liver Dis, V10, P165; LARUSSO NF, 1981, DIGEST DIS SCI, V26, P705, DOI 10.1007/BF01316859; LARUSSO NF, 1991, OXFORD CLIN HEPATOLO, P567; LEE SP, 1992, NEW ENGL J MED, V326, P589, DOI 10.1056/NEJM199202273260902; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LEUSCHNER U, 1985, DIGEST DIS SCI, V30, P642, DOI 10.1007/BF01308413; LEUSCHNER U, 1989, GASTROENTEROLOGY, V97, P1268, DOI 10.1016/0016-5085(89)91698-3; LINDOR KD, 1991, GASTROENTEROLOGY, V101, P250, DOI 10.1016/0016-5085(91)90486-5; LINDOR KD, 1987, DIGEST DIS SCI, V32, P720, DOI 10.1007/BF01296138; Ludwig J, 1990, Prog Liver Dis, V9, P555; MAKINO I, 1978, J LIPID RES, V19, P723; MALET PF, 1990, RADIOLOGY, V177, P167, DOI 10.1148/radiology.177.1.2399314; MALET PF, 1993, J STONE DIS, V5, P217; MALET PF, 1985, SCANNING ELECTRON MI, V2, P775; MATON PN, 1977, LANCET, V2, P1297, DOI 10.1016/s0140-6736(77)90358-0; MATON PN, 1982, MEDICINE, V61, P86, DOI 10.1097/00005792-198203000-00003; MATSUZAKI Y, 1990, AM J GASTROENTEROL, V85, P15; MAY GR, 1993, ALIMENT PHARM THERAP, V7, P139; MEKHJIAN HS, 1979, DIGEST DIS SCI, V24, P545, DOI 10.1007/BF01489324; MESSING B, 1983, GASTROENTEROLOGY, V84, P1012; MIYAI K, 1971, LAB INVEST, V24, P292; MIZUNO S, 1993, DIGEST DIS SCI, V38, P684, DOI 10.1007/BF01316801; NAGEL RA, 1989, LANCET, V2, P1422; NILSELL K, 1983, GASTROENTEROLOGY, V85, P1248; OBRIEN CB, 1991, HEPATOLOGY, V14, P838, DOI 10.1002/hep.1840140516; ODONNELL LDJ, 1988, GUT, V29, P655, DOI 10.1136/gut.29.5.655; OHYA T, 1993, GASTROENTEROLOGY, V104, P527, DOI 10.1016/0016-5085(93)90423-A; OTA M, 1977, HIROSHIMA J MED SCI, V26, P233; PALMA J, 1992, HEPATOLOGY, V15, P1043, DOI 10.1002/hep.1840150612; PARQUET M, 1985, EUR J CLIN INVEST, V15, P171, DOI 10.1111/j.1365-2362.1985.tb00164.x; PAZZI P, 1989, CURR THER RES CLIN E, V45, P476; PERDIGOTO R, 1992, GASTROENTEROLOGY, V102, P1389; PODDA M, 1989, GASTROENTEROLOGY, V96, P222, DOI 10.1016/0016-5085(89)90784-1; PODDA M, 1990, GASTROENTEROLOGY, V98, P1044, DOI 10.1016/0016-5085(90)90032-V; POLLI G, 1979, CURRENT THERAPEUTIC, V26, P230; POO JL, 1992, GASTROENTEROLOGY, V102, P1752, DOI 10.1016/0016-5085(92)91739-Q; POUPON R, 1987, LANCET, V1, P834; POUPON RE, 1991, NEW ENGL J MED, V324, P1548, DOI 10.1056/NEJM199105303242204; PROCHAZKA EJ, 1990, NEW ENGL J MED, V322, P1842, DOI 10.1056/NEJM199006283222603; QUIGLEY EM, 1991, GASTROENTEROLOGY, V104, P285; RANSOHOFF DF, 1993, ANN INTERN MED, V119, P606, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00010; REYES H, 1982, HEPATOLOGY, V2, P87; RODA E, 1982, HEPATOLOGY, V2, P804, DOI 10.1002/hep.1840020611; RODA E, 1989, DIGEST DIS SCI, V34, pS52, DOI 10.1007/BF01536664; ROS E, 1986, GASTROENTEROLOGY, V91, P703, DOI 10.1016/0016-5085(86)90642-6; ROS E, 1991, GASTROENTEROLOGY, V101, P1701, DOI 10.1016/0016-5085(91)90410-M; SACKMANN M, 1991, HEPATOLOGY, V14, P1136, DOI 10.1016/0270-9139(91)90140-Q; SACKMANN M, 1991, ANN INTERN MED, V114, P290, DOI 10.7326/0003-4819-114-4-290; SALEN G, 1991, GASTROENTEROL CLIN N, V20, P171; Sauerbruch T, 1992, Prog Liver Dis, V10, P193; SCHOENFI.LJ, 1967, NATURE, V213, P93, DOI 10.1038/213093b0; Schoenfield L., 1989, GASTROENTEROL INT, V2, P25; SCHOENFIELD LJ, 1990, NEW ENGL J MED, V323, P1239, DOI 10.1056/NEJM199011013231804; SCHOENFIELD LJ, 1981, ANN INTERN MED, V95, P257, DOI 10.7326/0003-4819-95-3-257; SCHOLMERICH J, 1990, J HEPATOL, V10, P280, DOI 10.1016/0168-8278(90)90133-C; SENIOR JR, 1990, GASTROENTEROLOGY, V99, P243, DOI 10.1016/0016-5085(90)91254-4; SEYM, 1991, SEYMOUR CA, P967; SEYMOUR CA, 1991, OXFORD TXB CLIN HEPA, P967; SHIBATA J, 1992, J GASTROEN HEPATOL, V7, P277, DOI 10.1111/j.1440-1746.1992.tb00980.x; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; STARZL TE, 1989, NEW ENGL J MED, V321, P1092, DOI 10.1056/NEJM198910193211606; STEFANIWSKY AB, 1985, GASTROENTEROLOGY, V89, P1000, DOI 10.1016/0016-5085(85)90200-8; STERN RC, 1976, GASTROENTEROLOGY, V70, P645; STIEHL A, 1990, HEPATOLOGY, V12, P492, DOI 10.1002/hep.1840120308; STIEHL A, 1988, GASTROENTEROLOGY, V94, P1201, DOI 10.1016/0016-5085(88)90013-3; SULLIVAN KM, 1988, BLOOD, V72, P546; TAKAHASHI H, 1975, CLIN REPORT, V9, P3223; TERASAKI S, 1991, AM J GASTROENTEROL, V86, P1194; TINT GS, 1982, ANN INTERN MED, V97, P351, DOI 10.7326/0003-4819-97-3-351; TROTMAN BW, 1975, GASTROENTEROLOGY, V68, P1563; VANDEWATER J, 1988, J EXP MED, V167, P1791, DOI 10.1084/jem.167.6.1791; VILLANOVA N, 1989, GASTROENTEROLOGY, V97, P726, DOI 10.1016/0016-5085(89)90644-6; WALKER S, 1992, GASTROENTEROLOGY, V102, P810, DOI 10.1016/0016-5085(92)90162-R; WARD A, 1984, DRUGS, V27, P95, DOI 10.2165/00003495-198427020-00001; WIESNER RH, 1993, MAYO CLIN PROC, V68, P69, DOI 10.1016/S0025-6196(12)60022-6; ZUSMAN I, 1990, ACTA ANAT, V138, P144; 1993, ANN INTERN MED, V119, P620	143	64	64	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					207	218		10.7326/0003-4819-121-3-199408010-00009	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00009			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017748				2022-12-28	WOS:A1994NY33800009
J	JEN, J; KIM, HG; PIANTADOSI, S; LIU, ZF; LEVITT, RC; SISTONEN, P; KINZLER, KW; VOGELSTEIN, B; HAMILTON, SR				JEN, J; KIM, HG; PIANTADOSI, S; LIU, ZF; LEVITT, RC; SISTONEN, P; KINZLER, KW; VOGELSTEIN, B; HAMILTON, SR			ALLELIC LOSS OF CHROMOSOME 18Q AND PROGNOSIS IN COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; SURGICAL ADJUVANT THERAPY; GENETIC ALTERATIONS; P53 GENE; MICROSATELLITE INSTABILITY; ADHESION MOLECULES; FLOW-CYTOMETRY; RECTAL-CANCER; CARCINOMA; DNA	Background. Colorectal cancer occurs in approximately 150,000 people each year in the United States. Prognostic assessment influences the treatment of patients with colorectal cancer, including decisions about adjuvant therapy. We evaluated chromosome 18q allelic loss, a genetic event associated with tumor progression, as a prognostic marker for this disease. Methods. We developed procedures to examine the status of chromosome 18q with microsatellite markers and DNA from formalin-fixed, paraffin-embedded tumors. Allelic loss of chromosome 18q was assessed in 145 consecutively resected stage II or III colorectal carcinomas.	JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ANESTHESIOL & CRIT CARE MED, BALTIMORE, MD 21205 USA; FINNISH RED CROSS & BLOOD TRANSFUS SERV, HELSINKI, FINLAND	Johns Hopkins University; Johns Hopkins University					NCI NIH HHS [CA-47527, CA-35494, CA-09243] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035494, T32CA009243, R37CA035494, R01CA047527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; [Anonymous], 1985, NEW ENGL J MED, V312, P1465; BAAS IO, 1994, J PATHOL, V172, P5, DOI 10.1002/path.1711720104; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BELL SM, 1993, GASTROENTEROLOGY, V104, P57, DOI 10.1016/0016-5085(93)90835-Z; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; COX DR, 1972, J R STAT SOC B, V34, P187; CRISSMAN JD, 1989, PATHOL ANNU, V24, P103; CRISSMAN JD, 1993, COLORECTAL CANCER, P57; DEANS GT, 1992, BRIT J SURG, V79, P608, DOI 10.1002/bjs.1800790706; DOUGLASS HO, 1986, NEW ENGL J MED, V315, P1294; ENSLEY JF, 1993, CYTOMETRY, V14, P550, DOI 10.1002/cyto.990140515; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRUIS NA, 1993, BRIT J CANCER, V68, P308, DOI 10.1038/bjc.1993.333; GUYER M, 1992, SCIENCE, V258, P67; HAHN M, 1993, CLIN CHEM, V39, P549; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HAMILTON SR, 1993, GASTROENTEROLOGY, V105, P3, DOI 10.1016/0016-5085(93)90003-U; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hedrick Lora, 1993, Trends in Cell Biology, V3, P36, DOI 10.1016/0962-8924(93)90148-T; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JASS JR, 1989, J CLIN PATHOL, V42, P254, DOI 10.1136/jcp.42.3.254; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERN SE, 1989, JAMA-J AM MED ASSOC, V262, P1952; KIM HG, 1994, AM J PATHOL, V145, P148; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; LITT M, 1993, BIOTECHNIQUES, V15, P280; LOUIS DN, 1992, AM J PATHOL, V141, P777; MANTEL N, 1959, J NATL CANCER I, V22, P719; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; NIGAM AK, 1993, BRIT J CANCER, V68, P507, DOI 10.1038/bjc.1993.377; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OCONNELL MJ, 1992, CANCER-AM CANCER SOC, V70, P1732, DOI 10.1002/1097-0142(19920915)70:4+<1732::AID-CNCR2820701614>3.0.CO;2-#; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1612, DOI 10.1016/0016-5085(92)91721-F; PELTOMAKI P, 1993, CANCER RES, V53, P5853; REMVIKOS Y, 1992, BRIT J CANCER, V66, P758, DOI 10.1038/bjc.1992.352; RISINGER JI, 1992, HUM MOL GENET, V1, P657, DOI 10.1093/hmg/1.8.657-a; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIBATA D, 1992, AM J PATHOL, V141, P539; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASEN HFA, 1991, LANCET, V338, P877, DOI 10.1016/0140-6736(91)91520-5; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WIELENGA VJM, 1993, CANCER RES, V53, P4754; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; 1993, CANCER FACTS FIGURES	57	639	653	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					213	221		10.1056/NEJM199407283310401	http://dx.doi.org/10.1056/NEJM199407283310401			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	8015568				2022-12-28	WOS:A1994NY33500001
J	MARKO, JF; SIGGIA, ED				MARKO, JF; SIGGIA, ED			FLUCTUATIONS AND SUPERCOILING OF DNA	SCIENCE			English	Article							HELICAL REPEAT; CIRCULAR DNAS; RING-CLOSURE; FLEXIBILITY; ELASTICITY; DIFFUSION; MOLECULES; DYNAMICS; TWIST	Frequently, DNA in vivo is organized into loops that are partially underwound and consequently form interwound helical supercoils. Methods from polymer statistical mechanics are used to show how the competition between entropy (thermal fluctuations) and elastic energy determines supercoil radius and pitch, in good agreement with recent experiments and simulations. Supercoil reorganization by means of slithering (reptation) of the DNA along the supercoil is argued to be a slow process. Extension of supercoiled DNA by an applied force shows a number of unexpected features, including coexistence of interwound and helical states.	CORNELL UNIV,ATOM & SOLID STATE PHYS LAB,ITHACA,NY 14853	Cornell University			Marko, John F./AAY-7111-2021	Marko, John F./0000-0003-4151-9530				BATES AD, 1993, DNA TOPOLOGY, pCH4; BEDNAR J, 1994, J MOL BIOL, V235, P825, DOI 10.1006/jmbi.1994.1042; BENHAM CJ, 1983, BIOPOLYMERS, V22, P2477, DOI 10.1002/bip.360221112; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; BERG OG, 1984, BIOPOLYMERS, V23, P1869, DOI 10.1002/bip.360231005; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; COZZARELLI NR, 1990, DNA TOPOLOGY ITS BIO, pCH4; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; DAOUD M, 1981, J PHYS-PARIS, V42, P1359, DOI 10.1051/jphys:0198100420100135900; DOI M, 1975, CHEM PHYS, V11, P115, DOI 10.1016/0301-0104(75)80044-9; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; LEBRET M, 1979, BIOPOLYMERS, V18, P1709, DOI 10.1002/bip.1979.360180710; LEBRET M, 1984, BIOPOLYMERS, V23, P1835, DOI 10.1002/bip.360231004; LEIBLER S, 1989, STATISTICAL MECHANIC, V5, P81; MARK JE, UNPUB; PARKER CN, 1991, CELL, V66, P781, DOI 10.1016/0092-8674(91)90121-E; RYBENKOV VV, 1993, P NATL ACAD SCI USA, V90, P5307, DOI 10.1073/pnas.90.11.5307; SCHLICK T, 1992, J MOL BIOL, V223, P1089, DOI 10.1016/0022-2836(92)90263-J; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; TANAKA F, 1985, J CHEM PHYS, V83, P6017, DOI 10.1063/1.449637; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P; WHITE JH, 1969, AM J MATH, V91, P693, DOI 10.2307/2373348; WOLFF AP, 1993, CHROMATIN	27	192	192	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					506	508		10.1126/science.8036491	http://dx.doi.org/10.1126/science.8036491			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036491				2022-12-28	WOS:A1994NY21600024
J	ALBERT, MS; CATES, GD; DRIEHUYS, B; HAPPER, W; SAAM, B; SPRINGER, CS; WISHNIA, A				ALBERT, MS; CATES, GD; DRIEHUYS, B; HAPPER, W; SAAM, B; SPRINGER, CS; WISHNIA, A			BIOLOGICAL MAGNETIC-RESONANCE-IMAGING USING LASER POLARIZED XE-129	NATURE			English	Article							NUCLEAR-SPIN RELAXATION; PROJECTION RECONSTRUCTION; XENON; GAS; EXCHANGE; NMR; SOLUBILITY; LIQUIDS; BRAIN	AS currently implemented, magnetic resonance imaging (MRI) relies on the protons of water molecules in tissue to provide the NMR signal. Protons are, however, notoriously difficult to image in some biological environments of interest, notably the lungs(1) and lipid bilayer membranes such as those in the brain(2). Here we show that Xe-129 gas can be used for high-resolution MRI when the nuclear-spin polarization of the atoms is increased by laser optical pumping and spin exchange(3-6). This process produces hyperpolarized Xe-129, in which the magnetization is enhanced by a factor of about 10(5). By introducing hyperpolarized Xe-129 into mouse lungs we have obtained images of the lung gas space with a speed and a resolution better than those available from proton MRI(1,7) or emission tomography(8,9). As xenon (a safe general anaesthetic) is rapidly-and safely transferred from the lungs to blood and thence to other tissues(8,9), where it is concentrated in lipid(10-15) and protein(13,15-18) components, images of the circulatory system, the brain and other vital organs can also be obtained. Because the magnetic behaviour of Xe-129 is very sensitive to its environment, and is different from that of (H2O)-H-1, MRI using hyperpolarized Xe-129 should involve distinct and sensitive mechanisms for tissue contrast.	PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544	Princeton University	ALBERT, MS (corresponding author), SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794, USA.			Driehuys, Bastiaan/0000-0002-1236-4210; Springer, Charles/0000-0002-5966-2135				ALBERT MS, 1993, MAGNET RESON MED, V29, P700, DOI 10.1002/mrm.1910290520; ALBERT MS, 1992, 11TH P SMRM ANN M NE, P2104; ALBERT MS, 1992, 11TH P SMRM ANN M NE, P4710; BARANY M, 1987, MAGN RESON IMAGING, V5, P393, DOI 10.1016/0730-725X(87)90128-7; BERGIN CJ, 1991, RADIOLOGY, V179, P777, DOI 10.1148/radiology.179.3.2027991; BHASKAR ND, 1982, PHYS REV LETT, V49, P25, DOI 10.1103/PhysRevLett.49.25; BLUMGART HL, 1927, J CLIN INVEST, V4, P423; BLUMGART HL, 1927, J CLIN INVEST, V4, P339; CATES GD, 1992, PHYS REV A, V45, P4631, DOI 10.1103/PhysRevA.45.4631; CATES GD, 1990, PHYS REV LETT, V65, P2591, DOI 10.1103/PhysRevLett.65.2591; DIEHL P, 1990, J MAGN RESON, V88, P660, DOI 10.1016/0022-2364(90)90299-O; FULLERTON GD, 1988, BIOMEDICAL MAGNETIC, P147; GATZKE M, 1993, PHYS REV LETT, V70, P690, DOI 10.1103/PhysRevLett.70.690; GEWALT SL, 1993, MAGNET RESON MED, V29, P99, DOI 10.1002/mrm.1910290117; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; HAPPER W, 1984, PHYS REV A, V29, P3092, DOI 10.1103/PhysRevA.29.3092; JAMESON CJ, 1988, J CHEM PHYS, V89, P4074, DOI 10.1063/1.454842; KNUDSEN GM, IN PRESS AM J PHYSL; MAYO JR, 1987, RADIOLOGY, V163, P507, DOI 10.1148/radiology.163.2.3562834; MILLER KW, 1981, P NATL ACAD SCI-BIOL, V78, P4946, DOI 10.1073/pnas.78.8.4946; NEWBURY NR, 1993, PHYS REV A, V48, P4411, DOI 10.1103/PhysRevA.48.4411; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; POLLACK GL, 1984, J CHEM PHYS, V81, P3239, DOI 10.1063/1.448032; RAFTERY D, 1991, PHYS REV LETT, V66, P584, DOI 10.1103/PhysRevLett.66.584; SCHOENBORN BP, 1969, J MOL BIOL, V45, P297, DOI 10.1016/0022-2836(69)90106-5; Susskind H, 1978, Prog Nucl Med, V5, P144; Susskind H, 1978, Prog Nucl Med, V5, P13; TILTON RF, 1982, BIOCHEMISTRY-US, V21, P6850, DOI 10.1021/bi00269a035; WILCOCK RJ, 1978, J CHEM THERMODYN, V10, P817, DOI 10.1016/0021-9614(78)90154-4; WILHELM E, 1977, CHEM REV, V77, P219, DOI 10.1021/cr60306a003; WISHNIA A, 1969, BIOCHEMISTRY-US, V8, P5064, DOI 10.1021/bi00840a058; WISHNIA A, 1969, BIOCHEMISTRY-US, V8, P5070, DOI 10.1021/bi00840a059	32	835	864	5	150	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					199	201		10.1038/370199a0	http://dx.doi.org/10.1038/370199a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028666				2022-12-28	WOS:A1994NX97100045
J	ALTMAN, DG; BLAND, JM				ALTMAN, DG; BLAND, JM			DIAGNOSTIC-TESTS-3 - RECEIVER OPERATING CHARACTERISTIC PLOTS .7.	BRITISH MEDICAL JOURNAL			English	Note									UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 1RE,ENGLAND	St Georges University London	ALTMAN, DG (corresponding author), IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND.							ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552; ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; BAGOT M, 1988, BRIT J HAEMATOL, V70, P403, DOI 10.1111/j.1365-2141.1988.tb02508.x; ZWEIG MH, 1993, CLIN CHEM, V39, P561	4	452	466	1	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					188	188		10.1136/bmj.309.6948.188	http://dx.doi.org/10.1136/bmj.309.6948.188			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044101	Green Published, Bronze			2022-12-28	WOS:A1994NY22900029
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION IN PRIMARY-CARE - SCREENING AND SELF-EXAMINATION FOR BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							WOMEN; MAMMOGRAPHY; ATTENDANCE; ATTITUDES	Breast cancer is the major form of cancer in women, with nearly 30 000 new cases and over 15 000 deaths in the United Kingdom each year. Breast screening by mammography has been shown in randomised trials to reduce mortality from breast cancer in women aged 50 and over. An NHS breast screening programme has been in operation in the United Kingdom since 1988. Its aim is to reduce mortality from breast cancer by 25% in the population of women invited to be screened. The uptake of mammography among the eligible population may be the single most important determinant if the programme is to be effective. Primary care teams have an important part to play in encouraging women to attend for screening and in providing information, advice, and reassurance at all stages of the screening process. To date, routine breast self examination has not been shown to be an effective method of screening for breast cancer and should not therefore be promoted as a primary screening procedure. There is, however, a case to be made for women to become more ''breast aware.''			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX2 6PE,ENGLAND.							AUSTOKER J, 1990, INVOLVING PRIMARY CA; AUSTOKER J, 1993, BREAST SCREENING ACC, P34; AUSTOKER J, 1992, BREAST CANCER SCREEN; Baines C. J., 1988, SCREENING BREAST CAN, P85; BAINES CJ, 1992, CANCER, V69, P1942, DOI 10.1002/1097-0142(19920401)69:7+<1942::AID-CNCR2820691712>3.0.CO;2-K; BAINES CJ, 1983, CAN MED ASSOC J, V128, P255; BERAL V, 1993, LANCET, V341, P1509, DOI 10.1016/0140-6736(93)90639-X; CHAMBERLAIN J, 1993, EUR J CANCER, V29A, P1804, DOI 10.1016/0959-8049(93)90524-J; CHAMBERLAIN J, BMJ, V353; CHAMPION V, 1992, CANCER, V69, P1985, DOI 10.1002/1097-0142(19920401)69:7+<1985::AID-CNCR2820691720>3.0.CO;2-C; CLOVER KA, 1991, MED J AUSTRALIA, V156, P91; COCKBURN J, 1989, MED J AUSTRALIA, V151, P391, DOI 10.5694/j.1326-5377.1989.tb101221.x; Coleman E A, 1991, J Cancer Educ, V6, P83; DAY NE, 1991, BRIT MED BULL, V47, P400, DOI 10.1093/oxfordjournals.bmb.a072479; FALLOWFIELD LJ, 1990, J ROY SOC MED, V83, P547, DOI 10.1177/014107689008300905; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; FRANK JW, 1985, LANCET, V2, P654; FRENCH K, 1982, BRIT MED J, V285, P617, DOI 10.1136/bmj.285.6342.617; HILL D, 1988, BRIT MED J, V297, P271, DOI 10.1136/bmj.297.6643.271; Kee F, 1992, Eur J Cancer Prev, V1, P231, DOI 10.1097/00008469-199204000-00004; KRUSE J, 1987, OBSTET GYNECOL, V70, P744; MACHARDY L, 1991, BREAST SCREENING PRI; MACLEAN U, 1984, J EPIDEMIOL COMMUN H, V38, P278, DOI 10.1136/jech.38.4.278; MANT D, 1991, BRIT MED BULL, V47, P455, DOI 10.1093/oxfordjournals.bmb.a072483; MANT D, 1992, BREAST, V1, P108; OMALLEY MS, 1987, JAMA-J AM MED ASSOC, V257, P2197; RIMER BK, 1989, RADIOLOGY, V172, P243, DOI 10.1148/radiology.172.1.2740510; SEMIGLAZOV VF, 1992, EUR J EPIDEMIOL, V8, P498, DOI 10.1007/BF00146366; WALD NJ, 1994, CONSENSUS C BREAST C; 1993, NHS BREAST SCREENING; 1991, FACTSHEET 7 BREAST C	31	51	51	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					168	174		10.1136/bmj.309.6948.168	http://dx.doi.org/10.1136/bmj.309.6948.168			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044097	Green Published			2022-12-28	WOS:A1994NY22900023
J	KREK, W; EWEN, ME; SHIRODKAR, S; ARANY, Z; KAELIN, WG; LIVINGSTON, DM				KREK, W; EWEN, ME; SHIRODKAR, S; ARANY, Z; KAELIN, WG; LIVINGSTON, DM			NEGATIVE REGULATION OF THE GROWTH-PROMOTING TRANSCRIPTION FACTOR E2F-1 BY A STABLY BOUND CYCLIN A-DEPENDENT PROTEIN-KINASE	CELL			English	Article							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; DIHYDROFOLATE-REDUCTASE; S-PHASE; VIRAL ONCOPROTEINS; COMPLEX-FORMATION; BINDING PROTEIN; IDENTIFICATION; CLONING; P107	Cyclin A-kinase, an enzyme required for coordinating S phase progression, forms stable in vivo complexes with E2F-1, a growth-promoting transcription factor, which binds to the retinoblastoma gene product and is involved in the timely activation of genes whose products contribute to G1 exit and S phase traversal. Complex formation results in a negative biochemical effect of cyclin A-kinase: the shut-off of E2F-1-dependent DNA binding function in S/G2. Thus, specific and timely cell cycle-dependent interactions of E2F-1 with proteins that inhibit its function (i.e., RB during G1 and cyclin A-kinase during S/G2) may contribute to the periodicity of expression of certain E2F-1-responsive genes at the G1/S transition.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	KREK, W (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.							AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; FLEMINGTON EK, 1993, IN PRESS P NATL ACAD; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; MARIDOR G, 1993, J CELL SCI, V106, P535; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; NEVINS JR, 1992, SCIENCE, V258, P424; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	44	445	457	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					161	172		10.1016/0092-8674(94)90582-7	http://dx.doi.org/10.1016/0092-8674(94)90582-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033208				2022-12-28	WOS:A1994NX32800018
J	SALMON, D; GEUSKENS, M; HANOCQ, F; HANOCQQUERTIER, J; NOLAN, D; RUBEN, L; PAYS, E				SALMON, D; GEUSKENS, M; HANOCQ, F; HANOCQQUERTIER, J; NOLAN, D; RUBEN, L; PAYS, E			A NOVEL HETERODIMERIC TRANSFERRIN RECEPTOR ENCODED BY A PAIR OF VSG EXPRESSION SITE-ASSOCIATED GENES IN TRYPANOSOMA-BRUCEI	CELL			English	Article							VARIANT SURFACE GLYCOPROTEIN; BLOOD-STREAM FORM; TRYPANOSOMA-BRUCEI; AFRICAN TRYPANOSOMES; MEDIATED ENDOCYTOSIS; FLAGELLAR POCKET; TRANSCRIPTION; MEMBRANE; IDENTIFICATION; LOCALIZATION	In T. brucei, a transferrin-binding protein has been found to share sequence homology with pESAG-7 and -6, the products of two related genes present in the VSG gene polycistronic transcription unit. When expressed in Xenopus oocytes, they appear as N-glycosylated proteins secreted in the medium (pESAG-7) and GPI anchored to the membrane (pESAG-6). These proteins are able to homo- or heterodimerize, probably through association in the same orientation. Only heterodimers can bind Tf, possibly two molecules per dimer. A comparison of Tf binding to pESAG-7/6-expressing oocytes and trypanosomes suggests that pESAG-7/6 is the Tf receptor of the parasite. In trypanosomes, the majority of pESAG-7/6 is released from the membrane and associates, together with Tf, with a glycosylated matrix present in the lumen of the flagellar pocket. Both pESAG-7/6 and Tf are internalized via coated pits and vesicles. These observations suggest a novel mode of Tf binding and uptake in trypanosomes.	SO METHODIST UNIV,DEPT BIOL SCI,DALLAS,TX 75275	Southern Methodist University	SALMON, D (corresponding author), UNIV BRUSSELS,DEPT MOLEC BIOL,B-1640 RHODE ST GENESE,BELGIUM.		Salmon, Didier/M-5670-2013	Nolan, Derek/0000-0002-3742-4304				ALEXANDRE S, 1988, MOL CELL BIOL, V8, P2367, DOI 10.1128/MCB.8.6.2367; AVRAMEAS S, 1971, IMMUNOCHEMISTRY, V8, P1175, DOI 10.1016/0019-2791(71)90395-8; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRINGAUD F, 1993, MOL CELL BIOL, V13, P1146, DOI 10.1128/MCB.13.2.1146; BULOW R, 1989, J CELL SCI, V93, P233; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; GEUSKENS M, 1982, ONCODEV BIOL MED, V3, P291; GRAB DJ, 1993, EUR J CELL BIOL, V62, P114; GRAB DJ, 1992, EUR J CELL BIOL, V59, P398; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; HOBBS MR, 1990, MOL BIOCHEM PARASIT, V43, P1, DOI 10.1016/0166-6851(90)90125-6; JACKSON DG, 1993, J BIOL CHEM, V268, P8085; KARIN M, 1981, J BIOL CHEM, V256, P3245; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; MAY WS, 1985, J MEMBRANE BIOL, V88, P205, DOI 10.1007/BF01871086; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; ROSS DT, 1991, EMBO J, V10, P2047, DOI 10.1002/j.1460-2075.1991.tb07735.x; SCALA C, 1992, J HISTOCHEM CYTOCHEM, V40, P1799, DOI 10.1177/40.11.1431065; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHELL D, 1991, PARASITOL RES, V77, P558, DOI 10.1007/BF00931012; SCHELL D, 1993, EMBO J, V12, P2990; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; STANLEY KK, 1984, EMBO J, V3, P1420; THIERY JP, 1967, J MICROSC-PARIS, V6, P987; THIERY JP, 1974, J MICROSC-PARIS, V21, P225; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; Vijayaraghavan P, 1992, Clin Physiol Biochem, V9, P138; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZIEGELBAUER K, 1993, INFECT IMMUN, V61, P4540, DOI 10.1128/IAI.61.11.4540-4545.1993; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	38	155	155	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					75	86		10.1016/0092-8674(94)90574-6	http://dx.doi.org/10.1016/0092-8674(94)90574-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033214				2022-12-28	WOS:A1994NX32800010
J	GLANTZ, SA; BERO, LA				GLANTZ, SA; BERO, LA			INAPPROPRIATE AND APPROPRIATE SELECTION OF PEERS IN GRANT REVIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC			Objective.-To assess the members of the California Tobacco Related Diseases Research Program Behavioral and Public Health Research on Tobacco Study Section and those of the Agency for Health Care Policy and Research (AHCPR) Dissemination Study Section as ''peers'' to review tobacco policy research. Both study sections reviewed a similar grant application on tobacco policy research written by one of us (S.A.G.). Design.-Search of MEDLINE for 1989 through 1993 with the keyword tobacco for Tobacco Related Diseases Research Program and AHCPR reviewers. As a control, the National Institutes of Health Cardiovascular Study Section, which reviewed a ventricular function grant submitted by the same author with the keyword heart, was analyzed. Setting.-Not applicable. Patients or Other Participants.-Study section members. Interventions.-None. Main Outcome Measures.-Publications by study section members in areas germane to the proposal being reviewed. Results.-Six (33%) of 18 Tobacco Related Diseases Research Program reviewers had no ''tobacco'' publications (median, two publications; interquartile range, zero to four). The members' ''tobacco'' publications concentrated on well-controlled experimental interventions on smoking cessation and prevention strategies, not tobacco policy. Only one member had primary expertise in tobacco policy research. None of the AHCPR reviewers had ''tobacco'' publications. All 31 (100%) of the National Institutes of Health reviewers had ''heart'' publications (median, nine publications; interquartile range, seven to 19). Five members had a primary interest in the subject of the National Heart, Lung, and Blood Institute application. Conclusions.-Study section members' professional interests play a critical role in the level of interest and enthusiasm they will have for a proposal, which affects the priority score. In contrast to the study section that reviewed the heart grant, the study sections that reviewed the tobacco control grant were not ''peers.'' The membership of these review committees has effectively precluded research on tobacco control policy.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	GLANTZ, SA (corresponding author), UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,BOX 0124,SAN FRANCISCO,CA 94143, USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				CHAPMAN S, 1993, TOBACCO CONTROL, V1, P81; COHEN J, 1993, SCIENCE, V261, P1678, DOI 10.1126/science.261.5129.1678; GARFUNKEL JM, 1990, JAMA-J AM MED ASSOC, V263, P1376, DOI 10.1001/jama.263.10.1376; HORROBIN DF, 1990, JAMA-J AM MED ASSOC, V263, P1438, DOI 10.1001/jama.263.10.1438; KNOLL E, 1990, JAMA-J AM MED ASSOC, V263, P1330, DOI 10.1001/jama.263.10.1330; NEUFELDT V, 1986, WEBSTERS NEW WORLD D, P996; 1993, CANCER LETT, V19, P5; 1993, 1992 U CAL OFF HLTH; 1991, 1991 U CAL OFF HLTH; 1992, 1992 U CAL OFF HLTH; 1992, U CALIFORNIA TOBACCO; 1992, NIH GUIDE GRANTS CON	12	26	26	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					114	116		10.1001/jama.272.2.114	http://dx.doi.org/10.1001/jama.272.2.114			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015118				2022-12-28	WOS:A1994NV42400008
J	NIGG, HN; RADULESCU, G				NIGG, HN; RADULESCU, G			SCIENTIFIC MISCONDUCT IN ENVIRONMENTAL SCIENCE AND TOXICOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	2nd International Congress on Peer Review in Biomedical Publication	SEP 09-11, 1993	AMER MED ASSOC, CHICAGO, IL		AMER MED ASSOC		PUBLICATION	Scientific misconduct easily occurs in environmental science and toxicology; we encountered four such cases. Only one case was discovered by editors; three were reported by other authors. All guilty authors were eventually banned from future publication in the Bulletin of Environmental Contamination and Toxicology. Cases in the Bulletin indicate that scientific misconduct may occur undetected across phyla, genera, and species; that distance from the publishing source makes detection more difficult; that editors and reviewers are not organized to take action against scientific misconduct; that plagiarized authors are likely to report plagiarism; and that there is only a small risk of censure from any source for authors engaging in scientific misconduct.	SPRINGER VERLAG,DIV JOURNALS,NEW YORK,NY	Springer Nature	NIGG, HN (corresponding author), UNIV FLORIDA,CTR CITRUS RES & EDUC,700 EXPT STN RD,LAKE ALFRED,FL 33850, USA.							BARD AJ, 1993, CHEM ENG NEWS   0531, P44; BARD AJ, 1993, CHEM ENG NEWS   0531, P54; FRIEDMAN PJ, 1990, JAMA-J AM MED ASSOC, V263, P1416; HUTH EJ, 1983, ANN INTERN MED, V99, P266; KRONICK DA, 1990, JAMA-J AM MED ASSOC, V263, P1321, DOI 10.1001/jama.263.10.1321; LAFOLLETTE MC, 1992, STEALING PRINT FRAUD, P294; LOCK S, 1984, BRIT MED J, V288, P42; LOCK S, 1984, BRIT MED J, V288, P43; MACDONALD JR, 1993, PHYSICS TODAY    AUG, P51; NOBEL JJ, 1990, JAMA-J AM MED ASSOC, V263, P1435, DOI 10.1001/jama.263.10.1435; PFEIFER MP, 1990, JAMA-J AM MED ASSOC, V263, P1420, DOI 10.1001/jama.263.10.1420; RENNIE D, 1993, JAMA-J AM MED ASSOC, V269, P915, DOI 10.1001/jama.269.7.915; SOJKA RE, 1992, RES ETHICS MANUSCRIP, P25; SUSSER M, 1993, AM J PUBLIC HEALTH, V83, P792, DOI 10.2105/AJPH.83.6.792; WILLIAMSON RCN, 1992, BRIT J SURG, V79, P3; ZURER P, 1993, CHEM ENG NEWS   0816, P5; 1993, LANCET, V342, P315	17	8	8	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					168	170		10.1001/jama.272.2.168	http://dx.doi.org/10.1001/jama.272.2.168			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015136				2022-12-28	WOS:A1994NV42400026
J	ZAKRZEWSKA, JM; FEEHALLY, J; GILKES, JJH				ZAKRZEWSKA, JM; FEEHALLY, J; GILKES, JJH			LESSON OF THE WEEK - VALUE OF OPINION BY ORAL PHYSICIAN IN DIAGNOSING WEGENERS-GRANULOMATOSIS	BRITISH MEDICAL JOURNAL			English	Article									UCL HOSP, LONDON WC1X 8LD, ENGLAND; LEICESTER GEN HOSP, LEICESTER LE5 4PW, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London; University Hospitals of Leicester NHS Trust; Leicester General Hospital	ZAKRZEWSKA, JM (corresponding author), EASTMAN DENT HOSP, JOINT DEPT MAXILLOFACIAL SURG & ORAL MED, LONDON WC1X 8LD, ENGLAND.		Zakrzewska, Joanna M./AAC-7378-2020	Zakrzewska, Joanna M./0000-0001-7805-5851				DICKEY W, 1992, J R SOC MED, V85, P516; EUFINGER H, 1992, INT J ORAL MAX SURG, V21, P50, DOI 10.1016/S0901-5027(05)80454-0; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; PATTEN SF, 1993, J AM ACAD DERMATOL, V28, P710, DOI 10.1016/0190-9622(93)70098-E; VANDERWOUDE FJ, 1985, LANCET, V1, P425; Wegener F, 1939, BEITR PATHOL ANAT AL, V102, P36	6	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					111	112		10.1136/bmj.309.6947.111	http://dx.doi.org/10.1136/bmj.309.6947.111			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038644	Green Published			2022-12-28	WOS:A1994NW71600029
J	EDEN, J				EDEN, J			BENEFIT DESIGN IN HEALTH-CARE SYSTEM REFORM - PATIENT COST-SHARING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1986, NEW ENGL J MED, V315, P1259	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					12	12		10.1001/jama.272.1.12	http://dx.doi.org/10.1001/jama.272.1.12			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NU485	8007062				2022-12-28	WOS:A1994NU48500007
J	BARTLEY, TD; BOGENBERGER, J; HUNT, P; LI, YS; LU, HS; MARTIN, F; CHANG, MS; SAMAL, B; NICHOL, JL; SWIFT, S; JOHNSON, MJ; HSU, RY; PARKER, VP; SUGGS, S; SKRINE, JD; MEREWETHER, LA; CLOGSTON, C; HSU, E; HOKOM, MM; HORNKOHL, A; CHOI, E; PANGELINAN, M; SUN, Y; MAR, V; MCNINCH, J; SIMONET, L; JACOBSEN, F; XIE, C; SHUTTER, J; CHUTE, H; BASU, R; SELANDER, L; TROLLINGER, D; SIEU, L; PADILLA, D; TRAIL, G; ELLIOTT, G; IZUMI, R; COVEY, T; CROUSE, J; GARCIA, A; XU, W; DELCASTILLO, J; BIRON, J; COLE, S; HU, MCT; PACIFICI, R; PONTING, I; SARIS, C; WEN, D; YUNG, YP; LIN, H; BOSSELMAN, RA				BARTLEY, TD; BOGENBERGER, J; HUNT, P; LI, YS; LU, HS; MARTIN, F; CHANG, MS; SAMAL, B; NICHOL, JL; SWIFT, S; JOHNSON, MJ; HSU, RY; PARKER, VP; SUGGS, S; SKRINE, JD; MEREWETHER, LA; CLOGSTON, C; HSU, E; HOKOM, MM; HORNKOHL, A; CHOI, E; PANGELINAN, M; SUN, Y; MAR, V; MCNINCH, J; SIMONET, L; JACOBSEN, F; XIE, C; SHUTTER, J; CHUTE, H; BASU, R; SELANDER, L; TROLLINGER, D; SIEU, L; PADILLA, D; TRAIL, G; ELLIOTT, G; IZUMI, R; COVEY, T; CROUSE, J; GARCIA, A; XU, W; DELCASTILLO, J; BIRON, J; COLE, S; HU, MCT; PACIFICI, R; PONTING, I; SARIS, C; WEN, D; YUNG, YP; LIN, H; BOSSELMAN, RA			IDENTIFICATION AND CLONING OF A MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR THAT IS A LIGAND FOR THE CYTOKINE RECEPTOR MPL	CELL			English	Article							COLONY-STIMULATING FACTOR; MYELOPROLIFERATIVE LEUKEMIA-VIRUS; EMBRYONIC KIDNEY-CELLS; FACTOR MEG-CSF; PARTIAL-PURIFICATION; HEMATOPOIETIC PROGENITORS; HUMAN ERYTHROPOIETIN; HUMAN INTERLEUKIN-1; COMPLEMENTARY-DNA; MOLECULAR-CLONING	A novel megakaryocyte growth and development factor (MGDF) has been identified in aplastic canine plasma, and its cDNAs have been cloned from canine, murine, and human sources. Purified canine MGDF isolated by procedures involving Mpl receptor affinity chromatography exists in at least two forms, with apparent molecular masses of 25 kDa and 31 kDa, that share the N-terminal amino acid sequence APPACDPRLLNKMLRDSHVLH. Human, dog, and mouse cDNAs for MGDF are highly conserved and encode open reading frames for proteins of 353, 352, and 356 amino acids, respectively, including predicted signal peptides. Canine MGDF and recombinant human MGDF support the development of megakaryocytes from human CD34(+) progenitor cell populations in liquid culture and promote the survival of a factor-dependent murine cell line (32D) engineered to express Mpl. These biological activities are blocked by the soluble extracellular domain of Mpl. These data demonstrate that MGDF is a novel cytokine that regulates megakaryocyte development and is a ligand for the MPI receptor.			BARTLEY, TD (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.		Samal, Babru/ABE-5931-2020; Samal, Babru B/C-5563-2008					BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERICKSONMILLER CL, 1993, BRIT J HAEMATOL, V84, P197, DOI 10.1111/j.1365-2141.1993.tb03052.x; ERICKSONMILLER CL, 1992, BLOOD CELL GROWTH FA, P204; EVATT BL, 1974, J LAB CLIN MED, V83, P364; GREENBERG SM, 1987, J BIOL CHEM, V262, P3269; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; HILL R, 1986, EXP HEMATOL, V14, P752; HILL RJ, 1992, EXP HEMATOL, V20, P354; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MAZUR EM, 1985, EXP HEMATOL, V13, P1164; MAZUR EM, 1990, BLOOD, V76, P1771; MCDONALD TP, 1975, BIOCHEM MED METAB B, V13, P101, DOI 10.1016/0006-2944(75)90145-3; MCDONALD TP, 1975, J LAB CLIN MED, V85, P59; METCALF D, 1991, BLOOD, V77, P2150; METHIA N, 1993, BLOOD, V82, P1395; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; ODELL TT, 1961, P SOC EXP BIOL MED, V108, P428; OGATA K, 1990, INT J CELL CLONING, V8, P103, DOI 10.1002/stem.5530080710; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; SCHMIDT JA, 1984, J EXP MED, V160, P772, DOI 10.1084/jem.160.3.772; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; TAYRIEN G, 1987, J BIOL CHEM, V262, P3262; TERAMURA M, 1992, BLOOD, V79, P327; Vignon I, 1992, P NATL ACAD SCI USA, V89, P5640; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; WENDLING F, 1989, BLOOD, V73, P1161; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YAMAGUCHI N, 1994, J BIOL CHEM, V269, P805; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0	42	869	935	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1117	1124		10.1016/0092-8674(94)90450-2	http://dx.doi.org/10.1016/0092-8674(94)90450-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020099				2022-12-28	WOS:A1994NV42500019
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION - SETTING THE SCENE	BRITISH MEDICAL JOURNAL			English	Article							HEALTH	Each year in the United Kingdom there are over 300 000 new cases of cancer and nearly 165 000 deaths from cancer. It is widely believed that as many as four fifths of all cancers are preventable by means that are already available. The Health of the Nation and the Europe Against Cancer programme have set targets and strategies for reducing the risk of cancer. An approach based on the whole population will achieve the greatest reductions in morbidity and mortality. Complementary to this is the individual approach, which can be based in primary care and targeted at high risk subjects, Health promotion and screening in primary care are not in themselves self evidently valuable. Their effectiveness must be tested rigorously and scientifically. Furthermore, because of limited time and resources, health education in primary care should be focused on interventions that are likely to achieve the greatest benefit, such as helping people to stop smoking.			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX2 6PE,ENGLAND.							CALNAN M, 1989, SOCIAL DILEMMAS CANC, P91; CALNAN M, 1992, CORONARY HEART DISEA; COULTER A, 1993, PREVENTION GENERAL P, P19; DELAMOTHE T, 1991, BRIT MED J, V303, P1046, DOI 10.1136/bmj.303.6809.1046; DICLEMENTE CC, 1991, J CONSULT CLIN PSYCH, V59, P295, DOI 10.1037/0022-006X.59.2.295; DOLL R, 1993, REDUCING RISK CANCER, P14; Doll R, 1981, THE CAUSES OF CANCER; KELLY MP, 1992, BRIT J GEN PRACT, V42, P223; Love R R, 1988, J Cancer Educ, V3, P71; MANT D, 1994, BRIT J GEN PRACT, V44, P51; Prochaska J. O., 1986, TREATING ADDICTIVE B, P3, DOI DOI 10.1007/978-1-4613-2191-0_; ROLLNICK S, 1993, BRIT MED J, V307, P188, DOI 10.1136/bmj.307.6897.188; Rollnick S, 1992, J MENT HEALTH, V1, P25, DOI DOI 10.3109/09638239209034509; Rose G., 1992, STRATEGY PREVENTIVE; STOATE HG, 1989, J ROY COLL GEN PRACT, V39, P193; STOTT N, 1994, BRIT MED J, V308, P285, DOI 10.1136/bmj.308.6924.285; WILSON JMJ, 1968, WHO PUBLIC HLTH PAPE, P34; WRIGH L, 1992, HLTH LIFESTYLES OXFO; 1992, HLTH NATION STRATEGY; 1994, BRIT MED J, V308, P313; 1993, CANCER RES CAMPAIGN; 1994, BRIT MED J, V308, P308; 1993, EUROPEAN CODE CANCER; 1992, CRC11 CANC RES CAMP; 1994, SCI YB	25	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1415	1420		10.1136/bmj.308.6941.1415	http://dx.doi.org/10.1136/bmj.308.6941.1415			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019255	Green Published			2022-12-28	WOS:A1994NP42000021
J	BROWN, SL; SALIVE, ME; HARRIS, TB; SIMONSICK, EM; GURALNIK, JM; KOHOUT, FJ				BROWN, SL; SALIVE, ME; HARRIS, TB; SIMONSICK, EM; GURALNIK, JM; KOHOUT, FJ			LOW-CHOLESTEROL CONCENTRATIONS AND SEVERE DEPRESSIVE SYMPTOMS IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							LOW SERUM-CHOLESTEROL; PRIMARY PREVENTION; MORTALITY; MEN; PROGRESS	Objective-To investigate the reported association between low serum cholestrol concentration and severe depressive symptoms in an elderly population. Design-Cross sectional analysis of pooled data from three communities of the established populations for epidemiologic studies of the elderly. Participants who completed their interview, including the Centers for Epidemiologic Studies' depression scale and consented to measurement of their cholesterol concentration were included in the study. Subjects-3939 men and women aged greater than or equal to 71. Methods-chi(2) analysis, t tests, and multivariate regression analysis of the association between low cholesterol concentration and severe depressive symptoms. All analyses were stratified by sex, and multivariate analyses were adjusted for age, self reported health, physical function, number of drugs used, and weight loss. Main outcome measure-Score of depressive symptoms on the Centers for Epidemiologic Studies' depression scale. Results-Depressive symptoms, cholesterol concentration, weight, and use of drugs were all associated with age in men and women. The relative odds of severe depressive symptoms (score greater than or equal to 16) for those with low cholesterol concentrations (<4.14 mmol/l) were 1.9 (95% confidence interval, 1.1 to 3.3) for the older group of men and 1.8 (1.1 to 2.9) for the older group of women. This association was also observed when depressive symptoms were analysed as a continuous rather than a categorical variable. In multivariate models that adjusted for age, self reported health, physical function, number of drugs used, and weight loss, the association was substantially weakened. Conclusions-After several factors relating to health had been controlled for, no significant association between low cholesterol concentration and severe depressive symptoms was found.	UNIV IOWA,COLL DENT,IOWA CITY,IA 52242	University of Iowa	BROWN, SL (corresponding author), NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,7201 WINSCONSIN AVE,SUITE 3C309,BETHESDA,MD 20892, USA.		Simonsick, Eleanor/W-6864-2019					ASBERG M, 1976, ARCH GEN PSYCHIAT, V9, P51; BLAZER D, 1991, J GERONTOL, V46, pM210, DOI 10.1093/geronj/46.6.M210; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CORNONIHUNTLEY J, 1986, US PHS NIH862443 PUB; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; Harris T, 1992, Ann Epidemiol, V2, P35, DOI 10.1016/1047-2797(92)90035-O; Hooker K., 1992, BEHAV HLTH AGING, V2, P81; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; PALINKAS LA, 1993, LANCET, V341, P563, DOI 10.1016/0140-6736(93)90328-E; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROY A, 1988, ACTA PSYCHIAT SCAND, V78, P529, DOI 10.1111/j.1600-0447.1988.tb06380.x; SMITH GD, 1993, LANCET, V341, P434; TRAN ZV, 1985, JAMA-J AM MED ASSOC, V254, P919, DOI 10.1001/jama.254.7.919	20	103	103	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1328	1332		10.1136/bmj.308.6940.1328	http://dx.doi.org/10.1136/bmj.308.6940.1328			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019218	Green Published			2022-12-28	WOS:A1994NM98900019
J	LITTLE, P				LITTLE, P			WHAT DO WESSEX GENERAL-PRACTITIONERS THINK ABOUT THE STRUCTURE OF HOSPITAL VOCATIONAL-TRAINING	BRITISH MEDICAL JOURNAL			English	Article							EXPERIENCE	Objectives- To assess the views of general practitioners about the structure and content of hospital vocational training and its relation to the training year. Design-Postal questionnaire. Setting-Wessex, England. Subjects-General practitioner trainees undertaking practice training year (n=144), course organisers (n=22), and a random sample of two thirds of trainers (n=135). Results-Questionnaires were returned from 86% (260): 84% of trainees (121), 92% of trainers (124), and 68% of course organisers (15). Most respondents in all groups (84.3%, 95% confidence interval 79.7% to 88.8%) wanted more jobs lasting two and three months to allow a greater range of hospital specialties to be experienced and some of the training year to be carried out before hospital jobs (66.3%, 60.4% to 72.1%). Most hospital specialties were rated at least 6 out of 10 as ''useful'' for general practice training. A substantial minority of training posts did not have regular weekly teaching (166/541; 30.7%, 26.8% to 34.6%) and had no half day (224/541; 41.4%, 37.3% to 45.6%), and over half gave no study leave (293/541; 54.2%, 50.0% to 58.4%). Conclusions-The structure of hospital training should be reviewed as it does not reflect the views of most trainees, course organisers, or trainers. Individual posts need closer supervision to ensure the availability of basic training requirements. More trainees should be allowed to spend a short time in the general practice before hospital rotations and to choose a greater range of shorter jobs.	NIGHTINGALE SURG,ROMSEY,HANTS,ENGLAND					Little, Paul/0000-0003-3664-1873	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHTON C, 1993, POSTGRADUATE ED GENE, V4, P214; BLIGH JG, 1990, MED TEACH, V12, P169, DOI 10.3109/01421599009006693; CHEW CA, 1991, BRIT MED J, V302, P472, DOI 10.1136/bmj.302.6774.472-c; CRAWLEY HS, 1990, BRIT MED J, V300, P911, DOI 10.1136/bmj.300.6729.911; KEARLEY K, 1990, BRIT J GEN PRACT, V40, P409; KELLY DR, 1991, BRIT MED J, V302, P28, DOI 10.1136/bmj.302.6767.28; PEREIRAGRAY DJ, 1979, 4 ROYAL COLL GEN PRA; REEVE H, 1989, BRIT MED J, V298, P1432, DOI 10.1136/bmj.298.6685.1432; SIMS J, 1992, MED MONITOR, V5, P5; STYLES W, 1993, POSTGRADUATE ED GENE, V4, P203; STYLES WM, 1990, BRIT J GEN PRACT, V40, P401; STYLES WM, 1991, BRIT J GEN PRACT, V41, P488; VARNAM MA, 1984, BRIT MED J, V289, P291, DOI 10.1136/bmj.289.6440.291	13	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1337	1339		10.1136/bmj.308.6940.1337	http://dx.doi.org/10.1136/bmj.308.6940.1337			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019223	Green Published			2022-12-28	WOS:A1994NM98900024
